<SEC-DOCUMENT>0001070081-19-000050.txt : 20190806
<SEC-HEADER>0001070081-19-000050.hdr.sgml : 20190806
<ACCEPTANCE-DATETIME>20190806171709
ACCESSION NUMBER:		0001070081-19-000050
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190806
DATE AS OF CHANGE:		20190806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		191003105

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ptct0630201910-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:9DBB4107F4355416B80C119B6AC44390,x:c024e2f5953a43a18857ea527f5ae5bd-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ptct="http://www.ptcbio.com/20190630" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:AmendmentFlag" id="Fact-32F7E375D789358D7FFFF1F30287671E-wk-Fact-32F7E375D789358D7FFFF1F30287671E" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-F87E7EA51572444D9769F1F302889445-wk-Fact-F87E7EA51572444D9769F1F302889445">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-8A54AA01D83AA50956C5F1F302898ACA-wk-Fact-8A54AA01D83AA50956C5F1F302898ACA">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-A409085F3D98FA211E57F1F3028971B8-wk-Fact-A409085F3D98FA211E57F1F3028971B8">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-2B475362F3647902B807F1F302865DA9-wk-Fact-2B475362F3647902B807F1F302865DA9">0001070081</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-AF0EC129FA8C6FAE2B1FF1F3028594CC-wk-Fact-AF0EC129FA8C6FAE2B1FF1F3028594CC">555000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-DBE6DA8EAA3E4036CEDFF1F30285BE68-wk-Fact-DBE6DA8EAA3E4036CEDFF1F30285BE68">150000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-575C62B9A5D1F6EC8F9FF1F3028C6805-wk-Fact-575C62B9A5D1F6EC8F9FF1F3028C6805">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-4167E7F93915062DD2BCF1F30284FE28-wk-Fact-4167E7F93915062DD2BCF1F30284FE28">0</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-83E7794543466525626FF1F3024DD85B-wk-Fact-83E7794543466525626FF1F3024DD85B">555000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-3B0488E1D42A24EC2F9CF1F302932790-wk-Fact-3B0488E1D42A24EC2F9CF1F302932790">150000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-E27FBEFB70C38968CA61F1F30293E7B6-wk-Fact-E27FBEFB70C38968CA61F1F30293E7B6">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember" name="ptct:AlternativeInvestmentMilestone" id="Fact-48FB19A4A892AFBCDB90F1F3026FA75E-wk-Fact-48FB19A4A892AFBCDB90F1F3026FA75E">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember" name="ptct:CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" id="Fact-B406DA9409DFD31F04B2F1F302A38093-wk-Fact-B406DA9409DFD31F04B2F1F302A38093">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember" name="ptct:CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" id="Fact-1F8CD98C8D198EBD1A8EF1F30299A289-wk-Fact-1F8CD98C8D198EBD1A8EF1F30299A289">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="ptct:DebtInstrumentConvertibleThresholdBusinessDays" id="Fact-2183F594CB3E050D0AF2F1F302ABE430-wk-Fact-2183F594CB3E050D0AF2F1F302ABE430">P5D</ix:nonNumeric><ix:nonNumeric contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" id="Fact-EDC8D70DBFD931617F46F1F302ACD295-wk-Fact-EDC8D70DBFD931617F46F1F302ACD295">P5D</ix:nonNumeric><ix:nonNumeric contextRef="D2017Q2May_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" name="ptct:DebtInstrumentInterestPaymentPeriod" id="Fact-A42BF7ACA0D4ACB28BA2F1F302AA7B99-wk-Fact-A42BF7ACA0D4ACB28BA2F1F302AA7B99">P24M</ix:nonNumeric><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-808762A8DF45C5E3C545F1F3028ACA02-wk-Fact-808762A8DF45C5E3C545F1F3028ACA02">0.08</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-2417CC4EB4732A2CD95DF1F3028C1F39-wk-Fact-2417CC4EB4732A2CD95DF1F3028C1F39">0.06</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-1A11E05518CCA50B3A9FF1F3028E1DE1-wk-Fact-1A11E05518CCA50B3A9FF1F3028E1DE1">0.94</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-EA9EA48568A6995A0D5AF1F3028AF28D-wk-Fact-EA9EA48568A6995A0D5AF1F3028AF28D">0.89</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-D57228901835E746BBA8F1F302872409-wk-Fact-D57228901835E746BBA8F1F302872409">30.86</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-4278E8B1A8929AFEA2A2F1F30284AA90-wk-Fact-4278E8B1A8929AFEA2A2F1F30284AA90">0.5959</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-DAC7C8D8C6C9C617E183F1F302890A15-wk-Fact-DAC7C8D8C6C9C617E183F1F302890A15">0.0263</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-DBBB461D68B86E0FEC1EF1F3028BC201-wk-Fact-DBBB461D68B86E0FEC1EF1F3028BC201">2520.00</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-E97B5C2625280CB6660CF1F3028D4E0F-wk-Fact-E97B5C2625280CB6660CF1F3028D4E0F">0.6048</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-41CFF85A54822DF369CAF1F3028C859C-wk-Fact-41CFF85A54822DF369CAF1F3028C859C">0.058</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-1B412FB0701569733F3CF1F302849E38-wk-Fact-1B412FB0701569733F3CF1F302849E38">0.02</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-0BEC8F0163CB81B65511F1F3028B015D-wk-Fact-0BEC8F0163CB81B65511F1F3028B015D">0.25</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-97FD46359E88313305B6F1F302887048-wk-Fact-97FD46359E88313305B6F1F302887048">0.25</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-D97D686C29FF78BB28DAF1F302868669-wk-Fact-D97D686C29FF78BB28DAF1F302868669">6.76</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-9E8CF927AC0F19AD82F8F1F30285C52E-wk-Fact-9E8CF927AC0F19AD82F8F1F30285C52E">0.4653</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-E24002A508645B12BC5CF1F3028D05F2-wk-Fact-E24002A508645B12BC5CF1F3028D05F2">0.0244</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-95A645A66E14A8066246F1F3028A5960-wk-Fact-95A645A66E14A8066246F1F3028A5960">128.00</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-B25950FA864385AAAAF9F1F3028AEABD-wk-Fact-B25950FA864385AAAAF9F1F3028AEABD">0.5939</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-51BA9B0F2B559F4BDDCFF1F302975F05-wk-Fact-51BA9B0F2B559F4BDDCFF1F302975F05">0.057</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-4573E2527A27C4424531F1F302510298-wk-Fact-4573E2527A27C4424531F1F302510298">0.06</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-6DF196CAE6348C01D2B6F1F30292B77E-wk-Fact-6DF196CAE6348C01D2B6F1F30292B77E">0.94</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-F4576FBAADB8EE19BF58F1F3026F7984-wk-Fact-F4576FBAADB8EE19BF58F1F3026F7984">0.89</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-B32D9ECD4CD1C63C37A3F1F3029614A4-wk-Fact-B32D9ECD4CD1C63C37A3F1F3029614A4">30.86</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-B86066FF60F9427F02B6F1F3024EE97D-wk-Fact-B86066FF60F9427F02B6F1F3024EE97D">2520.00</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-3C346214CFE215B36624F1F3026E6727-wk-Fact-3C346214CFE215B36624F1F3026E6727">0.23</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-8E6B8A992DFE6CC66B24F1F30297E387-wk-Fact-8E6B8A992DFE6CC66B24F1F30297E387">0.4841</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-60FCE20B73B5D62D0602F1F3024C1D1F-wk-Fact-60FCE20B73B5D62D0602F1F3024C1D1F">0.038</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-895BC0E3D18AB5D28021F1F3029214CF-wk-Fact-895BC0E3D18AB5D28021F1F3029214CF">0.02</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-9B43B0FA25521BA9B0C7F1F3024F395D-wk-Fact-9B43B0FA25521BA9B0C7F1F3024F395D">0.25</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-FB1465FCE8AE78203973F1F30253838D-wk-Fact-FB1465FCE8AE78203973F1F30253838D">0.25</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-D97794805DBC3C19A46AF1F3024D0815-wk-Fact-D97794805DBC3C19A46AF1F3024D0815">6.76</ix:nonFraction><ix:nonFraction decimals="2" unitRef="usdPerShare" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-455F1F09E973377E2440F1F302969403-wk-Fact-455F1F09E973377E2440F1F302969403">128.00</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-A523D79676CB93C8E981F1F30293B74B-wk-Fact-A523D79676CB93C8E981F1F30293B74B">0.10</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" name="us-gaap:AlternativeInvestmentMeasurementInput" id="Fact-F4408655886411E59511F1F3024EFEC6-wk-Fact-F4408655886411E59511F1F3024EFEC6">0.4759</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact-72009177156F75B7DF33F1F302A5E1AC-wk-Fact-72009177156F75B7DF33F1F302A5E1AC">2520.00</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact-421BCDDF7BD177C738EBF1F302A3089F-wk-Fact-421BCDDF7BD177C738EBF1F302A3089F">128.00</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact-19EDD21DF5636B04AAD7F1F302A3E808-wk-Fact-19EDD21DF5636B04AAD7F1F302A3E808">130</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact-28E643546BFFB6DD26E9F1F302A37EFD-wk-Fact-28E643546BFFB6DD26E9F1F302A37EFD">7030</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-61C3B0BCFE0BADAFFABDF1F30254604F-wk-Fact-61C3B0BCFE0BADAFFABDF1F30254604F">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-7DE80D8D5D5158E87ECFF1F30256F5BA-wk-Fact-7DE80D8D5D5158E87ECFF1F30256F5BA">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-2180A8D90AC0847E293BF1F302558B07-wk-Fact-2180A8D90AC0847E293BF1F302558B07">125000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesAuthorized" id="Fact-01FC164D704158BABF90F1F30256D0F7-wk-Fact-01FC164D704158BABF90F1F30256D0F7">125000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-F8CA01E5A02F0F320739F1F302576BEA-wk-Fact-F8CA01E5A02F0F320739F1F302576BEA">50606147</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesIssued" id="Fact-88BDA651284AFF581F60F1F30256F782-wk-Fact-88BDA651284AFF581F60F1F30256F782">58707185</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-03E8B1CEDBE88A597695F1F3025538C3-wk-Fact-03E8B1CEDBE88A597695F1F3025538C3">50606147</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesOutstanding" id="Fact-07E590A922AD96E27117F1F30255C42A-wk-Fact-07E590A922AD96E27117F1F30255C42A">57707185</ix:nonFraction><ix:nonFraction decimals="0" unitRef="day" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" id="Fact-B236EE9E45E1E8B70DB148C45B508394-wk-Fact-B236EE9E45E1E8B70DB148C45B508394">30</ix:nonFraction><ix:nonFraction decimals="0" unitRef="day" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" id="Fact-B297A42EE3292508867448C438C47793-wk-Fact-B297A42EE3292508867448C438C47793">20</ix:nonFraction><ix:nonNumeric contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentTerm" id="Fact-143B23403E88B65539B4F1F302AB52E8-wk-Fact-143B23403E88B65539B4F1F302AB52E8">P7Y</ix:nonNumeric><ix:nonFraction decimals="0" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-A9D734EC36C8445F4053F1F3026DE4A6-wk-Fact-A9D734EC36C8445F4053F1F3026DE4A6">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-A042308E6689E9CE52AAF1F302B157DC-wk-Fact-A042308E6689E9CE52AAF1F302B157DC">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-DEC1BF9620DE94F8EDEFF1F3029354FA-wk-Fact-DEC1BF9620DE94F8EDEFF1F3029354FA">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-C7ACB3B1D8F10AD1B6C962D2ACF7E315-wk-Fact-C7ACB3B1D8F10AD1B6C962D2ACF7E315">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="I2019Q3aug2_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" name="us-gaap:LessorOperatingLeaseRenewalTerm" id="Fact-A7BA1ED6623C675580A663134D468C47-wk-Fact-A7BA1ED6623C675580A663134D468C47">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="I2019Q3aug2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" name="us-gaap:LessorOperatingLeaseRenewalTerm" id="Fact-8C94C7E370A0687D630E5971A89EB449-wk-Fact-8C94C7E370A0687D630E5971A89EB449">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-71918016FA91010120D1F1F30296ED94-wk-Fact-71918016FA91010120D1F1F30296ED94">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-EEC77FC041D6D0F76C71F1F302A21053-wk-Fact-EEC77FC041D6D0F76C71F1F302A21053">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="I2011Q4Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="Fact-98F18E6BF07BB21F3BD1F1F302A2862A-wk-Fact-98F18E6BF07BB21F3BD1F1F302A2862A">P2Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember" name="us-gaap:Revenues" id="Fact-F69EF7A67B83B1BEA18DF1F30298B9D9-wk-Fact-F69EF7A67B83B1BEA18DF1F30298B9D9">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember" name="us-gaap:Revenues" id="Fact-B8898F7B38169C2D9477F1F3029750FB-wk-Fact-B8898F7B38169C2D9477F1F3029750FB">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember" name="us-gaap:Revenues" id="Fact-2ACE1E037EAC2EC33E90F1F302952CCD-wk-Fact-2ACE1E037EAC2EC33E90F1F302952CCD">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember" name="us-gaap:Revenues" id="Fact-571ED16C2E3933491EF9F1F302A212DF-wk-Fact-571ED16C2E3933491EF9F1F302A212DF">0</ix:nonFraction><ix:nonNumeric contextRef="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact-BDF9AAAFBB8D0F74829AF1F30280B7A0-wk-Fact-BDF9AAAFBB8D0F74829AF1F30280B7A0">P6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-024AE896CF429D124CF2F1F30280F7AE-wk-Fact-024AE896CF429D124CF2F1F30280F7AE">P4Y</ix:nonNumeric><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-E83835F549EA25D2AC79F1F3028B8B16-wk-Fact-E83835F549EA25D2AC79F1F3028B8B16">0.6309</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-BE16676EDA9B1B030D79F1F3029185D1-wk-Fact-BE16676EDA9B1B030D79F1F3029185D1">0.6190</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-9FF61DB2F080C63812FFF1F302863770-wk-Fact-9FF61DB2F080C63812FFF1F302863770">0.0263</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-165FA3FD522FA64DD496F1F3028BC84D-wk-Fact-165FA3FD522FA64DD496F1F3028BC84D">0.0198</ix:nonFraction><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-6E456835BC82EBE1AB8BF1F30287A115-wk-Fact-6E456835BC82EBE1AB8BF1F30287A115">P1Y3D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-F5594DCD71D8C97A99D1F1F30284D715-wk-Fact-F5594DCD71D8C97A99D1F1F30284D715">P8M19D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-FFF72160D538753F02A9F1F3028D628A-wk-Fact-FFF72160D538753F02A9F1F3028D628A">P3D</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-BF9AF61EFED70C0845C2F1F3028651DB-wk-Fact-BF9AF61EFED70C0845C2F1F3028651DB">P7M2D</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-4C09F6854984983AEF73F1F3028E0F0E-wk-Fact-4C09F6854984983AEF73F1F3028E0F0E">P6Y1M9D</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-2039E3E99119D9C1B23AF1F302890582-wk-Fact-2039E3E99119D9C1B23AF1F302890582">P6Y1M9D</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact-0D4B643D661FE3555A46F1F3024D3626-wk-Fact-0D4B643D661FE3555A46F1F3024D3626">P6M7D</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q2YTD_invest_InvestmentAxis_us-gaap_CommonStockMember" name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact-C17197A63E2D89C774FA1B630600FA23-wk-Fact-C17197A63E2D89C774FA1B630600FA23">100000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20190630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug5">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-08-23</xbrli:startDate>
			<xbrli:endDate>2018-08-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MarathonPharmaceuticalsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_TranslarnaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:TranslarnaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MarathonPharmaceuticalsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-20</xbrli:startDate>
			<xbrli:endDate>2017-04-20</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q3Aug1-Aug31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-08-01</xbrli:startDate>
			<xbrli:endDate>2014-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Aug23_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-08-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2May_invest_InvestmentAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_invest_InvestmentAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_invest_InvestmentAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Jan">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1SD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q2May1-May31_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-01</xbrli:startDate>
			<xbrli:endDate>2013-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-05</xbrli:startDate>
			<xbrli:endDate>2013-03-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q2May31_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q2May1-May31_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:LongTermIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-01</xbrli:startDate>
			<xbrli:endDate>2013-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2May1-May31_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-01</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-05</xbrli:startDate>
			<xbrli:endDate>2013-03-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q2_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2013Q2May31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptct:EmployeeDirectorAndConsultantStockOptionPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-08-01</xbrli:startDate>
			<xbrli:endDate>2015-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-08-01</xbrli:startDate>
			<xbrli:endDate>2015-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May-05_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-05</xbrli:startDate>
			<xbrli:endDate>2017-05-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-01</xbrli:startDate>
			<xbrli:endDate>2014-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2011Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-11-01</xbrli:startDate>
			<xbrli:endDate>2011-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-11-01</xbrli:startDate>
			<xbrli:endDate>2011-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-11-01</xbrli:startDate>
			<xbrli:endDate>2011-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q3Aug_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-08-01</xbrli:startDate>
			<xbrli:endDate>2013-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan1-Jan31_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptct:CollaborationAndDiscoveryAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:RocheAndSmaFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2011Q4Nov1-Nov30_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:RocheAndSmaFoundationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-11-01</xbrli:startDate>
			<xbrli:endDate>2011-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2011Q4Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2018-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:DiscoveryAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptct:CollaborationAndDiscoveryAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2018-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
					<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2018-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
				</xbrldi:typedMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptct:CollaborationAndDiscoveryAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:DiscoveryAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Apr-20_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:NewBuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Aug4-Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-04</xbrli:startDate>
			<xbrli:endDate>2019-08-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug4_us-gaap_DebtInstrumentAxis_ptct_FifthAnniversaryMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:FifthAnniversaryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3aug2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3aug2_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:NewBuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="product">
		<xbrli:measure>ptct:product</xbrli:measure>
	</xbrli:unit><xbrli:unit id="country">
		<xbrli:measure>ptct:country</xbrli:measure>
	</xbrli:unit><xbrli:unit id="member_state">
		<xbrli:measure>ptct:member_state</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="operating_lease">
		<xbrli:measure>ptct:operating_lease</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>ptct:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Feet">
		<xbrli:measure>ptct:Feet</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Term">
		<xbrli:measure>ptct:Term</xbrli:measure>
	</xbrli:unit><xbrli:unit id="day">
		<xbrli:measure>ptct:day</xbrli:measure>
	</xbrli:unit><xbrli:unit id="deliverable">
		<xbrli:measure>ptct:deliverable</xbrli:measure>
	</xbrli:unit><xbrli:unit id="compound">
		<xbrli:measure>ptct:compound</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s86DC739D002E59F98F1CB22A163363CB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;</span><span><ix:nonNumeric id="d41025170e396-wk-Fact-565F8422712A63AC75AAF1F3029B6AA2" name="dei:DocumentType" contextRef="FD2019Q2YTD"><span style="font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:24px;font-size:12pt;"><span><ix:nonNumeric id="d41025170e412-wk-Fact-7695866AF6FF16E4CC7FF5F7D223AF2D" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9745;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d41025170e427-wk-Fact-222857CB2A2415064A9AF1F302897942" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q2YTD" format="ixt:datemonthdayyearen">June 30, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">or</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:24px;font-size:12pt;"><span><ix:nonNumeric id="d41025170e441-wk-Fact-47739DAAC7655182F0041ADF7EECB52B" name="dei:DocumentTransitionReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number: </span><span><ix:nonNumeric id="d41025170e464-wk-Fact-7F1881AC90B3F563EED1F5F7EAE767BB" name="dei:EntityFileNumber" contextRef="FD2019Q2YTD"><span style="font-weight:bold;">001-35969</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span><ix:nonNumeric id="d41025170e474-wk-Fact-D456D4D4063380D70008F1F3029CA270" name="dei:EntityRegistrantName" contextRef="FD2019Q2YTD"><span style="font-size:18pt;font-weight:bold;">PTC Therapeutics,&#160;Inc.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:328px;"></td><td style="width:25px;"></td><td style="width:329px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41025170e498-wk-Fact-CC78D90251B375894F82F5F8A5347440" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41025170e508-wk-Fact-7938AB6A71597460B7EFF5F8E5BCA08A" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q2YTD">04-3416587</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:165px;"></td><td style="width:92px;"></td><td style="width:106px;"></td><td style="width:318px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41025170e543-wk-Fact-CE0CEAAB17A0D37FA4324144247911E5" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q2YTD">100 Corporate Court</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41025170e564-wk-Fact-347F22A54B4EF9FC827441444143CD8D" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q2YTD">South Plainfield,</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41025170e569-wk-Fact-8063275C58F8D0A27B89414472FB2403" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q2YTD">NJ</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d41025170e579-wk-Fact-B177C97AF3F581008BE2F5FA37217516" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q2YTD">07080</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d41025170e608-wk-Fact-F0B8D230D15F389B50D9F5FAC959FA23" name="dei:CityAreaCode" contextRef="FD2019Q2YTD"><span style="font-weight:bold;">908</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d41025170e613-wk-Fact-8C0BDD3F089D51058923F5FAE0E7F809" name="dei:LocalPhoneNumber" contextRef="FD2019Q2YTD"><span style="font-weight:bold;">222-7000</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:18%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41025170e656-wk-Fact-0BC3193529DDABBD7F5B62B2D19916DB" name="dei:Security12bTitle" contextRef="FD2019Q2YTD">Common Stock, $0.001 par value per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41025170e661-wk-Fact-509C831B24A3FD5FFAA462B2D194D13A" name="dei:TradingSymbol" contextRef="FD2019Q2YTD">PTCT</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41025170e666-wk-Fact-C4B8488573BA673AFE5062B2D18BA6C2" name="dei:SecurityExchangeName" contextRef="FD2019Q2YTD" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41025170e673-wk-Fact-E5F37D77B672542490B4F5FB153BA583" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q2YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#254;</span><span style="font-family:inherit;font-size:10pt;">&#160; No&#160;&#9744;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41025170e687-wk-Fact-5673FE7260E1041F0C91F5FB2FAC360F" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q2YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#254;</span><span style="font-family:inherit;font-size:10pt;">&#160; No&#160;&#9744;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:70.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:4%;"></td><td style="width:46%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41025170e721-wk-Fact-19C4E43F588D0404E652F5FB6B58A22A" name="dei:EntityFilerCategory" contextRef="FD2019Q2YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">&#254;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;">&#160;&#9744;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller reporting company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d41025170e782-wk-Fact-24BBE588861EE69320ADF5FB8DECA8F3" name="dei:EntitySmallBusiness" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d41025170e803-wk-Fact-80E937774B238723AEC4F5FB8EA904D5" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;   </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160; Yes&#160;</span><span><ix:nonNumeric id="d41025170e817-wk-Fact-2CE85836E5084E930DC2F5FC210FA389" name="dei:EntityShellCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160; No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#254;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">August&#160;5, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025170e834-wk-Fact-4AC953F0AF1062088AECF1F3029A838C" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q3Aug5" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,949,680</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Common Stock, $0.001 par value per share, outstanding.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s033C093E1854529994D3CC98BE6A07FC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Page No.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s7DA3220F90ED5600A43B68557F593F0A"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I&#8212;FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s83F071BFF0395549ABA49CC9FFAE39AC"><span style="font-family:inherit;font-size:10pt;">Item 1. Financial Statements (unaudited)</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s83F071BFF0395549ABA49CC9FFAE39AC">4</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s333FAE3C9F7E56D2B7CDDCECC90C547E"><span style="font-family:inherit;font-size:10pt;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s333FAE3C9F7E56D2B7CDDCECC90C547E">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCD53B19070A758C9B7514930B803D178"><span style="font-family:inherit;font-size:10pt;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCD53B19070A758C9B7514930B803D178">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5B20CD1E211451C290B55DD4D118E3C1"><span style="font-family:inherit;font-size:10pt;">Item 4. Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5B20CD1E211451C290B55DD4D118E3C1">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE81239AD76CE570F9FD72015DC838B47"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II&#8212;OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE8FB50F99A075868838D01F071AA4418"><span style="font-family:inherit;font-size:10pt;">Item 1. Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE8FB50F99A075868838D01F071AA4418">49</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3A03EB5C87C65A0EB3A2008A380DA5BF"><span style="font-family:inherit;font-size:10pt;">Item 1A. Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3A03EB5C87C65A0EB3A2008A380DA5BF">49</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA4AE6AD1C2235519B224D52CDDC74271"><span style="font-family:inherit;font-size:10pt;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA4AE6AD1C2235519B224D52CDDC74271">49</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s97C9496A84EB5EB8B0B3F5CFCDEE2901"><span style="font-family:inherit;font-size:10pt;">Item 6. Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s97C9496A84EB5EB8B0B3F5CFCDEE2901">50</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">i</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4BBB1CCD55345B2C99E526E84770CFCD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The forward-looking statements in this Quarterly Report on Form&#160;10-Q include, among other things, statements about:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to realize the anticipated benefits of our acquisition of Agilis Biotherapeutics, Inc., or Agilis, including the possibility that the expected impact of benefits from the acquisition, including with respect to the business of Agilis and our expectations with respect to the potential achievement of development, regulatory and sales milestones and our contingent payments to the former Agilis equityholders with respect thereto, will not be realized or will not be realized within the expected time period, significant transaction costs, the integration of Agilis's operations and employees into our business, our ability to obtain marketing approval of our gene therapy for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, or PTC-AADC, and other product candidates we acquired from Agilis, unknown liabilities, the risk of litigation and/or regulatory actions related to the acquisition, and other business effects, including the effects of industry, market, economic, political or regulatory conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for Emflaza&#8482; (deflazacort) for the treatment of Duchenne muscular dystrophy, or DMD, in the United States and for Translarna&#8482; (ataluren) for the treatment of nonsense mutation DMD, or nmDMD, in the European Economic Area, or EEA, and other countries in which we have or may obtain regulatory approval, or in which there exist significant reimbursed early access programs, or EAP programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to maintain our marketing authorization of Translarna for the treatment of nmDMD in the EEA (which is subject to the specific obligation to conduct and submit the results of Study 041 to the European Medicines Agency, or EMA, and annual review and renewal by the European Commission following reassessment of the benefit-risk balance of the authorization by the EMA);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to enroll, fund, and complete Study 041, a multicenter, randomized, double-blind, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open label extension, according to the protocol agreed with the EMA, and by the trial&#8217;s deadline;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the anticipated period of market exclusivity for Emflaza for the treatment of DMD in the United States under the Orphan Drug Act&#160;of 1983, or the Orphan Drug Act, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to complete the United States Food and Drug Administration, or FDA, post-marketing requirements to the marketing authorization of Emflaza; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to complete any dystrophin study necessary in order to resolve the matters set forth in the FDA&#8217;s denial of our appeal to the Complete Response Letter we received from the FDA in connection with our New Drug Application, or NDA, for Translarna for the treatment of nmDMD, and our ability to perform additional clinical trials, non-clinical studies or CMC assessments or analyses at significant cost; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and scope of our continued commercialization of Translarna as a treatment for nmDMD in the EEA or other territories outside of the United States;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of nmDMD on adequate terms, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations and the potential financial impact and benefits related to our Collaboration and Licensing Agreement with Akcea Therapeutics, Inc., or Akcea, including with respect to the timing of regulatory approval of Tegsedi</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;(inotersen)&#160;and Waylivra</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></span><span style="font-family:inherit;font-size:10pt;"> (volanesorsen) in countries in which we are licensed to commercialize them, the potential commercialization of Tegsedi&#160;and Waylivra, and our expectations with respect to contingent payments to Akcea based on the potential achievement of certain regulatory milestones and royalty payments by us to Akcea based on our potential achievement of certain net sales thresholds;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our estimates regarding the potential market opportunity for Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra, risdiplam or any other product candidate, including the size of eligible patient populations and our ability to identify such patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our estimates regarding expenses, future revenues, third-party discounts and rebates, capital requirements and needs for additional financing, including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and conduct of our ongoing, planned and potential future clinical trials and studies of Translarna for the treatment of nmDMD, aniridia, and Dravet syndrome/CDKL5, each caused by nonsense mutations, and Emflaza for the treatment of limb-girdle 2I, as well as studies in our gene therapy, splicing and oncology programs,&#160;including the timing of initiation, enrollment and completion of the trials and the period during which the results of the trials will become available;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance and clinical utility of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra and risdiplam;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing of, and our ability to obtain additional marketing authorizations for, Translarna, Tegsedi and our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra and risdiplam and our other product candidates to meet existing or future regulatory standards;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to maintain the current labeling under the marketing authorization in the EEA or expand the approved product label of Translarna for the treatment of nmDMD in non-ambulatory patients or otherwise;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential receipt of revenues from future sales of Translarna, Emflaza, and other product candidates, including our ability to earn a profit from sales or licenses of Translarna for the treatment of nmDMD in the countries in which we have or may obtain regulatory approval and of Emflaza for the treatment of DMD in the United States;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential impact that enrollment, funding and completion of Study 041 may have on our revenue growth;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our sales, marketing and distribution capabilities and strategy, including the ability of our third-party manufacturers to manufacture and deliver Translarna and Emflaza in clinically and commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy their other obligations to us; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish and maintain arrangements for the manufacture of Translarna, Emflaza and our other product candidates that are sufficient to meet clinical trial and commercial launch requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to increase our manufacturing capabilities for our gene therapy platform;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations with respect to the potential financial impact of our leased biologics facility and our ability to satisfy our obligations under the terms of the lease agreement for such facility;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to satisfy our obligations under the terms of the credit and security agreement with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and certain other financial institutions as lenders thereunder;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our other regulatory submissions, including with respect to timing and outcome of regulatory review;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our plans to pursue development of Translarna and Emflaza for additional indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to advance our earlier stage programs and pursue research and development of other product candidates, including our splicing, gene therapy and oncology programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">whether we may pursue business development opportunities, including potential collaborations, alliances, and acquisition or licensing of assets and our ability to successfully develop or commercialize any assets to which we may gain rights pursuant to such business development opportunities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential advantages of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra and risdiplam and any other product candidate;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our intellectual property position;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of government laws and regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing against others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our competitive position; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations with respect to the development and regulatory status of our product candidates and program directed against spinal muscular atrophy in collaboration with F. Hoffmann La Roche Ltd and Hoffmann La Roche Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or the SMA Foundation, and our estimates regarding future revenues from achievement of milestones in that program.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form&#160;10-Q, particularly in Part&#160;II,&#160;Item 1A. Risk Factors as well as in Part&#160;I,&#160;Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2018, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should read this Quarterly Report on Form&#160;10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form&#160;10-Q and our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2018 completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In this Quarterly Report on Form&#160;10-Q, unless otherwise stated or the context otherwise requires, references to &#8220;PTC,&#8221; &#8220;PTC Therapeutics,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar references refer to PTC Therapeutics,&#160;Inc. and, where appropriate, its subsidiaries. The trademarks, trade names and service marks appearing in this Quarterly Report on Form&#160;10-Q are the property of their respective owners.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All website addresses given in this Quarterly Report on Form&#160;10-Q are for information only and are not intended to be an active link or to incorporate any website information into this document.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7DA3220F90ED5600A43B68557F593F0A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I&#8212;FINANCIAL INFORMATION</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s83F071BFF0395549ABA49CC9FFAE39AC"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Financial Statements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s8EBEF6ABD3235C879D720F2A41DC4EBE"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets (unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">In thousands (except per share data)</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e534-wk-Fact-B14D2E1E0EB06795F714F1F30267E1D1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e553-wk-Fact-191CBC2919F5A5F84995F1F3025A10B1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">169,498</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e573-wk-Fact-2746B8D13E29DE627940F1F3026B6513" name="us-gaap:MarketableSecuritiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">227,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e592-wk-Fact-E4BFA9A7D705A1CC75FEF1F302611F8B" name="us-gaap:MarketableSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade receivables, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e617-wk-Fact-3657F478B1E2C7F2FA50F1F3025D767B" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e636-wk-Fact-69625077858D2627621DF1F30257B9B6" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e661-wk-Fact-0CC15B0857EF6B135B85F1F3025FC547" name="us-gaap:InventoryNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e680-wk-Fact-D68658CB72697A4B3826F1F302618800" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e705-wk-Fact-DEEBF55E27F064961B91F1F3025E9B6F" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e724-wk-Fact-D3A6C97B27F730F01FCBF1F302627E88" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e749-wk-Fact-CCE31C2CE176D12D45ABF1F3025EADBF" name="us-gaap:AssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">474,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e768-wk-Fact-40B0CF0EE14B3CA46505F1F3025EB8B3" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">320,857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e793-wk-Fact-DB59C29DA39EA367919FF1F30261E4AA" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e812-wk-Fact-C943C78203124BF01BD8F1F3025F13E1" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e837-wk-Fact-FB82E0CDB0A01DE863A7F1F30264B7A3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">702,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e856-wk-Fact-D2CD283CC8EAE37D7DFEF1F302572D07" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">701,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e882-wk-Fact-1348FCB698E0648159A7F1F302675838" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e901-wk-Fact-1EB21A18E23E5D5F1BC4F1F30259D460" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deposits and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e926-wk-Fact-8502CA0C004357170DC6F1F3025F721F" name="ptct:DepositsAndOtherAssetsNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e945-wk-Fact-1362B83CED862C9351A3F1F3026254EF" name="ptct:DepositsAndOtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e975-wk-Fact-41A0ED53D6A67F71F535F1F3025ADAD9" name="us-gaap:Assets" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,291,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e994-wk-Fact-F78EB275801B098749B7F1F302655047" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,119,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1109-wk-Fact-1873121A607E1419971AF1F3025B361E" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1128-wk-Fact-C91536B542435183E188F1F3026B65D7" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1148-wk-Fact-FAB0A43706F9AF4EB245F1F3025BE614" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1167-wk-Fact-FF00ABBA02D8E009E6B4F1F3026597A2" name="us-gaap:LongTermDebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1192-wk-Fact-AB3E81E0B7F2E69C9D61F1F302603762" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1211-wk-Fact-D4154181EBDC39552EB6F1F3025807BD" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1236-wk-Fact-5FB539DD32F578D754DDF1F3025CD70F" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1255-wk-Fact-848090190F5EB0948268F1F30269AEDB" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1280-wk-Fact-EC0E1729260E567BC2FDF1F3026DB201" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1298-wk-Fact-2DDB0A353C61D760CCEEF1F30268C765" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1323-wk-Fact-BFF6B983CBAB79B194ABF1F3026C781F" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">173,959</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1342-wk-Fact-1A5A8BB0F3938A8C13EBF1F3025C02B8" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1368-wk-Fact-6B14A9EB885DD4C6EC8CF1F30264E815" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1387-wk-Fact-BB989944AD065F9752E6F1F302677793" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1412-wk-Fact-81D6E17DF8EFDE680C10F1F3025B8E62" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">135,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1431-wk-Fact-26AE01168609E717E086F1F302634CD5" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1456-wk-Fact-BF6B9AE3049435F5E337F1F302664F07" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">336,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1475-wk-Fact-3BF2E6C8C62334DD6FB5F1F302677B55" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">310,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1500-wk-Fact-B1AD298526D12CB7B6F7F1F3025F2F0D" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1519-wk-Fact-F2D0F549D21810B7C228F1F302699CF9" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1544-wk-Fact-AC6D391B12EF7F04D403F1F302639810" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1563-wk-Fact-F7F92BEF4A3A3BA0F069F1F30261D2B2" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1588-wk-Fact-71022D5C11467F520486F1F3026C6ED6" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1607-wk-Fact-56155D0E8FB0F65D6F19F1F302588EED" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1632-wk-Fact-91A71F1F5CBEBA964627F1F3026B7C5B" name="us-gaap:Liabilities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">802,887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1651-wk-Fact-7541C6AA563A3A25B1BCF1F302644320" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">768,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding&#160;58,707,185 shares at June 30, 2019. Authorized 125,000,000 shares; issued and&#160;outstanding 50,606,147 shares at December&#160;31, 2018.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1721-wk-Fact-174D56740D7C3BE933C8F1F3026C9B90" name="us-gaap:CommonStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1740-wk-Fact-A243A4FE3F551BD2490CF1F3025C4C3B" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1765-wk-Fact-287C96823CDAFCC169A4F1F30263CF12" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,539,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1784-wk-Fact-3EF11F8AFFCA7A4FB5E6F1F30269F0AC" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,288,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1809-wk-Fact-2CD0E9340612B4BEADE1F1F302698C50" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1828-wk-Fact-504508D6DADEC5401F77F1F3026BFA59" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021057e1854-wk-Fact-37D23494F58D75300B84F1F30268AB36" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,052,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021057e1874-wk-Fact-638F8964B620A2EF842EF1F3025F2F40" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">938,923</ix:nonFraction></span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1900-wk-Fact-44B007521E6FA9A6DA45F1F302665AD4" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">488,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1919-wk-Fact-6297117AECFFB699AD17F1F302599BAE" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350,727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1949-wk-Fact-7D47EC781ED1439A3046F1F30258BFF0" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,291,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021057e1968-wk-Fact-9B119107D18BA081D5A5F1F30262BEF5" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,119,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying unaudited notes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s986877902352550990F2D386B64EFA69"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations (unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">In thousands (except per share data)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e663-wk-Fact-B5D87C0E294BB46D4147F1F30278A5C1" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e682-wk-Fact-C09A96C568ED097A4884F1F30283F5E2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e702-wk-Fact-34470714E069635311B8F1F302A5A9B8" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e721-wk-Fact-0226619864E515050F63F1F302836832" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration and grant revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e741-wk-Fact-945F7AD3573747C0C871F1F3026EC8EA" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e760-wk-Fact-051A029ADA6D742AAB45F1F3027283AD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e779-wk-Fact-0B9B4208B56D503D77ACF1F30253E389" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e799-wk-Fact-EA644FF5F8EFD7998282F1F30255C2E2" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e824-wk-Fact-77298C0E3BC3DFEC4BC6F1F302964BD5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e843-wk-Fact-006D8DBA01BB3AB996B1F1F3024F9348" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e862-wk-Fact-6AB84B39F5B5BA73D231F1F30290C546" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e882-wk-Fact-9044C89305C85CAEE6E3F1F30298E96C" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product sales, excluding amortization of acquired intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e990-wk-Fact-88FE8F01C334BEBEAE87F1F30281BCD4" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1009-wk-Fact-4985F97FCD8A310EAE17F1F302AF7DB0" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1028-wk-Fact-44BF77975B4708CA0FCCF1F3026A957D" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,587</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1048-wk-Fact-2A3C229F3854873F5C37F1F30266078F" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,616</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of acquired intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1073-wk-Fact-92D14BF4CCA1BDC29F82F1F30282E6B2" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1092-wk-Fact-C4CF34EB205DF1A3B2A5F1F30251FA59" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,593</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1111-wk-Fact-ECE26D3104453FC7246AF1F302701C17" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1131-wk-Fact-323CE23BB3B3AC707AEDF1F30294F6B4" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1156-wk-Fact-04CD828C994F27D885C6F1F3027FB3D1" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,979</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1175-wk-Fact-B89D22592B86FD7DDD27F1F30265B9D6" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,607</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1194-wk-Fact-BE6B6B53FEEDE2CB6E94F1F3028B0C50" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1214-wk-Fact-59DC19F6FEC571B77A40F1F3028320E5" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1239-wk-Fact-F6DE677FAEA16F6F5F29F1F3026E55EC" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1258-wk-Fact-B7B504EF14D3F2A5F40EF1F3027EBE2D" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,545</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1277-wk-Fact-84536C28E5E2E183CED6F1F302812E31" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">89,760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1297-wk-Fact-2A986C70536DDDFD55F9F1F30273F17B" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in the fair value of deferred and contingent     consideration  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1323-wk-Fact-9BFE31E97686745E9279F1F30291EE6A" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1342-wk-Fact-A7442E5D11A06F533515F1F302926B0A" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1361-wk-Fact-4AE8B6E6F431F82CD6C1412EA3EB19FD" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span><ix:nonFraction id="d41025438e1381-wk-Fact-69AFD2C8B45896C319BF412EA4F65FB7" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1406-wk-Fact-E48AE6A5AF6E3BC449B3F1F302996C45" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1425-wk-Fact-191517E55E7EB3B06D3EF1F3024E8D9E" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1444-wk-Fact-291C9031565CE8EBB816F1F3029471B9" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1464-wk-Fact-EAB21B1C24EDA589FEDBF1F3028264DF" name="us-gaap:OperatingExpenses" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">147,122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1489-wk-Fact-F03DC83685F3EFDF718BF1F3029B7A11" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">38,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1509-wk-Fact-72EAADF90E7835127512F1F302661E66" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1529-wk-Fact-1F909ED174D9BA62AB79F1F30250034C" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">107,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1550-wk-Fact-3F95336E082A89147278F1F30268FBD1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1576-wk-Fact-A2BF0CDD60E79B7BF5D2F1F30282FEC8" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,074</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1596-wk-Fact-CF04E2EEEFC3C4F1FA7DF1F302A9D62F" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1616-wk-Fact-4BBC2225C8F1B562A8AEF1F302A8E838" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1637-wk-Fact-C875681B6830D59C3B40F1F30268C6E6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (expense) income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1663-wk-Fact-0537833CAF9F23808912F1F302597540" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1683-wk-Fact-C5018CAB7ED35E10AB17F1F302522122" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1703-wk-Fact-309997F5D8EC47064CF3F1F3026047A1" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e1724-wk-Fact-06DF8A5D810FE6192AD7F1F302689FCC" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before income tax expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1749-wk-Fact-B6C129E894EEF1379FE1F1F302A0864E" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1769-wk-Fact-EAD549CB3B6240C14BDEF1F3026AFAC4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1789-wk-Fact-8D10F2EB6C15EA90F6EDF1F30295FB2F" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">112,552</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1810-wk-Fact-EDBC685EEADA9B6AD8A7F1F30291D6F7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1836-wk-Fact-24A9D337302890C75A5CF1F3025DFB94" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1856-wk-Fact-3D277FF267D5B04A4796F1F30285C61E" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1876-wk-Fact-72F892CB278918F9616FF1F302511160" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1897-wk-Fact-8F86956B8E6F72138B40F1F3025085E6" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1928-wk-Fact-651BF6E516962DCADDD067A08AE24A6F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1948-wk-Fact-77253079152E3EFA3F29F1F3027805CB" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1969-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e1989-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average shares outstanding:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted (in shares)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e2180-wk-Fact-A4B2822AB20BADD4161DF1F3027368B0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">55,912,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e2199-wk-Fact-18D1C97362E1A320D10AF1F30288CE54" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">46,137,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e2218-wk-Fact-53AF798862AF86240026F1F30299D7AA" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">57,113,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41025438e2238-wk-Fact-B1D37CC50BA3FB74C941F1F3028EA40A" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">46,257,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e2269-wk-Fact-7724A2F532F09ACED389F1F3025AA52A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e2289-wk-Fact-79112D852D0E45DBB532F1F3026BBDE5" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e2310-wk-Fact-A81E1E67ADE7F1FDE5FFF1F30267C69F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41025438e2330-wk-Fact-604CC67F0B1D65A308C7F1F3026AD791" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying unaudited notes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s093BF10B3959540380655191BB13C798"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">In thousands</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e580-wk-Fact-651BF6E516962DCADDD067A08AE24A6F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e600-wk-Fact-77253079152E3EFA3F29F1F3027805CB" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e621-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e641-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) on marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021933e745-wk-Fact-C217EF9F4BADDF8A9C63F1F3028BBFEF" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021933e764-wk-Fact-230E1298F23EE1BB3D1BF1F3028B1E1A" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021933e783-wk-Fact-F743F8F4B049B007FE3DF1F302883FD9" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e803-wk-Fact-8E16FD2302071E7BA8CFF1F3028D6542" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation gain (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41021933e829-wk-Fact-5D4F989CABF974215874F1F3028AF5A0" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e848-wk-Fact-BEF47F112632512139B8F1F3028EDFE2" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e868-wk-Fact-033423007AEEF287A9E2F1F3028CF427" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e889-wk-Fact-C536FCBEF75F12AEEDB0F1F302891AB4" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e920-wk-Fact-16D38F22460A6F509211F1F30290AC00" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e940-wk-Fact-CA92609032E73DD2A7FEF1F302907599" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e961-wk-Fact-79D52A4ADF7662CEB0D5F6084F1F7755" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41021933e981-wk-Fact-F60C0474CFF0A3AE21C0F1F3028FC69C" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,896</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying unaudited notes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="s45297068E7EC52AAA771D018507BDEFF"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Stockholders' Equity (unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">In thousands</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:37%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended June 30, 2019</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e662-wk-Fact-95DB597A79DF5E335008F1F302B1E708" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,418,790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e681-wk-Fact-BAC8B22E2D42382FB803F1F302B2E814" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e700-wk-Fact-E60E3878676DC834ECA0F1F302A90234" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,523,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e720-wk-Fact-FA8E4A7513A584AA36C3F1F302B052F8" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e739-wk-Fact-6DB8DB9211E5A392E087F1F302B40283" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,011,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e759-wk-Fact-34180B75B7123B23F6C749FB7444DEF2" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">512,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock related to equity offering</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e775-wk-Fact-D28F04FAC3688BF16503F1F30273239A" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e789-wk-Fact-1FE44E64464D64171493F1F302839627" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e808-wk-Fact-029C5DE007AA11845614F1F3024C3CC9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e866-wk-Fact-BF3BC81B0AFCDE086D31F1F30275E60F" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e887-wk-Fact-3D7D17351040BDC26143F1F3027A97B8" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">230,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e901-wk-Fact-EB1B796047D5DFE815D21B1A79A6D894" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="0" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e920-wk-Fact-A32A940D1E863B344612F1F3025CDC89" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e978-wk-Fact-2625F1489671172652141B1AAA205836" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted stock vesting and issuance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e999-wk-Fact-57BD59FD1F2B5318F140F1F302811193" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1090-wk-Fact-63B9D1F7197CD3E99597F1F3026BB004" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock in connection with an employee stock purchase plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1111-wk-Fact-703D1EB4ECEF44FAA2781B3FB0A5DD46" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">54,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1125-wk-Fact-CE777A92D7568CDF38EA1B4033A00AEA" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1144-wk-Fact-D0E9174FF95DD6CE7AE81B4033AE400F" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1202-wk-Fact-8BE4F04D7F0F0051DD281B403398CC5E" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1256-wk-Fact-BF3033F8166F3BD3377BF1F302821AD4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1314-wk-Fact-48DBC9D8057A07719207F1F302B1107C" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Receivable from investor</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1368-wk-Fact-3E37DF47E920BB2068901B3EE47BCE85" name="ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1426-wk-Fact-AA5038515B37F77C41231B3F0462F370" name="ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e1519-wk-Fact-DF4C6C632306D77471D4F1F3026B7906" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e1539-wk-Fact-651BF6E516962DCADDD067A08AE24A6F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1614-wk-Fact-39B3F33D3F195F19AD21F1F3027FD36A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1652-wk-Fact-97CC6FCCAE4E31A95A8FF1F302651C89" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1674-wk-Fact-0C6DE953182D3FB5D42CF1F302B177EB" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,707,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1693-wk-Fact-B4CFA9ECD87BB9326205F1F3026C52AF" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1712-wk-Fact-723357BBC475BC8FB7B0F1F30274C851" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,539,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1732-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e1751-wk-Fact-775FE7BD309380239C61F1F30252D4F9" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,052,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e1771-wk-Fact-44B007521E6FA9A6DA45F1F302665AD4" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">488,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:37%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended June 30, 2018</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(loss) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, March 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2080-wk-Fact-A833AF58E81B712B268D1B188E4C7FFF" name="us-gaap:SharesIssued" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,809,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2099-wk-Fact-F45B1B14714AABB7FE371B188FBA880F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2118-wk-Fact-201B9FC49165A2D795181B1891AA5305" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">975,418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2138-wk-Fact-DD2C2D8C2D8A8242FE611B1893311C65" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e2157-wk-Fact-CDD903483FEE20A797511B1894A05DC6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">830,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2177-wk-Fact-69C2EE77E6AB6F694E6D1B18961F5438" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">150,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock related to equity offering</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2193-wk-Fact-F663524989965717E3771B189C16A9CD" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,600,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2207-wk-Fact-A91AB830410B017D555D1B189E0AC9E6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2226-wk-Fact-556E7B1A68781C8D49991B189FFF2B0C" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,869</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2284-wk-Fact-FDD4CF71443CD68ADD391B18A37489AB" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2305-wk-Fact-57C54D40DB0E3E2482D81B18A97516B8" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">183,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2338-wk-Fact-22728C7E78DDCD0E46041B18ACE15C79" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2396-wk-Fact-DD54BB5CDFE7D1B685941B18B045CE77" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock in connection with an employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2417-wk-Fact-4A86DF103D4A48EAEAFA1B414C937173" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">87,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2431-wk-Fact-0F4D7CF18094C9CAA7A41B414EA541F2" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2450-wk-Fact-F046F7D1B2FDF29D544C1B4150C93173" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2508-wk-Fact-8068B74826CC86883AF51B415651BBE9" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2562-wk-Fact-C9435700DCE242F658131B415B873FEB" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2620-wk-Fact-8574DCCAB33760CAAF361B4161119B3C" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e2713-wk-Fact-C9AC77901609FAFDC68749FB7FE5D60A" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e2733-wk-Fact-77253079152E3EFA3F29F1F3027805CB" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e2808-wk-Fact-840A9AD8098BBA93E19B1B4178E6AEF1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e2847-wk-Fact-4969158F0E69912D3B271B417C156672" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2869-wk-Fact-992BF07E05523E22775F1B417CDD3F10" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">46,680,482</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2883-wk-Fact-B3D7AC47D86B4237B6141B417ED253C6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2902-wk-Fact-5C829F92E9BBC746106D1B4180CA47F0" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,105,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2922-wk-Fact-553FDB3216B94EB4C5C61B4182B80C5F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e2941-wk-Fact-B6DEC385A530265E66E61B4184DD6E59" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">839,624</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e2961-wk-Fact-691D664B8A51FE4CD8571B4186DC063F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">267,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:37%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30, 2019</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3275-wk-Fact-DE284704413D389BA1851B19D3417F28" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">50,606,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3294-wk-Fact-6E59208ED4F481B513E31B19D4A7911A" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3313-wk-Fact-65AD2E93E2E2E50C7DB51B19D6264DBA" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,288,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3333-wk-Fact-08D86BFFC9D39EF8C8211B19D7942B8E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e3352-wk-Fact-60FB490EA442A4ECE8C11B19DA0F757F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">938,923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3372-wk-Fact-6297117AECFFB699AD17F1F302599BAE" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350,727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock related to equity offering</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3388-wk-Fact-0C21EF1E97EA6450AC061B423F35F83F" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,563,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3402-wk-Fact-2AA3F514B01FF3EE93501B4241279ACD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3421-wk-Fact-1D4E8EFF5B4E6BB094DD1B42434DB0F9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">224,538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3479-wk-Fact-2AF38D0DE550F0A4FAA31B42488BCBBC" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">224,545</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3500-wk-Fact-FF4C82D0D0E1C50BD4DB1B42529B1B71" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">311,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3514-wk-Fact-4EB1D5241EBDDE4A9F5A1B4254AED33C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3533-wk-Fact-64C612103B7B14458C841B4256D65596" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3591-wk-Fact-D269BB7B134B9A814AD71B425BDA7CE6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted stock vesting and issuance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3612-wk-Fact-33301F88B0B52396395C1B425C871EF9" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">171,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3626-wk-Fact-287A182BFF97EEBFE38D1B42DD99B755" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3703-wk-Fact-D5ED2E24C1F41CAA92541B4264DABD72" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock in connection with an employee stock purchase plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3724-wk-Fact-00B2811938667F86A02A1B4265813DBC" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">54,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3738-wk-Fact-A682050EC80E250A47461B42676F2B2E" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3757-wk-Fact-DD59F17FF34312FBDD081B42696D9C86" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3815-wk-Fact-0D438A32806944AF87A51B426EECD909" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3869-wk-Fact-580C074606ED46EF3FD21B42732BC90E" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3927-wk-Fact-3B8CDDAC5FD72CAC16E71B4278D6D427" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Receivable from investor</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e3981-wk-Fact-9CFC729CDBB8302F3F2B1B427DB9A231" name="ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4039-wk-Fact-AF5891CE855C10978F441B4283C120E4" name="ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e4132-wk-Fact-38374EE002E1A4ADC9A71B428C0ACF43" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e4152-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4227-wk-Fact-8C213C64FCD5F27C822E1B42947FB8C8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4265-wk-Fact-60C8A2FEC6BB13A2B6B51B4297F04A15" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4287-wk-Fact-0C6DE953182D3FB5D42CF1F302B177EB" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">58,707,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4301-wk-Fact-B4CFA9ECD87BB9326205F1F3026C52AF" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4320-wk-Fact-723357BBC475BC8FB7B0F1F30274C851" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,539,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4340-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e4359-wk-Fact-775FE7BD309380239C61F1F30252D4F9" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,052,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4379-wk-Fact-44B007521E6FA9A6DA45F1F302665AD4" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">488,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:37%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six months ended June 30, 2018</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(loss) income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4693-wk-Fact-B52A49A945D5A2B7EF741B1A216B5D8F" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">41,612,395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4712-wk-Fact-B3BD4C5988302572CD3B1B1A22EB7134" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4731-wk-Fact-64C811C07D8036CAEE681B1A24CC6FB4" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">966,534</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4751-wk-Fact-257F6AB2C29863DD60991B1A266D9920" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e4770-wk-Fact-651ACA98494C9E0916841B1A28431DC2" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">814,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4790-wk-Fact-3290174E3FFE0A0B85521B1A2A330532" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjustments to accumulated deficit and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e4839-wk-Fact-D34A7039BE4D876246F367CEBCF8B45B" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4884-wk-Fact-B35A5601B2A96DFDC5BC1B48C3396F71" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4903-wk-Fact-DD2029FE20F1543CBAAA1B48C3425C98" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock related to equity offering</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4919-wk-Fact-9AA8439E9C0CEF378BB41B43B09069E6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,600,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4933-wk-Fact-67FCF77161B37D0D43851B43B2A4B4E5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e4952-wk-Fact-D9D02507170399A4D2771B43B4EA38B3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,869</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5010-wk-Fact-949A466829519F52A3031B43BAFB6061" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5031-wk-Fact-65D4090F1022D55E79F11B44342E6B67" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">260,879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5045-wk-Fact-EAC1995EBC09C68F53AA1B443655FD99" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5064-wk-Fact-4D11BD6570E7348489BD1B443847CE14" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5122-wk-Fact-892AB0C86701C3F185DA1B443DF9BF01" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted stock vesting and issuance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5143-wk-Fact-B12F58A171E997DBBE511B4997653F64" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">119,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5234-wk-Fact-930636481820854F96821B4B3FF5E20A" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common stock in connection with an employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5255-wk-Fact-92C21C5D918F59B566671B466EF3D404" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">87,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5269-wk-Fact-01C16661EA725C8A38761B4670ECE00D" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5288-wk-Fact-442449AA52B3BE44188E1B4672E4AB1F" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5346-wk-Fact-28BD05A01E5A45E6650C1B4677DEFED4" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5400-wk-Fact-1DF7D64354D8FBAB37FF1B46B47466E3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5458-wk-Fact-4981140E8DDFAC41103F1B46B9F5632B" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e5551-wk-Fact-729CA6AD328395BF7B151B479ED95C81" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e5576-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e5646-wk-Fact-23E2570F0BB81A54358A1B47A655A53F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e5685-wk-Fact-F836E465100BC7EB5B5B1B47A997B182" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance, June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5708-wk-Fact-992BF07E05523E22775F1B417CDD3F10" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">46,680,482</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5722-wk-Fact-B3D7AC47D86B4237B6141B417ED253C6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5741-wk-Fact-5C829F92E9BBC746106D1B4180CA47F0" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,105,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5761-wk-Fact-553FDB3216B94EB4C5C61B4182B80C5F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d41036265e5780-wk-Fact-B6DEC385A530265E66E61B4184DD6E59" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">839,624</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d41036265e5800-wk-Fact-691D664B8A51FE4CD8571B4186DC063F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">267,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying unaudited notes.</span></div><div><a id="s9F0ACD959F425B16B08B628CBCB2BC16"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics,&#160;Inc.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows (unaudited)                                                   In thousands</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e653-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e673-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e738-wk-Fact-4D5A35F392959832F9F6F1F30268169E" name="us-gaap:Depreciation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e757-wk-Fact-4B6E3EC96D997CFD7BC3F1F302A2434D" name="us-gaap:Depreciation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation of deferred and contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e782-wk-Fact-9DF764EDB975C759BC51F1F302A638D5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e800-wk-Fact-6FE5F96CB3CAEACA25B3F1F302781BDB" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain on MRI investment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e825-wk-Fact-DCF4AEC67B9A4547A95F59699303CB29" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e845-wk-Fact-11A7B1FE54DDA2AA2D08596992FF36A8" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e870-wk-Fact-A346CBC4C487FD020F8BF1F302A07135" name="us-gaap:PaidInKindInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e889-wk-Fact-51552986D574BC843CBBF1F3025132B9" name="us-gaap:PaidInKindInterest" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on disposal of asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e914-wk-Fact-B85411157DD0ADBBD1611FFDC3FB1669" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e933-wk-Fact-A6165D0D86AAEE376282F1F3029ABF84" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of discounts on investments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e959-wk-Fact-2DE4B0B9F8F3A8FE910FF1F3027F9795" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e979-wk-Fact-347840FD9EC3A9E7B4F4F1F3024D861D" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1005-wk-Fact-68654996ECF6CD80BD37F1F3024FD7C9" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1024-wk-Fact-947753E465369109B5F2F1F302605E05" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1049-wk-Fact-FEE24CF4ADA147E0D635F1F3025C8D58" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1068-wk-Fact-9F622E130110B31648B8F1F30255F1C5" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized foreign currency transaction losses (gains), net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1093-wk-Fact-AD37D371D358F260F1E2F1F302A28595" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1112-wk-Fact-85BC70F60CF5CAD3DA17F1F302B2F1F8" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">764</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1182-wk-Fact-9F906500C095D79CE83AF1F30258C35A" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1202-wk-Fact-FD2FE85C2076EC439BAEF1F3028289D0" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1228-wk-Fact-33AFCEF322F26FAACC2FF1F3024F82EB" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1248-wk-Fact-132293EFEAF8BCA04AE0F1F30266C2ED" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade receivables, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1273-wk-Fact-9DB94FC51483B472D48AF1F3024C48D6" name="us-gaap:IncreaseDecreaseInReceivables" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,702</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1293-wk-Fact-70AEA9AF64940CD4111BF1F3029DA5DF" name="us-gaap:IncreaseDecreaseInReceivables" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deposits and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1319-wk-Fact-11DB46CD52378B9E7BF8F1F3026D7152" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1339-wk-Fact-4E962F6D86A47152F809F1F3025BFEB0" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1365-wk-Fact-65C583EC4EC83A4FE731F1F302765F2E" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1385-wk-Fact-85ADC1A4271CA3B0542DF1F302A486DD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1410-wk-Fact-93E1C0851586805E9873F1F3026CAE32" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1429-wk-Fact-E39AB56CE1F9E6662FCBF1F302B14149" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1455-wk-Fact-FB7D121E236C88B5DA2BF1F30278E1BD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,511</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1474-wk-Fact-AFE3BBFEC3ACD95B9440F1F30282FB46" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1499-wk-Fact-EF15CFD4D4E15DD963CDF1F302526567" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1519-wk-Fact-4988388ABC5E447C46F1F1F302620B79" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of fixed assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1589-wk-Fact-D08B2FE9EF75A5CCB858F1F3026694C2" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1609-wk-Fact-683E0648185C0A47D045F1F302985DCB" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of equity investment in MRI</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1637-wk-Fact-E11E5CE78D9BC4D3BC2041394022E253" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1657-wk-Fact-60F4F8957BAC3817CFBE413941870C17" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1682-wk-Fact-345E83987B677215A261F1F3029566FA" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">226,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1702-wk-Fact-268D61745F86D0C05B67F1F30260B27B" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sale and redemption of marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1728-wk-Fact-A6C4C41417C51D17498EF1F3028126BF" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1747-wk-Fact-09CD7AD14131D8519DC7F1F3027D233B" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition of product rights and licenses</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1774-wk-Fact-31ABA908B2C688A9B3A11FFDC41D5827" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1794-wk-Fact-58A29E502CCDA1AB272BF1F3024DD390" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by investing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1819-wk-Fact-492932613CF79C25D822F1F30266D687" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">188,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1839-wk-Fact-7D1417F1060C83CA1B53F1F302804969" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from exercise of options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1908-wk-Fact-4D00704526A0A5AD7F31F1F302B1FF36" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1927-wk-Fact-4B2A5148D5813E9E0885F1F302A8373C" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net proceeds from public offerings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1953-wk-Fact-229BFCAE9FB4DCC75039F1F3026413C9" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">224,545</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e1972-wk-Fact-648FF0DF1B4C383D5655F1F302A335EB" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repayment of senior secured term loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e1997-wk-Fact-8D31B37031BB402ADD1E4137A8F72D54" name="us-gaap:RepaymentsOfDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2017-wk-Fact-E256E0F790010F9F665D4137A9204479" name="us-gaap:RepaymentsOfDebt" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from shares issued under employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2042-wk-Fact-1AA6B32B30F3AD533C081FFDC4160BFD" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2061-wk-Fact-F1F51D6ED4864B1BF689F1F302ABE64E" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2086-wk-Fact-638344EE7D57D9C774D7F1F30277E926" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">228,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2105-wk-Fact-75868A6F946ACCA5681EF1F3027E4F78" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange rate changes on cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e2130-wk-Fact-1D143CC4E7F9338958FDF1F3024C7C0F" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e2150-wk-Fact-7DC6C2270A3F3889DC5FF1F302AD09DA" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">990</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (decrease) increase in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e2176-wk-Fact-5B4F46AA88C596AECC33F1F3029B24E7" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2196-wk-Fact-0FD2D190878980C3F03DF1F302815E86" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111,996</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2221-wk-Fact-191CBC2919F5A5F84995F1F3025A10B1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">169,498</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2240-wk-Fact-8107EB4AD44FC89B9E5FF1F30281CC1B" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111,792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, end of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2270-wk-Fact-B14D2E1E0EB06795F714F1F30267E1D1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2289-wk-Fact-358CADCAB752154B6753F1F3027C2D50" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">223,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of cash information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2358-wk-Fact-B87556F0461FB8385527F1F30278014C" name="us-gaap:InterestPaidNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2377-wk-Fact-1011D7D78E5319B087FEF1F302B00875" name="us-gaap:InterestPaidNet" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2402-wk-Fact-A2E446E0533A60B9C3A5F1F3024C8EBF" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2421-wk-Fact-7864183FA1CA1ED4D55BF1F302A96E35" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosure of non-cash investing and financing activity</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in unrealized gain (loss) on marketable securities, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2493-wk-Fact-F743F8F4B049B007FE3DF1F302883FD9" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41028013e2512-wk-Fact-8E16FD2302071E7BA8CFF1F3028D6542" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2538-wk-Fact-4BC8F70D456635819552F1F302588A33" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,643</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2556-wk-Fact-3AD3C8DBFEE1CB5419B4F1F3028248C7" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition of product rights and licenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2581-wk-Fact-7FAF147B6C01754352ACF1F3029FF4C9" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41028013e2600-wk-Fact-63FF5D560FE029F45C351FFDC40DB4F9" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">See accompanying unaudited notes.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAE8C7469D3DA55D88A8AABFAD963712C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics,&#160;Inc.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">In thousands (except per share data unless otherwise noted)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC03D76D685DF5AC984E3FC9346E16922"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:NatureOfOperations" id="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-0-wk-Fact-85D408B9A840A523989AF1F3029B806B" continuedAt="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-1" continuedAt="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221; or &#8220;PTC&#8221;) is a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company&#8217;s ability to globally commercialize products is the foundation that drives its continued investment in a robust pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029061e371-wk-Fact-36B76295BC000EA9E64FF1F3029C66FA" name="ptct:NumberOfProducts" contextRef="FI2019Q2" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> products, Translarna</span><span style="font-family:inherit;font-size:8pt;">&#8482; </span><span style="font-family:inherit;font-size:10pt;">(ataluren) and Emflaza&#8482; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna received marketing authorization from the European Commission in August 2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged five years and older in the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029061e379-wk-Fact-8B5A034E4E1D8CD2FD3BF1F302990A3D" name="ptct:NumberOfStatesInEuropeanEconomicArea" contextRef="D2014Q3Aug1-Aug31" unitRef="member_state" decimals="INF" scale="0" format="ixt:numdotdecimal">31</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> member states of the European Economic Area, or EEA. In July 2018, the European Commission approved a label-extension request to the marketing authorization for Translarna in the EEA to include patients from two to up to five years of age. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a pipeline of gene therapy product candidates, including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, or AADC deficiency.  The Company is preparing a biologics license application, or BLA, for PTC-AADC for the treatment of AADC deficiency in the United States, which it anticipates submitting to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2019, with anticipated commercial launch in the United States in 2020, subject to approval. The Company is also preparing a marketing authorization application, or MAA, for PTC-AADC for the treatment of AADC deficiency in the European Union, or EU, for submission to the European Medicines Agency, or EMA, which will follow its BLA submission to the FDA. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company holds the rights for the commercialization of Tegsedi&#8482; (inotersen) and Waylivra&#8482; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean. Tegsedi has received marketing authorization in the U.S., EU and Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis. The Company filed for marketing authorization with ANVISA, the Brazilian health regulatory authority, which granted priority review. It expects approval in Brazil by the end of 2019. Waylivra has received conditional marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has a spinal muscular atrophy ("SMA") collaboration with F. Hoffman-La Roche&#160;Ltd and Hoffman-La Roche&#160;Inc., referred to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation. Currently, its collaboration has two pivotal clinical trials ongoing to evaluate the safety and effectiveness of risdiplam (RG7916, RO7034067), the lead compound in the SMA program. Roche is preparing an NDA and a MAA for risdiplam for the treatment of SMA in the United States and the EU, respectively, which Roche anticipates submitting to the FDA in the second half of 2019 and the EMA in the first half of 2020. In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The marketing authorization in the EEA was last renewed in July 2019 and is effective, unless extended, through August 5, 2020. The renewal was based on the Company&#8217;s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2014, the Company initiated reimbursed early access programs, or EAP programs, for Translarna for nmDMD patients in selected territories in the EEA and recorded its first sales of Translarna in the third quarter of 2014 pursuant to an EAP program. In December 2014, the Company recorded its first commercial sales in Germany. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, Translarna was available in over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029061e405-wk-Fact-050BF57D260B9FBFAAE7F1F3029BEA4D" name="ptct:NumberOfCountries" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_TranslarnaMember" unitRef="country" decimals="0" scale="0" format="ixt:numdotdecimal">40</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> countries on a commercial basis or pursuant to an EAP program. The Company expects to expand its commercial </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-2" continuedAt="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">activities across the EEA pursuant to the marketing authorization granted by the EMA throughout 2019 and future years, subject to continued renewal of its marketing authorization following annual EMA reassessments and successful completion of pricing and reimbursement negotiations. Concurrently, the Company plans to continue to pursue EAP programs in select countries where those mechanisms exist, both within the EEA and in other countries that will reference the marketing authorization in the EEA.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied PTC&#8217;s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#8217; muscles. The Company intends to follow the FDA&#8217;s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. The Company expects that a potential re-submission of an NDA could occur in 2020. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emflaza was initially approved in the United States for the treatment of DMD in patients five years and older. In June 2019, the FDA approved the Company's label expansion request for Emflaza for patients two to five years of age. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 20, 2017, the Company completed its acquisition of all rights to Emflaza, or the Transaction.  Emflaza is approved in the United States for the treatment of DMD in patients two years and older. The Transaction was completed pursuant to an asset purchase agreement, dated March 15, 2017, as amended on April 20, 2017, (the "Asset Purchase Agreement"), by and between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon. The Transaction was accounted for as an asset acquisition. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. The Company assumed certain liabilities and obligations in the Transaction arising out of, or relating to, the assets acquired in the Transaction. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the closing of the Transaction, the Company paid to Marathon total upfront consideration comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029061e425-wk-Fact-1C9191E6662D64283FA1F1F3029BC4F7" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, funded through cash on hand, and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029061e429-wk-Fact-844B192D14DD5E6A3A63F1F3029F04C5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,683,598</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. The number of shares of common stock issued at closing was determined by dividing </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029061e433-wk-Fact-A6C688A1C785E52292EDF1F3029B6BAE" name="ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" contextRef="I2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> by the volume-weighted average price per share of the Company&#8217;s common stock on the Nasdaq Stock Market for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41029061e437-wk-Fact-8A0897F7040E4AF687E2F1F3029DC2C1" name="ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" contextRef="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" format="ixt-sec:durday">15</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> trading-day period ending on the third trading day immediately preceding the closing. Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza, up to a specified aggregate maximum amount over the expected commercial life of the asset, and a single </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029061e441-wk-Fact-49F242A97E8AF0D5E000F1F3029E5D6C" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="I2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> sales-based milestone, in each case subject to the terms and conditions of the Asset Purchase Agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the &#8220;Merger Agreement&#8221;), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC (the "Merger"). </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029061e451-wk-Fact-3E12ECCB403DDF61B500F1F3029EDEAD" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029061e455-wk-Fact-A74CB65A3FF85F32B46BF1F3029DB95A" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,500,907</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock (the &#8220;Closing Stock Consideration&#8221;). The Closing Stock Consideration was determined by dividing </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029061e459-wk-Fact-122FBE20AACE25D81D6CF1F3029AB218" name="ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" contextRef="I2018Q3Aug23_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> by the volume-weighted average price per share of the Company&#8217;s common stock on the Nasdaq Global Select Market for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41029061e463-wk-Fact-55E6614AFBD012512D83F1F3029B98D6" name="ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" contextRef="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" format="ixt-sec:durday">10</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders may become entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products. Under the Merger Agreement, the Company is required to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029061e467-wk-Fact-ABFF01D1B6E4EC80C9E5F1F3029CA22B" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="I2018Q3Aug23_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029061e478-wk-Fact-B397C6E034C3C6FC2179F1F3029B51E5" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,052.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has financed its operations to date primarily through the private offering in August&#160;2015 of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029061e482-wk-Fact-5C029B069446D5431F6AF1F3029E5B6F" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2022 (see Note 10), public offerings of common stock in February 2014, October 2014, April 2018 and January 2019, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#8217;s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Company&#160;expects&#160;that&#160;cash&#160;flows&#160;from&#160;the&#160;sales&#160;of&#160;its&#160;products,&#160;together&#160;with&#160;the&#160;Company&#8217;s&#160;cash, cash equivalents and marketable securities,&#160;will&#160;be&#160;sufficient&#160;to&#160;fund&#160;its&#160;operations&#160;for&#160;at&#160;least&#160;the&#160;next&#160;twelve&#160;months.</span></div></ix:continuation><div><a id="s495214F8A9F15D03AB7A96F36066D6A1"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="TextSelection-64AE3985200CD2402215F1F302C04CC5-0-wk-Fact-DFE8731C3AE4CB018BF4F1F302AC2DAB" continuedAt="TextSelection-64AE3985200CD2402215F1F302C04CC5-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of significant accounting policies</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-64AE3985200CD2402215F1F302C04CC5-1" continuedAt="TextSelection-64AE3985200CD2402215F1F302C04CC5-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company&#8217;s audited financial statements as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> included in the Company&#8217;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (the "SEC") on March 1, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> (the "</span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Form&#160;10-K"). Additional significant accounting policies adopted during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are discussed in further detail below.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-51C051BA0B8D6554792AF1F302BF1078-0-wk-Fact-60A18E220A6F05084D0EF1F302AA9B60" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of presentation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying financial information as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and notes thereto included in the </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Form&#160;10-K.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the unaudited financial information as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or for any other interim period or for any other future year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:UseOfEstimates" id="TextSelection-E0EB789328CB83010B79F1F302C06EC5-0-wk-Fact-DEE75BE5FEE3FDE06F17F1F302ACE3B9" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#8217;s research and development expenses, stock-based compensation, valuation procedures for the convertible notes, allowance for doubtful accounts, inventory, acquired intangible assets, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="ptct:InventoriesAndCostOfProductSalesPolicyTextBlock" id="TextSelection-E762E6AF56057130AE8DF1F302C04E3C-0-wk-Fact-DAC02BD9798564A51075F1F302AEE65B" continuedAt="TextSelection-E762E6AF56057130AE8DF1F302C04E3C-1" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory and cost of product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Translarna and Emflaza product which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-83C14AF056A594345901F1F302C0B274-0-wk-Fact-2DFAE281878537B9F126F1F302ABE801" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e587-wk-Fact-6C090821B8D8BF4DA832F1F3028E611D" name="us-gaap:InventoryRawMaterials" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e606-wk-Fact-DEB7AA0E7AF4DEAD45F9F1F3028E3C41" name="us-gaap:InventoryRawMaterials" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e626-wk-Fact-3C1C43A24808654375CDF1F302864215" name="us-gaap:InventoryWorkInProcess" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e645-wk-Fact-0DF763FF845C61866711F1F302861986" name="us-gaap:InventoryWorkInProcess" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e670-wk-Fact-0707B742E51C08CCA361F1F30287AC0A" name="us-gaap:InventoryFinishedGoods" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e689-wk-Fact-99BBE7CCA7EE0AF30D23F1F3028B6883" name="us-gaap:InventoryFinishedGoods" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e719-wk-Fact-0CC15B0857EF6B135B85F1F3025FC547" name="us-gaap:InventoryNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e738-wk-Fact-D68658CB72697A4B3826F1F302618800" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value.  No write downs were recorded for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.  Additionally, though the Company&#8217;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, these amounts were immaterial.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-64AE3985200CD2402215F1F302C04CC5-2" continuedAt="TextSelection-64AE3985200CD2402215F1F302C04CC5-3"><ix:continuation id="TextSelection-E762E6AF56057130AE8DF1F302C04E3C-1" continuedAt="TextSelection-E762E6AF56057130AE8DF1F302C04E3C-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, including personnel costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-8FE2B9745919E5329B59F1F302BF4774-0-wk-Fact-217C4858C26B67496596F1F302A58E04" continuedAt="TextSelection-8FE2B9745919E5329B59F1F302BF4774-1" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><ix:continuation id="TextSelection-E762E6AF56057130AE8DF1F302C04E3C-2"></ix:continuation>Revenue recognition</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-9, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;.  ASU No. 2014-9 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-15, Revenue Recognition-Products (Topic 605) and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net product revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#8217;s performance obligations are to provide Translarna or Emflaza based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#8217;s customer obtains control of either Translarna or Emflaza, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to either product sales of Translarna or Emflaza.  In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. Historically, returns of Translarna and Emflaza are immaterial to the financial statements, except as related to labeling changes and changes in specialty pharmacies. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of ASC Topic 606 on January 1, 2018, the Company elected the following practical expedients:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying ASC Topic 606 to each individual contract.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant Financing Component - the Company expects the period between when it transfers a promised good to a customer and when the customer pays for the good or service to be one year or less. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immaterial Performance Obligations - the Company disregards promises deemed to be immaterial in the context of the contract. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and Handling Activities - the Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-64AE3985200CD2402215F1F302C04CC5-3" continuedAt="TextSelection-64AE3985200CD2402215F1F302C04CC5-4"><ix:continuation id="TextSelection-8FE2B9745919E5329B59F1F302BF4774-1"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#8220;Collaborative Arrangements&#8221; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="TextSelection-031E13D8A6E7561A26D0F1F302BFBE7F-0-wk-Fact-782304A5F1A048397436F1F302A91496" continuedAt="TextSelection-031E13D8A6E7561A26D0F1F302BFBE7F-1" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Allowance for doubtful accounts</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-031E13D8A6E7561A26D0F1F302BFBE7F-1">The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#8217;s financial condition and current economic trends.</ix:continuation> The allowance for doubtful accounts was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029076e897-wk-Fact-F2F87FC9EFB6B62CAE92F1F302A4BA7B" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029076e905-wk-Fact-13D19EFCD029F9977F1CF1F302A8FC11" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Bad debt expense was immaterial for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="TextSelection-B069FDD9861C25EB5111F1F302C00B7D-0-wk-Fact-C7FC77ACE0BD72A8F018F1F302A4F414" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets consist of in-process research and development ("IPR&amp;D"). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D acquired in a business combination. The Company utilizes the "income method&#8221;, and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&amp;D intangible assets that are determined to have had a drop in their fair value are adjusted downward and an impairment is recognized in the statement of operations. These assets are tested at least annually or sooner when a triggering event occurs that could indicate a potential impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="TextSelection-BBF82DABBC768E8262C7F1F302C0E2A4-0-wk-Fact-24596E15D7B070E9F617F1F302ACADFD" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-156E5A5FD85FCEB9D010F1F302BF5F40-0-wk-Fact-A5632AF2D3018021ED98F1F302AC47DD" continuedAt="TextSelection-156E5A5FD85FCEB9D010F1F302BF5F40-1" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-64AE3985200CD2402215F1F302C04CC5-4" continuedAt="TextSelection-64AE3985200CD2402215F1F302C04CC5-5"><ix:continuation id="TextSelection-156E5A5FD85FCEB9D010F1F302BF5F40-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded a deferred tax liability in conjunction with the Merger of $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41029076e984-wk-Fact-C72FF2E1C4693850BCB249EFDACCC540" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">122.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the tax basis difference in the IPR&amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, &#8220;Leases (Topic 842)&#8221; along with other amendments issued in 2017 and 2018. Topic 842 supersedes the lease accounting requirements in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Codification Topic 840, Leases</span><span style="font-family:inherit;font-size:10pt;">&#160;(Topic 840). Topic 842 requires organizations to recognize leased assets and liabilities on the balance sheet. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the standard, operating leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#8217;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease term for all of the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the "Impact of recently adopted accounting pronouncements" section within this Note below and Note 3 Leases for additional information.  The information presented for periods prior to January 1, 2019 has not been adjusted and is reported under Topic 840. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-9B8988F69F45B8936899F1F302BF0DAD-0-wk-Fact-8A24891BF337990E2CDFF1F302A5295D" continuedAt="TextSelection-9B8988F69F45B8936899F1F302BF0DAD-1" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently issued accounting standards</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#8220;Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This standard requires financial assets measured at amortized cost basis to be presented at the </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9B8988F69F45B8936899F1F302BF0DAD-1" continuedAt="TextSelection-9B8988F69F45B8936899F1F302BF0DAD-2"><ix:continuation id="TextSelection-64AE3985200CD2402215F1F302C04CC5-5" continuedAt="TextSelection-64AE3985200CD2402215F1F302C04CC5-6"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. The Company expects to adopt this guidance when effective and is assessing what effect the adoption of ASU 2016-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;. ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No. 2018-18 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of recently adopted accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-2, &#8220;Leases (Topic 842)&#8221;. This standard requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018, with early adoption permitted.  Additionally, in March 2019, the FASB issued ASU 2019-01,"Leases (Topic 842): Codification Improvements&#8221;.  ASU 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. The Company adopted the new guidance on January 1, 2019 using the modified retrospective method. Prior period results were not adjusted and continue to be presented under Topic 840 based on the accounting standards originally in effect for such periods. As part of the adoption, the Company has elected to utilize practical expedients including the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to: 1) carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements, 2) not separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component (the Company elected to apply this practical expedient to all underlying asset classes), 3) not apply the recognition requirements in ASC 842 to short-term leases, and 4) not record a right of use asset or right of use liability for leases with an asset or liability balance that would be considered immaterial. Upon adoption, the Company recorded an operating lease liability with a corresponding operating lease ROU asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029076e1055-wk-Fact-1A463F2579630F907F3AF1F302AD4E5C" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The adoption did not have a material impact on the consolidated results of operations, stockholder's equity, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. As the Company is not a lessor, the aspects of the new guidance pertaining to lessors was not applicable for the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, "Income Statement &#8212; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income". This standard permits the reclassification of tax effects stranded in other comprehensive income as a result of tax reform to retained earnings related to the change in federal </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9B8988F69F45B8936899F1F302BF0DAD-2"><ix:continuation id="TextSelection-64AE3985200CD2402215F1F302C04CC5-6"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">tax rate in addition to other stranded effects that relate to the 2017 Tax Act but do not directly relate to the change in the federal rate. ASU 2018-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance. The Company adopted this guidance on January 1, 2019 and elected not to reclassify the tax effects in other comprehensive income related to the 2017 Tax Act, as these amounts were immaterial. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "Compensation &#8212; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting". This standard expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in the entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The ASU retains the existing cost attribution guidance, which requires entities to recognize compensation cost for nonemployee awards in the same period and in the same manner they would if they paid cash for the goods or services, but it moves the guidance to ASC 718. ASU 2018-07 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance.  The Company adopted this guidance on January 1, 2019. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;.  ASU No. 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-15, Revenue Recognition-Products and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  On January 1, 2018, the Company adopted ASC Topic 606 using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The Company calculated a one-time transition adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41029076e1083-wk-Fact-30C03E199A909287D9BEF1F302AE387B" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded on January 1, 2018 to deferred revenue and accumulated deficit, related to the product sales of Emflaza. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January&#160;2016, the FASB issued ASU No.&#160;2016-01, &#8220;Financial Instruments &#8212; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&#8221;. This standard enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The new guidance affects all reporting organizations (whether public or private) that hold financial assets or owe financial liabilities. The Company adopted the guidance on January&#160;1, 2018.  In March 2018, the FASB issued ASU 2018-04, "Investments - Debt Securities (Topic 320) and Regulated Operations (Topic 980): Amendments to SEC Paragraphs Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 117 and SEC Release No. 33-9273 (SEC Update)". This standard supersedes SEC paragraphs in ASC 320, Investments- Debt Securities, as a result of the issuance of SAB 117 and also updates the Codification for a 2011 SEC release and is effective when a registrant adopts ASU 2016-01, which in the case of the Company was on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221;. This standard clarifies the presentation of certain specific cash flow issues in the Statement of Cash Flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-16, &#8220;Intra-Entity Transfers of Assets Other Than Inventory&#8221;.  ASU 2016-16 requires companies to account for the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) when the transfer occurs. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows (Topic 230): Restricted Cash&#8221;. This standard requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows and no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In May 2017, the FASB issued ASU No. 2017-09, "Stock Compensation (Topic 718): Scope of Modification Accounting". This standard clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as a modification, with entities applying the modification accounting guidance if the value, vesting conditions or classification of the award changes. In addition to all disclosures about modifications that are required under the current guidance, entities will be also required to disclose that compensation expense has not changed if applicable.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Company adopted the guidance on January&#160;1, 2018.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4E569F0CFBB35BEDA4B45BFEF7D05B17"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-768A470229B742CDECBCF1F302C16408-0-wk-Fact-490EA005EB25E3A75E86F1F3028314F7" continuedAt="TextSelection-768A470229B742CDECBCF1F302C16408-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-768A470229B742CDECBCF1F302C16408-1" continuedAt="TextSelection-768A470229B742CDECBCF1F302C16408-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases office space in South Plainfield, New Jersey for its principal office under </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e365-wk-Fact-672E7AAEBEDC5767831549F2E7F42F73" name="ptct:NumberOfOperatingLeases" contextRef="FI2019Q2" unitRef="operating_lease" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> noncancelable operating leases through May 2022 and August 2024, in addition to office space in various countries for international employees primarily through workspace providers. The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company&#8217;s operating leases have remaining lease terms ranging from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41038161e373-wk-Fact-9797109064D24E16C35AF1F302843230" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:duryear">0.4</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41038161e377-wk-Fact-C93CFEE02B51E766EC7AF1F30287CAFA" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">7.0</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years and certain of the leases include renewal options to extend the lease for up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41038161e381-wk-Fact-FF236EA5A764B0E92F2EF1F3028B9BFA" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2019Q2" format="ixt-sec:duryear">10</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-E585102F5AF4FB08BE10F1F302C08C7B-0-wk-Fact-831558A37D469C8C0DA0F1F3028A7ED1" continuedAt="TextSelection-6E4D4C0B944F5D326E92F1F302C099E8-0" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease expense were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Lease Cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e502-wk-Fact-E1B6CEE89BFE9C9D4927F1F3025B13E5" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e521-wk-Fact-D43D1C5BCFE72A67BE4C1B53029FF5FE" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e536-wk-Fact-419858A050455461E7C7F1F30262D3CF" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e555-wk-Fact-ABFF67B85F22CC8585351B53048EF693" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e575-wk-Fact-E824D94524D9E18F9DC7F1F30257CF9F" name="us-gaap:ShortTermLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e594-wk-Fact-888A6A529582EBA4CE471B53058893A3" name="us-gaap:ShortTermLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e619-wk-Fact-2B05B310D09A6CC5FD08F1F3025757BC" name="us-gaap:LeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e638-wk-Fact-E2D11C044DC91A26E9901B5306827084" name="us-gaap:LeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost is a component of operating expenses on the consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:35%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e720-wk-Fact-819E3199165BB975B66DF1F302A1BD35" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities- current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e761-wk-Fact-30E21B5807277A54D1F9F1F3029C16FA" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities- noncurrent</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e776-wk-Fact-26546B3A611373897A94F1F3029C790C" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e801-wk-Fact-7505CD9CE57621FE110EF1F30253374D" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset is a component of deposits and other assets on the consolidated balance sheet. The current portion of operating lease liability is a component of other current liabilities on the consolidated balance sheet. The long term portion of operating lease liabilities is a component of other long term liabilities on the consolidated balance sheet.</span></div><ix:continuation id="TextSelection-6E4D4C0B944F5D326E92F1F302C099E8-0"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental lease term and discount rate information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:74%;"></td><td style="width:25%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease terms - operating leases (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41038161e875-wk-Fact-BB5AFA09912A98512BC1F1F302516632" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q2" format="ixt-sec:duryear">4.51</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e890-wk-Fact-86F3FE55A2CC9080F7A0F1F302525377" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q2" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">7.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e971-wk-Fact-04BBFE4D6A49ABC85BF7F1F302831AEA" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,508</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1012-wk-Fact-4BC8F70D456635819552F1F302588A33" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,643</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-CF3048E36A11A0C22627F1F302C12801-0-wk-Fact-610BA8AC725102D371FCF1F302840353" continuedAt="TextSelection-CF3048E36A11A0C22627F1F302C12801-1" escape="true"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable leases as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-768A470229B742CDECBCF1F302C16408-2"><ix:continuation id="TextSelection-CF3048E36A11A0C22627F1F302C12801-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (Excludes the six months ended June 30, 2019)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1079-wk-Fact-BAA1FD66C6EBBBF7B04FF1F302541304" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1094-wk-Fact-B3CB8D648B69B30A4FCDF1F30254C3BF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1114-wk-Fact-8E1C3062EAAC64DEFD80F1F302565546" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1134-wk-Fact-A11A5B31FB75EE6DC017F1F3024FAF40" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1154-wk-Fact-7FCC09E0C656B79D13EEF1F302514139" name="ptct:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1174-wk-Fact-254C74FB65B01959AC77F1F3025691C5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1194-wk-Fact-78CAD2C2A9571FC382E3F1F302524039" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41038161e1219-wk-Fact-7505CD9CE57621FE110EF1F30253374D" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had no operating leases that had not yet commenced.</span></div></ix:continuation><div><a id="s32AA6DE348895C598FC8ADEE43A1CB23"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-EA69EAA470918D93D051F1F302C10888-0-wk-Fact-80C271D12092DF2E5CA4F1F302ACCA9E" continuedAt="TextSelection-EA69EAA470918D93D051F1F302C10888-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of financial instruments and marketable securities</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-EA69EAA470918D93D051F1F302C10888-1" continuedAt="TextSelection-EA69EAA470918D93D051F1F302C10888-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company follows the fair value measurement rules, which provide&#160;&#160;&#160;&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3&#8212;Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents and investments are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e397-wk-Fact-86BF833DF32428C4785B1B590EA6F5CE" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" contextRef="I2019Q2May_invest_InvestmentAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of shares of MRI Interventions, Inc.'s ("MRI") common stock, at a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e401-wk-Fact-DC1211D57374F9C38CB962CD897947DE" name="us-gaap:SharePrice" contextRef="I2019Q2May_invest_InvestmentAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.10</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, in connection with a securities purchase agreement that the Company entered into with MRI, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded an unrealized gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e413-wk-Fact-5F35478A56DAA77CDD111B613D382440" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="FD2019Q2QTD_invest_InvestmentAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which is a component of other (expense) income, net within the consolidated statement of operations. The fair value of the equity investment was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e418-wk-Fact-F8718F8122F3077133901B6588296351" name="ptct:InvestmentInMRI" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company classifies its equity investment in MRI as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews its investments on a periodic basis for other-than-temporary impairments. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may have a significant adverse effect on the fair value of the investment.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EA69EAA470918D93D051F1F302C10888-2" continuedAt="TextSelection-EA69EAA470918D93D051F1F302C10888-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-42FAF8A820E462FE5B36F1F302C12A79-0-wk-Fact-24066067B116C3B7812FF1F302B2888A" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents the fair value using the hierarchy described above for the Company&#8217;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e665-wk-Fact-8699DBB196D2DD3937C9F1F3025B66EA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">227,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e684-wk-Fact-AC1093E77CC0E15DB88FF1F3025E79D8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e704-wk-Fact-53B8E868B36D9C682B21F1F3025C69EA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">227,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e723-wk-Fact-DC20B9210D5BFA62A444F1F3025795E8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity investment in MRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e748-wk-Fact-363282EEA6460533946D1B652BCBC39B" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e767-wk-Fact-CDA2D3114C0581F874771B652BC466C4" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock appreciation rights liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e831-wk-Fact-F2EC4DACACCB8C5BDEE1F1F3025AB2B7" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e850-wk-Fact-23179008CB67A48AE387F1F3025FECC2" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e870-wk-Fact-AE1459069B5E6B73D535F1F302553A14" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e889-wk-Fact-D14A218601E355E15015F1F3025D7530" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e914-wk-Fact-5D79F64D173BE63FB924F1F30274AEC6" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e933-wk-Fact-8F01E68F0B243F4B2A42F1F3025A4083" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e953-wk-Fact-29E39A297B299B97429EF1F302631C32" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e972-wk-Fact-CA50ACACFC6F769501E5F1F30260863D" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e997-wk-Fact-413E6C4171E230754BF3F1F3026D4E55" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">277,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1015-wk-Fact-613B2155AECEFF0EFCEEF1F30260F8E6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1034-wk-Fact-750790629C110B1C96C3F1F302613518" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1052-wk-Fact-05F44F91286724A0A24AF1F3025A3892" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">277,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- net sales milestones and royalties </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1077-wk-Fact-C189191DC8966AB748EAF1F302624FCB" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1095-wk-Fact-CB45996BF6A35A52DB8AF1F3025BFB54" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1114-wk-Fact-2176518BB4DD73564198F1F30259014F" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1132-wk-Fact-AD3B264075056290231AF1F30255955B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">markets&#160;for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">identical&#160;assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1388-wk-Fact-248D23A2E5CAEEA24F2BF1F302657232" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1406-wk-Fact-55F2CC798AF3CEF72371F1F302550C3C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1425-wk-Fact-9850912D8794DC40832FF1F30264D637" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1443-wk-Fact-BF85BA749314D5B3DFABF1F30257C34E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock appreciation rights liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1468-wk-Fact-FA67DFD6D9AEA01961A8F1F3026EE88D" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1486-wk-Fact-630E52DE13C9848AF166F1F3026487AB" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1505-wk-Fact-37FAE824D07EB60921DEF1F3026227FD" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1523-wk-Fact-CD9CFB4E8A5EFCF73166F1F302541E07" name="ptct:StockAppreciationRightsLiabilityOutstanding" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1548-wk-Fact-B649910AB8A80B287F3EF1F3025BEA58" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1566-wk-Fact-722EF95B389B17ABA97CF1F30268E618" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1585-wk-Fact-86B7E02F35818A322F93F1F302692FE2" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1603-wk-Fact-660B0DF93FB8F4209826F1F302660FFD" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1628-wk-Fact-18304E986240F272766BF1F30259B407" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">257,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1646-wk-Fact-54F111D709C1A131666AF1F30266B04C" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1665-wk-Fact-9C5FBB86F1A3FC1E24D7F1F302692AA2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1683-wk-Fact-EEC3F9BF1622D9FDE290F1F302547168" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">257,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- net sales milestones and royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1708-wk-Fact-2E35180B71C6D3A7BA74F1F3026157C0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1726-wk-Fact-DDB8CAB9306AE588F434F1F302602B77" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1745-wk-Fact-30B90BB757D281800529F1F302655B00" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e1763-wk-Fact-7B207D88CE9B3ED6BAEBF1F302638856" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;"> transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="TextSelection-23E3B6A64ABB8FE1A30DF1F302C10A9B-0-wk-Fact-F2D8FB090E3ED11C1806F1F3029C12A0" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of marketable securities accounted for as available-for-sale securities at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2110-wk-Fact-282C6C1BB25BF5625634F1F302B32408" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2129-wk-Fact-34CB8357D99D297BF26EF1F30277E2C5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2149-wk-Fact-5B1DDD33356986E76248F1F30298B401" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2168-wk-Fact-B69915307E0D16C152D5F1F3027FDC1F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2188-wk-Fact-4433E2D7C478BCB46C3FF1F3027BFDC3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2207-wk-Fact-F20AE60B16225D6C2558F1F3027E5E42" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e2226-wk-Fact-031010602E18CB131275F1F3029D565D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2247-wk-Fact-9FD716E2F624883AB66CF1F302792F60" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2272-wk-Fact-6559FCDFD03D6885BCF3F1F3027BAD6C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2291-wk-Fact-DA0848700B66760E4BC8F1F302768C1A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2310-wk-Fact-A4A37A8ABB8C56F43423F1F3027ADEF6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2330-wk-Fact-6AE80742C78C074DD41DF1F302751E20" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2360-wk-Fact-A616C7A700C02F250119F1F3027ECCBD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">226,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2379-wk-Fact-35F320239E6D2587AAFEF1F3024C956C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e2399-wk-Fact-C75FFE760561FC77FDD3F1F302B33BDC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2419-wk-Fact-59E32E56163316E11940F1F3027A30F0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">227,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2733-wk-Fact-B3BEE8653E7F9F9BEDABF1F302530753" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2752-wk-Fact-6C1A2026C945A91B5A30F1F30252ED12" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e2772-wk-Fact-91A29380192FB680881DF1F30252EF5F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2792-wk-Fact-C06922BDABF7F3F847B4F1F30252EFA0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2812-wk-Fact-6DA6323D81EB434C5D97F1F30250F3A6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2831-wk-Fact-48833DAF01DEC4E6A006F1F30256A5A9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e2850-wk-Fact-080DFC2E26A535BF7045F1F3026307AB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2871-wk-Fact-77CBE385F4A63703E75AF1F30251AFB6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2901-wk-Fact-E3C392DDE612D404D31EF1F302538ED2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2920-wk-Fact-8F948DE86543BA201A41F1F3024FB984" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e2940-wk-Fact-206013F9BCA63D6C1A20F1F302523D21" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e2960-wk-Fact-9B8884E9D78EE24873ACF1F30253C726" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company held securities with an unrealized loss position that were not considered to be other-than-temporarily impaired as the Company has the ability to hold such investments until recovery of their fair value. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#8217; equity. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company did </span><span style="font-family:inherit;font-size:10pt;">not</span><span style="font-family:inherit;font-size:10pt;"> have any realized gains/losses from the sale of marketable securities.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EA69EAA470918D93D051F1F302C10888-3" continuedAt="TextSelection-EA69EAA470918D93D051F1F302C10888-4"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" id="TextSelection-3E6DDC253A2A9584182CF1F302C1E968-0-wk-Fact-E5467C3049F0361AD8ADF1F302B18A43" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position greater than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3439-wk-Fact-9A475B9FFA4757A8705FF1F302657D30" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3458-wk-Fact-0C75DD9B574E5669845DF1F30269220E" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3478-wk-Fact-DD42DA207ADD9089331DF1F3027702C4" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3497-wk-Fact-99085BF31A4EEA094842F1F302757C02" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3516-wk-Fact-63DDA15B0790F669CD14F1F30270C302" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3536-wk-Fact-7F012B2AFE28DC75D509F1F302570365" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e3556-wk-Fact-371ED2BAEC48A0E9B4E7F1F302638499" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3576-wk-Fact-AD0BA5A25B8EC2E2D698F1F30258294D" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3595-wk-Fact-E0263CB7D83B043D27C7F1F30269AA20" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3615-wk-Fact-C8033B33A0B9660C09DFF1F3026D7403" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e3634-wk-Fact-C8E0A62D17C44900383FF1F302662A78" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3655-wk-Fact-D033B619EDDD7BD2AB64F1F302710F83" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3680-wk-Fact-BF5FE09AA6DAE8890C06F1F30258F563" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3699-wk-Fact-4CE768D39E5EA4E571BEF1F3026EA252" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3718-wk-Fact-1C532F862AAA4BEF4211F1F302754294" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3738-wk-Fact-7EB6A564CC97651ECEE8F1F302659E45" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3757-wk-Fact-37B38778A5D06769A8E4F1F3026DC8E4" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3777-wk-Fact-D06851B1F9E8EE1566A9F1F3027259F6" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e3807-wk-Fact-BA517E7B906140EAB221F1F30276D705" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3827-wk-Fact-804211C52CAF7F71542FF1F302683224" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3847-wk-Fact-68E8A04AB205589127ABF1F302750A0C" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3866-wk-Fact-EAA97FBA933CA57D4DD6F1F3026EBC81" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e3885-wk-Fact-097BEBBDF2CFD8EE3075F1F3026D9CB0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e3906-wk-Fact-536B8AE651D4EB1C4988F1F30258532B" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position greater than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4351-wk-Fact-F591B03C26DC496A7449F1F302A862EE" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4370-wk-Fact-09C6E38B78F85F157F64F1F302A73B40" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4389-wk-Fact-B099FB47A1DC32E26978F1F302AA5BAE" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4407-wk-Fact-ABBC278AD279B89F53A0F1F302A50B70" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4425-wk-Fact-4482D9E487A21E1DC251F1F302AA7D4C" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4445-wk-Fact-CFA7577380036315258CF1F302A65253" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4465-wk-Fact-C399974E4651B1375405F1F302ACC634" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4484-wk-Fact-B6BBE4BF01FB3D1597F4F1F302A56B45" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4502-wk-Fact-481B09D9E1DAD8440BA2F1F302AB52C5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4522-wk-Fact-EDC1CF99283C2427F730F1F302A725EE" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4540-wk-Fact-FC819D0CAD998AEBF2B9F1F302A805C4" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4560-wk-Fact-DF22B99818BC7A8DFF50F1F302A5DB64" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4590-wk-Fact-152B9717148FE86FA3A3F1F302A71DB6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4609-wk-Fact-4E76C41ECD3C7717F7CCF1F302A574FE" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4628-wk-Fact-471532FC7D866FCB74B4F1F302A4B4C9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4647-wk-Fact-38553AC6CC23C3121F81F1F302A411D3" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e4665-wk-Fact-86F5FBCD1A040EE8BE19F1F302AE317D" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4685-wk-Fact-FE5437D15530DBBCFA87F1F302A4046B" name="us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:MarketableSecuritiesTextBlock" id="TextSelection-ABB4F9393CD707B057D8F1F302C16472-0-wk-Fact-6E0900F11D55147FB959F1F3029D564A" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities on the balance sheet at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> mature as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4844-wk-Fact-25F1FBB33C86A306838BF1F302A78A35" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4863-wk-Fact-1093637ABC09369F36F1F1F302AF9049" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4883-wk-Fact-D54D85377805D4620986F1F302AF1C7B" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4902-wk-Fact-998240BE6A36D40E5BC9F1F302AAD5BA" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4927-wk-Fact-25978C4B0B0140BB2A87F1F302AADA96" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4946-wk-Fact-C1D7B1D5233B96C807CAF1F302AB7098" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4976-wk-Fact-9FE97EB37959B2AB3E9EF1F302ADF748" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">161,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e4995-wk-Fact-81371EAE77B0AA8743BFF1F302A7BDF1" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5132-wk-Fact-48C703B6D8B0BB1ED59AF1F3025E72EB" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5151-wk-Fact-7C93D2E9806266A832FFF1F30259675F" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5171-wk-Fact-DF33A4AC8915B44C00D6F1F3025AAA50" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5190-wk-Fact-A7C799B646313C2A01C4F1F3025E723A" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5220-wk-Fact-239988C231588FA9932DF1F3025DFDB6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5239-wk-Fact-28F09441CEE6B60D82DAF1F3025F8953" name="ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies all of its securities as current as they are all available for sale and are available for current operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible 3.0% senior notes</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2015, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5262-wk-Fact-1E1351C22346003242E5F1F302B396A8" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5266-wk-Fact-E2F8C7C72F6AA405E68EF1F30278644A" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due August&#160;15, 2022 (the &#8220;Convertible Notes&#8221;). Interest is payable semi-annually on February&#160;15 and August&#160;15 of each year, beginning on February&#160;15, 2016. The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;10. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the Convertible Notes at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5278-wk-Fact-53D70FC75AD9D72E3F14F1F302A932A7" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">166.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5283-wk-Fact-979F816B96AB68270FA9F1F302AFB927" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">146.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and borrowings under the credit and security agreement with MidCap Financial Trust and other financial institutions (as further discussed in Note 10) approximate fair value because of the immediate or short-term maturity of these financial instruments. The carrying amounts for the credit and security agreement approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EA69EAA470918D93D051F1F302C10888-4" continuedAt="TextSelection-EA69EAA470918D93D051F1F302C10888-5"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred consideration payable</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Merger Agreement, Agilis equityholders may become entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5297-wk-Fact-E4352FF052F170C6ED82F1F30299E272" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5301-wk-Fact-ECD1AF8A8D555426A41DF1F3024EF182" name="ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">535.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is required to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5305-wk-Fact-9EFF4764375FB458FD8FF1F302AFC239" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved.  The fair value of the deferred consideration payable at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was estimated to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5313-wk-Fact-5D79F64D173BE63FB924F1F30274AEC6" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="6" format="ixt:numdotdecimal">38.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> by applying a discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#8217;s estimated development timelines for the acquired product candidates. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5322-wk-Fact-EC0E1729260E567BC2FDF1F3026DB201" name="ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="6" format="ixt:numdotdecimal">19.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the deferred consideration payable was classified as current on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3 valuation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#8217;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#8217;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-EC2C924CFFC89D805536F1F302C1638A-0">The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss in the consolidated statements of operations. The fair value of the development and r</ix:continuation>egulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#8217;s estimated development timelines for the acquired product candidate. The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="TextSelection-062B71416CB52BEE8B0C1AC915A7BB5D-0-wk-Fact-EAA88015E835A6E5EA921ACA01500B7F" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The changes in the fair value of the Company's Level 3 valuations for the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> were immaterial.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3 liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">SARs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent consideration payable- development and regulatory milestones</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent consideration payable- net sales milestones and royalties</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5525-wk-Fact-1F1BA3FD4691EC49F2FEF1F3027F8A9E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5544-wk-Fact-09475BA3B0AC41715F60F1F3027CE2B1" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">257,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5558-wk-Fact-EC3DD61C042441A20ED7F1F3027F12EF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5579-wk-Fact-4CA37A4AB16017CB86FB1ACA978553D2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5598-wk-Fact-9C3091F1A362693109E71ACAD33316DE" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5612-wk-Fact-F02B85E3C78836685D531ACA9789DFBE" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5638-wk-Fact-05DE5A82970B0FFDEC6AF1F3027B46A7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5657-wk-Fact-C307B89640B01DE0D997F1F3027B9A2A" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5671-wk-Fact-C981581804D903A04CFEF1F3027FEFD7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41054631e5697-wk-Fact-07F63556A54749CC512AF1F3027C5A4D" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5717-wk-Fact-FA577A4E1A8FF19B66F3F1F3027B697B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5730-wk-Fact-FB97D97D866BBC80BFD91ACAEA4E236E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5761-wk-Fact-D498AB18DF4D2EB26D89F1F3027DDD8C" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5780-wk-Fact-70C37A2DD3F4B5D5AFD2F1F3027CF69E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">277,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5794-wk-Fact-A1143A7F9E1142830FE7F1F3027B4DC2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EA69EAA470918D93D051F1F302C10888-5"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-C7CA0B0FBEFA241AC5ABF1F302C173A0-0-wk-Fact-8332DEAD437D53F1EF9DF1F302B40323" continuedAt="TextSelection-EC2C924CFFC89D805536F1F302C1638A-0" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the SARs liability, and the contingent consideration payable for the periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:19%;"></td><td style="width:2%;"></td><td style="width:13%;"></td><td style="width:2%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:2%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value </span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SARs</span></div></td><td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e5938-wk-Fact-B719A5A144B05A96A3F7F1F3027A11E2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,960</ix:nonFraction></span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e5968-wk-Fact-B0BF74F1EFD3CA90080EF1F302798028" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">49.70</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e6014-wk-Fact-69B721A306D6793C1C36F1F3027A1732" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.09</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Strike price</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6.76 - $30.86</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e6106-wk-Fact-52964B940606C5B94B42F1F3027BB9E8" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">45.00</ix:nonFraction></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.52 years</span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e6170-wk-Fact-E78CF43B7B9730C9248AF1F30279588B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">277,400</ix:nonFraction></span></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability-adjusted discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $555 million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 94%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.8% - 5.7%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2026</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent considerable payable- net sales milestones and royalties</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e6355-wk-Fact-BC8FC1BC4ABEC16B5B50F1F3027B20EC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,800</ix:nonFraction></span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model with Monte Carlo simulation</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential net sales milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $150 million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 89%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential percentage of net sales for royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2% - 6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e6525-wk-Fact-32920A506FDFFEC9C57EF1F3027A6B8E" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">14.5</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2038</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:19%;"></td><td style="width:2%;"></td><td style="width:13%;"></td><td style="width:2%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:2%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value </span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SARs</span></div></td><td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e6695-wk-Fact-6E8BAD8D2BB6FD610AD7F1F302914C27" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814</ix:nonFraction></span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46.53% - 59.59%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.44% - 2.63%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Strike price</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6.76 - $30.86</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e6863-wk-Fact-722484B7634AFAE9BFADF1F30291EEC2" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">34.32</ix:nonFraction></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.01 - 1.01 years</span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e6927-wk-Fact-7AA985E0ABAF8D2436F5F1F302908C1F" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">257,040</ix:nonFraction></span></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability-adjusted discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $555 million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 94%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.8% - 8.0%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2026</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent considerable payable- net sales milestones and royalties</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41054631e7112-wk-Fact-1A905B245B94DD2EABD2F1F30291E78D" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,200</ix:nonFraction></span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model with Monte Carlo simulation</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential net sales milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $150 million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 89%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential percentage of net sales for royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2% - 6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41054631e7282-wk-Fact-3048591972A7A62F4614F1F3029194A6" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">14.0</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2038</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration is classified as&#160;&#160;&#160;&#160;a Level 3 liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, including but not limited to, assumptions involving probability adjusted sales estimates for the Agilis platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.</span></div></ix:continuation><div><a id="sC2B70791921B5C2288FEE4A4575F708E"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="TextSelection-7F18B9DAFDAFDC13A591F1F302C12368-0-wk-Fact-36CB2285227900E0A8D1F1F3027BE2C1" continuedAt="TextSelection-7F18B9DAFDAFDC13A591F1F302C12368-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other comprehensive income (loss) and accumulated other comprehensive items</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-7F18B9DAFDAFDC13A591F1F302C12368-1"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-2CF58A6CA48743A6E762F1F302C22227-0-wk-Fact-AE499193FFC307255EC8F1F3027A0C7E" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">On</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities,&#160;net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at March&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e527-wk-Fact-AB161F34B4EA62A9F83C1B68ACF6C13C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e546-wk-Fact-255402D9183C4220ABF51B68AE982671" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e566-wk-Fact-FA8E4A7513A584AA36C3F1F302B052F8" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e586-wk-Fact-AD903DB5A3540FEFED7067A62B684CAE" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e605-wk-Fact-D929607FB06FD4EE443C67A62B721F68" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e624-wk-Fact-EA22921AC9852B66F6231B68B517832A" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from other comprehensive items</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e650-wk-Fact-5B3E584E3C4AB7B737501B68B550D1CD" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e669-wk-Fact-D0CA89402FC862590BEA1B68B6455707" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e688-wk-Fact-954B4529357F4E87781C1B68B72132A5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e714-wk-Fact-97EC248AA0C04008862A1B68B764DBA5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e733-wk-Fact-250CC01E1382EB6429741B68B84DFF5D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e752-wk-Fact-2EB915054EFBF4E0C03D1B68B9DF1319" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e783-wk-Fact-60F4E5A0907ED20EE4481B68BA863594" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e802-wk-Fact-1A73DC85FD0E264049EE1B68BC25E34A" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e822-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">On</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities,&#160;net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e968-wk-Fact-9EFF3A3EC5A0C2050550F1F3026E8CE0" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e987-wk-Fact-D35864364F12FCC67FD0F1F3026A93A5" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1007-wk-Fact-08D86BFFC9D39EF8C8211B19D7942B8E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1027-wk-Fact-3790DACDF803D6606D4CF1F30270513B" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41039540e1046-wk-Fact-F3F85596C5095E9B1230F1F3026D74E9" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1066-wk-Fact-F9FA1EBA8B464D0D4D7FF1F302563CA9" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from other comprehensive items</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1092-wk-Fact-EFF7AACFECE63B9242B8F1F3026C350D" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1111-wk-Fact-A05C66D02B3E8559752EF1F302700758" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1130-wk-Fact-C6DB18F7C473120EC14CF1F30272D825" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1156-wk-Fact-704F1F0E05AF6EDDF4B9F1F302734E84" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41039540e1175-wk-Fact-79EEBDB97BBB322C09A3F1F3026A157E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1195-wk-Fact-66316C63F6254C0EF926F1F3026789DC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1226-wk-Fact-60F4E5A0907ED20EE4481B68BA863594" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1245-wk-Fact-1A73DC85FD0E264049EE1B68BC25E34A" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41039540e1265-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s44942DF311835F2BA6DFCACB274CBC71"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="TextSelection-E0458920ED87E2A95E64F1F302C23236-0-wk-Fact-633AE40A4A76A5D96E09F1F3024E919F" continuedAt="TextSelection-E0458920ED87E2A95E64F1F302C23236-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounts payable and accrued expenses</span></div></ix:nonNumeric></td></tr></table><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="TextSelection-71A745715EBB25403006F1F302C2B08D-0-wk-Fact-A3D0F021490B5556D5C0F1F3024F18EA" escape="true"><ix:continuation id="TextSelection-E0458920ED87E2A95E64F1F302C23236-1"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> consist of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee compensation, benefits, and related accruals</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e462-wk-Fact-7A0FB445CB3CD739DBE3F1F3029C8AC8" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e481-wk-Fact-CB57026829D6AB5CB840F1F3029E8C33" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,629</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and contracted research</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e501-wk-Fact-02C178349D865295F4F6F1F3028A0CA4" name="ptct:AccruedConsultingAndContractedResearchCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e520-wk-Fact-9DBD6590124D8B90C1F5F1F3027EDFE1" name="ptct:AccruedConsultingAndContractedResearchCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e545-wk-Fact-EDD99A107C66FCF1EED8F1F302959D3A" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e564-wk-Fact-A5125F93BF36B034DDEEF1F302923FC8" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales allowance and other costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e589-wk-Fact-46CA585116611268F6AAF1F3027C51CE" name="ptct:SalesAllowanceAndOtherRelatedCosts" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,794</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e608-wk-Fact-432359A7022FB203B951F1F302847039" name="ptct:SalesAllowanceAndOtherRelatedCosts" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales rebates and royalties</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e633-wk-Fact-8DB54443C7E605A274A7F1F302940131" name="ptct:SalesRebatesAndRoyaltiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e652-wk-Fact-B75EEECC5D6C027A5CD2F1F3027E90ED" name="ptct:SalesRebatesAndRoyaltiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e677-wk-Fact-88FB5CB2DEE6A842D5CCF1F30284DF07" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e696-wk-Fact-F83C0F1014A7A8DF8167F1F3027C561E" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e721-wk-Fact-3F7D53844B1AAD6F317AF1F302A05DD9" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e740-wk-Fact-23C616000B03C48E2535F1F302504833" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e770-wk-Fact-1873121A607E1419971AF1F3025B361E" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41036773e789-wk-Fact-C91536B542435183E188F1F3026B65D7" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="s0ACECA116EF758BBA4CA147C15DCCF7D"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-2722680F2FCC80DB6005F1F302C2587B-0-wk-Fact-7E1E1EFAB75895E9A0C5F1F3026C0770" continuedAt="TextSelection-2722680F2FCC80DB6005F1F302C2587B-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Capitalization</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-2722680F2FCC80DB6005F1F302C2587B-1" continuedAt="TextSelection-2722680F2FCC80DB6005F1F302C2587B-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, the Company closed an underwritten public offering of its common stock pursuant to a registration statement on Form S-3. The Company issued and sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41040235e368-wk-Fact-22290768D62FEF9D7A3CF1F3026FE288" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q1Jan" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,563,725</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under the registration statement at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41040235e372-wk-Fact-78EA47286E1D1C50FB9DF1F30271C01A" name="us-gaap:SharePrice" contextRef="I2019Q1SD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">30.20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, including </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41040235e376-wk-Fact-513CD9A5C353CEBC482FF1F3026F3AE9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">843,725</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares issued upon exercise by the underwriter of its option to purchase additional shares in February 2019. The Company received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41040235e380-wk-Fact-F78D56498C2CE683CF78F1F302B3C92A" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2019Q1Jan" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">224.5</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s outstanding warrants were classified as liabilities as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> because they contained non-standard antidilution provisions. The fair value of the warrants as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was immaterial.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="TextSelection-05567988438094516D5BF1F302C22B26-0-wk-Fact-75623077144CB56D53C1F1F302707122" escape="true"><ix:continuation id="TextSelection-2722680F2FCC80DB6005F1F302C2587B-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s outstanding warrants as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41040235e516-wk-Fact-19CF7D9681568E452630F1F302954958" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41040235e534-wk-Fact-746BB0813DB213ADDECAF1F302957FB2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">128.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41040235e563-wk-Fact-B1D076DF8B90233A0B87F1F302971F32" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41040235e581-wk-Fact-53AA1621D7A6DDB024D6F1F30296E27B" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">2,520.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="sE673757CAE345603B41396239B67DE60"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</span><span style="font-family:inherit;font-size:3pt;font-weight:bold;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-676D1712C49DDB51A797F1F302C2A86F-0-wk-Fact-4ED9AD18DD8A2909CCD6F1F3028F7318" continuedAt="TextSelection-676D1712C49DDB51A797F1F302C2A86F-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</span></ix:nonNumeric></div><ix:continuation id="TextSelection-676D1712C49DDB51A797F1F302C2A86F-1"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares plus the effect of any dilutive potential common shares outstanding during the period.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-0E85D6C11CCD54BDC47CF1F302C27EC5-0-wk-Fact-005856FB902FEBBE0974F1F3028F6286" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables set forth the computation of basic and diluted net loss per share:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e671-wk-Fact-46143D9F1DAD6B240FD9F1F30270B637" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e691-wk-Fact-224DC358D24EA5D828A6F1F3026F5A46" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e711-wk-Fact-2DA3A1CEAF8FFEB31C7FF1F302AF1D8E" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e732-wk-Fact-9E93897F26957D660680F1F302A62467" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator for basic and diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e836-wk-Fact-A4B2822AB20BADD4161DF1F3027368B0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">55,912,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e855-wk-Fact-18D1C97362E1A320D10AF1F30288CE54" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">46,137,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e874-wk-Fact-53AF798862AF86240026F1F30299D7AA" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">57,113,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e894-wk-Fact-B1D37CC50BA3FB74C941F1F3028EA40A" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">46,257,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e1007-wk-Fact-7724A2F532F09ACED389F1F3025AA52A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e1027-wk-Fact-79112D852D0E45DBB532F1F3026BBDE5" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e1047-wk-Fact-A81E1E67ADE7F1FDE5FFF1F30267C69F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41041287e1068-wk-Fact-604CC67F0B1D65A308C7F1F3026AD791" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*In the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company experienced a net loss and therefore did not report any dilutive share impact.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-11D4C536D0BB346EA12FF1F302C2E905-0-wk-Fact-F46EA41FF3822AD2CA8AF1F3028D388F" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e1206-wk-Fact-4997A951108796FE30F1F1F3027D8212" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,853,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e1220-wk-Fact-613F8A2DA52AE3478BF2F1F3027A029A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,166,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e1235-wk-Fact-0B8AD514ED0F0C03D364F1F3027C65A7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">665,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e1249-wk-Fact-0820D99DE77E3DBE76B2F1F3027E2A00" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">584,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e1264-wk-Fact-79E5EB52FDE8F62AE407F1F302983B34" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,518,303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41041287e1278-wk-Fact-814C578D33DCBA7A8F61F1F302985DBC" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q2YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,750,584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s4058047C26315374842622DA156E7C8D"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-0-wk-Fact-3F2B3E7D0018A3DE8D0AF1F30293F9C0" continuedAt="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock award plan</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-1" continuedAt="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March&#160;5, 2013, the Company&#8217;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e368-wk-Fact-C00DE4AF7F3591762D00F1F302986358" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">739,937</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. On March&#160;5, 2013, the Board approved a grant of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e372-wk-Fact-3B56404D86B62EB4AF77F1F302A072B6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">735,324</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted stock and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e376-wk-Fact-0374BDEF7858048089A2F1F3028FEBAD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,613</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> stock options. There are </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e380-wk-Fact-2F0F44DB04EED4F238F2F1F302941C6F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional shares available for issuance under this plan.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2009, the Company&#8217;s shareholders approved the 2009 Equity and Long-Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards, subject to certain adjustments and annual increases. In May&#160;2013, the Company&#8217;s Board of Directors and stockholders increased by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e387-wk-Fact-A30EC1D11BF6DB47B063F1F302AAEF53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="D2013Q2May1-May31_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards. There are </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e391-wk-Fact-322324B9C281E5A40810F1F302887C3D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q2_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional shares available for issuance under this plan.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May&#160;2013, the Company&#8217;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#8217;s initial public offering.&#160; The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e398-wk-Fact-5250D88F288C881A2E7AF1F302934098" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="I2013Q2May31_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">122,296</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock available for issuance under the Company&#8217;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2) the number of shares (up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e402-wk-Fact-0147EFB32B72EF89E1EDF1F3029ED552" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" contextRef="I2013Q2May31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,040,444</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#8217;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-2" continuedAt="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e409-wk-Fact-CC07BC55B1EDBC78641FF1F30294F4C3" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" contextRef="D2013Q2May1-May31_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e413-wk-Fact-0DE4B3B4086329169068F1F302B0964F" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" contextRef="D2013Q2May1-May31_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#8217;s Board of Directors. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, awards for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e421-wk-Fact-2528F88BB4BEC07B2694F1F3029065FA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q2_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">302,538</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock are available for issuance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From January&#160;1, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company issued a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e436-wk-Fact-0453A29EFC4BA7AF8639F1F30290D4A4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,845,620</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> stock options to various employees.&#160; Of those, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e440-wk-Fact-1C02BA2A7888F601C977F1F30292E0DA" name="ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">579,700</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> were inducement grants for non-statutory stock options. The inducement grant awards were made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company's new hires&#8217; employment compensation and not under the 2013 Long Term Incentive Plan.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-EAF0FF5BDD5C28AD5554F1F302C369AF-0-wk-Fact-8147355B3CA01D492939F1F3028399F3" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of stock option activity is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of<br/>options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-<br/>average<br/>exercise<br/>price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>intrinsic<br/>value                 (in<br/>thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e631-wk-Fact-C06D4EFA0F27FD59E4BBF1F302830DD3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,534,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e650-wk-Fact-11D78E2D8F168DB8CD5AF1F302932A82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e700-wk-Fact-0453A29EFC4BA7AF8639F1F30290D4A4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,845,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e719-wk-Fact-D31FED56395D17071630F1F30283E973" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">33.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41045391e769-wk-Fact-696A9EE3F75D0B8BC251F1F30293FE75" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">311,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e789-wk-Fact-5688ABF2A69F9B7FE78AF1F30286839C" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/Cancelled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41045391e839-wk-Fact-AB075183D6A0B4E07326F1F302B0F8EB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">215,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e859-wk-Fact-F9E092F48096FBE36578F1F302B0DA5B" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">36.10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e909-wk-Fact-1835CBE4749B1E0724B3F1F302929D04" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,853,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e928-wk-Fact-49763C15DE934F743131F1F302902FEA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41045391e942-wk-Fact-91C3828B3547CDA264C3F1F30286C89D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" format="ixt-sec:duryear">7.59</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e958-wk-Fact-BFC1DEE60F48440B45C2F1F3028A6580" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">178,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested or Expected to vest at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e978-wk-Fact-1668E4A0C3299211CC72F1F302B32B91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,334,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e997-wk-Fact-446345CA8EFFC4E8601EF1F302B0FC29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41045391e1011-wk-Fact-8E8D9F4E8020575AEAB5F1F30290D337" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" format="ixt-sec:duryear">9.01</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1027-wk-Fact-0CA29662F9507A3375DAF1F3028E416D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84,446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1047-wk-Fact-16C393F50554A7A67458F1F302918131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,138,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1066-wk-Fact-D0906190D3CAE563E0FAF1F3028FFA39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41045391e1080-wk-Fact-B493513E4D0F44BBF5B0F1F302909BC3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" format="ixt-sec:duryear">5.98</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1096-wk-Fact-6CF974A9395B55A50803F1F302922ECA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-6C0D71D66C73D973CD06F1F302C31EF2-0-wk-Fact-35F4EECD1DFEE361D770F1F302B3646C" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of grants made in the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was contemporaneously estimated on the date of grant using the following assumptions:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:65%;"></td><td style="width:2%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.98 - 2.63%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61.90 - 63.09%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.11 years</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assumed </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1210-wk-Fact-73067F0E258C884861E3F1F302A8238A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="number" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> expected dividends for all grants. The weighted average grant date fair value of options granted during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41045391e1222-wk-Fact-5DEBD781DF068827D22BF1F302B2BC6C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">20.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the &#8220;simplified method&#8221; to determine the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, size, and financial leverage. The risk-free rate of the option is based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Awards</span><span style="font-family:inherit;font-size:10pt;">&#8212;Restricted stock awards are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards, which has been determined based upon the market value of the Company&#8217;s shares on the grant date, is expensed over the vesting period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</span><span style="font-family:inherit;font-size:10pt;">&#8212;Restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock units, which has been determined based upon the market value of the Company&#8217;s shares on the grant date, is expensed over the vesting period.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="TextSelection-540C9BDE0C40E8967D07F1F302C3F3D9-0-wk-Fact-8D5483453A014AA66004F1F302B31CBE" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes information on the Company&#8217;s restricted stock awards and units:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted&#160;Stock&#160;Awards&#160;and&#160;Units</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of<br/>Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1358-wk-Fact-72FC3CE65342C11D3BA5F1F302B22FF8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">571,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1377-wk-Fact-7D5C72BAF4AF1C133FA5F1F302B0A04A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1397-wk-Fact-B3812226D6397BFFF09BF1F302B29A3D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">304,549</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1416-wk-Fact-E82D43E57641AA4657F9F1F302A87BEE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">32.94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41045391e1436-wk-Fact-494BAB1392C1EBB3F248F1F302A91BC6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">179,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1456-wk-Fact-94AA594CA6F3C97DE2EDF1F302AC442E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41045391e1476-wk-Fact-1BE5251C954C223BEB02F1F302A73AD5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">31,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1496-wk-Fact-E7609F9DE503A37F7C14F1F302B1678A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1516-wk-Fact-94834C6E672961683E75F1F302A8449A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">665,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1535-wk-Fact-C378BD6F3F9AE6B85602F1F302AFB4B3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">24.45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights</span><span style="font-family:inherit;font-size:10pt;">&#8212;SARs entitle the holder to receive, upon exercise, an amount of the Company's common stock or cash (or a combination thereof) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of the Company's common stock over the measurement price based on the exercise date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May&#160;2016, a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1556-wk-Fact-1CA1C94D32E47C2904C2F1F30294468E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2016Q2May1-May31_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">897,290</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> SARs were granted to non-executive employees (the "2016 SARs"). The 2016 SARs will vest annually in equal installments over </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;"> years and will be settled in cash on each vest date, requiring the Company to remeasure the SARs at each reporting period until vesting occurs. For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1572-wk-Fact-9980CC2466054C1DD194F1F302B2AD37" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">157,930</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> SARs vested. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41045391e1585-wk-Fact-EF9EE63CFE760811F226F1F3029A3265" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41045391e1589-wk-Fact-00DB12D996A20EF32DCD3C117F2FEC50" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in compensation expense related to the 2016 SARs.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</span><span style="font-family:inherit;font-size:10pt;">&#8212;In June 2016, the Company established an Employee Stock Purchase Plan (&#8220;ESPP&#8221; or the "Plan&#8221;) for certain eligible employees. The Plan is administered by the Company&#8217;s Board of Directors or a committee appointed by the Company's Board of Directors. The total number of shares available for purchase under the Plan is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1598-wk-Fact-82ABF56A84D8E7AA0B25F1F302932481" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="FI2016Q2_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember" unitRef="shares" decimals="INF" scale="6" format="ixt-sec:numwordsen">one million</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. Employees may participate over a </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month period through payroll withholdings and may purchase, at the end of the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month period, the Company&#8217;s common stock at a purchase price of at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1610-wk-Fact-AB0685733846CD6E2F9FF1F302AA4F2F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the closing price of a share of the Company&#8217;s common stock on the first business day of the offering period or the closing price of a share of the Company&#8217;s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company&#8217;s common stock under the Plan if such participant would own more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1614-wk-Fact-33F2EECE13E251DD7751F1F302B2566F" name="ptct:EmployeeStockPurchasePlanVotingPercentageLimitPercent" contextRef="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41045391e1627-wk-Fact-775EB04C12B6DE82788EF1F3029AA5A6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41045391e1631-wk-Fact-C6CE57869310F236FBCE4159B3513D84" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in compensation expense related to the ESPP.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-0EF97413F04E3D675C04F1F302C36C6C-0-wk-Fact-EF04A6E30B16E66BB1F8F1F30292640A" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1860-wk-Fact-F929E5D9758DCC923C3DF1F3028C19CF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1879-wk-Fact-44C92C0546B24E7CE9EBF1F30287BF9E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,932</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1899-wk-Fact-30907BB9D4882E890FDAF1F30253D92D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1918-wk-Fact-CBC82135686C04EE724CF1F302ADE353" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,678</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1938-wk-Fact-C830EF0174209035A21DF1F30285CF92" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1957-wk-Fact-2E852CAA943BA9EC8E81F1F30288A8AF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1976-wk-Fact-238A0C8AF34A602F0386F1F302B0B767" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e1996-wk-Fact-407A6DDBD1E4A3ECC6B1F1F3025ECD62" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e2026-wk-Fact-C4AC33B0D6C7FDF6D489F1F3028F75B9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e2045-wk-Fact-C1F6AF6559A6EA786385F1F302884E08" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e2065-wk-Fact-35BFCCCC1B48ECE217BCF1F302AB478B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41045391e2084-wk-Fact-FBA2BC72D51F9496E03EF1F3024EA5A6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41045391e2104-wk-Fact-56C78E8854785AC12797F1F302A33440" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, the 2013 Long Term Incentive Plan and equity awards made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41045391e2108-wk-Fact-C82472D10248F9B55FE9F1F3028BB1FE" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q2YTD" format="ixt-sec:duryear">3.10</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCB62AD33AB7A5679A942C527440611A0"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LongTermDebtTextBlock" id="TextSelection-D24811A9D784D26AA609F1F302C3BA10-0-wk-Fact-5E2305720F725D803CE1F1F302992281" continuedAt="TextSelection-D24811A9D784D26AA609F1F302C3BA10-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-D24811A9D784D26AA609F1F302C3BA10-1" continuedAt="TextSelection-D24811A9D784D26AA609F1F302C3BA10-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Credit Facility</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into a credit and security agreement (the "Credit Facility") with MidCap Financial Trust, a Delaware statutory trust (&#8220;MidCap&#8221;), as administrative agent and MidCap and certain other financial institutions as lenders thereunder (the &#8220;Credit Agreement&#8221;) that provides for a senior secured term loan facility of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e371-wk-Fact-4F568B90B6E09DB9C5C0F1F302A61D47" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e375-wk-Fact-0FC2CCD0EB19B31DA808F1F3026386A1" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="D2017Q2May-05_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was drawn by the Company on May 5, 2017. The Company's ability to draw on the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e379-wk-Fact-27131AD0A3091F3AC62DF1F30298261A" name="ptct:LineOfCreditFacilityAdditionalCapacityAvailable" contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> under the senior secured term loan facility expired on December 31, 2018. The Company capitalized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e383-wk-Fact-21FD831711EE0D9B31B9F1F302645BD5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross" contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of debt issuance costs, which were netted against the carrying value of the Credit Facility and will be amortized over the term of the Credit Facility.  As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had made loan repayments of $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e392-wk-Fact-5A59B24D0C8E027B7AA1413DAFD76558" name="us-gaap:RepaymentsOfDebt" contextRef="FD2019Q2YTD_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> on the Credit Facility.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowings under the Credit Agreement bear interest at a rate per annum equal to LIBOR (with a LIBOR floor rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e399-wk-Fact-27A37AA36575CE58DE11F1F302A1B387" name="ptct:DebtInstrumentFloorInterestRate" contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">) plus </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e403-wk-Fact-471801C0F9D70EEB8638F1F3025A1C15" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="D2017Q2May_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.15</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. The Company was obligated to make interest only payments (payable monthly in arrears) through April 30, 2019. Commencing on May 1, 2019 and continuing for the remaining </span><span style="font-family:inherit;font-size:10pt;">twenty-four</span><span style="font-family:inherit;font-size:10pt;"> months of the facility, the Company is required to make monthly interest payments and monthly principal payments. The principal payments are to be made based on straight-line amortization of the principal over the </span><span style="font-family:inherit;font-size:10pt;">twenty-four</span><span style="font-family:inherit;font-size:10pt;"> month period. The maturity date of the Credit Agreement is May 1, 2021, unless terminated earlier.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Facility is subject to certain financial covenants. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with all required covenants.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Notes</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In&#160;August&#160;2015, the Company issued, at par value,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e428-wk-Fact-1E1351C22346003242E5F1F302B396A8" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;aggregate principal amount of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e432-wk-Fact-5C029B069446D5431F6AF1F3029E5B6F" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;convertible senior notes due 2022 (the "Convertible Notes"). The Convertible Notes bear cash interest at a rate of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e436-wk-Fact-5C029B069446D5431F6AF1F3029E5B6F" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per year, payable semi-annually on&#160;February&#160;15&#160;and&#160;August&#160;15&#160;of each year, beginning on&#160;February&#160;15, 2016. The Convertible Notes will mature on&#160;August&#160;15, 2022, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e440-wk-Fact-71C2D049A7D2E7E72149F1F3029A5386" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">145.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes are governed by an indenture (the "Convertible Notes Indenture") with U.S Bank National Association as trustee (the "Convertible Notes Trustee").</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;February&#160;15, 2022&#160;only under the following circumstances:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> during any calendar quarter commencing on or after&#160;September&#160;30, 2015&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least&#160;</span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;">&#160;trading days (whether or not consecutive) during a period of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e461-wk-Fact-44E74B8D35A84DA584854A000EED9C52" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="0" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e465-wk-Fact-A5EDF61F5A412D7AB971F1F3025F590D" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the conversion price on each applicable trading day;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> during the&#160;</span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">&#160;business day period after any&#160;</span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">&#160;consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the Convertible Notes Indenture) per </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e484-wk-Fact-692D399CDCA5CDD0151CF1F30269ECBF" name="ptct:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of Convertible Notes for each trading day of the measurement period was less than&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e488-wk-Fact-BE20E96D4D37FF69695DF1F30267CA84" name="ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> upon the occurrence of specified corporate events.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or after February&#160;15, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert their Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Convertible Notes to be converted and deliver shares of its common stock in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of Convertible Notes being converted.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion rate for the Convertible Notes was initially, and remains, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e513-wk-Fact-686801D205955D240C11F1F302627FB7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">17.7487</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock per </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e517-wk-Fact-692D399CDCA5CDD0151CF1F30269ECBF" name="ptct:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e521-wk-Fact-9CABBF2FD708BE591F28F1F302ADEA53" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">56.34</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share of the Company&#8217;s common stock.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was not permitted to redeem the Convertible Notes prior to August&#160;20, 2018. As of August 20, 2018, the Company may redeem for cash all or any portion of the Convertible Notes, at its option, if the last reported sale price of its common stock has been at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e528-wk-Fact-DBD3015F8CBB8BB83944F1F3029FBF92" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price then in effect on the last trading day of, and for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e532-wk-Fact-B63CB3A18912F2B63271F1F30254C298" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">19</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> other trading days </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-D24811A9D784D26AA609F1F302C3BA10-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(whether or not consecutive) during, any </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e539-wk-Fact-BE69E1EEFA5EEA8678AFF1F30272DAF1" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e543-wk-Fact-6F651CDA976CE77A4E8BF1F30260FABA" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e547-wk-Fact-ACBAAC5F79CB34D42E4FF1F3025AE53E" name="us-gaap:DebtInstrumentCumulativeSinkingFundPayments" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> sinking fund is provided for the Convertible Notes, which means that the Company is not required to redeem or retire the Convertible Notes periodically. There have been no redemptions to date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the Indenture governing the Convertible Notes Indenture), subject to certain conditions, holders of the Convertible Notes may require the Company to repurchase for cash all or part of their Convertible Notes at a repurchase price equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e554-wk-Fact-26B5A22DC18B934BFABBF1F30299E181" name="ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes Indenture contains customary events of default with respect to the Convertible Notes, including that upon certain events of default (including the Company&#8217;s failure to make any payment of principal or interest on the Convertible Notes when due and payable) occurring and continuing, the Convertible Notes Trustee by notice to the Company, or the holders of at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e561-wk-Fact-2671A8D37CB99E0F7F94F1F3029634CC" name="ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> in principal amount of the outstanding Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the Convertible Notes Trustee at the request of such holders (subject to the provisions of the Convertible Notes Indenture) shall, declare </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e565-wk-Fact-1C03816B19929BD3E461F1F3027D1E8E" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal of and accrued and unpaid interest, if any, on all the Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e569-wk-Fact-1C03816B19929BD3E461F1F3027D1E8E" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal of and accrued and unpaid interest on the Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;">-year term of the Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the Convertible Notes is&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e580-wk-Fact-1B8CFC653E566EC7573FF1F3026A24DF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and was recorded in additional paid-in capital.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accounting for the transaction costs related to the issuance of the Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;">-year term of the Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#8217; equity. Additionally, the Company initially recorded a net deferred tax liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41046530e591-wk-Fact-E59C4AE167646188831FF1F3026BA71F" name="ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments" contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the Notes.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ConvertibleDebtTableTextBlock" id="TextSelection-35CC4DAE940965DECA23F1F302C379F2-0-wk-Fact-73247683427E4C3C769BF1F302A393AA" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes consist of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability&#160;component</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e684-wk-Fact-8363C7A7E31D2D913852F1F3025D7236" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="3" format="ixt:numdotdecimal">150,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e703-wk-Fact-C355729C41B48FB1A7F9F1F30274C970" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="3" format="ixt:numdotdecimal">150,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41046530e723-wk-Fact-C335721B93ADFD0648E9F1F3026A3860" name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41046530e743-wk-Fact-D77E3F9942D6150148E4F1F302591FCB" name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Debt discount, net(1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41046530e769-wk-Fact-EFE07A57E4E9F098B044F1F3027463DD" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41046530e789-wk-Fact-D3CCE67420F073871852F1F30271F31D" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e820-wk-Fact-A25994A587E575E1F5FCF1F30260FCE1" name="us-gaap:LongTermDebt" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e839-wk-Fact-A04793096E3D117E73CAF1F3025CCF0A" name="us-gaap:LongTermDebt" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">113,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the Convertible Notes using the effective interest rate method.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the remaining contractual life of the Convertible Notes is approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41046530e875-wk-Fact-D748F214996095FD6699F1F3029E9CD2" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" format="ixt-sec:duryear">3.1</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" id="TextSelection-905615E676B6C0025346F1F302C356F5-0-wk-Fact-58FAC39D3E9112D47C70F1F3029763A1" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth total interest expense recognized related to the Convertible Notes:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1103-wk-Fact-5F0B231EDA660D8AC687F1F302960998" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1122-wk-Fact-04248ED55D03F2E4A05FF1F302972DE9" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1142-wk-Fact-17E01F6225C3B73D37A6F1F302979153" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1161-wk-Fact-7E870CE7F9E51D23D06DF1F3028FCDCD" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1181-wk-Fact-BE6BF72969CFAA440C84F1F30296A9BD" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1200-wk-Fact-5A7C47B87D16E3C18EE4F1F30288F9F4" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1219-wk-Fact-A0069D950F0CC7DC2343F1F3028D9CF4" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1239-wk-Fact-43E888E7ABA1E4FA2A66F1F302AB340C" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1264-wk-Fact-B7922CA296632AC424F3F1F3028D8A98" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,074</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1283-wk-Fact-68E7DD095275C0761E75F1F30295CA30" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1302-wk-Fact-1F7A40AC889CB77EB0E1F1F30285F6A6" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1322-wk-Fact-3CBF5548F1BF2F3DE1D5F1F30271226E" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1352-wk-Fact-C0918BFD1F671436F41BF1F30296CE89" name="us-gaap:InterestExpenseDebt" contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1371-wk-Fact-2916279B00BE5DFF2BF7F1F30295544C" name="us-gaap:InterestExpenseDebt" contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1391-wk-Fact-C942C58363440820EFE2F1F302920BB4" name="us-gaap:InterestExpenseDebt" contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,498</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1410-wk-Fact-E348A69F4187E718FF36F1F302AD0670" name="us-gaap:InterestExpenseDebt" contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1430-wk-Fact-8067E274E0C7082064FEF1F3028A1C05" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1450-wk-Fact-3D228D9A4DCBB30B5056F1F3028CB2E5" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2018Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1470-wk-Fact-8067E274E0C7082064FEF1F3028A1C05" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41046530e1491-wk-Fact-8400E5C0710CB060B868F1F302A661CF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3E454EA2A0105E97985DF0769E030DAA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-FE55791C4872D1C1DB94F1F302C3A965-0-wk-Fact-C18D2EF16D6DEB8AD9B2F1F3025D9699" continuedAt="TextSelection-FE55791C4872D1C1DB94F1F302C3A965-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">and contingencies</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-FE55791C4872D1C1DB94F1F302C3A965-1"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company's oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program.  Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company&#8217;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company&#8217;s first such milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e372-wk-Fact-A8AD0EAF1A667269BA27F1F3029DC110" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="FI2016Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> payable to Wellcome Trust occurred in the second quarter of 2016.  Additional milestone payments of up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e376-wk-Fact-9C1E25C6F3769A608565F1F3026336B5" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_RangeAxis_srt_MaximumMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> may become payable by the Company to Wellcome Trust under this agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from its licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#8217;s obligation to make such payments would end upon the Company's payment to the SMA Foundation of a specified amount.&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Merger Agreement with Agilis, Agilis equityholders may become entitled to receive contingent consideration payments from the Company based on (i)&#160;the achievement of certain development milestones up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e386-wk-Fact-E4352FF052F170C6ED82F1F30299E272" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, (ii)&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e390-wk-Fact-ECD1AF8A8D555426A41DF1F3024EF182" name="ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">535.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, (iii)&#160;the achievement of certain net sales milestones up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e394-wk-Fact-8607AC3A8D258E7A38B4F1F3029A2C54" name="ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and (iv)&#160;a percentage of annual net sales for&#160;Friedreich Ataxia and Angelman Syndrome during specified terms, ranging from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41047457e398-wk-Fact-78682E0B45B76933DD4BF1F3025DE7B1" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41047457e402-wk-Fact-7C7A49C16B45D88375A2F1F30262CA18" name="ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is required to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e407-wk-Fact-9EFF4764375FB458FD8FF1F302AFC239" name="ptct:DevelopmentMilestonePaymentObligations" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has a Collaboration and License Agreement with Akcea Therapeutics, Inc. ("Akcea") for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean (the "Akcea Collaboration and License Agreement").  Pursuant to the agreement, the Company paid Akcea an upfront licensing fee, which included an initial payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e414-wk-Fact-EF3A00E4AE8943DD6374F1F3026B7149" name="ptct:UpfrontLicensingFee" contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. An additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e418-wk-Fact-FD8341D271A3D00AB5FCF1F30264A297" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid to Akcea in the three month period ended June 30, 2019 upon regulatory approval of Waylivra from the EMA. In addition, Akcea is eligible to receive milestone payments, on a Product-by-Product basis, of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e422-wk-Fact-7F06E055EDF0F850595CF1F3025CCBC7" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon receipt of regulatory approval for a product from ANVISA, subject to a maximum aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41047457e426-wk-Fact-7086229CAB0BE4D78BCAF1F3025942F0" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_srt_RangeAxis_srt_MaximumMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for all such products. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement. The Company filed a request for marketing authorizations for Tegsedi with ANVISA. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna and Emflaza product net sales, payable quarterly or annually in accordance with the terms of the related agreements. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in the Company's clinical trials or otherwise gain access to its product candidates. The Company is not currently aware of any material legal proceedings against it.</span></div></ix:continuation><div><a id="sA04F2FC761925CBBA3C46390C62E44BE"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12.</span><span style="font-family:inherit;font-size:3pt;font-weight:bold;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-EE71FA280AD76CF140DBF1F302C40070-0-wk-Fact-AC08DABB5723D94A3A9CF1F302A132DB" continuedAt="TextSelection-EE71FA280AD76CF140DBF1F302C40070-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</span></ix:nonNumeric></div><ix:continuation id="TextSelection-EE71FA280AD76CF140DBF1F302C40070-1" continuedAt="TextSelection-EE71FA280AD76CF140DBF1F302C40070-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company views its operations and manages its business in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e369-wk-Fact-F37D3921A64F1450D66AF1F302A23204" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q2YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> operating segment. During the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, net product sales in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e381-wk-Fact-F45A6BE0409031CA7044F1F302B3D48B" name="ptct:NetProductSales" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e385-wk-Fact-A18B1885EBA08BBD4586F1F3029FECB5" name="ptct:NetProductSales" contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, consisting solely of Emflaza, and net product sales not in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e390-wk-Fact-627A11DAFD39DA071FA9F1F302A167CB" name="ptct:NetProductSales" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e394-wk-Fact-0A6EFF80B46CA3073F0EF1F302A4A3AC" name="ptct:NetProductSales" contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, consisting of Translarna and Tegsedi.  During the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, net product sales in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e406-wk-Fact-5B38A2F0C9B7F241E4D7415B9FD20D52" name="ptct:NetProductSales" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EE71FA280AD76CF140DBF1F302C40070-2" continuedAt="TextSelection-EE71FA280AD76CF140DBF1F302C40070-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e411-wk-Fact-CAD236100DC7338EBA2B415BBBB6F75B" name="ptct:NetProductSales" contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, consisting solely of Emflaza, and net product sales not in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e415-wk-Fact-86DDBA47F855E8F7B6EE415C0C68ACB0" name="ptct:NetProductSales" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e419-wk-Fact-06C09B99EF3754F8D510415C2ABF2F84" name="ptct:NetProductSales" contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">84.6</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively, consisting of Translarna and Tegsedi.  </span></div><ix:continuation id="TextSelection-91A01C3380EAF019C428F1F302C4FF14-0"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the Company&#8217;s contract liabilities from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606 Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>June&#160;30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e601-wk-Fact-896D56AF2A39EC4539FCF1F302A0A2F6" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e620-wk-Fact-7F7B2A4E8C1C279CCF81F1F302A0A6C9" name="ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,864</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e640-wk-Fact-EC02470105D9DE34E9C1F1F3029E201C" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e659-wk-Fact-DF6CB9299E34F453677FF1F3029F8118" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e678-wk-Fact-0777C08B9E325C5B472048BA3F88695B" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>December&#160;31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606 Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>June&#160;30, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e841-wk-Fact-E858A5059B9BADFCCC95F1F3027C9FBE" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,891</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e860-wk-Fact-29E0A4A4E06A05FE4590F1F3027DF0C4" name="ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e880-wk-Fact-E3706527A9E02EBFBDD9F1F3027D836B" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d41055937e899-wk-Fact-23C0F9529FAE9EBB3BD6F1F3027C53C9" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e919-wk-Fact-754A4B5738D0E79C29E8F1F3027DC3B3" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,540</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company did not have any contract assets for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="TextSelection-A5BEA6C76CF81F9D9021F1F302C30C57-0-wk-Fact-000536BE7A1BC89EF927F1F302A0D53C" continuedAt="TextSelection-91A01C3380EAF019C428F1F302C4FF14-0" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue in the period from:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1087-wk-Fact-5D05FBD3C1DE3D1625C7F1F3024E8263" name="ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1106-wk-Fact-151261F48096A73F0B75F1F302515DB4" name="ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1126-wk-Fact-F60135EBDC7EC3E5E3DAF1F30277F1A0" name="ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1140-wk-Fact-B1FC2FA2F1FD7C7CAA711B6B0F151079" name="ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied in previous period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1160-wk-Fact-5F3122A9DB39C36298B6F1F3024E50A2" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1179-wk-Fact-AC5514D9E4B96551DB14F1F3024F5108" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1198-wk-Fact-521B1D6FA0819C172D9DF1F30279685B" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1213-wk-Fact-D7FC2371AEB5B05705111B6B100961CC" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied in current period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1238-wk-Fact-B5D87C0E294BB46D4147F1F30278A5C1" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1257-wk-Fact-40816A1D82A5B03175A6F1F302509192" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1276-wk-Fact-4533BDB7A731C0C6EFEAF1F302784AA8" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1291-wk-Fact-CAFD1880A4D9D8FD097148BA331B18B4" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1321-wk-Fact-E9E34DA2CDA93D48CA40F1F302540F43" name="ptct:NetProductSales" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1340-wk-Fact-F52D63DDF7FC1641C550F1F3024FDB8D" name="ptct:NetProductSales" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1360-wk-Fact-92CB2F7965BB8E00AFCA48BA3301CBF1" name="ptct:NetProductSales" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1374-wk-Fact-C15A169D03222844F94A1B6B11FFCA18" name="ptct:NetProductSales" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remaining performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining performance obligations&#160;represent the transaction price for goods the Company has yet to provide. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of transaction price allocated to&#160;remaining performance obligations&#160;relating to Translarna net product revenue was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1418-wk-Fact-DC5B0EF70E92BCF54974F1F302A15579" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1422-wk-Fact-E0DB240141D4557587CA48BA35DA3FEA" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company expects to recognize revenue over the next </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers&#8217; needs and schedules.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has ongoing collaborations with the Spinal Muscular Atrophy Foundation ("SMA Foundation") and F. Hoffman-La Roche&#160;Ltd and Hoffman- La Roche&#160;Inc. (collectively, "Roche") and early stage discovery arrangements with other institutions. The following are the key terms to the Company&#8217;s (i)&#160;ongoing collaborations and (ii)&#160;early stage discovery and development arrangements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Roche and SMA Foundation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2011, the Company and the SMA Foundation entered into a licensing and collaboration agreement with Roche for a spinal muscular atrophy program. Under the terms of the agreement, Roche acquired an exclusive worldwide license to the Company&#8217;s spinal muscular atrophy program, which includes </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1452-wk-Fact-A3F73705C6C007F816FDF1F302A6D67B" name="ptct:CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment" contextRef="D2011Q4Nov1-Nov30_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="compound" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> compounds currently in preclinical development, as well as potential back-up compounds. The Company received a nonrefundable upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1456-wk-Fact-7303DBDAD072CC7A9E52F1F302B0EC76" name="ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts" contextRef="D2011Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the research term, which was terminated effective December&#160;31, 2014, after which Roche provided the Company with funding, based on an agreed- upon full-time equivalent rate, for an agreed-upon number of full-time equivalent employees that the Company contributed to the research program.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company identified </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1463-wk-Fact-2BD5C9EF7CD37BC10CCFF1F302A23F7A" name="ptct:CollaborativeArrangementsNumberOfSignificantDeliverables" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="deliverable" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> material promises in the collaboration agreement, the license and the research activities. The Company evaluated whether these material promises are distinct and determined that the license does not have standalone functionality and there is a significant integration of the license and research activities. As such, both promises were bundled into one distinct performance obligation. As a result, the Company deferred the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1467-wk-Fact-DF45766329A4D5CC79A9F1F302A3CDAD" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="I2011Q4Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment which was recognized over the </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EE71FA280AD76CF140DBF1F302C40070-3" continuedAt="TextSelection-EE71FA280AD76CF140DBF1F302C40070-4"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">estimated performance period of </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> years, which was the contracted research period. As of adoption of ASC Topic 606 on January 1, 2018, all performance obligations had been satisfied and the balance of the remaining deferred upfront payment was fully recognized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1481-wk-Fact-A827833681607E806697F1F302A0C334" name="ptct:RevenueRecognitionMilestonePotentialAchievements" contextRef="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">135.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development event milestones, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1485-wk-Fact-A833023FE51E2FA4F552F1F302A14BE0" name="ptct:RevenueRecognitionMilestonePotentialAchievements" contextRef="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">325.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2013, a lead development compound, RG7800, was selected to move into IND-enabling studies, which triggered a milestone payment to the Company from Roche of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1492-wk-Fact-2AA439FAD912F7965D87F1F3024BC355" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2013Q3Aug_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2013.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2014, the Company announced the initiation of a Phase&#160;1 clinical program in its spinal muscular atrophy collaboration with Roche and the SMA Foundation which triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1499-wk-Fact-3974780EB1182484CD50F1F302A1F01C" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2014Q1Jan1-Jan31_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2014.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2014, the Company announced the initiation of a Phase&#160;2 study in adult and pediatric patients in its spinal muscular atrophy collaboration with Roche and the SMA Foundation which triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1507-wk-Fact-C4561AAC0C145E7F20D7F1F302A6A9E4" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2014Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> payment from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2014.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, the Company announced that the Sunfish, a two-part clinical trial in pediatric and adult type 2 and type 3 spinal muscular atrophy initiated in the fourth quarter of 2016 with Roche and SMA Foundation, had transitioned into the pivotal second part of its study. The achievement of this milestone triggered a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1514-wk-Fact-0BEC7561A6B07E941464F1F302B27D99" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2017Q4Oct_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;payment to the Company from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2017.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The remaining potential research and development event milestones that can be received as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1525-wk-Fact-7006AF0C7B164F013FE0F1F302A2DAAD" name="ptct:RevenueRecognitionMilestonePotentialAchievements" contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">87.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The remaining potential sales milestones as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1533-wk-Fact-079DE53E9589569B490BF1F302A83888" name="ptct:RevenueRecognitionMilestonePotentialAchievements" contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">325.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon achievement of certain sales events. In addition, the Company is eligible to receive up to double digit royalties on worldwide annual net sales of a commercial product.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue related to the licensing and collaboration agreement with Roche of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1548-wk-Fact-131B8D30514C9DE1AD85F1F302A72DBA" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1552-wk-Fact-DF8EAD55F85EE0EB9E2148AD72CB28F0" name="us-gaap:Revenues" contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue related to the licensing and collaboration agreement with Roche of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1569-wk-Fact-0D2C9799991712E92A2B4A11399C1FE5" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1573-wk-Fact-0EDE2D6CE255B3BC665E4A1167E50F1B" name="us-gaap:Revenues" contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.   </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Early stage collaboration and discovery agreements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company has arrangements with several organizations pursuant to which the Company uses its discovery technologies to help identify potential drug candidates. The Company does not take ownership of the potential compounds, but rather provides research services to the collaborator using its specialized technology platform.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, these arrangements are structured such that the collaborator and the Company work together to jointly select targets from which to apply its discovery technologies. The research period for the Company to apply its technology is generally </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;"> years. The Company will typically receive a nonrefundable, upfront cash payment and the collaborator agrees to provide funding for research activities performed on its behalf.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41055937e1597-wk-Fact-10005E59551DEF55FCFAF1F3029FB78B" name="ptct:CollaborativeArrangementsNumberOfSignificantDeliverables" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember" unitRef="deliverable" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> material promises in these arrangements are the license and the research activities. The Company evaluated whether these material promises are distinct and determined that the license does not have standalone functionality and there is a significant integration of the license and research activities. As such, both promises are bundled into one distinct performance obligation. As of adoption of ASC Topic 606 on January 1, 2018, all deferred revenue related to these arrangements had been recognized. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company did </span><span style="font-family:inherit;font-size:10pt;">not</span><span style="font-family:inherit;font-size:10pt;"> recognize any revenue related to discovery agreements. </span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-EE71FA280AD76CF140DBF1F302C40070-4" continuedAt="TextSelection-EE71FA280AD76CF140DBF1F302C40070-5"><span style="font-family:inherit;font-size:10pt;">The Company is eligible to receive additional payments from its early stage discovery research arrangements if the discovery compounds are ultimately developed and commercialized. The aggregate potential payments the Company is eligible for if all products are developed is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1620-wk-Fact-155C73D4D67E1668E5A8F1F302987CDA" name="ptct:RevenueRecognitionMilestonePotentialAchievements" contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">143.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41055937e1624-wk-Fact-8DD84FCF3A930C552CAFF1F302997E0D" name="ptct:RevenueRecognitionMilestonePotentialAchievements" contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">252.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in sales milestones upon achievement of specified sales events and up to double digit royalties on worldwide annual net sales of the licensed product.  The Company will recognize revenue when it is probable the milestones will be achieved (see Note 2).  For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company did </span><span style="font-family:inherit;font-size:10pt;">not</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-EE71FA280AD76CF140DBF1F302C40070-5"> recognize any revenue related to early stage collaborations.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB36A558E78F8581F8CD655F0290C406F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-F4D81D79033A62BE86D1F1F302C42CAD-0-wk-Fact-7C0A933EA2D2F0DF19B7F1F30276341D" continuedAt="TextSelection-F4D81D79033A62BE86D1F1F302C42CAD-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible assets and goodwill</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-F4D81D79033A62BE86D1F1F302C42CAD-1" continuedAt="TextSelection-F4D81D79033A62BE86D1F1F302C42CAD-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Definite-lived intangibles</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 20, 2017, the Company completed its previously announced acquisition of all rights to Emflaza pursuant to the Asset Purchase Agreement, dated March 15, 2017, and amended on April 20, 2017, by and between the Company and Marathon. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. In accordance with ASU No. 2017-01, the Company determined that substantially all of the fair value is concentrated in the Emflaza rights intangible asset and as such accounted for the transaction as an asset acquisition under ASC 805-50 and recorded an intangible asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e368-wk-Fact-20C98DC26C1ACC727F69F1F302714175" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2017Q2Apr-20_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Emflaza rights intangible asset is being amortized to cost of product sales over its expected useful life of approximately </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> years on a straight line basis.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company will record the milestone payment when it becomes payable to Marathon and increase the cost basis for the Emflaza rights intangible asset. For the three month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e390-wk-Fact-579B5043BED29B25D7761B76D93E1EA5" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e394-wk-Fact-267D2AF2A31DE80E88241B772FB86C6F" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" contextRef="FI2018Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded, respectively. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Akcea Collaboration and License Agreement, in May 2019 the Company made a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e405-wk-Fact-FD8341D271A3D00AB5FCF1F30264A297" name="ptct:MilestonePotentialAchievementsRegulatoryApproval" contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment to Akcea upon regulatory approval of Waylivra from the EMA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately ten years on a straight line basis. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement related to sales of Waylivra. In accordance with the guidance for an asset acquisition, the Company will record royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra intangible asset. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized amortization expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e420-wk-Fact-7232569FDF3B3D252437F1F302770C6C" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e424-wk-Fact-BA2068543A375AA18018F1F30255188F" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the Emflaza rights and Waylivra intangible assets. For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized amortization expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e441-wk-Fact-6814295B802475874516415D51ED620E" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e445-wk-Fact-1CC91D1B6BAC2F187075415D7942A4B5" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the Emflaza rights and Waylivra intangible assets. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-6B4B9C3AE12C44FFF745F1F302C4BD2A-0-wk-Fact-AB5E9CF463B446D8A475F1F3027256DA" escape="true"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated future amortization of the Emflaza rights and Waylivra intangible asset is expected to be as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41049013e510-wk-Fact-FCFDF5C2C44B763604331B7335CEC1FC" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41049013e530-wk-Fact-60FBBDE505E65DCE2D321B7343677E44" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41049013e555-wk-Fact-C27AB59F31807FB725C31B735108D5F6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41049013e580-wk-Fact-DBE754D963C6D80ACA381B735D9DCC46" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41049013e605-wk-Fact-6FC1D4058DF54396572D1B736B2AFA90" name="ptct:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41049013e635-wk-Fact-44AD0A35AB7AF9AF58A21B7376F2EE67" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Indefinite-lived intangibles</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Agilis, the Company acquired rights to PTC-AADC, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The Agilis platform also includes a gene therapy asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. An investigational new drug ("IND") submission with the FDA for this program is expected in late 2019. Additionally, the Agilis platform includes two other gene therapy programs targeting CNS disorders, including Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition.  The Company classified the fair value of the acquired IPR&amp;D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts.&#160;The value allocated to the indefinite lived intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e655-wk-Fact-DF8B758291E61905CF81F1F30254BC1B" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F4D81D79033A62BE86D1F1F302C42CAD-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the Merger on August 23, 2018, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41049013e666-wk-Fact-CBB81CB885D77F156E2A49F757E9F36A" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill. There were no changes to the recorded value of goodwill for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="sD0837C7668005C49B5BD115D3B006E09"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">14.</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-1948262E7F892FE91559F1F302C45528-0-wk-Fact-6FAAFC5DDD2DD6189BC6F1F302774EA5" continuedAt="TextSelection-1948262E7F892FE91559F1F302C45528-1" escape="true"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent events</span></div></ix:nonNumeric></td></tr></table><ix:continuation id="TextSelection-1948262E7F892FE91559F1F302C45528-1"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 4, 2019, the Company and Bristol-Myers Squibb Company, (the &#8220;Landlord&#8221;) entered into a Lease Agreement&#160;(the &#8220;Lease&#8221;), relating to the lease&#160;of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41056046e368-wk-Fact-889C5CEBE638BEEA7EA5630DCF3B0927" name="ptct:Feet" contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Feet" decimals="0" scale="0" format="ixt:numdotdecimal">185,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office, production and laboratory space at a facility located in Hopewell Township, New Jersey (the &#8220;Campus&#8221;).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The rental term of the Lease is currently estimated to commence on July 1, 2020 (the &#8220;Commencement Date&#8221;). Upon the Commencement Date, the Lease has an initial term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41056046e375-wk-Fact-03F7CD2D99605747FB22596F5934F927" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen">fifteen years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> (the &#8220;Initial Term&#8221;), with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41056046e379-wk-Fact-958BCC56444A041FB17F630B9DBC968B" name="ptct:Numberofterms" contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Term" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;">-year renewal periods at the Company&#8217;s option.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate rent for the Initial Term will be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41056046e390-wk-Fact-450EF874FEBE8344B4095972DC02B510" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">88.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The rental rate for the renewal periods will be </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41056046e394-wk-Fact-064F91DD6B891B3F729C6315B4DC083A" name="ptct:PercentOfMarketRate" contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">95</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Prevailing Market Rate (as defined in the Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of the Lease, the Company has a right of first refusal to rent certain other space of the Campus, which would be triggered upon the Landlord&#8217;s issuance of a second round proposal or letter of intent to another tenant for such space. The Company also may seek to build a new separate building on the Campus, which may not contain less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41056046e401-wk-Fact-24BDD99087C66685D8A4630F44E65E4B" name="ptct:Feet" contextRef="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Feet" decimals="0" scale="0" format="ixt:numdotdecimal">75,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet (the &#8220;New Building&#8221;). Upon receipt of notice of the Company&#8217;s intention to build the New Building, the Landlord may, in its sole discretion, construct and lease the New Building to the Company or enter into a ground lease with the Company permitting the Company to construct the New Building. The term for the New Building will be </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41056046e405-wk-Fact-89A3F4549E71471F5A436311EC1FA113" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen">fifteen years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d41056046e409-wk-Fact-A4CAD95F40E65C622A9163128EF00D7E" name="ptct:Numberofterms" contextRef="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Term" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive five-year renewal rights. Rent terms for the New Building will be determined based on the land value, construction and project costs subject to whether the Landlord or Company constructs the New Building.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also obligated to provide the Landlord with either an unconditional, irrevocable and transferable letter of credit (the &#8220;Letter of Credit&#8221;) in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41056046e416-wk-Fact-B4A1385DF86BDAAEC2695973FF4D0662" name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, for a term of not less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d41056046e420-wk-Fact-AE02DA7E8CCEF683970F63ABCA2F2E2A" name="ptct:Termforletterofcredit" contextRef="D2019Q3Aug4-Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, as a security deposit, or the same amount as a cash security deposit within thirty days upon entering into the Lease. The Letter of Credit shall remain in effect continuously and shall either expire (i) sixty days after the Expiration Date (as defined in the Lease) or (ii) be automatically self-renewing until the Expiration Date. If the Lease is extended, the Company must continue to provide and maintain the Letter of Credit until sixty days after the extended Expiration Date. If after the fifth anniversary of the Commencement Date, the Company has not received notice of being in default of the Lease, then the Letter of Credit shall be reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d41056046e424-wk-Fact-39E589A8E59E1A8DA87F62DAB416FE21" name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="I2019Q3Aug4_us-gaap_DebtInstrumentAxis_ptct_FifthAnniversaryMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Lease contains customary events of default, representations, warranties and covenants.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The foregoing summary of the Lease and Letter of Credit are not complete and are qualified in their entirety by reference to the Lease and Letter of Credit, which will be filed as exhibits to the Company&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2019.</span></div></ix:continuation><div><a id="s333FAE3C9F7E56D2B7CDDCECC90C547E"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this Quarterly Report on Form&#160;10-Q and the audited consolidated financial statements and notes thereto and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended&#160;December&#160;31, 2018 included in our Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission on March 1, 2019, or our 2018 Annual Report. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth in Part&#160;II,&#160;Item 1A. (Risk Factors) of this Quarterly Report on Form&#160;10-Q and Part&#160;I,&#160;Item 1A. (Risk Factors) of our 2018 Annual Report, and  our actual results may differ materially from those anticipated in these forward-looking statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Company</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Our ability to commercialize products is the foundation that drives our continued investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. Our strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage our global commercial infrastructure to maximize value for our patients and other stakeholders.</span></div><div><a id="sA206ED73537557208B7161664B35DA5A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Updates</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">DMD Franchise</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have two products, Translarna&#8482;&#160;(ataluren) and Emflaza&#8482; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. &#160;Translarna received marketing authorization from the European Commission in August 2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged&#160;five&#160;years and older in the&#160;31&#160;member states of the European Economic Area, or EEA. In July 2018, the European Commission approved a label-extension request to our marketing authorization for Translarna in the EEA to include patients from two to up to five years of age.&#160;During the quarter ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized </span><span style="font-family:inherit;font-size:10pt;">$57.8 million</span><span style="font-family:inherit;font-size:10pt;"> in net sales of Translarna. </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;">Translarna is currently available for the treatment of nmDMD in over </span><span style="font-family:inherit;font-size:10pt;">40</span><span style="font-family:inherit;font-size:10pt;"> countries on a commercial basis or through a reimbursed early access program, or EAP program. We hold worldwide commercialization rights to Translarna for all indications in all territories. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. During the quarter ended&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, Emflaza achieved net sales of </span><span style="font-family:inherit;font-size:10pt;">$27.6 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the European Medicines Agency, or EMA, of the benefit-risk balance of the authorization, which we refer to as the annual EMA reassessment. In July 2019, the European Commission renewed our marketing authorization, making it effective, unless extended, through August 5, 2020.&#160;This marketing authorization is further subject to a specific obligation to conduct and submit the results of an 18-month, placebo-controlled trial, followed by an 18-month open-label extension, which we refer to together as Study 041. The final report on the trial and open-label extension is to be submitted by us to the EMA by the end of the third quarter of 2022. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we submitted to the EMA a label-extension request to our marketing authorization in the EEA to include patients who are non-ambulatory. In June 2019, the Committee for Medicinal Products for Human Use, or CHMP, of the EMA informed us that it had adopted a negative opinion of our label-extension request. We have requested a re-examination of the procedure and expect the new examination to last approximately four months.&#160;However, there can be no assurances that we will successfully obtain such label extension. In conjunction with informing us of the negative opinion of our label-extension request, we were also informed by EMA representatives that the European Public Assessment Report, or EPAR, would be updated to clarify that patients who start Translarna while ambulatory are not required to discontinue treatment after loss of ambulation. Subsequently, we were informed that the EPAR could not be changed in the context of the current procedure. Should the re-examination of our label-extension request end with a negative opinion, we expect to continue our discussions with the EMA about their ability to change the EPAR as originally communicated to us.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019 we received approval for marketing authorization for Translarna in Brazil from ANVISA, the Brazilian health regulatory authority, for the treatment of nmDMD in ambulatory patients aged&#160;five&#160;years and older.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each country, including each member state of the EEA, has its own pricing and reimbursement regulations. In order to commence commercial sale of product pursuant to our Translarna marketing authorization in any particular country in the EEA, we must finalize pricing and reimbursement negotiations with the applicable government body in such country. As a result, our commercial launch will continue to be on a country-by-country basis.&#160;We also have made, and expect to continue to make, product available under EAP programs, both in countries in the EEA and other territories. Our ability to negotiate, secure and maintain reimbursement for product under commercial and EAP programs can be subject to challenge in any particular country and can also be affected by political, economic and regulatory developments in such country.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is substantial risk that if we are unable to renew our EEA marketing authorization during any annual renewal cycle, or if our product label is materially restricted, or if Study 041 does not provide the data necessary to maintain our marketing authorization, we would lose all, or a significant portion of, our ability to generate revenue from sales of Translarna in the EEA and other territories.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, we filed a New Drug Application, or NDA, for Translarna for the treatment of nmDMD over protest with the United States Food and Drug Administration, or FDA. In October 2017, the Office of Drug Evaluation I of the FDA issued a Complete Response Letter for the NDA, stating that it was unable to approve the application in its current form. In response, we filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied our appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#8217; muscles. We intend to follow the FDA&#8217;s recommendation and will collect, using newer technologies via procedures and methods that we designed, such dystrophin data in a new study, Study 045, which we initiated in the fourth quarter of 2018. We expect that a potential re-submission of an NDA could occur in 2020. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is substantial risk that Study 045, or any other studies we may use to collect the dystrophin data, will not provide the necessary data to support a marketing approval for Translarna for the treatment of nmDMD in the U.S.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emflaza was initially approved in the United States for the treatment of DMD in patients five years and older. In June 2019, the FDA approved our label expansion request for Emflaza for patients two to five years of age. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gene Therapy Platform</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system, or CNS, including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, or AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. We are preparing a biologics license application, or BLA, for PTC-AADC for the treatment of AADC deficiency in the United States, which we anticipate submitting to the FDA in the fourth quarter of 2019, with an anticipated commercial launch in the United States in 2020. We are also preparing a marketing authorization application, or MAA, for PTC-AADC for the treatment of AADC deficiency in the European Union, or EU, for submission to the EMA, which will follow our BLA submission to the FDA.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Akcea Partnership</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We hold the rights for the commercialization of Tegsedi&#8482; (inotersen) and Waylivra&#8482; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean, or the PTC Territory, pursuant to our collaboration and license agreement with Akcea Therapeutics, Inc, or the Akcea Agreement.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tegsedi has received marketing authorization in the U.S., EU and Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis. We filed for marketing authorization with ANVISA, the Brazilian health regulatory authority, which granted priority review. We expect approval in Brazil by the end of 2019. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Waylivra has received conditional marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. In connection with the conditional marketing approval for Waylivra in the EU, the European Commission is requiring&#160;Akcea to provide results of a study based on a registry of patients to investigate how blood checks and adjustments to frequency of injections are carried out in practice and how well they work to prevent thrombocytopenia and bleeding&#160;in FCS patients taking Waylivra.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neither Tegsedi nor Waylivra is currently approved for marketing in the PTC Territory.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Splicing Platform</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have a spinal muscular atrophy, or SMA, collaboration with F. Hoffman-La Roche&#160;Ltd. and Hoffman-La Roche&#160;Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation. Currently, our collaboration has two pivotal clinical trials ongoing to evaluate the safety and effectiveness of risdiplam (RG7916, RO7034067), the lead compound in the SMA program. Roche is preparing an NDA and a MAA for risdiplam for the treatment of SMA in the United States and the EU, respectively, which Roche anticipates submitting to the FDA in the second half of 2019 and the EMA in the first half of 2020.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pre-clinical and other programs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we have a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div><a id="s0DAB37208CDB5AA6AF84ED7B01A20C63"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Funding</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The success of our products, product candidates and any other product candidates we may develop, depends largely on obtaining and maintaining reimbursement from governments and third-party insurers. Our revenues are primarily generated from sales of Translarna for the treatment of nmDMD in territories where we are permitted to distribute Translarna under our EAP programs and in countries in the EEA where we were able to obtain acceptable commercial pricing and reimbursement terms, and from sales of Emflaza for the treatment of DMD in the United States.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, we have financed our operations primarily through our offering of 3.0% convertible senior notes due August&#160;15, 2022, or the Convertible Notes offering, our public offerings of common stock in February&#160;2014, October&#160;2014, April 2018, and January 2019, our initial public offering of common stock in June&#160;2013, private placements of our preferred stock, collaborations, bank debt and convertible debt financings, a credit and security agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and other certain institutions as lenders thereto, and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. Since 2014, we have also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and in May 2017, we began to recognize revenue generated from net sales of Emflaza for the treatment of DMD in the United States. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement provides for a senior secured term loan facility of $60 million, of which $40 million was drawn by us on May 5, 2017. Our ability to draw on the remaining $20 million under the senior secured term loan facility expired on December 31, 2018. The maturity date of the Credit Agreement is May 1, 2021, unless terminated earlier. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we made loan repayments of $</span><span style="font-family:inherit;font-size:10pt;">1.7 million</span><span style="font-family:inherit;font-size:10pt;"> on the Credit Facility.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, we closed an underwritten public offering of our common stock pursuant to a registration statement on Form S-3. We issued and sold an aggregate of 7,563,725 shares of common stock under the registration statement at a public offering price of $30.20 per share, including 843,725 shares issued upon exercise by the underwriter of its option to purchase additional shares in February 2019. We received net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;">$224.5 million</span><span style="font-family:inherit;font-size:10pt;"> after deducting underwriting discounts and commissions and other offering expenses payable by us.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$1,052.8 million</span><span style="font-family:inherit;font-size:10pt;">. We had a net loss of </span><span style="font-family:inherit;font-size:10pt;">$113.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$28.8 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate that our expenses will continue to increase&#160;in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including the expansion of our infrastructure and corresponding sales and marketing, legal and regulatory, distribution and manufacturing and administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur significant costs&#160;in connection with Study 041 and Study 045 and our open label extension trials of Translarna for the treatment of nmDMD as well as our studies for nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5 and our FDA post-marketing requirements with respect to Emflaza in the United States and studies for limb-girdle 2I. We also expect to incur ongoing research and development expenses for our other product candidates, including our gene therapy, splicing and oncology programs. In addition, we may incur substantial costs in connection with our efforts to advance our regulatory submissions. We have begun seeking and intend to continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories outside of the EEA and we may also seek marketing authorization for Translarna for other indications. In the fourth quarter of 2019, we plan to submit a request for marketing authorization for PTC-AADC with the FDA, followed by a request for marketing authorization for PTC-AADC with the EMA and we recently submitted a request for marketing authorization for Tegsedi with ANVISA. These efforts may significantly impact the timing and extent of our commercialization expenses.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may seek to continue to expand and diversify our product pipeline through opportunistically in-licensing or acquiring the rights to products, product candidates or technologies and we may incur expenses, including with respect to transaction costs, subsequent development costs or any upfront, milestone or other payments or other financial obligations associated with any such transaction, which would increase our future capital requirements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to our outstanding Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which require total funding of $4.5 million annually. Additionally, under the terms of our Credit Agreement cash interest and principal payments are payable monthly in arrears. Furthermore, as a result of our initial public offering in June&#160;2013, we have incurred and expect to continue to incur additional costs associated with operating as a public company including significant legal, accounting, investor relations and other expenses. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never been profitable and we will need to generate significant revenues to achieve and sustain profitability, and we may never do so. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or our commercialization efforts.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial operations overview</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, our net product sales have consisted primarily of sales of Translarna for the treatment of nmDMD in territories outside of the United States and sales of Emflaza for the treatment of DMD in the United States. Our process for recognizing revenue is described below under &#8220;Critical accounting policies and significant judgments and estimates&#8212;Revenue recognition&#8221;.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Roche and the SMA Foundation Collaboration.</span><span style="font-family:inherit;font-size:10pt;">&#160; In November&#160;2011, we entered into a license and collaboration agreement, or licensing agreement, with Roche and the SMA Foundation pursuant to which we are collaborating with Roche and the SMA Foundation to further develop and commercialize compounds identified under our SMA program with the SMA Foundation. The research component of this agreement terminated effective December&#160;31, 2014. The licensing agreement included a $30 million upfront payment made in 2011 which was recognized on a deferred basis over the research term, and the potential for up to $460 million in milestone payments and royalties on net sales.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2013, we announced the selection of a development candidate. The achievement of this milestone triggered a $10.0 million payment to us from Roche, which we recorded as collaboration revenue for the year ended December&#160;31, 2013.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January&#160;2014, we initiated a Phase 1 clinical program, which triggered a $7.5 million milestone payment to us from Roche which we recorded as collaboration revenue for the year ended December&#160;31, 2014.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November&#160;2014, we announced that our joint development program in SMA with Roche and the SMA Foundation had started a Phase 2 study in adult and pediatric patients. The achievement of this milestone triggered a $10.0 million payment to us from Roche which we recorded as collaboration revenue for the year ended December&#160;31, 2014.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we announced that the joint development program in SMA with Roche and SMA Foundation had transitioned into the pivotal second part of its study evaluating the efficacy and safety of RG7916 in pediatric and adult Type 2/3 SMA patients. The achievement of this milestone triggered a $20.0 million payment to us from Roche which we recorded as collaboration revenue at time of achievement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Grant revenue.</span><span style="font-family:inherit;font-size:10pt;">&#160; From time to time, we receive grant funding from various institutions and governmental bodies. The grants are typically for early discovery research, and generally such grant programs last from two to five years.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expense</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses consist of the costs associated with our research activities, as well as the costs associated with our drug discovery efforts, conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;&#160;&#160;&#160;&#160;external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;&#160;&#160;&#160;&#160;employee-related expenses, which include salaries and benefits, including share-based compensation, for the personnel involved in our drug discovery and development activities; and</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;&#160;&#160;&#160;&#160;facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities,&#160;IT, human resources and other support functions, depreciation of leasehold improvements and equipment, and laboratory and other supplies.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use our employee and infrastructure resources across multiple research projects, including our drug development programs. We track expenses related to our clinical programs and certain preclinical programs on a per project basis.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect our research and development expenses to fluctuate in connection with our ongoing activities, particularly in connection with Study 041 and other studies for Translarna for the treatment of nmDMD, our studies of Translarna in nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5, our studies of Emflaza in limb-girdle 2I, activities under our gene therapy, splicing and oncology programs, and performance of our FDA post-marketing requirements with respect to Emflaza in the United States. The timing and amount of these expenses will depend upon the outcome of our ongoing clinical trials and the costs associated with our planned clinical trials. The timing and amount of these expenses will also depend on the costs associated with potential future clinical trials of our products or product candidates and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs, and product and product candidate manufacturing costs.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide research and development expense for our most advanced principal product development programs, for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Translarna (nmDMD, aniridia and Dravet)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,942</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,305</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,833</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,081</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emflaza</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,381</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,754</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other research and preclinical</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,439</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,830</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59,979</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32,607</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Translarna (nmDMD, aniridia and Dravet)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34,778</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34,470</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gene Therapy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,740</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,204</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,314</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emflaza</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,382</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,823</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other research and preclinical</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,440</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,363</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">112,544</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63,970</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The successful development of our products and product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, rate of progress and expense of our clinical trials and other research and development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential benefits of our products and product candidates over other therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to market, commercialize and achieve market acceptance for any of our products or product candidates that we are developing or may develop in the future, including our ability to negotiate pricing and reimbursement terms acceptable to us and to obtain and maintain marketing authorizations we currently have or may receive in the future for our products and product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the terms and timing of regulatory approvals; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A change in the outcome of any of these variables with respect to the development of our products or product candidates could mean a significant change in the costs and timing associated with the development of that product or product candidate. For example, if the EMA or FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of Translarna or any other product candidate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expense</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses consist primarily of salaries and other related costs for personnel, including share-based compensation expenses, in our executive, legal, business development, commercial, finance, accounting, information technology and human resource functions. Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development expense; advertising and promotional expenses; costs associated with industry and trade shows; and professional fees for legal services, including patent-related expenses, accounting services and miscellaneous selling costs.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that selling, general and administrative expenses will increase in future periods in connection with our continued efforts to commercialize Emflaza in the United States, our continued efforts to commercialize Translarna for the treatment of nmDMD in territories outside the United States, our efforts to commercialize Waylivra and Tegsedi in Latin America and the Caribbean and to support our operations, including increased payroll, expanded infrastructure, commercial operations, increased consulting, legal, accounting and investor relations expenses.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense, net</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net consists of interest income earned on investments and interest expense from the Convertible Notes outstanding and interest expense from the Credit Agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical accounting policies and significant judgments and estimates</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were no material changes to our critical accounting policies as reported in our 2018 Annual Report on Form&#160;10-K, other than those disclosed below.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Product Revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. We recognize revenue when performance obligations with customers have been satisfied.  Our performance obligations are to provide Translarna or Emflaza based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when our customer obtains control of either Translarna or Emflaza, which is typically upon delivery. We invoice customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of invoice date.  We determine the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods not yet provided. As we have identified only one distinct performance obligation, the transaction price is allocated entirely to either product sales of Translarna or Emflaza.  In determining the transaction price, a significant financing component does not exist since the timing from when we deliver product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record product sales net of any variable consideration, which includes discounts, allowances, rebates and distribution fees. We use the expected value or most likely amount method when estimating variable consideration, unless discount or rebate terms are specified within contracts. Historically, returns of Translarna and Emflaza have been immaterial to our financial statements, except as related to labeling changes and changes in specialty pharmacies. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In relation to customer contracts, we incur costs to fulfill a contract but do not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of ASC Topic 606 on January 1, 2018, we have elected the following practical expedients:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio Approach - We applied the Portfolio Approach to contract reviews within identified revenue streams that have similar characteristics and we believe this approach would not differ materially than if applying ASC Topic 606 to each individual contract.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant Financing Component - We expect the period between when we transfer a promised good or service to a customer and when the customer pays for the good or service to be one year or less. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immaterial Performance Obligations - We disregard promises deemed to be immaterial in the context of the contract. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and Handling Activities - We consider any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of these agreements typically include payments to us of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, we generate service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of a collaboration arrangement, we need to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#8220;Collaborative Arrangements&#8221; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, we assess the promises in the arrangement to identify distinct performance obligations.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For licenses of intellectual property, we assess, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. We determine if the bundled performance </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obligation is satisfied over time or at a point in time.  If we conclude that the nonrefundable, upfront license fees will be recognized over time, we assess the appropriate method of measuring proportional performance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For milestone payments, we assess, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, we will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within our control.  If it is probable that a significant revenue reversal will not occur, we will estimate the milestone payments using the most likely amount method.  We will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. We record these reimbursements as revenue and not as a reduction of research and development expenses as we have the risks and rewards as the principal in the research and development activities.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, &#8220;Leases (Topic 842)&#8221; along with other amendments issued in 2017 and 2018. Topic 842 supersedes the lease accounting requirements in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Codification Topic 840, Leases</span><span style="font-family:inherit;font-size:10pt;">&#160;(Topic 840). Topic 842 requires organizations to recognize leased assets and liabilities on the balance sheet. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to us the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to us if we obtain the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. We have lease agreements which include lease and non-lease components, which we account for as a single lease component for all leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the standard, operating leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease payments associated with our leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in our consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and we recognize lease expense for these leases on a straight-line basis over the lease term. We apply this policy to all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. We give consideration to our recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating our incremental borrowing rates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease term for all of our leases includes the non-cancellable period of the lease plus any additional periods covered by either our option to extend (or not to terminate) the lease that we are reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.</span></div><div><a id="s2B060C7FC55D53DDBC2236CDD2DE6016"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> Results of operations</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three months ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> compared to three months ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes revenues and selected expense and other income data for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85,476</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68,170</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,306</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration and grant revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">573</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(527</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product sales, excluding amortization of acquired intangible asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,211</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,572</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">639</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of acquired intangible asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,593</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">982</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59,979</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32,607</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,372</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49,215</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,545</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,670</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in the fair value of deferred and contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,300</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,300</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,074</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,884</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">810</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(183</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(673</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">490</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(774</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(389</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(385</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net product revenues.</span><span style="font-family:inherit;font-size:10pt;"> Net product revenues were </span><span style="font-family:inherit;font-size:10pt;">$85.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$17.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">25%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$68.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The increase in net product revenue was primarily due to the increase in net product sales in existing markets where Translarna is available as well as continued geographic expansion into new territories, in addition to an increase of $7.3 million in net product sales of Emflaza.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration and grant revenues.</span><span style="font-family:inherit;font-size:10pt;"> Collaboration and grant revenues were </span><span style="font-family:inherit;font-size:10pt;">$0.1</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$0.5 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">92%</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$0.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The decrease in collaboration and grant revenues is related to our ongoing collaboration arrangements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of product sales, excluding amortization of acquired intangible asset</span><span style="font-family:inherit;font-size:10pt;">. Cost of product sales, excluding amortization of acquired intangible asset, were </span><span style="font-family:inherit;font-size:10pt;">$3.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$0.6 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">25%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$2.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. Cost of product sales consist primarily of royalty payments associated with Emflaza and Translarna net product sales, excluding contingent payments to Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC) or Marathon, and costs associated with Emflaza and Translarna product sold during the period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization of acquired intangible asset</span><span style="font-family:inherit;font-size:10pt;">. Amortization of our intangible assets were </span><span style="font-family:inherit;font-size:10pt;">$6.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$1.0 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$5.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. These amounts are related to the acquisition of all rights to Emflaza acquired in May 2017, Marathon contingent payments, and the Waylivra intangible asset.  The increase is primarily related to additional Marathon contingent payments. The amount allocated to the Emflaza intangible asset is amortized on a straight-line basis over its estimated useful life of approximately seven years from the date of the completion of the acquisition of all rights to Emflaza, the period of estimated future cash flows. The Marathon contingent payments are amortized prospectively as incurred, straight-line, over the remaining useful life of the Emflaza intangible asset. The Waylivra asset is amortized on a straight-line basis over its estimated useful life of approximately ten years. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense.</span><span style="font-family:inherit;font-size:10pt;"> Research and development expense was </span><span style="font-family:inherit;font-size:10pt;">$60.0</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$27.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">84%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$32.6</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> reflects costs associated with advancing the gene therapy platform and increased investment in research programs as well as advancement of the clinical pipeline.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expense.</span><span style="font-family:inherit;font-size:10pt;"> Selling, general and administrative expense was </span><span style="font-family:inherit;font-size:10pt;">$49.2</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$15.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">47%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$33.5</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to continued investment to support our commercial activities including our expanding commercial portfolio.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Change in the fair value of deferred and contingent consideration.  </span><span style="font-family:inherit;font-size:10pt;">The change in the fair value of deferred and contingent consideration was </span><span style="font-family:inherit;font-size:10pt;">$5.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The change is related to the fair valuation of the potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc., or Agilis, as a result of our merger with Agilis which closed in August 2018. Changes in the fair value were due to the re-calculation of discounted cash flows for the passage of time and changes to certain other estimated assumptions.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense, net.</span><span style="font-family:inherit;font-size:10pt;"> &#160;Interest expense, net was </span><span style="font-family:inherit;font-size:10pt;">$2.1 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$0.8 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">28%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$2.9 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">.&#160; The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in interest expense, net was primarily due to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increased interest income from investments, which partially offset current year interest expense recorded from the Convertible Notes and the Credit Agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other expense, net</span><span style="font-family:inherit;font-size:10pt;">. Other expense, net was </span><span style="font-family:inherit;font-size:10pt;">$0.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a decrease of </span><span style="font-family:inherit;font-size:10pt;">$0.5 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">73%</span><span style="font-family:inherit;font-size:10pt;">, from other expense, net of </span><span style="font-family:inherit;font-size:10pt;">$0.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The decrease in other expense, net resulted primarily from exchange rate changes in the current period and an unrealized gain on our equity investment in MRI Interventions, Inc. of $0.1 million.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income tax expense.</span><span style="font-family:inherit;font-size:10pt;"> Income tax expense was </span><span style="font-family:inherit;font-size:10pt;">$0.8</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$0.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. We incurred income tax expense in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions. We are paying minimum income taxes in the United States because of incurred losses in the various state jurisdictions. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Six months ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> compared to six months ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2018</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes revenues and selected expense and other income data for the six months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">138,530</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">124,151</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,379</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Collaboration and grant revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">575</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">654</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(79</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product sales, excluding amortization of acquired intangible asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,587</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,616</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(29</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of acquired intangible asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,652</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,022</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,630</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">112,544</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63,970</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48,574</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89,760</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66,514</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,246</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in the fair value of deferred and contingent consideration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26,460</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26,460</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,362</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6,187</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,825</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (expense) income, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(292</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">332</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(624</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,350</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(610</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(740</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net product revenues.</span><span style="font-family:inherit;font-size:10pt;"> Net product revenues were </span><span style="font-family:inherit;font-size:10pt;">$138.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$14.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$124.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The increase in net product revenue was primarily due to the increase in net product sales in existing markets where Translarna is available as well as continued geographic expansion into new territories, in addition to an increase of $5.9 million in net product sales of Emflaza.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration and grant revenues.</span><span style="font-family:inherit;font-size:10pt;"> Collaboration and grant revenues were </span><span style="font-family:inherit;font-size:10pt;">$0.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">12%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$0.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The decrease in collaboration and grant revenues is related to our ongoing collaboration arrangements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of product sales, excluding amortization of acquired intangible asset</span><span style="font-family:inherit;font-size:10pt;">. Cost of product sales, excluding amortization of acquired intangible asset, were </span><span style="font-family:inherit;font-size:10pt;">$5.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, which remained consistent from </span><span style="font-family:inherit;font-size:10pt;">$5.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. Cost of product sales consist primarily of royalty payments associated with Emflaza and Translarna net product sales, excluding contingent payments to Marathon, and costs associated with Emflaza and Translarna product sold during the period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization of acquired intangible asset</span><span style="font-family:inherit;font-size:10pt;">. Amortization of our intangible assets were </span><span style="font-family:inherit;font-size:10pt;">$12.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$1.6 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">15%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$11.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. These amounts are related to the acquisition of all rights to Emflaza acquired in May 2017, Marathon contingent payments, and our Waylivra intangible asset.  The increase is primarily related to additional Marathon contingent payments. The amount allocated to the Emflaza intangible asset is amortized on a straight-line basis over its estimated useful life of approximately seven years from the date of the completion of the acquisition of all rights to Emflaza, the period of estimated future cash flows. The Marathon contingent payments are amortized prospectively as incurred, straight-line, over the remaining useful life of the Emflaza intangible asset. The Waylivra asset is amortized on a straight-line basis over its estimated useful life of approximately ten years. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense.</span><span style="font-family:inherit;font-size:10pt;"> Research and development expense was </span><span style="font-family:inherit;font-size:10pt;">$112.5</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$48.6 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">76%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$64.0</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> reflects costs associated with advancing the gene therapy platform and increased investment in research programs as well as advancement of the clinical pipeline.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expense.</span><span style="font-family:inherit;font-size:10pt;"> Selling, general and administrative expense was </span><span style="font-family:inherit;font-size:10pt;">$89.8</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$23.2 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">35%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$66.5</span><span style="font-family:inherit;font-size:10pt;"> million for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to continued investment to support our commercial activities including our expanding commercial portfolio.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Change in the fair value of deferred and contingent consideration.  </span><span style="font-family:inherit;font-size:10pt;">The change in the fair value of deferred and contingent consideration was </span><span style="font-family:inherit;font-size:10pt;">$26.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The change is related to the fair valuation of the potential future consideration to be paid to former equity holders of Agilis, as a result of our merger with Agilis which closed in August 2018. Changes in the fair value were due to the re-calculation of discounted cash flows for the passage of time and changes to certain other estimated assumptions.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense, net.</span><span style="font-family:inherit;font-size:10pt;"> &#160;Interest expense, net was </span><span style="font-family:inherit;font-size:10pt;">$4.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$1.8 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">29%</span><span style="font-family:inherit;font-size:10pt;">, from </span><span style="font-family:inherit;font-size:10pt;">$6.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">.&#160; The </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in interest expense, net was primarily due to increased interest income from investments, which partially offset current year interest expense recorded from the Convertible Notes and the Credit Agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (expense) income, net</span><span style="font-family:inherit;font-size:10pt;">. Other expense, net was </span><span style="font-family:inherit;font-size:10pt;">$0.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a change of </span><span style="font-family:inherit;font-size:10pt;">$0.6 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">188%</span><span style="font-family:inherit;font-size:10pt;">, from other income, net of </span><span style="font-family:inherit;font-size:10pt;">$0.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The change in other (expense) income, net resulted primarily from exchange rate changes in the current period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income tax expense.</span><span style="font-family:inherit;font-size:10pt;"> Income tax expense was </span><span style="font-family:inherit;font-size:10pt;">$1.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$0.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. We incurred income tax expense in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions. We are paying minimum income taxes in the United States because of incurred losses in the various state jurisdictions. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and capital resources</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sources of liquidity</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, we have incurred significant operating losses.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a growing commercial-stage biopharmaceutical company, we are engaging in significant commercialization efforts for Translarna for nmDMD and Emflaza for the treatment of DMD while also devoting a substantial portion of our efforts on research and development related to our products, product candidates and other programs. To date, almost all of our product revenue has been attributable to sales of Translarna for the treatment of nmDMD in territories outside of the United States and from Emflaza for the treatment of DMD in the United States.  Our ongoing ability to generate revenue from sales of Translarna for the treatment of nmDMD is dependent upon our ability to maintain our marketing authorization in the EEA and secure market access through commercial programs following the conclusion of pricing and reimbursement terms at sustainable levels in the member states of the EEA or through EAP programs in the EEA and other territories. The marketing authorization requires annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization and is subject to the specific obligation to conduct Study 041. Our ability to generate product revenue from Emflaza will largely depend on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have historically financed our operations primarily through the issuance and sale of our common stock in public offerings, the private placements of our preferred stock, collaborations, bank debt, convertible debt financings, the Credit Agreement and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. Since 2014, we have also relied on revenues generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, we have recognized revenue generated from net sales of Emflaza for the treatment of DMD in the United States. Based on our current commercial, research and development plans, we expect to continue to incur significant operating expenses for the foreseeable future, which we anticipate will be partially offset by revenues generated from the sale of both Translarna and Emflaza, as well as Waylivra and Tegsedi once our commercialization efforts for them commence.  As a result, while we expect to continue to generate operating losses in 2019, we anticipate that operating losses generated in future periods should decline versus prior periods.  The net losses we incur may fluctuate significantly from quarter to quarter.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August&#160;2015, we closed a private offering of $150 million in aggregate principal amount of 3.00% convertible senior notes due 2022 including the exercise by the initial purchasers of an option to purchase an additional $25 million in aggregate principal amount of the Convertible Notes. The Convertible Notes bear cash interest payable on February&#160;15 and August&#160;15 of each year, beginning on February&#160;15, 2016. The Convertible Notes are senior unsecured obligations of ours and will mature on August&#160;15, 2022, unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date. We received net proceeds from the offering of approximately $145.4 million, after deducting the initial purchasers&#8217; discounts and commissions and the estimated offering expenses payable by us.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 5, 2017, we entered into the Credit Agreement with MidCap Financial, which provides for a senior secured term loan facility of $60 million, of which $40 million was drawn by us on May 5, 2017. Our ability to draw on the remaining $20 million under the senior secured term loan facility expired on December 31, 2018.  The maturity date of the Credit Agreement is May 1, 2021, unless terminated earlier. The facility is structured to require only monthly interest payments for the initial two years with principal amortization beginning in years three and four.  The facility bears interest at a rate per annum equal to LIBOR (with a LIBOR floor rate of 1.00%) plus 6.15%, as well as additional upfront and administrative fees and expenses. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, we closed an underwritten public offering of our common stock pursuant to a registration statement on Form S-3. We issued and sold an aggregate of 7,563,725 shares of common stock under the registration statement at a public offering price of $30.20 per share, including 843,725 shares issued upon exercise by the underwriter of its option to purchase additional shares in February 2019. We received net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;">$224.5 million</span><span style="font-family:inherit;font-size:10pt;"> after deducting underwriting discounts and commissions and other offering expenses payable by us.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash flows</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and marketable securities of $</span><span style="font-family:inherit;font-size:10pt;">363.5</span><span style="font-family:inherit;font-size:10pt;"> million.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information regarding our cash flows and our capital expenditures for the periods indicated.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash (used in) provided by:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(72,931</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(15,875</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(188,669</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,096</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">228,571</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">122,765</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash </span><span style="font-family:inherit;font-size:10pt;">used in</span><span style="font-family:inherit;font-size:10pt;"> operating activities was </span><span style="font-family:inherit;font-size:10pt;">$72.9 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$15.9 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The net cash </span><span style="font-family:inherit;font-size:10pt;">used in</span><span style="font-family:inherit;font-size:10pt;"> operating activities primarily relates to supporting clinical development and commercial activities.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash </span><span style="font-family:inherit;font-size:10pt;">used in</span><span style="font-family:inherit;font-size:10pt;"> investing activities was </span><span style="font-family:inherit;font-size:10pt;">$188.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Cash </span><span style="font-family:inherit;font-size:10pt;">used in</span><span style="font-family:inherit;font-size:10pt;"> investing activities for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was primarily related to net purchases of marketable securities.  Cash provided by investing activities for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$6.1 million</span><span style="font-family:inherit;font-size:10pt;"> and was primarily related to net sales of marketable securities. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash </span><span style="font-family:inherit;font-size:10pt;">provided by</span><span style="font-family:inherit;font-size:10pt;"> financing activities was </span><span style="font-family:inherit;font-size:10pt;">$228.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$122.8 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. Cash provided by financing activities for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was primarily attributable to our equity offering in January 2019 and the exercise of options. Cash provided by financing activities for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> was primarily attributable to our equity offering in April 2018 and the exercise of options.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Funding requirements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate that our expenses will continue to increase&#160;in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including the expansion of our infrastructure and corresponding sales and marketing, legal and regulatory, distribution and manufacturing and administrative and employee-based expenses. In addition to the foregoing, we expect to continue to incur significant costs&#160;in connection with Study 041 and Study 045 and our open label extension trials of Translarna for the treatment of nmDMD as well as our studies for nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5 and our FDA post-marketing requirements with respect to Emflaza in the United States and our studies for limb-girdle 2I. We also expect to incur ongoing research and development expenses for our other product candidates, including our gene therapy, splicing and oncology programs. In addition, we may incur substantial costs in connection with our efforts to advance our regulatory submissions. We have begun seeking and intend to continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories outside of the EEA and we may also seek marketing authorization for Translarna for other indications. In the fourth quarter of 2019, we plan to submit a request for marketing authorization for PTC-AADC with the FDA, followed by a request for marketing authorization for PTC-AADC with the EMA and we recently submitted a request for marketing authorization for Tegsedi with ANVISA. These efforts may significantly impact the timing and extent of our commercialization expenses.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our expenses will increase if and as we:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek to integrate Agilis's operations and employees into our business and seek to satisfy contractual and regulatory obligations we assumed in connection with the Agilis acquisition;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek to satisfy contractual and regulatory obligations in conjunction with the Akcea Agreement, including the potential commercialization of Tegsedi and Waylivra in the PTC Territory;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">execute our strategy for Emflaza in the United States, including commercialization and integration efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">satisfy contractual and regulatory obligations that we assumed through the Emflaza acquisition;&#160;&#160;&#160;&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">are required to complete any additional clinical trials, non-clinical studies or CMC assessments or analyses in order to advance Translarna for the treatment of nmDMD in the United States or elsewhere;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">are required to take other steps, in addition to Study 041, to maintain our current marketing authorization in the EEA for Translarna for the treatment of nmDMD or to obtain further marketing authorizations for Translarna for the treatment of nmDMD or other indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">initiate or continue the research and development of Translarna and Emflaza for additional indications and of our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek to discover and develop additional product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek to expand and diversify our product pipeline through strategic transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintain, expand and protect our intellectual property portfolio; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our cash flows from product sales, together with existing cash and cash equivalents, including the net proceeds from our term loan facility with MidCap Financial, our offering of the Convertible Notes, public offerings of common stock, marketable securities and research funding that we expect to receive under our collaborations, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our future capital requirements will depend on many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to commercialize and market Emflaza for the treatment of DMD in the United States;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms, on a timely basis, with third-party payors for Emflaza for the treatment of DMD in the United States and for Translarna for the treatment of nmDMD in the EEA and other territories outside of the United States;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to maintain orphan exclusivity for, and successfully complete all FDA post-marketing requirements with respect to, Emflaza;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to maintain the marketing authorization in the EEA for Translarna for the treatment of nmDMD, including whether the EMA determines on an annual basis that the benefit-risk balance of Translarna supports renewal of our marketing authorization in the EEA, on the current approved label;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs, timing and outcome of Study 041;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs, timing and outcome of our efforts to advance Translarna for the treatment of nmDMD in the United States, including, whether we will be required to perform additional clinical trials, non-clinical studies or CMC assessments or analyses at significant cost which, if successful, may enable FDA review of an NDA submission by us and, ultimately, may support approval of Translarna for nmDMD in the United States;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to commercialize and market Tegsedi and Waylivra in the PTC Territory;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the progress and results of our open label extension clinical trials of Translarna for the treatment of nmDMD as well as our studies for nonsense mutation aniridia, nonsense mutation Dravet syndrome/CDKL5 and limb-girdle 2I and activities under our gene therapy, splicing and oncology programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, costs and timing of our commercialization activities, including product sales, marketing, legal, regulatory, distribution and manufacturing, for both Emflaza for the treatment of DMD and Translarna for the treatment of nmDMD, for Tegsedi, for Waylivra and for any of our other product candidates that may receive marketing authorization or any additional indications or territories in which we receive authorization to market Translarna;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs, timing and outcome of regulatory review of our other product candidates, including those in our gene therapy and oncology programs, and Translarna in other territories or for indications other than nmDMD;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to satisfy our obligations under the terms of the lease agreement for our leased biologics facility;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to satisfy our obligations under the terms of the Credit Agreement with MidCap Financial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and scope of growth in our employee base;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for Translarna and Emflaza for additional indications and for our other product candidates, including those in our gene therapy and oncology programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">revenue received from commercial sales of Translarna, Emflaza, Tegsedi, Waylivra, or any of our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of nmDMD on adequate terms, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications, maintaining, and protecting our intellectual property rights and defending against intellectual property-related claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which we acquire or invest in other businesses, products, product candidates, and technologies, including the success of any acquisition, in-licensing or other strategic transaction we may pursue, and the costs of subsequent development requirements and commercialization efforts, including with respect to our acquisition of Emflaza, our acquisition of Agilis, and our licensing of Tegsedi and Waylivra; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish and maintain collaborations, including our collaborations with Roche and the SMA Foundation, and our ability to obtain research funding and achieve milestones under these agreements.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to our outstanding Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which require total funding of $4.5 million annually. Additionally, under the terms of our Credit Agreement cash interest and principal payments are payable monthly in arrears. Furthermore, as a result of our initial public offering in June 2013, we have incurred and expect to continue to incur additional costs associated with operating as a public company. These costs include significant legal, accounting, investor relations and other expenses that we did not incur as a private company. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never been profitable and we will need to generate significant revenues to achieve and sustain profitability, and we may never do so. We may need to obtain substantial additional funding in connection with our continuing operations. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs primarily through a combination of equity offerings, debt financings, collaborations, strategic alliances, grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product and product candidates and marketing, distribution or licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to raise additional funds through equity or debt financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under Securities and Exchange Commission rules.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual obligations</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were no material changes to our contractual obligations and commitments outside the ordinary course of business from those disclosed under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Contractual Obligations&#8221; in our 2018 Annual Report.</span></div><div><a id="sCD53B19070A758C9B7514930B803D178"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading &#8220;Quantitative and Qualitative Disclosures about Market Risk&#8221; in our 2018 Annual Report.</span></div><div><a id="s5B20CD1E211451C290B55DD4D118E3C1"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The term &#8220;disclosure controls and procedures&#8221;, as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2019, we implemented an enterprise resource planning (&#8220;ERP&#8221;) system, Oracle, on a worldwide basis, which is expected to improve the efficiency of certain financial and related transactional processes. We have completed the implementation of certain processes, including the financial consolidation and reporting, sales order to cash, fixed assets, supplier management and indirect procure-to-pay processes, and have revised and updated the related controls. These changes did not materially affect our internal control over financial reporting for the three and six months ended June 30, 2019. As we implement the remaining functionality under this ERP system over the next several years, we will continue to assess the impact on our internal control over financial reporting. No other changes in our internal control over financial reporting occurred during the quarter ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><a id="sE81239AD76CE570F9FD72015DC838B47"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II&#8212;OTHER INFORMATION</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sE8FB50F99A075868838D01F071AA4418"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Legal Proceedings. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time in the ordinary course of our business, we are subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in our clinical trials or otherwise gain access to our product candidates. We are not currently aware of any material legal proceedings to which we are a party or of which any of our property is subject.</span></div><div><a id="s3A03EB5C87C65A0EB3A2008A380DA5BF"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.&#160; Risk Factors</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have set forth in Item 1A to our Annual Report on Form 10-K for the year ended December&#160;31, 2018, risk factors relating to our business, our industry, our structure and our common stock. Readers of this Quarterly Report on Form 10-Q are referred to such Item 1A for a more complete understanding of risks concerning us. There have been no material changes in our risk factors since those published in such Form 10-K for the year ended December&#160;31, 2018. </span></div><div><a id="sA4AE6AD1C2235519B224D52CDDC74271"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inducement grant awards.</span><span style="font-family:inherit;font-size:10pt;"> Pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception, during the quarter ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we issued options to purchase an aggregate of </span><span style="font-family:inherit;font-size:10pt;">287,150</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock to certain new hire employees at a weighted-average exercise price of </span><span style="font-family:inherit;font-size:10pt;">$36.82</span><span style="font-family:inherit;font-size:10pt;"> per share. The shares underlying these options will be registered on a Form&#160;S-8 registration statement prior to the first vesting event applicable to each such award.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><a id="s97C9496A84EB5EB8B0B3F5CFCDEE2901"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. Exhibits. </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:4%;"></td><td style="width:84%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit&#160;Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description&#160;of&#160;Exhibit</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex101employmentagreeme.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, as amended, between the Registrant and Emily Hill</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit102utteremploym.htm"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, as amended, between the Registrant and Christine Utter</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ptct06302019ex-311.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ptct06302019ex-312.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ptct06302019ex-321.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ptct06302019ex-322.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Instance Document*</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document*</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document*</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Label Linkbase Database*</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document*</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document*</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* Submitted electronically herewith.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">+ Management contract, compensatory plan or arrangement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed. </span></div><div><a id="s1B3AE36CB8325F13B8421093D7D0C2A1"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s033C093E1854529994D3CC98BE6A07FC"><span style="font-family:inherit;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:7%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC THERAPEUTICS,&#160;INC.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: August&#160;6, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Emily Hill</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emily Hill</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Financial Officer and Duly Authorized Signatory)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101employmentagreeme.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s703B7F353E313164A1BF67D2B4D0CADC"></a></div><div><div style="line-height:120%;text-align:left;text-indent:624px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This EMPLOYMENT AGREEMENT (the &#8220;Agreement&#8221;) is made as of December 11, 2017 (the &#8220;Effective Date&#8221;), by and between PTC Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;) and Emily Hill (&#8220;Executive&#8221;).  In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:12pt;">.  The Company agrees to continue to employ Executive and Executive agrees to continue to be employed by the Company on the terms and conditions set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Capacity</font><font style="font-family:inherit;font-size:12pt;">.  Executive shall serve the Company as Vice President, Head of Investor Relations reporting to Stuart Peltz, or such other senior executive as the Company shall specify.  Executive shall have the responsibilities, duties and authority commensurate with the position of Vice President, Head of Investor Relations.  In addition to Executive&#8217;s primary duties, Executive shall perform such other services for the Company that are consistent with his/her position as Vice President, Head of Investor Relations as may be reasonably assigned to Executive from time to time by the individual to whom s/he reports or the Board of Directors of the Company (the &#8220;Board&#8221;) or their respective designees.  The principal location at which Executive shall perform such services shall be the Company&#8217;s corporate headquarters currently located at 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ  07080, subject to relocation and Section 2(c)(i) of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Devotion of Duties; Representations</font><font style="font-family:inherit;font-size:12pt;">.  During the Term (as defined below) of Executive&#8217;s employment with the Company, Executive shall devote his/her best efforts and full business time and energies to the business and affairs of the Company, and shall endeavor to perform the duties and services contemplated hereunder to the reasonable satisfaction of the  individual to whom s/he reports and the Board.  During the Term of Executive&#8217;s employment with the Company, Executive shall not, without the prior written approval of the Company (by action of the Board), undertake any other employment from any person or entity or serve as a director of any other company; provided, however, that (i) the Company will entertain requests as to such other employment or directorships in good faith and (ii) Executive will be eligible to participate in any policy relating to outside activities that is applicable to the senior executives of the Company and approved by the Board after the date hereof.    </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term of Employment</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Executive&#8217;s employment hereunder shall continue on the Effective Date.  Executive&#8217;s employment hereunder shall be terminated upon the first to occur of the following:</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:12pt;">Immediately upon Executive&#8217;s death;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">By the Company</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to Executive effective the date of such notice, following the Disability of Executive.  &#8220;Disability&#8221; means that Executive (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">result in death or can be expected to last for a continuous period of not less than 12 months, or (ii) is, by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under an accident and health plan covering employees of the Company.  Such incapacity shall be determined by a physician chosen by the Company and reasonably satisfactory to Executive (or Executive&#8217;s legal representative) upon examination requested by the Company (to which Executive hereby agrees to submit). Notwithstanding the foregoing, such Disability must result in Executive becoming &#8220;Disabled&#8221; within the meaning of Section 409A(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the guidance issued thereunder.  (In this Agreement we refer to Section 409A of the Code and any guidance issued thereunder as &#8220;Section 409A&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to Executive, effective the date of such notice, for Cause (as defined below); or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to Executive, effective ninety (90) days after the date of such notice and subject to Section 4 hereof, without Cause; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">By Executive</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">At any time by written notice to the Company, effective forty-five (45) days after the date of such notice</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">;</font><font style="font-family:inherit;font-size:12pt;">&#32;or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to the Company for Good Reason (as defined below), effective on the date specified in such notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The term of Executive&#8217;s employment by the Company under this Agreement is referred to herein as the &#8220;Term.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Cause&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of this Agreement, &#8220;Cause&#8221; shall, pursuant to the reasonable good faith determination by a majority of the Board (excluding Executive) as documented in writing, include:</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(i) the willful and continued failure by Executive to substantially perform Executive&#8217;s material duties or responsibilities under this Agreement (other than such a failure as a result of Disability); (ii) any action or</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">omission by Executive involving willful misconduct or gross negligence with regard to the Company, which has a detrimental effect on the Company; (iii) Executive&#8217;s conviction of a felony, either in connection with the performance of Executive&#8217;s obligations to the Company or which otherwise shall adversely affect Executive&#8217;s ability to perform such obligations or shall materially adversely affect the business activities, reputation, goodwill or image of the Company;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(iv) the material breach of a fiduciary duty to the Company; or (v) the material breach by Executive of any of the provisions of this Agreement, provided that any breach of Executive&#8217;s obligations with respect to Sections 5 or 6 of this Agreement, subject to the cure provision in the next sentence, shall be deemed &#8220;material.&#8221;  In respect of the events described in clauses (i) and (v) above, the Company shall give Executive notice of the failure of performance or breach, reasonable as to time, place and manner in the circumstances, and a 30-day opportunity to cure, provided that such failure of </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">performance or breach is reasonably amenable to cure as determined by the Board in its sole discretion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Good Reason&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of this Agreement, a &#8220;Good Reason&#8221; shall mean any of the following, unless (i) the basis for such Good Reason is cured within a reasonable period of time (determined in the light of the cure appropriate to the basis of such Good Reason, but in no event less than thirty (30) nor more than ninety (90) days) after the Company receives written notice (which must be received from Executive within ninety (90) days of the initial existence of the condition giving rise to such Good Reason) specifying the basis for such Good Reason or (ii) Executive has consented to the condition that would otherwise be a basis for Good Reason:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A change in the principal location at which Executive provides services to the Company to a location more than fifty (50) miles from such principal location and/or to a location in New York City (either of which change, the Company has reasonably determined as of the date hereof, would constitute a material change in the geographic location at which Executive provides services to the Company), provided that such a relocation shall not be deemed to occur under circumstances where Executive&#8217;s responsibilities require him/her to work at a location other than the corporate headquarters for a reasonable period of time; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A material adverse change by the Company in Executive&#8217;s duties, authority or responsibilities as Vice President, Head of Investor Relations of the Company which causes Executive&#8217;s position with the Company to become of materially less responsibility or authority than Executive&#8217;s position immediately following the Effective Date.  For purposes of this definition of &#8220;Good Reason,&#8221; a &#8220;material adverse change&#8221; following a Corporate Change shall not include any diminution in authority, duties or responsibilities that is solely attributable to the change in the Company&#8217;s ownership structure but does not otherwise change Executive&#8217;s authority, duties or responsibilities (except in a positive manner) otherwise with respect to the Company&#8217;s business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A material reduction in Executive&#8217;s base compensation (including Base Salary) except if the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A material breach of this Agreement by the Company which has not been cured within thirty (30) days after written notice thereof by Executive; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Failure to obtain the assumption (assignment) of this Agreement by any successor to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Corporate Change&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of this Agreement, &#8220;Corporate Change&#8221; shall mean any circumstance in which (i) the Company is not the surviving entity in any merger, consolidation or other reorganization (or survives only as a subsidiary or affiliate of an entity other than a previously wholly-owned subsidiary of the Company); (ii) the Company sells, leases or exchanges or agrees to sell, lease or exchange all or substantially all of </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">its assets to any other person or entity (other than a wholly-owned subsidiary of the Company); (iii) any person or entity, including a &#8220;group&#8221; as contemplated by Section 13(d)(3) of the Securities Exchange Act of 1934 (excluding, for this purpose, the Company or any Subsidiary, or any employee benefit plan of the Company or any Subsidiary, or any &#8220;group&#8221; in which all or substantially all of its members or its members&#8217; affiliates are individuals or entities who are or were beneficial owners of the Company&#8217;s outstanding shares prior to the initial public offering, if any, of the Company&#8217;s stock), acquires or gains ownership or control (including, without limitations, powers to vote) of more than 50% of the outstanding shares of the Company&#8217;s voting stock (based upon voting power); or (iv) as a result of or in connection with a contested election of directors, the persons who were directors of the Company before such election shall cease to constitute a majority of the Board of Directors of the Company.  Notwithstanding the foregoing, a &#8220;Corporate Change&#8221; shall not occur as a result of an initial public offering of the Company&#8217;s common stock, or as a result of a merger, consolidation, reorganization or restructuring after which either (1) a majority of the Board of Directors of the controlling entity consists of persons who were directors of the Company prior to the merger, consolidation, reorganization or restructuring or (2) Executive forms part of an executive management team that consists of substantially the same group of individuals and Executive is performing in a similar role, with similar authority and responsibility (other than changes solely attributable to the change in ownership structure), to that which existed prior to the reorganization or restructuring.  Notwithstanding the foregoing, for any payments or benefits hereunder that are subject to Section 409A, the Corporate Change must constitute a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">.  Executive&#8217;s minimum base salary during the Term shall be at the rate of $235,000.08 per year (the &#8220;Base Salary&#8221;).  Base Salary shall be payable in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, less any amounts required to be withheld under applicable law.  The Base Salary will be subject to adjustment from time to time in the sole discretion of the Board; provided that, the Company covenants that it shall not reduce the Base Salary below $235,000.08 or the Base Salary then in effect immediately prior to the reduction unless (i) Executive consents to such reduction, or (ii) the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">.  In addition to the Base Salary, the Company may pay Executive an annual bonus (the &#8220;Bonus&#8221;) as determined by the Board, solely in its discretion (it being understood that Executive&#8217;s target annual bonus shall be at 30% of Base Salary, but may be higher or lower in any year in the Board&#8217;s discretion).  The Board&#8217;s decision to issue a Bonus to Executive in any particular year shall have no effect on the absolute discretion of the Board to grant or not to grant a Bonus in subsequent years.  Any Bonus for a particular year shall be paid or provided to Executive in a lump sum no later than March 15</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;of the calendar year following the calendar year in which the Bonus was earned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity Compensation</font><font style="font-family:inherit;font-size:12pt;">.  Executive shall be eligible to participate in PTC&#8217;s annual equity and long term incentive plan(s) and may be eligible to receive discretionary awards </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">under such plan(s), subject to the terms and conditions of such plan(s).  Except as explicitly set forth below, Executive&#8217;s rights with respect to equity (including stock options) shall be covered in PTC&#8217;s equity and long term incentive plan(s) and separate stock option certificates or agreements for each grant.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accelerated Vesting</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For the avoidance of doubt, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason, no unvested equity awards granted under the Company&#8217;s equity and long-term incentive plan(s) following the date hereof shall be subject to any accelerated vesting except as otherwise provided for in the applicable award agreement or in Section 3(c)(i)(B) below. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as otherwise provided in the applicable award, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason within the period of three (3) months prior to (but only if negotiations relating to the particular Corporate Change that occurs are ongoing at the date of the notice of termination) or twelve (12) months after a Corporate Change that occurs during the Term (such fifteen-month period, the &#8220;Protected Period&#8221;), one hundred percent (100%) of all of Executive&#8217;s outstanding unvested equity awards granted under the Company&#8217;s equity and long-term incentive plan(s) following the date hereof shall vest immediately. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  Executive is eligible for time off programs outlined in the Company&#8217;s Time Off Policy.  Executive shall accrue over the calendar year 160 hours of paid vacation.   Executive may accrue up to 200 hours of vacation.  Once Executive has reached the maximum accrual, no further vacation time will be accrued unless and until the Executive uses vacation time. Upon termination of employment, the value of Executive&#8217;s current balance of accrued but unused vacation shall be paid out in cash based on his/her Base Salary that was in effect immediately prior to his/her termination of employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fringe Benefits</font><font style="font-family:inherit;font-size:12pt;">.  Executive shall be entitled to participate in any employee benefit plans that the Company makes available to its senior executives (including, without limitation, group life, disability, medical, dental and other insurance, retirement, pension, profit-sharing and similar plans) (collectively, the &#8220;Fringe Benefits&#8221;), provided that the Fringe Benefits shall not include any stock option or similar plans relating to the grant of equity securities of the Company.  These benefits may be modified or changed from time to time at the sole discretion of the Company.  Where a particular benefit is subject to a formal plan (for example, medical or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document, and eligibility to participate in such plan(s) may be dependent upon, among other things, a physical examination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement of Expenses</font><font style="font-family:inherit;font-size:12pt;">.  Executive shall be entitled to reimbursement for all ordinary and reasonable out-of-pocket business expenses that are reasonably incurred by him/her in furtherance of the Company&#8217;s business in accordance with reasonable policies adopted from time to time by the Company for senior executives.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 6 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Taxes and Withholdings</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall deduct and withhold from all compensation and benefits under this Agreement all social security and other federal, state and local taxes and charges which currently are or which hereafter may be required by law to be so deducted and withheld.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severance Compensation</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event of any termination of Executive&#8217;s employment for any reason the Company shall pay Executive (or Executive&#8217;s estate) such portions of Executive&#8217;s Base Salary as have accrued prior to such termination and have not yet been paid, together with (i) amounts for accrued unused vacation days (as provided above), (ii) any amounts for expense reimbursement which have been properly incurred or the Company has become obligated to pay prior to termination and have not been paid as of the date of such termination and (iii) the amount of any Bonus previously granted to Executive by the Board but not yet paid, which amount shall not include any pro rata portion of any Bonus which would have been earned if such termination had not occurred (the &#8220;Accrued Obligations&#8221;).  Such amounts shall be paid as soon as possible after termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for a Good Reason or (ii) by the Company without Cause, the Company shall pay to Executive the Accrued Obligations.  In addition, the Company shall pay to Executive the severance benefits set forth below for six (6) months following Executive&#8217;s termination of employment (the &#8220;Severance Period&#8221;).  The receipt of any severance benefits provided in this Section shall be dependent upon Executive&#8217;s execution (and, as applicable, non-revocation) of a standard separation agreement and general release of claims, substantially in the form attached hereto as Exhibit A (the &#8220;Release&#8221;).  The Company will also consider in good faith (but without any binding commitment) requests from Executive that the Company include in the Release a release of Executive by the Company from matters specifically disclosed to the Company by Executive in writing in advance of execution of the Release and not involving any illegality, fraud, concealment, criminal acts or acts outside the scope of Executive's employment.  The distribution of severance benefits in this Section 4 is subject to section (iii) of this Section 4(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case before or after the Protected Period, the Company shall pay Executive his/her Base Salary, less any amounts required to be withheld under applicable law, for the Severance Period in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, commencing no later than sixty (60) days following the effective date of such termination.  If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his/her Base Salary for the Severance Period, which total amount shall be payable in a lump sum no later than sixty (60) days following Executive&#8217;s termination of employment.  In each case, payments shall commence or be paid provided that the Release has been executed and any applicable revocation period has expired as of the 60</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day following Executive&#8217;s termination.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 7 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company shall continue to provide Executive and his/her then-enrolled eligible dependents with group health insurance and shall continue to pay the amount of the premium as in effect on the date of such termination for the Severance Period commencing on the effective date of such termination, subject to applicable law and the terms of the respective policies; provided that the Company&#8217;s obligation to provide the benefits contemplated herein shall terminate upon Executive&#8217;s becoming eligible for coverage under the medical benefits program of a subsequent employer.  The foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required by Federal law.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance with Section 409A</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the provisions in this Section 4(b)(iii), any severance payments or benefits under this Agreement shall begin only upon the date of Executive&#8217;s &#8220;separation from service&#8221; (determined as set forth below) which occurs on or after the date of termination of Executive&#8217;s employment.  The following rules shall apply with respect to the distribution of the severance payments and benefits, if any, to be provided to Executive under this Agreement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A.  Neither the Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and such payments and benefits shall be paid or provided on the dates and terms set forth in this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each installment of the severance payments and benefits due this Agreement that is not described in Section 4(b)(iii)(3)(A) above and that would, absent this subsection, be paid within the six-month period following Executive&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, Executive&#8217;s death), with any such installments that are </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 8 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following Executive&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).  Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of Executive&#8217;s second taxable year following the taxable year in which the separation from service occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The determination of whether and when Executive&#8217;s separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h).  Solely for purposes of this Section 4(b)(iii), &#8220;Company&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Sections 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything herein to the contrary, the Company shall have no liability to Executive or to any other person if the payments and benefits provided hereunder that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for other than a Good Reason, or (ii) by the Company for Cause, or (iii) as a result of Executive&#8217;s death or Disability, then the Company will pay to Executive the Accrued Obligations.  The Company shall have no obligation to pay Executive (or Executive&#8217;s estate) any other compensation following such termination except as provided in Section 4(a). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Modified Section 280G Cutback</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 9 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, except as set forth in Section 4(d)(ii), in the event that the Company undergoes a &#8220;Change in Ownership or Control&#8221; (as defined below), the Company shall not be obligated to provide to Executive a portion of any &#8220;Contingent Compensation Payments&#8221; (as defined below) that Executive would otherwise be entitled to receive to the extent necessary to eliminate any &#8220;excess parachute payments&#8221; (as defined in Section 280G(b)(1) of the Code) for Executive.  For purposes of this Section&#160;4(d), the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Payments&#8221; and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Amount.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii) &#160;&#160;&#160;&#160;Notwithstanding the provisions of Section 4(d)(i), no such reduction in Contingent Compensation Payments shall be made if (1) the Eliminated Amount (computed without regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in accordance with Treasury Regulation Section&#160;1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by Executive if the Eliminated Payments (determined without regard to this sentence) were paid to him/her (including, state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of Executive&#8217;s &#8220;base amount&#8221; (as defined in Section 280G(b)(3) of the Code), and any withholding taxes).  The override of such reduction in Contingent Compensation Payments pursuant to this Section&#160;4(d)(ii) shall be referred to as a &#8220;Section&#160;4(d)(ii) Override.&#8221;  For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;For purposes of this Section 4(d) the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)&#160;&#160;&#160;&#160;&#8220;Change in Ownership or Control&#8221; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)&#160;&#160;&#160;&#160;&#8220;Contingent Compensation Payment&#8221; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to a &#8220;disqualified individual&#8221; (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)&#160;&#160;&#160;&#160;Any payments or other benefits otherwise due to Executive following a Change in Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the &#8220;Potential </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 10 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payments&#8221;) shall not be made until the dates provided for in this Section&#160;4(d)(iv).  Within 30 days after each date on which Executive first becomes entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify Executive (with reasonable detail regarding the basis for its determinations) (1) which Potential Payments constitute Contingent Compensation Payments, (2) the Eliminated Amount and (3)&#160;whether the Section&#160;4(d)(ii) Override is applicable.  Within 30 days after delivery of such notice to Executive, Executive shall deliver a response to the Company (the &#8220;Executive Response&#8221;) stating either (A) that s/he agrees with the Company&#8217;s determination pursuant to the preceding sentence or (B) that s/he disagrees with such determination, in which case</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">s/he</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall set forth (x) which Potential Payments should be characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section&#160;4(d)(ii) Override is applicable.  In the event that Executive fails to deliver an Executive Response on or before the required date, the Company&#8217;s initial determination shall be final.  If Executive states in the Executive Response that s/he</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">agrees with the Company&#8217;s determination, the Company shall make the Potential Payments to Executive within three business days following delivery to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  If Executive states in the Executive Response that s/he disagrees with the Company&#8217;s determination, then, for a period of 60 days following delivery of the Executive Response, Executive and the Company shall use good faith efforts to resolve such dispute.  If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in South Plainfield, New Jersey, in accordance with the rules of the American Arbitration Association then in effect.  Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction.  The Company shall, within three business days following delivery to the Company of the Executive Response, make to Executive those Potential Payments as to which there is no dispute between the Company and Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  The balance of the Potential Payments shall be made within three business days following the resolution of such dispute.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;(v)&#160;&#160;&#160;&#160;The Contingent Compensation Payments to be treated as Eliminated Payments shall be determined by the Company by determining the &#8220;Contingent Compensation Payment Ratio&#8221; (as defined below) for each Contingent Compensation Payment and then reducing the Contingent Compensation Payments in order beginning with the Contingent Compensation Payment with the highest Contingent Compensation Payment Ratio.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payment shall be reduced based on the time of payment of such Contingent Compensation Payments with amounts having later payment dates being reduced first.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio and the same time of payment, such Contingent Compensation Payments shall be reduced on a pro rata basis (but not below zero) prior to reducing Contingent Compensation Payment with a lower Contingent Compensation Payment Ratio.  The term &#8220;Contingent Compensation Payment Ratio&#8221; shall mean a fraction the numerator of which is the value </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 11 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of the applicable Contingent Compensation Payment that must be taken into account by Executive for purposes of Section 4999(a) of the Code, and the denominator of which is the actual amount to be received by Executive in respect of the applicable Contingent Compensation Payment.  For example, in the case of an equity grant that is treated as contingent on the Change in Ownership or Control because the time at which the payment is made or the payment vests is accelerated, the denominator shall be determined by reference to the fair market value of the equity at the acceleration date, and not in accordance with the methodology for determining the value of accelerated payments set forth in Treasury Regulation Section 1.280G-1Q/A-24(b) or (c)). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)&#160;&#160;&#160;&#160;The provisions of this Section 4(d) are intended to apply to any and all payments or benefits available to Executive under this Agreement or any other agreement or plan of the Company under which Executive receives Contingent Compensation Payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)&#160;&#160;&#160;&#160;Notwithstanding Sections 4(d)(i)-(vi) hereof, until the closing of the first underwritten public offering of common stock of the Company, in the event that it shall be determined that any payment or benefit (including any accelerated vesting of options or other equity awards) made or provided, or to be made or provided, by the Company (or any successor thereto or affiliate thereof) to or for the benefit of Executive, whether pursuant to the terms of this Agreement, any other agreement, plan, program or arrangement of or with the Company (or any successor thereto or affiliate thereof) or otherwise, may be subject to the excise tax imposed by Section 4999 of the Code or any comparable tax imposed by any replacement or successor provision of United States tax law, then upon the request of Executive, the Company shall use reasonable efforts to procure a shareholder vote in satisfaction of the shareholder approval requirements described in Treas. Reg. Section 1.280G-1, Q&amp;A-7.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Executive Covenants</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">.  Executive recognizes and acknowledges the competitive and proprietary aspects of the business of the Company, and that as a result of Executive&#8217;s employment, Executive recognizes and acknowledges that s/he has had and will continue to have access to, and has been and will continue to be involved in the development of, Confidential Information (as defined below) of the Company.  As used herein, &#8220;Confidential Information&#8221; shall mean and include trade secrets, knowledge and other confidential information of the Company, which Executive has acquired, no matter from whom or on what matter such knowledge or information may have been acquired, heretofore or hereafter, concerning the content and details of the business of the Company, and which is not known to the general public, including but not limited to: (a) new products, product betterments and other inventions, formulas, processes, methods, materials, material combinations, manner of preparations, technical production procedures and information, alarm and security codes and procedures, sources of technology, and sources of supply of raw and finished materials and other products; (b) financial and accounting records; (c) the identity of employees, consultants, independent contractors, customers, business development partners, licensees, suppliers, creditors or other parties with which the Company has business dealings, the nature of the relationship with such persons, or any other information relating to such persons or the Company&#8217;s dealings with such </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 12 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">persons; and (d) computer software used by the Company or provided to the customers of the Company unless publicly available.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For as long as Executive is employed and at all times thereafter, Executive shall not, directly or indirectly, communicate, disclose or divulge to any person or entity, or use for Executive&#8217;s own benefit or the benefit of any person (other than the Company), any Confidential Information, except as permitted in subparagraph (iii) below.  Upon termination of Executive&#8217;s employment, or at any other time at the request of the Company, Executive agrees to deliver promptly to the Company all Confidential Information, including, but not limited to, customer and supplier lists, files and records, in Executive&#8217;s possession or under Executive&#8217;s control.  Executive further agrees that s/he will not make or retain any copies of any of the foregoing and will so represent to the Company upon termination of Executive&#8217;s employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Executive shall disclose immediately to the Company any trade secrets or other Confidential Information conceived or developed by Executive at any time during Executive&#8217;s employment.  Executive hereby assigns and agrees to assign to the Company Executive&#8217;s entire right, title and interest in and to all Confidential Information.  Such assignment shall include, without limitation, the rights to obtain patent or copyright protection, thereon in the United States and foreign countries.  Executive agrees to provide all reasonable assistance to enable the Company to prepare and prosecute any application before any governmental agency for patent or copyright protection or any similar application with respect to any Confidential Information.  Executive further agrees to execute all documents and assignments and to make all oaths necessary to vest ownership of such intellectual property rights in the Company, as the Company may request.  These obligations shall apply whether or not the subject thereof was conceived or developed at the suggestion of the Company, and whether or not developed during regular hours of work or while on the premises of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Executive shall at all times, both during and after termination of this Agreement by either Executive or the Company, maintain in confidence and shall not, without prior written consent of the Company, use, except in the course of performance of Executive&#8217;s duties for the Company or as required by legal process (provided that Executive will promptly notify the Company of such legal process except with respect to any confidential government investigation), disclose or give to others any Confidential Information.  In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to any such information or any other secret or confidential work of the Company, or concerning any fact or circumstance relating thereto, Executive will promptly notify the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Competition and Non-Solicitation</font><font style="font-family:inherit;font-size:12pt;">.  Executive recognizes that the Company is engaged in a competitive business and that the Company has a legitimate interest in protecting its trade secrets, confidential business information, and customer, business development partner, licensee, supplier, and credit and/or financial relationships.  Accordingly, in exchange for valuable consideration, including without limitation Executive&#8217;s access to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 13 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">confidential business information and continued at-will employment, Executive agrees that, during the Term hereof and for a period of nine (9) months thereafter, Executive shall not:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">directly or indirectly, whether for himself or for any other person or entity, and whether as a proprietor, principal, shareholder, partner, agent, employee, consultant, independent contractor, or in any other capacity whatsoever, undertake or have any interest in (other than the passive ownership of publicly registered securities representing an ownership interest of less than 1%), engage in or assume any role involving directly or indirectly the Company&#8217;s Field of Interest (or any portion thereof) or any other business in which the Company is engaged and for which the employee has rendered services while employed by the Company, or enter into any agreement to do any of the foregoing; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">initiate contact with (including without limitation phone calls, press releases and the sending or delivering of announcements), or in any manner solicit, directly or indirectly, any customers, business development partners, licensors, licensees, or creditors (including institutional lenders, bonding companies and trade creditors) of the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to transfer any of their business with the Company to any person or entity other than the Company; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">initiate contact with, or in any manner solicit, directly or indirectly, any supplier of goods, services or materials to the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to supply the same or similar inventory, goods, services or materials (except generally available inventory, goods, services or materials) to any person or entity other than the Company; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">directly or indirectly recruit, solicit or otherwise induce or influence any employee or independent contractor of the Company to discontinue or modify his or her employment or engagement with the Company, or employ or contract with any such employee or contractor for the provision of services.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Field of Interest&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  The term Company&#8217;s &#8220;Field of Interest&#8221; shall mean the research, development and commercialization of products and strategies relating to: (i) therapies for genetic disorders or diseases that include cystic fibrosis, Duchenne muscular dystrophy, other diseases caused in whole or part by nonsense (or stop) codons, and other genetic diseases as to which the Company engages in the research, development or commercialization of drugs; anti-angiogenic therapies that target VEGF protein production for cancer; and antiviral therapies for the Hepatitis C virus (HCV); and (ii) other therapeutic targets, mechanisms of action and/or therapies in which the Company has a research, development or commercialization program. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Customer&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  The term &#8220;customer&#8221; or &#8220;customers&#8221; shall include any person or entity (a) that is a current customer of the Company, (b) that was a customer of the Company at any time during the preceding twenty-four (24) months or (c) to which the Company made a written presentation for the solicitation of business at any time during the preceding twenty-four (24) months.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 14 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reasonableness of Restrictions</font><font style="font-family:inherit;font-size:12pt;">.  Executive further recognizes and acknowledges that (i) the types of employment which are prohibited by this Section 5 are narrow and reasonable in relation to the skills which represent Executive&#8217;s principal salable asset both to the Company and to Executive&#8217;s other prospective employers, and (ii) the broad geographical scope of the provisions of this Section 5 is reasonable, legitimate and fair to Executive in light of the global nature of the Company&#8217;s business, particularly pharmaceutical research and development, and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which Executive is qualified to earn Executive&#8217;s livelihood. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Remedies</font><font style="font-family:inherit;font-size:12pt;">.  Executive acknowledges that a breach of this Section 5 will cause great and irreparable injury and damage, which cannot be reasonably or adequately compensated by money damages.  Accordingly, Executive acknowledges that the remedies of injunction and specific performance shall be available in the event of such a breach, in addition to money damages, costs and attorneys&#8217; fees, and other legal or equitable remedies, and that the Company shall be entitled as a matter of course to an injunction pending trial, without the posting of bond or other security.  Any period of restriction set forth in this Section 5 shall be extended for a period of time equal to the duration of any breach or violation hereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notification</font><font style="font-family:inherit;font-size:12pt;">.  Any person employing Executive or evidencing any intention to employ Executive may be notified as to the existence and provisions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Modification of Covenants; Enforceability</font><font style="font-family:inherit;font-size:12pt;">.  In the event that any provision of this Section 5 is held to be in any respect an unreasonable restriction, then the court so holding may modify the terms thereof, including the period of time during which it operates or the geographic area to which it applies, or effect any other change to the extent necessary to render this section enforceable, it being acknowledged by the parties that the representations and covenants set forth herein are of the essence of this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Subsidiaries</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of Sections 5 and 6 of this Agreement, &#8220;Company&#8221; shall include all direct and indirect subsidiaries of the Company.  An entity shall be deemed to be a subsidiary of the Company if the Company directly or indirectly owns or controls 50% or more of the equity interest in such entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ownership of Ideas, Copyrights and Patents</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Property of the Company</font><font style="font-family:inherit;font-size:12pt;">.  Executive agrees that all ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know&#8209;how, inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks and formulae, whether patentable, copyrightable or not, which Executive may conceive, reduce to practice or develop, alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of the Company, or otherwise, in the course of performing services for the Company in any capacity, whether heretofore or hereafter, (collectively, &#8220;the Inventions&#8221;) are and shall be the sole and exclusive property of the Company, and that Executive shall not publish any of the Inventions without the prior written consent of the Company.  Executive hereby assigns to the Company all of Executive&#8217;s right, title and interest in and to all of the foregoing.  Executive </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 15 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">further represents and agrees that to the best of Executive&#8217;s knowledge and belief none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of any person, firm or corporation and that Executive will use his/her best efforts to prevent any such violation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cooperation</font><font style="font-family:inherit;font-size:12pt;">.  At any time during or after the Term, Executive agrees that s/he will fully cooperate with the Company, its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company&#8217;s rights in and to any of such Inventions, including, but not limited to, executing any lawful document (including, but not limited to, applications, assignments, oaths, declarations and affidavits) and joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights of the United States and of any and all other countries on such Inventions, provided that any patent or other legal right so issued to Executive, personally, shall be assigned by Executive to the Company without charge by Executive.  Executive further designates the Company as his/her agent for, and grants to the Company a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of effecting the foregoing assignments from Executive to the Company.  Company will bear the reasonable expenses which it causes to be incurred in Executive&#8217;s assisting and cooperating hereunder.  Executive waives all claims to moral rights in any Inventions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosure to Future Employers</font><font style="font-family:inherit;font-size:12pt;">.  The Company may provide in its discretion, a copy of the covenants contained in Sections 5 and 6 of this Agreement to any business or enterprise which Executive may directly, or indirectly, own, manage, operate, finance, join, control or in which Executive participates in the ownership, management, operation, financing, or control, or with which Executive may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Records</font><font style="font-family:inherit;font-size:12pt;">.  Upon termination of Executive&#8217;s relationship with the Company, Executive shall deliver to the Company any property of the Company which may be in Executive&#8217;s possession including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  The Company, in its sole discretion, may apply for and procure in its own name (whether or not for its own benefit) policies of insurance insuring Executive&#8217;s life.  Executive agrees to submit to reasonable medical or other examinations and to execute and deliver any applications or other instruments in writing that are reasonably necessary to effectuate such insurance.  No adverse employment actions may be based upon the results of any such exam or the failure by the Company to obtain such insurance.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Conflicting Agreements</font><font style="font-family:inherit;font-size:12pt;">.  Executive hereby represents and warrants that Executive has no commitments or obligations inconsistent with this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#8220;Market Stand-Off&#8221; Agreement</font><font style="font-family:inherit;font-size:12pt;">.  Executive agrees, if requested by the Company and an underwriter of common stock (or other securities) of the Company, not to sell or otherwise transfer or dispose of any common stock (or other securities) of the Company held by Executive during a period not to exceed one hundred and eighty (180) days following the effective date of the first underwritten public offering of common stock of the Company, offered on a firm commitment basis pursuant to a registration statement filed with the Securities and </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 16 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exchange Commission (or any successor agency of the Federal government administrating the Securities Act of 1933, as amend, and the Securities Exchange Act of 1934, as amended) under the Securities Act of 1933, as amended, on Form S-1 or its then equivalent, and to enter into an agreement to such effect.  The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said period. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party&#8217;s address as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to the Company:&#160;&#160;&#160;&#160;PTC Therapeutics Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100 Corporate Court</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;South Plainfield, NJ 07080</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;USA</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attention: Legal Department</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Telephone: (908) 222-7000</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With an email copy to: legal@ptcbio.com</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to Executive: &#160;&#160;&#160;&#160;Emily Hill</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">230 Hamilton Road</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ridgewood, NJ 07450</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or to such other address as a party may designate by notice hereunder, and shall be either (i)&#160;delivered by hand, (ii)&#160;sent by overnight courier, or (iii)&#160;sent by registered or certified mail, return receipt requested, postage prepaid.  All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i)&#160;if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii)&#160;if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, except with respect to the equity and fringe benefit arrangements referred to in Subsections 3(c) and (e) above.  No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Modifications and Amendments</font><font style="font-family:inherit;font-size:12pt;">.  The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waivers and Consents</font><font style="font-family:inherit;font-size:12pt;">.  The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 17 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the party entitled to the benefits of such terms or provisions.  No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar.  Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business or that aspect of the Company&#8217;s business in which Executive is principally involved.  Executive may not assign Executive&#8217;s rights and obligations under this Agreement without the prior written consent of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit</font><font style="font-family:inherit;font-size:12pt;">.  All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto.  Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third&#8209;party beneficiary of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the law of The State of New Jersey, without giving effect to the conflict of law principles thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Jurisdiction and Service of Process</font><font style="font-family:inherit;font-size:12pt;">.  Any legal action or proceeding with respect to this Agreement shall be brought in the courts of The State of New Jersey or of the United States of America for the</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">District of New Jersey.  By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts.  Each of the parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its address set forth in Section 12(a) hereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  The parties intend this Agreement to be enforced as written.  However, (i) if any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law; and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby or otherwise, the Company and Executive agrees that the court making such determination shall have the power to reduce the duration and/or geographic area of such provision, and/or to delete specific words and phrases (&#8220;blue-penciling&#8221;), and in its reduced or blue-penciled form such provision shall then be enforceable and shall be enforced.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Headings and Captions; Interpretation</font><font style="font-family:inherit;font-size:12pt;">.  The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify, or affect the meaning or construction of any of the terms or provisions hereof.  The provisions of the following Sections of this Agreement are in addition to, and do not limit, each </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 18 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">other: Sections 6 and 5(a); Sections 7 and 5(g); Sections 12(k) and 12(f); and Sections 12(l) and 12(d).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Injunctive Relief</font><font style="font-family:inherit;font-size:12pt;">.  Executive hereby expressly acknowledges that any breach or threatened breach of any of the terms and/or conditions set forth in Section 5 or 6 of this Agreement will result in substantial, continuing and irreparable injury to the Company.  Therefore, Executive hereby agrees that, in addition to any other remedy that may be available to the Company, the Company shall be entitled to injunctive or other equitable relief by a court of appropriate jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Waiver of Rights, Powers and Remedies</font><font style="font-family:inherit;font-size:12pt;">.  No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party.  No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.  The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies.  No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Survival</font><font style="font-family:inherit;font-size:12pt;">.  The provisions of Sections 4, 5, 6, 7, 8, 11 and 12 shall survive the termination of this Agreement and Executive&#8217;s employment hereunder in accordance with their terms.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">WAIVER OF TRIAL BY JURY</font><font style="font-family:inherit;font-size:12pt;">.  THE PARTIES IRREVOCABLY WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY REGARDING ANY DISPUTE, CLAIM OR CAUSE OF ACTION ARISING OUT OF, CONCERNING, OR RELATED TO EXECUTIVE&#8217;S EMPLOYMENT WITH THE COMPANY OR THIS AGREEMENT.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowing and Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;">.  Executive acknowledges and agrees that Executive is executing this Agreement knowingly and voluntarily and without any duress or undue influence by PTC or anyone else.  Executive further acknowledges and agrees that Executive has carefully read this Agreement and fully understands it, including that Executive is waiving the right to a jury trial.  Executive further agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive&#8217;s choice before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS THEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PTC Therapeutics, Inc.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 19 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Mark E. Boulding&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:  Mark E. Boulding</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: &#160;&#160;&#160;&#160;EVP, Chief Legal Officer</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreed and Accepted</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Emily Hill&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Emily Hill</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sA43BC573FA70023F375A67D2B528041A"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sample Separation and Release Agreement</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Date]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Name]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Address]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dear </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Name]</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In connection with the termination of your employment with PTC Therapeutics, Inc. (the &#8220;Company&#8221;) on </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Termination Date]</font><font style="font-family:inherit;font-size:12pt;">, you are eligible to receive the Severance Compensation as described in Section 4 of the Employment Agreement executed between you and the Company on [</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insert Date</font><font style="font-family:inherit;font-size:12pt;">] (the &#8220;Employment Agreement&#8221;) if you sign and return this letter agreement to me by </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Return Date &#8211; e.g., 21 days from date of receipt of this letter agreement] </font><font style="font-family:inherit;font-size:12pt;">and it becomes binding between you and the Company.  By signing and returning this letter agreement and not revoking your acceptance, you will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3.  Therefore, you are advised to consult with an attorney before signing this letter agreement and you may take up to twenty-one (21) days to do so.  If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) day period after you have signed it by notifying me  in writing.  If you do not so revoke, this letter agreement will become a binding agreement between you and the Company upon the expiration of the seven (7) day period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you choose not to sign and return this letter agreement by </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Return Date-Same as Above]</font><font style="font-family:inherit;font-size:12pt;">, or if you timely revoke your acceptance in writing, you shall not receive any Severance Compensation from the Company.  You will, however, receive payment for your final wages and any unused vacation time accrued through the Termination Date, as defined below, on the Company&#8217;s regular payroll date immediately following the Termination Date.  Also, regardless of signing this letter agreement, you may elect to continue receiving group medical insurance pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167;&#160;1161 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If you so elect, you shall pay all premium costs on a monthly basis for as long as, and to the extent that, you remain eligible for COBRA  continuation.  You should consult the COBRA materials to be provided by the Company for details regarding these benefits.  All other benefits will cease upon your Termination Date in accordance with the plan documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The following numbered paragraphs set forth the terms and conditions that will apply if you timely sign and return this letter agreement and do not revoke it in writing within the seven (7) day period.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination Date</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; Your effective date of termination from the Company is&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Date]</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;Termination Date&#8221;).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; In consideration of the payment of the Severance Compensation, which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:12pt;">irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#8220;Released Parties&#8221;) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#8217; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the Americans With Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &#167; 2000ff </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, the Worker Adjustment and Retraining Notification Act (&#8220;WARN&#8221;), 29 U.S.C. &#167; 2101 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, and the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C. &#167; 1001 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, all as amended; all claims arising out of the New Jersey Law Against Discrimination, N.J. Stat. Ann.&#160;&#167;&#160;10:5-1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the New Jersey Family Leave Act, N.J. Stat. Ann. &#167; 34:11B-1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the New Jersey Conscientious Employee Protection Act, N.J. Stat. Ann. &#160;&#167;&#160;34:19-1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, and the N.J. Stat. Ann.&#160;&#167;&#160;34:11-56.1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">&#32;(New Jersey equal pay law), all as amended; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract, including without limitation, all claims arising from the Employment Agreement; all state and federal whistleblower claims to the maximum extent permitted by law; all claims to any non-vested ownership interest in the Company, contractual or otherwise; and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement shall (i) prevent you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding) or (ii) deprive you of any rights you may have to be indemnified by the Company as provided in any agreement between the Company and you or pursuant to the Company&#8217;s Certificate of Incorporation or by-laws.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Disclosure, Non-Competition and Non-Solicitation</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; You acknowledge and reaffirm your obligation to keep confidential and not disclose all non-public information concerning the Company and its clients that you acquired during the course of your employment with the Company, as stated more fully in Section 5 of the Employment Agreement,</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">which remains in full force and effect.  </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Return of Company Property</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones, smartphones, tablets, etc.), Company identification, and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to those which you developed or helped to develop during your employment.  You further confirm that you have cancelled all accounts for your benefit, if any, in the Company's name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or wireless data accounts and computer accounts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Business Expenses and Final Compensation</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you.  You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses and accrued, unused vacation time, and that no other compensation is owed to you except as provided herein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Disparagement</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, for a period of five years following the date hereof you shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company&#8217;s business affairs and financial condition. Further, for a period of five years following the date hereof, neither the Company, nor any of its executive officers or members of its Board will directly or indirectly make, or cause to be made, any false statement, observation or opinion, disparaging your reputation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Continued Assistance</font><font style="font-family:inherit;font-size:12pt;">&#32;- You agree that after the Termination Date you will provide all reasonable cooperation to the Company, including but not limited to, assisting the Company transition your job duties, assisting the Company in defending against and/or prosecuting any litigation or threatened litigation, and performing any other tasks as reasonably requested by the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Cooperation</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; To the extent permitted by law, you agree to cooperate fully with the Company in the defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">,</font><font style="font-family:inherit;font-size:12pt;">&#32;whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator.  Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative hearing or a mediation or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company.  You agree that you will notify the Company promptly in the event that you are served with a subpoena or in the event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company.  </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendment and Waiver</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.  This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.  No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Validity</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">11.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidentiality</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except to the extent required by federal or state law or as otherwise agreed to in writing by the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; You understand and agree that this letter agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Acknowledgments</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#8211; </font><font style="font-family:inherit;font-size:12pt;">You acknowledge that you have been given at least twenty-one (21) days to consider this letter agreement, and that the Company advised you to consult with an attorney of your own choosing prior to signing this letter agreement.  You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration of this seven (7) day revocation period. You understand and agree that by entering into this agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefits Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Assent</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement.  You state and represent that you have had an opportunity to fully discuss and review the terms of this letter agreement with an attorney.  You further state and represent that you have carefully read this letter agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof and sign your name of your own free act.</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Applicable Law</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; This letter agreement shall be interpreted and construed by the laws of the State of New Jersey, without regard to conflict of laws provisions.  You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the State of New Jersey, or if appropriate, a federal court located in the State of New Jersey (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your Severance Compensation and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;">Nothing in this paragraph, however, shall modify, cancel or supersede your obligations set forth in paragraph 3 herein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tax Acknowledgement</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; In connection with the payments and consideration provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such payments and consideration under applicable law.  You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the Severance Compensation set forth in Section 4 of the Employment Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you have any questions about the matters covered in this letter agreement, please call me at </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Phone Number]</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Very truly yours,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;__________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Name]</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;text-indent:336px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Title]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">I hereby agree to the terms and conditions set forth above.  I have been given at least twenty-one (21) days to consider this letter agreement and I have chosen to execute this on the date below.  I intend that this letter agreement will become a binding agreement between me and the Company if I do not revoke my acceptance in seven (7) days.</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_____________________________</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Name]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_________________________</font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To be returned to me</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">by </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Return Date &#8211; e.g., 21 days from date of receipt of this letter]</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sFF522CF88D5E5A67B46767D2B562B2C6"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AMENDMENT TO EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Amendment (the &#8220;Amendment&#8221;) is made by and between Emily Hill (&#8220;Executive&#8221;) and PTC Therapeutics, Inc. (the &#8220;Company&#8221;) (collectively, &#8220;the Parties&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Executive is employed by PTC pursuant to an Employment Agreement between Executive and PTC dated December 11, 2017 (the &#8220;Employment Agreement&#8221;); and  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, on January 1, 2019 (the &#8220;Amendment Effective Date&#8221;), in connection with Executive&#8217;s promotion, the Company is authorized to enter in to an amendment to Executive&#8217;s Employment Agreement to reflect the title of Senior Vice President, with conforming changes to the Employment Agreement with respect to title, severance compensation, and annual bonus target;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is acknowledged hereby, and in consideration of the mutual covenants and undertakings set forth herein, the Parties agree that the following sections of the Employment Agreement are amended and restated as follows as of the Amendment Effective Date:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 1(a), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Capacity:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;Executive shall serve the Company as Senior Vice President, Head of Investor Relations reporting to Stu Peltz or such other senior executive as the Company shall specify.  Executive shall have the responsibilities, duties and authority commensurate with the position of Senior Vice President, Head of Investor Relations.  In addition to Executive&#8217;s primary duties, Executive shall perform such other services for the Company that are consistent with her position as Senior Vice President, Head of Investor Relations as may be reasonably assigned to Executive from time to time by the individual to whom she reports or the Board of Directors of the Company (the &#8220;Board&#8221;) or their respective designees.  The principal location at which Executive shall perform such services shall be the Company&#8217;s corporate headquarters currently located at 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ  07080, subject to relocation and Section 2(c)(i) of this Agreement.&#8221;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2(c), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Definition of &#8220;Good Reason&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, clause (ii):</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;A material adverse change by the Company in Executive&#8217;s duties, authority or responsibilities as Senior Vice President, Head of Investor Relations of the Company which causes Executive&#8217;s position with the Company to become of materially less responsibility or authority than Executive&#8217;s position immediately following the Effective Date.  For purposes of this definition of &#8220;Good Reason,&#8221; a &#8220;material adverse change&#8221; following a Corporate Change shall not include any diminution in authority, duties or responsibilities that is solely attributable to the change in the Company&#8217;s ownership structure but does not otherwise change Executive&#8217;s authority, duties or responsibilities (except in a positive manner) otherwise with respect to the Company&#8217;s business.&#8221;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3(b), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Bonus:</font><font style="font-family:inherit;font-size:12pt;">&#32;In addition to the Base Salary, the Company may pay Executive an annual bonus (the &#8220;Bonus&#8221;) as determined by the Board, solely in its discretion (it being understood that Executive&#8217;s target annual bonus shall be at 40% of Base Salary, but may be higher or lower in any year in the Board&#8217;s discretion).  The Board&#8217;s decision to issue a Bonus to Executive in any particular year shall have no effect on the absolute discretion of the Board to grant or not to grant a Bonus in subsequent years.  Any Bonus for a particular year shall be paid or provided to Executive in a lump sum no later than March 15th of the calendar year following the calendar year in which the Bonus was earned.&#8221;</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 4, </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severance Compensation</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, subsection (b):</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for a Good Reason or (ii) by the Company without Cause, the Company shall pay to Executive the Accrued Obligations.  In addition, the Company shall pay to Executive the severance benefits set forth below for twelve (12) months following Executive&#8217;s termination of employment (the &#8220;Severance Period&#8221;).  The receipt of any severance benefits provided in this Section shall be dependent upon Executive&#8217;s execution and nonrevocation of a standard separation agreement and general release of claims, substantially in the form attached hereto as Exhibit A (the &#8220;Release&#8221;).  The Company will also consider in good faith (but without any binding commitment) requests from Executive that the Company include in the Release a release of Executive by the Company from matters specifically disclosed to the Company by Executive in writing in advance of execution of the Release and not involving any illegality, fraud, concealment, criminal acts or acts outside the scope of Executive's employment.  The distribution of severance benefits in this Section 4 is subject to section (iii) of this Section 4(b).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i) If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case before or after the Protected Period, the Company shall pay Executive her Base Salary, less any amounts required to be withheld under applicable law, for the Severance Period in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, commencing 30 days following the effective date of such termination.  If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive her Base Salary for the Severance Period, which total amount shall be payable in a lump sum commencing no later than sixty (60) days following Executive&#8217;s termination of employment.   In each case, payments shall commence or be paid provided that the Release has been executed and any applicable revocation period has expired as of the 60th day following Executive&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii) Only if Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his target annual bonus, described in section 3(b) hereof, for the year in which the termination of employment occurs, which total amount shall be payable in a lump sum commencing no later than sixty (60) days following Executive&#8217;s termination of employment, provided that the Release has been executed and any applicable revocation period has expired as of such date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii) The Company shall continue to provide Executive and her then-enrolled eligible dependents with group health insurance and shall continue to pay the amount of the premium as in effect on the date of such termination for the Severance Period commencing on the effective date of such termination, subject to applicable law and the terms of the respective policies; provided that the Company&#8217;s obligation to provide the benefits contemplated herein shall terminate upon Executive&#8217;s becoming eligible for coverage under the medical benefits program of a subsequent employer.  The foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required by Federal law. &#8221;;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With the following subsections of subsection (4)(b) to be renumbered and referenced consistent with the insertion of the new subsection (4)(b)(ii) set forth above and the renumbering of the prior subsection 4(b)(ii) as subsection 4(b)(iii).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">No Other Changes.</font><font style="font-family:inherit;font-size:12pt;">&#32;Except as explicitly provided above, the Parties agree that there are no other changes or amendments to the Employment Agreement and that the Employment Agreement, as amended by this Amendment, remains in full force and effect.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREED AND ACCEPTED</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: _</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Mark E. Boulding</font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;">_____</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: _</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Mark E. Boulding</font><font style="font-family:inherit;font-size:12pt;">______</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: _</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CLO and EVP</font><font style="font-family:inherit;font-size:12pt;">___________</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: _______________________</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREED AND ACCEPTED:</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Emily Hill</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: _</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Emily Hill</font><font style="font-family:inherit;font-size:12pt;">_____________</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: _______________________</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="s3DA6BA4EF5935857706567D2B5793804"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;"><img src="employmentagreementhi_image1.jpg" alt="employmentagreementhi_image1.jpg" style="height:74px;width:337px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">May 31, 2019</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Emily Hill</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">125 Glenwood Road </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ridgewood, NJ 07450</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dear Emily,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Congratulations on your promotion to Chief Financial Officer. Your success at PTC has been impressive and we look forward to your continued contributions to PTC&#8217;s success.  The effective date of your promotion is May 31, 2019.  In this new role you will continue to report to CEO Stu Peltz.  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Outlined below are details of your promotion:  </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Your new annual base salary is $415,000 annually, subject to deductions for taxes and other withholdings as required by law.  </font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Your bonus target will continue to be 40.00% of your annual salaried earnings paid in accordance with the terms of conditions of PTC&#8217;s annual incentive compensation plan. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">You will receive a one-time promotion grant of 50,000 stock options to purchase shares of common stock of PTC, with 25% of options vesting after one year, and then 6.25% vesting quarterly thereafter.  This promotion grant is subject to formal approval of the Compensation Committee of the Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On behalf of PTC, let me again congratulate you on your promotion.  We look forward to this next step in your career.  Please feel free to contact me if you have any questions concerning your promotion.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sincerely,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accepted by:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Martin Rexroad&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Emily Hill</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Martin Rexroad</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SVP, Human Resources </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cc:&#160;&#160;&#160;&#160;Stu Peltz</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102utteremploym.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4AD3F85D5F43A1ACB063ADE1C3D3AA49"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 10.7</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This EMPLOYMENT AGREEMENT (the &#8220;Agreement&#8221;) is made as of August 16, 2014 (the &#8220;Effective Date&#8221;), by and between PTC Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;) and Christine Utter (&#8220;Executive&#8221;).  In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Employment</font><font style="font-family:inherit;font-size:12pt;">.  The Company agrees to continue to employ Executive and Executive agrees to continue to be employed by the Company on the terms and conditions set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Capacity</font><font style="font-family:inherit;font-size:12pt;">.  Executive shall serve the Company as Vice President, Finance reporting to Shane Kovacs, CFO, or such other senior executive as the Company shall specify.  Executive shall have the responsibilities, duties and authority commensurate with the position of Vice President, Finance.  In addition to Executive&#8217;s primary duties, Executive shall perform such other services for the Company that are consistent with his/her position as Vice President, Finance as may be reasonably assigned to Executive from time to time by the individual to whom s/he reports or the Board of Directors of the Company (the &#8220;Board&#8221;) or their respective designees.  The principal location at which Executive shall perform such services shall be the Company&#8217;s corporate headquarters currently located at 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ  07080, subject to relocation and Section 2(c)(i) of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Devotion of Duties; Representations</font><font style="font-family:inherit;font-size:12pt;">.  During the Term (as defined below) of Executive&#8217;s employment with the Company, Executive shall devote his/her best efforts and full business time and energies to the business and affairs of the Company, and shall endeavor to perform the duties and services contemplated hereunder to the reasonable satisfaction of the  individual to whom s/he reports and the Board.  During the Term of Executive&#8217;s employment with the Company, Executive shall not, without the prior written approval of the Company (by action of the Board), undertake any other employment from any person or entity or serve as a director of any other company; provided, however, that (i) the Company will entertain requests as to such other employment or directorships in good faith and (ii) Executive will be eligible to participate in any policy relating to outside activities that is applicable to the senior executives of the Company and approved by the Board after the date hereof.    </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term of Employment</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Executive&#8217;s employment hereunder shall continue on the Effective Date.  Executive&#8217;s employment hereunder shall be terminated upon the first to occur of the following:</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:12pt;">Immediately upon Executive&#8217;s death;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">By the Company</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to Executive effective the date of such notice, following the Disability of Executive.  &#8220;Disability&#8221; means that Executive (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12 months, or (ii) is, by reason of any medically determinable physical or mental impairment which can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under an accident and health plan covering employees of the Company.  Such incapacity shall be determined by a physician chosen by the Company and reasonably satisfactory to Executive (or Executive&#8217;s legal representative) upon examination requested by the Company (to which Executive hereby agrees to submit). Notwithstanding the foregoing, such Disability must result in Executive becoming &#8220;Disabled&#8221; within the meaning of Section 409A(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the guidance issued thereunder.  (In this Agreement we refer to Section 409A of the Code and any guidance issued thereunder as &#8220;Section 409A&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to Executive, effective the date of such notice, for Cause (as defined below); or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to Executive, effective ninety (90) days after the date of such notice and subject to Section 4 hereof, without Cause; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">By Executive</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">At any time by written notice to the Company, effective forty-five (45) days after the date of such notice</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">;</font><font style="font-family:inherit;font-size:12pt;">&#32;or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By written notice to the Company for Good Reason (as defined below), effective on the date specified in such notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The term of Executive&#8217;s employment by the Company under this Agreement is referred to herein as the &#8220;Term.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Cause&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of this Agreement, &#8220;Cause&#8221; shall, pursuant to the reasonable good faith determination by a majority of the Board (excluding Executive) as documented in writing, include:</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(i) the willful and continued failure by Executive to substantially perform Executive&#8217;s material duties or responsibilities under this Agreement (other than such a failure as a result of Disability); (ii) any action or</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">omission by Executive involving willful misconduct or gross negligence with regard to the Company, which has a detrimental effect on the Company; (iii) Executive&#8217;s conviction of a felony, either in connection with the performance of Executive&#8217;s obligations to the Company or which otherwise shall adversely affect Executive&#8217;s ability to perform such obligations or shall materially adversely affect the business activities, reputation, goodwill or image of the Company;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(iv) the material breach of a fiduciary duty to the Company; or (v) the material breach by Executive of any of the provisions of this Agreement, provided that any breach of Executive&#8217;s obligations with respect to Sections 5 or 6 of this Agreement, subject to the cure provision in the next sentence, shall be deemed &#8220;material.&#8221;  In respect of the events described in clauses (i) and (v) above, the Company shall give Executive notice of the failure of performance or breach, reasonable as to time, place and manner in the circumstances, and a 30-day opportunity to cure, provided that such failure of performance or breach is reasonably amenable to cure as determined by the Board in its sole discretion.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Good Reason&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of this Agreement, a &#8220;Good Reason&#8221; shall mean any of the following, unless (i) the basis for such Good Reason is cured within a reasonable period of time (determined in the light of the cure appropriate to the basis of such Good Reason, but in no event less than thirty (30) nor more than ninety (90) days) after the Company receives written notice (which must be received from Executive within ninety (90) days of the initial existence of the condition giving rise to such Good Reason) specifying the basis for such Good Reason or (ii) Executive has consented to the condition that would otherwise be a basis for Good Reason:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A change in the principal location at which Executive provides services to the Company to a location more than fifty (50) miles from such principal location and/or to a location in New York City (either of which change, the Company has reasonably determined as of the date hereof, would constitute a material change in the geographic location at which Executive provides services to the Company), provided that such a relocation shall not be deemed to occur under circumstances where Executive&#8217;s responsibilities require him/her to work at a location other than the corporate headquarters for a reasonable period of time; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A material adverse change by the Company in Executive&#8217;s duties, authority or responsibilities as Vice President, Finance of the Company which causes Executive&#8217;s position with the Company to become of materially less responsibility or authority than Executive&#8217;s position immediately following the Effective Date.  For purposes of this definition of &#8220;Good Reason,&#8221; a &#8220;material adverse change&#8221; following a Corporate Change shall not include any diminution in authority, duties or responsibilities that is solely attributable to the change in the Company&#8217;s ownership structure but does not otherwise change Executive&#8217;s authority, duties or responsibilities (except in a positive manner) otherwise with respect to the Company&#8217;s business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A material reduction in Executive&#8217;s base compensation (including Base Salary) except if  the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">A material breach of this Agreement by the Company which has not been cured within thirty (30) days after written notice thereof by Executive; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Failure to obtain the assumption (assignment) of this Agreement by any successor to the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Corporate Change&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of this Agreement, &#8220;Corporate Change&#8221; shall mean any circumstance in which (i) the Company is not the surviving entity in any merger, consolidation or other reorganization (or survives only as a subsidiary or affiliate of an entity other than a previously wholly-owned subsidiary of the Company); (ii) the Company sells, leases or exchanges or agrees to sell, lease or exchange all or substantially all of its assets to any other person or entity (other than a wholly-owned subsidiary of the Company); (iii) any person or entity, including a &#8220;group&#8221; as contemplated by Section 13(d)(3) of the Securities Exchange Act of 1934 (excluding, for this purpose, the Company or any Subsidiary, or any employee benefit plan of the Company or any Subsidiary, or any &#8220;group&#8221; in which all or </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">substantially all of its members or its members&#8217; affiliates are individuals or entities who are or were beneficial owners of the Company&#8217;s outstanding shares prior to the initial public offering, if any, of the Company&#8217;s stock), acquires or gains ownership or control (including, without limitations, powers to vote) of more than 50% of the outstanding shares of the Company&#8217;s voting stock (based upon voting power); or (iv) as a result of or in connection with a contested election of directors, the persons who were directors of the Company before such election shall cease to constitute a majority of the Board of Directors of the Company.  Notwithstanding the foregoing, a &#8220;Corporate Change&#8221; shall not occur as a result of an initial public offering of the Company&#8217;s common stock, or as a result of a merger, consolidation, reorganization or restructuring after which either (1) a majority of the Board of Directors of the controlling entity consists of persons who were directors of the Company prior to the merger, consolidation, reorganization or restructuring or (2) Executive forms part of an executive management team that consists of substantially the same group of individuals and Executive is performing in a similar role, with similar authority and responsibility (other than changes solely attributable to the change in ownership structure), to that which existed prior to the reorganization or restructuring.  Notwithstanding the foregoing, for any payments or benefits hereunder that are subject to Section 409A, the Corporate Change must constitute a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compensation</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:12pt;">.  Executive&#8217;s minimum base salary during the Term shall be at the rate of $220,000 per year (the &#8220;Base Salary&#8221;).  Base Salary shall be payable in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, less any amounts required to be withheld under applicable law.  The Base Salary will be subject to adjustment from time to time in the sole discretion of the Board; provided that, the Company covenants that it shall not reduce the Base Salary below $220,000 or the Base Salary then in effect immediately prior to the reduction unless (i) Executive consents to such reduction, or (ii) the reduction is in connection with a general reduction of not more than 20% in compensation of senior executives of the Company generally that occurs prior to the effective date of any Corporate Change.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:12pt;">.  In addition to the Base Salary, the Company may pay Executive an annual bonus (the &#8220;Bonus&#8221;) as determined by the Board, solely in its discretion (it being understood that Executive&#8217;s target annual bonus shall be at 30% of Base Salary, but may be higher or lower in any year in the Board&#8217;s discretion).  The Board&#8217;s decision to issue a Bonus to Executive in any particular year shall have no effect on the absolute discretion of the Board to grant or not to grant a Bonus in subsequent years.  Any Bonus for a particular year shall be paid or provided to Executive in a lump sum no later than March 15</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;of the calendar year following the calendar year in which the Bonus was earned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Equity Compensation</font><font style="font-family:inherit;font-size:12pt;">.  Except as explicitly set forth below, Executive&#8217;s rights with respect to equity (including stock options) shall be covered in PTC&#8217;s equity and long term incentive plan(s) and separate stock option certificates or agreements for each grant.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Accelerated Vesting</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For the avoidance of doubt, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason, no unvested equity awards granted under the Company&#8217;s equity and long-term incentive plan(s) following the date hereof shall be subject to any accelerated vesting except as otherwise provided for in the applicable award agreement or in Section 3(c)(i)(B) below. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except as otherwise provided in the applicable award, in the event that Executive&#8217;s employment hereunder is terminated by the Company without Cause or by Executive for Good Reason within the period of three (3) months prior to (but only if negotiations relating to the particular Corporate Change that occurs are ongoing at the date of the notice of termination) or twelve (12) months after a Corporate Change that occurs during the Term (such fifteen-month period, the &#8220;Protected Period&#8221;), one hundred percent (100%) of all of Executive&#8217;s outstanding unvested equity awards granted under the Company&#8217;s equity and long-term incentive plan(s) following the date hereof shall vest immediately. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Vacation</font><font style="font-family:inherit;font-size:12pt;">.  Executive is eligible for time off programs outlined in the Company&#8217;s Time Off Policy.  Executive shall accrue over the calendar year 160 hours of paid vacation.   Executive may accrue up to 200 hours of vacation.  Once Executive has reached the maximum accrual, no further vacation time will be accrued unless and until the Executive uses vacation time. Upon termination of employment, the value of Executive&#8217;s current balance of accrued but unused vacation shall be paid out in cash based on his/her Base Salary that was in effect immediately prior to his/her termination of employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Fringe Benefits</font><font style="font-family:inherit;font-size:12pt;">.  Executive shall be entitled to participate in any employee benefit plans that the Company makes available to its senior executives (including, without limitation, group life, disability, medical, dental and other insurance, retirement, pension, profit-sharing and similar plans) (collectively, the &#8220;Fringe Benefits&#8221;), provided that the Fringe Benefits shall not include any stock option or similar plans relating to the grant of equity securities of the Company.  These benefits may be modified or changed from time to time at the sole discretion of the Company.  Where a particular benefit is subject to a formal plan (for example, medical or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document, and eligibility to participate in such plan(s) may be dependent upon, among other things, a physical examination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reimbursement of Expenses</font><font style="font-family:inherit;font-size:12pt;">.  Executive shall be entitled to reimbursement for all ordinary and reasonable out-of-pocket business expenses that are reasonably incurred by him/her in furtherance of the Company&#8217;s business in accordance with reasonable policies adopted from time to time by the Company for senior executives.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Taxes and Withholdings</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall deduct and withhold from all compensation and benefits under this Agreement all social security and other federal, state and local taxes and charges which currently are or which hereafter may be required by law to be so deducted and withheld.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severance Compensation</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 6 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event of any termination of Executive&#8217;s employment for any reason the Company shall pay Executive (or Executive&#8217;s estate) such portions of Executive&#8217;s Base Salary as have accrued prior to such termination and have not yet been paid, together with (i) amounts for accrued unused vacation days (as provided above), (ii) any amounts for expense reimbursement which have been properly incurred or the Company has become obligated to pay prior to termination and have not been paid as of the date of such termination and (iii) the amount of any Bonus previously granted to Executive by the Board but not yet paid, which amount shall not include any pro rata portion of any Bonus which would have been earned if such termination had not occurred (the &#8220;Accrued Obligations&#8221;).  Such amounts shall be paid as soon as possible after termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for a Good Reason or (ii) by the Company without Cause, the Company shall pay to Executive the Accrued Obligations.  In addition, the Company shall pay to Executive the severance benefits set forth below for six (6) months following Executive&#8217;s termination of employment (the &#8220;Severance Period&#8221;).  The receipt of any severance benefits provided in this Section shall be dependent upon Executive&#8217;s execution (and, as applicable, non-revocation) of a standard separation agreement and general release of claims, substantially in the form attached hereto as Exhibit A (the &#8220;Release&#8221;).  The Company will also consider in good faith (but without any binding commitment) requests from Executive that the Company include in the Release a release of Executive by the Company from matters specifically disclosed to the Company by Executive in writing in advance of execution of the Release and not involving any illegality, fraud, concealment, criminal acts or acts outside the scope of Executive's employment.  The distribution of severance benefits in this Section 4 is subject to section (iii) of this Section 4(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case before or after the Protected Period, the Company shall pay Executive his/her Base Salary, less any amounts required to be withheld under applicable law, for the Severance Period in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, commencing no later than sixty (60) days following the effective date of such termination.  If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his/her Base Salary for the Severance Period, which total amount shall be payable in a lump sum no later than sixty (60) days following Executive&#8217;s termination of employment.  In each case, payments shall commence or be paid provided that the Release has been executed and any applicable revocation period has expired as of the 60</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day following Executive&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company shall continue to provide Executive and his/her then-enrolled eligible dependents with group health insurance and shall continue to pay the amount of the premium as in effect on the date of such termination for the Severance Period commencing on the effective date of such termination, subject to applicable law and the terms of the respective policies; provided that the Company&#8217;s obligation to provide the benefits contemplated herein shall terminate upon Executive&#8217;s becoming eligible for coverage under the medical benefits program of a subsequent employer.  The </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 7 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required by Federal law.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance with Section 409A</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the provisions in this Section 4(b)(iii), any severance payments or benefits under this Agreement shall begin only upon the date of Executive&#8217;s &#8220;separation from service&#8221; (determined as set forth below) which occurs on or after the date of termination of Executive&#8217;s employment.  The following rules shall apply with respect to the distribution of the severance payments and benefits, if any, to be provided to Executive under this Agreement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A.  Neither the Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is not a &#8220;specified employee&#8221; (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If, as of the date of Executive&#8217;s &#8220;separation from service&#8221; from the Company, Executive is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and such payments and benefits shall be paid or provided on the dates and terms set forth in this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each installment of the severance payments and benefits due this Agreement that is not described in Section 4(b)(iii)(3)(A) above and that would, absent this subsection, be paid within the six-month period following Executive&#8217;s &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, Executive&#8217;s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following Executive&#8217;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 8 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service).  Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of Executive&#8217;s second taxable year following the taxable year in which the separation from service occurs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The determination of whether and when Executive&#8217;s separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h).  Solely for purposes of this Section 4(b)(iii), &#8220;Company&#8221; shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(5)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Sections 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(6)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything herein to the contrary, the Company shall have no liability to Executive or to any other person if the payments and benefits provided hereunder that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for other than a Good Reason, or (ii) by the Company for Cause, or (iii) as a result of Executive&#8217;s death or Disability, then the Company will pay to Executive the Accrued Obligations.  The Company shall have no obligation to pay Executive (or Executive&#8217;s estate) any other compensation following such termination except as provided in Section 4(a). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Modified Section 280G Cutback</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Agreement, except as set forth in Section 4(d)(ii), in the event that the Company undergoes a &#8220;Change in Ownership or Control&#8221; (as defined below), the Company shall not be obligated to provide to Executive a portion of any &#8220;Contingent Compensation Payments&#8221; (as defined below) that Executive would otherwise be entitled to receive to the extent necessary to eliminate any &#8220;excess parachute payments&#8221; (as defined in Section 280G(b)(1) of the Code) for Executive.  For purposes of this Section&#160;4(d), the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Payments&#8221; and the aggregate amount </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 9 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated Amount.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii) &#160;&#160;&#160;&#160;Notwithstanding the provisions of Section 4(d)(i), no such reduction in Contingent Compensation Payments shall be made if (1) the Eliminated Amount (computed without regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in accordance with Treasury Regulation Section&#160;1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by Executive if the Eliminated Payments (determined without regard to this sentence) were paid to him/her (including, state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of Executive&#8217;s &#8220;base amount&#8221; (as defined in Section 280G(b)(3) of the Code), and any withholding taxes).  The override of such reduction in Contingent Compensation Payments pursuant to this Section&#160;4(d)(ii) shall be referred to as a &#8220;Section&#160;4(d)(ii) Override.&#8221;  For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)&#160;&#160;&#160;&#160;For purposes of this Section 4(d) the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(1)&#160;&#160;&#160;&#160;&#8220;Change in Ownership or Control&#8221; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(2)&#160;&#160;&#160;&#160;&#8220;Contingent Compensation Payment&#8221; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to a &#8220;disqualified individual&#8221; (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)&#160;&#160;&#160;&#160;Any payments or other benefits otherwise due to Executive following a Change in Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the &#8220;Potential Payments&#8221;) shall not be made until the dates provided for in this Section&#160;4(d)(iv).  Within 30 days after each date on which Executive first becomes entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify Executive (with reasonable detail regarding the basis for its determinations) (1) which Potential Payments constitute Contingent Compensation Payments, (2) the Eliminated Amount and (3)&#160;whether the Section&#160;4(d)(ii) Override is applicable.  Within 30 days after delivery of such notice to Executive, Executive shall deliver a response to the Company (the &#8220;Executive </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 10 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Response&#8221;) stating either (A) that s/he agrees with the Company&#8217;s determination pursuant to the preceding sentence or (B) that s/he disagrees with such determination, in which case</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">s/he</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall set forth (x) which Potential Payments should be characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section&#160;4(d)(ii) Override is applicable.  In the event that Executive fails to deliver an Executive Response on or before the required date, the Company&#8217;s initial determination shall be final.  If Executive states in the Executive Response that s/he</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">agrees with the Company&#8217;s determination, the Company shall make the Potential Payments to Executive within three business days following delivery to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  If Executive states in the Executive Response that s/he disagrees with the Company&#8217;s determination, then, for a period of 60 days following delivery of the Executive Response, Executive and the Company shall use good faith efforts to resolve such dispute.  If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in South Plainfield, New Jersey, in accordance with the rules of the American Arbitration Association then in effect.  Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction.  The Company shall, within three business days following delivery to the Company of the Executive Response, make to Executive those Potential Payments as to which there is no dispute between the Company and Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).  The balance of the Potential Payments shall be made within three business days following the resolution of such dispute.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;(v)&#160;&#160;&#160;&#160;The Contingent Compensation Payments to be treated as Eliminated Payments shall be determined by the Company by determining the &#8220;Contingent Compensation Payment Ratio&#8221; (as defined below) for each Contingent Compensation Payment and then reducing the Contingent Compensation Payments in order beginning with the Contingent Compensation Payment with the highest Contingent Compensation Payment Ratio.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payment shall be reduced based on the time of payment of such Contingent Compensation Payments with amounts having later payment dates being reduced first.  For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio and the same time of payment, such Contingent Compensation Payments shall be reduced on a pro rata basis (but not below zero) prior to reducing Contingent Compensation Payment with a lower Contingent Compensation Payment Ratio.  The term &#8220;Contingent Compensation Payment Ratio&#8221; shall mean a fraction the numerator of which is the value of the applicable Contingent Compensation Payment that must be taken into account by Executive for purposes of Section 4999(a) of the Code, and the denominator of which is the actual amount to be received by Executive in respect of the applicable Contingent Compensation Payment.  For example, in the case of an equity grant that is treated as contingent on the Change in Ownership or Control because the time at which the payment is made or the payment vests is accelerated, the denominator shall be determined by reference to the fair market value of the equity at the acceleration date, and </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 11 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">not in accordance with the methodology for determining the value of accelerated payments set forth in Treasury Regulation Section 1.280G-1Q/A-24(b) or (c)). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)&#160;&#160;&#160;&#160;The provisions of this Section 4(d) are intended to apply to any and all payments or benefits available to Executive under this Agreement or any other agreement or plan of the Company under which Executive receives Contingent Compensation Payments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)&#160;&#160;&#160;&#160;Notwithstanding Sections 4(d)(i)-(vi) hereof, until the closing of the first underwritten public offering of common stock of the Company, in the event that it shall be determined that any payment or benefit (including any accelerated vesting of options or other equity awards) made or provided, or to be made or provided, by the Company (or any successor thereto or affiliate thereof) to or for the benefit of Executive, whether pursuant to the terms of this Agreement, any other agreement, plan, program or arrangement of or with the Company (or any successor thereto or affiliate thereof) or otherwise, may be subject to the excise tax imposed by Section 4999 of the Code or any comparable tax imposed by any replacement or successor provision of United States tax law, then upon the request of Executive, the Company shall use reasonable efforts to procure a shareholder vote in satisfaction of the shareholder approval requirements described in Treas. Reg. Section 1.280G-1, Q&amp;A-7.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Executive Covenants</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">.  Executive recognizes and acknowledges the competitive and proprietary aspects of the business of the Company, and that as a result of Executive&#8217;s employment, Executive recognizes and acknowledges that s/he has had and will continue to have access to, and has been and will continue to be involved in the development of, Confidential Information (as defined below) of the Company.  As used herein, &#8220;Confidential Information&#8221; shall mean and include trade secrets, knowledge and other confidential information of the Company, which Executive has acquired, no matter from whom or on what matter such knowledge or information may have been acquired, heretofore or hereafter, concerning the content and details of the business of the Company, and which is not known to the general public, including but not limited to: (a) new products, product betterments and other inventions, formulas, processes, methods, materials, material combinations, manner of preparations, technical production procedures and information, alarm and security codes and procedures, sources of technology, and sources of supply of raw and finished materials and other products; (b) financial and accounting records; (c) the identity of employees, consultants, independent contractors, customers, business development partners, licensees, suppliers, creditors or other parties with which the Company has business dealings, the nature of the relationship with such persons, or any other information relating to such persons or the Company&#8217;s dealings with such persons; and (d) computer software used by the Company or provided to the customers of the Company unless publicly available.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">For as long as Executive is employed and at all times thereafter, Executive shall not, directly or indirectly, communicate, disclose or divulge to any person or entity, or use for Executive&#8217;s own benefit or the benefit of any person (other than the Company), any Confidential Information, except as permitted in subparagraph (iii) </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 12 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">below.  Upon termination of Executive&#8217;s employment, or at any other time at the request of the Company, Executive agrees to deliver promptly to the Company all Confidential Information, including, but not limited to, customer and supplier lists, files and records, in Executive&#8217;s possession or under Executive&#8217;s control.  Executive further agrees that s/he will not make or retain any copies of any of the foregoing and will so represent to the Company upon termination of Executive&#8217;s employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Executive shall disclose immediately to the Company any trade secrets or other Confidential Information conceived or developed by Executive at any time during Executive&#8217;s employment.  Executive hereby assigns and agrees to assign to the Company Executive&#8217;s entire right, title and interest in and to all Confidential Information.  Such assignment shall include, without limitation, the rights to obtain patent or copyright protection, thereon in the United States and foreign countries.  Executive agrees to provide all reasonable assistance to enable the Company to prepare and prosecute any application before any governmental agency for patent or copyright protection or any similar application with respect to any Confidential Information.  Executive further agrees to execute all documents and assignments and to make all oaths necessary to vest ownership of such intellectual property rights in the Company, as the Company may request.  These obligations shall apply whether or not the subject thereof was conceived or developed at the suggestion of the Company, and whether or not developed during regular hours of work or while on the premises of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Executive shall at all times, both during and after termination of this Agreement by either Executive or the Company, maintain in confidence and shall not, without prior written consent of the Company, use, except in the course of performance of Executive&#8217;s duties for the Company or as required by legal process (provided that Executive will promptly notify the Company of such legal process except with respect to any confidential government investigation), disclose or give to others any Confidential Information.  In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to any such information or any other secret or confidential work of the Company, or concerning any fact or circumstance relating thereto, Executive will promptly notify the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Competition and Non-Solicitation</font><font style="font-family:inherit;font-size:12pt;">.  Executive recognizes that the Company is engaged in a competitive business and that the Company has a legitimate interest in protecting its trade secrets, confidential business information, and customer, business development partner, licensee, supplier, and credit and/or financial relationships.  Accordingly, in exchange for valuable consideration, including without limitation Executive&#8217;s access to confidential business information and continued at-will employment, Executive agrees that, during the Term hereof and for a period of eighteen (18) months thereafter, Executive shall not:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">directly or indirectly, whether for himself or for any other person or entity, and whether as a proprietor, principal, shareholder, partner, agent, employee, consultant, independent contractor, or in any other capacity whatsoever, undertake or have any interest in (other than the passive ownership of publicly registered securities representing an ownership interest of less than 1%), engage in or assume any role </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 13 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">involving directly or indirectly the Company&#8217;s Field of Interest (or any portion thereof) or any other business in which the Company is engaged and for which the employee has rendered services while employed by the Company, or enter into any agreement to do any of the foregoing; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">initiate contact with (including without limitation phone calls, press releases and the sending or delivering of announcements), or in any manner solicit, directly or indirectly, any customers, business development partners, licensors, licensees, or creditors (including institutional lenders, bonding companies and trade creditors) of the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to transfer any of their business with the Company to any person or entity other than the Company; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">initiate contact with, or in any manner solicit, directly or indirectly, any supplier of goods, services or materials to the Company in an attempt to induce or motivate them either to discontinue or modify their then prevailing or future relationship with the Company or to supply the same or similar inventory, goods, services or materials (except generally available inventory, goods, services or materials) to any person or entity other than the Company; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">directly or indirectly recruit, solicit or otherwise induce or influence any employee or independent contractor of the Company to discontinue or modify his or her employment or engagement with the Company, or employ or contract with any such employee or contractor for the provision of services.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Field of Interest&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  The term Company&#8217;s &#8220;Field of Interest&#8221; shall mean the research, development and commercialization of products and strategies relating to: (i) therapies for genetic disorders or diseases that include cystic fibrosis, Duchenne muscular dystrophy, other diseases caused in whole or part by nonsense (or stop) codons, and other genetic diseases as to which the Company engages in the research, development or commercialization of drugs; anti-angiogenic therapies that target VEGF protein production for cancer; and antiviral therapies for the Hepatitis C virus (HCV); and (ii) other therapeutic targets, mechanisms of action and/or therapies in which the Company has a research, development or commercialization program. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Definition of &#8220;Customer&#8221;</font><font style="font-family:inherit;font-size:12pt;">.  The term &#8220;customer&#8221; or &#8220;customers&#8221; shall include any person or entity (a) that is a current customer of the Company, (b) that was a customer of the Company at any time during the preceding twenty-four (24) months or (c) to which the Company made a written presentation for the solicitation of business at any time during the preceding twenty-four (24) months.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reasonableness of Restrictions</font><font style="font-family:inherit;font-size:12pt;">.  Executive further recognizes and acknowledges that (i) the types of employment which are prohibited by this Section 5 are narrow and reasonable in relation to the skills which represent Executive&#8217;s principal salable asset both to the Company and to Executive&#8217;s other prospective employers, and (ii) the broad geographical scope of the provisions of this Section 5 is reasonable, legitimate and fair to Executive in light of the global nature of the Company&#8217;s business, particularly pharmaceutical research and development, and in light of the limited restrictions on the type of employment prohibited herein </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 14 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">compared to the types of employment for which Executive is qualified to earn Executive&#8217;s livelihood. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Remedies</font><font style="font-family:inherit;font-size:12pt;">.  Executive acknowledges that a breach of this Section 5 will cause great and irreparable injury and damage, which cannot be reasonably or adequately compensated by money damages.  Accordingly, Executive acknowledges that the remedies of injunction and specific performance shall be available in the event of such a breach, in addition to money damages, costs and attorneys&#8217; fees, and other legal or equitable remedies, and that the Company shall be entitled as a matter of course to an injunction pending trial, without the posting of bond or other security.  Any period of restriction set forth in this Section 5 shall be extended for a period of time equal to the duration of any breach or violation hereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notification</font><font style="font-family:inherit;font-size:12pt;">.  Any person employing Executive or evidencing any intention to employ Executive may be notified as to the existence and provisions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Modification of Covenants; Enforceability</font><font style="font-family:inherit;font-size:12pt;">.  In the event that any provision of this Section 5 is held to be in any respect an unreasonable restriction, then the court so holding may modify the terms thereof, including the period of time during which it operates or the geographic area to which it applies, or effect any other change to the extent necessary to render this section enforceable, it being acknowledged by the parties that the representations and covenants set forth herein are of the essence of this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Subsidiaries</font><font style="font-family:inherit;font-size:12pt;">.  For purposes of Sections 5 and 6 of this Agreement, &#8220;Company&#8221; shall include all direct and indirect subsidiaries of the Company.  An entity shall be deemed to be a subsidiary of the Company if the Company directly or indirectly owns or controls 50% or more of the equity interest in such entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ownership of Ideas, Copyrights and Patents</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Property of the Company</font><font style="font-family:inherit;font-size:12pt;">.  Executive agrees that all ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know&#8209;how, inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks and formulae, whether patentable, copyrightable or not, which Executive may conceive, reduce to practice or develop, alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of the Company, or otherwise, in the course of performing services for the Company in any capacity, whether heretofore or hereafter, (collectively, &#8220;the Inventions&#8221;) are and shall be the sole and exclusive property of the Company, and that Executive shall not publish any of the Inventions without the prior written consent of the Company.  Executive hereby assigns to the Company all of Executive&#8217;s right, title and interest in and to all of the foregoing.  Executive further represents and agrees that to the best of Executive&#8217;s knowledge and belief none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of any person, firm or corporation and that Executive will use his/her best efforts to prevent any such violation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cooperation</font><font style="font-family:inherit;font-size:12pt;">.  At any time during or after the Term, Executive agrees that s/he will fully cooperate with the Company, its attorneys and agents in the preparation and filing </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 15 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of all papers and other documents as may be required to perfect the Company&#8217;s rights in and to any of such Inventions, including, but not limited to, executing any lawful document (including, but not limited to, applications, assignments, oaths, declarations and affidavits) and joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights of the United States and of any and all other countries on such Inventions, provided that any patent or other legal right so issued to Executive, personally, shall be assigned by Executive to the Company without charge by Executive.  Executive further designates the Company as his/her agent for, and grants to the Company a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of effecting the foregoing assignments from Executive to the Company.  Company will bear the reasonable expenses which it causes to be incurred in Executive&#8217;s assisting and cooperating hereunder.  Executive waives all claims to moral rights in any Inventions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosure to Future Employers</font><font style="font-family:inherit;font-size:12pt;">.  The Company may provide in its discretion, a copy of the covenants contained in Sections 5 and 6 of this Agreement to any business or enterprise which Executive may directly, or indirectly, own, manage, operate, finance, join, control or in which Executive participates in the ownership, management, operation, financing, or control, or with which Executive may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Records</font><font style="font-family:inherit;font-size:12pt;">.  Upon termination of Executive&#8217;s relationship with the Company, Executive shall deliver to the Company any property of the Company which may be in Executive&#8217;s possession including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  The Company, in its sole discretion, may apply for and procure in its own name (whether or not for its own benefit) policies of insurance insuring Executive&#8217;s life.  Executive agrees to submit to reasonable medical or other examinations and to execute and deliver any applications or other instruments in writing that are reasonably necessary to effectuate such insurance.  No adverse employment actions may be based upon the results of any such exam or the failure by the Company to obtain such insurance.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Conflicting Agreements</font><font style="font-family:inherit;font-size:12pt;">.  Executive hereby represents and warrants that Executive has no commitments or obligations inconsistent with this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#8220;Market Stand-Off&#8221; Agreement</font><font style="font-family:inherit;font-size:12pt;">.  Executive agrees, if requested by the Company and an underwriter of common stock (or other securities) of the Company, not to sell or otherwise transfer or dispose of any common stock (or other securities) of the Company held by Executive during a period not to exceed one hundred and eighty (180) days following the effective date of the first underwritten public offering of common stock of the Company, offered on a firm commitment basis pursuant to a registration statement filed with the Securities and Exchange Commission (or any successor agency of the Federal government administrating the Securities Act of 1933, as amend, and the Securities Exchange Act of 1934, as amended) under the Securities Act of 1933, as amended, on Form S-1 or its then equivalent, and to enter into an agreement to such effect.  The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said period. </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 16 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.  All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party&#8217;s address as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to the Company:&#160;&#160;&#160;&#160;PTC Therapeutics Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100 Corporate Court</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;South Plainfield, NJ 07080</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;USA</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attention: Legal Department</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Telephone: (908) 222-7000</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With an email copy to: legal@ptcbio.com</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If to Executive: &#160;&#160;&#160;&#160;Christine Utter</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3 Pembroke Court</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Marlboro, NJ 07746</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or to such other address as a party may designate by notice hereunder, and shall be either (i)&#160;delivered by hand, (ii)&#160;sent by overnight courier, or (iii)&#160;sent by registered or certified mail, return receipt requested, postage prepaid.  All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i)&#160;if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii)&#160;if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof, except with respect to the equity and fringe benefit arrangements referred to in Subsections 3(c) and (e) above.  No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Modifications and Amendments</font><font style="font-family:inherit;font-size:12pt;">.  The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waivers and Consents</font><font style="font-family:inherit;font-size:12pt;">.  The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions.  No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar.  Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 17 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business or that aspect of the Company&#8217;s business in which Executive is principally involved.  Executive may not assign Executive&#8217;s rights and obligations under this Agreement without the prior written consent of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Benefit</font><font style="font-family:inherit;font-size:12pt;">.  All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto.  Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third&#8209;party beneficiary of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the law of The State of New Jersey, without giving effect to the conflict of law principles thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Jurisdiction and Service of Process</font><font style="font-family:inherit;font-size:12pt;">.  Any legal action or proceeding with respect to this Agreement shall be brought in the courts of The State of New Jersey or of the United States of America for the</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">District of New Jersey.  By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts.  Each of the parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its address set forth in Section 12(a) hereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  The parties intend this Agreement to be enforced as written.  However, (i) if any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law; and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby or otherwise, the Company and Executive agrees that the court making such determination shall have the power to reduce the duration and/or geographic area of such provision, and/or to delete specific words and phrases (&#8220;blue-penciling&#8221;), and in its reduced or blue-penciled form such provision shall then be enforceable and shall be enforced.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Headings and Captions; Interpretation</font><font style="font-family:inherit;font-size:12pt;">.  The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify, or affect the meaning or construction of any of the terms or provisions hereof.  The provisions of the following Sections of this Agreement are in addition to, and do not limit, each other: Sections 6 and 5(a); Sections 7 and 5(g); Sections 12(k) and 12(f); and Sections 12(l) and 12(d).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Injunctive Relief</font><font style="font-family:inherit;font-size:12pt;">.  Executive hereby expressly acknowledges that any breach or threatened breach of any of the terms and/or conditions set forth in Section 5 or 6 of this Agreement will result in substantial, continuing and irreparable injury to the Company.  </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 18 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Therefore, Executive hereby agrees that, in addition to any other remedy that may be available to the Company, the Company shall be entitled to injunctive or other equitable relief by a court of appropriate jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Waiver of Rights, Powers and Remedies</font><font style="font-family:inherit;font-size:12pt;">.  No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party.  No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.  The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies.  No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Survival</font><font style="font-family:inherit;font-size:12pt;">.  The provisions of Sections 4, 5, 6, 7, 8, 11 and 12 shall survive the termination of this Agreement and Executive&#8217;s employment hereunder in accordance with their terms.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">WAIVER OF TRIAL BY JURY</font><font style="font-family:inherit;font-size:12pt;">.  THE PARTIES IRREVOCABLY WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY REGARDING ANY DISPUTE, CLAIM OR CAUSE OF ACTION ARISING OUT OF, CONCERNING, OR RELATED TO EXECUTIVE&#8217;S EMPLOYMENT WITH THE COMPANY OR THIS AGREEMENT.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowing and Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;">.  Executive acknowledges and agrees that Executive is executing this Agreement knowingly and voluntarily and without any duress or undue influence by PTC or anyone else.  Executive further acknowledges and agrees that Executive has carefully read this Agreement and fully understands it, including that Executive is waiving the right to a jury trial.  Executive further agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive&#8217;s choice before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS THEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PTC Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;/s/ Mark Boulding&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Mark Boulding </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: &#160;&#160;&#160;&#160;Executive Vice President &amp; Chief Legal Officer</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 19 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreed and Accepted</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;/s/ Christine Utter&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Christine Utter</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="s12B6D99E33FE82F98785ADE1C42D64E0"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sample Separation and Release Agreement</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Date]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Name]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Address]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dear </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Name]</font><font style="font-family:inherit;font-size:12pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In connection with the termination of your employment with PTC Therapeutics, Inc. (the &#8220;Company&#8221;) on </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Termination Date]</font><font style="font-family:inherit;font-size:12pt;">, you are eligible to receive the Severance Compensation as described in Section 4 of the Employment Agreement executed between you and the Company on [</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insert Date</font><font style="font-family:inherit;font-size:12pt;">] (the &#8220;Employment Agreement&#8221;) if you sign and return this letter agreement to me by </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Return Date &#8211; e.g., 21 days from date of receipt of this letter agreement] </font><font style="font-family:inherit;font-size:12pt;">and it becomes binding between you and the Company.  By signing and returning this letter agreement [and not revoking your acceptance], you will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3.  Therefore, you are advised to consult with an attorney before signing this letter agreement and you may take up to [twenty-one (21) days] to do so.  [If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) day period after you have signed it by notifying me  in writing.  If you do not so revoke, this letter agreement will become a binding agreement between you and the Company upon the expiration of the seven (7) day period.]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you choose not to sign and return this letter agreement by </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Return Date-Same as Above][</font><font style="font-family:inherit;font-size:12pt;">, or if you timely revoke your acceptance in writing], you shall not receive any Severance Compensation from the Company.  </font><font style="font-family:inherit;font-size:12pt;">You will, however, receive payment for your final wages and any unused vacation time accrued through the Termination Date, as defined below, on the Company&#8217;s regular payroll date immediately following the Termination Date.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Also, regardless of signing this letter agreement, you may elect to continue receiving group medical insurance pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167;&#160;1161 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;If you so elect, you shall pay all premium costs on a monthly basis for as long as, and to the extent that, you remain eligible for COBRA  continuation.  You should consult the COBRA materials to be provided by the Company for details regarding these benefits.  All other benefits will cease upon your Termination Date in accordance with the plan documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The following numbered paragraphs set forth the terms and conditions that will apply if you timely sign and return this letter agreement and do not revoke it in writing within the seven (7) day period.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination Date</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; Your effective date of termination from the Company is&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Date]</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;Termination Date&#8221;).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; In consideration of the payment of the Severance Compensation, which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 2 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:12pt;">irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#8220;Released Parties&#8221;) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#8217; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the Americans With Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &#167; 2000ff </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, the Worker Adjustment and Retraining Notification Act (&#8220;WARN&#8221;), 29 U.S.C. &#167; 2101 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, and the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C. &#167; 1001 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:12pt;">, all as amended; all claims arising out of the New Jersey Law Against Discrimination, N.J. Stat. Ann.&#160;&#167;&#160;10:5-1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the New Jersey Family Leave Act, N.J. Stat. Ann. &#167; 34:11B-1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, the New Jersey Conscientious Employee Protection Act, N.J. Stat. Ann. &#160;&#167;&#160;34:19-1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">, and the N.J. Stat. Ann.&#160;&#167;&#160;34:11-56.1 </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:12pt;">&#32;(New Jersey equal pay law), all as amended; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract, including without limitation, all claims arising from the Employment Agreement; all state and federal whistleblower claims to the maximum extent permitted by law; all claims to any non-vested ownership interest in the Company, contractual or otherwise; and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement shall (i) prevent you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding) or (ii) deprive you of any rights you may have to be indemnified by the Company as provided in any agreement between the Company and you or pursuant to the Company&#8217;s Certificate of Incorporation or by-laws.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Disclosure, Non-Competition and Non-Solicitation</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; You acknowledge and reaffirm your obligation to keep confidential and not disclose all non-public information concerning the Company and its clients that you acquired during the course of your employment with the Company, as stated more fully in Section 5 of the Employment Agreement,</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">which remains in full force and effect.  </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 3 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Return of Company Property</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones, smartphones, tablets, etc.), Company identification, and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to those which you developed or helped to develop during your employment.  You further confirm that you have cancelled all accounts for your benefit, if any, in the Company's name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or wireless data accounts and computer accounts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Business Expenses and Final Compensation</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you.  You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses and accrued, unused vacation time, and that no other compensation is owed to you except as provided herein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Non-Disparagement</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, for a period of five years following the date hereof you shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company&#8217;s business affairs and financial condition. Further, for a period of five years following the date hereof, neither the Company, nor any of its executive officers or members of its Board will directly or indirectly make, or cause to be made, any false statement, observation or opinion, disparaging your reputation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Continued Assistance</font><font style="font-family:inherit;font-size:12pt;">&#32;- You agree that after the Termination Date you will provide all reasonable cooperation to the Company, including but not limited to, assisting the Company transition your job duties, assisting the Company in defending against and/or prosecuting any litigation or threatened litigation, and performing any other tasks as reasonably requested by the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Cooperation</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; To the extent permitted by law, you agree to cooperate fully with the Company in the defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">,</font><font style="font-family:inherit;font-size:12pt;">&#32;whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator.  Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative hearing or a mediation or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company.  You agree that you will notify the Company promptly in the event that you are served with a subpoena or in the event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company.  </font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 4 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Amendment and Waiver</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.  This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.  No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">10.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Validity</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">11.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidentiality</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; To the extent permitted by law, you understand and agree that as a condition for payment to you of the Severance Compensation herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except to the extent required by federal or state law or as otherwise agreed to in writing by the Company.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">12.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Nature of Agreement</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8211; You understand and agree that this letter agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">13.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Acknowledgments</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#8211; </font><font style="font-family:inherit;font-size:12pt;">You acknowledge that you have been given at least [twenty-one (21) days] to consider this letter agreement, and that the Company advised you to consult with an attorney of your own choosing prior to signing this letter agreement.  [You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration of this seven (7) day revocation period.] You understand and agree that by entering into this agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefits Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">14.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Voluntary Assent</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement.  You state and represent that you have had an opportunity to fully discuss and review the terms of this letter agreement with an attorney.  You further state and represent that you have carefully read this letter agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof and sign your name of your own free act.</font></div></td></tr></table><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">- 5 -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">15.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Applicable Law</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; This letter agreement shall be interpreted and construed by the laws of the State of New Jersey, without regard to conflict of laws provisions.  You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the State of New Jersey, or if appropriate, a federal court located in the State of New Jersey (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">16.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your Severance Compensation and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;">Nothing in this paragraph, however, shall modify, cancel or supersede your obligations set forth in paragraph 3 herein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">17.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:left;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tax Acknowledgement</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; In connection with the payments and consideration provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such payments and consideration under applicable law.  You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the Severance Compensation set forth in Section 4 of the Employment Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If you have any questions about the matters covered in this letter agreement, please call me at </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Phone Number]</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Very truly yours,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;__________________________________</font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Name]</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;text-indent:336px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Title]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">I hereby agree to the terms and conditions set forth above.  I have been given at least [twenty-one (21) days] to consider this letter agreement and I have chosen to execute this on the date below.  I intend that this letter agreement will become a binding agreement between me and the Company [if I do not revoke my acceptance in seven (7) days].</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_____________________________</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Insert Employee Name]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_________________________</font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">To be returned to me</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">by </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Return Date &#8211; e.g., 21 days from date of receipt of this letter]</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sEA3D9D4C7684C53C8B42ADE1C4625351"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AMENDMENT TO EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Amendment (the &#8220;Amendment&#8221;) is made by and between Christine Utter (&#8220;Executive&#8221;) and PTC Therapeutics, Inc. (the &#8220;Company&#8221;) (collectively, &#8220;the Parties&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Executive is employed by PTC pursuant to an Employment Agreement between Executive and PTC dated August 16, 2014 (the &#8220;Employment Agreement&#8221;); and  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, on January 1, 2017 (the &#8220;Amendment Effective Date&#8221;), in connection with Executive&#8217;s promotion, the Company is authorized to enter in to an amendment to Executive&#8217;s Employment Agreement to reflect the title of Senior Vice President, with conforming changes to the Employment Agreement with respect to title, severance compensation, and annual bonus target;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is acknowledged hereby, and in consideration of the mutual covenants and undertakings set forth herein, the Parties agree that the following sections of the Employment Agreement are amended and restated as follows as of the Amendment Effective Date:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 1(a), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Capacity:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;Executive shall serve the Company as Senior Vice President, Finance reporting to Shane Kovacs or such other senior executive as the Company shall specify.  Executive shall have the responsibilities, duties and authority commensurate with the position of Senior Vice President, Finance.  In addition to Executive&#8217;s primary duties, Executive shall perform such other services for the Company that are consistent with his position as Senior Vice President, Finance as may be reasonably assigned to Executive from time to time by the individual to whom he reports or the Board of Directors of the Company (the &#8220;Board&#8221;) or their respective designees.  The principal location at which Executive shall perform such services shall be the Company&#8217;s corporate headquarters currently located at 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ  07080, subject to relocation and Section 2(c)(i) of this Agreement.&#8221;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 2(c), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Definition of &#8220;Good Reason&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, clause (ii):</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;A material adverse change by the Company in Executive&#8217;s duties, authority or responsibilities as Senior Vice President, Finance of the Company which causes Executive&#8217;s position with the Company to become of materially less responsibility or authority than Executive&#8217;s position immediately following the Effective Date.  For purposes of this definition of &#8220;Good Reason,&#8221; a &#8220;material adverse change&#8221; following a Corporate Change shall not include any diminution in authority, duties or responsibilities that is solely attributable to the change in the Company&#8217;s ownership structure but does not otherwise change Executive&#8217;s authority, duties or responsibilities (except in a positive manner) otherwise with respect to the Company&#8217;s business.&#8221;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 3(b), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Bonus:</font><font style="font-family:inherit;font-size:12pt;">&#32;In addition to the Base Salary, the Company may pay Executive an annual bonus (the &#8220;Bonus&#8221;) as determined by the Board, solely in its discretion (it being understood that Executive&#8217;s target annual bonus shall be at 40% of Base Salary, but may be higher or lower in any year in the Board&#8217;s discretion).  The Board&#8217;s decision to issue a Bonus to Executive in any particular year shall have no effect on the absolute discretion of the Board to grant or not to grant a Bonus in subsequent years.  Any Bonus for a particular year shall be paid or provided to Executive in a lump sum no later than March 15th of the calendar year following the calendar year in which the Bonus was earned.&#8221;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:100%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Amendment to Employment Agreement for SVP Promotion</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 4, </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severance Compensation</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, subsection (b):</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;In the event that Executive&#8217;s employment hereunder is terminated (i) by Executive for a Good Reason or (ii) by the Company without Cause, the Company shall pay to Executive the Accrued Obligations.  In addition, the Company shall pay to Executive the severance benefits set forth below for twelve (12) months following Executive&#8217;s termination of employment (the &#8220;Severance Period&#8221;).  The receipt of any severance benefits provided in this Section shall be dependent upon Executive&#8217;s execution and nonrevocation of a standard separation agreement and general release of claims, substantially in the form attached hereto as Exhibit A (the &#8220;Release&#8221;).  The Company will also consider in good faith (but without any binding commitment) requests from Executive that the Company include in the Release a release of Executive by the Company from matters specifically disclosed to the Company by Executive in writing in advance of execution of the Release and not involving any illegality, fraud, concealment, criminal acts or acts outside the scope of Executive's employment.  The distribution of severance benefits in this Section 4 is subject to section (iii) of this Section 4(b).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i) If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case before or after the Protected Period, the Company shall pay Executive his Base Salary, less any amounts required to be withheld under applicable law, for the Severance Period in substantially equal installments in accordance with the Company&#8217;s payroll practices as in effect from time to time, commencing 30 days following the effective date of such termination.  If Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his Base Salary for the Severance Period, which total amount shall be payable in a lump sum commencing no later than sixty (60) days following Executive&#8217;s termination of employment.   In each case, payments shall commence or be paid provided that the Release has been executed and any applicable revocation period has expired as of the 60th day following Executive&#8217;s termination.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii) Only if Executive&#8217;s employment is terminated (A) by Executive for a Good Reason or (B) by the Company without Cause, in either case during the Protected Period, the Company shall pay Executive his target annual bonus, described in section 3(b) hereof, for the year in which the termination of employment occurs, which total amount shall be payable in a lump sum commencing no later than sixty (60) days following Executive&#8217;s termination of employment, provided that the Release has been executed and any applicable revocation period has expired as of such date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii) The Company shall continue to provide Executive and his then-enrolled eligible dependents with group health insurance and shall continue to pay the amount of the premium as in effect on the date of such termination for the Severance Period commencing on the effective date of such termination, subject to applicable law and the terms of the respective policies; provided that the Company&#8217;s obligation to provide the benefits contemplated herein shall terminate upon Executive&#8217;s becoming eligible for coverage under the medical benefits program of a subsequent employer.  The foregoing shall not be construed to extend any period of continuation coverage (e.g., COBRA) required by Federal law.&#8221;;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With the following subsections of subsection (4)(b) to be renumbered and referenced consistent with the insertion of the new subsection (4)(b)(ii) set forth above and the renumbering of the prior subsection 4(b)(ii) as subsection 4(b)(iii).</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Amendment to Employment Agreement for SVP Promotion</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">No Other Changes.</font><font style="font-family:inherit;font-size:12pt;">&#32;Except as explicitly provided above, the Parties agree that there are no other changes or amendments to the Employment Agreement and that the Employment Agreement, as amended by this Amendment, remains in full force and effect.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.50655021834062%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREED AND ACCEPTED</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: _</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Mark E. Boulding</font><font style="font-family:inherit;font-size:12pt;">_______</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Mark E. Boulding</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: EVP, Chief Legal Officer</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: January 17, 2017</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREED AND ACCEPTED:</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Christine Utter</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: _</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Christine Utter</font><font style="font-family:inherit;font-size:12pt;">_________</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: __</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">January 30, 2017</font><font style="font-family:inherit;font-size:12pt;">_______</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sa75fec4ab52240c0853a45f13b965edb"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;"><img src="ptclogoimagea01.jpg" alt="ptclogoimagea01.jpg" style="height:86px;width:152px;"></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">June 1, 2017</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Christine Utter</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3 Pembroke Court</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Marlboro, NJ 07746</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dear Christine,</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Congratulations on your offer of promotion to Principal Financial Officer of PTC Therapeutics, Inc. Your success with PTC has been impressive and we look forward to your continued contributions to PTC&#8217;s success.  The effective date of your appointment is the date of your signature below.  In this new role you will report to CEO and Founder, Stu Peltz.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Outlined below are details of your compensation following the promotion, subject to your acceptance of this offer:  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Your annual base salary will be increased to $330,000 annually, subject to deductions for taxes and other withholdings as required by law.  This represents an increase of 10% over your current base salary.   </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Your bonus target will continue to be 40.00% of your annual salaried earnings paid in accordance with the terms of conditions of PTC&#8217;s annual incentive compensation plan. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You will receive a one-time grant of 25,000 stock options to purchase shares of common stock of PTC, following a 2 year vesting scheme (50% vesting after one year, and in equal amounts each quarter thereafter).</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You are eligible to receive a one-time appointment bonus of $25,000, payable with acceptance of this letter.  Payment will be made as soon as practical taking into account the announcement of the appointment and payroll cycle.    </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On behalf of PTC, let me again congratulate you on your offer of promotion.  We look forward to this next step in your career.  Please feel free to contact me if you have any questions concerning your offer of promotion and appointment.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Sincerely,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accepted by:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Stuart Peltz&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Christine Utter</font><font style="font-family:inherit;font-size:11pt;">_</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Date: 6/2/17</font><font style="font-family:inherit;font-size:11pt;">_</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Stuart Peltz, CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Christine Utter </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">cc: Martin Rexroad, SVP, Human Resources </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s55fce16c5c1d460a99ba4d537c245076"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">AMENDMENT TO EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Amendment (the &#8220;Amendment&#8221;) is made by and between Christine Utter (&#8220;Executive&#8221;) and PTC Therapeutics, Inc. (the &#8220;Company&#8221;) (collectively, &#8220;the Parties&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Executive is employed by PTC pursuant to an Employment Agreement between Executive and PTC dated August 16, 2014, as amended on January 1, 2017 (the &#8220;Employment Agreement&#8221;); and  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, on May 31, 2019 (the &#8220;Amendment Effective Date&#8221;), the Company is authorized to enter into an amendment to Executive&#8217;s Employment Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is acknowledged hereby, and in consideration of the mutual covenants and undertakings set forth herein, the Parties agree that the following sections of the Employment Agreement are amended and restated as follows as of the Amendment Effective Date:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section 1(a), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Capacity:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;Executive shall serve the Company as Senior Vice President, Finance &amp; Chief Accounting Officer reporting to Emily Hill or such other senior executive as the Company shall specify.  Executive shall have the responsibilities, duties and authority commensurate with the position of Senior Vice President, Finance &amp; Chief Accounting Officer.  In addition to Executive&#8217;s primary duties, Executive shall perform such other services for the Company that are consistent with his position as Senior Vice President, Finance &amp; Chief Accounting Officer as may be reasonably assigned to Executive from time to time by the individual to whom she reports or the Board of Directors of the Company (the &#8220;Board&#8221;) or their respective designees.  The principal location at which Executive shall perform such services shall be the Company&#8217;s corporate headquarters currently located at 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ  07080, subject to relocation and Section 2(c)(i) of this Agreement.&#8221;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">No Other Changes.</font><font style="font-family:inherit;font-size:12pt;">&#32;Except as explicitly provided above, the Parties agree that there are no other changes or amendments to the Employment Agreement and that the Employment Agreement, as amended by this Amendment, remains in full force and effect.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.50655021834062%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREED AND ACCEPTED</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">__/s/ Mark E. Boulding ______</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Mark E. Boulding</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: EVP, Chief Legal Officer</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: May 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AGREED AND ACCEPTED:</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Christine Utter</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">_/s/ Christine Utter _________</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date: May 31, 2019</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ptct06302019ex-311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB99AFC5369375681AAE7DB23076F3AD6"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Stuart W. Peltz, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;I have reviewed this Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc.;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:6%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;6, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ STUART W. PELTZ</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stuart W. Peltz</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ptct06302019ex-312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s091575201562532383D1BA2B872D51FB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Emily Hill, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;I have reviewed this Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc.;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:6%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;6, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ EMILY HILL</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emily Hill</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ptct06302019ex-321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA43EC1BE46F1566FAC42CE103E912C79"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Stuart W. Peltz, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:6%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;6, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ STUART W. PELTZ</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stuart W. Peltz</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ptct06302019ex-322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5D47A836186550B9B7F2B37E110EDDF7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form&#160;10-Q of PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Emily Hill, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:50px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:50px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font><font style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:7%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;6, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ EMILY HILL</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emily Hill</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ptct-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ptcbio.com/20190630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ptct="http://www.ptcbio.com/20190630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccountsPayableAndAccruedExpenses" roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses">
        <link:definition>2107100 - Disclosure - Accounts payable and accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedExpensesNarrativeDetails" roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Accounts payable and accrued expenses - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedExpensesTables" roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables">
        <link:definition>2307301 - Disclosure - Accounts payable and accrued expenses - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombination" roleURI="http://www.ptcbio.com/role/BusinessCombination">
        <link:definition>2104100 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationAssetsAndLiabilitiesDetails" roleURI="http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails">
        <link:definition>2404404 - Disclosure - Business Combination - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationConsiderationTransferedDetails" roleURI="http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails">
        <link:definition>2404403 - Disclosure - Business Combination - Consideration Transfered (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationNarrativeDetails" roleURI="http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails">
        <link:definition>2404402 - Disclosure - Business Combination - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationProFormaFinancialInformationDetails" roleURI="http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails">
        <link:definition>2404405 - Disclosure - Business Combination - Pro-forma financial information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationTables" roleURI="http://www.ptcbio.com/role/BusinessCombinationTables">
        <link:definition>2304301 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.ptcbio.com/role/Capitalization">
        <link:definition>2108100 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationNarrativeDetails" roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails">
        <link:definition>2408402 - Disclosure - Capitalization - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationTables" roleURI="http://www.ptcbio.com/role/CapitalizationTables">
        <link:definition>2308301 - Disclosure - Capitalization - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationWarrantsDetails" roleURI="http://www.ptcbio.com/role/CapitalizationWarrantsDetails">
        <link:definition>2408403 - Disclosure - Capitalization - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2413401 - Disclosure - Commitments and contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Company" roleURI="http://www.ptcbio.com/role/Company">
        <link:definition>2101100 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyNarrativeDetails" roleURI="http://www.ptcbio.com/role/CompanyNarrativeDetails">
        <link:definition>2401401 - Disclosure - The Company - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLossUnaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cover" roleURI="http://www.ptcbio.com/role/Cover">
        <link:definition>0001000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverDei" roleURI="http://www.ptcbio.com/role/CoverDei">
        <link:definition>0001001 - Document - Cover DEI</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.ptcbio.com/role/Debt">
        <link:definition>2112100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertibleNotesDetails" roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails">
        <link:definition>2412403 - Disclosure - Debt - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails">
        <link:definition>2412404 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails">
        <link:definition>2412402 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.ptcbio.com/role/DebtTables">
        <link:definition>2312301 - Disclosure - Debt - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecurities" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities">
        <link:definition>2105100 - Disclosure - Fair value of financial instruments and marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails">
        <link:definition>2405404 - Disclosure - Fair value of financial instruments and marketable securities - Available for sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails">
        <link:definition>2405405 - Disclosure - Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails">
        <link:definition>2405403 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails">
        <link:definition>2405407 - Disclosure - Fair value of financial instruments and marketable securities - Marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails">
        <link:definition>2405402 - Disclosure - Fair value of financial instruments and marketable securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Fair value of financial instruments and marketable securities - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails">
        <link:definition>2405406 - Disclosure - Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails">
        <link:definition>2405408 - Disclosure - Fair value of financial instruments and marketable securities - Warrants and SARs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2116100 - Disclosure - Intangible assets and goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillFutureAmortizationDetails" roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails">
        <link:definition>2416403 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillNarrativeDetails" roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails">
        <link:definition>2416402 - Disclosure - Intangible assets and goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2316301 - Disclosure - Intangible assets and goodwill - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ptcbio.com/role/Leases">
        <link:definition>2103100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.ptcbio.com/role/LeasesLeaseCostsDetails">
        <link:definition>2403403 - Disclosure - Leases - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePaymentsDetails" roleURI="http://www.ptcbio.com/role/LeasesLeasePaymentsDetails">
        <link:definition>2403404 - Disclosure - Leases - Lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePaymentsDetailsCalc2" roleURI="http://www.ptcbio.com/role/LeasesLeasePaymentsDetailsCalc2">
        <link:definition>2403404 - Disclosure - Leases - Lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails">
        <link:definition>2403402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ptcbio.com/role/LeasesTables">
        <link:definition>2303301 - Disclosure - Leases - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.ptcbio.com/role/NetLossPerShare">
        <link:definition>2109100 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveDetails" roleURI="http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails">
        <link:definition>2409403 - Disclosure - Net loss per share - Antidilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareNumeratorAndDenominatorDetails" roleURI="http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails">
        <link:definition>2409402 - Disclosure - Net loss per share - Numerator and Denominator (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.ptcbio.com/role/NetLossPerShareTables">
        <link:definition>2309301 - Disclosure - Net loss per share - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Notes" roleURI="http://www.ptcbio.com/role/Notes">
        <link:definition>2113100 - Disclosure - - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems">
        <link:definition>2106100 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails">
        <link:definition>2406402 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables">
        <link:definition>2306301 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.ptcbio.com/role/RevenueRecognition">
        <link:definition>2115100 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractLiabilitiesRollforwardDetails" roleURI="http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails">
        <link:definition>2415403 - Disclosure - Revenue recognition - Contract Liabilities, Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2415402 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionPerformanceObligationsDetails" roleURI="http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails">
        <link:definition>2415405 - Disclosure - Revenue recognition - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRecognizedRevenueInPeriodDetails" roleURI="http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails">
        <link:definition>2415404 - Disclosure - Revenue recognition - Recognized revenue in the period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.ptcbio.com/role/RevenueRecognitionTables">
        <link:definition>2315301 - Disclosure - Revenue recognition - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockAwardPlan" roleURI="http://www.ptcbio.com/role/StockAwardPlan">
        <link:definition>2111100 - Disclosure - Stock award plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockAwardPlanNarrativeDetails" roleURI="http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails">
        <link:definition>2411402 - Disclosure - Stock award plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockAwardPlanRestrictedStockDetails" roleURI="http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails">
        <link:definition>2411404 - Disclosure - Stock award plan - Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockAwardPlanShareBaseCompensationDetails" roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails">
        <link:definition>2411403 - Disclosure - Stock award plan - Share Base Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockAwardPlanShareBasedCompensationExpenseDetails" roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails">
        <link:definition>2411405 - Disclosure - Stock award plan - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockAwardPlanTables" roleURI="http://www.ptcbio.com/role/StockAwardPlanTables">
        <link:definition>2311301 - Disclosure - Stock award plan - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.ptcbio.com/role/SubsequentEvents">
        <link:definition>2117100 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNarrativeDetails" roleURI="http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails">
        <link:definition>2417401 - Disclosure - Subsequent events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails">
        <link:definition>2402403 - Disclosure - Summary of significant accounting policies - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402404 - Disclosure - Summary of significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of significant accounting policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of significant accounting policies - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ptct_AccruedConsultingAndContractedResearchCurrent" name="AccruedConsultingAndContractedResearchCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" name="AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_AgilisMember" name="AgilisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_AkceaMember" name="AkceaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_AlternativeInvestmentMilestone" name="AlternativeInvestmentMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" name="BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" name="BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" name="BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" name="BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_CollaborationAndDiscoveryAgreementsMember" name="CollaborationAndDiscoveryAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment" name="CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_CollaborativeArrangementsNumberOfSignificantDeliverables" name="CollaborativeArrangementsNumberOfSignificantDeliverables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" name="CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" name="ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" name="ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" name="ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" name="ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts" name="ContractWithCustomerLiabilityIncreaseFromCashReceipts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" name="ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" name="ConvertibleSeniorNotes3.0PercentDue2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_CoverpageAbstract" name="CoverpageAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" name="DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_DebtInstrumentConvertibleThresholdBusinessDays" name="DebtInstrumentConvertibleThresholdBusinessDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" name="DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" name="DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_DebtInstrumentFloorInterestRate" name="DebtInstrumentFloorInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_DebtInstrumentInterestPaymentPeriod" name="DebtInstrumentInterestPaymentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" name="DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ptct_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ptct_DevelopmentMilestonePaymentObligations" name="DevelopmentMilestonePaymentObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_DevelopmentandRegulatoryMilestoneMember" name="DevelopmentandRegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_DiscoveryAgreementsMember" name="DiscoveryAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_EarlyStageCollaborationsMember" name="EarlyStageCollaborationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_EmflazaassetacquisitionMember" name="EmflazaassetacquisitionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" name="EmployeeDirectorAndConsultantStockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" name="EmployeeStockPurchasePlanVotingPercentageLimitPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" name="Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_EquityAndLongTermIncentivePlan2009Member" name="EquityAndLongTermIncentivePlan2009Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_Feet" name="Feet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_FifthAnniversaryMember" name="FifthAnniversaryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_GrantAndCollaborationMember" name="GrantAndCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" name="InventoriesAndCostOfProductSalesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_InvestmentInMRI" name="InvestmentInMRI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" name="LiabilityDevelopmentandRegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" name="LiabilityNetSalesMilestonesandRoyaltiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_LicensingAndCollaborationAgreementMember" name="LicensingAndCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_LineOfCreditFacilityAdditionalCapacityAvailable" name="LineOfCreditFacilityAdditionalCapacityAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_LongTermIncentivePlan2013Member" name="LongTermIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_MarathonPharmaceuticalsLLCMember" name="MarathonPharmaceuticalsLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_MidCapFinancialTrustMember" name="MidCapFinancialTrustMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_MilestoneAxis" name="MilestoneAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_MilestoneDomain" name="MilestoneDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_MilestonePotentialAchievementsRegulatoryApproval" name="MilestonePotentialAchievementsRegulatoryApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" name="MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" name="NetDeferredTaxLiabilitiesConvertibleDebtInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_NetProductSales" name="NetProductSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_NewBuildingMember" name="NewBuildingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_NumberOfCountries" name="NumberOfCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_NumberOfOperatingLeases" name="NumberOfOperatingLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_NumberOfProducts" name="NumberOfProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_NumberOfStatesInEuropeanEconomicArea" name="NumberOfStatesInEuropeanEconomicArea" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_Numberofterms" name="Numberofterms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_PercentOfMarketRate" name="PercentOfMarketRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_PercentageofSalesforRoyaltiesMember" name="PercentageofSalesforRoyaltiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_ProbabilityofSuccessMember" name="ProbabilityofSuccessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_ResearchAndDevelopmentEventMilestonesMember" name="ResearchAndDevelopmentEventMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_RestrictedStockAndRestrictedStockUnitsMember" name="RestrictedStockAndRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_RevenueRecognitionMilestonePotentialAchievements" name="RevenueRecognitionMilestonePotentialAchievements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ptct_RocheAndSmaFoundationMember" name="RocheAndSmaFoundationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_RocheMember" name="RocheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_SalesAllowanceAndOtherRelatedCosts" name="SalesAllowanceAndOtherRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_SalesMilestonesMember" name="SalesMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_SalesRebatesAndRoyaltiesCurrent" name="SalesRebatesAndRoyaltiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" name="ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_StockAppreciationRightsLiabilityOutstanding" name="StockAppreciationRightsLiabilityOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ptct_StockIncentivePlan2013Member" name="StockIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_Termforletterofcredit" name="Termforletterofcredit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_TranslarnaMember" name="TranslarnaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ptct_UpfrontLicensingFee" name="UpfrontLicensingFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ptct_WellcomeTrustLimitedMember" name="WellcomeTrustLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ptct-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombination" xlink:href="ptct-20190630.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationConsiderationTransferedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationTables" xlink:href="ptct-20190630.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Capitalization" xlink:href="ptct-20190630.xsd#Capitalization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:href="ptct-20190630.xsd#CapitalizationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationTables" xlink:href="ptct-20190630.xsd#CapitalizationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationWarrantsDetails" xlink:href="ptct-20190630.xsd#CapitalizationWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="ptct-20190630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Company" xlink:href="ptct-20190630.xsd#Company" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CompanyNarrativeDetails" xlink:href="ptct-20190630.xsd#CompanyNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="ptct-20190630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Cover" xlink:href="ptct-20190630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverDei" xlink:href="ptct-20190630.xsd#CoverDei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Debt" xlink:href="ptct-20190630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:href="ptct-20190630.xsd#DebtConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:href="ptct-20190630.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:href="ptct-20190630.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtTables" xlink:href="ptct-20190630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Leases" xlink:href="ptct-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeaseCostsDetails" xlink:href="ptct-20190630.xsd#LeasesLeaseCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasePaymentsDetails" xlink:href="ptct-20190630.xsd#LeasesLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasePaymentsDetailsCalc2" xlink:href="ptct-20190630.xsd#LeasesLeasePaymentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:href="ptct-20190630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesTables" xlink:href="ptct-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShare" xlink:href="ptct-20190630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails" xlink:href="ptct-20190630.xsd#NetLossPerShareAntidilutiveDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails" xlink:href="ptct-20190630.xsd#NetLossPerShareNumeratorAndDenominatorDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareTables" xlink:href="ptct-20190630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Notes" xlink:href="ptct-20190630.xsd#Notes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognition" xlink:href="ptct-20190630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionPerformanceObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionTables" xlink:href="ptct-20190630.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlan" xlink:href="ptct-20190630.xsd#StockAwardPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanRestrictedStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanShareBaseCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanTables" xlink:href="ptct-20190630.xsd#StockAwardPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequentEvents" xlink:href="ptct-20190630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails" xlink:href="ptct-20190630.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AccruedConsultingAndContractedResearchCurrent" xlink:label="loc_ptct_AccruedConsultingAndContractedResearchCurrent_4dda62c5-5211-e939-43e1-f1f319f6bd94" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_ptct_AccruedConsultingAndContractedResearchCurrent_4dda62c5-5211-e939-43e1-f1f319f6bd94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesAllowanceAndOtherRelatedCosts" xlink:label="loc_ptct_SalesAllowanceAndOtherRelatedCosts_50509f2c-3539-45e1-f667-f1f31a2405da" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_ptct_SalesAllowanceAndOtherRelatedCosts_50509f2c-3539-45e1-f667-f1f31a2405da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesRebatesAndRoyaltiesCurrent" xlink:label="loc_ptct_SalesRebatesAndRoyaltiesCurrent_61040b10-1354-40e9-3434-f1f31a01073b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_ptct_SalesRebatesAndRoyaltiesCurrent_61040b10-1354-40e9-3434-f1f31a01073b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/BusinessCombination" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Capitalization" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CapitalizationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CapitalizationWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Company" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CompanyNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_4909d223-7980-3e65-3e19-5f45ac16b538" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_LongTermDebtCurrent_4909d223-7980-3e65-3e19-5f45ac16b538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_036128b7-a1e8-8f7b-b20a-f1f319dafe63" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_036128b7-a1e8-8f7b-b20a-f1f319dafe63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eaedbb6a-5feb-d7b5-74ff-83d9e06de663" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eaedbb6a-5feb-d7b5-74ff-83d9e06de663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_aec86b81-11aa-859e-2a56-c42f4bdc8086" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_1586be61-ab0a-d2e6-099a-f1f319ed5ca1" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_1586be61-ab0a-d2e6-099a-f1f319ed5ca1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e5ed56be-b332-3e5a-5302-f555a962d258" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e5ed56be-b332-3e5a-5302-f555a962d258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_ptct_DepositsAndOtherAssetsNoncurrent_cdbf2076-797d-4a98-b2c4-f1f319fef414" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_ptct_DepositsAndOtherAssetsNoncurrent_cdbf2076-797d-4a98-b2c4-f1f319fef414" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_848cd271-4e03-8c13-d21d-e6ec9c3916f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_Depreciation_848cd271-4e03-8c13-d21d-e6ec9c3916f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_25f3d0af-ced3-016f-c911-7e8b9a22875d" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_25f3d0af-ced3-016f-c911-7e8b9a22875d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_bbef1d7c-5ca4-2e69-2da7-2c7dad4e25a3" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_PaidInKindInterest_bbef1d7c-5ca4-2e69-2da7-2c7dad4e25a3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_73cabc52-c416-1a4a-0557-7c2672849759" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_73cabc52-c416-1a4a-0557-7c2672849759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_71f47be9-f88f-b596-0981-57b65c400f18" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_71f47be9-f88f-b596-0981-57b65c400f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_a6b55487-86c4-3218-b33b-75029447f45e" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_a6b55487-86c4-3218-b33b-75029447f45e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_83a472e4-c878-e341-48cf-71faca10a716" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_83a472e4-c878-e341-48cf-71faca10a716" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_06da844c-6ee0-0b1d-0eaf-6f589c92b21e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_06da844c-6ee0-0b1d-0eaf-6f589c92b21e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f6cd34b6-f238-abf8-9b6c-ac9d5fcdd140" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f6cd34b6-f238-abf8-9b6c-ac9d5fcdd140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_53ccf68b-cae8-c2bb-bc94-e3588a9c5ab9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_53ccf68b-cae8-c2bb-bc94-e3588a9c5ab9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_a73d82d7-3d54-5ea8-2d2f-c40454b71639" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_a73d82d7-3d54-5ea8-2d2f-c40454b71639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1292ec45-46d1-e31e-9b88-8085df9cd4b2" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfDebt_1292ec45-46d1-e31e-9b88-8085df9cd4b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_32f0c8eb-accb-9ab7-5d53-b9d2845af404" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b2425514-ebf2-89bc-8a6a-e6b6edfea6c3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_32f0c8eb-accb-9ab7-5d53-b9d2845af404" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bab93ab9-d249-c671-e786-575d618bea25" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bab93ab9-d249-c671-e786-575d618bea25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_71d11517-34f8-505e-4c4b-e25ef3111aee" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_71d11517-34f8-505e-4c4b-e25ef3111aee" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2919f63b-33a2-2107-5264-212ca7a03283" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2919f63b-33a2-2107-5264-212ca7a03283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ee6f6897-b14b-45ca-c6e4-4fc17aaf1e37" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ee6f6897-b14b-45ca-c6e4-4fc17aaf1e37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_bd3666d6-25ea-ffb7-8a5a-a09208c20299" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_bd3666d6-25ea-ffb7-8a5a-a09208c20299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Cover" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CoverDei" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_440d49bc-ab70-2673-3639-4fbbaa711932" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_440d49bc-ab70-2673-3639-4fbbaa711932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_133a62ef-4f15-79a5-1ce7-91f3db28df83" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_133a62ef-4f15-79a5-1ce7-91f3db28df83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8707b686-ab67-5afd-96da-fedb3cce1b93" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8707b686-ab67-5afd-96da-fedb3cce1b93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_a4567c23-eef7-473f-21b3-15ac8f57524e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_a4567c23-eef7-473f-21b3-15ac8f57524e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_64e23ddb-ad65-cdbd-d562-3e6299c3a146" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_0ba7a231-6c8d-d491-aacb-6bc82e6dda66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_64e23ddb-ad65-cdbd-d562-3e6299c3a146" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_0ba7a231-6c8d-d491-aacb-6bc82e6dda66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_58eba6d8-9ca2-2c51-6e52-78c02bd035e7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_64e23ddb-ad65-cdbd-d562-3e6299c3a146" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_58eba6d8-9ca2-2c51-6e52-78c02bd035e7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_161efa93-4fc3-b3e6-9a97-d8d9aeebe0cc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_161efa93-4fc3-b3e6-9a97-d8d9aeebe0cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:label="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_0669a3ca-b4e0-3c23-4f27-f1f319cf0ffe" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_0669a3ca-b4e0-3c23-4f27-f1f319cf0ffe" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesLeaseCostsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:label="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_80c39aeb-cc9a-fa23-366f-f1f319f500e6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_80c39aeb-cc9a-fa23-366f-f1f319f500e6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasePaymentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_E1FA6AE95E1456EA4E146336DCFAE56A_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_E1FA6AE95E1456EA4E146336DCFAE56A_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_E1FA6AE95E1456EA4E146336DCFAE56A_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_E1FA6AE95E1456EA4E146336DCFAE56A_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_E1FA6AE95E1456EA4E146336DCFAE56A_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_E1FA6AE95E1456EA4E146336DCFAE56A_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_E1FA6AE95E1456EA4E146336DCFAE56A_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/Notes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_78f9a384-d8cc-c622-a09d-cab78e8426f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_78f9a384-d8cc-c622-a09d-cab78e8426f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e65d9f5e-a3fd-2fc8-3ef3-eaaec4ec01a5" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e65d9f5e-a3fd-2fc8-3ef3-eaaec4ec01a5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:type="extended">
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetProductSales" xlink:label="loc_ptct_NetProductSales_489c96ad-1b3b-b158-8544-f1f31a38766a" xlink:type="locator" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" xlink:label="loc_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_21cd16b8-dc94-be5e-d9c7-f1f31a1e47cc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptct_NetProductSales_489c96ad-1b3b-b158-8544-f1f31a38766a" xlink:to="loc_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_21cd16b8-dc94-be5e-d9c7-f1f31a1e47cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c14e44ee-9ed2-d0a7-2325-8f4bad5775af" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptct_NetProductSales_489c96ad-1b3b-b158-8544-f1f31a38766a" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c14e44ee-9ed2-d0a7-2325-8f4bad5775af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57cbd7df-7e25-c8b5-2eaa-6ac8279f4bf6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptct_NetProductSales_489c96ad-1b3b-b158-8544-f1f31a38766a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57cbd7df-7e25-c8b5-2eaa-6ac8279f4bf6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_02c38264-930d-9c2f-e0a7-6a0838599d0b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryWorkInProcess_02c38264-930d-9c2f-e0a7-6a0838599d0b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_4b469d73-0d86-8f9c-e98a-661ef709c068" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryFinishedGoods_4b469d73-0d86-8f9c-e98a-661ef709c068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_fc662cb4-22a7-eaf1-57df-aa538af7744b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryRawMaterials_fc662cb4-22a7-eaf1-57df-aa538af7744b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ptct-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombination" xlink:href="ptct-20190630.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationConsiderationTransferedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationTables" xlink:href="ptct-20190630.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Capitalization" xlink:href="ptct-20190630.xsd#Capitalization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:href="ptct-20190630.xsd#CapitalizationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationTables" xlink:href="ptct-20190630.xsd#CapitalizationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationWarrantsDetails" xlink:href="ptct-20190630.xsd#CapitalizationWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="ptct-20190630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Company" xlink:href="ptct-20190630.xsd#Company" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CompanyNarrativeDetails" xlink:href="ptct-20190630.xsd#CompanyNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="ptct-20190630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Cover" xlink:href="ptct-20190630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverDei" xlink:href="ptct-20190630.xsd#CoverDei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Debt" xlink:href="ptct-20190630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:href="ptct-20190630.xsd#DebtConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:href="ptct-20190630.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:href="ptct-20190630.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtTables" xlink:href="ptct-20190630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Leases" xlink:href="ptct-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeaseCostsDetails" xlink:href="ptct-20190630.xsd#LeasesLeaseCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasePaymentsDetails" xlink:href="ptct-20190630.xsd#LeasesLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:href="ptct-20190630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesTables" xlink:href="ptct-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShare" xlink:href="ptct-20190630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails" xlink:href="ptct-20190630.xsd#NetLossPerShareAntidilutiveDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails" xlink:href="ptct-20190630.xsd#NetLossPerShareNumeratorAndDenominatorDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareTables" xlink:href="ptct-20190630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Notes" xlink:href="ptct-20190630.xsd#Notes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognition" xlink:href="ptct-20190630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionPerformanceObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionTables" xlink:href="ptct-20190630.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlan" xlink:href="ptct-20190630.xsd#StockAwardPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanRestrictedStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanShareBaseCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanTables" xlink:href="ptct-20190630.xsd#StockAwardPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequentEvents" xlink:href="ptct-20190630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails" xlink:href="ptct-20190630.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/BusinessCombination" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D90C9FA5770D572CFD726336DCE7D902" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D94729CD253C7337B0D66336DCE588DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D90C9FA5770D572CFD726336DCE7D902" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D94729CD253C7337B0D66336DCE588DF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CFCCE222ED00E60770566336DCE69B56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D94729CD253C7337B0D66336DCE588DF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CFCCE222ED00E60770566336DCE69B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CFCCE222ED00E60770566336DCE69B56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CFCCE222ED00E60770566336DCE69B56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_311A87BC005CD7D3BD9C6336DCE6175C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC" xlink:to="loc_ptct_AgilisMember_311A87BC005CD7D3BD9C6336DCE6175C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_349694CCE6202703C6346336DCE766FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D90C9FA5770D572CFD726336DCE7D902" xlink:to="loc_us-gaap_Goodwill_349694CCE6202703C6346336DCE766FF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1A1DDBD53F846541F3876336DCEAC58A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1A1DDBD53F846541F3876336DCEAC58A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_41CDCCD428539450B5386336DCEAAAA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1A1DDBD53F846541F3876336DCEAC58A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_41CDCCD428539450B5386336DCEAAAA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41CDCCD428539450B5386336DCEAAAA6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41CDCCD428539450B5386336DCEAAAA6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_B9B4FA10026AE21297186336DCEBCFBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9" xlink:to="loc_ptct_AgilisMember_B9B4FA10026AE21297186336DCEBCFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_D9FEC177DE20849770B16336DCEB6F57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_D9FEC177DE20849770B16336DCEB6F57" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_8E316A557AA25645185F6336DCEBF7CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_8E316A557AA25645185F6336DCEBF7CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3A4BBD3812EF8230026336DCEB1CA8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3A4BBD3812EF8230026336DCEB1CA8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F9AAE2B41AF74382CDD56336DCF02E1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:to="loc_srt_RangeAxis_F9AAE2B41AF74382CDD56336DCF02E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F9AAE2B41AF74382CDD56336DCF02E1C" xlink:to="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F9AAE2B41AF74382CDD56336DCF02E1C" xlink:to="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_38EF2F9CD6FB993ADE756336DCF05658" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:to="loc_srt_MaximumMember_38EF2F9CD6FB993ADE756336DCF05658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FA0BF5A9543D43704C7D6336DCF119C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:to="loc_srt_MinimumMember_FA0BF5A9543D43704C7D6336DCF119C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AD9D2C449BD197D5EE216336DCF1C10D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AD9D2C449BD197D5EE216336DCF1C10D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AD9D2C449BD197D5EE216336DCF1C10D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AD9D2C449BD197D5EE216336DCF1C10D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_6ABC734916EAE67A10046336DCF1A9D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA" xlink:to="loc_ptct_AgilisMember_6ABC734916EAE67A10046336DCF1A9D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_BECED549541AAC2C1AB46336DCF2CD04" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_BECED549541AAC2C1AB46336DCF2CD04" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_50CCB8763ED51690D4356336DCF28577" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_50CCB8763ED51690D4356336DCF28577" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_A5843026836DAAADB7FF6336DCF3743C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_A5843026836DAAADB7FF6336DCF3743C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_40857099E6539F2D40146336DCF3CB04" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_40857099E6539F2D40146336DCF3CB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5DCC8FB69034F6B28FD66336DCF324AF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5DCC8FB69034F6B28FD66336DCF324AF" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_1784CE4BB4ABC3CC217F6336DCF3EF78" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_1784CE4BB4ABC3CC217F6336DCF3EF78" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_76786E2CB1BEEE89A0096336DCE28E2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_76786E2CB1BEEE89A0096336DCE28E2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76786E2CB1BEEE89A0096336DCE28E2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76786E2CB1BEEE89A0096336DCE28E2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_5B058E116BB71A7CD5286336DCE3B548" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9" xlink:to="loc_ptct_AgilisMember_5B058E116BB71A7CD5286336DCE3B548" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Capitalization" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_AD366545576DD26FA3336336DC909D55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_AD366545576DD26FA3336336DC909D55" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_AD366545576DD26FA3336336DC909D55" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:to="loc_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:to="loc_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9D1707F77BAD4BA736126336DC916C41" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9D1707F77BAD4BA736126336DC916C41" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CapitalizationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CapitalizationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_02FE5FA0F806F9B4CC726336DC8962D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="loc_us-gaap_StatementClassOfStockAxis_02FE5FA0F806F9B4CC726336DC8962D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_02FE5FA0F806F9B4CC726336DC8962D6" xlink:to="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_02FE5FA0F806F9B4CC726336DC8962D6" xlink:to="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9EB4FE1F33DFD91CA15F6336DC8A0515" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9" xlink:to="loc_us-gaap_CommonStockMember_9EB4FE1F33DFD91CA15F6336DC8A0515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_BD2BCA993A2AA68E0C176336DC8A9C1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_BD2BCA993A2AA68E0C176336DC8A9C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_BD2BCA993A2AA68E0C176336DC8A9C1A" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_BD2BCA993A2AA68E0C176336DC8A9C1A" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D3A73916AD960C9EBE766336DC8CF372" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:to="loc_us-gaap_WarrantMember_D3A73916AD960C9EBE766336DC8CF372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BE36A37370531A3B77C56336DC131BC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_srt_ProductOrServiceAxis_BE36A37370531A3B77C56336DC131BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_BE36A37370531A3B77C56336DC131BC3" xlink:to="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_BE36A37370531A3B77C56336DC131BC3" xlink:to="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6" xlink:to="loc_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_185E08CCB3EB35A22D286336DC1337C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_185E08CCB3EB35A22D286336DC1337C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_185E08CCB3EB35A22D286336DC1337C2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_185E08CCB3EB35A22D286336DC1337C2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_EF9CE4FAEEEA0FC2C76F6336DC14856F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5" xlink:to="loc_ptct_AgilisMember_EF9CE4FAEEEA0FC2C76F6336DC14856F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AB3F5D45F7D458DBFA3F6336DC14CEAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AB3F5D45F7D458DBFA3F6336DC14CEAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AB3F5D45F7D458DBFA3F6336DC14CEAF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AB3F5D45F7D458DBFA3F6336DC14CEAF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_2563FC6BBFA16BA3289B6336DC15F4F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_2563FC6BBFA16BA3289B6336DC15F4F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_3299DAEEC34D3A5BBD8D6336DC15439C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_srt_CounterpartyNameAxis_3299DAEEC34D3A5BBD8D6336DC15439C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3299DAEEC34D3A5BBD8D6336DC15439C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3299DAEEC34D3A5BBD8D6336DC15439C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_WellcomeTrustLimitedMember" xlink:label="loc_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:to="loc_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AkceaMember" xlink:label="loc_ptct_AkceaMember_DB7415A8CB38D9DCEC996336DC163637" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:to="loc_ptct_AkceaMember_DB7415A8CB38D9DCEC996336DC163637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3C908E67AAD179C661EE6336DC16BD4C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_srt_RangeAxis_3C908E67AAD179C661EE6336DC16BD4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3C908E67AAD179C661EE6336DC16BD4C" xlink:to="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3C908E67AAD179C661EE6336DC16BD4C" xlink:to="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E6620AD89C232FB2E18C6336DC16D263" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7" xlink:to="loc_srt_MaximumMember_E6620AD89C232FB2E18C6336DC16D263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:to="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_UpfrontLicensingFee" xlink:label="loc_ptct_UpfrontLicensingFee_EE48CB5B125C0D33982A6336DC17FFA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_UpfrontLicensingFee_EE48CB5B125C0D33982A6336DC17FFA3" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_44F62A4C51E735A90C006336DC17B361" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_44F62A4C51E735A90C006336DC17B361" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_A5C85B5A16BE68D97AC56336DC17061F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_A5C85B5A16BE68D97AC56336DC17061F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_96D04595C10C8BA95F6B6336DC176C21" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_96D04595C10C8BA95F6B6336DC176C21" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_B33CF88A23BD516095456336DC184276" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_B33CF88A23BD516095456336DC184276" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_953D0BE72A652D4A0B3A6336DC1800C2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_953D0BE72A652D4A0B3A6336DC1800C2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Company" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CompanyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ACEB866374B084C144156336DD27FEE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ACEB866374B084C144156336DD27FEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ACEB866374B084C144156336DD27FEE5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ACEB866374B084C144156336DD27FEE5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_4877C1AD649331A05FBE6336DD289EAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A" xlink:to="loc_ptct_AgilisMember_4877C1AD649331A05FBE6336DD289EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B18643D23AFFA97EA7B96336DD281BE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_srt_ProductOrServiceAxis_B18643D23AFFA97EA7B96336DD281BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B18643D23AFFA97EA7B96336DD281BE9" xlink:to="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B18643D23AFFA97EA7B96336DD281BE9" xlink:to="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_TranslarnaMember" xlink:label="loc_ptct_TranslarnaMember_CE822651A68EA16386396336DD28DBFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E" xlink:to="loc_ptct_TranslarnaMember_CE822651A68EA16386396336DD28DBFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A05219FFA63084DEED506336DD29D6B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A05219FFA63084DEED506336DD29D6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A05219FFA63084DEED506336DD29D6B9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A05219FFA63084DEED506336DD29D6B9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_7D1703395266F5C1ADA26336DD29D7E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_7D1703395266F5C1ADA26336DD29D7E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E102C76D43B7D70179036336DD293400" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_srt_CounterpartyNameAxis_E102C76D43B7D70179036336DD293400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_E102C76D43B7D70179036336DD293400" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_E102C76D43B7D70179036336DD293400" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MarathonPharmaceuticalsLLCMember" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF" xlink:to="loc_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_811C046760239DA2C02D6336DD2AB1DE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_811C046760239DA2C02D6336DD2AB1DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_811C046760239DA2C02D6336DD2AB1DE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_811C046760239DA2C02D6336DD2AB1DE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_B0CA2D483E9674B426A36336DD2BF636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A" xlink:to="loc_us-gaap_ConvertibleDebtMember_B0CA2D483E9674B426A36336DD2BF636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7F9D58C7847645681CD86336DD2B1F4D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_DebtInstrumentAxis_7F9D58C7847645681CD86336DD2B1F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7F9D58C7847645681CD86336DD2B1F4D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7F9D58C7847645681CD86336DD2B1F4D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_474C75C12B46D0C601816336DD2C6F52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_474C75C12B46D0C601816336DD2C6F52" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfProducts" xlink:label="loc_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfStatesInEuropeanEconomicArea" xlink:label="loc_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfCountries" xlink:label="loc_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_E1D253F1CF4870C366496336DD2D145A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_E1D253F1CF4870C366496336DD2D145A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B36F24A6CF2E8151EC086336DD2D7DF2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B36F24A6CF2E8151EC086336DD2D7DF2" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_3A7B6BAE3FFD5EA200546336DD2D94E5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_3A7B6BAE3FFD5EA200546336DD2D94E5" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_242CAD52C202589584D36336DD2DB4E8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_242CAD52C202589584D36336DD2DB4E8" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_E0552F477DD36F2E81CB6336DD2DE160" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_E0552F477DD36F2E81CB6336DD2DE160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5027ADB58680D7592A2E6336DD2ED4B7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5027ADB58680D7592A2E6336DD2ED4B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_444C4B1A8899A9D353EE6336DD2E4E8F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_444C4B1A8899A9D353EE6336DD2E4E8F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_15E514896AB0CB17EB496336DD639E88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_StatementTable_15E514896AB0CB17EB496336DD639E88" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_461318CFF4659AEB98C66336DD63ABC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_15E514896AB0CB17EB496336DD639E88" xlink:to="loc_srt_ProductOrServiceAxis_461318CFF4659AEB98C66336DD63ABC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_461318CFF4659AEB98C66336DD63ABC7" xlink:to="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_461318CFF4659AEB98C66336DD63ABC7" xlink:to="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:to="loc_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_GrantAndCollaborationMember" xlink:label="loc_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:to="loc_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_203A06A7E3E6B3AB434B6336DD649A70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_203A06A7E3E6B3AB434B6336DD649A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_EDD2292A666838C982586336DD65FC15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_EDD2292A666838C982586336DD65FC15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_867B1B67D6A4C49505FC6336DD66CE30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_867B1B67D6A4C49505FC6336DD66CE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_CC249F7DF8CC230C82496336DD66A8BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_CC249F7DF8CC230C82496336DD66A8BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:to="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32D4024FF758C023B6E267CEC09CD10E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32D4024FF758C023B6E267CEC09CD10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32D4024FF758C023B6E267CEC09CD10E" xlink:to="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32D4024FF758C023B6E267CEC09CD10E" xlink:to="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FE36D9479BBB9B5A057467CEC09CDC4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_CommonStockMember_FE36D9479BBB9B5A057467CEC09CDC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C624E308DDB693F5154D67CEC09D7306" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C624E308DDB693F5154D67CEC09D7306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6CAD7EAB05151772157267CEC09EA81C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockholdersEquity_6CAD7EAB05151772157267CEC09EA81C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" xlink:label="loc_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2F718117F59FE913D06267CEC0A71232" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_NetIncomeLoss_2F718117F59FE913D06267CEC0A71232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Cover" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CoverDei" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D9336DE62A9B886EEE4D6336DC27D44A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:to="loc_us-gaap_DebtInstrumentAxis_D9336DE62A9B886EEE4D6336DC27D44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_D9336DE62A9B886EEE4D6336DC27D44A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_D9336DE62A9B886EEE4D6336DC27D44A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_687CB83CDCF6C22ADEA16336DC287DE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_687CB83CDCF6C22ADEA16336DC287DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9F69453CA45CA53E305E6336DC28382B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9F69453CA45CA53E305E6336DC28382B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9F69453CA45CA53E305E6336DC28382B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9F69453CA45CA53E305E6336DC28382B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_FE132556274F89695EE56336DC29644E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF" xlink:to="loc_us-gaap_ConvertibleDebtMember_FE132556274F89695EE56336DC29644E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_945A2A3683956F421F846336DC29DD39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_945A2A3683956F421F846336DC29DD39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9AD97C34EADCF69C159C6336DC209807" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9AD97C34EADCF69C159C6336DC209807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9AD97C34EADCF69C159C6336DC209807" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9AD97C34EADCF69C159C6336DC209807" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_682192987C444556B4C36336DC200F54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6" xlink:to="loc_us-gaap_ConvertibleDebtMember_682192987C444556B4C36336DC200F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_981AE88351CC574C17416336DC215B35" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:to="loc_us-gaap_DebtInstrumentAxis_981AE88351CC574C17416336DC215B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_981AE88351CC574C17416336DC215B35" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_981AE88351CC574C17416336DC215B35" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_1E47209D8AAA19D2548A6336DC217E09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_1E47209D8AAA19D2548A6336DC217E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:to="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:to="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MidCapFinancialTrustMember" xlink:label="loc_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:to="loc_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FEACA4F3F36DFE593FDF6336DC340C7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FEACA4F3F36DFE593FDF6336DC340C7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FEACA4F3F36DFE593FDF6336DC340C7A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FEACA4F3F36DFE593FDF6336DC340C7A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_DAE8C80332B827B53DBE6336DC347A91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9" xlink:to="loc_us-gaap_ConvertibleDebtMember_DAE8C80332B827B53DBE6336DC347A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F517E8F6A5C6567F93BC6336DC3551F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_DebtInstrumentAxis_F517E8F6A5C6567F93BC6336DC3551F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F517E8F6A5C6567F93BC6336DC3551F8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F517E8F6A5C6567F93BC6336DC3551F8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_0C05D9FC4493D3977A9F6336DC353EB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_0C05D9FC4493D3977A9F6336DC353EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:label="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:to="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:label="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentFloorInterestRate" xlink:label="loc_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentInterestPaymentPeriod" xlink:label="loc_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC3A849D8C9BE70C53276336DC3853C0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC3A849D8C9BE70C53276336DC3853C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="loc_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:label="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:label="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:label="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:label="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4E5C7A377B075CB348666336DC3BA6D8" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4E5C7A377B075CB348666336DC3BA6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_2A73D5F74CA82D1A61FA632C613110A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_2A73D5F74CA82D1A61FA632C613110A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6FC14C7EEF8BC08122B5632C613129E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6FC14C7EEF8BC08122B5632C613129E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_62A37EBB4892B8A0E2D3632C6131CCEA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_62A37EBB4892B8A0E2D3632C6131CCEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_163B3FCCEDCCED2FA8866336DCD0C6F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_163B3FCCEDCCED2FA8866336DCD0C6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_163B3FCCEDCCED2FA8866336DCD0C6F8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_163B3FCCEDCCED2FA8866336DCD0C6F8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_65D3265C35C2129CC39B6336DCD03E11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5" xlink:to="loc_ptct_AgilisMember_65D3265C35C2129CC39B6336DCD03E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_D06E501E5FD056F1B8E66336DCD14F86" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_D06E501E5FD056F1B8E66336DCD14F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D06E501E5FD056F1B8E66336DCD14F86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D06E501E5FD056F1B8E66336DCD14F86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember" xlink:label="loc_us-gaap_CommitmentsMember_545ACED46955CBC2216F6336DCD1AC88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D" xlink:to="loc_us-gaap_CommitmentsMember_545ACED46955CBC2216F6336DCD1AC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C0A0A7DE3AC922B775836336DCD1106E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_AwardTypeAxis_C0A0A7DE3AC922B775836336DCD1106E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C0A0A7DE3AC922B775836336DCD1106E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C0A0A7DE3AC922B775836336DCD1106E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_4F1E004E1FE379EEC71B6336DCD2E291" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_4F1E004E1FE379EEC71B6336DCD2E291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0E46BB2DB2358EDF593F6336DCD2A520" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0E46BB2DB2358EDF593F6336DCD2A520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AD04671FA0A5A3C32AD6336DCD20234_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0E46BB2DB2358EDF593F6336DCD2A520" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AD04671FA0A5A3C32AD6336DCD20234_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AD04671FA0A5A3C32AD6336DCD20234" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0E46BB2DB2358EDF593F6336DCD2A520" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AD04671FA0A5A3C32AD6336DCD20234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_51AF0162F6168B32A74F6336DCD99717" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_51AF0162F6168B32A74F6336DCD99717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51AF0162F6168B32A74F6336DCD99717" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51AF0162F6168B32A74F6336DCD99717" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_263E1769E7688C061E576336DCDA1166" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE" xlink:to="loc_ptct_AgilisMember_263E1769E7688C061E576336DCDA1166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FA84217E113DE17453BB6336DCDAB0B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FA84217E113DE17453BB6336DCDAB0B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FA84217E113DE17453BB6336DCDAB0B5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FA84217E113DE17453BB6336DCDAB0B5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_F27D7C7FF2E37D66EF626336DCDA4787" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_F27D7C7FF2E37D66EF626336DCDA4787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_575307E3FB8FAAF639766336DCDB5A63" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_575307E3FB8FAAF639766336DCDB5A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_575307E3FB8FAAF639766336DCDB5A63" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_575307E3FB8FAAF639766336DCDB5A63" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4FA8E03BDEBA38112F5E6336DCDC71BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4FA8E03BDEBA38112F5E6336DCDC71BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_35503290A384E2B53E8C6336DCDCDFA4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_35503290A384E2B53E8C6336DCDCDFA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6047A596F2CB427B3D886336DCDC8A64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_35503290A384E2B53E8C6336DCDCDFA4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6047A596F2CB427B3D886336DCDC8A64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_35503290A384E2B53E8C6336DCDCDFA4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6047A596F2CB427B3D886336DCDC8A64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6047A596F2CB427B3D886336DCDC8A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8894A2285E85EE13223B6336DCDD00FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8894A2285E85EE13223B6336DCDD00FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_88AD25420FB7B41E78C46336DCDD130F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_88AD25420FB7B41E78C46336DCDD130F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DAC8570281BE4D4246876336DCDEE7E7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DAC8570281BE4D4246876336DCDEE7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6053FA8E7F766B323A146336DCDEAD3C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6053FA8E7F766B323A146336DCDEAD3C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:to="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:to="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:label="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:to="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:to="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:to="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:to="loc_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:to="loc_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:to="loc_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:to="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:to="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:to="loc_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:to="loc_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:to="loc_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember" xlink:label="loc_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:to="loc_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:label="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_InvestmentInMRI" xlink:label="loc_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B88C2CB0F683FC6053BA6336DCC8DEF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B88C2CB0F683FC6053BA6336DCC8DEF1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2080C931B9C7AAC53E446336DCC8A319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B88C2CB0F683FC6053BA6336DCC8DEF1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2080C931B9C7AAC53E446336DCC8A319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2080C931B9C7AAC53E446336DCC8A319" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2080C931B9C7AAC53E446336DCC8A319" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_90800AB9176DBD3A36756336DCC8B49C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_90800AB9176DBD3A36756336DCC8B49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6C44BF9CA6207E61914E6336DCC9253B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6C44BF9CA6207E61914E6336DCC9253B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_35B58CD090F1EDF7B4216336DCC972CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_35B58CD090F1EDF7B4216336DCC972CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CBA7615D41D2494576A76336DCB28BE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CBA7615D41D2494576A76336DCB28BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CBA7615D41D2494576A76336DCB28BE2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CBA7615D41D2494576A76336DCB28BE2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0FBB9278CA7F2F3F11856336DCB362BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0FBB9278CA7F2F3F11856336DCB362BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AB93D6DEEC2FF57148606336DCB390A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AB93D6DEEC2FF57148606336DCB390A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB93D6DEEC2FF57148606336DCB390A4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB93D6DEEC2FF57148606336DCB390A4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_04F0BFB145E260249ACC6336DCB4821F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6" xlink:to="loc_ptct_AgilisMember_04F0BFB145E260249ACC6336DCB4821F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_7F968EE7C2512A6806226336DCB456EA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_7F968EE7C2512A6806226336DCB456EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_7F968EE7C2512A6806226336DCB456EA" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_7F968EE7C2512A6806226336DCB456EA" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_5BD9DD57A6F5AA96BF486336DCB539FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_5BD9DD57A6F5AA96BF486336DCB539FE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:to="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:to="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:to="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_37587C92D56C17CE2D136336DCB53054" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:to="loc_us-gaap_CommonStockMember_37587C92D56C17CE2D136336DCB53054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1BBA1CBDC17A63F572A56336DCB6D47B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_srt_RangeAxis_1BBA1CBDC17A63F572A56336DCB6D47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1BBA1CBDC17A63F572A56336DCB6D47B" xlink:to="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1BBA1CBDC17A63F572A56336DCB6D47B" xlink:to="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2E1B4745BACB927FBEAD6336DCB69FAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:to="loc_srt_MinimumMember_2E1B4745BACB927FBEAD6336DCB69FAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3A380655A43BD17417346336DCB6C556" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:to="loc_srt_MaximumMember_3A380655A43BD17417346336DCB6C556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_A05F9AEA74D182CA8D7D6336DCB7545C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_A05F9AEA74D182CA8D7D6336DCB7545C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_A05F9AEA74D182CA8D7D6336DCB7545C" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_A05F9AEA74D182CA8D7D6336DCB7545C" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_76F1867D4CC33CF14F2A6336DCB75420" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_76F1867D4CC33CF14F2A6336DCB75420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_872E9306C23B70613A616336DCB8532B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_872E9306C23B70613A616336DCB8532B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesMilestonesMember" xlink:label="loc_ptct_SalesMilestonesMember_8FF59A6B56691DC4729F6336DCB8FEE9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_SalesMilestonesMember_8FF59A6B56691DC4729F6336DCB8FEE9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ProbabilityofSuccessMember" xlink:label="loc_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_PercentageofSalesforRoyaltiesMember" xlink:label="loc_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentandRegulatoryMilestoneMember" xlink:label="loc_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_FA0DD74FE9B8C1F764816336DCB920FA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_FA0DD74FE9B8C1F764816336DCB920FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_FA0DD74FE9B8C1F764816336DCB920FA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_FA0DD74FE9B8C1F764816336DCB920FA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_DBEEF1AD05CC919F3DC06336DCB9162C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:to="loc_us-gaap_WarrantMember_DBEEF1AD05CC919F3DC06336DCB9162C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember" xlink:label="loc_us-gaap_CommitmentsMember_D7FC12D405CB99AF28126336DCBA1C97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:to="loc_us-gaap_CommitmentsMember_D7FC12D405CB99AF28126336DCBA1C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_11918C48402F334659A86336DCBA0D44" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_11918C48402F334659A86336DCBA0D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_EEF55D6568AD5D940FBB6336DCBA454C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_AwardTypeAxis_EEF55D6568AD5D940FBB6336DCBA454C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_EEF55D6568AD5D940FBB6336DCBA454C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_EEF55D6568AD5D940FBB6336DCBA454C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_300266E2CCEC4B420DAD6336DCBA3E64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_300266E2CCEC4B420DAD6336DCBA3E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AlternativeInvestmentMilestone" xlink:label="loc_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_A372617558F2321DB8B16336DCBC59E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_A372617558F2321DB8B16336DCBC59E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1F44FFD4DCC85C18B6D56336DCBC4481" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1F44FFD4DCC85C18B6D56336DCBC4481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_FCA746A634C753BD2A296336DCBC9419" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_FCA746A634C753BD2A296336DCBC9419" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6BA4129F2EBBB672EA596336DBB9D1D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6BA4129F2EBBB672EA596336DBB9D1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6BA4129F2EBBB672EA596336DBB9D1D9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6BA4129F2EBBB672EA596336DBB9D1D9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmflazaassetacquisitionMember" xlink:label="loc_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6" xlink:to="loc_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_46ADE9F30A531A948B8D6336DBBAE978" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_46ADE9F30A531A948B8D6336DBBAE978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_46ADE9F30A531A948B8D6336DBBAE978" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_46ADE9F30A531A948B8D6336DBBAE978" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_BA17DC75F96DF08093006336DBBA0B8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_BA17DC75F96DF08093006336DBBA0B8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_7A2E31153BDE35FE60486336DBBAA6EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="loc_srt_CounterpartyNameAxis_7A2E31153BDE35FE60486336DBBAA6EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7A2E31153BDE35FE60486336DBBAA6EC" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7A2E31153BDE35FE60486336DBBAA6EC" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AkceaMember" xlink:label="loc_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E" xlink:to="loc_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_1F7A3763207C997D854E6336DBBC0646" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_1F7A3763207C997D854E6336DBBC0646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0ADF303858225CA86FEA6336DBBC6989" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_Goodwill_0ADF303858225CA86FEA6336DBBC6989" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_UpfrontLicensingFee" xlink:label="loc_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesLeaseCostsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F90A2652D35F5D9129B06336DD08F90C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:to="loc_srt_RangeAxis_F90A2652D35F5D9129B06336DD08F90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F90A2652D35F5D9129B06336DD08F90C" xlink:to="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F90A2652D35F5D9129B06336DD08F90C" xlink:to="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D550EA718C636154753B6336DD099F64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:to="loc_srt_MinimumMember_D550EA718C636154753B6336DD099F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_EF3F06D9AD6ED2045D296336DD090A64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:to="loc_srt_MaximumMember_EF3F06D9AD6ED2045D296336DD090A64" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfOperatingLeases" xlink:label="loc_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="loc_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:to="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/Notes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:to="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:to="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:to="loc_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenueRecognition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:to="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:to="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RocheMember" xlink:label="loc_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:to="loc_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3201FB8B8BBC1AED11AC6336DBDBE07D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_RangeAxis_3201FB8B8BBC1AED11AC6336DBDBE07D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3201FB8B8BBC1AED11AC6336DBDBE07D" xlink:to="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3201FB8B8BBC1AED11AC6336DBDBE07D" xlink:to="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C9908F38070B748302196336DBDB1464" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:to="loc_srt_MinimumMember_C9908F38070B748302196336DBDB1464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A78461ACEDA3774739C26336DBDC37FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:to="loc_srt_MaximumMember_A78461ACEDA3774739C26336DBDC37FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A561DAA22D8B79D8B88B6336DBDC23D8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A561DAA22D8B79D8B88B6336DBDC23D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A561DAA22D8B79D8B88B6336DBDC23D8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A561DAA22D8B79D8B88B6336DBDC23D8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborationAndDiscoveryAgreementsMember" xlink:label="loc_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:to="loc_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RocheAndSmaFoundationMember" xlink:label="loc_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:to="loc_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:to="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:to="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:to="loc_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:to="loc_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:to="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:to="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_TranslarnaMember" xlink:label="loc_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LicensingAndCollaborationAgreementMember" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DiscoveryAgreementsMember" xlink:label="loc_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EarlyStageCollaborationsMember" xlink:label="loc_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestoneAxis" xlink:label="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestoneDomain" xlink:label="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:to="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2_default" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestoneDomain" xlink:label="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:to="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:label="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:to="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesMilestonesMember" xlink:label="loc_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:to="loc_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetProductSales" xlink:label="loc_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:label="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment" xlink:label="loc_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsNumberOfSignificantDeliverables" xlink:label="loc_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_636D9056C406546093826336DBE219E5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_636D9056C406546093826336DBE219E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:label="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4E5B52F231A8C44698996336DBC6CECF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="loc_srt_ProductOrServiceAxis_4E5B52F231A8C44698996336DBC6CECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4E5B52F231A8C44698996336DBC6CECF" xlink:to="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4E5B52F231A8C44698996336DBC6CECF" xlink:to="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_TranslarnaMember" xlink:label="loc_ptct_TranslarnaMember_434DF590AB34E93669D86336DBC71060" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:to="loc_ptct_TranslarnaMember_434DF590AB34E93669D86336DBC71060" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LicensingAndCollaborationAgreementMember" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_E97ACF67918ABF456D816336DBC7CE8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_E97ACF67918ABF456D816336DBC7CE8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_91F36E8BC1EAF3FE38666336DBC7BA9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="loc_srt_RangeAxis_91F36E8BC1EAF3FE38666336DBC7BA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_91F36E8BC1EAF3FE38666336DBC7BA9E" xlink:to="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_91F36E8BC1EAF3FE38666336DBC7BA9E" xlink:to="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_DFDA4CDB45BBF75F6D7B6336DBC86E24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:to="loc_srt_MinimumMember_DFDA4CDB45BBF75F6D7B6336DBC86E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_79193C571E274BA9D7566336DBC89078" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:to="loc_srt_MaximumMember_79193C571E274BA9D7566336DBC89078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9C8D0B0932B47E050FAF6336DBC98030" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9C8D0B0932B47E050FAF6336DBC98030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockAwardPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:to="loc_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:to="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:to="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_StockIncentivePlan2013Member" xlink:label="loc_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EquityAndLongTermIncentivePlan2009Member" xlink:label="loc_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:label="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LongTermIncentivePlan2013Member" xlink:label="loc_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A4F37770AA294AD12BA96336DC6AEB0C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_AwardTypeAxis_A4F37770AA294AD12BA96336DC6AEB0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A4F37770AA294AD12BA96336DC6AEB0C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A4F37770AA294AD12BA96336DC6AEB0C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_0B7B8905554F308546CB6336DC6A863C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_us-gaap_RestrictedStockMember_0B7B8905554F308546CB6336DC6A863C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_804A85F5D86C2FA489876336DC6A92B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_us-gaap_StockOptionMember_804A85F5D86C2FA489876336DC6A92B9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:label="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_AC55E4BE3E1B7CD6BE4B6336DC6B4C9A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_AC55E4BE3E1B7CD6BE4B6336DC6B4C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47F625A2E42E2A0A165C6336DC6B96F6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47F625A2E42E2A0A165C6336DC6B96F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47F625A2E42E2A0A165C6336DC6B96F6" xlink:to="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47F625A2E42E2A0A165C6336DC6B96F6" xlink:to="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_41A139AE925D9AAB22C66336DC6BC59B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4" xlink:to="loc_us-gaap_CommonStockMember_41A139AE925D9AAB22C66336DC6BC59B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_86AF22E656094B64CC3A6336DC6C3FFE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_srt_RangeAxis_86AF22E656094B64CC3A6336DC6C3FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_86AF22E656094B64CC3A6336DC6C3FFE" xlink:to="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_86AF22E656094B64CC3A6336DC6C3FFE" xlink:to="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7DCB3DC63F53BD7FE3806336DC6CCD4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:to="loc_srt_MaximumMember_7DCB3DC63F53BD7FE3806336DC6CCD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5A9DF65ACEF5ED83224A6336DC6CAE24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:to="loc_srt_MinimumMember_5A9DF65ACEF5ED83224A6336DC6CAE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C17C6F1ABE99464E8D56336DC6DF2AF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C17C6F1ABE99464E8D56336DC6DF2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_AE45276C98BCF02C37D66336DC6FF7BD" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_AE45276C98BCF02C37D66336DC6FF7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:label="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_76219832E0A4278ADF166336DC4C7E0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:to="loc_us-gaap_AwardTypeAxis_76219832E0A4278ADF166336DC4C7E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_76219832E0A4278ADF166336DC4C7E0C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_76219832E0A4278ADF166336DC4C7E0C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698" xlink:to="loc_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9AD2C48124B3686A17756336DC5642BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:to="loc_us-gaap_AwardTypeAxis_9AD2C48124B3686A17756336DC5642BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9AD2C48124B3686A17756336DC5642BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9AD2C48124B3686A17756336DC5642BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5" xlink:to="loc_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AC9593CC013AB8AAA3C26336DC57ACE8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:to="loc_srt_RangeAxis_AC9593CC013AB8AAA3C26336DC57ACE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_AC9593CC013AB8AAA3C26336DC57ACE8" xlink:to="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_AC9593CC013AB8AAA3C26336DC57ACE8" xlink:to="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FEA631CB2CF462F2177C6336DC58FBB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:to="loc_srt_MinimumMember_FEA631CB2CF462F2177C6336DC58FBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_100975D177ED8C10E4EA6336DC58440C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:to="loc_srt_MaximumMember_100975D177ED8C10E4EA6336DC58440C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D023E84D41DE4F1429996336DC5D74EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D023E84D41DE4F1429996336DC5D74EF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_774D7C41CABC9ADCF2226336DC464FE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_774D7C41CABC9ADCF2226336DC464FE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_774D7C41CABC9ADCF2226336DC464FE6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NewBuildingMember" xlink:label="loc_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:to="loc_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_945F84CF3220AF20EA5D678B2E862DB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="loc_us-gaap_DebtInstrumentAxis_945F84CF3220AF20EA5D678B2E862DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_945F84CF3220AF20EA5D678B2E862DB9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_945F84CF3220AF20EA5D678B2E862DB9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_FifthAnniversaryMember" xlink:label="loc_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0" xlink:to="loc_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:to="loc_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Feet" xlink:label="loc_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A37850BE1824963D3836678B2E88B925" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A37850BE1824963D3836678B2E88B925" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Numberofterms" xlink:label="loc_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_PercentOfMarketRate" xlink:label="loc_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Termforletterofcredit" xlink:label="loc_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ptct-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:type="arc" />
    <link:label id="lab_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE_terseLabel_en-US" xlink:label="lab_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts included in contract liabilities at the beginning of the period</link:label>
    <link:label id="lab_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE_label_en-US" xlink:label="lab_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Amounts Recognized Beginning Of Measurement Period</link:label>
    <link:label id="lab_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE_documentation_en-US" xlink:label="lab_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Amounts Recognized Beginning Of Measurement Period</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" xlink:label="loc_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:to="lab_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations satisfied in previous period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations satisfied in current period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54" xlink:type="arc" />
    <link:label id="lab_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1_totalLabel_en-US" xlink:label="lab_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total product revenue</link:label>
    <link:label id="lab_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1_label_en-US" xlink:label="lab_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Product Sales</link:label>
    <link:label id="lab_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1_documentation_en-US" xlink:label="lab_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of revenue earned from product sales during the reporting period.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetProductSales" xlink:label="loc_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:to="lab_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_28C858292D3CFAB496DB6336DD0F794B_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_28C858292D3CFAB496DB6336DD0F794B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_28C858292D3CFAB496DB6336DD0F794B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_28C858292D3CFAB496DB6336DD0F794B" xlink:to="lab_us-gaap_LeasesAbstract_28C858292D3CFAB496DB6336DD0F794B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_093946E24FDFD9B0DBCE6336DD12F710_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_093946E24FDFD9B0DBCE6336DD12F710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_093946E24FDFD9B0DBCE6336DD12F710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_093946E24FDFD9B0DBCE6336DD12F710" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_093946E24FDFD9B0DBCE6336DD12F710" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease ROU asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 606 Adjustment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4C5BE9106EA149F045CA6336DCACEC0A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4C5BE9106EA149F045CA6336DCACEC0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4C5BE9106EA149F045CA6336DCACEC0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4C5BE9106EA149F045CA6336DCACEC0A" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4C5BE9106EA149F045CA6336DCACEC0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) and accumulated other comprehensive items</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 (Excludes the six months ended June 30, 2019)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25" xlink:type="arc" />
    <link:label id="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF_terseLabel_en-US" xlink:label="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and thereafter</link:label>
    <link:label id="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF_label_en-US" xlink:label="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter</link:label>
    <link:label id="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF_documentation_en-US" xlink:label="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:label="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:to="lab_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290" xlink:to="lab_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F" xlink:to="lab_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F" xlink:type="arc" />
    <link:label id="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF_terseLabel_en-US" xlink:label="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory and cost of product sales</link:label>
    <link:label id="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF_label_en-US" xlink:label="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories And Cost Of Product Sales [Policy Text Block]</link:label>
    <link:label id="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF_documentation_en-US" xlink:label="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for inventories and cost of revenue.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:label="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:to="lab_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently issued accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22C71E606083E63CB43E6336DD31FBC0_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22C71E606083E63CB43E6336DD31FBC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22C71E606083E63CB43E6336DD31FBC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22C71E606083E63CB43E6336DD31FBC0" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22C71E606083E63CB43E6336DD31FBC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8" xlink:to="lab_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB" xlink:to="lab_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED" xlink:to="lab_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03" xlink:to="lab_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1_label_en-US" xlink:label="lab_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1" xlink:to="lab_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58A2E6D24F102FAE9BB26336DC78A076_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58A2E6D24F102FAE9BB26336DC78A076" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58A2E6D24F102FAE9BB26336DC78A076" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58A2E6D24F102FAE9BB26336DC78A076" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58A2E6D24F102FAE9BB26336DC78A076" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock award plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ED712B7F9CE4E5E504026336DCC212AB_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_ED712B7F9CE4E5E504026336DCC212AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ED712B7F9CE4E5E504026336DCC212AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ED712B7F9CE4E5E504026336DCC212AB" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_ED712B7F9CE4E5E504026336DCC212AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:to="lab_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:to="lab_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities on the balance sheet</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:to="lab_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Marketable securities, Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:type="arc" />
    <link:label id="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B_terseLabel_en-US" xlink:label="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Marketable securities, More Than 12 Months</link:label>
    <link:label id="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B_label_en-US" xlink:label="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities Over One Year Fair Value</link:label>
    <link:label id="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B_documentation_en-US" xlink:label="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:label="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:to="lab_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F" xlink:to="lab_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of computation of basic and diluted net loss available to common stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of historical dilutive common share equivalents outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E_terseLabel_en-US" xlink:label="lab_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E_label_en-US" xlink:label="lab_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:to="lab_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888_terseLabel_en-US" xlink:label="lab_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888_label_en-US" xlink:label="lab_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:to="lab_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:to="lab_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:to="lab_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86_terseLabel_en-US" xlink:label="lab_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86_label_en-US" xlink:label="lab_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangement Other than Collaborative [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:to="lab_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:type="arc" />
    <link:label id="lab_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7_terseLabel_en-US" xlink:label="lab_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agilis</link:label>
    <link:label id="lab_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7_label_en-US" xlink:label="lab_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agilis [Member]</link:label>
    <link:label id="lab_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7_documentation_en-US" xlink:label="lab_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agilis [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:to="lab_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:to="lab_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:type="arc" />
    <link:label id="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5_terseLabel_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.00% Convertible senior notes due 2022</link:label>
    <link:label id="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5_label_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes3.0 Percent Due2022 [Member]</link:label>
    <link:label id="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5_documentation_en-US" xlink:label="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to 3.00% convertible senior notes due 2022.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:to="lab_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:to="lab_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:to="lab_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARs</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199_label_en-US" xlink:label="lab_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:to="lab_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2_terseLabel_en-US" xlink:label="lab_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2_label_en-US" xlink:label="lab_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:to="lab_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635_label_en-US" xlink:label="lab_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:to="lab_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72_label_en-US" xlink:label="lab_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:to="lab_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171_label_en-US" xlink:label="lab_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:to="lab_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1_label_en-US" xlink:label="lab_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember" xlink:label="loc_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:to="lab_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Principal Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:label="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:to="lab_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate ( as a percent )</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:to="lab_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B_label_en-US" xlink:label="lab_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:to="lab_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:type="arc" />
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone, potential achievements, product sales</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099_label_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:to="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:type="arc" />
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154_terseLabel_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone payments which the entity is obligated to pay</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154_label_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Payment Obligations</link:label>
    <link:label id="lab_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154_documentation_en-US" xlink:label="lab_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:to="lab_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:type="arc" />
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone, potential achievements, priority review voucher amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00_label_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:to="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:type="arc" />
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4_terseLabel_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone, potential achievements, net sales amount</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4_label_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone</link:label>
    <link:label id="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4_documentation_en-US" xlink:label="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:to="lab_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:type="arc" />
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B_terseLabel_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of deferred consideration payable</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B_label_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B_documentation_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:to="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:type="arc" />
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44_terseLabel_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred consideration payable</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44_label_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</link:label>
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44_documentation_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:to="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:type="arc" />
    <link:label id="lab_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B_terseLabel_en-US" xlink:label="lab_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment In MRI</link:label>
    <link:label id="lab_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B_label_en-US" xlink:label="lab_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment In MRI</link:label>
    <link:label id="lab_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B_documentation_en-US" xlink:label="lab_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment In MRI</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_InvestmentInMRI" xlink:label="loc_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:to="lab_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_E331462BAD698F52B0866336DC33134D_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_E331462BAD698F52B0866336DC33134D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E331462BAD698F52B0866336DC33134D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E331462BAD698F52B0866336DC33134D" xlink:to="lab_us-gaap_DebtDisclosureAbstract_E331462BAD698F52B0866336DC33134D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="lab_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:to="lab_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:to="lab_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:type="arc" />
    <link:label id="lab_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2_terseLabel_en-US" xlink:label="lab_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MidCap Financial Trust</link:label>
    <link:label id="lab_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2_label_en-US" xlink:label="lab_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MidCap Financial Trust [Member]</link:label>
    <link:label id="lab_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2_documentation_en-US" xlink:label="lab_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MidCap Financial Trust [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MidCapFinancialTrustMember" xlink:label="loc_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:to="lab_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:type="arc" />
    <link:label id="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption on or after August 20, 2018</link:label>
    <link:label id="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3_label_en-US" xlink:label="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Period On Or After August202018 [Member]</link:label>
    <link:label id="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the debt instrument redemption period on or after August 20, 2018.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:label="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:to="lab_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="lab_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:type="arc" />
    <link:label id="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8_terseLabel_en-US" xlink:label="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, additional capacity available, net product revenue threshold</link:label>
    <link:label id="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8_label_en-US" xlink:label="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Additional Capacity Available</link:label>
    <link:label id="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8_documentation_en-US" xlink:label="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Additional Capacity Available</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:label="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:to="lab_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:to="lab_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:type="arc" />
    <link:label id="lab_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, floor interest rate</link:label>
    <link:label id="lab_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC_label_en-US" xlink:label="lab_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:label id="lab_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Floor Interest Rate</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentFloorInterestRate" xlink:label="loc_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:to="lab_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:type="arc" />
    <link:label id="lab_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest payment period</link:label>
    <link:label id="lab_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F_label_en-US" xlink:label="lab_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Payment Period</link:label>
    <link:label id="lab_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Payment Period</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentInterestPaymentPeriod" xlink:label="loc_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:to="lab_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt principal amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading days, number</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consecutive trading days, period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:type="arc" />
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business days, period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C_label_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Threshold Business Days</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:to="lab_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:type="arc" />
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consecutive trading-day period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1_label_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Threshold Consecutive Trading Day Period</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:to="lab_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:type="arc" />
    <link:label id="lab_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock per principal amount</link:label>
    <link:label id="lab_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C_label_en-US" xlink:label="lab_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Principal Amount Denomination For Conversion Into Common Stock</link:label>
    <link:label id="lab_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the denomination of the principal amount of debt that is used in conversion calculations.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="loc_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:to="lab_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:type="arc" />
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402_terseLabel_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402_label_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum</link:label>
    <link:label id="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402_documentation_en-US" xlink:label="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:to="lab_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sinking fund</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Cumulative Sinking Fund Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:label="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:to="lab_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:type="arc" />
    <link:label id="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7_terseLabel_en-US" xlink:label="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible instruments principal and unpaid interest payable upon events of default</link:label>
    <link:label id="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7_label_en-US" xlink:label="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Instruments Principal And Unpaid Interest Payable Upon Events Of Default</link:label>
    <link:label id="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7_documentation_en-US" xlink:label="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the debt instrument principal and unpaid interest payable upon events of default.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:label="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:to="lab_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:type="arc" />
    <link:label id="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD_terseLabel_en-US" xlink:label="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default</link:label>
    <link:label id="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD_label_en-US" xlink:label="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Percentage Of Debt Principal Amount By Instrument Holders</link:label>
    <link:label id="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD_documentation_en-US" xlink:label="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum percentage of debt principal amount by instrument holders.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:label="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:to="lab_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of the convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:to="lab_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to additional paid in capital, equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:type="arc" />
    <link:label id="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D_terseLabel_en-US" xlink:label="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability in connection with convertible notes</link:label>
    <link:label id="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D_label_en-US" xlink:label="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Liabilities Convertible Debt Instruments</link:label>
    <link:label id="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D_documentation_en-US" xlink:label="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net deferred tax liability attributable to taxable temporary differences from issuance of convertible debt instruments.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:label="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:to="lab_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining contractual life of the convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of assumptions used to estimate fair values of grants made on the date of grant</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of information on the Company's restricted stock</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation expense recorded in the statement of operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation, benefits, and related accruals</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A" xlink:type="arc" />
    <link:label id="lab_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E_terseLabel_en-US" xlink:label="lab_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting and contracted research</link:label>
    <link:label id="lab_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E_label_en-US" xlink:label="lab_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Consulting and Contracted Research Current</link:label>
    <link:label id="lab_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E_documentation_en-US" xlink:label="lab_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AccruedConsultingAndContractedResearchCurrent" xlink:label="loc_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:to="lab_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B" xlink:type="arc" />
    <link:label id="lab_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E_terseLabel_en-US" xlink:label="lab_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales allowance and other costs</link:label>
    <link:label id="lab_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E_label_en-US" xlink:label="lab_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Allowance And Other Related Costs</link:label>
    <link:label id="lab_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E_documentation_en-US" xlink:label="lab_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Allowance And Other Related Costs</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesAllowanceAndOtherRelatedCosts" xlink:label="loc_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:to="lab_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:type="arc" />
    <link:label id="lab_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877_terseLabel_en-US" xlink:label="lab_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales rebates and royalties</link:label>
    <link:label id="lab_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877_label_en-US" xlink:label="lab_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Rebates And Royalties, Current</link:label>
    <link:label id="lab_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877_documentation_en-US" xlink:label="lab_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Rebates And Royalties, Current</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesRebatesAndRoyaltiesCurrent" xlink:label="loc_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:to="lab_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE" xlink:to="lab_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:to="lab_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:to="lab_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9" xlink:to="lab_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_4E843ECC716D93F728DC6336DD7AFEA6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_4E843ECC716D93F728DC6336DD7AFEA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4E843ECC716D93F728DC6336DD7AFEA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_4E843ECC716D93F728DC6336DD7AFEA6" xlink:to="lab_us-gaap_InventoryNet_4E843ECC716D93F728DC6336DD7AFEA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49" xlink:to="lab_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43_label_en-US" xlink:label="lab_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43" xlink:to="lab_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43" xlink:type="arc" />
    <link:label id="lab_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02_terseLabel_en-US" xlink:label="lab_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02_label_en-US" xlink:label="lab_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits and Other Assets Noncurrent</link:label>
    <link:label id="lab_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02_documentation_en-US" xlink:label="lab_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:to="lab_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C_label_en-US" xlink:label="lab_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C" xlink:to="lab_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_946CC9AA44225C7C2C546336DD7C6103_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_946CC9AA44225C7C2C546336DD7C6103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_946CC9AA44225C7C2C546336DD7C6103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_946CC9AA44225C7C2C546336DD7C6103" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_946CC9AA44225C7C2C546336DD7C6103" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9" xlink:to="lab_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4" xlink:to="lab_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C" xlink:type="arc" />
    <link:label id="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_00D3542A16F2134334536336DD7D407D_verboseLabel_en-US" xlink:label="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_00D3542A16F2134334536336DD7D407D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred consideration payable</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_00D3542A16F2134334536336DD7D407D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_00D3542A16F2134334536336DD7D407D" xlink:to="lab_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_00D3542A16F2134334536336DD7D407D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71_label_en-US" xlink:label="lab_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71" xlink:to="lab_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:to="lab_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding 58,707,185 shares at June 30, 2019. Authorized 125,000,000 shares; issued and outstanding 50,606,147 shares at December 31, 2018.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8" xlink:to="lab_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E" xlink:to="lab_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A4BC3718B7404476175B6336DD7F7E79_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A4BC3718B7404476175B6336DD7F7E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A4BC3718B7404476175B6336DD7F7E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A4BC3718B7404476175B6336DD7F7E79" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_A4BC3718B7404476175B6336DD7F7E79" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA" xlink:to="lab_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_29C47A093E99DBBE92196336DC94087B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_29C47A093E99DBBE92196336DC94087B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_29C47A093E99DBBE92196336DC94087B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_29C47A093E99DBBE92196336DC94087B" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_29C47A093E99DBBE92196336DC94087B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the Company's outstanding warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:type="arc" />
    <link:label id="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068_terseLabel_en-US" xlink:label="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestones and Royalties</link:label>
    <link:label id="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068_label_en-US" xlink:label="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Net Sales Milestones and Royalties [Member]</link:label>
    <link:label id="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068_documentation_en-US" xlink:label="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Net Sales Milestones and Royalties [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:to="lab_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs (level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payable- net sales milestones and royalties</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:to="lab_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Awards and Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BF38A1AC39646719882B6336DC4EAD81_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BF38A1AC39646719882B6336DC4EAD81" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BF38A1AC39646719882B6336DC4EAD81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BF38A1AC39646719882B6336DC4EAD81" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BF38A1AC39646719882B6336DC4EAD81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4F0FEE2E8DB6B5CCFC826336DC4FC126_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4F0FEE2E8DB6B5CCFC826336DC4FC126" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4F0FEE2E8DB6B5CCFC826336DC4FC126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4F0FEE2E8DB6B5CCFC826336DC4FC126" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4F0FEE2E8DB6B5CCFC826336DC4FC126" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA" xlink:to="lab_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5" xlink:to="lab_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2" xlink:to="lab_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74_label_en-US" xlink:label="lab_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74" xlink:to="lab_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities- current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities- noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_48A4E5A241B2CE2F9EAF6336DD036AF5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_48A4E5A241B2CE2F9EAF6336DD036AF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_48A4E5A241B2CE2F9EAF6336DD036AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_48A4E5A241B2CE2F9EAF6336DD036AF5" xlink:to="lab_us-gaap_OperatingLeaseLiability_48A4E5A241B2CE2F9EAF6336DD036AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease terms - operating leases (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate - operating leases ( as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455" xlink:to="lab_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:to="lab_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:type="arc" />
    <link:label id="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD_terseLabel_en-US" xlink:label="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards and units</link:label>
    <link:label id="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD_label_en-US" xlink:label="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD_documentation_en-US" xlink:label="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Restricted Stock and Restricted Stock Units (RSUs).</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:to="lab_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shares excluded from calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0DBEC0AEE6D4245B95156336DBC2D08B_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0DBEC0AEE6D4245B95156336DBC2D08B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0DBEC0AEE6D4245B95156336DBC2D08B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0DBEC0AEE6D4245B95156336DBC2D08B" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0DBEC0AEE6D4245B95156336DBC2D08B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:to="lab_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:to="lab_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:type="arc" />
    <link:label id="lab_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321_terseLabel_en-US" xlink:label="lab_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321_label_en-US" xlink:label="lab_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321_documentation_en-US" xlink:label="lab_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RocheMember" xlink:label="loc_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:to="lab_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:to="lab_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:type="arc" />
    <link:label id="lab_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2_terseLabel_en-US" xlink:label="lab_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration And Discovery Agreements</link:label>
    <link:label id="lab_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2_label_en-US" xlink:label="lab_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And Discovery Agreements [Member]</link:label>
    <link:label id="lab_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2_documentation_en-US" xlink:label="lab_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to early stage collaboration and discovery agreements.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborationAndDiscoveryAgreementsMember" xlink:label="loc_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:to="lab_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:to="lab_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:type="arc" />
    <link:label id="lab_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D_terseLabel_en-US" xlink:label="lab_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche And Sma Foundation</link:label>
    <link:label id="lab_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D_label_en-US" xlink:label="lab_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche And Sma Foundation [Member]</link:label>
    <link:label id="lab_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D_documentation_en-US" xlink:label="lab_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Roche and SMA Foundation</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RocheAndSmaFoundationMember" xlink:label="loc_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:to="lab_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:to="lab_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:to="lab_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:type="arc" />
    <link:label id="lab_country_US_29ABECC716AAA56343906336DBDEC4FC_terseLabel_en-US" xlink:label="lab_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_29ABECC716AAA56343906336DBDEC4FC_label_en-US" xlink:label="lab_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:to="lab_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625_label_en-US" xlink:label="lab_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:to="lab_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:to="lab_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="lab_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:type="arc" />
    <link:label id="lab_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15_terseLabel_en-US" xlink:label="lab_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translarna</link:label>
    <link:label id="lab_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15_label_en-US" xlink:label="lab_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Translarna [Member]</link:label>
    <link:label id="lab_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15_documentation_en-US" xlink:label="lab_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Translarna [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_TranslarnaMember" xlink:label="loc_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:to="lab_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:type="arc" />
    <link:label id="lab_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6_terseLabel_en-US" xlink:label="lab_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing And Collaboration Agreement</link:label>
    <link:label id="lab_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6_label_en-US" xlink:label="lab_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6_documentation_en-US" xlink:label="lab_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LicensingAndCollaborationAgreementMember" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:to="lab_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:type="arc" />
    <link:label id="lab_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97_terseLabel_en-US" xlink:label="lab_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery Agreements</link:label>
    <link:label id="lab_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97_label_en-US" xlink:label="lab_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery Agreements [Member]</link:label>
    <link:label id="lab_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97_documentation_en-US" xlink:label="lab_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery Agreements [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DiscoveryAgreementsMember" xlink:label="loc_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:to="lab_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:type="arc" />
    <link:label id="lab_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369_terseLabel_en-US" xlink:label="lab_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early Stage Collaborations</link:label>
    <link:label id="lab_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369_label_en-US" xlink:label="lab_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Stage Collaborations [Member]</link:label>
    <link:label id="lab_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369_documentation_en-US" xlink:label="lab_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Stage Collaborations [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EarlyStageCollaborationsMember" xlink:label="loc_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:to="lab_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:type="arc" />
    <link:label id="lab_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272_terseLabel_en-US" xlink:label="lab_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272_label_en-US" xlink:label="lab_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272_documentation_en-US" xlink:label="lab_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by categories of milestones achieved.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestoneAxis" xlink:label="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:to="lab_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:type="arc" />
    <link:label id="lab_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2_terseLabel_en-US" xlink:label="lab_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2_label_en-US" xlink:label="lab_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2_documentation_en-US" xlink:label="lab_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Different categories of milestones defined by agreements.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestoneDomain" xlink:label="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:to="lab_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:type="arc" />
    <link:label id="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A_terseLabel_en-US" xlink:label="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Event Milestones</link:label>
    <link:label id="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A_label_en-US" xlink:label="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Event Milestones [Member]</link:label>
    <link:label id="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A_documentation_en-US" xlink:label="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:label="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:to="lab_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:type="arc" />
    <link:label id="lab_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B_terseLabel_en-US" xlink:label="lab_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Milestones</link:label>
    <link:label id="lab_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B_label_en-US" xlink:label="lab_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B_documentation_en-US" xlink:label="lab_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to certain sales events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesMilestonesMember" xlink:label="loc_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:to="lab_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:to="lab_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:to="lab_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:type="arc" />
    <link:label id="lab_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545_terseLabel_en-US" xlink:label="lab_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenue</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetProductSales" xlink:label="loc_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:to="lab_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:type="arc" />
    <link:label id="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4_verboseLabel_en-US" xlink:label="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4_label_en-US" xlink:label="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Increase From Cash Receipts</link:label>
    <link:label id="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4_documentation_en-US" xlink:label="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Increase from Cash Receipts</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:label="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:to="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:type="arc" />
    <link:label id="lab_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1_terseLabel_en-US" xlink:label="lab_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of compounds in preclinical development</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1_label_en-US" xlink:label="lab_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements Number of Compounds in Preclinical Development</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1_documentation_en-US" xlink:label="lab_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of compounds included in preclinical development.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment" xlink:label="loc_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:to="lab_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:type="arc" />
    <link:label id="lab_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410_terseLabel_en-US" xlink:label="lab_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of significant deliverables</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410_label_en-US" xlink:label="lab_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements Number of Significant Deliverables</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410_documentation_en-US" xlink:label="lab_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of significant deliverables under a contractual agreement.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsNumberOfSignificantDeliverables" xlink:label="loc_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:to="lab_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:type="arc" />
    <link:label id="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A_terseLabel_en-US" xlink:label="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition, milestone, potential achievements</link:label>
    <link:label id="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A_label_en-US" xlink:label="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone, Potential Achievements</link:label>
    <link:label id="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A_documentation_en-US" xlink:label="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone, Potential Achievements</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:to="lab_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D_label_en-US" xlink:label="lab_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:to="lab_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:type="arc" />
    <link:label id="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD_terseLabel_en-US" xlink:label="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements research period for applying discovery technology</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD_label_en-US" xlink:label="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements Research Period for Applying Discovery Technology</link:label>
    <link:label id="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD_documentation_en-US" xlink:label="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research period for applying discovery technology.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:label="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:to="lab_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:to="lab_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains/(Losses) On Marketable Securities, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) and accumulated other comprehensive items</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:to="lab_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from other comprehensive items</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_281CD40F96B2E3954D1D67AB331FBB57_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_281CD40F96B2E3954D1D67AB331FBB57" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_281CD40F96B2E3954D1D67AB331FBB57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_281CD40F96B2E3954D1D67AB331FBB57" xlink:to="lab_us-gaap_StockholdersEquity_281CD40F96B2E3954D1D67AB331FBB57" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE" xlink:to="lab_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_532A38BFD73539A328A26336DCE256BB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_532A38BFD73539A328A26336DCE256BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_532A38BFD73539A328A26336DCE256BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_532A38BFD73539A328A26336DCE256BB" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_532A38BFD73539A328A26336DCE256BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_9B0AF14699A236A1606F6336DBADD212_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_9B0AF14699A236A1606F6336DBADD212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9B0AF14699A236A1606F6336DBADD212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9B0AF14699A236A1606F6336DBADD212" xlink:to="lab_us-gaap_SubsequentEventsAbstract_9B0AF14699A236A1606F6336DBADD212" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C" xlink:to="lab_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51" xlink:type="arc" />
    <link:label id="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7_terseLabel_en-US" xlink:label="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and thereafter</link:label>
    <link:label id="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7_label_en-US" xlink:label="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter</link:label>
    <link:label id="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7_documentation_en-US" xlink:label="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:label="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:to="lab_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077" xlink:type="arc" />
    <link:label id="lab_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60_label_en-US" xlink:label="lab_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:label id="lab_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60_documentation_en-US" xlink:label="lab_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="lab_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB_label_en-US" xlink:label="lab_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB" xlink:to="lab_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A" xlink:to="lab_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34" xlink:to="lab_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632" xlink:to="lab_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C_label_en-US" xlink:label="lab_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C" xlink:to="lab_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7_label_en-US" xlink:label="lab_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7" xlink:to="lab_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61" xlink:to="lab_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE" xlink:to="lab_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2" xlink:to="lab_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8" xlink:to="lab_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF" xlink:to="lab_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A" xlink:to="lab_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0_label_en-US" xlink:label="lab_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0" xlink:to="lab_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B" xlink:to="lab_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1" xlink:to="lab_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738" xlink:to="lab_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4_label_en-US" xlink:label="lab_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4" xlink:to="lab_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F" xlink:to="lab_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0" xlink:to="lab_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA_label_en-US" xlink:label="lab_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA" xlink:to="lab_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1_label_en-US" xlink:label="lab_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1" xlink:to="lab_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215_label_en-US" xlink:label="lab_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215" xlink:to="lab_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81_label_en-US" xlink:label="lab_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81" xlink:to="lab_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:to="lab_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized, Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized, Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:type="arc" />
    <link:label id="lab_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020_terseLabel_en-US" xlink:label="lab_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:label id="lab_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020_label_en-US" xlink:label="lab_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:label id="lab_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020_documentation_en-US" xlink:label="lab_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Operating Leases</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfOperatingLeases" xlink:label="loc_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:to="lab_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of Contract ( in years )</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal Term ( in years )</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:type="arc" />
    <link:label id="lab_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5_terseLabel_en-US" xlink:label="lab_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Emflaza asset acquisition</link:label>
    <link:label id="lab_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5_label_en-US" xlink:label="lab_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emflaza asset acquisition [Member]</link:label>
    <link:label id="lab_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5_documentation_en-US" xlink:label="lab_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Emflaza asset acquisition [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmflazaassetacquisitionMember" xlink:label="loc_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:to="lab_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:type="arc" />
    <link:label id="lab_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C_terseLabel_en-US" xlink:label="lab_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Akcea</link:label>
    <link:label id="lab_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C_label_en-US" xlink:label="lab_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Akcea [Member]</link:label>
    <link:label id="lab_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C_documentation_en-US" xlink:label="lab_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Akcea [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AkceaMember" xlink:label="loc_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:to="lab_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:type="arc" />
    <link:label id="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9_terseLabel_en-US" xlink:label="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone, Potential Achievements, Regulatory Approval</link:label>
    <link:label id="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9_label_en-US" xlink:label="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone, Potential Achievements, Regulatory Approval</link:label>
    <link:label id="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9_documentation_en-US" xlink:label="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment which the entity is obliged to receive upon regulatory approval</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:to="lab_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total allocation of IPR&amp;D assets</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:type="arc" />
    <link:label id="lab_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD_terseLabel_en-US" xlink:label="lab_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront licensing fee</link:label>
    <link:label id="lab_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD_label_en-US" xlink:label="lab_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Licensing Fee</link:label>
    <link:label id="lab_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD_documentation_en-US" xlink:label="lab_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Licensing Fee</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_UpfrontLicensingFee" xlink:label="loc_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:to="lab_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:to="lab_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate of the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, rollforward and revenue recognition</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6" xlink:to="lab_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24" xlink:type="arc" />
    <link:label id="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9_terseLabel_en-US" xlink:label="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of interest expense recognized related to the Convertible Notes</link:label>
    <link:label id="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9_label_en-US" xlink:label="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Interest Expense Recognized Related To Convertible Debt [Table Text Block]</link:label>
    <link:label id="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9_documentation_en-US" xlink:label="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of interest expense recognized related to convertible debt.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:label="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:to="lab_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments and marketable securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator for basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69_label_en-US" xlink:label="lab_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69" xlink:to="lab_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation of deferred and contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_2EC3B476DB4E44DC6425676CE62D5E84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_2EC3B476DB4E44DC6425676CE62D5E84" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on MRI investment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2EC3B476DB4E44DC6425676CE62D5E84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_2EC3B476DB4E44DC6425676CE62D5E84" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_2EC3B476DB4E44DC6425676CE62D5E84" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84" xlink:to="lab_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of asset</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B" xlink:to="lab_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency transaction gains, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deposit Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD" xlink:to="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of equity investment in MRI</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of product rights and licenses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in (provided by) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from public offerings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584" xlink:to="lab_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5B81DA706681D9FE6E6A676CE632EB44_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5B81DA706681D9FE6E6A676CE632EB44" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5B81DA706681D9FE6E6A676CE632EB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5B81DA706681D9FE6E6A676CE632EB44" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5B81DA706681D9FE6E6A676CE632EB44" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18D48D5CAC9DDF0E3180676CE6339131_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18D48D5CAC9DDF0E3180676CE6339131" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18D48D5CAC9DDF0E3180676CE6339131" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18D48D5CAC9DDF0E3180676CE6339131" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18D48D5CAC9DDF0E3180676CE6339131" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6" xlink:to="lab_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activity</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Interest Issued, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:type="arc" />
    <link:label id="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D_terseLabel_en-US" xlink:label="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator for calculation of number of shares of equity interests issued to acquire entity</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D_label_en-US" xlink:label="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D_documentation_en-US" xlink:label="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:to="lab_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:type="arc" />
    <link:label id="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883_terseLabel_en-US" xlink:label="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading day period</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883_label_en-US" xlink:label="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period</link:label>
    <link:label id="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883_documentation_en-US" xlink:label="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:to="lab_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="lab_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:type="arc" />
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:type="arc" />
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:type="arc" />
    <link:label id="lab_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926_terseLabel_en-US" xlink:label="lab_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Building</link:label>
    <link:label id="lab_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926_label_en-US" xlink:label="lab_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Building [Member]</link:label>
    <link:label id="lab_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926_documentation_en-US" xlink:label="lab_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Building [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NewBuildingMember" xlink:label="loc_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:to="lab_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:type="arc" />
    <link:label id="lab_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09_terseLabel_en-US" xlink:label="lab_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fifth Anniversary [Member]</link:label>
    <link:label id="lab_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09_label_en-US" xlink:label="lab_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fifth Anniversary [Member]</link:label>
    <link:label id="lab_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09_documentation_en-US" xlink:label="lab_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fifth Anniversary [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_FifthAnniversaryMember" xlink:label="loc_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:to="lab_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:to="lab_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="lab_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:type="arc" />
    <link:label id="lab_ptct_Feet_231BF844F703CD144168678B2E88A483_terseLabel_en-US" xlink:label="lab_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Square feet of office</link:label>
    <link:label id="lab_ptct_Feet_231BF844F703CD144168678B2E88A483_label_en-US" xlink:label="lab_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Feet</link:label>
    <link:label id="lab_ptct_Feet_231BF844F703CD144168678B2E88A483_documentation_en-US" xlink:label="lab_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Feet</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Feet" xlink:label="loc_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:to="lab_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:type="arc" />
    <link:label id="lab_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F_terseLabel_en-US" xlink:label="lab_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of terms</link:label>
    <link:label id="lab_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F_label_en-US" xlink:label="lab_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of terms</link:label>
    <link:label id="lab_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F_documentation_en-US" xlink:label="lab_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of terms</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Numberofterms" xlink:label="loc_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:to="lab_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate rent, Initial term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:type="arc" />
    <link:label id="lab_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644_terseLabel_en-US" xlink:label="lab_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent Of Market Rate</link:label>
    <link:label id="lab_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644_label_en-US" xlink:label="lab_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent Of Market Rate</link:label>
    <link:label id="lab_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644_documentation_en-US" xlink:label="lab_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent Of Market Rate</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_PercentOfMarketRate" xlink:label="loc_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:to="lab_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:type="arc" />
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal Term (in years)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:to="lab_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of Credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:type="arc" />
    <link:label id="lab_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9_terseLabel_en-US" xlink:label="lab_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for letter of credit (in years)</link:label>
    <link:label id="lab_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9_label_en-US" xlink:label="lab_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term for letter of credit</link:label>
    <link:label id="lab_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9_documentation_en-US" xlink:label="lab_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term for letter of credit</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Termforletterofcredit" xlink:label="loc_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:to="lab_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:type="arc" />
    <link:label id="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103_terseLabel_en-US" xlink:label="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103_label_en-US" xlink:label="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Development and Regulatory Milestone [Member]</link:label>
    <link:label id="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103_documentation_en-US" xlink:label="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Development and Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:to="lab_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:to="lab_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:to="lab_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Option Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:type="arc" />
    <link:label id="lab_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04_terseLabel_en-US" xlink:label="lab_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of Success [Member]</link:label>
    <link:label id="lab_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04_label_en-US" xlink:label="lab_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probability of Success [Member]</link:label>
    <link:label id="lab_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04_documentation_en-US" xlink:label="lab_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probability of Success [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ProbabilityofSuccessMember" xlink:label="loc_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:to="lab_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:type="arc" />
    <link:label id="lab_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4_terseLabel_en-US" xlink:label="lab_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Sales for Royalties</link:label>
    <link:label id="lab_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4_label_en-US" xlink:label="lab_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Sales for Royalties [Member]</link:label>
    <link:label id="lab_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4_documentation_en-US" xlink:label="lab_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Sales for Royalties [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_PercentageofSalesforRoyaltiesMember" xlink:label="loc_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:to="lab_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:type="arc" />
    <link:label id="lab_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A_terseLabel_en-US" xlink:label="lab_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A_label_en-US" xlink:label="lab_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone [Member]</link:label>
    <link:label id="lab_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A_documentation_en-US" xlink:label="lab_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentandRegulatoryMilestoneMember" xlink:label="loc_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:to="lab_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:type="arc" />
    <link:label id="lab_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B_terseLabel_en-US" xlink:label="lab_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alternative Investment, Milestone</link:label>
    <link:label id="lab_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B_label_en-US" xlink:label="lab_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Milestone</link:label>
    <link:label id="lab_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B_documentation_en-US" xlink:label="lab_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alternative Investment, Milestone</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AlternativeInvestmentMilestone" xlink:label="loc_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:to="lab_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in the fair value of warrant liability and SARs liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">December 31, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DAD2E764FBC144F8A0316336DCBC31DC_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DAD2E764FBC144F8A0316336DCBC31DC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">June 30, 2019</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DAD2E764FBC144F8A0316336DCBC31DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DAD2E764FBC144F8A0316336DCBC31DC" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DAD2E764FBC144F8A0316336DCBC31DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1" xlink:to="lab_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC_label_en-US" xlink:label="lab_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC" xlink:to="lab_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68" xlink:to="lab_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3" xlink:to="lab_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0" xlink:to="lab_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6D32F6C38671C012D1896336DC1B1997_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6D32F6C38671C012D1896336DC1B1997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6D32F6C38671C012D1896336DC1B1997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6D32F6C38671C012D1896336DC1B1997" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6D32F6C38671C012D1896336DC1B1997" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467" xlink:type="arc" />
    <link:label id="lab_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F_terseLabel_en-US" xlink:label="lab_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marathon Pharmaceuticals, LLC</link:label>
    <link:label id="lab_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F_label_en-US" xlink:label="lab_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marathon Pharmaceuticals, LLC [Member]</link:label>
    <link:label id="lab_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F_documentation_en-US" xlink:label="lab_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marathon Pharmaceuticals, LLC [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MarathonPharmaceuticalsLLCMember" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:to="lab_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:type="arc" />
    <link:label id="lab_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680_terseLabel_en-US" xlink:label="lab_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products</link:label>
    <link:label id="lab_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680_label_en-US" xlink:label="lab_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Products</link:label>
    <link:label id="lab_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680_documentation_en-US" xlink:label="lab_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Products</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfProducts" xlink:label="loc_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:to="lab_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:type="arc" />
    <link:label id="lab_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4_terseLabel_en-US" xlink:label="lab_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of member states of the European Economic Area</link:label>
    <link:label id="lab_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4_label_en-US" xlink:label="lab_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of States In European Economic Area</link:label>
    <link:label id="lab_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4_documentation_en-US" xlink:label="lab_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of states in European economic area.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfStatesInEuropeanEconomicArea" xlink:label="loc_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:to="lab_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:type="arc" />
    <link:label id="lab_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91_terseLabel_en-US" xlink:label="lab_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of countries ( over )</link:label>
    <link:label id="lab_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91_label_en-US" xlink:label="lab_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Countries</link:label>
    <link:label id="lab_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91_documentation_en-US" xlink:label="lab_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of countries.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfCountries" xlink:label="loc_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:to="lab_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred consideration payable</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, performance obligation, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_12C0B4C8DD2599C9A71267CEC099E164_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_12C0B4C8DD2599C9A71267CEC099E164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_12C0B4C8DD2599C9A71267CEC099E164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_12C0B4C8DD2599C9A71267CEC099E164" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_12C0B4C8DD2599C9A71267CEC099E164" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3_label_en-US" xlink:label="lab_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:to="lab_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:to="lab_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:to="lab_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976_label_en-US" xlink:label="lab_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:to="lab_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to accumulated deficit</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock related to equity offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock related to equity offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock vesting and issuance</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock vesting and issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock vesting and issuance</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with an employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with an employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:type="arc" />
    <link:label id="lab_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648_terseLabel_en-US" xlink:label="lab_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid In Capital, Receivable from Investor</link:label>
    <link:label id="lab_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648_label_en-US" xlink:label="lab_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid In Capital, Receivable from Investor</link:label>
    <link:label id="lab_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648_documentation_en-US" xlink:label="lab_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" xlink:label="loc_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:to="lab_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_4C95DAF84F8248C3FB4A67CEC0A8F5CA_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_4C95DAF84F8248C3FB4A67CEC0A8F5CA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_4C95DAF84F8248C3FB4A67CEC0A8F5CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_4C95DAF84F8248C3FB4A67CEC0A8F5CA" xlink:to="lab_us-gaap_SharesIssued_4C95DAF84F8248C3FB4A67CEC0A8F5CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:to="lab_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F67A87B54C9D262A3CD36336DC59CF98_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F67A87B54C9D262A3CD36336DC59CF98" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F67A87B54C9D262A3CD36336DC59CF98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F67A87B54C9D262A3CD36336DC59CF98" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F67A87B54C9D262A3CD36336DC59CF98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or Expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71815A971324A206B5EF6336DC5BD331_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71815A971324A206B5EF6336DC5BD331" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71815A971324A206B5EF6336DC5BD331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71815A971324A206B5EF6336DC5BD331" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71815A971324A206B5EF6336DC5BD331" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or Expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or Expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:type="arc" />
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or Expected to vest at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF_label_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:to="lab_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8AE1EA613FFFB83E4B2E6336DBD110D6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_8AE1EA613FFFB83E4B2E6336DBD110D6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8AE1EA613FFFB83E4B2E6336DBD110D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_8AE1EA613FFFB83E4B2E6336DBD110D6" xlink:to="lab_us-gaap_ContractWithCustomerLiability_8AE1EA613FFFB83E4B2E6336DBD110D6" xlink:type="arc" />
    <link:label id="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_BF8FC811637F0EB6E86A6336DBD1925B_terseLabel_en-US" xlink:label="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_BF8FC811637F0EB6E86A6336DBD1925B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:label="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_BF8FC811637F0EB6E86A6336DBD1925B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_BF8FC811637F0EB6E86A6336DBD1925B" xlink:to="lab_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_BF8FC811637F0EB6E86A6336DBD1925B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_BDACD6AA29AC8FBF0AD86336DBD29B6B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_BDACD6AA29AC8FBF0AD86336DBD29B6B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_BDACD6AA29AC8FBF0AD86336DBD29B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_BDACD6AA29AC8FBF0AD86336DBD29B6B" xlink:to="lab_us-gaap_ContractWithCustomerLiability_BDACD6AA29AC8FBF0AD86336DBD29B6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of components of accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225_label_en-US" xlink:label="lab_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:to="lab_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:type="arc" />
    <link:label id="lab_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188_terseLabel_en-US" xlink:label="lab_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wellcome trust</link:label>
    <link:label id="lab_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188_label_en-US" xlink:label="lab_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wellcome Trust Limited [Member]</link:label>
    <link:label id="lab_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188_documentation_en-US" xlink:label="lab_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to The Wellcome Trust Limited.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_WellcomeTrustLimitedMember" xlink:label="loc_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:to="lab_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:to="lab_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="lab_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted prices in active markets for identical assets (level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant other observable inputs (level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:to="lab_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:type="arc" />
    <link:label id="lab_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A_terseLabel_en-US" xlink:label="lab_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock appreciation rights liability</link:label>
    <link:label id="lab_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A_label_en-US" xlink:label="lab_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights Liability Outstanding</link:label>
    <link:label id="lab_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A_documentation_en-US" xlink:label="lab_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of outstanding stock appreciation rights liability.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:to="lab_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Securities in an unrealized loss position less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Securities in an unrealized loss position greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Nonrecurring Value Measurement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities in an unrealized loss position less than 12 months</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities in an unrealized loss position greater than 12 months</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Five</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Five [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:to="lab_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:to="lab_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="lab_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:type="arc" />
    <link:label id="lab_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8_terseLabel_en-US" xlink:label="lab_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 Stock Incentive Plan</link:label>
    <link:label id="lab_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8_label_en-US" xlink:label="lab_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan2013 [Member]</link:label>
    <link:label id="lab_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8_documentation_en-US" xlink:label="lab_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the 2013 Stock Incentive Plan.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_StockIncentivePlan2013Member" xlink:label="loc_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:to="lab_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:type="arc" />
    <link:label id="lab_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8_terseLabel_en-US" xlink:label="lab_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2009 Equity and Long Term Incentive Plan</link:label>
    <link:label id="lab_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8_label_en-US" xlink:label="lab_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity And Long Term Incentive Plan2009 [Member]</link:label>
    <link:label id="lab_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8_documentation_en-US" xlink:label="lab_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the 2009 Equity and Long-Term Incentive Plan.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EquityAndLongTermIncentivePlan2009Member" xlink:label="loc_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:to="lab_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:type="arc" />
    <link:label id="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F_terseLabel_en-US" xlink:label="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan</link:label>
    <link:label id="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F_label_en-US" xlink:label="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity2009 And Long Term Incentive Plan And Stock Incentive Plan2013 [Member]</link:label>
    <link:label id="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F_documentation_en-US" xlink:label="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:label="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:to="lab_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:type="arc" />
    <link:label id="lab_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852_terseLabel_en-US" xlink:label="lab_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 Long Term Incentive Plan</link:label>
    <link:label id="lab_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852_label_en-US" xlink:label="lab_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Incentive Plan2013 [Member]</link:label>
    <link:label id="lab_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852_documentation_en-US" xlink:label="lab_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the 2013 Long Term Incentive Plan.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LongTermIncentivePlan2013Member" xlink:label="loc_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:to="lab_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:type="arc" />
    <link:label id="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79_terseLabel_en-US" xlink:label="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1998 Employee, Director and Consultant Stock Option Plan</link:label>
    <link:label id="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79_label_en-US" xlink:label="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Director And Consultant Stock Option Plan [Member]</link:label>
    <link:label id="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79_documentation_en-US" xlink:label="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 1998 Employee, Director and Consultant Stock Option Plan</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:label="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:to="lab_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:type="arc" />
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares subject to outstanding awards (in shares)</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Shares Subject to Outstanding Awards</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of shares subject to outstanding awards used to calculate authorized shares.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:type="arc" />
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in the number of shares (in shares) on the first day of the fiscal year</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:type="arc" />
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in the number of shares outstanding on the first day of the fiscal year</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase as Percentage of Stock Outstanding</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:type="arc" />
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97_terseLabel_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement grants for non-statutory stock options (in shares)</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97_label_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Grants For Non-Statutory Stock Options</link:label>
    <link:label id="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97_documentation_en-US" xlink:label="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the inducement grants for non-statutory stock options.</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:to="lab_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:type="arc" />
    <link:label id="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566_terseLabel_en-US" xlink:label="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, voting percentage limit</link:label>
    <link:label id="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566_label_en-US" xlink:label="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Voting Percentage Limit, Percent</link:label>
    <link:label id="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566_documentation_en-US" xlink:label="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Voting Percentage Limit, Percent</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:label="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:to="lab_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining service period for recognition of unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8AFCF4E2E6465C9780716336DD632B07_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_8AFCF4E2E6465C9780716336DD632B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_8AFCF4E2E6465C9780716336DD632B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_8AFCF4E2E6465C9780716336DD632B07" xlink:to="lab_us-gaap_IncomeStatementAbstract_8AFCF4E2E6465C9780716336DD632B07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:to="lab_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:type="arc" />
    <link:label id="lab_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F_terseLabel_en-US" xlink:label="lab_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and grant revenue</link:label>
    <link:label id="lab_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F_label_en-US" xlink:label="lab_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant And Collaboration [Member]</link:label>
    <link:label id="lab_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F_documentation_en-US" xlink:label="lab_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant And Collaboration [Member]</link:label>
    <link:loc xlink:href="ptct-20190630.xsd#ptct_GrantAndCollaborationMember" xlink:label="loc_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:to="lab_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:to="lab_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="lab_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales, excluding amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in the fair value of deferred and contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:to="lab_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:to="lab_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:to="lab_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share-basic and diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:to="lab_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share&#8212;basic and diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of marketable securities accounted for as available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of unrealized losses and fair values of available-for-sale securities in a continuous unrealized loss position</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of marketable securities on the balance sheet</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability and SARs liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB_negatedLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Debt discount, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:to="lab_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:to="lab_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:to="lab_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ptct-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="ptct-20190630.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombination" xlink:href="ptct-20190630.xsd#BusinessCombination" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationConsiderationTransferedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:href="ptct-20190630.xsd#BusinessCombinationProFormaFinancialInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/BusinessCombinationTables" xlink:href="ptct-20190630.xsd#BusinessCombinationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Capitalization" xlink:href="ptct-20190630.xsd#Capitalization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:href="ptct-20190630.xsd#CapitalizationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationTables" xlink:href="ptct-20190630.xsd#CapitalizationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CapitalizationWarrantsDetails" xlink:href="ptct-20190630.xsd#CapitalizationWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="ptct-20190630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Company" xlink:href="ptct-20190630.xsd#Company" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CompanyNarrativeDetails" xlink:href="ptct-20190630.xsd#CompanyNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="ptct-20190630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ptct-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Cover" xlink:href="ptct-20190630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverDei" xlink:href="ptct-20190630.xsd#CoverDei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Debt" xlink:href="ptct-20190630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:href="ptct-20190630.xsd#DebtConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:href="ptct-20190630.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:href="ptct-20190630.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DebtTables" xlink:href="ptct-20190630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:href="ptct-20190630.xsd#FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="ptct-20190630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Leases" xlink:href="ptct-20190630.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeaseCostsDetails" xlink:href="ptct-20190630.xsd#LeasesLeaseCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesLeasePaymentsDetails" xlink:href="ptct-20190630.xsd#LeasesLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:href="ptct-20190630.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/LeasesTables" xlink:href="ptct-20190630.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShare" xlink:href="ptct-20190630.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails" xlink:href="ptct-20190630.xsd#NetLossPerShareAntidilutiveDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails" xlink:href="ptct-20190630.xsd#NetLossPerShareNumeratorAndDenominatorDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/NetLossPerShareTables" xlink:href="ptct-20190630.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/Notes" xlink:href="ptct-20190630.xsd#Notes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:href="ptct-20190630.xsd#OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognition" xlink:href="ptct-20190630.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionPerformanceObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:href="ptct-20190630.xsd#RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/RevenueRecognitionTables" xlink:href="ptct-20190630.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlan" xlink:href="ptct-20190630.xsd#StockAwardPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanRestrictedStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanShareBaseCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails" xlink:href="ptct-20190630.xsd#StockAwardPlanShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/StockAwardPlanTables" xlink:href="ptct-20190630.xsd#StockAwardPlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequentEvents" xlink:href="ptct-20190630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails" xlink:href="ptct-20190630.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptct-20190630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0DF355CB2ECA392400416336DCA0D735" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0DF355CB2ECA392400416336DCA0D735" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_AB2554785962E001DBAC6336DCA033CF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_F94400DCC59F6C4C6FD46336DC9AF15A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AccruedConsultingAndContractedResearchCurrent" xlink:label="loc_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_ptct_AccruedConsultingAndContractedResearchCurrent_2FADD7282C4C20B822CE6336DC9AEE7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_34A1BC25F3C2CA1FB7596336DC9AAD0B" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesAllowanceAndOtherRelatedCosts" xlink:label="loc_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_ptct_SalesAllowanceAndOtherRelatedCosts_9AD6DC530B67511B50646336DC9BDC3E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesRebatesAndRoyaltiesCurrent" xlink:label="loc_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_ptct_SalesRebatesAndRoyaltiesCurrent_CEBF3EDF7234CF9A08296336DC9B4877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_us-gaap_AccountsPayableCurrent_16BA85B2685FEA9FA5896336DC9B2BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F76866A58109678DB99E6336DC9B8140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B442B4A59ADA378111896336DC9AA1C4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87023AB096ED860964CA6336DC9B246C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_B61EEA8564A41385B57A6336DC9EB591" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B61EEA8564A41385B57A6336DC9EB591" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_CB75C96CAA1DDC8B67756336DC9E9B68" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_25BAB8A1AC6633A396536336DCE5909E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D94729CD253C7337B0D66336DCE588DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_25BAB8A1AC6633A396536336DCE5909E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D94729CD253C7337B0D66336DCE588DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CFCCE222ED00E60770566336DCE69B56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D94729CD253C7337B0D66336DCE588DF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CFCCE222ED00E60770566336DCE69B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CFCCE222ED00E60770566336DCE69B56" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_311A87BC005CD7D3BD9C6336DCE6175C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64A26D5C83C03B776C6D6336DCE604BC" xlink:to="loc_ptct_AgilisMember_311A87BC005CD7D3BD9C6336DCE6175C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D90C9FA5770D572CFD726336DCE7D902" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_D94729CD253C7337B0D66336DCE588DF" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_D90C9FA5770D572CFD726336DCE7D902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_349694CCE6202703C6346336DCE766FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D90C9FA5770D572CFD726336DCE7D902" xlink:to="loc_us-gaap_Goodwill_349694CCE6202703C6346336DCE766FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_18616927FDFCB9D550796336DCE90693" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1A1DDBD53F846541F3876336DCEAC58A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_18616927FDFCB9D550796336DCE90693" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1A1DDBD53F846541F3876336DCEAC58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_41CDCCD428539450B5386336DCEAAAA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1A1DDBD53F846541F3876336DCEAC58A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_41CDCCD428539450B5386336DCEAAAA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_41CDCCD428539450B5386336DCEAAAA6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_B9B4FA10026AE21297186336DCEBCFBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D3816968DA86390DFE7C6336DCEAF7E9" xlink:to="loc_ptct_AgilisMember_B9B4FA10026AE21297186336DCEBCFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1A1DDBD53F846541F3876336DCEAC58A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_D9FEC177DE20849770B16336DCEB6F57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_D9FEC177DE20849770B16336DCEB6F57" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_8E316A557AA25645185F6336DCEBF7CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_8E316A557AA25645185F6336DCEBF7CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3A4BBD3812EF8230026336DCEB1CA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AA9D63592C873FBBE3216336DCEB22DD" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1A3A4BBD3812EF8230026336DCEB1CA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F001EF820C9CDDBDABF26336DCEFA734" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F001EF820C9CDDBDABF26336DCEFA734" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F9AAE2B41AF74382CDD56336DCF02E1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:to="loc_srt_RangeAxis_F9AAE2B41AF74382CDD56336DCF02E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F9AAE2B41AF74382CDD56336DCF02E1C" xlink:to="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_38EF2F9CD6FB993ADE756336DCF05658" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:to="loc_srt_MaximumMember_38EF2F9CD6FB993ADE756336DCF05658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FA0BF5A9543D43704C7D6336DCF119C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FEE94A1830E23D4F003D6336DCF0B5E1" xlink:to="loc_srt_MinimumMember_FA0BF5A9543D43704C7D6336DCF119C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AD9D2C449BD197D5EE216336DCF1C10D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AD9D2C449BD197D5EE216336DCF1C10D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AD9D2C449BD197D5EE216336DCF1C10D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_6ABC734916EAE67A10046336DCF1A9D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0E96338BC717D0591D516336DCF113DA" xlink:to="loc_ptct_AgilisMember_6ABC734916EAE67A10046336DCF1A9D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5A9D91EC2F834BF50926336DCEF052E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_AF76B6B3522DD8063D386336DCF2A25E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1912027CF781852384DA6336DCF2714E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_517B7991DFD58708D2946336DCF2F30D" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_69E253A71A9A73E6A9186336DCF2E883" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_BECED549541AAC2C1AB46336DCF2CD04" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_BECED549541AAC2C1AB46336DCF2CD04" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_50CCB8763ED51690D4356336DCF28577" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_50CCB8763ED51690D4356336DCF28577" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_A5843026836DAAADB7FF6336DCF3743C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_A5843026836DAAADB7FF6336DCF3743C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_40857099E6539F2D40146336DCF3CB04" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_40857099E6539F2D40146336DCF3CB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5DCC8FB69034F6B28FD66336DCF324AF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5DCC8FB69034F6B28FD66336DCF324AF" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_1784CE4BB4ABC3CC217F6336DCF3EF78" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312F548A58644638D72A6336DCF18AA0" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_1784CE4BB4ABC3CC217F6336DCF3EF78" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_532A38BFD73539A328A26336DCE256BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_532A38BFD73539A328A26336DCE256BB" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_76786E2CB1BEEE89A0096336DCE28E2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_76786E2CB1BEEE89A0096336DCE28E2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76786E2CB1BEEE89A0096336DCE28E2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_5B058E116BB71A7CD5286336DCE3B548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84D1AA15F108B4800B256336DCE29ED9" xlink:to="loc_ptct_AgilisMember_5B058E116BB71A7CD5286336DCE3B548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_56E2D2164080C24D492E6336DCE283B6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_221A8792959C6D6333536336DCE32F25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_40ADCB14921FE6CB1E8A6336DC96A16A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_40ADCB14921FE6CB1E8A6336DC96A16A" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33C184DF2528856D3A8B6336DC96B826" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CapitalizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_F5649C70C7D2E5A44C566336DC8F55F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_AD366545576DD26FA3336336DC909D55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_F5649C70C7D2E5A44C566336DC8F55F1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_AD366545576DD26FA3336336DC909D55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_AD366545576DD26FA3336336DC909D55" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5487800B12EF94425DEC6336DC9031C5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1A43551FF2F47B912DE46336DC907338" xlink:to="loc_us-gaap_OverAllotmentOptionMember_4B74DF4EC3ACF7EAA79C6336DC900030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_AD366545576DD26FA3336336DC909D55" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_E0FE17FCB18B68E8C9946336DC91882B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:to="loc_us-gaap_SharePrice_839E3BF33CCD277127176336DC916166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9D1707F77BAD4BA736126336DC916C41" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_12EC3F87530383E65BD66336DC9151C2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9D1707F77BAD4BA736126336DC916C41" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CapitalizationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_29C47A093E99DBBE92196336DC94087B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_29C47A093E99DBBE92196336DC94087B" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10839C959FE96BE4737C6336DC94C513" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CapitalizationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_97E9C7EDAE90EBC1715C6336DC895F44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_97E9C7EDAE90EBC1715C6336DC895F44" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_02FE5FA0F806F9B4CC726336DC8962D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="loc_us-gaap_StatementClassOfStockAxis_02FE5FA0F806F9B4CC726336DC8962D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_02FE5FA0F806F9B4CC726336DC8962D6" xlink:to="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9EB4FE1F33DFD91CA15F6336DC8A0515" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6B3531A7517587F1B6416336DC8A4CF9" xlink:to="loc_us-gaap_CommonStockMember_9EB4FE1F33DFD91CA15F6336DC8A0515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_BD2BCA993A2AA68E0C176336DC8A9C1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_BD2BCA993A2AA68E0C176336DC8A9C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_BD2BCA993A2AA68E0C176336DC8A9C1A" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_01ABC7BE7BA0D6FB8A6F6336DC8BB288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_50C30E043B526F632D796336DC8AC1E0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_DC490359F759A13849176336DC8B3CAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_764BD450397171D91F806336DC8B1EF3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D3A73916AD960C9EBE766336DC8CF372" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6D3EB5612CB6278BE04B6336DC8B200F" xlink:to="loc_us-gaap_WarrantMember_D3A73916AD960C9EBE766336DC8CF372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9256299141EF2AC267BC6336DC892B28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_857D8D3E48A330875B1B6336DC8C88B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_D5C8445E9EB438C757346336DC8CB758" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7B4CBDAFCFD1D8E400C46336DC8C1330" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_99AE63AC217C18C2F4E76336DC1258FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_99AE63AC217C18C2F4E76336DC1258FD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BE36A37370531A3B77C56336DC131BC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_srt_ProductOrServiceAxis_BE36A37370531A3B77C56336DC131BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_BE36A37370531A3B77C56336DC131BC3" xlink:to="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AB179E42A72455B9B5196336DC1365C6" xlink:to="loc_us-gaap_ProductMember_C72DCB5B39FD47977F6A6336DC136225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_185E08CCB3EB35A22D286336DC1337C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_185E08CCB3EB35A22D286336DC1337C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_185E08CCB3EB35A22D286336DC1337C2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_EF9CE4FAEEEA0FC2C76F6336DC14856F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_EA914494A8B69FA20EAB6336DC14F6D5" xlink:to="loc_ptct_AgilisMember_EF9CE4FAEEEA0FC2C76F6336DC14856F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AB3F5D45F7D458DBFA3F6336DC14CEAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AB3F5D45F7D458DBFA3F6336DC14CEAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AB3F5D45F7D458DBFA3F6336DC14CEAF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_2563FC6BBFA16BA3289B6336DC15F4F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5718EFE01A20BF8630786336DC14A48C" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_2563FC6BBFA16BA3289B6336DC15F4F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_3299DAEEC34D3A5BBD8D6336DC15439C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_srt_CounterpartyNameAxis_3299DAEEC34D3A5BBD8D6336DC15439C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3299DAEEC34D3A5BBD8D6336DC15439C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_WellcomeTrustLimitedMember" xlink:label="loc_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:to="loc_ptct_WellcomeTrustLimitedMember_B0CE2D6AF43CF50A03336336DC158188" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AkceaMember" xlink:label="loc_ptct_AkceaMember_DB7415A8CB38D9DCEC996336DC163637" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1B31843C533D82AD00256336DC15CB09" xlink:to="loc_ptct_AkceaMember_DB7415A8CB38D9DCEC996336DC163637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3C908E67AAD179C661EE6336DC16BD4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_srt_RangeAxis_3C908E67AAD179C661EE6336DC16BD4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3C908E67AAD179C661EE6336DC16BD4C" xlink:to="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E6620AD89C232FB2E18C6336DC16D263" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9B70458597D0988B8B556336DC1680D7" xlink:to="loc_srt_MaximumMember_E6620AD89C232FB2E18C6336DC16D263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C6E563AAB135535441C46336DC121478" xlink:to="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0E8B04D9CFBAC9FCFBF16336DC16B939" xlink:to="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_UpfrontLicensingFee" xlink:label="loc_ptct_UpfrontLicensingFee_EE48CB5B125C0D33982A6336DC17FFA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_UpfrontLicensingFee_EE48CB5B125C0D33982A6336DC17FFA3" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_44F62A4C51E735A90C006336DC17B361" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_44F62A4C51E735A90C006336DC17B361" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_A5C85B5A16BE68D97AC56336DC17061F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_A5C85B5A16BE68D97AC56336DC17061F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_96D04595C10C8BA95F6B6336DC176C21" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_96D04595C10C8BA95F6B6336DC176C21" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_B33CF88A23BD516095456336DC184276" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_B33CF88A23BD516095456336DC184276" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_953D0BE72A652D4A0B3A6336DC1800C2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_256097F3778487B52FEA6336DC172225" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_953D0BE72A652D4A0B3A6336DC1800C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Company" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22C71E606083E63CB43E6336DD31FBC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22C71E606083E63CB43E6336DD31FBC0" xlink:to="loc_us-gaap_NatureOfOperations_A32F6EBA1AFA0C318F4A6336DD31D9D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CompanyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42630C7781D5B3C271846336DD265578" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42630C7781D5B3C271846336DD265578" xlink:to="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ACEB866374B084C144156336DD27FEE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ACEB866374B084C144156336DD27FEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ACEB866374B084C144156336DD27FEE5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_4877C1AD649331A05FBE6336DD289EAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E970F6BB73DCA3A2A2306336DD27E42A" xlink:to="loc_ptct_AgilisMember_4877C1AD649331A05FBE6336DD289EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B18643D23AFFA97EA7B96336DD281BE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_srt_ProductOrServiceAxis_B18643D23AFFA97EA7B96336DD281BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B18643D23AFFA97EA7B96336DD281BE9" xlink:to="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_TranslarnaMember" xlink:label="loc_ptct_TranslarnaMember_CE822651A68EA16386396336DD28DBFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_66E034F713200EF736256336DD28469E" xlink:to="loc_ptct_TranslarnaMember_CE822651A68EA16386396336DD28DBFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A05219FFA63084DEED506336DD29D6B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A05219FFA63084DEED506336DD29D6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A05219FFA63084DEED506336DD29D6B9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_7D1703395266F5C1ADA26336DD29D7E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_EFF2D384DC3EC819638E6336DD29DBE2" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_7D1703395266F5C1ADA26336DD29D7E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E102C76D43B7D70179036336DD293400" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_srt_CounterpartyNameAxis_E102C76D43B7D70179036336DD293400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_E102C76D43B7D70179036336DD293400" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MarathonPharmaceuticalsLLCMember" xlink:label="loc_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_B09C235EA71D5966C25B6336DD2AC4AF" xlink:to="loc_ptct_MarathonPharmaceuticalsLLCMember_5FA026B6AB16053975BA6336DD2AF85F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_811C046760239DA2C02D6336DD2AB1DE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_811C046760239DA2C02D6336DD2AB1DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_811C046760239DA2C02D6336DD2AB1DE" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_B0CA2D483E9674B426A36336DD2BF636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_46F70D1CCCE0634915186336DD2BB92A" xlink:to="loc_us-gaap_ConvertibleDebtMember_B0CA2D483E9674B426A36336DD2BF636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7F9D58C7847645681CD86336DD2B1F4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_DebtInstrumentAxis_7F9D58C7847645681CD86336DD2B1F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7F9D58C7847645681CD86336DD2B1F4D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_474C75C12B46D0C601816336DD2C6F52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B5646A180CC14863BF176336DD2B0C7E" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_474C75C12B46D0C601816336DD2C6F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A94614D364239E9034746336DD27CDD8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfProducts" xlink:label="loc_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_NumberOfProducts_AB601743B6073B78B07C6336DD2CB680" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfStatesInEuropeanEconomicArea" xlink:label="loc_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_NumberOfStatesInEuropeanEconomicArea_4E04D74455FBC80D46D46336DD2CE1F4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfCountries" xlink:label="loc_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_NumberOfCountries_309C6EEA233B446841326336DD2D8D91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_E1D253F1CF4870C366496336DD2D145A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_E1D253F1CF4870C366496336DD2D145A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B36F24A6CF2E8151EC086336DD2D7DF2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_B36F24A6CF2E8151EC086336DD2D7DF2" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity" xlink:label="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_3A7B6BAE3FFD5EA200546336DD2D94E5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity_3A7B6BAE3FFD5EA200546336DD2D94E5" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod" xlink:label="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_242CAD52C202589584D36336DD2DB4E8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod_242CAD52C202589584D36336DD2DB4E8" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_E0552F477DD36F2E81CB6336DD2DE160" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_E0552F477DD36F2E81CB6336DD2DE160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5027ADB58680D7592A2E6336DD2ED4B7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5027ADB58680D7592A2E6336DD2ED4B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_444C4B1A8899A9D353EE6336DD2E4E8F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E02BFD3CD5C87A0ADBD56336DD2C5755" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_444C4B1A8899A9D353EE6336DD2E4E8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D" xlink:to="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D708F5601AEBAD7335ED6336DD79D006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_E6D98B6CA90E547E7AB16336DD79FF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:to="loc_us-gaap_ReceivablesNetCurrent_C5B5FAB9F649D4FDD4466336DD7AE0F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4E843ECC716D93F728DC6336DD7AFEA6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:to="loc_us-gaap_InventoryNet_4E843ECC716D93F728DC6336DD7AFEA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_161252CF1D10CE266DA36336DD7A090C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_801F61799DA50EB73CF06336DD792684" xlink:to="loc_us-gaap_AssetsCurrent_8A35EB8C777E35B8DBA36336DD7AFA49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_71A05D8FC490FE7D47626336DD7A422C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3500CEAAA63DD21085326336DD7AB422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:to="loc_us-gaap_Goodwill_3702FE02F055BEB8A3896336DD7B2F43" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:to="loc_ptct_DepositsAndOtherAssetsNoncurrent_A6FE65F4B2F2CF75E8816336DD7B3C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_85EDA5106571CDB69B286336DD790EA7" xlink:to="loc_us-gaap_Assets_7586F6BE965BD095659C6336DD7B888C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_988EB81F89F8FDF3409D6336DD78392D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_946CC9AA44225C7C2C546336DD7C6103" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_946CC9AA44225C7C2C546336DD7C6103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:to="loc_us-gaap_LongTermDebtCurrent_3BEF390E235F52C118306336DD7CD9B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_54958BDD97486936EF496336DD7CF669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_292362DAF3C5629E9D6D6336DD7C67D7" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_CD7AA6BA640975186A7A6336DD7CBF8E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_CD7AA6BA640975186A7A6336DD7CBF8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_D7E2B9E75B2C4FE290006336DD7C1C34" xlink:to="loc_us-gaap_LiabilitiesCurrent_D7AE30A813F7BA57BFF26336DD7D2AD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7B55764FB6889FF19FFA6336DD7D4760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9F8AD4BFFB6C4C916C256336DD7D0724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13A1742F3AA16D30BC246336DD7D411C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_00D3542A16F2134334536336DD7D407D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_00D3542A16F2134334536336DD7D407D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF4E8AEC1B562C25E9AF6336DD7D3967" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF4E8AEC1B562C25E9AF6336DD7D3967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_34F3CC2EDAACC46F759C6336DD7E77A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_Liabilities_E1670903A295DC9494666336DD7E7E71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:to="loc_us-gaap_CommonStockValue_D048C9C97F005CDEF0806336DD7E41A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:to="loc_us-gaap_AdditionalPaidInCapital_EAABF4DDC82E1B87940D6336DD7E263E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EBB1498BDDED12F6E18E6336DD7E27D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A4BC3718B7404476175B6336DD7F7E79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_A4BC3718B7404476175B6336DD7F7E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_CA8355CDDC9B1D8ADEF26336DD7E012D" xlink:to="loc_us-gaap_StockholdersEquity_FA22C410FB31761847246336DD7FC3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E68D2A6EE68121EFE6756336DD7BC9EB" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_410D1C30425FFED9E2906336DD7FEC11" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1EECCFB91A99E310BDC96336DD6E16C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EECCFB91A99E310BDC96336DD6E16C9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F7E7577561916391B8456336DD6E16D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EECCFB91A99E310BDC96336DD6E16C9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6ACC86D4A51265CDB7ED6336DD6E0212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EECCFB91A99E310BDC96336DD6E16C9" xlink:to="loc_us-gaap_CommonStockSharesIssued_65DF17B191BFD9E1853A6336DD6E9E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EECCFB91A99E310BDC96336DD6E16C9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_C22B53E7DFFF447598526336DD6ECAEC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0718518E1F6A0A5D6AC3676CE62C1C88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:to="loc_us-gaap_NetIncomeLoss_0718518E1F6A0A5D6AC3676CE62C1C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_Depreciation_E0B57863C5C0A6AABCC6676CE62DFA69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3E101987E29C174C409B676CE62DD7A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2EC3B476DB4E44DC6425676CE62D5E84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2EC3B476DB4E44DC6425676CE62D5E84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_PaidInKindInterest_D36022FE47AEB3BFE5F7676CE62DFC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_1AEC885FCCC9A3EB03CE676CE62D7FA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D9B0F1A17B376F269662676CE62E6969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_F0D6ACB241B1CB94F1D7676CE62E9DC6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_F0D6ACB241B1CB94F1D7676CE62E9DC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_ShareBasedCompensation_1595E33E017649748D91676CE62EBC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2C8972BB3160E1914B65676CE62ECA7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BEFA50F2B6F78B6D1837676CE62DB542" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_67842F74E186B1E26807676CE62EE662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D929EBB783D8DEE17593676CE62F539F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_5333927815274110AAAB676CE62F6C75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_84084BBCB4CD3D0A51ED676CE62F2ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_E2599AE4DE930B9CAAFA676CE62F4288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_D87DDEAAA09E962F4305676CE62F868B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76FE1FF278C5610BA8A9676CE62E6B08" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_FFC13CF209D372AC5575676CE62F4218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9A90E24036D8A65B4521676CE62CE043" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4B39A12985E1EFCD49B8676CE630DED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_217259427BC67B2BDCA8676CE6308C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_53908F8B9B590422DA3C676CE630EBAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_08AB56276A38BAA35167676CE630BBC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_A02C84AC42A3D57F4D56676CE6303C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_E7B992FF0C988853FC95676CE6316E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_E21EF4A51DAD0B0CFBA2676CE630CDB4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2A572855940D7CC52419676CE631D576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_103D090C4FBB80BE2855676CE631E6E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2EE5D78B552831BC805E676CE631EDE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_E313BD6602991EE4FF25676CE6327C55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:to="loc_us-gaap_RepaymentsOfDebt_E313BD6602991EE4FF25676CE6327C55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:to="loc_us-gaap_ProceedsFromStockPlans_E09BE59F31FF8CDBB5B4676CE632A584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_6CFF3919D6D4E2A54F20676CE631BBB0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ECCE4F55E0FCA3EA293676CE632BDDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_120AE88E1C1C39068F2B676CE632CC2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_9D8C928BE2AA511C0497676CE632816B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5B81DA706681D9FE6E6A676CE632EB44" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5B81DA706681D9FE6E6A676CE632EB44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18D48D5CAC9DDF0E3180676CE6339131" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18D48D5CAC9DDF0E3180676CE6339131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:to="loc_us-gaap_InterestPaidNet_0004AE8D606A9DF3DD30676CE63346B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_70C81E6098687DA28C93676CE6337936" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_370B69D08D03088D8C59676CE633A64A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_13A360879D2E0BC89BAD676CE62C38F1" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9888936DAE5FA8AF88EA676CE633AC4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9888936DAE5FA8AF88EA676CE633AC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_FF92907ABA1ACFE1040C676CE634D513" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_FF92907ABA1ACFE1040C676CE634D513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_D6B8997106190B3532A8676CE6332E00" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9BB303FAC5E4FE4BB4EB676CE634B03D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:to="loc_us-gaap_NetIncomeLoss_8DC75ED9C394F178535267A6576DD8A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_C2EA9C3D58116B1408B967A6576DC2CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1DB739060D315D3F80AB67A6576DE145" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_DFABA3BBD82A41D7A55567A6576D595C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59564405324FD178703F67A6576C57FE" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2E7542DF26EF02495C9A67A6576E1193" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_8AFCF4E2E6465C9780716336DD632B07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_15E514896AB0CB17EB496336DD639E88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8AFCF4E2E6465C9780716336DD632B07" xlink:to="loc_us-gaap_StatementTable_15E514896AB0CB17EB496336DD639E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_461318CFF4659AEB98C66336DD63ABC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_15E514896AB0CB17EB496336DD639E88" xlink:to="loc_srt_ProductOrServiceAxis_461318CFF4659AEB98C66336DD63ABC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_461318CFF4659AEB98C66336DD63ABC7" xlink:to="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:to="loc_us-gaap_ProductMember_9ECC95EEC05A2DED307D6336DD644FEE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_GrantAndCollaborationMember" xlink:label="loc_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_360965CA5C94D8CC83246336DD63AD9C" xlink:to="loc_ptct_GrantAndCollaborationMember_81BAD6EDEC1ADFEEBF656336DD648B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_15E514896AB0CB17EB496336DD639E88" xlink:to="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_203A06A7E3E6B3AB434B6336DD649A70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_203A06A7E3E6B3AB434B6336DD649A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_EDD2292A666838C982586336DD65FC15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0B74969064BF77DE4DE56336DD65EB93" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_EDD2292A666838C982586336DD65FC15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_89C819C5D6CC90ECD1656336DD657F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_867B1B67D6A4C49505FC6336DD66CE30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_867B1B67D6A4C49505FC6336DD66CE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_CC249F7DF8CC230C82496336DD66A8BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_CC249F7DF8CC230C82496336DD66A8BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F9F321230D00390E24526336DD6676D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_A4657987B080E66822936336DD66747D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A70EA69F3F52691CC5A86336DD65E779" xlink:to="loc_us-gaap_OperatingExpenses_BA93259E2545D83765D56336DD6695CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_OperatingIncomeLoss_84A06191AE108B6D533A6336DD66BCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_E54415CA06C4D3D946DF6336DD67F1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_F191FEE65DDA8154AA0D6336DD67D83D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_104DF7A99693DC0855116336DD679949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8DD18FC924B51FA29E736336DD678FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_NetIncomeLoss_CFF7D7C28E9B403F87E86336DD67D118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_BEF61F26C7D1FFB7D53C6336DD67684F" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81C0700FC1B866742BEE6336DD6807CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_46EDF246948C3C5FDF896336DD64AAD8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BC2AD429B5A5D19CFCFF6336DD686416" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_65F08997045A1EB5327C6336DD68ED50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_12C0B4C8DD2599C9A71267CEC099E164" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_12C0B4C8DD2599C9A71267CEC099E164" xlink:to="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32D4024FF758C023B6E267CEC09CD10E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32D4024FF758C023B6E267CEC09CD10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32D4024FF758C023B6E267CEC09CD10E" xlink:to="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FE36D9479BBB9B5A057467CEC09CDC4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_CommonStockMember_FE36D9479BBB9B5A057467CEC09CDC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9800C7A0C58BDAF39B5C67CEC09D9346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C624E308DDB693F5154D67CEC09D7306" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C624E308DDB693F5154D67CEC09D7306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_61BC5BFC98002575846067CEC09C7BA3" xlink:to="loc_us-gaap_RetainedEarningsMember_F186BD477106B25AAEB167CEC09D3C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DA9732A78CD803A5E68E67CEC09B79D3" xlink:to="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_535FE6B2C9B0A73B571167CEC09DFC81" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_SharesIssued_B9AF6282A645397AAA7C67CEC09EA976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6CAD7EAB05151772157267CEC09EA81C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockholdersEquity_6CAD7EAB05151772157267CEC09EA81C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_42D427E1E2A181401D7C67CEC09E97BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_FC77869457CDC055634C67CEC0A01C83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2DFD575F9B57DA8CEB6E67CEC0A08CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_146933E9662F16D4005767CEC0A0FCD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0D6B63B7A13004CC150467CEC0A15416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_06C81DA1EB876C76C4A567CEC0A182BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0DB6BEF731B4EAD8DE6067CEC0A1D5BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_F33493E5FE1C74E38D4F67CEC0A13DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_E53697A9E6336301FD4E67CEC0A176EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_77BFDAD15723A57A3D3467CEC0A182F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_45E212EDF313F3F53EB867CEC0A2D1D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B8323B16C57B4BD65A4A67CEC0A2CA31" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor" xlink:label="loc_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor_00243489D74F3F4B9BC467CEC0A72648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2F718117F59FE913D06267CEC0A71232" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_NetIncomeLoss_2F718117F59FE913D06267CEC0A71232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_02FF6225E92DDB07999467CEC0A89BEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_4C95DAF84F8248C3FB4A67CEC0A8F5CA" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_SharesIssued_4C95DAF84F8248C3FB4A67CEC0A8F5CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_AD5C25838F171B760CB967CEC0A8A206" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2BABB36A38EDD8D1022067CEC09E1A67" xlink:to="loc_us-gaap_StockholdersEquity_AD5C25838F171B760CB967CEC0A8A206" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_DocumentType_FBDA67F01B26E889C4836336DD8A9FDB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_DocumentQuarterlyReport_5DA2F9C8804B2EDC2F0A6336DD8B666A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_DocumentPeriodEndDate_603CD54B85079D3B3E566336DD8B2C34" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_DocumentTransitionReport_1044EDC19CC76DD4C6686336DD8B3632" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityFileNumber_A9C5CFFF0ABC36E7B0FA6336DD8BC56C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityRegistrantName_5C6DD908E8920716F6B66336DD8B29E7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityIncorporationStateCountryCode_BABA834C1F1F8C8835DB6336DD8C4E61" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityTaxIdentificationNumber_6F25F297B0D68C5CACB26336DD8C5FBE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityAddressAddressLine1_D183C5B1554E40B775ED6336DD8CB6B2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityAddressCityOrTown_E433548D21FBD2E879B26336DD8C3CB8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityAddressStateOrProvince_443F3CEE9ACA76EA723C6336DD8C1ACF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityAddressPostalZipCode_884389BD4FAC43AACEA46336DD8CE26A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_CityAreaCode_AF9F14749457F59429186336DD8DCAD0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_LocalPhoneNumber_E4F8D4433DD8731B08366336DD8D748B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityCurrentReportingStatus_D16DE0609FDFF523D7086336DD8D66F1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityInteractiveDataCurrent_3AF3835C530A73BD4E1A6336DD8DF738" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityFilerCategory_CC019774D9E87772EDC96336DD8D26A4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntitySmallBusiness_321A782307900E2BC2D46336DD8EF48F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityEmergingGrowthCompany_E196C0C0DF542083053B6336DD8EC5F0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityShellCompany_A3FAEA3AFA2D393F68B56336DD8EA6BA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_Security12bTitle_69396A667C741CB10F836336DD8E7AC1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_TradingSymbol_6DAEC1BD9BAE6A4A143C6336DD8E6215" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_SecurityExchangeName_4E3E2B6893BCD941D6016336DD8F6B81" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_A1BB3726C8963F6F87986336DD8AAF60" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_75F10C4D7A4264FD3BDE6336DD8F9D68" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CoverDei" xlink:type="extended">
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_019CB475B797994D8FB16336DD852116" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_019CB475B797994D8FB16336DD852116" xlink:to="loc_dei_EntityCentralIndexKey_CC48FD0D28F4C9894C036336DD85CFA1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_019CB475B797994D8FB16336DD852116" xlink:to="loc_dei_AmendmentFlag_4C693249DF364031733B6336DD8526EC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_019CB475B797994D8FB16336DD852116" xlink:to="loc_dei_CurrentFiscalYearEndDate_0C61C763AF424D41644E6336DD852C68" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_019CB475B797994D8FB16336DD852116" xlink:to="loc_dei_DocumentFiscalYearFocus_9D2C54A8BFE387BF38D26336DD869FB3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_019CB475B797994D8FB16336DD852116" xlink:to="loc_dei_DocumentFiscalPeriodFocus_BFC313298E7FE29A338D6336DD8651F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F7F00CC1CAE86968B4306336DC43AFB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F7F00CC1CAE86968B4306336DC43AFB2" xlink:to="loc_us-gaap_LongTermDebtTextBlock_EA14C01A58EAD2D2C62C6336DC431EAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C05F55A3EEB1D90945EC6336DC27C267" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C05F55A3EEB1D90945EC6336DC27C267" xlink:to="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_D9336DE62A9B886EEE4D6336DC27D44A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:to="loc_us-gaap_DebtInstrumentAxis_D9336DE62A9B886EEE4D6336DC27D44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_D9336DE62A9B886EEE4D6336DC27D44A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_687CB83CDCF6C22ADEA16336DC287DE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FA659FEEB5B250F956E56336DC28496B" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_687CB83CDCF6C22ADEA16336DC287DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9F69453CA45CA53E305E6336DC28382B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9F69453CA45CA53E305E6336DC28382B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9F69453CA45CA53E305E6336DC28382B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_FE132556274F89695EE56336DC29644E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_02994669C35CC95C720D6336DC28E5EF" xlink:to="loc_us-gaap_ConvertibleDebtMember_FE132556274F89695EE56336DC29644E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9CACAC804DCB9491FDAF6336DC27F46C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_945A2A3683956F421F846336DC29DD39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_945A2A3683956F421F846336DC29DD39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_F7E45F7B5499290C08E16336DC29A4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32CD7DFEDF8848CB5FC66336DC2A6FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D14965F7FBDAD34D3C216336DC29E24E" xlink:to="loc_us-gaap_LongTermDebt_13FC65FA96C45E571CB46336DC2A11FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8D0FCF7EF8D15D91204D6336DC1F5E3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8D0FCF7EF8D15D91204D6336DC1F5E3F" xlink:to="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9AD97C34EADCF69C159C6336DC209807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9AD97C34EADCF69C159C6336DC209807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9AD97C34EADCF69C159C6336DC209807" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_682192987C444556B4C36336DC200F54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_F5A3103D3AF4D738D40B6336DC20CCC6" xlink:to="loc_us-gaap_ConvertibleDebtMember_682192987C444556B4C36336DC200F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_981AE88351CC574C17416336DC215B35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:to="loc_us-gaap_DebtInstrumentAxis_981AE88351CC574C17416336DC215B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_981AE88351CC574C17416336DC215B35" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_1E47209D8AAA19D2548A6336DC217E09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D96F3DE21A21761772A26336DC21240E" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_1E47209D8AAA19D2548A6336DC217E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_66AF71C7BA6D3B09375D6336DC1FC9ED" xlink:to="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_CCA4D3D567D085BC6D206336DC217F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_32062495CEC7525B6DAE6336DC22C0DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0C3137EA69F3A68F49F26336DC22B35F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_InterestExpenseDebt_9538360AC812710BCFED6336DC226D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C79EA0519979782503106336DC21CD7D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78AF51B3A5902FA0BB1B6336DC22C5C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E331462BAD698F52B0866336DC33134D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E331462BAD698F52B0866336DC33134D" xlink:to="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_AEEFF00F412E7025F1A26336DC336390" xlink:to="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MidCapFinancialTrustMember" xlink:label="loc_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_10D6FF1F2005EBA12D416336DC33063C" xlink:to="loc_ptct_MidCapFinancialTrustMember_482DDA0A7C4D0360C5146336DC34E4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FEACA4F3F36DFE593FDF6336DC340C7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FEACA4F3F36DFE593FDF6336DC340C7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FEACA4F3F36DFE593FDF6336DC340C7A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_DAE8C80332B827B53DBE6336DC347A91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E397313E39F6E5C041246336DC34BDB9" xlink:to="loc_us-gaap_ConvertibleDebtMember_DAE8C80332B827B53DBE6336DC347A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F517E8F6A5C6567F93BC6336DC3551F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_DebtInstrumentAxis_F517E8F6A5C6567F93BC6336DC3551F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F517E8F6A5C6567F93BC6336DC3551F8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_0C05D9FC4493D3977A9F6336DC353EB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D05C9B28B28F357005996336DC351CD9" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_0C05D9FC4493D3977A9F6336DC353EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_B2EF0F925DC2C2948D9F6336DC35EF46" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member" xlink:label="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_D4EA0DB298C27DAE8C226336DC35C059" xlink:to="loc_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_C6BD66A0E6BB1DD4B4796336DC36B4B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86487275E761A1738C7B6336DC3335D9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B52283FDFDD604BD04526336DC36D09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_A1530AD5E81E1A0E8E3B6336DC36A2DB" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LineOfCreditFacilityAdditionalCapacityAvailable" xlink:label="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_LineOfCreditFacilityAdditionalCapacityAvailable_C4BCBF22B72FF7885C296336DC3684A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_F83DEAD665F73F39E1256336DC37DCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_RepaymentsOfDebt_BED3AC48A11B49036DDC6336DC371B3D" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentFloorInterestRate" xlink:label="loc_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentFloorInterestRate_B4F23FFB0970BF4027C26336DC37ABFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_D9BE4A6BD8AD6DEC37AE6336DC37C881" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentInterestPaymentPeriod" xlink:label="loc_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentInterestPaymentPeriod_5765CC5E5D840748317E6336DC37026F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_53D0C622FBCCD978C1D66336DC382CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC3A849D8C9BE70C53276336DC3853C0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EC3A849D8C9BE70C53276336DC3853C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8CE92157F6DA21EB9B666336DC388233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1763E844F89F1C45CED76336DC3801DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_3B486D900F409D57BB0B6336DC383163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_2546EF52D05904A3A0236336DC38B389" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdBusinessDays" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdBusinessDays_B14ECE010DCFE05AB0D26336DC38144C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod_D353EFE66100E26BE9E26336DC39D2B1" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="loc_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_40C92232F6F5600F5CC36336DC39EC4C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum" xlink:label="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum_244AE8FA7BD2FE315F216336DC39B402" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1702197119E5E0D972F76336DC395FE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_520D20F70AFC9FBA1D1C6336DC39B987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_971867955991D49591C66336DC396EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCumulativeSinkingFundPayments" xlink:label="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentCumulativeSinkingFundPayments_FCC4E50900F54E89AC756336DC3A32CD" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault" xlink:label="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault_85BCB90DC71B941DE11C6336DC3A04F7" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders" xlink:label="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders_CE88BD51DBDD99FD9C9B6336DC3AD9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentTerm_570E8D276B4B22BE65AE6336DC3A7467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9E14868A7A324FB6593F6336DC3A62A0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments" xlink:label="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments_97058BCC27480DC74C236336DC3ADD8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4E5C7A377B075CB348666336DC3BA6D8" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4E5C7A377B075CB348666336DC3BA6D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9FE0B7A69C7E516B4F916336DC3665CC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_E4C7BE41600CD0E44B016336DC3B290D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A85DD3D2EF8A1FB6D39B6336DC4145A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A85DD3D2EF8A1FB6D39B6336DC4145A9" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_E6F2AF306919D15CBAB06336DC41FA24" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock" xlink:label="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A85DD3D2EF8A1FB6D39B6336DC4145A9" xlink:to="loc_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock_D9C23E8F2CA74FD064C36336DC4178E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83B67753EC39EEF69E8E632CAB562DEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83B67753EC39EEF69E8E632CAB562DEF" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_C8B8FD829CC53B4ADD76632CAB57E726" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ECFC5B8991A92F245914632C612F6182" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ECFC5B8991A92F245914632C612F6182" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E501D218BA3E903C5015632C6130FE62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_2A73D5F74CA82D1A61FA632C613110A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_2A73D5F74CA82D1A61FA632C613110A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6FC14C7EEF8BC08122B5632C613129E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6FC14C7EEF8BC08122B5632C613129E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_62A37EBB4892B8A0E2D3632C6131CCEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3530C906B7AB03608C11632C6130BC64" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_62A37EBB4892B8A0E2D3632C6131CCEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7AB5FAB98F99C11F5BB0632C6130740F" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D95FBFF2631C55B8E408632C61312107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E20BB867C46DA377B38F632C613282BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1237F4B6480AF31A41D3632C61320222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_E8FBB713ED52784F8FC4632C6131A8D0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0275906DB2878E71AACD632C61320CD1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4EC4FC3E8E3933DF85066336DCCF766D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4EC4FC3E8E3933DF85066336DCCF766D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4C0FD0B7BA5B0A3A30EF6336DCCF30ED" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_7768C8B13EFB1F25E3606336DCCF64B0" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_DC93D1717146A5C96EAC6336DCD09068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_163B3FCCEDCCED2FA8866336DCD0C6F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_163B3FCCEDCCED2FA8866336DCD0C6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_163B3FCCEDCCED2FA8866336DCD0C6F8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_65D3265C35C2129CC39B6336DCD03E11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_E5289AF8268AC0B1286A6336DCD030D5" xlink:to="loc_ptct_AgilisMember_65D3265C35C2129CC39B6336DCD03E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_D06E501E5FD056F1B8E66336DCD14F86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_D06E501E5FD056F1B8E66336DCD14F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D06E501E5FD056F1B8E66336DCD14F86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember" xlink:label="loc_us-gaap_CommitmentsMember_545ACED46955CBC2216F6336DCD1AC88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_236C420CD569A4F2B4EC6336DCD15A1D" xlink:to="loc_us-gaap_CommitmentsMember_545ACED46955CBC2216F6336DCD1AC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C0A0A7DE3AC922B775836336DCD1106E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_AwardTypeAxis_C0A0A7DE3AC922B775836336DCD1106E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C0A0A7DE3AC922B775836336DCD1106E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_4F1E004E1FE379EEC71B6336DCD2E291" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D606E2FF92A96AF009EF6336DCD21D5E" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_4F1E004E1FE379EEC71B6336DCD2E291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0E46BB2DB2358EDF593F6336DCD2A520" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0E46BB2DB2358EDF593F6336DCD2A520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AD04671FA0A5A3C32AD6336DCD20234" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0E46BB2DB2358EDF593F6336DCD2A520" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5AD04671FA0A5A3C32AD6336DCD20234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74F89F782E3A4DC070716336DCD2283E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11D641F900F08A133A826336DCD33B0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9C7BFFE265104268CEE56336DCD33C66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6EDFF9A8D7063B3976E46336DCCF3BFE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_A45822D6DCEE4089729C6336DCD38A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2A75270BA02A7346E85E6336DCD45DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_734270CFF0FA855259BE6336DCD4482D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2EAF16F724247A45EA226336DCD33EC2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_82B972BE8BEB7BF091336336DCD46938" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_671802A5001D611994136336DCD99A26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_671802A5001D611994136336DCD99A26" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_51AF0162F6168B32A74F6336DCD99717" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_51AF0162F6168B32A74F6336DCD99717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51AF0162F6168B32A74F6336DCD99717" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_263E1769E7688C061E576336DCDA1166" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2EA0F27914E7F771FFC96336DCDA42FE" xlink:to="loc_ptct_AgilisMember_263E1769E7688C061E576336DCDA1166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FA84217E113DE17453BB6336DCDAB0B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FA84217E113DE17453BB6336DCDAB0B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_FA84217E113DE17453BB6336DCDAB0B5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_F27D7C7FF2E37D66EF626336DCDA4787" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0A8787A516D64957D7B86336DCDAE981" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_F27D7C7FF2E37D66EF626336DCDA4787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_575307E3FB8FAAF639766336DCDB5A63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_575307E3FB8FAAF639766336DCDB5A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_575307E3FB8FAAF639766336DCDB5A63" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_54287C5CF59A3F53431B6336DCDBE468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_60935F99D192A6E0ADEC6336DCDC8022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4FA8E03BDEBA38112F5E6336DCDC71BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A5451C3982F41B43AA436336DCDB367B" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4FA8E03BDEBA38112F5E6336DCDC71BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_35503290A384E2B53E8C6336DCDCDFA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_35503290A384E2B53E8C6336DCDCDFA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_35503290A384E2B53E8C6336DCDCDFA4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6047A596F2CB427B3D886336DCDC8A64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6047A596F2CB427B3D886336DCDC8A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8894A2285E85EE13223B6336DCDD00FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A97413F9978D60A20AFC6336DCDC2C2F" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8894A2285E85EE13223B6336DCDD00FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6FD15277DE6F867B450E6336DCD94216" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2ED6EC798ADE98AE49656336DCDD15B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3272A092813153C90D716336DCDD9321" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_StockAppreciationRightsLiabilityOutstanding" xlink:label="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_ptct_StockAppreciationRightsLiabilityOutstanding_2CABE981E60C48DF6FA16336DCDDDA6A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_88AD25420FB7B41E78C46336DCDD130F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_88AD25420FB7B41E78C46336DCDD130F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DAC8570281BE4D4246876336DCDEE7E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DAC8570281BE4D4246876336DCDEE7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6053FA8E7F766B323A146336DCDEAD3C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_943D52CD49B1A141181D6336DCDDC160" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6053FA8E7F766B323A146336DCDEAD3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ED712B7F9CE4E5E504026336DCC212AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ED712B7F9CE4E5E504026336DCC212AB" xlink:to="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:to="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0BD8D0B8ED68B4FAE4816336DCC39570" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_44FAC4833DDAECC48B3F6336DCC35B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_C285E923AA483742E4746336DCC3E231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_804679CF8370F2DDBE906336DCC32A73" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_3D468C0A796E60F0ED276336DCC48155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_38FF2F2D0F2C456946F36336DCC2E24E" xlink:to="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7E4FFA30639A2EC798916336DCC42EAD" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue" xlink:label="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_090A8B1118BA34DA3F076336DCC4B34E" xlink:to="loc_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue_3E1B9FC5241137EEF0FF6336DCC4653B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8316CBF32AD86AECC928632CA85E1295" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8316CBF32AD86AECC928632CA85E1295" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentAxis_821641D7CEACF96BE832632CA85F576E" xlink:to="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentDomain_841312990C246A9B4A8E632CA85F4888" xlink:to="loc_us-gaap_CommonStockMember_A6899915A0EE60D981E6632CA85F4090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_676E1983380FB31F8B5F632CA85F83D6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_58A71B694F5445E8D19E632CA860D0CD" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_20286D30C6DD687142C0632CA8604018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_318D87535A849A8BA76B632CA860608F" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_D3F7A8A970A6B051B102632CA861503B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5A703AC97E2510B5E3F3632CA860A4C4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_E8B0DF3F09A4101F4D83632CA861D109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5A9C46202B730D81D977632CA861747B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07111920AD334176AEEE632CA861255B" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_F6554B1C206A7C164F8C632CA8627F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DA2E597EAA7A71E3148D632CA862E1C1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C210BA1D817CA6091777632CA862FE70" xlink:to="loc_ptct_AgilisMember_21D159E5A05A6D3F2E1D632CA8628FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_48D57D585EDE7AE09B41632CA863D8FC" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3EECD3EAA11DFC44D28E632CA8639693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_F818A3F5042D29240A87632CA863C388" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_D97EC8B7F40B24F09A63632CA8634C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6F1C9BEF331E6E5A6999632CA8632538" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ConvertibleSeniorNotes3.0PercentDue2022Member" xlink:label="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1B57045E2E68EE100480632CA864079F" xlink:to="loc_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_BEB58C3F587EC9EACD63632CA869CAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C8A14BDEB240048C8785632CA8690516" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584132F503DD1EE21AC3632CA86A45DF" xlink:to="loc_us-gaap_ConvertibleDebtMember_CCA93B2636EE7BFBE0A3632CA86A890E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0229E338EFC85AB8FC49632CA86A3337" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54D2E02EA68B66362E2D632CA86A4221" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_5EA2D06161ACEBB57D7F632CA86BECB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_69C7F9BFAFF9590D84F6632CA86B8199" xlink:to="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:to="loc_srt_MinimumMember_D59AB2525939C82C24E0632CA86B4635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CC9C0E51ED8326C74767632CA86BE4C2" xlink:to="loc_srt_MaximumMember_B9811EFE2EE5DC56B71F632CA86C1A72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3FDA444E7BB2A97C7A0E632CA86C26D5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:to="loc_us-gaap_WarrantMember_A198FBE6CCE5052718BD632CA86C5171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember" xlink:label="loc_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_D266252A20D11EDA5FDA632CA86C6C6D" xlink:to="loc_us-gaap_CommitmentsMember_084A2D0991A36679DB0E632CA86C71A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_A3602753AD845398DC33632CA85E8672" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:label="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_InvestmentOwnedBalancePrincipalAmount_85AC51E5A0903C117363632CA86D9F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_5A9F3AF4EFB80E0644AC632CA86D8A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_41541C5A8D6554FEFB70632CA86D0B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_41BC82F19B83475CA2CF632CA86EB79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_64AD30E6A4DA204F2F68632CA86E3A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_SharePrice_4032A103FE76662E883C632CA86E2C9B" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage_9FB81025BD94CC6DEC37632CA86E9099" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_611169301520CAD11645632CA86EB154" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount_7A325246FF3F1459A73F632CA86EBB00" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone" xlink:label="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone_3CC57AE1E6601F108B5C632CA86E6AB4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable_B0C54A3814B070328E26632CA86F467B" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent" xlink:label="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent_21639B5A5294C049F8EB632CA86F6C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_6FD03FB17702849ED9A1632CA86F64A4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_InvestmentInMRI" xlink:label="loc_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ABE41B9F64104A0A7C3632CA86D30DC" xlink:to="loc_ptct_InvestmentInMRI_343A87DF1502291AA46D632CA86F088B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_756098079BE45E43622B632CAD0E3E73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_756098079BE45E43622B632CAD0E3E73" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_44BF118A72262E6D29FE632CAD0E1286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_756098079BE45E43622B632CAD0E3E73" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_CA232A4EE7B229C0D659632CAD0E5FEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_756098079BE45E43622B632CAD0E3E73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_D9A81D8B4668FEFFC9D3632CAD0EC923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_756098079BE45E43622B632CAD0E3E73" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_56FB2885586573CB97A0632CAD0E112D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_756098079BE45E43622B632CAD0E3E73" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_E60F01FD1BA202D434E2632CAD0F36D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_756098079BE45E43622B632CAD0E3E73" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2AD1822012B4FB8D18EB632CAD0F2DD8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4A6F1B0344AE66D385FB6336DCC7BE6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B88C2CB0F683FC6053BA6336DCC8DEF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4A6F1B0344AE66D385FB6336DCC7BE6A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B88C2CB0F683FC6053BA6336DCC8DEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2080C931B9C7AAC53E446336DCC8A319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B88C2CB0F683FC6053BA6336DCC8DEF1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2080C931B9C7AAC53E446336DCC8A319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2080C931B9C7AAC53E446336DCC8A319" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_90800AB9176DBD3A36756336DCC8B49C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_90800AB9176DBD3A36756336DCC8B49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6C44BF9CA6207E61914E6336DCC9253B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6C44BF9CA6207E61914E6336DCC9253B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_35B58CD090F1EDF7B4216336DCC972CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_063B0D232F58B14705486336DCC8B711" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_35B58CD090F1EDF7B4216336DCC972CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_B88C2CB0F683FC6053BA6336DCC8DEF1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3D982D85E8CE5FFEACA26336DCC92798" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9EB6D90F3660B3DA53A46336DCCA4439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7517D522F13EA89A97076336DCC9F216" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_B713803F4DAE5F1BE5DC6336DCCAFA2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2EE68564EEB0071C07A86336DCC9586A" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_9E3951698F3170B34FB16336DCCA117E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_7599250F3F36D6E98D046336DCCB96AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_C8EEC931C35B17961F0C6336DCCA1809" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue_AA6A5128DA0B77E4836A6336DCCBDF6A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9431CC3118E08ABE5ADF6336DCB24ACA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9431CC3118E08ABE5ADF6336DCB24ACA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CBA7615D41D2494576A76336DCB28BE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CBA7615D41D2494576A76336DCB28BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_CBA7615D41D2494576A76336DCB28BE2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0FBB9278CA7F2F3F11856336DCB362BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_94F3E3421EFBFC63B2036336DCB3AA0E" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0FBB9278CA7F2F3F11856336DCB362BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AB93D6DEEC2FF57148606336DCB390A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AB93D6DEEC2FF57148606336DCB390A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB93D6DEEC2FF57148606336DCB390A4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AgilisMember" xlink:label="loc_ptct_AgilisMember_04F0BFB145E260249ACC6336DCB4821F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5D3F276554D95BBDE7B16336DCB3E6C6" xlink:to="loc_ptct_AgilisMember_04F0BFB145E260249ACC6336DCB4821F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_7F968EE7C2512A6806226336DCB456EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_7F968EE7C2512A6806226336DCB456EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_7F968EE7C2512A6806226336DCB456EA" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityNetSalesMilestonesandRoyaltiesMember" xlink:label="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_5BD9DD57A6F5AA96BF486336DCB539FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:to="loc_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_5BD9DD57A6F5AA96BF486336DCB539FE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LiabilityDevelopmentandRegulatoryMilestoneMember" xlink:label="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2DA67B6F1023CE7D4A766336DCB4BAE4" xlink:to="loc_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_CC373270A201B3536DA36336DCB59103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B92E1238C71DA91683856336DCB52449" xlink:to="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_37587C92D56C17CE2D136336DCB53054" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CB5FE28ECB0FACB7815D6336DCB53D68" xlink:to="loc_us-gaap_CommonStockMember_37587C92D56C17CE2D136336DCB53054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1BBA1CBDC17A63F572A56336DCB6D47B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_srt_RangeAxis_1BBA1CBDC17A63F572A56336DCB6D47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1BBA1CBDC17A63F572A56336DCB6D47B" xlink:to="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2E1B4745BACB927FBEAD6336DCB69FAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:to="loc_srt_MinimumMember_2E1B4745BACB927FBEAD6336DCB69FAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3A380655A43BD17417346336DCB6C556" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_67DE5568CB99995FBA626336DCB6FA20" xlink:to="loc_srt_MaximumMember_3A380655A43BD17417346336DCB6C556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_A05F9AEA74D182CA8D7D6336DCB7545C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_A05F9AEA74D182CA8D7D6336DCB7545C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_A05F9AEA74D182CA8D7D6336DCB7545C" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_58D1DA17DE984074C6A76336DCB74F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_76F1867D4CC33CF14F2A6336DCB75420" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_76F1867D4CC33CF14F2A6336DCB75420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_872E9306C23B70613A616336DCB8532B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_872E9306C23B70613A616336DCB8532B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_00BB7C3A2AA9A8857AB66336DCB8EF58" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesMilestonesMember" xlink:label="loc_ptct_SalesMilestonesMember_8FF59A6B56691DC4729F6336DCB8FEE9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_SalesMilestonesMember_8FF59A6B56691DC4729F6336DCB8FEE9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ProbabilityofSuccessMember" xlink:label="loc_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_ProbabilityofSuccessMember_DD2626C637A3DBA7687B6336DCB86E04" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_PercentageofSalesforRoyaltiesMember" xlink:label="loc_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_PercentageofSalesforRoyaltiesMember_0D1FF3EEF5F9136AD69A6336DCB84CF4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentandRegulatoryMilestoneMember" xlink:label="loc_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_ptct_DevelopmentandRegulatoryMilestoneMember_9E9C6711D1F4346E337C6336DCB8FA2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_C9CED468DEDA480C42AB6336DCB7D74C" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_E00E2CC75310BC136A206336DCB98D34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_FA0DD74FE9B8C1F764816336DCB920FA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_FA0DD74FE9B8C1F764816336DCB920FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_FA0DD74FE9B8C1F764816336DCB920FA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_DBEEF1AD05CC919F3DC06336DCB9162C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:to="loc_us-gaap_WarrantMember_DBEEF1AD05CC919F3DC06336DCB9162C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsMember" xlink:label="loc_us-gaap_CommitmentsMember_D7FC12D405CB99AF28126336DCBA1C97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:to="loc_us-gaap_CommitmentsMember_D7FC12D405CB99AF28126336DCBA1C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_11918C48402F334659A86336DCBA0D44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_396ECCBAA0C558B9D4F76336DCB913E6" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_11918C48402F334659A86336DCBA0D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_EEF55D6568AD5D940FBB6336DCBA454C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_AwardTypeAxis_EEF55D6568AD5D940FBB6336DCBA454C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_EEF55D6568AD5D940FBB6336DCBA454C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BBB01CAEFE8BCA457F126336DCBA7A4C" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_11918C48402F334659A86336DCBA0D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_331DB8AE69D0D06414236336DCB29C27" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_AE5C13DE72EA10E806E06336DCBB7FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8B18E9929B5327D250766336DCBB3813" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AlternativeInvestmentMilestone" xlink:label="loc_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_ptct_AlternativeInvestmentMilestone_06FBC9CA5E12E2BBC6846336DCBB9C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3FEA68A57556E0163EDD6336DCBAFCD0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_521C10F337C6392E72D16336DCBBC657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_A372617558F2321DB8B16336DCBC59E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_A372617558F2321DB8B16336DCBC59E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1F44FFD4DCC85C18B6D56336DCBC4481" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1F44FFD4DCC85C18B6D56336DCBC4481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_FCA746A634C753BD2A296336DCBC9419" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_FCA746A634C753BD2A296336DCBC9419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DAD2E764FBC144F8A0316336DCBC31DC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_02C8E2A88D7ADD3F3B536336DCBB465D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DAD2E764FBC144F8A0316336DCBC31DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0DBEC0AEE6D4245B95156336DBC2D08B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0DBEC0AEE6D4245B95156336DBC2D08B" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_87ACD25C4B466D12C3FB6336DBC2FB93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60391A40B936A42284F66336DBB2C3D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60391A40B936A42284F66336DBB2C3D4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_B56EA73988D7E35DE7916336DBB2D777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60391A40B936A42284F66336DBB2C3D4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_CEC6154AFE721F38B11A6336DBB22889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60391A40B936A42284F66336DBB2C3D4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_FE3C3E5A43B0CE0287416336DBB296E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60391A40B936A42284F66336DBB2C3D4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_E2E12A2BCE630CAC2DFC6336DBB31E51" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter" xlink:label="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60391A40B936A42284F66336DBB2C3D4" xlink:to="loc_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter_A27C9D3D16C13E9574176336DBB35EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_60391A40B936A42284F66336DBB2C3D4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AACF5C65A52431FE8BDE6336DBB3F077" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D22FE990C5A32B1C1E06336DBB9890A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D22FE990C5A32B1C1E06336DBB9890A" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6BA4129F2EBBB672EA596336DBB9D1D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6BA4129F2EBBB672EA596336DBB9D1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6BA4129F2EBBB672EA596336DBB9D1D9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmflazaassetacquisitionMember" xlink:label="loc_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838ED8DD8A9BDABB8E336336DBBAEFC6" xlink:to="loc_ptct_EmflazaassetacquisitionMember_AB515D4384943CC5EEB06336DBBAFBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_46ADE9F30A531A948B8D6336DBBAE978" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_46ADE9F30A531A948B8D6336DBBAE978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_46ADE9F30A531A948B8D6336DBBAE978" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_BA17DC75F96DF08093006336DBBA0B8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E40A7C4882E166BD9E316336DBBA279F" xlink:to="loc_us-gaap_NoncollaborativeArrangementTransactionsMember_BA17DC75F96DF08093006336DBBA0B8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_7A2E31153BDE35FE60486336DBBAA6EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="loc_srt_CounterpartyNameAxis_7A2E31153BDE35FE60486336DBBAA6EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7A2E31153BDE35FE60486336DBBAA6EC" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_AkceaMember" xlink:label="loc_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D15E353885960D2C0E216336DBBA386E" xlink:to="loc_ptct_AkceaMember_A477441CC69E3C2A82F06336DBBB382C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F61C403C486C80E8D45A6336DBB944CF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_FB695E082291067111C66336DBBB4877" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestonePotentialAchievementsRegulatoryApproval" xlink:label="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_ptct_MilestonePotentialAchievementsRegulatoryApproval_E5B7B3402F52334C8F696336DBBB85A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2F69FCC618AAFED5C9C56336DBBCE98A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DevelopmentMilestonePaymentObligations" xlink:label="loc_ptct_DevelopmentMilestonePaymentObligations_1F7A3763207C997D854E6336DBBC0646" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_ptct_DevelopmentMilestonePaymentObligations_1F7A3763207C997D854E6336DBBC0646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5FE53208D34AD9238C656336DBBC8957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_AC79CB218AF035E97AFC6336DBBC04D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0ADF303858225CA86FEA6336DBBC6989" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_Goodwill_0ADF303858225CA86FEA6336DBBC6989" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_UpfrontLicensingFee" xlink:label="loc_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_ptct_UpfrontLicensingFee_74FBF4A17EC335DFEF1A6336DBBC92DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA5F690CDAC6DBEFF2B76336DBBB337E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_CC44542E8B16FD9F4D416336DBBDB67F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F32EA4D4A1A51A3629016336DBC0318E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F32EA4D4A1A51A3629016336DBC0318E" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BE16944A6B540FD50CE16336DBC064F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_28C858292D3CFAB496DB6336DD0F794B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_28C858292D3CFAB496DB6336DD0F794B" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_C7823C26B5613A210B7A6336DD0F610D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_OperatingLeaseCost_53187D703D6020C5D23E6336DD0268FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_VariableLeaseCost_C50F59A5EFF995CC6D3C6336DD02EAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_ShortTermLeaseCost_654C95B2841CF5EDB3966336DD02A9F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_LeaseCost_BE2B7BC56FFEF4FD696F6336DD027E74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7ACE5B723C778897C2FE6336DD03EA47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7ACE5B723C778897C2FE6336DD03EA47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_56AD48B5578F997C5C706336DD033746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22A02D55027DC87739066336DD031ED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_48A4E5A241B2CE2F9EAF6336DD036AF5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_3DD72E743ECFFB1071416336DD03962A" xlink:to="loc_us-gaap_OperatingLeaseLiability_48A4E5A241B2CE2F9EAF6336DD036AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8735D7F14607F834016E6336DD04F5C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17F67602684CEBC524EB6336DD043EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_OperatingLeasePayments_5BE50530F3B00542DCB66336DD043455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4D045AE21EF5A67094A16336DD026927" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CAED3BED72430291C5156336DD0424CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9260D89ABAD1BADAAF766336DCFDC589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5E12CCA74DF7D7AFCF8E6336DCFD2D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58E230670CFDCC8011AB6336DCFD829B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_A1BE3240EB371CB5B6916336DCFD5B25" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter" xlink:label="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter_4FE2153829AABA7C59416336DCFD3DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6CFEAE66F0A17C5B8AA16336DCFEF4CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_D245D5F1DE7C62E8FDC36336DCFE907A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85D23C1FA25CBCA530D86336DCFC7FCD" xlink:to="loc_us-gaap_OperatingLeaseLiability_5F641EEFBACC1A4252726336DCFE9290" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_902266E3ABD8711DD7686336DD0833C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_902266E3ABD8711DD7686336DD0833C6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F90A2652D35F5D9129B06336DD08F90C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:to="loc_srt_RangeAxis_F90A2652D35F5D9129B06336DD08F90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F90A2652D35F5D9129B06336DD08F90C" xlink:to="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D550EA718C636154753B6336DD099F64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:to="loc_srt_MinimumMember_D550EA718C636154753B6336DD099F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_EF3F06D9AD6ED2045D296336DD090A64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3954F677160CA634A0596336DD0920D8" xlink:to="loc_srt_MaximumMember_EF3F06D9AD6ED2045D296336DD090A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0CB4FE089820F11E6C986336DD08D8F6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NumberOfOperatingLeases" xlink:label="loc_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="loc_ptct_NumberOfOperatingLeases_9490D7EE78E5D2AD74EE6336DD0AD020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_030CD4CB768A9432AD506336DD0A6153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_C2AE6818AB4FBEB3FE9F6336DD0AD13F" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7C8BF0B707DA0BE1C40B6336DD0AF060" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_425348A160CF301529BB6336DD0D3A64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_425348A160CF301529BB6336DD0D3A64" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6A9DBA15A7B9CCA62B1D6336DD0DE82F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_425348A160CF301529BB6336DD0D3A64" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D737954CEA6E0FFC99346336DD0DD1CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BDACA7E74B7145DBD3436336DC86B4DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BDACA7E74B7145DBD3436336DC86B4DA" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0E54A7B46677F243FF746336DC86E473" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A0ECB50603D1D06EE5E06336DC7BFBE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A0ECB50603D1D06EE5E06336DC7BFBE8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2711C86FC052F60C0EDD6336DC7BFC58" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AFE94FBCE3333BCBFE5F6336DC7C4CBA" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2D4D2E86A4F8BC507B806336DC7BD5F6" xlink:to="loc_ptct_RestrictedStockAndRestrictedStockUnitsMember_E23B1BFE5CBFA5DE77BC6336DC7CE5BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_EF90EE4988F865C061966336DC7B2BDC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_96085BDA83F5CAE9A5516336DC7C8C19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93C15286AAAD0D9B5A2D6336DC7C3317" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_28783EF730E8084D2B5A6336DC7F38E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_28783EF730E8084D2B5A6336DC7F38E0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_F06D625C64FF965F7E966336DC7F68F7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_138DEEDE975F424C07776336DC8026CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_51797F0DA0E5C500816B6336DC806020" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4230482EFCC3A660E1166336DC80D2D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_BA0C81BB5BD85451663F6336DC7FA947" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_607C0E4F5C2268BF431B6336DC8073C9" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_7332FD67F47E527CE10F6336DC81E26B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A9A1ED5AFE14F117D6046336DC832155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4C5D720B8EFEC5444C8C6336DC83AB2F" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4354EDC5121B333ED19E6336DC848138" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/Notes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6D32F6C38671C012D1896336DC1B1997" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6D32F6C38671C012D1896336DC1B1997" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C953395202F0E06C3FA46336DC1BB467" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4C5BE9106EA149F045CA6336DCACEC0A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4C5BE9106EA149F045CA6336DCACEC0A" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_A4EDE9000071B9A6B6326336DCAC41F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_133AD7E0D5FCA64A33AA67AB331B3BE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_133AD7E0D5FCA64A33AA67AB331B3BE1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D31895B8BFC9B2FDAA9C67AB331CDBEE" xlink:to="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6560BA06CFCE9B5E3DA367AB331DE387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_C8A5FDA16A6C77D95F5967AB331D0CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9AE758C60B364F05E5DE67AB331C09CC" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0FE899480258C01EA54D67AB331DD2D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DBE718DCCE40F2FC86A67AB331C6840" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:to="loc_us-gaap_StockholdersEquity_1FF8BD72BDB707EA380F67AB331EA98B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3757BF60EBCB2D59302167AB331EA58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0268744C723347525E0B67AB331E5533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_F41CCFFB727B5D26B87667AB331ECCDE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B72034E1BA7D70F97F1667AB331FBCA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_281CD40F96B2E3954D1D67AB331FBB57" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_A31C5681CFD9197EF16567AB331D0D39" xlink:to="loc_us-gaap_StockholdersEquity_281CD40F96B2E3954D1D67AB331FBB57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_EB5C62E3B6820D38D5D26336DCAAC4A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_EB5C62E3B6820D38D5D26336DCAAC4A3" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05CD997AB7531BF545456336DCAAF865" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0188471FB9C971D0E38E6336DBE9C1BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0188471FB9C971D0E38E6336DBE9C1BE" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_300CDEEAB65A75F0B0936336DBE969F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6AB3CFB6E87D825731196336DBD130E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6AB3CFB6E87D825731196336DBD130E3" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8AE1EA613FFFB83E4B2E6336DBD110D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8AE1EA613FFFB83E4B2E6336DBD110D6" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:label="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_BF8FC811637F0EB6E86A6336DBD1925B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:to="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_BF8FC811637F0EB6E86A6336DBD1925B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_1B99A2BBA145B2D241386336DBD2D55E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_20FE40580B70EF43F23A6336DBD28348" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_20FE40580B70EF43F23A6336DBD28348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_BDACD6AA29AC8FBF0AD86336DBD29B6B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_9EEC5328CDE23E2CD2C06336DBD169FF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_BDACD6AA29AC8FBF0AD86336DBD29B6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4C21EEDB641AB34AC9286336DBD942C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4C21EEDB641AB34AC9286336DBD942C9" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_FE730BA60AF0849E61DD6336DBDAA218" xlink:to="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RocheMember" xlink:label="loc_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8F35861799ED00B06B606336DBDAF12E" xlink:to="loc_ptct_RocheMember_EE8C6BDD86C1AADB6E4D6336DBDAC321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3201FB8B8BBC1AED11AC6336DBDBE07D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_RangeAxis_3201FB8B8BBC1AED11AC6336DBDBE07D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3201FB8B8BBC1AED11AC6336DBDBE07D" xlink:to="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C9908F38070B748302196336DBDB1464" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:to="loc_srt_MinimumMember_C9908F38070B748302196336DBDB1464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A78461ACEDA3774739C26336DBDC37FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65E1D62D794ADACEBF5A6336DBDBC771" xlink:to="loc_srt_MaximumMember_A78461ACEDA3774739C26336DBDC37FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A561DAA22D8B79D8B88B6336DBDC23D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A561DAA22D8B79D8B88B6336DBDC23D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A561DAA22D8B79D8B88B6336DBDC23D8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5F936FB8B077F6E5DACF6336DBDC5AC1" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborationAndDiscoveryAgreementsMember" xlink:label="loc_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93AE0D1622A712674B406336DBDC8CE4" xlink:to="loc_ptct_CollaborationAndDiscoveryAgreementsMember_D21FD63C0FAFF307E5906336DBDCD9C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_72230AD96CF35BD29EE96336DBDD0AD5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RocheAndSmaFoundationMember" xlink:label="loc_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ED4987D8B427F8FF3FCF6336DBDD3F8C" xlink:to="loc_ptct_RocheAndSmaFoundationMember_5EC1CEEF7B47494BC3C56336DBDD0B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_C5516A0F97469F7921576336DBDD6858" xlink:to="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:to="loc_country_US_29ABECC716AAA56343906336DBDEC4FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1B39C09703B2AA8C7E736336DBDEAECC" xlink:to="loc_us-gaap_NonUsMember_3E595E9E9F7FE92D0C2A6336DBDEE625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_F37C8AE3F0430FDEEE376336DBDE8017" xlink:to="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_TranslarnaMember" xlink:label="loc_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_TranslarnaMember_5B50D31858C2979B3B0A6336DBDF9D15" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LicensingAndCollaborationAgreementMember" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_F8DB8FD9307F70830F0C6336DBDF56E6" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_DiscoveryAgreementsMember" xlink:label="loc_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_DiscoveryAgreementsMember_10B5D71C1181E7C489166336DBDF0D97" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EarlyStageCollaborationsMember" xlink:label="loc_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8A5AEF21AF3AD5CBA64F6336DBDEE8DC" xlink:to="loc_ptct_EarlyStageCollaborationsMember_9AFABA4FAE30407C706A6336DBDF7369" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestoneAxis" xlink:label="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_MilestoneDomain" xlink:label="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_MilestoneAxis_C090058BF53466B38EF46336DBDFB272" xlink:to="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ResearchAndDevelopmentEventMilestonesMember" xlink:label="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:to="loc_ptct_ResearchAndDevelopmentEventMilestonesMember_AEE37150DEE17BD417486336DBE09C1A" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_SalesMilestonesMember" xlink:label="loc_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_MilestoneDomain_387B849595EB94476ADE6336DBDFC4A2" xlink:to="loc_ptct_SalesMilestonesMember_422F4B8598D8514B618C6336DBE0DE2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_B95F5BE02AB1B94381FE6336DBD9B10C" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_12715A4E49FAF583BB396336DBE0678E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7C594D98937275840ECF6336DBE1B408" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetProductSales" xlink:label="loc_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_NetProductSales_5B2DF848BF2A727846886336DBE1B545" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:label="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts_B6687B7888B7D95C3B9A6336DBE1ADF4" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment" xlink:label="loc_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment_4ACFDA02B422EC0042186336DBE133C1" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsNumberOfSignificantDeliverables" xlink:label="loc_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables_614A7648F59C1C6780A16336DBE19410" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_RevenueRecognitionMilestonePotentialAchievements" xlink:label="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_RevenueRecognitionMilestonePotentialAchievements_53BB38F90CB2058DEEDE6336DBE15B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_840F2A1D273A16F818D96336DBE2F292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_636D9056C406546093826336DBE219E5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_636D9056C406546093826336DBE219E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_us-gaap_Revenues_606E1F327154B7ACA3E26336DBE2114D" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology" xlink:label="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_D7624B10BE6AB8D06D8B6336DBE012EF" xlink:to="loc_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology_682E5E4545D00D9C69AE6336DBE29EFD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9DC2CC7363FA60241C8A6336DBC6FEE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9DC2CC7363FA60241C8A6336DBC6FEE1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_316FEFCFA1D60BBE6CE56336DBC68880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4E5B52F231A8C44698996336DBC6CECF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="loc_srt_ProductOrServiceAxis_4E5B52F231A8C44698996336DBC6CECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4E5B52F231A8C44698996336DBC6CECF" xlink:to="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_TranslarnaMember" xlink:label="loc_ptct_TranslarnaMember_434DF590AB34E93669D86336DBC71060" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:to="loc_ptct_TranslarnaMember_434DF590AB34E93669D86336DBC71060" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LicensingAndCollaborationAgreementMember" xlink:label="loc_ptct_LicensingAndCollaborationAgreementMember_E97ACF67918ABF456D816336DBC7CE8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_E5C03CF485B13EA152F76336DBC70DEE" xlink:to="loc_ptct_LicensingAndCollaborationAgreementMember_E97ACF67918ABF456D816336DBC7CE8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_91F36E8BC1EAF3FE38666336DBC7BA9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="loc_srt_RangeAxis_91F36E8BC1EAF3FE38666336DBC7BA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_91F36E8BC1EAF3FE38666336DBC7BA9E" xlink:to="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_DFDA4CDB45BBF75F6D7B6336DBC86E24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:to="loc_srt_MinimumMember_DFDA4CDB45BBF75F6D7B6336DBC86E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_79193C571E274BA9D7566336DBC89078" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4F2F12D0BE5D9FA3915A6336DBC8449F" xlink:to="loc_srt_MaximumMember_79193C571E274BA9D7566336DBC89078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_854ECAE4A31B4109D90B6336DBC6DE47" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9C8D0B0932B47E050FAF6336DBC98030" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9C8D0B0932B47E050FAF6336DBC98030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_2D36A1E645059F12BD046336DBC99250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_12AA4F0DB5FF19F3E04B6336DBC83A4F" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_F1E32BAB2E3A26CC0DFF6336DBC948E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:type="locator" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod" xlink:label="loc_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:to="loc_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod_647D6FDCD6E23A45482E6336DBCD04DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_24C5F5BC545C2D7E34186336DBCE6C12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_F9A263FA25244244DA4B6336DBCE2B54" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NetProductSales" xlink:label="loc_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_698A1D3327209E739BFB6336DBCD3DFD" xlink:to="loc_ptct_NetProductSales_5D0F1129C8F30EC31A546336DBCEB5C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3482AE6C52E12535A8B26336DBE7C9E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3482AE6C52E12535A8B26336DBE7C9E9" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_EF53728C401CF74D311F6336DBE75514" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58A2E6D24F102FAE9BB26336DC78A076" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58A2E6D24F102FAE9BB26336DC78A076" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04317470CD237B89D16C6336DC785BD9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B40E4DA5FF2CA85C9F586336DC67FDE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B40E4DA5FF2CA85C9F586336DC67FDE8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_2A6491850036E544975C6336DC686B4C" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1EE81A6C0E74658EC1316336DC68E677" xlink:to="loc_us-gaap_EmployeeStockMember_A1808862015F30E9DB986336DC6861AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ABA4614986A170BEA7536336DC692B24" xlink:to="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_StockIncentivePlan2013Member" xlink:label="loc_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_StockIncentivePlan2013Member_12BEE99AEEA8C04DC9866336DC691AF8" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EquityAndLongTermIncentivePlan2009Member" xlink:label="loc_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_EquityAndLongTermIncentivePlan2009Member_FC7F390C799800C34CA76336DC6912B8" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member" xlink:label="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_0BB8A113A395D52823576336DC69D53F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_LongTermIncentivePlan2013Member" xlink:label="loc_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_D3DF36ED240CF330450F6336DC699DBF" xlink:to="loc_ptct_LongTermIncentivePlan2013Member_C63361F89D158B4E23806336DC69B852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A4F37770AA294AD12BA96336DC6AEB0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_AwardTypeAxis_A4F37770AA294AD12BA96336DC6AEB0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A4F37770AA294AD12BA96336DC6AEB0C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_0B7B8905554F308546CB6336DC6A863C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_us-gaap_RestrictedStockMember_0B7B8905554F308546CB6336DC6A863C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_804A85F5D86C2FA489876336DC6A92B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_us-gaap_StockOptionMember_804A85F5D86C2FA489876336DC6A92B9" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmployeeDirectorAndConsultantStockOptionPlanMember" xlink:label="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_B91ABB8941E0457AEEA86336DC6B8C79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_AC55E4BE3E1B7CD6BE4B6336DC6B4C9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC7A1B2A688DFE7A718F6336DC6AA269" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_AC55E4BE3E1B7CD6BE4B6336DC6B4C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47F625A2E42E2A0A165C6336DC6B96F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47F625A2E42E2A0A165C6336DC6B96F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47F625A2E42E2A0A165C6336DC6B96F6" xlink:to="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_41A139AE925D9AAB22C66336DC6BC59B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05EE2CB9938110C1B1B46336DC6BB6A4" xlink:to="loc_us-gaap_CommonStockMember_41A139AE925D9AAB22C66336DC6BC59B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_86AF22E656094B64CC3A6336DC6C3FFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_srt_RangeAxis_86AF22E656094B64CC3A6336DC6C3FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_86AF22E656094B64CC3A6336DC6C3FFE" xlink:to="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7DCB3DC63F53BD7FE3806336DC6CCD4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:to="loc_srt_MaximumMember_7DCB3DC63F53BD7FE3806336DC6CCD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5A9DF65ACEF5ED83224A6336DC6CAE24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9A7981860BCF7F412D2F6336DC6C3535" xlink:to="loc_srt_MinimumMember_5A9DF65ACEF5ED83224A6336DC6CAE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DE13572F7ADE83F85BC46336DC678241" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ED336E8837EEA67F18326336DC6DDC65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67644C02907DA241FD0B6336DC6D01CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C17C6F1ABE99464E8D56336DC6DF2AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9C17C6F1ABE99464E8D56336DC6DF2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_D872E7051B45424ECD966336DC6DE2AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_92600173F3B5A89BCA196336DC6DB562" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards_6CFE3394223B748C90D96336DC6D50BB" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber_91449ABA4BC65E1235C66336DC6E6423" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding_6C982189A0234C929A2A6336DC6E9479" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions_1921F17959FFFCDA04526336DC6EEE97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7EF13E6640E8D957C3566336DC6E994B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FFB5CFC41449DBE2C83B6336DC6E9837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0A5E272A93B5AA6A78616336DC6EAEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C4398428D9FDD45C942D6336DC6FCCEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_AE45276C98BCF02C37D66336DC6FF7BD" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_AE45276C98BCF02C37D66336DC6FF7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_517FF8B16F07055763DB6336DC6F2490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_DCF8CB7B7161D60F76AE6336DC6FE45C" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent" xlink:label="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent_0950454390390F4BC03C6336DC6FD566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_60B5AA6AC13B2380ED106336DC6F7AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46C144DF7BE4A57BC6726336DC6C1CE0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E836F19BA5A2AB9A04D86336DC70C5F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_118F45AD7BC6BDF7883B6336DC4BAC93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_118F45AD7BC6BDF7883B6336DC4BAC93" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_76219832E0A4278ADF166336DC4C7E0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:to="loc_us-gaap_AwardTypeAxis_76219832E0A4278ADF166336DC4C7E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_76219832E0A4278ADF166336DC4C7E0C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6302C0B4567096812A7D6336DC4C4698" xlink:to="loc_us-gaap_RestrictedStockMember_AEF3DFB52D6384222E8A6336DC4C1CCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_139457D94AD73DBD1FD56336DC4B0EC7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DE72E775C3AE506EC436336DC4D75D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10B4C63A241DA345EADD6336DC4DE1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F3E8FE8D6E60427C715F6336DC4D75C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6C10A663351AB87B87E16336DC4E28C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BF38A1AC39646719882B6336DC4EAD81" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F4A7D5FA8E7DAEA31A756336DC4DA15D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BF38A1AC39646719882B6336DC4EAD81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9D696C3F3C393E57AA326336DC4C46B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_017D5282136AA4F55E556336DC4E41EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E025C05EB40782E9ADDF6336DC4E153B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_672297A0CBB9A06A76D56336DC4E6765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70D91DA2242CF8BB1CB86336DC4FA33D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4F0FEE2E8DB6B5CCFC826336DC4FC126" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_491981A382FC671AFA506336DC4E7038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4F0FEE2E8DB6B5CCFC826336DC4FC126" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0EC672015FDF5EB330946336DC562F76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0EC672015FDF5EB330946336DC562F76" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9AD2C48124B3686A17756336DC5642BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:to="loc_us-gaap_AwardTypeAxis_9AD2C48124B3686A17756336DC5642BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9AD2C48124B3686A17756336DC5642BA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3031BCC2FF87754A7606336DC5757C5" xlink:to="loc_us-gaap_StockOptionMember_22B39483A4A0B8C51BCC6336DC574122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_AC9593CC013AB8AAA3C26336DC57ACE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:to="loc_srt_RangeAxis_AC9593CC013AB8AAA3C26336DC57ACE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_AC9593CC013AB8AAA3C26336DC57ACE8" xlink:to="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FEA631CB2CF462F2177C6336DC58FBB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:to="loc_srt_MinimumMember_FEA631CB2CF462F2177C6336DC58FBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_100975D177ED8C10E4EA6336DC58440C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7B7C4868C16C4FC8F1E76336DC58472F" xlink:to="loc_srt_MaximumMember_100975D177ED8C10E4EA6336DC58440C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ECBA4AF8E9E6FBE98CA6336DC560C9E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C64525F29FC88CDF497A6336DC5856D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66C7FB436D10D4D3DB136336DC593A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D8491DB7F3B11A9262126336DC595523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_304761837A10C250746C6336DC595903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F67A87B54C9D262A3CD36336DC59CF98" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ACA12126B224F3B561716336DC5823DD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F67A87B54C9D262A3CD36336DC59CF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1EFFC723AF54C86834D96336DC5A04F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0AE922120E2D8BBB8CCB6336DC5A866F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4CC49A3373CD0F42FC3C6336DC5AEF28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5CC3DBB36D40AA5C49566336DC5A9073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7E1FE8D2AD9BEC6348466336DC5A57B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50F0D90838A1788698716336DC5BD2D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71815A971324A206B5EF6336DC5BD331" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_502A882A32E174DB71AE6336DC5AF24F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_71815A971324A206B5EF6336DC5BD331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_98D4EA10359C8E14A9236336DC5B4D51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7A2DC4879DEA137C36B26336DC5B03BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B8FDC6124CF392EFC33E6336DC5BA049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8DE8E468E291FFAE21486336DC5C7B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7AE0E2EE43BD91C6B4A86336DC5B75CC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_BDD8FD57FCD29D675CDF6336DC5CB820" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward" xlink:label="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CFBB3A78DC77E94E62686336DC5CA4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_E24759CD05BAB7A2DA2A6336DC5C342F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward_AF81E6A30FE894AB10EA6336DC5C79C9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9DC9AD24B9DA9D03E12B6336DC5D1612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_560AF9C7F604034721026336DC5813FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C1F9E94967D49F125CB86336DC5DE801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_B4FB8FAA916CAE974BB26336DC5D46F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D023E84D41DE4F1429996336DC5D74EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_68B1845D3D2AAE485FA86336DC5DA679" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D023E84D41DE4F1429996336DC5D74EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7049F448D4770CD5D9FD6336DC462287" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_774D7C41CABC9ADCF2226336DC464FE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7049F448D4770CD5D9FD6336DC462287" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_774D7C41CABC9ADCF2226336DC464FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_774D7C41CABC9ADCF2226336DC464FE6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2B6950D2D66D5A99695B6336DC46F441" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B6488010EC283F15E106336DC473754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3105A63D03908238F8F16336DC46ADB1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_108FE5DC31533629124A6336DC47697C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_774D7C41CABC9ADCF2226336DC464FE6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9722E3DB68EB146EB0CC6336DC476075" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6D680EFE4676EB7D2F1F6336DC477D34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/StockAwardPlanTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DBF35AFB3BF573242E036336DC75715F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DBF35AFB3BF573242E036336DC75715F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_024148DCFA6F661A30D96336DC76082B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DBF35AFB3BF573242E036336DC75715F" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_EBB9B841C1507394328E6336DC760900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DBF35AFB3BF573242E036336DC75715F" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_D1CA1B6304CFF123D4D16336DC768F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DBF35AFB3BF573242E036336DC75715F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3C2755EB3978B929760F6336DC763B71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9B0AF14699A236A1606F6336DBADD212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9B0AF14699A236A1606F6336DBADD212" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5D43468BAE850B9FB8766336DBAD5465" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2DC1CB5D58872D2B6660678B2E822B8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2DC1CB5D58872D2B6660678B2E822B8D" xlink:to="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D66569A05B5FB67ACB18678B2E86B266" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_NewBuildingMember" xlink:label="loc_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5F681DC165AA04DCB547678B2E864AF0" xlink:to="loc_ptct_NewBuildingMember_BD35BF26774D1689E214678B2E86E926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_945F84CF3220AF20EA5D678B2E862DB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="loc_us-gaap_DebtInstrumentAxis_945F84CF3220AF20EA5D678B2E862DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_945F84CF3220AF20EA5D678B2E862DB9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_FifthAnniversaryMember" xlink:label="loc_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8C791709B4FB1A202CB5678B2E87ADF0" xlink:to="loc_ptct_FifthAnniversaryMember_29AA36F82EEC9F875BEC678B2E871B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D95D522EC27B3CAB37F678B2E8772F3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_98225915302864A483A4678B2E8710A9" xlink:to="loc_us-gaap_SubsequentEventMember_4B1E6D98D5F5ABDB5237678B2E882C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5420A6BB25CEA5EA5C65678B2E850A18" xlink:to="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Feet" xlink:label="loc_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_Feet_231BF844F703CD144168678B2E88A483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A37850BE1824963D3836678B2E88B925" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A37850BE1824963D3836678B2E88B925" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Numberofterms" xlink:label="loc_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_Numberofterms_510E74DF8437917F7144678B2E89813F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63C292A04FB7734488E1678D2C224F17" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_PercentOfMarketRate" xlink:label="loc_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_PercentOfMarketRate_1E52EAB8CCB2CD9A33A2678B2E890644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_A63D131917063E521671678B2E89B9A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_FD454A7C0403CD7A8872678B2E89EB20" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_Termforletterofcredit" xlink:label="loc_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7D6D57CE1AEE466D5466678B2E882575" xlink:to="loc_ptct_Termforletterofcredit_7FB3729DFBC6DBDA6101678B2E8942F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D6DEF3D7B57FBDC740026336DD21D159" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D6DEF3D7B57FBDC740026336DD21D159" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_AA48F8FFDCFFB3EE8DC66336DD2279F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_72FE2C56F41421C0AB566336DD177CCC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72FE2C56F41421C0AB566336DD177CCC" xlink:to="loc_us-gaap_InventoryRawMaterials_3C6BAE11D95EBA094D9D6336DD17A8CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72FE2C56F41421C0AB566336DD177CCC" xlink:to="loc_us-gaap_InventoryWorkInProcess_709F0FD1E7AB56FF5D2B6336DD18BCED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72FE2C56F41421C0AB566336DD177CCC" xlink:to="loc_us-gaap_InventoryFinishedGoods_7D3A05395C59A313C4476336DD185D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72FE2C56F41421C0AB566336DD177CCC" xlink:to="loc_us-gaap_InventoryNet_D2C10C90D2229D4CE3DA6336DD187CB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_093946E24FDFD9B0DBCE6336DD12F710" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_093946E24FDFD9B0DBCE6336DD12F710" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_7048673B5F3D2A5520E66336DD1291C6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_C65DDB5302C98BE64DB26336DD12AB83" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_95531127BE08BC4BB9F66336DD13A720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_1A8C78DB17809C123EBB6336DD12F150" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E317B960977B0E79ED066336DD133559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9028FC3877AD193F4CA86336DD131987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_36E1D876CF5822BFD6A96336DD14EFF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_213F3E520A5D113E23996336DD14604B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_939CD74C2131CC5E121E6336DD13D1AB" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5C06AA01BD34B26D00D66336DD14FE8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D695D9FDB6C0BADE9F336336DD1D6257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_UseOfEstimates_4F83F4569490EC73D3A16336DD1E185F" xlink:type="arc" />
    <link:loc xlink:href="ptct-20190630.xsd#ptct_InventoriesAndCostOfProductSalesPolicyTextBlock" xlink:label="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock_D89EA75F58314EDC94E86336DD1EF7AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_58FE7B196E3BBD0260536336DD1EAD7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_461ED605E6136107A1656336DD1E096C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_AD7CA7823C2943911D216336DD1E441F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2B0B4DFEC54F27FC5CCC6336DD1EC1F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_33E693A379F2C8BF881D6336DD1ECE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CE813472610C34BB7026336DD1D71A3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5653E8BB44A95FB459BE6336DD1F72B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E71B90FCB73814D8AC266336DD1A4E8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E71B90FCB73814D8AC266336DD1A4E8D" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1C69C9209E3D7FD2D24D6336DD1AF7FD" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>employmentagreementhi_image1.jpg
<TEXT>
begin 644 employmentagreementhi_image1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #C _0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSXO_ /!S:_X4?\15_A#_ *(SXO\ _!S:_P"%']E8K^3\5_F!^L-%>*_\$_\
M]LZQ_;Y_9GTOXE:;H-]X;M=4N[NT6PNYTFEC-O.\))9/E(8H2/8U[57#.$H2
M<9;H HHJMJVLV>@:?-=WUU;V=K;J7EGGD$<<2CJ68\ >YJ0+-&<5\)_M._\
M!PW^SW^S[K5UH^AZIJ7Q.UJT)66+PS$LME"PSP;QRL#'/!$;.1Z5\4_'+_@Z
M1^)WB>>:'X=_#?P?X3M>/+N=>NIM7N?KY<1@1?IN:O0HY7B:FJC9>>G_  0/
MW"S1FOYP_%'_  7O_:H\3W+2+\0['1U;_EEIN@6<:#Z>8DC?K7-O_P %IOVI
MGDW'XR:]]!86('Y>176LBK]9+\?\@/Z8,T9K^;31?^"Z/[5.BR*W_"U)KP*<
M[;K1;"13]<0@_K7IWP^_X.7/VC?"-ZK:UIOPU\76B]8I]+GL9F]?WL4Q4?\
M?LX]ZF61XA;-/Y_\ #]_:Y_X@?"S0/BAI@M=<TRWODCR8W8;982>Z./F4_0U
M^8/PH_X.IO!E_!$OC[X5^)O#S(@-Q=:/J,.IP+_>8*XA<*.N &/UK]0/A;\1
M+'XN_#70/%6EPZA!IOB33X-3M([ZT>TNDBFC$B"2%P'C?:PRK $'@C->5CLM
M?(Z>*@G&6EG9I_FC:C7JT:BJT9.,ELT[-?-'S7\9/V%M1\.+/J'A&>35;-%W
MFPG8?:DQUV-PK^P.#[DUX'<6\ME=20W$4MO-$=KQRH4=#Z%3R#]:_2ZO//CA
M^S?H7QLL?,N$^PZQ#&4M]0A7YU[@..CKGL>>N"*_(^(_#:E43KY5[LOY'L_1
MO9^3T]$?J?#?B55I-4,U]Z/\ZW7JNJ\UKZL^$L9IKHK+RM=)\3?A5K/P?\1M
MIFM6XC=AN@GC^:&Z3^\A_F#R._8GG:_&<1AZE"HZ-:+C):-/='[3A\13KTXU
MJ,E*,M4ULSUSX/?MD>)?AT\-IJC-X@T=?E*SO_I4*_[$A^]CT?/U%?6'PV^+
M&A?%G0UOM$OH[E,?O8C\LUNW]UT/*G]#VR*_/.M+PAXPU3P#XAAU31[R6QOH
M>!(AX<=U=>C*?0\?CS7W'#?'N,R^2I8ENI2[-^\O1O?T>G9H^&XDX!P68)UL
M*E2J]TO=?JEMZK7NF?H]17D_[.G[4>G_ !GMDT^]6/3O$<,0:2#.([K'5XN<
MD=RIY'N.:]8S7[QEN98?'T%B<++FB_P\FNC78_!,RRW$X"N\-BH\LE_5T^J?
M<****[CA"BBB@ HHHH **** "BBB@ HHHH **** "O.O#_\ R=)XE_[%^P_]
M'7%>BUYUX?\ ^3I/$O\ V+]A_P"CKBO(S3^+AO\ KY_[9,]?*_X6)_Z]_P#M
M\#T6BBBO7/("BBB@ HHHH **** "BBB@ HHHH **X?\ :8^.-G^S/^SWXT^(
M6H6-UJ=CX*T:ZUFXM+9E6:Y2"-I&1"Q"AB%P,G%?G7;_ /!U)\-7*M-\+/B!
M'#D;W%U9-MS[>8!^HKIHX.M67-3C= ?J917@O[('_!1GX<_MP? 76O'G@6ZO
M9HO#?FQZOI-Y#]GU#3)DC\WRI$)(^9,%74LC \,<$#XAT7_@ZW^&NMZ5;W4?
MPI\?!;B)9<&\LLJ& .#\]53P->;<8Q=UN!^K%%?*?_!,[_@J[X9_X*;2^,E\
M.^%M>\-_\(8;07']I3P2?:/M E*[?+8XQY1SGU%>/_MI?\'$OPY_92^.>L?#
M_1_!_B+Q_JWANX:SU6YL[F&TL[>X49DA1WRTC)G#$*%# KDE6 4<#7E4=)1]
MY ?H917S'_P3>_X*H_#[_@I3X;UE_#,.H:#XD\-^4=5T'4BGVF".7=Y<\;J2
MLL+%67<O1E(8*<9^G#6-2G*G+DFK, HK\NM<_P"#I'X<Z%XGU?2V^%_CJ:;1
M]0N=/D=+RSVNT,SQ%A\^<$H2,]C7O?\ P3<_X++^$_\ @I5\5/$WA3P[X/\
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MPLKH2HXR5.6Z3_- ?#YHIIF7/WE_.CSE_O+^=?3 .HIOG+_>7\Z=F@ HHHH
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M@'R=9\2?+\EX2S&ULB3P1-)&Q=?^>4;@XW@U_2/! EM"L<:JD<8"JJC 4#H
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M(XB@[QDKI_U^/8_F7&82KA:\L/75I1=FOZ_#N%%%%=)S!1110 4444 %%%%
M!1110 4444 %>=>'_P#DZ3Q+_P!B_8?^CKBO1:\Z\/\ _)TGB7_L7[#_ -'7
M%>1FG\7#?]?/_;)GKY7_  L3_P!>_P#V^!Z+1117KGD!1110 4444 %%%% !
M1110 4444 ?/_P#P5;/_ !K0^/'_ &(VK?\ I+)7P#_P;R>.OAAX0_X)Z_%E
M?B=J7@ZTT5O%-U)>P:Y+!MFL_P"S+(/^[DY=#AQ@ Y.0,GBOO[_@JU_RC1^/
M'_8C:M_Z2R5^3'_!%7_@C_\ "_\ X*+_ +/WB;Q=XZO_ !5:ZCX?\3-HT$>E
MW<4,3PK:6LX+;XG;=NF;D$< =^:]O!\GU*?M&TN9;?(?0]/_ .#5Z"2X^(7Q
MSDLTD'AUK?34A213QF:\,2D'N(CR#STJO_P<U^&M-\/?'GX QZ?I]C8QR)=A
MTMX%C5_],LL9"@9ZGKZFOU(_8^_8E^''["GPL/A'X;Z"ND:;-<->7D\LK7%[
MJ5P0 9KB=R7D;:%49.%50J@  5^8O_!T(?\ B_\ ^S[_ +EY_P"EEE5X?$*O
MF/M([/\ 16!;G[":1X:TWP^TC6&GV-B9L>8;>!8_,QTSM SC)ZU^+O\ P;D:
M-:^*_P#@H'^T!J&J6\.I7T4-VZ3W""213-JT_FD$_P!_:N?7 K]L*_%C_@VG
M;/[=G[0?.";>7 [_ /(6N*Y<&_\ 9J_HOS$?3O\ P39_X)!>,OV&_P!O#XB?
M$J\U[PC-X-\51ZG!IFD:4DZ3V,5Q?I<0(X90FV.-2N%. 3QQ7Z%5\8?L6?\
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MO-=?7H2SZ.HHS17B@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?DW_P '6/\ R2OX*_\ 8=U'_P!)4K\8Z_9S_@ZQ_P"25_!7_L.ZC_Z2
MI7XQU]EE/^ZQ^?YCZ!39/O1_]=4_]"%.ILGWH_\ KJG_ *$*]-;B1_71X?\
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M+V?_ ,;H_P"';?[/?_1$?A5_X2]G_P#&Z]KHKQ_;U/YG]X'BA_X)N?L^ ?\
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MZCLK:2:1ML<*EV/H!R:]7<#H/AE\,O$7QH^(6C^$_">C7WB'Q)KTXMK#3[-
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MO7AEG<L3A)8"J[RI:K_"_P#)_@TBE1FH#-FFFXY_^M7YD?I_*ST7]G'XR/\
M!GXD0WDC;M+U#;:Z@N>D9/$@]T)S]"P[U]Y12+-$K*P96 ((Z$5^8SS*0<\@
M]:^UOV)/BROQ$^%"Z=<7!FU3PX1:2[VR[0D9B<^N5!7/JAK]<\,<]<:DLKJO
M1WE#U^TOFM?DWU/R'Q0R!.G'-:2U5HS]/LOY/3YKL>RT445^T'XH%%%% !11
M10 4444 %%%% !1110 5YUX?_P"3I/$O_8OV'_HZXKT6O.O#_P#R=)XE_P"Q
M?L/_ $=<5Y&:?Q<-_P!?/_;)GKY7_"Q/_7O_ -O@>BT445ZYY 4444 %%%%
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M_B'X&^!'Q0\&Q_"/XG,T.I1:I<265]#:MN41,!;SG>L3F)I89(S*@&0IQC]
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M!K[6HHKFK5I5)<\@"BBBLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.KZ\KJ/.TZ/RQ]GT]B./W*LY;''F2R]1BOM:OC,TQ"K8AN.RT_KY@%%%%><
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M44 %%%% !1110 5YUX?_ .3I/$O_ &+]A_Z.N*]%KSKP_P#\G2>)?^Q?L/\
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M_)7OC3_V!])_]'7=?M)7XM_\&J?_ "5[XT_]@?2?_1UW7[25\=G'^]2^7Y(
MHHHKS /YF_\ @L?^SFO[,?\ P4>^)&D6\'V?2_$EY_PE>FJ%VJ8;XM))MQQ@
M7 N%_P" U\QU^[7_  <A_L-WGQ[_ &<=*^*?AK39+_Q)\*Q/)J$5NFZ>ZT>7
M:;@@=6\AD2; Y""7&2<5^$JMO4,.0>01WK[?+\0JU",NJT?R *LZ)KVH>%-=
MT_5M'O9M-UC2+J*^L+R$XDM+B)Q)%(ONKJI]\8JM17:!_4/_ ,$X_P!N70/V
M_OV7M#\;:3+##JRH+'Q!IH;]YI6H1@"6)AUVG[Z-T9'4CK7O-?RY?\$^OV_/
M&/\ P3N^.L?B_P ,K_:FDZ@B6OB#0)IC';ZU:JV[ ;!$<Z?,8Y<'&XJ058BO
MZ(?V)?\ @H!\-?V^?ANFO^ ]<BFNH %U+1KHK%J>CR_W)X<DCV=<HXY5B*^/
MS++I4)<\5[C_  \F![91117E@%%%% !114-Q?PVLT,<DL<<EPQ6)68!I"!D@
M#N< GCL* )J*** "BBB@ KR7]N74?[-_98\6OG'F01Q?]]S1K_6O6J^;_P#@
MJ#XN70?V>;73@VV37-7@@QZI&'F;_P! %>'Q-65+*L1-_P DE\VK+\6?2<'X
M66(SS"4H_P#/R+^2:;_!,^$?M7O33<XJD;BD\[WK^9#^S/9LN&YR::T_'7%5
M3<8__73&N*97LS]'_P#@G2/^,5=&;^]=WA_\F)!_2O<J\;_8 TUM._9+\)LP
MV_:XYKH<=I)Y&'Z$5[)7].\.Q<<JPT7_ ,^X?^DH_B[BV2EG>+:_Y^S_ /2F
M%%%%>R?/!1110 4444 %%%% !1110 5YUX?_ .3I/$O_ &+]A_Z.N*]%KSKP
M_P#\G2>)?^Q?L/\ T=<5Y&:?Q<-_U\_]LF>OE?\ "Q/_ %[_ /;X'HM%%%>N
M>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%4UUN"37&T]&$EQ'$)I%!_U2DD*6_P!XAL?[IJ922W*C%O8_*?\ X.L?^25_
M!7_L.ZC_ .DJ5^,=?LY_P=8_\DK^"O\ V'=1_P#25*_&.OM,I_W6/S_,04V3
M[T?_ %U3_P!"%.ILGWH_^NJ?^A"O2$?U[>'O^0!8_P#7O'_Z"*N53\/?\@"Q
M_P"O>/\ ]!%7*_.P"BBB@ HHHH **** "BBB@ /2OY,_VDO^3E/B3_V-VL?^
MET]?UF'I7\F?[27_ "<I\2?^QNUC_P!+IZ^@R#XI_+]1HXNBBBOI!'ZN?\&J
M?_)7OC3_ -@?2?\ T==U^TE?BW_P:I_\E>^-/_8'TG_T==U^TE?'9Q_O4OE^
M2 ****\P"*]LXM0LYK>XBCGAF0QR1R*&612,%2#P01Q@U_.Y_P %F/\ @E-J
M'[ GQ7NO%?A>RFG^#_BF]+6$P8-_PCUW*S,;"3N(LY\ENFW$9P57?_116%\2
M_AGH'QA\#:IX9\4:18:[H.LP-;7MC>0B6&YC/564_F#U!P1@BN[ XV6&J<RV
M>Z _D<HK]$/^"G7_  0)\8_LKW>H>,/A':ZIXZ^&L<;W-QIRYN-;\/J.2-BK
MFZ@5<X=<RJ%^97Y>OSKM[F.ZBWQNKKR,@]"."/PK[&C7IUH\]-W7];@25J^!
M?'NO?"SQ?9^(O"NN:MX9\0:<VZUU+2[IK:Z@/LZG)4]U.58<$$<5E45J!^A7
M[/O_  <I_'?X365M9^,=)\+_ !0M8=J-/=*=)U%E&!DRP(T3-CUA&3U-?7'@
M'_@Z7^$NL60_X23X<_$;0+K'*VHM-0BS[/YL;?FHK\/:*\^IE>&GJXV]-/\
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MC:U9ZXN@_P!K/-K'B?4(K=HX_*5QNC+MN)E7'RXZ\BL,)@%6C.3G91ZV]?\
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M\"("3CU/8#N2!6MFOA7_ (*]_M.?8[*S^%^ER(9;KR]1UMU;+1Q@[H8,=BS
M2'/.$7^]7DYYFD<OP<\3+=:)=Y/9?Y^5SZ;@_ARKGF:TLOI[2=Y/M!?$_NT7
M=M+J?'?Q;^*E]\:?BAKGBK4BXNM<N6GV,<^1&,+'$/9(PJ_@3WKG?,QWK/$_
M-!GY[5_.-3GJ3=2;NV[M]V]V?WAA\)"C2C1HJT8I));))62^2+_VA<_>I#<K
MFJ)G!':FF?!ZU/LS;V;.X^!7PMNOCS\8O#_A&SC=O[9NE2X=1_J+9?FFD)[
M(&Y]2H[U^T6DZ9#HNEVUG;1K%;VD20Q(O1$4 *!] !7Q)_P1R^ 4VF:!K7Q(
MU",*VL9TO25(^801MF:7/H\@51_UQ/K7W'BOVS@'*?JN!>)FO>JZ_P#;JV^_
M5^C1_(WC1Q&L=G"R^D[PPZ:]9NW-]UE'U3[A1117W1^.!1110 4444 %%%%
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M[_Z-T^OZ**_G7_:]_P"5A6X_[*WX=_\ 1NGU[.2_'/\ PO\ -#1_117\W/\
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M1?V?OBK-:Z?IS3/:>%=;N/WFG74,[%EL+G(*Q89F6-V/ENK*AVL%W_L%XO\
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MQ_P2Y_9XT[]G'X!ZA\4?&4D.CZAX@LVO)+C4&%O'I&EH-ZERV-FX RN6Q@;
M<;:]SA_)99CC(T/LK67HOU>R^_H?$^(/%4.'<GGC/^7DO=IKO)K?TBO>?I;J
MCZV\#>"M,^&_@[3- T6UCL=)T>VCM+2",?+%&BA5'Y#KU)YK6KR'PS^W_P#
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MK['ZAQ?XA4,XRBAE.'P[I1I.-FY)W48N*5N5=R6BBBOLC\O"OYT_VOKR%?\
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M^!9YI-#T'1='DN5"S/8V,5NTH&2 Q11D#)QGIDUV8K&8>JI-4[2?6X'XS?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O.O#_\ R=)XE_[%^P_]'7%>BUYUX?\ ^3I/$O\ V+]A
M_P"CKBO(S3^+AO\ KY_[9,]?*_X6)_Z]_P#M\#T6BBBO7/("BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\Z\/_ /)TGB7_ +%^P_\ 1UQ7HM<!H.G7,?[2WB*Z
M:WG6UET*RC28QGRW82SDJ&Z$C(R.V17DYG%NKA[?\_/_ &R9ZV622IXB_P#S
M[_\ ;X'?T445ZQY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ptclogoimagea01.jpg
<TEXT>
begin 644 ptclogoimagea01.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M!>('+/.)<O2,4_6U_P FC^I_"C!S?#\)RVE*37I>WYIGZA_L:^)/^$H_9O\
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MMPN!;PW,D<$KAE4JTL*QR%0"%+E0S8W'T*BBOIWOH?EX4444@"BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>ptct0630201910-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptct="http://www.ptcbio.com/20190630"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ptct-20190630.xsd" xlink:type="simple"/>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Aug5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-08-05</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:GrantAndCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-23</startDate>
            <endDate>2018-08-23</endDate>
        </period>
    </context>
    <context id="I2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MarathonPharmaceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-20</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_TranslarnaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:TranslarnaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:MarathonPharmaceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-20</startDate>
            <endDate>2017-04-20</endDate>
        </period>
    </context>
    <context id="D2014Q3Aug1-Aug31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="I2018Q3Aug23_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-23</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2019Q2May_invest_InvestmentAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_invest_InvestmentAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:PercentageofSalesforRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityNetSalesMilestonesandRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:ProbabilityofSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ptct:LiabilityDevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ptct:DevelopmentandRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_invest_InvestmentAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="invest:InvestmentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2019Q1Jan">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="I2019Q1SD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="D2019Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ptct:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="D2013Q2May1-May31_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-01</startDate>
            <endDate>2013-05-31</endDate>
        </period>
    </context>
    <context id="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-05</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:EquityAndLongTermIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-05</startDate>
            <endDate>2013-03-05</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2013Q2May31_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-05-31</instant>
        </period>
    </context>
    <context id="D2013Q2May1-May31_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:LongTermIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-01</startDate>
            <endDate>2013-05-31</endDate>
        </period>
    </context>
    <context id="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-03-05</instant>
        </period>
    </context>
    <context id="D2016Q2May1-May31_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-05</startDate>
            <endDate>2013-03-05</endDate>
        </period>
    </context>
    <context id="FI2016Q2_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="I2013Q2May31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptct:EmployeeDirectorAndConsultantStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptct:Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-05-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q2May-05_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-05</startDate>
            <endDate>2017-05-05</endDate>
        </period>
    </context>
    <context id="D2017Q2May_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ptct:MidCapFinancialTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ptct:DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q3_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:ConvertibleSeniorNotes3.0PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2016Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:WellcomeTrustLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:AgilisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2014Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="D2011Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-11-01</startDate>
            <endDate>2011-11-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-11-01</startDate>
            <endDate>2011-11-30</endDate>
        </period>
    </context>
    <context id="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-11-01</startDate>
            <endDate>2011-11-30</endDate>
        </period>
    </context>
    <context id="D2013Q3Aug_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Oct_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2014Q1Jan1-Jan31_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptct:CollaborationAndDiscoveryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ptct:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:ResearchAndDevelopmentEventMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:RocheAndSmaFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2011Q4Nov1-Nov30_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:RocheAndSmaFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-11-01</startDate>
            <endDate>2011-11-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ptct:MilestoneAxis">ptct:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2011Q4Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:LicensingAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2018-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2011-11-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:DiscoveryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptct:CollaborationAndDiscoveryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2018-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2018-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptct:CollaborationAndDiscoveryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:DiscoveryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptct:EarlyStageCollaborationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="I2017Q2Apr-20_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-20</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ptct:EmflazaassetacquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptct:AkceaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-04</instant>
        </period>
    </context>
    <context id="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:NewBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-04</instant>
        </period>
    </context>
    <context id="D2019Q3Aug4-Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-04</startDate>
            <endDate>2019-08-04</endDate>
        </period>
    </context>
    <context id="I2019Q3Aug4_us-gaap_DebtInstrumentAxis_ptct_FifthAnniversaryMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptct:FifthAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-04</instant>
        </period>
    </context>
    <context id="I2019Q3aug2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-02</instant>
        </period>
    </context>
    <context id="I2019Q3aug2_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ptct:NewBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-02</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product">
        <measure>ptct:product</measure>
    </unit>
    <unit id="country">
        <measure>ptct:country</measure>
    </unit>
    <unit id="member_state">
        <measure>ptct:member_state</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="operating_lease">
        <measure>ptct:operating_lease</measure>
    </unit>
    <unit id="segment">
        <measure>ptct:segment</measure>
    </unit>
    <unit id="Feet">
        <measure>ptct:Feet</measure>
    </unit>
    <unit id="Term">
        <measure>ptct:Term</measure>
    </unit>
    <unit id="day">
        <measure>ptct:day</measure>
    </unit>
    <unit id="deliverable">
        <measure>ptct:deliverable</measure>
    </unit>
    <unit id="compound">
        <measure>ptct:compound</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q2YTD"
      id="Fact-32F7E375D789358D7FFFF1F30287671E-wk-Fact-32F7E375D789358D7FFFF1F30287671E">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q2YTD"
      id="Fact-F87E7EA51572444D9769F1F302889445-wk-Fact-F87E7EA51572444D9769F1F302889445">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q2YTD"
      id="Fact-8A54AA01D83AA50956C5F1F302898ACA-wk-Fact-8A54AA01D83AA50956C5F1F302898ACA">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q2YTD"
      id="Fact-A409085F3D98FA211E57F1F3028971B8-wk-Fact-A409085F3D98FA211E57F1F3028971B8">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q2YTD"
      id="Fact-2B475362F3647902B807F1F302865DA9-wk-Fact-2B475362F3647902B807F1F302865DA9">0001070081</dei:EntityCentralIndexKey>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember"
      decimals="-6"
      id="Fact-AF0EC129FA8C6FAE2B1FF1F3028594CC-wk-Fact-AF0EC129FA8C6FAE2B1FF1F3028594CC"
      unitRef="usd">555000000</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember"
      decimals="-6"
      id="Fact-DBE6DA8EAA3E4036CEDFF1F30285BE68-wk-Fact-DBE6DA8EAA3E4036CEDFF1F30285BE68"
      unitRef="usd">150000000</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember"
      decimals="-6"
      id="Fact-575C62B9A5D1F6EC8F9FF1F3028C6805-wk-Fact-575C62B9A5D1F6EC8F9FF1F3028C6805"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember"
      decimals="-5"
      id="Fact-4167E7F93915062DD2BCF1F30284FE28-wk-Fact-4167E7F93915062DD2BCF1F30284FE28"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember"
      decimals="-6"
      id="Fact-83E7794543466525626FF1F3024DD85B-wk-Fact-83E7794543466525626FF1F3024DD85B"
      unitRef="usd">555000000</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember"
      decimals="-6"
      id="Fact-3B0488E1D42A24EC2F9CF1F302932790-wk-Fact-3B0488E1D42A24EC2F9CF1F302932790"
      unitRef="usd">150000000</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember"
      decimals="-6"
      id="Fact-E27FBEFB70C38968CA61F1F30293E7B6-wk-Fact-E27FBEFB70C38968CA61F1F30293E7B6"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:AlternativeInvestmentMilestone
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_SalesMilestonesMember"
      decimals="-5"
      id="Fact-48FB19A4A892AFBCDB90F1F3026FA75E-wk-Fact-48FB19A4A892AFBCDB90F1F3026FA75E"
      unitRef="usd">0</ptct:AlternativeInvestmentMilestone>
    <ptct:CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember"
      id="Fact-B406DA9409DFD31F04B2F1F302A38093-wk-Fact-B406DA9409DFD31F04B2F1F302A38093">P4Y</ptct:CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology>
    <ptct:CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember"
      id="Fact-1F8CD98C8D198EBD1A8EF1F30299A289-wk-Fact-1F8CD98C8D198EBD1A8EF1F30299A289">P3Y</ptct:CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology>
    <ptct:DebtInstrumentConvertibleThresholdBusinessDays
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="Fact-2183F594CB3E050D0AF2F1F302ABE430-wk-Fact-2183F594CB3E050D0AF2F1F302ABE430">P5D</ptct:DebtInstrumentConvertibleThresholdBusinessDays>
    <ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="Fact-EDC8D70DBFD931617F46F1F302ACD295-wk-Fact-EDC8D70DBFD931617F46F1F302ACD295">P5D</ptct:DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod>
    <ptct:DebtInstrumentInterestPaymentPeriod
      contextRef="D2017Q2May_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      id="Fact-A42BF7ACA0D4ACB28BA2F1F302AA7B99-wk-Fact-A42BF7ACA0D4ACB28BA2F1F302AA7B99">P24M</ptct:DebtInstrumentInterestPaymentPeriod>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="2"
      id="Fact-808762A8DF45C5E3C545F1F3028ACA02-wk-Fact-808762A8DF45C5E3C545F1F3028ACA02"
      unitRef="number">0.08</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember"
      decimals="2"
      id="Fact-2417CC4EB4732A2CD95DF1F3028C1F39-wk-Fact-2417CC4EB4732A2CD95DF1F3028C1F39"
      unitRef="number">0.06</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-1A11E05518CCA50B3A9FF1F3028E1DE1-wk-Fact-1A11E05518CCA50B3A9FF1F3028E1DE1"
      unitRef="number">0.94</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-EA9EA48568A6995A0D5AF1F3028AF28D-wk-Fact-EA9EA48568A6995A0D5AF1F3028AF28D"
      unitRef="number">0.89</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="2"
      id="Fact-D57228901835E746BBA8F1F302872409-wk-Fact-D57228901835E746BBA8F1F302872409"
      unitRef="usdPerShare">30.86</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="4"
      id="Fact-4278E8B1A8929AFEA2A2F1F30284AA90-wk-Fact-4278E8B1A8929AFEA2A2F1F30284AA90"
      unitRef="number">0.5959</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact-DAC7C8D8C6C9C617E183F1F302890A15-wk-Fact-DAC7C8D8C6C9C617E183F1F302890A15"
      unitRef="number">0.0263</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember"
      decimals="2"
      id="Fact-DBBB461D68B86E0FEC1EF1F3028BC201-wk-Fact-DBBB461D68B86E0FEC1EF1F3028BC201"
      unitRef="usdPerShare">2520.00</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="4"
      id="Fact-E97B5C2625280CB6660CF1F3028D4E0F-wk-Fact-E97B5C2625280CB6660CF1F3028D4E0F"
      unitRef="number">0.6048</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="3"
      id="Fact-41CFF85A54822DF369CAF1F3028C859C-wk-Fact-41CFF85A54822DF369CAF1F3028C859C"
      unitRef="number">0.058</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember"
      decimals="2"
      id="Fact-1B412FB0701569733F3CF1F302849E38-wk-Fact-1B412FB0701569733F3CF1F302849E38"
      unitRef="number">0.02</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-0BEC8F0163CB81B65511F1F3028B015D-wk-Fact-0BEC8F0163CB81B65511F1F3028B015D"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-97FD46359E88313305B6F1F302887048-wk-Fact-97FD46359E88313305B6F1F302887048"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="2"
      id="Fact-D97D686C29FF78BB28DAF1F302868669-wk-Fact-D97D686C29FF78BB28DAF1F302868669"
      unitRef="usdPerShare">6.76</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="4"
      id="Fact-9E8CF927AC0F19AD82F8F1F30285C52E-wk-Fact-9E8CF927AC0F19AD82F8F1F30285C52E"
      unitRef="number">0.4653</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact-E24002A508645B12BC5CF1F3028D05F2-wk-Fact-E24002A508645B12BC5CF1F3028D05F2"
      unitRef="number">0.0244</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember"
      decimals="2"
      id="Fact-95A645A66E14A8066246F1F3028A5960-wk-Fact-95A645A66E14A8066246F1F3028A5960"
      unitRef="usdPerShare">128.00</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="4"
      id="Fact-B25950FA864385AAAAF9F1F3028AEABD-wk-Fact-B25950FA864385AAAAF9F1F3028AEABD"
      unitRef="number">0.5939</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="3"
      id="Fact-51BA9B0F2B559F4BDDCFF1F302975F05-wk-Fact-51BA9B0F2B559F4BDDCFF1F302975F05"
      unitRef="number">0.057</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember"
      decimals="2"
      id="Fact-4573E2527A27C4424531F1F302510298-wk-Fact-4573E2527A27C4424531F1F302510298"
      unitRef="number">0.06</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-6DF196CAE6348C01D2B6F1F30292B77E-wk-Fact-6DF196CAE6348C01D2B6F1F30292B77E"
      unitRef="number">0.94</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-F4576FBAADB8EE19BF58F1F3026F7984-wk-Fact-F4576FBAADB8EE19BF58F1F3026F7984"
      unitRef="number">0.89</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="2"
      id="Fact-B32D9ECD4CD1C63C37A3F1F3029614A4-wk-Fact-B32D9ECD4CD1C63C37A3F1F3029614A4"
      unitRef="usdPerShare">30.86</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember"
      decimals="2"
      id="Fact-B86066FF60F9427F02B6F1F3024EE97D-wk-Fact-B86066FF60F9427F02B6F1F3024EE97D"
      unitRef="usdPerShare">2520.00</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      decimals="2"
      id="Fact-3C346214CFE215B36624F1F3026E6727-wk-Fact-3C346214CFE215B36624F1F3026E6727"
      unitRef="number">0.23</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="4"
      id="Fact-8E6B8A992DFE6CC66B24F1F30297E387-wk-Fact-8E6B8A992DFE6CC66B24F1F30297E387"
      unitRef="number">0.4841</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="3"
      id="Fact-60FCE20B73B5D62D0602F1F3024C1D1F-wk-Fact-60FCE20B73B5D62D0602F1F3024C1D1F"
      unitRef="number">0.038</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_PercentageofSalesforRoyaltiesMember"
      decimals="2"
      id="Fact-895BC0E3D18AB5D28021F1F3029214CF-wk-Fact-895BC0E3D18AB5D28021F1F3029214CF"
      unitRef="number">0.02</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-9B43B0FA25521BA9B0C7F1F3024F395D-wk-Fact-9B43B0FA25521BA9B0C7F1F3024F395D"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_ProbabilityofSuccessMember"
      decimals="2"
      id="Fact-FB1465FCE8AE78203973F1F30253838D-wk-Fact-FB1465FCE8AE78203973F1F30253838D"
      unitRef="number">0.25</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="2"
      id="Fact-D97794805DBC3C19A46AF1F3024D0815-wk-Fact-D97794805DBC3C19A46AF1F3024D0815"
      unitRef="usdPerShare">6.76</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember"
      decimals="2"
      id="Fact-455F1F09E973377E2440F1F302969403-wk-Fact-455F1F09E973377E2440F1F302969403"
      unitRef="usdPerShare">128.00</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      decimals="2"
      id="Fact-A523D79676CB93C8E981F1F30293B74B-wk-Fact-A523D79676CB93C8E981F1F30293B74B"
      unitRef="number">0.10</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="4"
      id="Fact-F4408655886411E59511F1F3024EFEC6-wk-Fact-F4408655886411E59511F1F3024EFEC6"
      unitRef="number">0.4759</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact-72009177156F75B7DF33F1F302A5E1AC-wk-Fact-72009177156F75B7DF33F1F302A5E1AC"
      unitRef="usdPerShare">2520.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact-421BCDDF7BD177C738EBF1F302A3089F-wk-Fact-421BCDDF7BD177C738EBF1F302A3089F"
      unitRef="usdPerShare">128.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact-19EDD21DF5636B04AAD7F1F302A3E808-wk-Fact-19EDD21DF5636B04AAD7F1F302A3E808"
      unitRef="shares">130</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="FI2018Q4_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact-28E643546BFFB6DD26E9F1F302A37EFD-wk-Fact-28E643546BFFB6DD26E9F1F302A37EFD"
      unitRef="shares">7030</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-61C3B0BCFE0BADAFFABDF1F30254604F-wk-Fact-61C3B0BCFE0BADAFFABDF1F30254604F"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-7DE80D8D5D5158E87ECFF1F30256F5BA-wk-Fact-7DE80D8D5D5158E87ECFF1F30256F5BA"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-2180A8D90AC0847E293BF1F302558B07-wk-Fact-2180A8D90AC0847E293BF1F302558B07"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-01FC164D704158BABF90F1F30256D0F7-wk-Fact-01FC164D704158BABF90F1F30256D0F7"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-F8CA01E5A02F0F320739F1F302576BEA-wk-Fact-F8CA01E5A02F0F320739F1F302576BEA"
      unitRef="shares">50606147</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-88BDA651284AFF581F60F1F30256F782-wk-Fact-88BDA651284AFF581F60F1F30256F782"
      unitRef="shares">58707185</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-03E8B1CEDBE88A597695F1F3025538C3-wk-Fact-03E8B1CEDBE88A597695F1F3025538C3"
      unitRef="shares">50606147</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-07E590A922AD96E27117F1F30255C42A-wk-Fact-07E590A922AD96E27117F1F30255C42A"
      unitRef="shares">57707185</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact-B236EE9E45E1E8B70DB148C45B508394-wk-Fact-B236EE9E45E1E8B70DB148C45B508394"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact-B297A42EE3292508867448C438C47793-wk-Fact-B297A42EE3292508867448C438C47793"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentTerm
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="Fact-143B23403E88B65539B4F1F302AB52E8-wk-Fact-143B23403E88B65539B4F1F302AB52E8">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="Fact-A9D734EC36C8445F4053F1F3026DE4A6-wk-Fact-A9D734EC36C8445F4053F1F3026DE4A6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="Fact-A042308E6689E9CE52AAF1F302B157DC-wk-Fact-A042308E6689E9CE52AAF1F302B157DC"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD"
      id="Fact-DEC1BF9620DE94F8EDEFF1F3029354FA-wk-Fact-DEC1BF9620DE94F8EDEFF1F3029354FA">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      id="Fact-C7ACB3B1D8F10AD1B6C962D2ACF7E315-wk-Fact-C7ACB3B1D8F10AD1B6C962D2ACF7E315">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LessorOperatingLeaseRenewalTerm
      contextRef="I2019Q3aug2_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="Fact-A7BA1ED6623C675580A663134D468C47-wk-Fact-A7BA1ED6623C675580A663134D468C47">P5Y</us-gaap:LessorOperatingLeaseRenewalTerm>
    <us-gaap:LessorOperatingLeaseRenewalTerm
      contextRef="I2019Q3aug2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="Fact-8C94C7E370A0687D630E5971A89EB449-wk-Fact-8C94C7E370A0687D630E5971A89EB449">P10Y</us-gaap:LessorOperatingLeaseRenewalTerm>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01"
      id="Fact-71918016FA91010120D1F1F30296ED94-wk-Fact-71918016FA91010120D1F1F30296ED94">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01"
      id="Fact-EEC77FC041D6D0F76C71F1F302A21053-wk-Fact-EEC77FC041D6D0F76C71F1F302A21053">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="I2011Q4Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01"
      id="Fact-98F18E6BF07BB21F3BD1F1F302A2862A-wk-Fact-98F18E6BF07BB21F3BD1F1F302A2862A">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember"
      decimals="INF"
      id="Fact-F69EF7A67B83B1BEA18DF1F30298B9D9-wk-Fact-F69EF7A67B83B1BEA18DF1F30298B9D9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember"
      decimals="INF"
      id="Fact-B8898F7B38169C2D9477F1F3029750FB-wk-Fact-B8898F7B38169C2D9477F1F3029750FB"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_DiscoveryAgreementsMember"
      decimals="INF"
      id="Fact-2ACE1E037EAC2EC33E90F1F302952CCD-wk-Fact-2ACE1E037EAC2EC33E90F1F302952CCD"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember"
      decimals="INF"
      id="Fact-571ED16C2E3933491EF9F1F302A212DF-wk-Fact-571ED16C2E3933491EF9F1F302A212DF"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember"
      id="Fact-BDF9AAAFBB8D0F74829AF1F30280B7A0-wk-Fact-BDF9AAAFBB8D0F74829AF1F30280B7A0">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      id="Fact-024AE896CF429D124CF2F1F30280F7AE-wk-Fact-024AE896CF429D124CF2F1F30280F7AE">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="4"
      id="Fact-E83835F549EA25D2AC79F1F3028B8B16-wk-Fact-E83835F549EA25D2AC79F1F3028B8B16"
      unitRef="number">0.6309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="4"
      id="Fact-BE16676EDA9B1B030D79F1F3029185D1-wk-Fact-BE16676EDA9B1B030D79F1F3029185D1"
      unitRef="number">0.6190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="4"
      id="Fact-9FF61DB2F080C63812FFF1F302863770-wk-Fact-9FF61DB2F080C63812FFF1F302863770"
      unitRef="number">0.0263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="4"
      id="Fact-165FA3FD522FA64DD496F1F3028BC84D-wk-Fact-165FA3FD522FA64DD496F1F3028BC84D"
      unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact-6E456835BC82EBE1AB8BF1F30287A115-wk-Fact-6E456835BC82EBE1AB8BF1F30287A115">P1Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact-F5594DCD71D8C97A99D1F1F30284D715-wk-Fact-F5594DCD71D8C97A99D1F1F30284D715">P8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact-FFF72160D538753F02A9F1F3028D628A-wk-Fact-FFF72160D538753F02A9F1F3028D628A">P3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact-BF9AF61EFED70C0845C2F1F3028651DB-wk-Fact-BF9AF61EFED70C0845C2F1F3028651DB">P7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      id="Fact-4C09F6854984983AEF73F1F3028E0F0E-wk-Fact-4C09F6854984983AEF73F1F3028E0F0E">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      id="Fact-2039E3E99119D9C1B23AF1F302890582-wk-Fact-2039E3E99119D9C1B23AF1F302890582">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact-0D4B643D661FE3555A46F1F3024D3626-wk-Fact-0D4B643D661FE3555A46F1F3024D3626">P6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="FD2019Q2YTD_invest_InvestmentAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact-C17197A63E2D89C774FA1B630600FA23-wk-Fact-C17197A63E2D89C774FA1B630600FA23"
      unitRef="usd">100000</us-gaap:UnrealizedGainLossOnInvestments>
    <dei:DocumentType
      contextRef="FD2019Q2YTD"
      id="d41025170e396-wk-Fact-565F8422712A63AC75AAF1F3029B6AA2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q2YTD"
      id="d41025170e412-wk-Fact-7695866AF6FF16E4CC7FF5F7D223AF2D">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q2YTD"
      id="d41025170e427-wk-Fact-222857CB2A2415064A9AF1F302897942">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q2YTD"
      id="d41025170e441-wk-Fact-47739DAAC7655182F0041ADF7EECB52B">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q2YTD"
      id="d41025170e464-wk-Fact-7F1881AC90B3F563EED1F5F7EAE767BB">001-35969</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q2YTD"
      id="d41025170e474-wk-Fact-D456D4D4063380D70008F1F3029CA270">PTC Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q2YTD"
      id="d41025170e498-wk-Fact-CC78D90251B375894F82F5F8A5347440">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q2YTD"
      id="d41025170e508-wk-Fact-7938AB6A71597460B7EFF5F8E5BCA08A">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q2YTD"
      id="d41025170e543-wk-Fact-CE0CEAAB17A0D37FA4324144247911E5">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q2YTD"
      id="d41025170e564-wk-Fact-347F22A54B4EF9FC827441444143CD8D">South Plainfield,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q2YTD"
      id="d41025170e569-wk-Fact-8063275C58F8D0A27B89414472FB2403">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q2YTD"
      id="d41025170e579-wk-Fact-B177C97AF3F581008BE2F5FA37217516">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q2YTD"
      id="d41025170e608-wk-Fact-F0B8D230D15F389B50D9F5FAC959FA23">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q2YTD"
      id="d41025170e613-wk-Fact-8C0BDD3F089D51058923F5FAE0E7F809">222-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q2YTD"
      id="d41025170e656-wk-Fact-0BC3193529DDABBD7F5B62B2D19916DB">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q2YTD"
      id="d41025170e661-wk-Fact-509C831B24A3FD5FFAA462B2D194D13A">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q2YTD"
      id="d41025170e666-wk-Fact-C4B8488573BA673AFE5062B2D18BA6C2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q2YTD"
      id="d41025170e673-wk-Fact-E5F37D77B672542490B4F5FB153BA583">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q2YTD"
      id="d41025170e687-wk-Fact-5673FE7260E1041F0C91F5FB2FAC360F">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q2YTD"
      id="d41025170e721-wk-Fact-19C4E43F588D0404E652F5FB6B58A22A">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q2YTD"
      id="d41025170e782-wk-Fact-24BBE588861EE69320ADF5FB8DECA8F3">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q2YTD"
      id="d41025170e803-wk-Fact-80E937774B238723AEC4F5FB8EA904D5">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q2YTD"
      id="d41025170e817-wk-Fact-2CE85836E5084E930DC2F5FC210FA389">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q3Aug5"
      decimals="INF"
      id="d41025170e834-wk-Fact-4AC953F0AF1062088AECF1F3029A838C"
      unitRef="shares">58949680</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e534-wk-Fact-B14D2E1E0EB06795F714F1F30267E1D1"
      unitRef="usd">136094000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e553-wk-Fact-191CBC2919F5A5F84995F1F3025A10B1"
      unitRef="usd">169498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e573-wk-Fact-2746B8D13E29DE627940F1F3026B6513"
      unitRef="usd">227447000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e592-wk-Fact-E4BFA9A7D705A1CC75FEF1F302611F8B"
      unitRef="usd">58088000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e617-wk-Fact-3657F478B1E2C7F2FA50F1F3025D767B"
      unitRef="usd">77104000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e636-wk-Fact-69625077858D2627621DF1F30257B9B6"
      unitRef="usd">67907000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e661-wk-Fact-0CC15B0857EF6B135B85F1F3025FC547"
      unitRef="usd">16897000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e680-wk-Fact-D68658CB72697A4B3826F1F302618800"
      unitRef="usd">16117000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e705-wk-Fact-DEEBF55E27F064961B91F1F3025E9B6F"
      unitRef="usd">17424000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e724-wk-Fact-D3A6C97B27F730F01FCBF1F302627E88"
      unitRef="usd">9247000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e749-wk-Fact-CCE31C2CE176D12D45ABF1F3025EADBF"
      unitRef="usd">474966000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e768-wk-Fact-40B0CF0EE14B3CA46505F1F3025EB8B3"
      unitRef="usd">320857000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e793-wk-Fact-DB59C29DA39EA367919FF1F30261E4AA"
      unitRef="usd">15391000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e812-wk-Fact-C943C78203124BF01BD8F1F3025F13E1"
      unitRef="usd">12694000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e837-wk-Fact-FB82E0CDB0A01DE863A7F1F30264B7A3"
      unitRef="usd">702729000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e856-wk-Fact-D2CD283CC8EAE37D7DFEF1F302572D07"
      unitRef="usd">701031000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e882-wk-Fact-1348FCB698E0648159A7F1F302675838"
      unitRef="usd">82341000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e901-wk-Fact-1EB21A18E23E5D5F1BC4F1F30259D460"
      unitRef="usd">82341000</us-gaap:Goodwill>
    <ptct:DepositsAndOtherAssetsNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e926-wk-Fact-8502CA0C004357170DC6F1F3025F721F"
      unitRef="usd">16145000</ptct:DepositsAndOtherAssetsNoncurrent>
    <ptct:DepositsAndOtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e945-wk-Fact-1362B83CED862C9351A3F1F3026254EF"
      unitRef="usd">2299000</ptct:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e975-wk-Fact-41A0ED53D6A67F71F535F1F3025ADAD9"
      unitRef="usd">1291572000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e994-wk-Fact-F78EB275801B098749B7F1F302655047"
      unitRef="usd">1119222000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1109-wk-Fact-1873121A607E1419971AF1F3025B361E"
      unitRef="usd">122375000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1128-wk-Fact-C91536B542435183E188F1F3026B65D7"
      unitRef="usd">128199000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1148-wk-Fact-FAB0A43706F9AF4EB245F1F3025BE614"
      unitRef="usd">20000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1167-wk-Fact-FF00ABBA02D8E009E6B4F1F3026597A2"
      unitRef="usd">11667000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1192-wk-Fact-AB3E81E0B7F2E69C9D61F1F302603762"
      unitRef="usd">8005000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1211-wk-Fact-D4154181EBDC39552EB6F1F3025807BD"
      unitRef="usd">3716000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1236-wk-Fact-5FB539DD32F578D754DDF1F3025CD70F"
      unitRef="usd">4179000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1255-wk-Fact-848090190F5EB0948268F1F30269AEDB"
      unitRef="usd">3814000</us-gaap:OtherLiabilitiesCurrent>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1280-wk-Fact-EC0E1729260E567BC2FDF1F3026DB201"
      unitRef="usd">19400000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1298-wk-Fact-2DDB0A353C61D760CCEEF1F30268C765"
      unitRef="usd">19400000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1323-wk-Fact-BFF6B983CBAB79B194ABF1F3026C781F"
      unitRef="usd">173959000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1342-wk-Fact-1A5A8BB0F3938A8C13EBF1F3025C02B8"
      unitRef="usd">166796000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1368-wk-Fact-6B14A9EB885DD4C6EC8CF1F30264E815"
      unitRef="usd">7797000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1387-wk-Fact-BB989944AD065F9752E6F1F302677793"
      unitRef="usd">9722000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1412-wk-Fact-81D6E17DF8EFDE680C10F1F3025B8E62"
      unitRef="usd">135683000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1431-wk-Fact-26AE01168609E717E086F1F302634CD5"
      unitRef="usd">141347000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1456-wk-Fact-BF6B9AE3049435F5E337F1F302664F07"
      unitRef="usd">336200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1475-wk-Fact-3BF2E6C8C62334DD6FB5F1F302677B55"
      unitRef="usd">310240000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1500-wk-Fact-B1AD298526D12CB7B6F7F1F3025F2F0D"
      unitRef="usd">18800000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1519-wk-Fact-F2D0F549D21810B7C228F1F302699CF9"
      unitRef="usd">18300000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1544-wk-Fact-AC6D391B12EF7F04D403F1F302639810"
      unitRef="usd">122032000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1563-wk-Fact-F7F92BEF4A3A3BA0F069F1F30261D2B2"
      unitRef="usd">122032000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1588-wk-Fact-71022D5C11467F520486F1F3026C6ED6"
      unitRef="usd">8416000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1607-wk-Fact-56155D0E8FB0F65D6F19F1F302588EED"
      unitRef="usd">58000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1632-wk-Fact-91A71F1F5CBEBA964627F1F3026B7C5B"
      unitRef="usd">802887000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1651-wk-Fact-7541C6AA563A3A25B1BCF1F302644320"
      unitRef="usd">768495000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1721-wk-Fact-174D56740D7C3BE933C8F1F3026C9B90"
      unitRef="usd">58000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1740-wk-Fact-A243A4FE3F551BD2490CF1F3025C4C3B"
      unitRef="usd">51000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1765-wk-Fact-287C96823CDAFCC169A4F1F30263CF12"
      unitRef="usd">1539530000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1784-wk-Fact-3EF11F8AFFCA7A4FB5E6F1F30269F0AC"
      unitRef="usd">1288137000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1809-wk-Fact-2CD0E9340612B4BEADE1F1F302698C50"
      unitRef="usd">1922000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1828-wk-Fact-504508D6DADEC5401F77F1F3026BFA59"
      unitRef="usd">1462000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1854-wk-Fact-37D23494F58D75300B84F1F30268AB36"
      unitRef="usd">-1052825000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1874-wk-Fact-638F8964B620A2EF842EF1F3025F2F40"
      unitRef="usd">-938923000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1900-wk-Fact-44B007521E6FA9A6DA45F1F302665AD4"
      unitRef="usd">488685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1919-wk-Fact-6297117AECFFB699AD17F1F302599BAE"
      unitRef="usd">350727000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41021057e1949-wk-Fact-7D47EC781ED1439A3046F1F30258BFF0"
      unitRef="usd">1291572000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41021057e1968-wk-Fact-9B119107D18BA081D5A5F1F30262BEF5"
      unitRef="usd">1119222000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e663-wk-Fact-B5D87C0E294BB46D4147F1F30278A5C1"
      unitRef="usd">85476000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d41025438e682-wk-Fact-C09A96C568ED097A4884F1F30283F5E2"
      unitRef="usd">68170000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d41025438e702-wk-Fact-34470714E069635311B8F1F302A5A9B8"
      unitRef="usd">138530000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d41025438e721-wk-Fact-0226619864E515050F63F1F302836832"
      unitRef="usd">124151000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember"
      decimals="-3"
      id="d41025438e741-wk-Fact-945F7AD3573747C0C871F1F3026EC8EA"
      unitRef="usd">46000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember"
      decimals="-3"
      id="d41025438e760-wk-Fact-051A029ADA6D742AAB45F1F3027283AD"
      unitRef="usd">573000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember"
      decimals="-3"
      id="d41025438e779-wk-Fact-0B9B4208B56D503D77ACF1F30253E389"
      unitRef="usd">575000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q2YTD_srt_ProductOrServiceAxis_ptct_GrantAndCollaborationMember"
      decimals="-3"
      id="d41025438e799-wk-Fact-EA644FF5F8EFD7998282F1F30255C2E2"
      unitRef="usd">654000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e824-wk-Fact-77298C0E3BC3DFEC4BC6F1F302964BD5"
      unitRef="usd">85522000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e843-wk-Fact-006D8DBA01BB3AB996B1F1F3024F9348"
      unitRef="usd">68743000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e862-wk-Fact-6AB84B39F5B5BA73D231F1F30290C546"
      unitRef="usd">139105000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e882-wk-Fact-9044C89305C85CAEE6E3F1F30298E96C"
      unitRef="usd">124805000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e990-wk-Fact-88FE8F01C334BEBEAE87F1F30281BCD4"
      unitRef="usd">3211000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1009-wk-Fact-4985F97FCD8A310EAE17F1F302AF7DB0"
      unitRef="usd">2572000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1028-wk-Fact-44BF77975B4708CA0FCCF1F3026A957D"
      unitRef="usd">5587000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1048-wk-Fact-2A3C229F3854873F5C37F1F30266078F"
      unitRef="usd">5616000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1073-wk-Fact-92D14BF4CCA1BDC29F82F1F30282E6B2"
      unitRef="usd">6575000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1092-wk-Fact-C4CF34EB205DF1A3B2A5F1F30251FA59"
      unitRef="usd">5593000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1111-wk-Fact-ECE26D3104453FC7246AF1F302701C17"
      unitRef="usd">12652000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1131-wk-Fact-323CE23BB3B3AC707AEDF1F30294F6B4"
      unitRef="usd">11022000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1156-wk-Fact-04CD828C994F27D885C6F1F3027FB3D1"
      unitRef="usd">59979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1175-wk-Fact-B89D22592B86FD7DDD27F1F30265B9D6"
      unitRef="usd">32607000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1194-wk-Fact-BE6B6B53FEEDE2CB6E94F1F3028B0C50"
      unitRef="usd">112544000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1214-wk-Fact-59DC19F6FEC571B77A40F1F3028320E5"
      unitRef="usd">63970000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1239-wk-Fact-F6DE677FAEA16F6F5F29F1F3026E55EC"
      unitRef="usd">49215000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1258-wk-Fact-B7B504EF14D3F2A5F40EF1F3027EBE2D"
      unitRef="usd">33545000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1277-wk-Fact-84536C28E5E2E183CED6F1F302812E31"
      unitRef="usd">89760000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1297-wk-Fact-2A986C70536DDDFD55F9F1F30273F17B"
      unitRef="usd">66514000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1323-wk-Fact-9BFE31E97686745E9279F1F30291EE6A"
      unitRef="usd">-5300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1342-wk-Fact-A7442E5D11A06F533515F1F302926B0A"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1361-wk-Fact-4AE8B6E6F431F82CD6C1412EA3EB19FD"
      unitRef="usd">-26460000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1381-wk-Fact-69AFD2C8B45896C319BF412EA4F65FB7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1406-wk-Fact-E48AE6A5AF6E3BC449B3F1F302996C45"
      unitRef="usd">124280000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1425-wk-Fact-191517E55E7EB3B06D3EF1F3024E8D9E"
      unitRef="usd">74317000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1444-wk-Fact-291C9031565CE8EBB816F1F3029471B9"
      unitRef="usd">247003000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1464-wk-Fact-EAB21B1C24EDA589FEDBF1F3028264DF"
      unitRef="usd">147122000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1489-wk-Fact-F03DC83685F3EFDF718BF1F3029B7A11"
      unitRef="usd">-38758000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1509-wk-Fact-72EAADF90E7835127512F1F302661E66"
      unitRef="usd">-5574000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1529-wk-Fact-1F909ED174D9BA62AB79F1F30250034C"
      unitRef="usd">-107898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1550-wk-Fact-3F95336E082A89147278F1F30268FBD1"
      unitRef="usd">-22317000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1576-wk-Fact-A2BF0CDD60E79B7BF5D2F1F30282FEC8"
      unitRef="usd">-2074000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1596-wk-Fact-CF04E2EEEFC3C4F1FA7DF1F302A9D62F"
      unitRef="usd">-2884000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1616-wk-Fact-4BBC2225C8F1B562A8AEF1F302A8E838"
      unitRef="usd">-4362000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1637-wk-Fact-C875681B6830D59C3B40F1F30268C6E6"
      unitRef="usd">-6187000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1663-wk-Fact-0537833CAF9F23808912F1F302597540"
      unitRef="usd">-183000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1683-wk-Fact-C5018CAB7ED35E10AB17F1F302522122"
      unitRef="usd">-673000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1703-wk-Fact-309997F5D8EC47064CF3F1F3026047A1"
      unitRef="usd">-292000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1724-wk-Fact-06DF8A5D810FE6192AD7F1F302689FCC"
      unitRef="usd">332000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1749-wk-Fact-B6C129E894EEF1379FE1F1F302A0864E"
      unitRef="usd">-41015000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1769-wk-Fact-EAD549CB3B6240C14BDEF1F3026AFAC4"
      unitRef="usd">-9131000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1789-wk-Fact-8D10F2EB6C15EA90F6EDF1F30295FB2F"
      unitRef="usd">-112552000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1810-wk-Fact-EDBC685EEADA9B6AD8A7F1F30291D6F7"
      unitRef="usd">-28172000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1836-wk-Fact-24A9D337302890C75A5CF1F3025DFB94"
      unitRef="usd">774000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1856-wk-Fact-3D277FF267D5B04A4796F1F30285C61E"
      unitRef="usd">389000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1876-wk-Fact-72F892CB278918F9616FF1F302511160"
      unitRef="usd">1350000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1897-wk-Fact-8F86956B8E6F72138B40F1F3025085E6"
      unitRef="usd">610000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41025438e1928-wk-Fact-651BF6E516962DCADDD067A08AE24A6F"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41025438e1948-wk-Fact-77253079152E3EFA3F29F1F3027805CB"
      unitRef="usd">-9520000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41025438e1969-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41025438e1989-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398"
      unitRef="usd">-28782000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d41025438e2180-wk-Fact-A4B2822AB20BADD4161DF1F3027368B0"
      unitRef="shares">55912748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="0"
      id="d41025438e2199-wk-Fact-18D1C97362E1A320D10AF1F30288CE54"
      unitRef="shares">46137833</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d41025438e2218-wk-Fact-53AF798862AF86240026F1F30299D7AA"
      unitRef="shares">57113141</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q2YTD"
      decimals="0"
      id="d41025438e2238-wk-Fact-B1D37CC50BA3FB74C941F1F3028EA40A"
      unitRef="shares">46257397</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d41025438e2269-wk-Fact-7724A2F532F09ACED389F1F3025AA52A"
      unitRef="usdPerShare">-0.75</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d41025438e2289-wk-Fact-79112D852D0E45DBB532F1F3026BBDE5"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d41025438e2310-wk-Fact-A81E1E67ADE7F1FDE5FFF1F30267C69F"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d41025438e2330-wk-Fact-604CC67F0B1D65A308C7F1F3026AD791"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41021933e580-wk-Fact-651BF6E516962DCADDD067A08AE24A6F"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41021933e600-wk-Fact-77253079152E3EFA3F29F1F3027805CB"
      unitRef="usd">-9520000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41021933e621-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41021933e641-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398"
      unitRef="usd">-28782000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41021933e745-wk-Fact-C217EF9F4BADDF8A9C63F1F3028BBFEF"
      unitRef="usd">839000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41021933e764-wk-Fact-230E1298F23EE1BB3D1BF1F3028B1E1A"
      unitRef="usd">40000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41021933e783-wk-Fact-F743F8F4B049B007FE3DF1F302883FD9"
      unitRef="usd">898000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41021933e803-wk-Fact-8E16FD2302071E7BA8CFF1F3028D6542"
      unitRef="usd">-83000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41021933e829-wk-Fact-5D4F989CABF974215874F1F3028AF5A0"
      unitRef="usd">278000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41021933e848-wk-Fact-BEF47F112632512139B8F1F3028EDFE2"
      unitRef="usd">-3138000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41021933e868-wk-Fact-033423007AEEF287A9E2F1F3028CF427"
      unitRef="usd">-438000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41021933e889-wk-Fact-C536FCBEF75F12AEEDB0F1F302891AB4"
      unitRef="usd">-2031000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41021933e920-wk-Fact-16D38F22460A6F509211F1F30290AC00"
      unitRef="usd">-40672000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41021933e940-wk-Fact-CA92609032E73DD2A7FEF1F302907599"
      unitRef="usd">-12618000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41021933e961-wk-Fact-79D52A4ADF7662CEB0D5F6084F1F7755"
      unitRef="usd">-113442000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41021933e981-wk-Fact-F60C0474CFF0A3AE21C0F1F3028FC69C"
      unitRef="usd">-30896000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e662-wk-Fact-95DB597A79DF5E335008F1F302B1E708"
      unitRef="shares">58418790</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e681-wk-Fact-BAC8B22E2D42382FB803F1F302B2E814"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e700-wk-Fact-E60E3878676DC834ECA0F1F302A90234"
      unitRef="usd">1523115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e720-wk-Fact-FA8E4A7513A584AA36C3F1F302B052F8"
      unitRef="usd">805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e739-wk-Fact-6DB8DB9211E5A392E087F1F302B40283"
      unitRef="usd">-1011036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-3"
      id="d41036265e759-wk-Fact-34180B75B7123B23F6C749FB7444DEF2"
      unitRef="usd">512942000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e775-wk-Fact-D28F04FAC3688BF16503F1F30273239A"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e789-wk-Fact-1FE44E64464D64171493F1F302839627"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e808-wk-Fact-029C5DE007AA11845614F1F3024C3CC9"
      unitRef="usd">106000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41036265e866-wk-Fact-BF3BC81B0AFCDE086D31F1F30275E60F"
      unitRef="usd">106000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e887-wk-Fact-3D7D17351040BDC26143F1F3027A97B8"
      unitRef="shares">230176</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d41036265e901-wk-Fact-EB1B796047D5DFE815D21B1A79A6D894"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e920-wk-Fact-A32A940D1E863B344612F1F3025CDC89"
      unitRef="usd">2847000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41036265e978-wk-Fact-2625F1489671172652141B1AAA205836"
      unitRef="usd">2847000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e999-wk-Fact-57BD59FD1F2B5318F140F1F302811193"
      unitRef="shares">3500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41036265e1090-wk-Fact-63B9D1F7197CD3E99597F1F3026BB004"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e1111-wk-Fact-703D1EB4ECEF44FAA2781B3FB0A5DD46"
      unitRef="shares">54719</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e1125-wk-Fact-CE777A92D7568CDF38EA1B4033A00AEA"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e1144-wk-Fact-D0E9174FF95DD6CE7AE81B4033AE400F"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41036265e1202-wk-Fact-8BE4F04D7F0F0051DD281B403398CC5E"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e1256-wk-Fact-BF3033F8166F3BD3377BF1F302821AD4"
      unitRef="usd">10920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41036265e1314-wk-Fact-48DBC9D8057A07719207F1F302B1107C"
      unitRef="usd">10920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e1368-wk-Fact-3E37DF47E920BB2068901B3EE47BCE85"
      unitRef="usd">978000</ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor>
    <ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41036265e1426-wk-Fact-AA5038515B37F77C41231B3F0462F370"
      unitRef="usd">978000</ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e1519-wk-Fact-DF4C6C632306D77471D4F1F3026B7906"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41036265e1539-wk-Fact-651BF6E516962DCADDD067A08AE24A6F"
      unitRef="usd">-41789000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e1614-wk-Fact-39B3F33D3F195F19AD21F1F3027FD36A"
      unitRef="usd">1117000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41036265e1652-wk-Fact-97CC6FCCAE4E31A95A8FF1F302651C89"
      unitRef="usd">1117000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e1674-wk-Fact-0C6DE953182D3FB5D42CF1F302B177EB"
      unitRef="shares">58707185</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e1693-wk-Fact-B4CFA9ECD87BB9326205F1F3026C52AF"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e1712-wk-Fact-723357BBC475BC8FB7B0F1F30274C851"
      unitRef="usd">1539530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e1732-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920"
      unitRef="usd">1922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e1751-wk-Fact-775FE7BD309380239C61F1F30252D4F9"
      unitRef="usd">-1052825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036265e1771-wk-Fact-44B007521E6FA9A6DA45F1F302665AD4"
      unitRef="usd">488685000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e2080-wk-Fact-A833AF58E81B712B268D1B188E4C7FFF"
      unitRef="shares">41809398</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e2099-wk-Fact-F45B1B14714AABB7FE371B188FBA880F"
      unitRef="usd">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e2118-wk-Fact-201B9FC49165A2D795181B1891AA5305"
      unitRef="usd">975418000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e2138-wk-Fact-DD2C2D8C2D8A8242FE611B1893311C65"
      unitRef="usd">4953000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e2157-wk-Fact-CDD903483FEE20A797511B1894A05DC6"
      unitRef="usd">-830104000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1"
      decimals="-3"
      id="d41036265e2177-wk-Fact-69C2EE77E6AB6F694E6D1B18961F5438"
      unitRef="usd">150309000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e2193-wk-Fact-F663524989965717E3771B189C16A9CD"
      unitRef="shares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e2207-wk-Fact-A91AB830410B017D555D1B189E0AC9E6"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e2226-wk-Fact-556E7B1A68781C8D49991B189FFF2B0C"
      unitRef="usd">117869000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41036265e2284-wk-Fact-FDD4CF71443CD68ADD391B18A37489AB"
      unitRef="usd">117874000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e2305-wk-Fact-57C54D40DB0E3E2482D81B18A97516B8"
      unitRef="shares">183567</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e2338-wk-Fact-22728C7E78DDCD0E46041B18ACE15C79"
      unitRef="usd">2455000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41036265e2396-wk-Fact-DD54BB5CDFE7D1B685941B18B045CE77"
      unitRef="usd">2455000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e2417-wk-Fact-4A86DF103D4A48EAEAFA1B414C937173"
      unitRef="shares">87517</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e2431-wk-Fact-0F4D7CF18094C9CAA7A41B414EA541F2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e2450-wk-Fact-F046F7D1B2FDF29D544C1B4150C93173"
      unitRef="usd">1298000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41036265e2508-wk-Fact-8068B74826CC86883AF51B415651BBE9"
      unitRef="usd">1298000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e2562-wk-Fact-C9435700DCE242F658131B415B873FEB"
      unitRef="usd">8084000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41036265e2620-wk-Fact-8574DCCAB33760CAAF361B4161119B3C"
      unitRef="usd">8084000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e2713-wk-Fact-C9AC77901609FAFDC68749FB7FE5D60A"
      unitRef="usd">-9520000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41036265e2733-wk-Fact-77253079152E3EFA3F29F1F3027805CB"
      unitRef="usd">-9520000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e2808-wk-Fact-840A9AD8098BBA93E19B1B4178E6AEF1"
      unitRef="usd">-3098000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41036265e2847-wk-Fact-4969158F0E69912D3B271B417C156672"
      unitRef="usd">-3098000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e2869-wk-Fact-992BF07E05523E22775F1B417CDD3F10"
      unitRef="shares">46680482</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e2883-wk-Fact-B3D7AC47D86B4237B6141B417ED253C6"
      unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e2902-wk-Fact-5C829F92E9BBC746106D1B4180CA47F0"
      unitRef="usd">1105124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e2922-wk-Fact-553FDB3216B94EB4C5C61B4182B80C5F"
      unitRef="usd">1855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e2941-wk-Fact-B6DEC385A530265E66E61B4184DD6E59"
      unitRef="usd">-839624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-3"
      id="d41036265e2961-wk-Fact-691D664B8A51FE4CD8571B4186DC063F"
      unitRef="usd">267402000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e3275-wk-Fact-DE284704413D389BA1851B19D3417F28"
      unitRef="shares">50606147</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e3294-wk-Fact-6E59208ED4F481B513E31B19D4A7911A"
      unitRef="usd">51000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e3313-wk-Fact-65AD2E93E2E2E50C7DB51B19D6264DBA"
      unitRef="usd">1288137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e3333-wk-Fact-08D86BFFC9D39EF8C8211B19D7942B8E"
      unitRef="usd">1462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e3352-wk-Fact-60FB490EA442A4ECE8C11B19DA0F757F"
      unitRef="usd">-938923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036265e3372-wk-Fact-6297117AECFFB699AD17F1F302599BAE"
      unitRef="usd">350727000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e3388-wk-Fact-0C21EF1E97EA6450AC061B423F35F83F"
      unitRef="shares">7563725</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e3402-wk-Fact-2AA3F514B01FF3EE93501B4241279ACD"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e3421-wk-Fact-1D4E8EFF5B4E6BB094DD1B42434DB0F9"
      unitRef="usd">224538000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e3479-wk-Fact-2AF38D0DE550F0A4FAA31B42488BCBBC"
      unitRef="usd">224545000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e3500-wk-Fact-FF4C82D0D0E1C50BD4DB1B42529B1B71"
      unitRef="shares">311002</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e3514-wk-Fact-4EB1D5241EBDDE4A9F5A1B4254AED33C"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e3533-wk-Fact-64C612103B7B14458C841B4256D65596"
      unitRef="usd">4129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e3591-wk-Fact-D269BB7B134B9A814AD71B425BDA7CE6"
      unitRef="usd">4129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e3612-wk-Fact-33301F88B0B52396395C1B425C871EF9"
      unitRef="shares">171592</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e3626-wk-Fact-287A182BFF97EEBFE38D1B42DD99B755"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e3703-wk-Fact-D5ED2E24C1F41CAA92541B4264DABD72"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e3724-wk-Fact-00B2811938667F86A02A1B4265813DBC"
      unitRef="shares">54719</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e3738-wk-Fact-A682050EC80E250A47461B42676F2B2E"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e3757-wk-Fact-DD59F17FF34312FBDD081B42696D9C86"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e3815-wk-Fact-0D438A32806944AF87A51B426EECD909"
      unitRef="usd">1564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e3869-wk-Fact-580C074606ED46EF3FD21B42732BC90E"
      unitRef="usd">20184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e3927-wk-Fact-3B8CDDAC5FD72CAC16E71B4278D6D427"
      unitRef="usd">20184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e3981-wk-Fact-9CFC729CDBB8302F3F2B1B427DB9A231"
      unitRef="usd">978000</ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor>
    <ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e4039-wk-Fact-AF5891CE855C10978F441B4283C120E4"
      unitRef="usd">978000</ptct:AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e4132-wk-Fact-38374EE002E1A4ADC9A71B428C0ACF43"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e4152-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e4227-wk-Fact-8C213C64FCD5F27C822E1B42947FB8C8"
      unitRef="usd">460000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41036265e4265-wk-Fact-60C8A2FEC6BB13A2B6B51B4297F04A15"
      unitRef="usd">460000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e4287-wk-Fact-0C6DE953182D3FB5D42CF1F302B177EB"
      unitRef="shares">58707185</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e4301-wk-Fact-B4CFA9ECD87BB9326205F1F3026C52AF"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e4320-wk-Fact-723357BBC475BC8FB7B0F1F30274C851"
      unitRef="usd">1539530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e4340-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920"
      unitRef="usd">1922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e4359-wk-Fact-775FE7BD309380239C61F1F30252D4F9"
      unitRef="usd">-1052825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036265e4379-wk-Fact-44B007521E6FA9A6DA45F1F302665AD4"
      unitRef="usd">488685000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e4693-wk-Fact-B52A49A945D5A2B7EF741B1A216B5D8F"
      unitRef="shares">41612395</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e4712-wk-Fact-B3BD4C5988302572CD3B1B1A22EB7134"
      unitRef="usd">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e4731-wk-Fact-64C811C07D8036CAEE681B1A24CC6FB4"
      unitRef="usd">966534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e4751-wk-Fact-257F6AB2C29863DD60991B1A266D9920"
      unitRef="usd">3969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e4770-wk-Fact-651ACA98494C9E0916841B1A28431DC2"
      unitRef="usd">-814108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d41036265e4790-wk-Fact-3290174E3FFE0A0B85521B1A2A330532"
      unitRef="usd">156437000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e4839-wk-Fact-D34A7039BE4D876246F367CEBCF8B45B"
      unitRef="usd">-1000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e4884-wk-Fact-B35A5601B2A96DFDC5BC1B48C3396F71"
      unitRef="usd">3266000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="FI2018Q2"
      decimals="-3"
      id="d41036265e4903-wk-Fact-DD2029FE20F1543CBAAA1B48C3425C98"
      unitRef="usd">3265000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e4919-wk-Fact-9AA8439E9C0CEF378BB41B43B09069E6"
      unitRef="shares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e4933-wk-Fact-67FCF77161B37D0D43851B43B2A4B4E5"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e4952-wk-Fact-D9D02507170399A4D2771B43B4EA38B3"
      unitRef="usd">117869000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41036265e5010-wk-Fact-949A466829519F52A3031B43BAFB6061"
      unitRef="usd">117874000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e5031-wk-Fact-65D4090F1022D55E79F11B44342E6B67"
      unitRef="shares">260879</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e5045-wk-Fact-EAC1995EBC09C68F53AA1B443655FD99"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e5064-wk-Fact-4D11BD6570E7348489BD1B443847CE14"
      unitRef="usd">3592000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41036265e5122-wk-Fact-892AB0C86701C3F185DA1B443DF9BF01"
      unitRef="usd">3592000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="0"
      id="d41036265e5143-wk-Fact-B12F58A171E997DBBE511B4997653F64"
      unitRef="shares">119691</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41036265e5234-wk-Fact-930636481820854F96821B4B3FF5E20A"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e5255-wk-Fact-92C21C5D918F59B566671B466EF3D404"
      unitRef="shares">87517</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e5269-wk-Fact-01C16661EA725C8A38761B4670ECE00D"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e5288-wk-Fact-442449AA52B3BE44188E1B4672E4AB1F"
      unitRef="usd">1299000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41036265e5346-wk-Fact-28BD05A01E5A45E6650C1B4677DEFED4"
      unitRef="usd">1299000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e5400-wk-Fact-1DF7D64354D8FBAB37FF1B46B47466E3"
      unitRef="usd">15831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41036265e5458-wk-Fact-4981140E8DDFAC41103F1B46B9F5632B"
      unitRef="usd">15831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e5551-wk-Fact-729CA6AD328395BF7B151B479ED95C81"
      unitRef="usd">-28782000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41036265e5576-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398"
      unitRef="usd">-28782000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e5646-wk-Fact-23E2570F0BB81A54358A1B47A655A53F"
      unitRef="usd">-2114000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41036265e5685-wk-Fact-F836E465100BC7EB5B5B1B47A997B182"
      unitRef="usd">-2114000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41036265e5708-wk-Fact-992BF07E05523E22775F1B417CDD3F10"
      unitRef="shares">46680482</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d41036265e5722-wk-Fact-B3D7AC47D86B4237B6141B417ED253C6"
      unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d41036265e5741-wk-Fact-5C829F92E9BBC746106D1B4180CA47F0"
      unitRef="usd">1105124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41036265e5761-wk-Fact-553FDB3216B94EB4C5C61B4182B80C5F"
      unitRef="usd">1855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d41036265e5780-wk-Fact-B6DEC385A530265E66E61B4184DD6E59"
      unitRef="usd">-839624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-3"
      id="d41036265e5800-wk-Fact-691D664B8A51FE4CD8571B4186DC063F"
      unitRef="usd">267402000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e653-wk-Fact-0820D2A7C52640F63E37F1F3027D8E18"
      unitRef="usd">-113902000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e673-wk-Fact-693F59BD6E4DB2AB5327F1F302A5E398"
      unitRef="usd">-28782000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e738-wk-Fact-4D5A35F392959832F9F6F1F30268169E"
      unitRef="usd">14760000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e757-wk-Fact-4B6E3EC96D997CFD7BC3F1F302A2434D"
      unitRef="usd">12243000</us-gaap:Depreciation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e782-wk-Fact-9DF764EDB975C759BC51F1F302A638D5"
      unitRef="usd">26460000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e800-wk-Fact-6FE5F96CB3CAEACA25B3F1F302781BDB"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e825-wk-Fact-DCF4AEC67B9A4547A95F59699303CB29"
      unitRef="usd">129000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e845-wk-Fact-11A7B1FE54DDA2AA2D08596992FF36A8"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:PaidInKindInterest
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e870-wk-Fact-A346CBC4C487FD020F8BF1F302A07135"
      unitRef="usd">4055000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e889-wk-Fact-51552986D574BC843CBBF1F3025132B9"
      unitRef="usd">3644000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e914-wk-Fact-B85411157DD0ADBBD1611FFDC3FB1669"
      unitRef="usd">-50000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e933-wk-Fact-A6165D0D86AAEE376282F1F3029ABF84"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e959-wk-Fact-2DE4B0B9F8F3A8FE910FF1F3027F9795"
      unitRef="usd">907000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e979-wk-Fact-347840FD9EC3A9E7B4F4F1F3024D861D"
      unitRef="usd">230000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1005-wk-Fact-68654996ECF6CD80BD37F1F3024FD7C9"
      unitRef="usd">280000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1024-wk-Fact-947753E465369109B5F2F1F302605E05"
      unitRef="usd">256000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1049-wk-Fact-FEE24CF4ADA147E0D635F1F3025C8D58"
      unitRef="usd">20184000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1068-wk-Fact-9F622E130110B31648B8F1F30255F1C5"
      unitRef="usd">15831000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1093-wk-Fact-AD37D371D358F260F1E2F1F302A28595"
      unitRef="usd">-62000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1112-wk-Fact-85BC70F60CF5CAD3DA17F1F302B2F1F8"
      unitRef="usd">764000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1182-wk-Fact-9F906500C095D79CE83AF1F30258C35A"
      unitRef="usd">852000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1202-wk-Fact-FD2FE85C2076EC439BAEF1F3028289D0"
      unitRef="usd">3393000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1228-wk-Fact-33AFCEF322F26FAACC2FF1F3024F82EB"
      unitRef="usd">7250000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1248-wk-Fact-132293EFEAF8BCA04AE0F1F30266C2ED"
      unitRef="usd">-254000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1273-wk-Fact-9DB94FC51483B472D48AF1F3024C48D6"
      unitRef="usd">9702000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1293-wk-Fact-70AEA9AF64940CD4111BF1F3029DA5DF"
      unitRef="usd">20429000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1319-wk-Fact-11DB46CD52378B9E7BF8F1F3026D7152"
      unitRef="usd">9656000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1339-wk-Fact-4E962F6D86A47152F809F1F3025BFEB0"
      unitRef="usd">419000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1365-wk-Fact-65C583EC4EC83A4FE731F1F302765F2E"
      unitRef="usd">-7546000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1385-wk-Fact-85ADC1A4271CA3B0542DF1F302A486DD"
      unitRef="usd">2225000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1410-wk-Fact-93E1C0851586805E9873F1F3026CAE32"
      unitRef="usd">8651000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1429-wk-Fact-E39AB56CE1F9E6662FCBF1F302B14149"
      unitRef="usd">485000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1455-wk-Fact-FB7D121E236C88B5DA2BF1F30278E1BD"
      unitRef="usd">2511000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1474-wk-Fact-AFE3BBFEC3ACD95B9440F1F30282FB46"
      unitRef="usd">3204000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1499-wk-Fact-EF15CFD4D4E15DD963CDF1F302526567"
      unitRef="usd">-72931000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1519-wk-Fact-4988388ABC5E447C46F1F1F302620B79"
      unitRef="usd">-15875000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1589-wk-Fact-D08B2FE9EF75A5CCB858F1F3026694C2"
      unitRef="usd">4851000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1609-wk-Fact-683E0648185C0A47D045F1F302985DCB"
      unitRef="usd">1187000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1637-wk-Fact-E11E5CE78D9BC4D3BC2041394022E253"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1657-wk-Fact-60F4F8957BAC3817CFBE413941870C17"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1682-wk-Fact-345E83987B677215A261F1F3029566FA"
      unitRef="usd">226261000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1702-wk-Fact-268D61745F86D0C05B67F1F30260B27B"
      unitRef="usd">28656000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1728-wk-Fact-A6C4C41417C51D17498EF1F3028126BF"
      unitRef="usd">58424000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1747-wk-Fact-09CD7AD14131D8519DC7F1F3027D233B"
      unitRef="usd">35939000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1774-wk-Fact-31ABA908B2C688A9B3A11FFDC41D5827"
      unitRef="usd">11981000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1794-wk-Fact-58A29E502CCDA1AB272BF1F3024DD390"
      unitRef="usd">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1819-wk-Fact-492932613CF79C25D822F1F30266D687"
      unitRef="usd">-188669000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1839-wk-Fact-7D1417F1060C83CA1B53F1F302804969"
      unitRef="usd">6096000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1908-wk-Fact-4D00704526A0A5AD7F31F1F302B1FF36"
      unitRef="usd">4129000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1927-wk-Fact-4B2A5148D5813E9E0885F1F302A8373C"
      unitRef="usd">3592000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1953-wk-Fact-229BFCAE9FB4DCC75039F1F3026413C9"
      unitRef="usd">224545000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e1972-wk-Fact-648FF0DF1B4C383D5655F1F302A335EB"
      unitRef="usd">117874000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e1997-wk-Fact-8D31B37031BB402ADD1E4137A8F72D54"
      unitRef="usd">1667000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2017-wk-Fact-E256E0F790010F9F665D4137A9204479"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2042-wk-Fact-1AA6B32B30F3AD533C081FFDC4160BFD"
      unitRef="usd">1564000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2061-wk-Fact-F1F51D6ED4864B1BF689F1F302ABE64E"
      unitRef="usd">1299000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2086-wk-Fact-638344EE7D57D9C774D7F1F30277E926"
      unitRef="usd">228571000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2105-wk-Fact-75868A6F946ACCA5681EF1F3027E4F78"
      unitRef="usd">122765000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2130-wk-Fact-1D143CC4E7F9338958FDF1F3024C7C0F"
      unitRef="usd">-375000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2150-wk-Fact-7DC6C2270A3F3889DC5FF1F302AD09DA"
      unitRef="usd">-990000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2176-wk-Fact-5B4F46AA88C596AECC33F1F3029B24E7"
      unitRef="usd">-33404000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2196-wk-Fact-0FD2D190878980C3F03DF1F302815E86"
      unitRef="usd">111996000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41028013e2221-wk-Fact-191CBC2919F5A5F84995F1F3025A10B1"
      unitRef="usd">169498000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d41028013e2240-wk-Fact-8107EB4AD44FC89B9E5FF1F30281CC1B"
      unitRef="usd">111792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41028013e2270-wk-Fact-B14D2E1E0EB06795F714F1F30267E1D1"
      unitRef="usd">136094000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q2"
      decimals="-3"
      id="d41028013e2289-wk-Fact-358CADCAB752154B6753F1F3027C2D50"
      unitRef="usd">223788000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2358-wk-Fact-B87556F0461FB8385527F1F30278014C"
      unitRef="usd">3111000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2377-wk-Fact-1011D7D78E5319B087FEF1F302B00875"
      unitRef="usd">3838000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2402-wk-Fact-A2E446E0533A60B9C3A5F1F3024C8EBF"
      unitRef="usd">1013000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2421-wk-Fact-7864183FA1CA1ED4D55BF1F302A96E35"
      unitRef="usd">758000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2493-wk-Fact-F743F8F4B049B007FE3DF1F302883FD9"
      unitRef="usd">898000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2512-wk-Fact-8E16FD2302071E7BA8CFF1F3028D6542"
      unitRef="usd">-83000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2538-wk-Fact-4BC8F70D456635819552F1F302588A33"
      unitRef="usd">11643000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2556-wk-Fact-3AD3C8DBFEE1CB5419B4F1F3028248C7"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41028013e2581-wk-Fact-7FAF147B6C01754352ACF1F3029FF4C9"
      unitRef="usd">8269000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41028013e2600-wk-Fact-63FF5D560FE029F45C351FFDC40DB4F9"
      unitRef="usd">3903000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NatureOfOperations
      contextRef="FD2019Q2YTD"
      id="TextSelection-641191F6CC24E5E1F12EF1F302BFC07F-0-wk-Fact-85D408B9A840A523989AF1F3029B806B">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;PTC Therapeutics,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;PTC&#x201d;) is a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company&#x2019;s ability to globally commercialize products is the foundation that drives its continued investment in a robust pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; products, Translarna&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#x2122; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(ataluren) and Emflaza&#x2122; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna received marketing authorization from the European Commission in August 2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged five years and older in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; member states of the European Economic Area, or EEA. In July 2018, the European Commission approved a label-extension request to the marketing authorization for Translarna in the EEA to include patients from two to up to five years of age. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has a pipeline of gene therapy product candidates, including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, or AADC deficiency.  The Company is preparing a biologics license application, or BLA, for PTC-AADC for the treatment of AADC deficiency in the United States, which it anticipates submitting to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2019, with anticipated commercial launch in the United States in 2020, subject to approval. The Company is also preparing a marketing authorization application, or MAA, for PTC-AADC for the treatment of AADC deficiency in the European Union, or EU, for submission to the European Medicines Agency, or EMA, which will follow its BLA submission to the FDA. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company holds the rights for the commercialization of Tegsedi&#x2122; (inotersen) and Waylivra&#x2122; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean. Tegsedi has received marketing authorization in the U.S., EU and Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis. The Company filed for marketing authorization with ANVISA, the Brazilian health regulatory authority, which granted priority review. It expects approval in Brazil by the end of 2019. Waylivra has received conditional marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company also has a spinal muscular atrophy ("SMA") collaboration with F. Hoffman-La Roche&#160;Ltd and Hoffman-La Roche&#160;Inc., referred to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation. Currently, its collaboration has two pivotal clinical trials ongoing to evaluate the safety and effectiveness of risdiplam (RG7916, RO7034067), the lead compound in the SMA program. Roche is preparing an NDA and a MAA for risdiplam for the treatment of SMA in the United States and the EU, respectively, which Roche anticipates submitting to the FDA in the second half of 2019 and the EMA in the first half of 2020. In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The marketing authorization in the EEA was last renewed in July 2019 and is effective, unless extended, through August 5, 2020. The renewal was based on the Company&#x2019;s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2014, the Company initiated reimbursed early access programs, or EAP programs, for Translarna for nmDMD patients in selected territories in the EEA and recorded its first sales of Translarna in the third quarter of 2014 pursuant to an EAP program. In December 2014, the Company recorded its first commercial sales in Germany. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Translarna was available in over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; countries on a commercial basis or pursuant to an EAP program. The Company expects to expand its commercial &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;activities across the EEA pursuant to the marketing authorization granted by the EMA throughout 2019 and future years, subject to continued renewal of its marketing authorization following annual EMA reassessments and successful completion of pricing and reimbursement negotiations. Concurrently, the Company plans to continue to pursue EAP programs in select countries where those mechanisms exist, both within the EEA and in other countries that will reference the marketing authorization in the EEA.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied PTC&#x2019;s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#x2019; muscles. The Company intends to follow the FDA&#x2019;s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. The Company expects that a potential re-submission of an NDA could occur in 2020. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Emflaza was initially approved in the United States for the treatment of DMD in patients five years and older. In June 2019, the FDA approved the Company's label expansion request for Emflaza for patients two to five years of age. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 20, 2017, the Company completed its acquisition of all rights to Emflaza, or the Transaction.  Emflaza is approved in the United States for the treatment of DMD in patients two years and older. The Transaction was completed pursuant to an asset purchase agreement, dated March 15, 2017, as amended on April 20, 2017, (the "Asset Purchase Agreement"), by and between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon. The Transaction was accounted for as an asset acquisition. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. The Company assumed certain liabilities and obligations in the Transaction arising out of, or relating to, the assets acquired in the Transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upon the closing of the Transaction, the Company paid to Marathon total upfront consideration comprised of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash, funded through cash on hand, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,683,598&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock. The number of shares of common stock issued at closing was determined by dividing &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$65.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; by the volume-weighted average price per share of the Company&#x2019;s common stock on the Nasdaq Stock Market for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; trading-day period ending on the third trading day immediately preceding the closing. Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza, up to a specified aggregate maximum amount over the expected commercial life of the asset, and a single &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; sales-based milestone, in each case subject to the terms and conditions of the Asset Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the &#x201c;Merger Agreement&#x201d;), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC (the "Merger"). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$49.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,500,907&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock (the &#x201c;Closing Stock Consideration&#x201d;). The Closing Stock Consideration was determined by dividing &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; by the volume-weighted average price per share of the Company&#x2019;s common stock on the Nasdaq Global Select Market for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders may become entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products. Under the Merger Agreement, the Company is required to pay &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accumulated deficit of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,052.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company has financed its operations to date primarily through the private offering in August&#160;2015 of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2022 (see Note 10), public offerings of common stock in February 2014, October 2014, April 2018 and January 2019, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#x2019;s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Company&#160;expects&#160;that&#160;cash&#160;flows&#160;from&#160;the&#160;sales&#160;of&#160;its&#160;products,&#160;together&#160;with&#160;the&#160;Company&#x2019;s&#160;cash, cash equivalents and marketable securities,&#160;will&#160;be&#160;sufficient&#160;to&#160;fund&#160;its&#160;operations&#160;for&#160;at&#160;least&#160;the&#160;next&#160;twelve&#160;months.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ptct:NumberOfProducts
      contextRef="FI2019Q2"
      decimals="INF"
      id="d41029061e371-wk-Fact-36B76295BC000EA9E64FF1F3029C66FA"
      unitRef="product">2</ptct:NumberOfProducts>
    <ptct:NumberOfStatesInEuropeanEconomicArea
      contextRef="D2014Q3Aug1-Aug31"
      decimals="INF"
      id="d41029061e379-wk-Fact-8B5A034E4E1D8CD2FD3BF1F302990A3D"
      unitRef="member_state">31</ptct:NumberOfStatesInEuropeanEconomicArea>
    <ptct:NumberOfCountries
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_ptct_TranslarnaMember"
      decimals="0"
      id="d41029061e405-wk-Fact-050BF57D260B9FBFAAE7F1F3029BEA4D"
      unitRef="country">40</ptct:NumberOfCountries>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="-5"
      id="d41029061e425-wk-Fact-1C9191E6662D64283FA1F1F3029BC4F7"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="INF"
      id="d41029061e429-wk-Fact-844B192D14DD5E6A3A63F1F3029F04C5"
      unitRef="shares">6683598</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity
      contextRef="I2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="-5"
      id="d41029061e433-wk-Fact-A6C688A1C785E52292EDF1F3029B6BAE"
      unitRef="usd">65000000.0</ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity>
    <ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod
      contextRef="D2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      id="d41029061e437-wk-Fact-8A0897F7040E4AF687E2F1F3029DC2C1">P15D</ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="I2017Q2Apr-20_srt_CounterpartyNameAxis_ptct_MarathonPharmaceuticalsLLCMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="-5"
      id="d41029061e441-wk-Fact-49F242A97E8AF0D5E000F1F3029E5D6C"
      unitRef="usd">50000000.0</ptct:DevelopmentMilestonePaymentObligations>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41029061e451-wk-Fact-3E12ECCB403DDF61B500F1F3029EDEAD"
      unitRef="usd">49200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="INF"
      id="d41029061e455-wk-Fact-A74CB65A3FF85F32B46BF1F3029DB95A"
      unitRef="shares">3500907</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity
      contextRef="I2018Q3Aug23_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41029061e459-wk-Fact-122FBE20AACE25D81D6CF1F3029AB218"
      unitRef="usd">150000000.0</ptct:BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity>
    <ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod
      contextRef="D2018Q3Aug_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      id="d41029061e463-wk-Fact-55E6614AFBD012512D83F1F3029B98D6">P10D</ptct:BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="I2018Q3Aug23_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41029061e467-wk-Fact-ABFF01D1B6E4EC80C9E5F1F3029CA22B"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q2"
      decimals="-5"
      id="d41029061e478-wk-Fact-B397C6E034C3C6FC2179F1F3029B51E5"
      unitRef="usd">-1052800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41029061e482-wk-Fact-5C029B069446D5431F6AF1F3029E5B6F"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-64AE3985200CD2402215F1F302C04CC5-0-wk-Fact-DFE8731C3AE4CB018BF4F1F302AC2DAB">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company&#x2019;s audited financial statements as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; included in the Company&#x2019;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (the "SEC") on March 1, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the "&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Form&#160;10-K"). Additional significant accounting policies adopted during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are discussed in further detail below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying financial information as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and notes thereto included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the opinion of management, the unaudited financial information as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results to be expected for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or for any other interim period or for any other future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#x2019;s research and development expenses, stock-based compensation, valuation procedures for the convertible notes, allowance for doubtful accounts, inventory, acquired intangible assets, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inventory and cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Translarna and Emflaza product which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the components of the Company&#x2019;s inventory for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value.  No write downs were recorded for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  Additionally, though the Company&#x2019;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, these amounts were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Costs of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, including personnel costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-9, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d;.  ASU No. 2014-9 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 605-15, Revenue Recognition-Products (Topic 605) and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net product revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#x2019;s performance obligations are to provide Translarna or Emflaza based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#x2019;s customer obtains control of either Translarna or Emflaza, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to either product sales of Translarna or Emflaza.  In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. Historically, returns of Translarna and Emflaza are immaterial to the financial statements, except as related to labeling changes and changes in specialty pharmacies. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upon adoption of ASC Topic 606 on January 1, 2018, the Company elected the following practical expedients:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying ASC Topic 606 to each individual contract.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Significant Financing Component - the Company expects the period between when it transfers a promised good to a customer and when the customer pays for the good or service to be one year or less. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Immaterial Performance Obligations - the Company disregards promises deemed to be immaterial in the context of the contract. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shipping and Handling Activities - the Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#x201c;Collaborative Arrangements&#x201d; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#x2019;s financial condition and current economic trends. The allowance for doubtful accounts was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Bad debt expense was immaterial for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Indefinite-lived intangible assets consist of in-process research and development ("IPR&amp;amp;D"). IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;amp;D projects acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;amp;D acquired in a business combination. The Company utilizes the "income method&#x201d;, and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&amp;amp;D intangible assets that are determined to have had a drop in their fair value are adjusted downward and an impairment is recognized in the statement of operations. These assets are tested at least annually or sooner when a triggering event occurs that could indicate a potential impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s tangible assets. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recorded a deferred tax liability in conjunction with the Merger of $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to the tax basis difference in the IPR&amp;amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-2, &#x201c;Leases (Topic 842)&#x201d; along with other amendments issued in 2017 and 2018. Topic 842 supersedes the lease accounting requirements in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Standards Codification Topic 840, Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;(Topic 840). Topic 842 requires organizations to recognize leased assets and liabilities on the balance sheet. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the standard, operating leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease payments associated with the Company&#x2019;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#x2019;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Topic 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The lease term for all of the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;See the "Impact of recently adopted accounting pronouncements" section within this Note below and Note 3 Leases for additional information.  The information presented for periods prior to January 1, 2019 has not been adjusted and is reported under Topic 840. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#x201c;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;. This standard requires financial assets measured at amortized cost basis to be presented at the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. The Company expects to adopt this guidance when effective and is assessing what effect the adoption of ASU 2016-13 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d;. ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No. 2018-18 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Impact of recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-2, &#x201c;Leases (Topic 842)&#x201d;. This standard requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018, with early adoption permitted.  Additionally, in March 2019, the FASB issued ASU 2019-01,"Leases (Topic 842): Codification Improvements&#x201d;.  ASU 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. The Company adopted the new guidance on January 1, 2019 using the modified retrospective method. Prior period results were not adjusted and continue to be presented under Topic 840 based on the accounting standards originally in effect for such periods. As part of the adoption, the Company has elected to utilize practical expedients including the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to: 1) carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements, 2) not separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component (the Company elected to apply this practical expedient to all underlying asset classes), 3) not apply the recognition requirements in ASC 842 to short-term leases, and 4) not record a right of use asset or right of use liability for leases with an asset or liability balance that would be considered immaterial. Upon adoption, the Company recorded an operating lease liability with a corresponding operating lease ROU asset of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The adoption did not have a material impact on the consolidated results of operations, stockholder's equity, and cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As the Company is not a lessor, the aspects of the new guidance pertaining to lessors was not applicable for the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the FASB issued ASU 2018-02, "Income Statement &#x2014; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income". This standard permits the reclassification of tax effects stranded in other comprehensive income as a result of tax reform to retained earnings related to the change in federal &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;tax rate in addition to other stranded effects that relate to the 2017 Tax Act but do not directly relate to the change in the federal rate. ASU 2018-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance. The Company adopted this guidance on January 1, 2019 and elected not to reclassify the tax effects in other comprehensive income related to the 2017 Tax Act, as these amounts were immaterial. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU 2018-07, "Compensation &#x2014; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting". This standard expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in the entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The ASU retains the existing cost attribution guidance, which requires entities to recognize compensation cost for nonemployee awards in the same period and in the same manner they would if they paid cash for the goods or services, but it moves the guidance to ASC 718. ASU 2018-07 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance.  The Company adopted this guidance on January 1, 2019. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d;.  ASU No. 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 605-15, Revenue Recognition-Products and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  On January 1, 2018, the Company adopted ASC Topic 606 using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The Company calculated a one-time transition adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was recorded on January 1, 2018 to deferred revenue and accumulated deficit, related to the product sales of Emflaza. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January&#160;2016, the FASB issued ASU No.&#160;2016-01, &#x201c;Financial Instruments &#x2014; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&#x201d;. This standard enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The new guidance affects all reporting organizations (whether public or private) that hold financial assets or owe financial liabilities. The Company adopted the guidance on January&#160;1, 2018.  In March 2018, the FASB issued ASU 2018-04, "Investments - Debt Securities (Topic 320) and Regulated Operations (Topic 980): Amendments to SEC Paragraphs Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 117 and SEC Release No. 33-9273 (SEC Update)". This standard supersedes SEC paragraphs in ASC 320, Investments- Debt Securities, as a result of the issuance of SAB 117 and also updates the Codification for a 2011 SEC release and is effective when a registrant adopts ASU 2016-01, which in the case of the Company was on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15, &#x201c;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#x201d;. This standard clarifies the presentation of certain specific cash flow issues in the Statement of Cash Flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2016, the FASB issued ASU 2016-16, &#x201c;Intra-Entity Transfers of Assets Other Than Inventory&#x201d;.  ASU 2016-16 requires companies to account for the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) when the transfer occurs. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &#x201c;Statement of Cash Flows (Topic 230): Restricted Cash&#x201d;. This standard requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows and no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;In May 2017, the FASB issued ASU No. 2017-09, "Stock Compensation (Topic 718): Scope of Modification Accounting". This standard clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as a modification, with entities applying the modification accounting guidance if the value, vesting conditions or classification of the award changes. In addition to all disclosures about modifications that are required under the current guidance, entities will be also required to disclose that compensation expense has not changed if applicable.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted the guidance on January&#160;1, 2018.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-51C051BA0B8D6554792AF1F302BF1078-0-wk-Fact-60A18E220A6F05084D0EF1F302AA9B60">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying financial information as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and notes thereto included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the opinion of management, the unaudited financial information as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results to be expected for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or for any other interim period or for any other future year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q2YTD"
      id="TextSelection-E0EB789328CB83010B79F1F302C06EC5-0-wk-Fact-DEE75BE5FEE3FDE06F17F1F302ACE3B9">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#x2019;s research and development expenses, stock-based compensation, valuation procedures for the convertible notes, allowance for doubtful accounts, inventory, acquired intangible assets, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <ptct:InventoriesAndCostOfProductSalesPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E762E6AF56057130AE8DF1F302C04E3C-0-wk-Fact-DAC02BD9798564A51075F1F302AEE65B">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inventory and cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Translarna and Emflaza product which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the components of the Company&#x2019;s inventory for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value.  No write downs were recorded for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  Additionally, though the Company&#x2019;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, these amounts were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Costs of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, including personnel costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.&lt;/span&gt;&lt;/div&gt;</ptct:InventoriesAndCostOfProductSalesPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-83C14AF056A594345901F1F302C0B274-0-wk-Fact-2DFAE281878537B9F126F1F302ABE801">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the components of the Company&#x2019;s inventory for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41029076e587-wk-Fact-6C090821B8D8BF4DA832F1F3028E611D"
      unitRef="usd">2089000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41029076e606-wk-Fact-DEB7AA0E7AF4DEAD45F9F1F3028E3C41"
      unitRef="usd">1431000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41029076e626-wk-Fact-3C1C43A24808654375CDF1F302864215"
      unitRef="usd">8341000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41029076e645-wk-Fact-0DF763FF845C61866711F1F302861986"
      unitRef="usd">9324000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41029076e670-wk-Fact-0707B742E51C08CCA361F1F30287AC0A"
      unitRef="usd">6467000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41029076e689-wk-Fact-99BBE7CCA7EE0AF30D23F1F3028B6883"
      unitRef="usd">5362000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41029076e719-wk-Fact-0CC15B0857EF6B135B85F1F3025FC547"
      unitRef="usd">16897000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41029076e738-wk-Fact-D68658CB72697A4B3826F1F302618800"
      unitRef="usd">16117000</us-gaap:InventoryNet>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-8FE2B9745919E5329B59F1F302BF4774-0-wk-Fact-217C4858C26B67496596F1F302A58E04">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-9, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d;.  ASU No. 2014-9 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 605-15, Revenue Recognition-Products (Topic 605) and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net product revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#x2019;s performance obligations are to provide Translarna or Emflaza based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#x2019;s customer obtains control of either Translarna or Emflaza, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to either product sales of Translarna or Emflaza.  In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. Historically, returns of Translarna and Emflaza are immaterial to the financial statements, except as related to labeling changes and changes in specialty pharmacies. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upon adoption of ASC Topic 606 on January 1, 2018, the Company elected the following practical expedients:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying ASC Topic 606 to each individual contract.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Significant Financing Component - the Company expects the period between when it transfers a promised good to a customer and when the customer pays for the good or service to be one year or less. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Immaterial Performance Obligations - the Company disregards promises deemed to be immaterial in the context of the contract. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shipping and Handling Activities - the Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#x201c;Collaborative Arrangements&#x201d; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="FD2019Q2YTD"
      id="TextSelection-031E13D8A6E7561A26D0F1F302BFBE7F-0-wk-Fact-782304A5F1A048397436F1F302A91496">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#x2019;s financial condition and current economic trends.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2019Q2"
      decimals="-5"
      id="d41029076e897-wk-Fact-F2F87FC9EFB6B62CAE92F1F302A4BA7B"
      unitRef="usd">500000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2018Q4"
      decimals="-5"
      id="d41029076e905-wk-Fact-13D19EFCD029F9977F1CF1F302A8FC11"
      unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy
      contextRef="FD2019Q2YTD"
      id="TextSelection-B069FDD9861C25EB5111F1F302C00B7D-0-wk-Fact-C7FC77ACE0BD72A8F018F1F302A4F414">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Indefinite-lived intangible assets consist of in-process research and development ("IPR&amp;amp;D"). IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;amp;D projects acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;amp;D acquired in a business combination. The Company utilizes the "income method&#x201d;, and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&amp;amp;D intangible assets that are determined to have had a drop in their fair value are adjusted downward and an impairment is recognized in the statement of operations. These assets are tested at least annually or sooner when a triggering event occurs that could indicate a potential impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="FD2019Q2YTD"
      id="TextSelection-BBF82DABBC768E8262C7F1F302C0E2A4-0-wk-Fact-24596E15D7B070E9F617F1F302ACADFD">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. &lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-156E5A5FD85FCEB9D010F1F302BF5F40-0-wk-Fact-A5632AF2D3018021ED98F1F302AC47DD">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s tangible assets. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recorded a deferred tax liability in conjunction with the Merger of $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to the tax basis difference in the IPR&amp;amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d41029076e984-wk-Fact-C72FF2E1C4693850BCB249EFDACCC540"
      unitRef="usd">122000000.0</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9B8988F69F45B8936899F1F302BF0DAD-0-wk-Fact-8A24891BF337990E2CDFF1F302A5295D">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#x201c;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;. This standard requires financial assets measured at amortized cost basis to be presented at the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. The Company expects to adopt this guidance when effective and is assessing what effect the adoption of ASU 2016-13 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d;. ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No. 2018-18 will have on its consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Impact of recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-2, &#x201c;Leases (Topic 842)&#x201d;. This standard requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018, with early adoption permitted.  Additionally, in March 2019, the FASB issued ASU 2019-01,"Leases (Topic 842): Codification Improvements&#x201d;.  ASU 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. The Company adopted the new guidance on January 1, 2019 using the modified retrospective method. Prior period results were not adjusted and continue to be presented under Topic 840 based on the accounting standards originally in effect for such periods. As part of the adoption, the Company has elected to utilize practical expedients including the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to: 1) carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements, 2) not separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component (the Company elected to apply this practical expedient to all underlying asset classes), 3) not apply the recognition requirements in ASC 842 to short-term leases, and 4) not record a right of use asset or right of use liability for leases with an asset or liability balance that would be considered immaterial. Upon adoption, the Company recorded an operating lease liability with a corresponding operating lease ROU asset of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The adoption did not have a material impact on the consolidated results of operations, stockholder's equity, and cash flows for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As the Company is not a lessor, the aspects of the new guidance pertaining to lessors was not applicable for the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the FASB issued ASU 2018-02, "Income Statement &#x2014; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income". This standard permits the reclassification of tax effects stranded in other comprehensive income as a result of tax reform to retained earnings related to the change in federal &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;tax rate in addition to other stranded effects that relate to the 2017 Tax Act but do not directly relate to the change in the federal rate. ASU 2018-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance. The Company adopted this guidance on January 1, 2019 and elected not to reclassify the tax effects in other comprehensive income related to the 2017 Tax Act, as these amounts were immaterial. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU 2018-07, "Compensation &#x2014; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting". This standard expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in the entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The ASU retains the existing cost attribution guidance, which requires entities to recognize compensation cost for nonemployee awards in the same period and in the same manner they would if they paid cash for the goods or services, but it moves the guidance to ASC 718. ASU 2018-07 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance.  The Company adopted this guidance on January 1, 2019. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &#x201c;Revenue from Contracts with Customers (Topic 606)&#x201d;.  ASU No. 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic 605-15, Revenue Recognition-Products and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  On January 1, 2018, the Company adopted ASC Topic 606 using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The Company calculated a one-time transition adjustment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was recorded on January 1, 2018 to deferred revenue and accumulated deficit, related to the product sales of Emflaza. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January&#160;2016, the FASB issued ASU No.&#160;2016-01, &#x201c;Financial Instruments &#x2014; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&#x201d;. This standard enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The new guidance affects all reporting organizations (whether public or private) that hold financial assets or owe financial liabilities. The Company adopted the guidance on January&#160;1, 2018.  In March 2018, the FASB issued ASU 2018-04, "Investments - Debt Securities (Topic 320) and Regulated Operations (Topic 980): Amendments to SEC Paragraphs Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 117 and SEC Release No. 33-9273 (SEC Update)". This standard supersedes SEC paragraphs in ASC 320, Investments- Debt Securities, as a result of the issuance of SAB 117 and also updates the Codification for a 2011 SEC release and is effective when a registrant adopts ASU 2016-01, which in the case of the Company was on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15, &#x201c;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#x201d;. This standard clarifies the presentation of certain specific cash flow issues in the Statement of Cash Flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2016, the FASB issued ASU 2016-16, &#x201c;Intra-Entity Transfers of Assets Other Than Inventory&#x201d;.  ASU 2016-16 requires companies to account for the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) when the transfer occurs. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2016, the FASB issued ASU No. 2016-18, &#x201c;Statement of Cash Flows (Topic 230): Restricted Cash&#x201d;. This standard requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows and no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;In May 2017, the FASB issued ASU No. 2017-09, "Stock Compensation (Topic 718): Scope of Modification Accounting". This standard clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as a modification, with entities applying the modification accounting guidance if the value, vesting conditions or classification of the award changes. In addition to all disclosures about modifications that are required under the current guidance, entities will be also required to disclose that compensation expense has not changed if applicable.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company adopted the guidance on January&#160;1, 2018.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01"
      decimals="-5"
      id="d41029076e1055-wk-Fact-1A463F2579630F907F3AF1F302AD4E5C"
      unitRef="usd">11300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member"
      decimals="-5"
      id="d41029076e1083-wk-Fact-30C03E199A909287D9BEF1F302AE387B"
      unitRef="usd">3300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-768A470229B742CDECBCF1F302C16408-0-wk-Fact-490EA005EB25E3A75E86F1F3028314F7">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company leases office space in South Plainfield, New Jersey for its principal office under &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; noncancelable operating leases through May 2022 and August 2024, in addition to office space in various countries for international employees primarily through workspace providers. The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company&#x2019;s operating leases have remaining lease terms ranging from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years and certain of the leases include renewal options to extend the lease for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.4921875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating Lease Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease cost is a component of operating expenses on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.3515625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities- current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities- noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease ROU asset is a component of deposits and other assets on the consolidated balance sheet. The current portion of operating lease liability is a component of other current liabilities on the consolidated balance sheet. The long term portion of operating lease liabilities is a component of other long term liabilities on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental lease term and discount rate information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease terms - operating leases (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,643&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable leases as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.359375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019 (Excludes the six months ended June 30, 2019)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had no operating leases that had not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ptct:NumberOfOperatingLeases
      contextRef="FI2019Q2"
      decimals="INF"
      id="d41038161e365-wk-Fact-672E7AAEBEDC5767831549F2E7F42F73"
      unitRef="operating_lease">3</ptct:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember"
      id="d41038161e373-wk-Fact-9797109064D24E16C35AF1F302843230">P0Y4M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember"
      id="d41038161e377-wk-Fact-C93CFEE02B51E766EC7AF1F30287CAFA">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q2"
      id="d41038161e381-wk-Fact-FF236EA5A764B0E92F2EF1F3028B9BFA">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E585102F5AF4FB08BE10F1F302C08C7B-0-wk-Fact-831558A37D469C8C0DA0F1F3028A7ED1">&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.4921875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating Lease Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease cost is a component of operating expenses on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.3515625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease ROU asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities- current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities- noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total operating lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental lease term and discount rate information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease terms - operating leases (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,643&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41038161e502-wk-Fact-E1B6CEE89BFE9C9D4927F1F3025B13E5"
      unitRef="usd">835000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41038161e521-wk-Fact-D43D1C5BCFE72A67BE4C1B53029FF5FE"
      unitRef="usd">1647000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41038161e536-wk-Fact-419858A050455461E7C7F1F30262D3CF"
      unitRef="usd">161000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41038161e555-wk-Fact-ABFF67B85F22CC8585351B53048EF693"
      unitRef="usd">304000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41038161e575-wk-Fact-E824D94524D9E18F9DC7F1F30257CF9F"
      unitRef="usd">88000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41038161e594-wk-Fact-888A6A529582EBA4CE471B53058893A3"
      unitRef="usd">141000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41038161e619-wk-Fact-2B05B310D09A6CC5FD08F1F3025757BC"
      unitRef="usd">1084000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41038161e638-wk-Fact-E2D11C044DC91A26E9901B5306827084"
      unitRef="usd">2092000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e720-wk-Fact-819E3199165BB975B66DF1F302A1BD35"
      unitRef="usd">10387000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e761-wk-Fact-30E21B5807277A54D1F9F1F3029C16FA"
      unitRef="usd">2143000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e776-wk-Fact-26546B3A611373897A94F1F3029C790C"
      unitRef="usd">8416000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e801-wk-Fact-7505CD9CE57621FE110EF1F30253374D"
      unitRef="usd">10559000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q2"
      id="d41038161e875-wk-Fact-BB5AFA09912A98512BC1F1F302516632">P4Y6M3D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q2"
      decimals="4"
      id="d41038161e890-wk-Fact-86F3FE55A2CC9080F7A0F1F302525377"
      unitRef="number">0.0718</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41038161e971-wk-Fact-04BBFE4D6A49ABC85BF7F1F302831AEA"
      unitRef="usd">1508000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41038161e1012-wk-Fact-4BC8F70D456635819552F1F302588A33"
      unitRef="usd">11643000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-CF3048E36A11A0C22627F1F302C12801-0-wk-Fact-610BA8AC725102D371FCF1F302840353">&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under non-cancelable leases as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.359375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019 (Excludes the six months ended June 30, 2019)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1079-wk-Fact-BAA1FD66C6EBBBF7B04FF1F302541304"
      unitRef="usd">1371000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1094-wk-Fact-B3CB8D648B69B30A4FCDF1F30254C3BF"
      unitRef="usd">3023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1114-wk-Fact-8E1C3062EAAC64DEFD80F1F302565546"
      unitRef="usd">2494000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1134-wk-Fact-A11A5B31FB75EE6DC017F1F3024FAF40"
      unitRef="usd">2147000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ptct:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1154-wk-Fact-7FCC09E0C656B79D13EEF1F302514139"
      unitRef="usd">2160000</ptct:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1174-wk-Fact-254C74FB65B01959AC77F1F3025691C5"
      unitRef="usd">11195000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1194-wk-Fact-78CAD2C2A9571FC382E3F1F302524039"
      unitRef="usd">636000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41038161e1219-wk-Fact-7505CD9CE57621FE110EF1F30253374D"
      unitRef="usd">10559000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-EA69EAA470918D93D051F1F302C10888-0-wk-Fact-80C271D12092DF2E5CA4F1F302ACCA9E">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair value of financial instruments and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company follows the fair value measurement rules, which provide&#160;&#160;&#160;&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#xb7;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#xb7;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#xb7;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3&#x2014;Inputs are unobservable and reflect the Company&#x2019;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents and investments are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2019, the Company purchased &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of shares of MRI Interventions, Inc.'s ("MRI") common stock, at a purchase price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, in connection with a securities purchase agreement that the Company entered into with MRI, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded an unrealized gain of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is a component of other (expense) income, net within the consolidated statement of operations. The fair value of the equity investment was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company classifies its equity investment in MRI as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company reviews its investments on a periodic basis for other-than-temporary impairments. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may have a significant adverse effect on the fair value of the investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following represents the fair value using the hierarchy described above for the Company&#x2019;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity investment in MRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock appreciation rights liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in&#160;active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;markets&#160;for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;identical&#160;assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock appreciation rights liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;No&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;226,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;656&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held securities with an unrealized loss position that were not considered to be other-than-temporarily impaired as the Company has the ability to hold such investments until recovery of their fair value. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#x2019; equity. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;not&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; have any realized gains/losses from the sale of marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities on the balance sheet at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; mature as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;More&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;161,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;More&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company classifies all of its securities as current as they are all available for sale and are available for current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Convertible 3.0% senior notes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2015, the Company issued &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due August&#160;15, 2022 (the &#x201c;Convertible Notes&#x201d;). Interest is payable semi-annually on February&#160;15 and August&#160;15 of each year, beginning on February&#160;15, 2016. The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;10. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#x2019;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the Convertible Notes at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$166.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$146.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and borrowings under the credit and security agreement with MidCap Financial Trust and other financial institutions (as further discussed in Note 10) approximate fair value because of the immediate or short-term maturity of these financial instruments. The carrying amounts for the credit and security agreement approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred consideration payable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Merger Agreement, Agilis equityholders may become entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$535.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company is required to pay &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved.  The fair value of the deferred consideration payable at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was estimated to be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$38.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; by applying a discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#x2019;s estimated development timelines for the acquired product candidates. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the deferred consideration payable was classified as current on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3 valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#x2019;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#x2019;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss in the consolidated statements of operations. The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#x2019;s estimated development timelines for the acquired product candidate. The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The changes in the fair value of the Company's Level 3 valuations for the period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3 liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning balance as of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,961&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Ending balance as of June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following significant unobservable inputs were used in the valuation of the SARs liability, and the contingent consideration payable for the periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49.70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.09%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$6.76 - $30.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.52 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $555 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3.8% - 5.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020 - 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model with Monte Carlo simulation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential net sales milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 89%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.5%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021 - 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;46.53% - 59.59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.44% - 2.63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$6.76 - $30.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$34.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.01 - 1.01 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $555 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.8% - 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020 - 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model with Monte Carlo simulation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential net sales milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 89%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021 - 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The contingent consideration is classified as&#160;&#160;&#160;&#160;a Level 3 liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, including but not limited to, assumptions involving probability adjusted sales estimates for the Agilis platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount
      contextRef="I2019Q2May_invest_InvestmentAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d41054631e397-wk-Fact-86BF833DF32428C4785B1B590EA6F5CE"
      unitRef="usd">4000000.0</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:SharePrice
      contextRef="I2019Q2May_invest_InvestmentAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="d41054631e401-wk-Fact-DC1211D57374F9C38CB962CD897947DE"
      unitRef="usdPerShare">3.10</us-gaap:SharePrice>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="FD2019Q2QTD_invest_InvestmentAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d41054631e413-wk-Fact-5F35478A56DAA77CDD111B613D382440"
      unitRef="usd">100000</us-gaap:UnrealizedGainLossOnInvestments>
    <ptct:InvestmentInMRI
      contextRef="FI2019Q2"
      decimals="-5"
      id="d41054631e418-wk-Fact-F8718F8122F3077133901B6588296351"
      unitRef="usd">4100000</ptct:InvestmentInMRI>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-42FAF8A820E462FE5B36F1F302C12A79-0-wk-Fact-24066067B116C3B7812FF1F302B2888A">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following represents the fair value using the hierarchy described above for the Company&#x2019;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;prices&lt;br/&gt;in&#160;active&lt;br/&gt;markets&#160;for&lt;br/&gt;identical&#160;assets&lt;br/&gt;(level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;other&lt;br/&gt;observable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity investment in MRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock appreciation rights liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in&#160;active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;markets&#160;for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;identical&#160;assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(level&#160;1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(level&#160;2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(level&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock appreciation rights liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred consideration payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- net sales milestones and royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e665-wk-Fact-8699DBB196D2DD3937C9F1F3025B66EA"
      unitRef="usd">227447000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e684-wk-Fact-AC1093E77CC0E15DB88FF1F3025E79D8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e704-wk-Fact-53B8E868B36D9C682B21F1F3025C69EA"
      unitRef="usd">227447000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e723-wk-Fact-DC20B9210D5BFA62A444F1F3025795E8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e748-wk-Fact-363282EEA6460533946D1B652BCBC39B"
      unitRef="usd">4129000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e767-wk-Fact-CDA2D3114C0581F874771B652BC466C4"
      unitRef="usd">4129000</us-gaap:EquitySecuritiesFvNi>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e831-wk-Fact-F2EC4DACACCB8C5BDEE1F1F3025AB2B7"
      unitRef="usd">1960000</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e850-wk-Fact-23179008CB67A48AE387F1F3025FECC2"
      unitRef="usd">0</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e870-wk-Fact-AE1459069B5E6B73D535F1F302553A14"
      unitRef="usd">0</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e889-wk-Fact-D14A218601E355E15015F1F3025D7530"
      unitRef="usd">1960000</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e914-wk-Fact-5D79F64D173BE63FB924F1F30274AEC6"
      unitRef="usd">38200000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e933-wk-Fact-8F01E68F0B243F4B2A42F1F3025A4083"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e953-wk-Fact-29E39A297B299B97429EF1F302631C32"
      unitRef="usd">38200000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e972-wk-Fact-CA50ACACFC6F769501E5F1F30260863D"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e997-wk-Fact-413E6C4171E230754BF3F1F3026D4E55"
      unitRef="usd">277400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1015-wk-Fact-613B2155AECEFF0EFCEEF1F30260F8E6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1034-wk-Fact-750790629C110B1C96C3F1F302613518"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1052-wk-Fact-05F44F91286724A0A24AF1F3025A3892"
      unitRef="usd">277400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1077-wk-Fact-C189191DC8966AB748EAF1F302624FCB"
      unitRef="usd">58800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1095-wk-Fact-CB45996BF6A35A52DB8AF1F3025BFB54"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1114-wk-Fact-2176518BB4DD73564198F1F30259014F"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d41054631e1132-wk-Fact-AD3B264075056290231AF1F30255955B"
      unitRef="usd">58800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1388-wk-Fact-248D23A2E5CAEEA24F2BF1F302657232"
      unitRef="usd">58088000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1406-wk-Fact-55F2CC798AF3CEF72371F1F302550C3C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1425-wk-Fact-9850912D8794DC40832FF1F30264D637"
      unitRef="usd">58088000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1443-wk-Fact-BF85BA749314D5B3DFABF1F30257C34E"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1468-wk-Fact-FA67DFD6D9AEA01961A8F1F3026EE88D"
      unitRef="usd">3814000</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1486-wk-Fact-630E52DE13C9848AF166F1F3026487AB"
      unitRef="usd">0</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1505-wk-Fact-37FAE824D07EB60921DEF1F3026227FD"
      unitRef="usd">0</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:StockAppreciationRightsLiabilityOutstanding
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1523-wk-Fact-CD9CFB4E8A5EFCF73166F1F302541E07"
      unitRef="usd">3814000</ptct:StockAppreciationRightsLiabilityOutstanding>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1548-wk-Fact-B649910AB8A80B287F3EF1F3025BEA58"
      unitRef="usd">37700000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1566-wk-Fact-722EF95B389B17ABA97CF1F30268E618"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1585-wk-Fact-86B7E02F35818A322F93F1F302692FE2"
      unitRef="usd">37700000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1603-wk-Fact-660B0DF93FB8F4209826F1F302660FFD"
      unitRef="usd">0</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1628-wk-Fact-18304E986240F272766BF1F30259B407"
      unitRef="usd">257040000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1646-wk-Fact-54F111D709C1A131666AF1F30266B04C"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1665-wk-Fact-9C5FBB86F1A3FC1E24D7F1F302692AA2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1683-wk-Fact-EEC3F9BF1622D9FDE290F1F302547168"
      unitRef="usd">257040000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1708-wk-Fact-2E35180B71C6D3A7BA74F1F3026157C0"
      unitRef="usd">53200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1726-wk-Fact-DDB8CAB9306AE588F434F1F302602B77"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e1745-wk-Fact-30B90BB757D281800529F1F302655B00"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d41054631e1763-wk-Fact-7B207D88CE9B3ED6BAEBF1F302638856"
      unitRef="usd">53200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-23E3B6A64ABB8FE1A30DF1F302C10A9B-0-wk-Fact-F2D8FB090E3ED11C1806F1F3029C12A0">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of marketable securities accounted for as available-for-sale securities at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;226,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;656&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,657&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2110-wk-Fact-282C6C1BB25BF5625634F1F302B32408"
      unitRef="usd">70185000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2129-wk-Fact-34CB8357D99D297BF26EF1F30277E2C5"
      unitRef="usd">116000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2149-wk-Fact-5B1DDD33356986E76248F1F30298B401"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2168-wk-Fact-B69915307E0D16C152D5F1F3027FDC1F"
      unitRef="usd">70301000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2188-wk-Fact-4433E2D7C478BCB46C3FF1F3027BFDC3"
      unitRef="usd">129252000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2207-wk-Fact-F20AE60B16225D6C2558F1F3027E5E42"
      unitRef="usd">464000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2226-wk-Fact-031010602E18CB131275F1F3029D565D"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2247-wk-Fact-9FD716E2F624883AB66CF1F302792F60"
      unitRef="usd">129706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e2272-wk-Fact-6559FCDFD03D6885BCF3F1F3027BAD6C"
      unitRef="usd">27364000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e2291-wk-Fact-DA0848700B66760E4BC8F1F302768C1A"
      unitRef="usd">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e2310-wk-Fact-A4A37A8ABB8C56F43423F1F3027ADEF6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e2330-wk-Fact-6AE80742C78C074DD41DF1F302751E20"
      unitRef="usd">27440000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e2360-wk-Fact-A616C7A700C02F250119F1F3027ECCBD"
      unitRef="usd">226801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e2379-wk-Fact-35F320239E6D2587AAFEF1F3024C956C"
      unitRef="usd">656000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e2399-wk-Fact-C75FFE760561FC77FDD3F1F302B33BDC"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e2419-wk-Fact-59E32E56163316E11940F1F3027A30F0"
      unitRef="usd">227447000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2733-wk-Fact-B3BEE8653E7F9F9BEDABF1F302530753"
      unitRef="usd">31657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2752-wk-Fact-6C1A2026C945A91B5A30F1F30252ED12"
      unitRef="usd">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2772-wk-Fact-91A29380192FB680881DF1F30252EF5F"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e2792-wk-Fact-C06922BDABF7F3F847B4F1F30252EFA0"
      unitRef="usd">31699000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2812-wk-Fact-6DA6323D81EB434C5D97F1F30250F3A6"
      unitRef="usd">26399000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2831-wk-Fact-48833DAF01DEC4E6A006F1F30256A5A9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2850-wk-Fact-080DFC2E26A535BF7045F1F3026307AB"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e2871-wk-Fact-77CBE385F4A63703E75AF1F30251AFB6"
      unitRef="usd">26389000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e2901-wk-Fact-E3C392DDE612D404D31EF1F302538ED2"
      unitRef="usd">58056000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e2920-wk-Fact-8F948DE86543BA201A41F1F3024FB984"
      unitRef="usd">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e2940-wk-Fact-206013F9BCA63D6C1A20F1F302523D21"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e2960-wk-Fact-9B8884E9D78EE24873ACF1F30253C726"
      unitRef="usd">58088000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-3E6DDC253A2A9584182CF1F302C1E968-0-wk-Fact-E5467C3049F0361AD8ADF1F302B18A43">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position less than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities in an unrealized loss position greater than 12 months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e3439-wk-Fact-9A475B9FFA4757A8705FF1F302657D30"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e3458-wk-Fact-0C75DD9B574E5669845DF1F30269220E"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e3478-wk-Fact-DD42DA207ADD9089331DF1F3027702C4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e3497-wk-Fact-99085BF31A4EEA094842F1F302757C02"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e3516-wk-Fact-63DDA15B0790F669CD14F1F30270C302"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e3536-wk-Fact-7F012B2AFE28DC75D509F1F302570365"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e3556-wk-Fact-371ED2BAEC48A0E9B4E7F1F302638499"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e3576-wk-Fact-AD0BA5A25B8EC2E2D698F1F30258294D"
      unitRef="usd">17684000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e3595-wk-Fact-E0263CB7D83B043D27C7F1F30269AA20"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e3615-wk-Fact-C8033B33A0B9660C09DFF1F3026D7403"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e3634-wk-Fact-C8E0A62D17C44900383FF1F302662A78"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e3655-wk-Fact-D033B619EDDD7BD2AB64F1F302710F83"
      unitRef="usd">17684000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e3680-wk-Fact-BF5FE09AA6DAE8890C06F1F30258F563"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e3699-wk-Fact-4CE768D39E5EA4E571BEF1F3026EA252"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e3718-wk-Fact-1C532F862AAA4BEF4211F1F302754294"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e3738-wk-Fact-7EB6A564CC97651ECEE8F1F302659E45"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e3757-wk-Fact-37B38778A5D06769A8E4F1F3026DC8E4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e3777-wk-Fact-D06851B1F9E8EE1566A9F1F3027259F6"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e3807-wk-Fact-BA517E7B906140EAB221F1F30276D705"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e3827-wk-Fact-804211C52CAF7F71542FF1F302683224"
      unitRef="usd">17684000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e3847-wk-Fact-68E8A04AB205589127ABF1F302750A0C"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e3866-wk-Fact-EAA97FBA933CA57D4DD6F1F3026EBC81"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e3885-wk-Fact-097BEBBDF2CFD8EE3075F1F3026D9CB0"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e3906-wk-Fact-536B8AE651D4EB1C4988F1F30258532B"
      unitRef="usd">17684000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4351-wk-Fact-F591B03C26DC496A7449F1F302A862EE"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4370-wk-Fact-09C6E38B78F85F157F64F1F302A73B40"
      unitRef="usd">1993000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4389-wk-Fact-B099FB47A1DC32E26978F1F302AA5BAE"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4407-wk-Fact-ABBC278AD279B89F53A0F1F302A50B70"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4425-wk-Fact-4482D9E487A21E1DC251F1F302AA7D4C"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4445-wk-Fact-CFA7577380036315258CF1F302A65253"
      unitRef="usd">1993000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4465-wk-Fact-C399974E4651B1375405F1F302ACC634"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4484-wk-Fact-B6BBE4BF01FB3D1597F4F1F302A56B45"
      unitRef="usd">14230000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4502-wk-Fact-481B09D9E1DAD8440BA2F1F302AB52C5"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4522-wk-Fact-EDC1CF99283C2427F730F1F302A725EE"
      unitRef="usd">10087000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4540-wk-Fact-FC819D0CAD998AEBF2B9F1F302A805C4"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4560-wk-Fact-DF22B99818BC7A8DFF50F1F302A5DB64"
      unitRef="usd">24317000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e4590-wk-Fact-152B9717148FE86FA3A3F1F302A71DB6"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e4609-wk-Fact-4E76C41ECD3C7717F7CCF1F302A574FE"
      unitRef="usd">16223000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e4628-wk-Fact-471532FC7D866FCB74B4F1F302A4B4C9"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e4647-wk-Fact-38553AC6CC23C3121F81F1F302A411D3"
      unitRef="usd">10087000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e4665-wk-Fact-86F5FBCD1A040EE8BE19F1F302AE317D"
      unitRef="usd">11000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e4685-wk-Fact-FE5437D15530DBBCFA87F1F302A4046B"
      unitRef="usd">26310000</us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-ABB4F9393CD707B057D8F1F302C16472-0-wk-Fact-6E0900F11D55147FB959F1F3029D564A">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities on the balance sheet at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; mature as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;More&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;70,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;161,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Less&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;More&#160;Than&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;12&#160;Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,389&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4844-wk-Fact-25F1FBB33C86A306838BF1F302A78A35"
      unitRef="usd">70301000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e4863-wk-Fact-1093637ABC09369F36F1F1F302AF9049"
      unitRef="usd">0</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4883-wk-Fact-D54D85377805D4620986F1F302AF1C7B"
      unitRef="usd">70192000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e4902-wk-Fact-998240BE6A36D40E5BC9F1F302AAD5BA"
      unitRef="usd">59514000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e4927-wk-Fact-25978C4B0B0140BB2A87F1F302AADA96"
      unitRef="usd">20639000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="FI2019Q2_us-gaap_InvestmentTypeAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d41054631e4946-wk-Fact-C1D7B1D5233B96C807CAF1F302AB7098"
      unitRef="usd">6801000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e4976-wk-Fact-9FE97EB37959B2AB3E9EF1F302ADF748"
      unitRef="usd">161132000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e4995-wk-Fact-81371EAE77B0AA8743BFF1F302A7BDF1"
      unitRef="usd">66315000</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e5132-wk-Fact-48C703B6D8B0BB1ED59AF1F3025E72EB"
      unitRef="usd">31699000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="d41054631e5151-wk-Fact-7C93D2E9806266A832FFF1F30259675F"
      unitRef="usd">0</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e5171-wk-Fact-DF33A4AC8915B44C00D6F1F3025AAA50"
      unitRef="usd">26389000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d41054631e5190-wk-Fact-A7C799B646313C2A01C4F1F3025E723A"
      unitRef="usd">0</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e5220-wk-Fact-239988C231588FA9932DF1F3025DFDB6"
      unitRef="usd">58088000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41054631e5239-wk-Fact-28F09441CEE6B60D82DAF1F3025F8953"
      unitRef="usd">0</ptct:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41054631e5262-wk-Fact-1E1351C22346003242E5F1F302B396A8"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41054631e5266-wk-Fact-E2F8C7C72F6AA405E68EF1F30278644A"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d41054631e5278-wk-Fact-53D70FC75AD9D72E3F14F1F302A932A7"
      unitRef="usd">166200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d41054631e5283-wk-Fact-979F816B96AB68270FA9F1F302AFB927"
      unitRef="usd">146600000</us-gaap:DebtInstrumentFairValue>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41054631e5297-wk-Fact-E4352FF052F170C6ED82F1F30299E272"
      unitRef="usd">60000000.0</ptct:DevelopmentMilestonePaymentObligations>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41054631e5301-wk-Fact-ECD1AF8A8D555426A41DF1F3024EF182"
      unitRef="usd">535000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="-5"
      id="d41054631e5305-wk-Fact-9EFF4764375FB458FD8FF1F302AFC239"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligations>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d41054631e5313-wk-Fact-5D79F64D173BE63FB924F1F30274AEC6"
      unitRef="usd">38200000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable>
    <ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41054631e5322-wk-Fact-EC0E1729260E567BC2FDF1F3026DB201"
      unitRef="usd">19400000</ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-062B71416CB52BEE8B0C1AC915A7BB5D-0-wk-Fact-EAA88015E835A6E5EA921ACA01500B7F">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The changes in the fair value of the Company's Level 3 valuations for the period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3 liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contingent consideration payable- net sales milestones and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Beginning balance as of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,961&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,815&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Ending balance as of June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-3"
      id="d41054631e5525-wk-Fact-1F1BA3FD4691EC49F2FEF1F3027F8A9E"
      unitRef="usd">3814000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember"
      decimals="-3"
      id="d41054631e5544-wk-Fact-09475BA3B0AC41715F60F1F3027CE2B1"
      unitRef="usd">257040000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d41054631e5558-wk-Fact-EC3DD61C042441A20ED7F1F3027F12EF"
      unitRef="usd">53200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41054631e5579-wk-Fact-4CA37A4AB16017CB86FB1ACA978553D2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember"
      decimals="-3"
      id="d41054631e5598-wk-Fact-9C3091F1A362693109E71ACAD33316DE"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d41054631e5612-wk-Fact-F02B85E3C78836685D531ACA9789DFBE"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-3"
      id="d41054631e5638-wk-Fact-05DE5A82970B0FFDEC6AF1F3027B46A7"
      unitRef="usd">1961000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember"
      decimals="-3"
      id="d41054631e5657-wk-Fact-C307B89640B01DE0D997F1F3027B9A2A"
      unitRef="usd">20360000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d41054631e5671-wk-Fact-C981581804D903A04CFEF1F3027FEFD7"
      unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-3"
      id="d41054631e5697-wk-Fact-07F63556A54749CC512AF1F3027C5A4D"
      unitRef="usd">3815000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2YTD_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember"
      id="d41054631e5717-wk-Fact-FA577A4E1A8FF19B66F3F1F3027B697B"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2YTD_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d41054631e5730-wk-Fact-FB97D97D866BBC80BFD91ACAEA4E236E"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-3"
      id="d41054631e5761-wk-Fact-D498AB18DF4D2EB26D89F1F3027DDD8C"
      unitRef="usd">1960000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember"
      decimals="-3"
      id="d41054631e5780-wk-Fact-70C37A2DD3F4B5D5AFD2F1F3027CF69E"
      unitRef="usd">277400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d41054631e5794-wk-Fact-A1143A7F9E1142830FE7F1F3027B4DC2"
      unitRef="usd">58800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C7CA0B0FBEFA241AC5ABF1F302C173A0-0-wk-Fact-8332DEAD437D53F1EF9DF1F302B40323">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following significant unobservable inputs were used in the valuation of the SARs liability, and the contingent consideration payable for the periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49.70%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.09%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$6.76 - $30.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.52 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$277,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $555 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3.8% - 5.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020 - 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$58,800&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model with Monte Carlo simulation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential net sales milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 89%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.5%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021 - 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;46.53% - 59.59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.44% - 2.63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$6.76 - $30.86&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$34.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;0.01 - 1.01 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration payable- development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$257,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential development and regulatory milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $555 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 94%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;5.8% - 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020 - 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contingent considerable payable- net sales milestones and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$53,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option-pricing model with Monte Carlo simulation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential net sales milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0 - $150 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Probabilities of success&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25% - 89%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Potential percentage of net sales for royalties &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2% - 6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Projected years of payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021 - 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss in the consolidated statements of operations. The fair value of the development and r</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-3"
      id="d41054631e5938-wk-Fact-B719A5A144B05A96A3F7F1F3027A11E2"
      unitRef="usd">1960000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="4"
      id="d41054631e5968-wk-Fact-B0BF74F1EFD3CA90080EF1F302798028"
      unitRef="number">0.4970</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="d41054631e6014-wk-Fact-69B721A306D6793C1C36F1F3027A1732"
      unitRef="number">0.0209</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="d41054631e6106-wk-Fact-52964B940606C5B94B42F1F3027BB9E8"
      unitRef="usdPerShare">45.00</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember"
      decimals="-3"
      id="d41054631e6170-wk-Fact-E78CF43B7B9730C9248AF1F30279588B"
      unitRef="usd">277400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"
      decimals="-3"
      id="d41054631e6355-wk-Fact-BC8FC1BC4ABEC16B5B50F1F3027B20EC"
      unitRef="usd">58800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="3"
      id="d41054631e6525-wk-Fact-32920A506FDFFEC9C57EF1F3027A6B8E"
      unitRef="number">0.145</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-3"
      id="d41054631e6695-wk-Fact-6E8BAD8D2BB6FD610AD7F1F302914C27"
      unitRef="usd">3814000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="d41054631e6863-wk-Fact-722484B7634AFAE9BFADF1F30291EEC2"
      unitRef="usdPerShare">34.32</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember"
      decimals="-3"
      id="d41054631e6927-wk-Fact-7AA985E0ABAF8D2436F5F1F302908C1F"
      unitRef="usd">257040000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember"
      decimals="-3"
      id="d41054631e7112-wk-Fact-1A905B245B94DD2EABD2F1F30291E78D"
      unitRef="usd">53200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityNetSalesMilestonesandRoyaltiesMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="3"
      id="d41054631e7282-wk-Fact-3048591972A7A62F4614F1F3029194A6"
      unitRef="number">0.140</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-7F18B9DAFDAFDC13A591F1F302C12368-0-wk-Fact-36CB2285227900E0A8D1F1F3027BE2C1">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Other comprehensive income (loss) and accumulated other comprehensive items&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;On&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities,&#160;net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;of&#160;tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Translation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Comprehensive&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at March&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;On&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities,&#160;net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;of&#160;tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Translation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Comprehensive&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-2CF58A6CA48743A6E762F1F302C22227-0-wk-Fact-AE499193FFC307255EC8F1F3027A0C7E">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;On&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities,&#160;net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;of&#160;tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Translation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Comprehensive&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at March&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;On&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Securities,&#160;net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;of&#160;tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Translation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Comprehensive&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,431&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from other comprehensive items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e527-wk-Fact-AB161F34B4EA62A9F83C1B68ACF6C13C"
      unitRef="usd">90000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e546-wk-Fact-255402D9183C4220ABF51B68AE982671"
      unitRef="usd">715000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41039540e566-wk-Fact-FA8E4A7513A584AA36C3F1F302B052F8"
      unitRef="usd">805000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e586-wk-Fact-AD903DB5A3540FEFED7067A62B684CAE"
      unitRef="usd">839000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e605-wk-Fact-D929607FB06FD4EE443C67A62B721F68"
      unitRef="usd">278000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41039540e624-wk-Fact-EA22921AC9852B66F6231B68B517832A"
      unitRef="usd">1117000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e650-wk-Fact-5B3E584E3C4AB7B737501B68B550D1CD"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e669-wk-Fact-D0CA89402FC862590BEA1B68B6455707"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41039540e688-wk-Fact-954B4529357F4E87781C1B68B72132A5"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e714-wk-Fact-97EC248AA0C04008862A1B68B764DBA5"
      unitRef="usd">839000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e733-wk-Fact-250CC01E1382EB6429741B68B84DFF5D"
      unitRef="usd">278000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41039540e752-wk-Fact-2EB915054EFBF4E0C03D1B68B9DF1319"
      unitRef="usd">1117000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e783-wk-Fact-60F4E5A0907ED20EE4481B68BA863594"
      unitRef="usd">929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e802-wk-Fact-1A73DC85FD0E264049EE1B68BC25E34A"
      unitRef="usd">993000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41039540e822-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920"
      unitRef="usd">1922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e968-wk-Fact-9EFF3A3EC5A0C2050550F1F3026E8CE0"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e987-wk-Fact-D35864364F12FCC67FD0F1F3026A93A5"
      unitRef="usd">1431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41039540e1007-wk-Fact-08D86BFFC9D39EF8C8211B19D7942B8E"
      unitRef="usd">1462000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e1027-wk-Fact-3790DACDF803D6606D4CF1F30270513B"
      unitRef="usd">898000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e1046-wk-Fact-F3F85596C5095E9B1230F1F3026D74E9"
      unitRef="usd">-438000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41039540e1066-wk-Fact-F9FA1EBA8B464D0D4D7FF1F302563CA9"
      unitRef="usd">460000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e1092-wk-Fact-EFF7AACFECE63B9242B8F1F3026C350D"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e1111-wk-Fact-A05C66D02B3E8559752EF1F302700758"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41039540e1130-wk-Fact-C6DB18F7C473120EC14CF1F30272D825"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e1156-wk-Fact-704F1F0E05AF6EDDF4B9F1F302734E84"
      unitRef="usd">898000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e1175-wk-Fact-79EEBDB97BBB322C09A3F1F3026A157E"
      unitRef="usd">-438000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41039540e1195-wk-Fact-66316C63F6254C0EF926F1F3026789DC"
      unitRef="usd">460000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d41039540e1226-wk-Fact-60F4E5A0907ED20EE4481B68BA863594"
      unitRef="usd">929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d41039540e1245-wk-Fact-1A73DC85FD0E264049EE1B68BC25E34A"
      unitRef="usd">993000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d41039540e1265-wk-Fact-8B35117F62DB54C9AB7FF1F302AEB920"
      unitRef="usd">1922000</us-gaap:StockholdersEquity>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E0458920ED87E2A95E64F1F302C23236-0-wk-Fact-633AE40A4A76A5D96E09F1F3024E919F">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued expenses at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consist of the following:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee compensation, benefits, and related accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,039&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Consulting and contracted research&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales allowance and other costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,794&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales rebates and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;128,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-71A745715EBB25403006F1F302C2B08D-0-wk-Fact-A3D0F021490B5556D5C0F1F3024F18EA">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued expenses at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consist of the following:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee compensation, benefits, and related accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,039&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Consulting and contracted research&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales allowance and other costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,794&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales rebates and royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;128,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e462-wk-Fact-7A0FB445CB3CD739DBE3F1F3029C8AC8"
      unitRef="usd">19039000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e481-wk-Fact-CB57026829D6AB5CB840F1F3029E8C33"
      unitRef="usd">27629000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ptct:AccruedConsultingAndContractedResearchCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e501-wk-Fact-02C178349D865295F4F6F1F3028A0CA4"
      unitRef="usd">12373000</ptct:AccruedConsultingAndContractedResearchCurrent>
    <ptct:AccruedConsultingAndContractedResearchCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e520-wk-Fact-9DBD6590124D8B90C1F5F1F3027EDFE1"
      unitRef="usd">11267000</ptct:AccruedConsultingAndContractedResearchCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e545-wk-Fact-EDD99A107C66FCF1EED8F1F302959D3A"
      unitRef="usd">4116000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e564-wk-Fact-A5125F93BF36B034DDEEF1F302923FC8"
      unitRef="usd">5574000</us-gaap:AccruedProfessionalFeesCurrent>
    <ptct:SalesAllowanceAndOtherRelatedCosts
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e589-wk-Fact-46CA585116611268F6AAF1F3027C51CE"
      unitRef="usd">36794000</ptct:SalesAllowanceAndOtherRelatedCosts>
    <ptct:SalesAllowanceAndOtherRelatedCosts
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e608-wk-Fact-432359A7022FB203B951F1F302847039"
      unitRef="usd">29417000</ptct:SalesAllowanceAndOtherRelatedCosts>
    <ptct:SalesRebatesAndRoyaltiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e633-wk-Fact-8DB54443C7E605A274A7F1F302940131"
      unitRef="usd">29449000</ptct:SalesRebatesAndRoyaltiesCurrent>
    <ptct:SalesRebatesAndRoyaltiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e652-wk-Fact-B75EEECC5D6C027A5CD2F1F3027E90ED"
      unitRef="usd">31874000</ptct:SalesRebatesAndRoyaltiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e677-wk-Fact-88FB5CB2DEE6A842D5CCF1F30284DF07"
      unitRef="usd">10219000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e696-wk-Fact-F83C0F1014A7A8DF8167F1F3027C561E"
      unitRef="usd">6001000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e721-wk-Fact-3F7D53844B1AAD6F317AF1F302A05DD9"
      unitRef="usd">10385000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e740-wk-Fact-23C616000B03C48E2535F1F302504833"
      unitRef="usd">16437000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41036773e770-wk-Fact-1873121A607E1419971AF1F3025B361E"
      unitRef="usd">122375000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41036773e789-wk-Fact-C91536B542435183E188F1F3026B65D7"
      unitRef="usd">128199000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-2722680F2FCC80DB6005F1F302C2587B-0-wk-Fact-7E1E1EFAB75895E9A0C5F1F3026C0770">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Capitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2019, the Company closed an underwritten public offering of its common stock pursuant to a registration statement on Form S-3. The Company issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,563,725&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the registration statement at a public offering price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share, including &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;843,725&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares issued upon exercise by the underwriter of its option to purchase additional shares in February 2019. The Company received net proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$224.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;All of the Company&#x2019;s outstanding warrants were classified as liabilities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; because they contained non-standard antidilution provisions. The fair value of the warrants as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s outstanding warrants as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;128.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,520.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q1Jan"
      decimals="INF"
      id="d41040235e368-wk-Fact-22290768D62FEF9D7A3CF1F3026FE288"
      unitRef="shares">7563725</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="I2019Q1SD"
      decimals="INF"
      id="d41040235e372-wk-Fact-78EA47286E1D1C50FB9DF1F30271C01A"
      unitRef="usdPerShare">30.20</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2019Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="d41040235e376-wk-Fact-513CD9A5C353CEBC482FF1F3026F3AE9"
      unitRef="shares">843725</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2019Q1Jan"
      decimals="-5"
      id="d41040235e380-wk-Fact-F78D56498C2CE683CF78F1F302B3C92A"
      unitRef="usd">224500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-05567988438094516D5BF1F302C22B26-0-wk-Fact-75623077144CB56D53C1F1F302707122">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s outstanding warrants as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Warrant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;128.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,520.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41040235e516-wk-Fact-19CF7D9681568E452630F1F302954958"
      unitRef="shares">7030</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41040235e534-wk-Fact-746BB0813DB213ADDECAF1F302957FB2"
      unitRef="usdPerShare">128.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41040235e563-wk-Fact-B1D076DF8B90233A0B87F1F302971F32"
      unitRef="shares">130</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41040235e581-wk-Fact-53AA1621D7A6DDB024D6F1F30296E27B"
      unitRef="usdPerShare">2520.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-676D1712C49DDB51A797F1F302C2A86F-0-wk-Fact-4ED9AD18DD8A2909CCD6F1F3028F7318">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss per share&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares plus the effect of any dilutive potential common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables set forth the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.796875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Numerator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(41,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,520&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(113,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(28,782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator for basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,912,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,137,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57,113,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,257,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.015625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company experienced a net loss and therefore did not report any dilutive share impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,853,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,166,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock awards and units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;665,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;584,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,518,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,750,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0E85D6C11CCD54BDC47CF1F302C27EC5-0-wk-Fact-005856FB902FEBBE0974F1F3028F6286">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables set forth the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.796875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Numerator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(41,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,520&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(113,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(28,782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator for basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;55,912,748&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,137,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57,113,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,257,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.015625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company experienced a net loss and therefore did not report any dilutive share impact.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41041287e671-wk-Fact-46143D9F1DAD6B240FD9F1F30270B637"
      unitRef="usd">-41789000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41041287e691-wk-Fact-224DC358D24EA5D828A6F1F3026F5A46"
      unitRef="usd">-9520000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41041287e711-wk-Fact-2DA3A1CEAF8FFEB31C7FF1F302AF1D8E"
      unitRef="usd">-113902000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41041287e732-wk-Fact-9E93897F26957D660680F1F302A62467"
      unitRef="usd">-28782000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="0"
      id="d41041287e836-wk-Fact-A4B2822AB20BADD4161DF1F3027368B0"
      unitRef="shares">55912748</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="0"
      id="d41041287e855-wk-Fact-18D1C97362E1A320D10AF1F30288CE54"
      unitRef="shares">46137833</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d41041287e874-wk-Fact-53AF798862AF86240026F1F30299D7AA"
      unitRef="shares">57113141</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q2YTD"
      decimals="0"
      id="d41041287e894-wk-Fact-B1D37CC50BA3FB74C941F1F3028EA40A"
      unitRef="shares">46257397</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d41041287e1007-wk-Fact-7724A2F532F09ACED389F1F3025AA52A"
      unitRef="usdPerShare">-0.75</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d41041287e1027-wk-Fact-79112D852D0E45DBB532F1F3026BBDE5"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d41041287e1047-wk-Fact-A81E1E67ADE7F1FDE5FFF1F30267C69F"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2YTD"
      decimals="2"
      id="d41041287e1068-wk-Fact-604CC67F0B1D65A308C7F1F3026AD791"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-11D4C536D0BB346EA12FF1F302C2E905-0-wk-Fact-F46EA41FF3822AD2CA8AF1F3028D388F">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,853,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,166,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock awards and units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;665,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;584,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,518,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,750,584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="d41041287e1206-wk-Fact-4997A951108796FE30F1F1F3027D8212"
      unitRef="shares">10853301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="d41041287e1220-wk-Fact-613F8A2DA52AE3478BF2F1F3027A029A"
      unitRef="shares">8166403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember"
      decimals="0"
      id="d41041287e1235-wk-Fact-0B8AD514ED0F0C03D364F1F3027C65A7"
      unitRef="shares">665002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember"
      decimals="0"
      id="d41041287e1249-wk-Fact-0820D99DE77E3DBE76B2F1F3027E2A00"
      unitRef="shares">584181</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD"
      decimals="0"
      id="d41041287e1264-wk-Fact-79E5EB52FDE8F62AE407F1F302983B34"
      unitRef="shares">11518303</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q2YTD"
      decimals="0"
      id="d41041287e1278-wk-Fact-814C578D33DCBA7A8F61F1F302985DBC"
      unitRef="shares">8750584</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-11E4E21FFF6E4B354CF7F1F302C3D925-0-wk-Fact-3F2B3E7D0018A3DE8D0AF1F30293F9C0">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On March&#160;5, 2013, the Company&#x2019;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;739,937&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. On March&#160;5, 2013, the Board approved a grant of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;735,324&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of restricted stock and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,613&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; stock options. There are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional shares available for issuance under this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2009, the Company&#x2019;s shareholders approved the 2009 Equity and Long-Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards, subject to certain adjustments and annual increases. In May&#160;2013, the Company&#x2019;s Board of Directors and stockholders increased by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards. There are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional shares available for issuance under this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May&#160;2013, the Company&#x2019;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#x2019;s initial public offering.&#160; The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,296&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock available for issuance under the Company&#x2019;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2) the number of shares (up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,040,444&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#x2019;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#x2019;s Board of Directors. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, awards for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;302,538&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock are available for issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From January&#160;1, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company issued a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,845,620&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; stock options to various employees.&#160; Of those, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;579,700&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were inducement grants for non-statutory stock options. The inducement grant awards were made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company's new hires&#x2019; employment compensation and not under the 2013 Long Term Incentive Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of stock option activity is as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value                 (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,534,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,845,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(311,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(215,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,853,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.59 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;178,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested or Expected to vest at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,334,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.01 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84,446&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,138,717&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.98 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of grants made in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was contemporaneously estimated on the date of grant using the following assumptions:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:33%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six months ended&lt;br/&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.98 - 2.63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;61.90 - 63.09%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;6.11 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assumed &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; expected dividends for all grants. The weighted average grant date fair value of options granted during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company uses the &#x201c;simplified method&#x201d; to determine the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, size, and financial leverage. The risk-free rate of the option is based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Restricted stock awards are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards, which has been determined based upon the market value of the Company&#x2019;s shares on the grant date, is expensed over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock units, which has been determined based upon the market value of the Company&#x2019;s shares on the grant date, is expensed over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information on the Company&#x2019;s restricted stock awards and units:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Restricted&#160;Stock&#160;Awards&#160;and&#160;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&#160;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;571,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;304,549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(179,577&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(31,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;665,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Appreciation Rights&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;SARs entitle the holder to receive, upon exercise, an amount of the Company's common stock or cash (or a combination thereof) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of the Company's common stock over the measurement price based on the exercise date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May&#160;2016, a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;897,290&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; SARs were granted to non-executive employees (the "2016 SARs"). The 2016 SARs will vest annually in equal installments over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years and will be settled in cash on each vest date, requiring the Company to remeasure the SARs at each reporting period until vesting occurs. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month period ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157,930&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; SARs vested. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in compensation expense related to the 2016 SARs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In June 2016, the Company established an Employee Stock Purchase Plan (&#x201c;ESPP&#x201d; or the "Plan&#x201d;) for certain eligible employees. The Plan is administered by the Company&#x2019;s Board of Directors or a committee appointed by the Company's Board of Directors. The total number of shares available for purchase under the Plan is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock. Employees may participate over a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month period through payroll withholdings and may purchase, at the end of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-month period, the Company&#x2019;s common stock at a purchase price of at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the closing price of a share of the Company&#x2019;s common stock on the first business day of the offering period or the closing price of a share of the Company&#x2019;s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company&#x2019;s common stock under the Plan if such participant would own more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in compensation expense related to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,932&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,678&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$105.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, the 2013 Long Term Incentive Plan and equity awards made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41045391e368-wk-Fact-C00DE4AF7F3591762D00F1F302986358"
      unitRef="shares">739937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member"
      decimals="INF"
      id="d41045391e372-wk-Fact-3B56404D86B62EB4AF77F1F302A072B6"
      unitRef="shares">735324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D2013Q1Mar5-Mar5_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member"
      decimals="INF"
      id="d41045391e376-wk-Fact-0374BDEF7858048089A2F1F3028FEBAD"
      unitRef="shares">4613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="I2013Q1Mar5_us-gaap_PlanNameAxis_ptct_StockIncentivePlan2013Member"
      decimals="INF"
      id="d41045391e380-wk-Fact-2F0F44DB04EED4F238F2F1F302941C6F"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="D2013Q2May1-May31_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member"
      decimals="INF"
      id="d41045391e387-wk-Fact-A30EC1D11BF6DB47B063F1F302AAEF53"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q2_us-gaap_PlanNameAxis_ptct_EquityAndLongTermIncentivePlan2009Member"
      decimals="INF"
      id="d41045391e391-wk-Fact-322324B9C281E5A40810F1F302887C3D"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="I2013Q2May31_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41045391e398-wk-Fact-5250D88F288C881A2E7AF1F302934098"
      unitRef="shares">122296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards
      contextRef="I2013Q2May31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptct_EmployeeDirectorAndConsultantStockOptionPlanMember_us-gaap_PlanNameAxis_ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41045391e402-wk-Fact-0147EFB32B72EF89E1EDF1F3029ED552"
      unitRef="shares">3040444</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber
      contextRef="D2013Q2May1-May31_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member"
      decimals="INF"
      id="d41045391e409-wk-Fact-CC07BC55B1EDBC78641FF1F30294F4C3"
      unitRef="shares">2500000</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding
      contextRef="D2013Q2May1-May31_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptct_LongTermIncentivePlan2013Member"
      decimals="INF"
      id="d41045391e413-wk-Fact-0DE4B3B4086329169068F1F302B0964F"
      unitRef="number">0.04</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q2_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d41045391e421-wk-Fact-2528F88BB4BEC07B2694F1F3029065FA"
      unitRef="shares">302538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e436-wk-Fact-0453A29EFC4BA7AF8639F1F30290D4A4"
      unitRef="shares">2845620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e440-wk-Fact-1C02BA2A7888F601C977F1F30292E0DA"
      unitRef="shares">579700</ptct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-EAF0FF5BDD5C28AD5554F1F302C369AF-0-wk-Fact-8147355B3CA01D492939F1F3028399F3">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of stock option activity is as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value                 (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,534,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,845,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(311,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(215,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,853,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.59 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;178,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested or Expected to vest at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,334,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.01 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;84,446&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,138,717&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.98 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e631-wk-Fact-C06D4EFA0F27FD59E4BBF1F302830DD3"
      unitRef="shares">8534358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e650-wk-Fact-11D78E2D8F168DB8CD5AF1F302932A82"
      unitRef="usdPerShare">28.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e700-wk-Fact-0453A29EFC4BA7AF8639F1F30290D4A4"
      unitRef="shares">2845620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e719-wk-Fact-D31FED56395D17071630F1F30283E973"
      unitRef="usdPerShare">33.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e769-wk-Fact-696A9EE3F75D0B8BC251F1F30293FE75"
      unitRef="shares">311002</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e789-wk-Fact-5688ABF2A69F9B7FE78AF1F30286839C"
      unitRef="usdPerShare">16.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e839-wk-Fact-AB075183D6A0B4E07326F1F302B0F8EB"
      unitRef="shares">215675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e859-wk-Fact-F9E092F48096FBE36578F1F302B0DA5B"
      unitRef="usdPerShare">36.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e909-wk-Fact-1835CBE4749B1E0724B3F1F302929D04"
      unitRef="shares">10853301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e928-wk-Fact-49763C15DE934F743131F1F302902FEA"
      unitRef="usdPerShare">30.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      id="d41045391e942-wk-Fact-91C3828B3547CDA264C3F1F30286C89D">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="-3"
      id="d41045391e958-wk-Fact-BFC1DEE60F48440B45C2F1F3028A6580"
      unitRef="usd">178906000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e978-wk-Fact-1668E4A0C3299211CC72F1F302B32B91"
      unitRef="shares">5334168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e997-wk-Fact-446345CA8EFFC4E8601EF1F302B0FC29"
      unitRef="usdPerShare">29.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      id="d41045391e1011-wk-Fact-8E8D9F4E8020575AEAB5F1F30290D337">P9Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="-3"
      id="d41045391e1027-wk-Fact-0CA29662F9507A3375DAF1F3028E416D"
      unitRef="usd">84446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e1047-wk-Fact-16C393F50554A7A67458F1F302918131"
      unitRef="shares">5138717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e1066-wk-Fact-D0906190D3CAE563E0FAF1F3028FFA39"
      unitRef="usdPerShare">30.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      id="d41045391e1080-wk-Fact-B493513E4D0F44BBF5B0F1F302909BC3">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="-3"
      id="d41045391e1096-wk-Fact-6CF974A9395B55A50803F1F302922ECA"
      unitRef="usd">88423000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-6C0D71D66C73D973CD06F1F302C31EF2-0-wk-Fact-35F4EECD1DFEE361D770F1F302B3646C">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of grants made in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was contemporaneously estimated on the date of grant using the following assumptions:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:33%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six months ended&lt;br/&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.98 - 2.63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;61.90 - 63.09%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;6.11 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="INF"
      id="d41045391e1210-wk-Fact-73067F0E258C884861E3F1F302A8238A"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember"
      decimals="2"
      id="d41045391e1222-wk-Fact-5DEBD781DF068827D22BF1F302B2BC6C"
      unitRef="usdPerShare">20.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-540C9BDE0C40E8967D07F1F302C3F3D9-0-wk-Fact-8D5483453A014AA66004F1F302B31CBE">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information on the Company&#x2019;s restricted stock awards and units:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Restricted&#160;Stock&#160;Awards&#160;and&#160;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&#160;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;571,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;304,549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(179,577&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(31,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested at June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;665,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="d41045391e1358-wk-Fact-72FC3CE65342C11D3BA5F1F302B22FF8"
      unitRef="shares">571479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d41045391e1377-wk-Fact-7D5C72BAF4AF1C133FA5F1F302B0A04A"
      unitRef="usdPerShare">17.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="d41045391e1397-wk-Fact-B3812226D6397BFFF09BF1F302B29A3D"
      unitRef="shares">304549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d41045391e1416-wk-Fact-E82D43E57641AA4657F9F1F302A87BEE"
      unitRef="usdPerShare">32.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="d41045391e1436-wk-Fact-494BAB1392C1EBB3F248F1F302A91BC6"
      unitRef="shares">179577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d41045391e1456-wk-Fact-94AA594CA6F3C97DE2EDF1F302AC442E"
      unitRef="usdPerShare">17.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="d41045391e1476-wk-Fact-1BE5251C954C223BEB02F1F302A73AD5"
      unitRef="shares">31449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d41045391e1496-wk-Fact-E7609F9DE503A37F7C14F1F302B1678A"
      unitRef="usdPerShare">21.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="d41045391e1516-wk-Fact-94834C6E672961683E75F1F302A8449A"
      unitRef="shares">665002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d41045391e1535-wk-Fact-C378BD6F3F9AE6B85602F1F302AFB4B3"
      unitRef="usdPerShare">24.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D2016Q2May1-May31_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="INF"
      id="d41045391e1556-wk-Fact-1CA1C94D32E47C2904C2F1F30294468E"
      unitRef="shares">897290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="INF"
      id="d41045391e1572-wk-Fact-9980CC2466054C1DD194F1F302B2AD37"
      unitRef="shares">157930</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-5"
      id="d41045391e1585-wk-Fact-EF9EE63CFE760811F226F1F3029A3265"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember"
      decimals="-5"
      id="d41045391e1589-wk-Fact-00DB12D996A20EF32DCD3C117F2FEC50"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="FI2016Q2_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d41045391e1598-wk-Fact-82ABF56A84D8E7AA0B25F1F302932481"
      unitRef="shares">1000000000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d41045391e1610-wk-Fact-AB0685733846CD6E2F9FF1F302AA4F2F"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <ptct:EmployeeStockPurchasePlanVotingPercentageLimitPercent
      contextRef="D2016Q2June_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="d41045391e1614-wk-Fact-33F2EECE13E251DD7751F1F302B2566F"
      unitRef="number">0.05</ptct:EmployeeStockPurchasePlanVotingPercentageLimitPercent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d41045391e1627-wk-Fact-775EB04C12B6DE82788EF1F3029AA5A6"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d41045391e1631-wk-Fact-C6CE57869310F236FBCE4159B3513D84"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0EF97413F04E3D675C04F1F302C36C6C-0-wk-Fact-EF04A6E30B16E66BB1F8F1F30292640A">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,932&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,678&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d41045391e1860-wk-Fact-F929E5D9758DCC923C3DF1F3028C19CF"
      unitRef="usd">5516000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d41045391e1879-wk-Fact-44C92C0546B24E7CE9EBF1F30287BF9E"
      unitRef="usd">3932000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d41045391e1899-wk-Fact-30907BB9D4882E890FDAF1F30253D92D"
      unitRef="usd">10203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d41045391e1918-wk-Fact-CBC82135686C04EE724CF1F302ADE353"
      unitRef="usd">7678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d41045391e1938-wk-Fact-C830EF0174209035A21DF1F30285CF92"
      unitRef="usd">5404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d41045391e1957-wk-Fact-2E852CAA943BA9EC8E81F1F30288A8AF"
      unitRef="usd">4152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d41045391e1976-wk-Fact-238A0C8AF34A602F0386F1F302B0B767"
      unitRef="usd">9981000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d41045391e1996-wk-Fact-407A6DDBD1E4A3ECC6B1F1F3025ECD62"
      unitRef="usd">8153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41045391e2026-wk-Fact-C4AC33B0D6C7FDF6D489F1F3028F75B9"
      unitRef="usd">10920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41045391e2045-wk-Fact-C1F6AF6559A6EA786385F1F302884E08"
      unitRef="usd">8084000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41045391e2065-wk-Fact-35BFCCCC1B48ECE217BCF1F302AB478B"
      unitRef="usd">20184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41045391e2084-wk-Fact-FBA2BC72D51F9496E03EF1F3024EA5A6"
      unitRef="usd">15831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q2"
      decimals="-5"
      id="d41045391e2104-wk-Fact-56C78E8854785AC12797F1F302A33440"
      unitRef="usd">105800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q2YTD"
      id="d41045391e2108-wk-Fact-C82472D10248F9B55FE9F1F3028BB1FE">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:LongTermDebtTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-D24811A9D784D26AA609F1F302C3BA10-0-wk-Fact-5E2305720F725D803CE1F1F302992281">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2017 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the Company entered into a credit and security agreement (the "Credit Facility") with MidCap Financial Trust, a Delaware statutory trust (&#x201c;MidCap&#x201d;), as administrative agent and MidCap and certain other financial institutions as lenders thereunder (the &#x201c;Credit Agreement&#x201d;) that provides for a senior secured term loan facility of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was drawn by the Company on May 5, 2017. The Company's ability to draw on the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under the senior secured term loan facility expired on December 31, 2018. The Company capitalized approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of debt issuance costs, which were netted against the carrying value of the Credit Facility and will be amortized over the term of the Credit Facility.  As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had made loan repayments of $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Borrowings under the Credit Agreement bear interest at a rate per annum equal to LIBOR (with a LIBOR floor rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.00%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;) plus &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company was obligated to make interest only payments (payable monthly in arrears) through April 30, 2019. Commencing on May 1, 2019 and continuing for the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twenty-four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months of the facility, the Company is required to make monthly interest payments and monthly principal payments. The principal payments are to be made based on straight-line amortization of the principal over the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twenty-four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month period. The maturity date of the Credit Agreement is May 1, 2021, unless terminated earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Credit Facility is subject to certain financial covenants. As of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company was in compliance with all required covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In&#160;August&#160;2015, the Company issued, at par value,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;aggregate principal amount of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;convertible senior notes due 2022 (the "Convertible Notes"). The Convertible Notes bear cash interest at a rate of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per year, payable semi-annually on&#160;February&#160;15&#160;and&#160;August&#160;15&#160;of each year, beginning on&#160;February&#160;15, 2016. The Convertible Notes will mature on&#160;August&#160;15, 2022, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$145.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;after deducting the initial purchasers&#x2019; discounts and commissions and the offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes are governed by an indenture (the "Convertible Notes Indenture") with U.S Bank National Association as trustee (the "Convertible Notes Trustee").&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;February&#160;15, 2022&#160;only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#xb7;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:3pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during any calendar quarter commencing on or after&#160;September&#160;30, 2015&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#x2019;s common stock for at least&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;20&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;trading days (whether or not consecutive) during a period of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#xb7;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:3pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;business day period after any&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price (as defined in the Convertible Notes Indenture) per &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; principal amount of Convertible Notes for each trading day of the measurement period was less than&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#xb7;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:3pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#xb7;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:3pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon the occurrence of specified corporate events.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On or after February&#160;15, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert their Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Convertible Notes to be converted and deliver shares of its common stock in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of Convertible Notes being converted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The conversion rate for the Convertible Notes was initially, and remains, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.7487&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock per &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$56.34&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company was not permitted to redeem the Convertible Notes prior to August&#160;20, 2018. As of August 20, 2018, the Company may redeem for cash all or any portion of the Convertible Notes, at its option, if the last reported sale price of its common stock has been at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the conversion price then in effect on the last trading day of, and for at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; other trading days &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(whether or not consecutive) during, any &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; sinking fund is provided for the Convertible Notes, which means that the Company is not required to redeem or retire the Convertible Notes periodically. There have been no redemptions to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If the Company undergoes a &#x201c;fundamental change&#x201d; (as defined in the Indenture governing the Convertible Notes Indenture), subject to certain conditions, holders of the Convertible Notes may require the Company to repurchase for cash all or part of their Convertible Notes at a repurchase price equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes Indenture contains customary events of default with respect to the Convertible Notes, including that upon certain events of default (including the Company&#x2019;s failure to make any payment of principal or interest on the Convertible Notes when due and payable) occurring and continuing, the Convertible Notes Trustee by notice to the Company, or the holders of at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in principal amount of the outstanding Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the Convertible Notes Trustee at the request of such holders (subject to the provisions of the Convertible Notes Indenture) shall, declare &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the principal of and accrued and unpaid interest, if any, on all the Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the principal of and accrued and unpaid interest on the Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for the Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;seven&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year term of the Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the Convertible Notes is&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$57.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and was recorded in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accounting for the transaction costs related to the issuance of the Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;seven&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year term of the Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#x2019; equity. Additionally, the Company initially recorded a net deferred tax liability of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$22.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in connection with the Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes consist of the following:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Liability&#160;component&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Debt discount, net(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(30,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(35,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net carrying amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;117,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;113,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the Convertible Notes using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the remaining contractual life of the Convertible Notes is approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth total interest expense recognized related to the Convertible Notes:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,074&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,067&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate of the liability component&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      decimals="INF"
      id="d41046530e371-wk-Fact-4F568B90B6E09DB9C5C0F1F302A61D47"
      unitRef="usd">60000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="D2017Q2May-05_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      decimals="-5"
      id="d41046530e375-wk-Fact-0FC2CCD0EB19B31DA808F1F3026386A1"
      unitRef="usd">40000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <ptct:LineOfCreditFacilityAdditionalCapacityAvailable
      contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      decimals="-5"
      id="d41046530e379-wk-Fact-27131AD0A3091F3AC62DF1F30298261A"
      unitRef="usd">20000000.0</ptct:LineOfCreditFacilityAdditionalCapacityAvailable>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross
      contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      decimals="-5"
      id="d41046530e383-wk-Fact-21FD831711EE0D9B31B9F1F302645BD5"
      unitRef="usd">400000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsGross>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2019Q2YTD_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      decimals="-5"
      id="d41046530e392-wk-Fact-5A59B24D0C8E027B7AA1413DAFD76558"
      unitRef="usd">1700000</us-gaap:RepaymentsOfDebt>
    <ptct:DebtInstrumentFloorInterestRate
      contextRef="I2017Q2May-31_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      decimals="INF"
      id="d41046530e399-wk-Fact-27A37AA36575CE58DE11F1F302A1B387"
      unitRef="number">0.0100</ptct:DebtInstrumentFloorInterestRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="D2017Q2May_us-gaap_CreditFacilityAxis_ptct_MidCapFinancialTrustMember"
      decimals="INF"
      id="d41046530e403-wk-Fact-471801C0F9D70EEB8638F1F3025A1C15"
      unitRef="number">0.0615</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e428-wk-Fact-1E1351C22346003242E5F1F302B396A8"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e432-wk-Fact-5C029B069446D5431F6AF1F3029E5B6F"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e436-wk-Fact-5C029B069446D5431F6AF1F3029E5B6F"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d41046530e440-wk-Fact-71C2D049A7D2E7E72149F1F3029A5386"
      unitRef="usd">145400000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="d41046530e461-wk-Fact-44E74B8D35A84DA584854A000EED9C52"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e465-wk-Fact-A5EDF61F5A412D7AB971F1F3025F590D"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <ptct:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e484-wk-Fact-692D399CDCA5CDD0151CF1F30269ECBF"
      unitRef="usd">1000</ptct:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e488-wk-Fact-BE20E96D4D37FF69695DF1F30267CA84"
      unitRef="number">0.98</ptct:DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e513-wk-Fact-686801D205955D240C11F1F302627FB7"
      unitRef="number">17.7487</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <ptct:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e517-wk-Fact-692D399CDCA5CDD0151CF1F30269ECBF"
      unitRef="usd">1000</ptct:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e521-wk-Fact-9CABBF2FD708BE591F28F1F302ADEA53"
      unitRef="usdPerShare">56.34</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e528-wk-Fact-DBD3015F8CBB8BB83944F1F3029FBF92"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e532-wk-Fact-B63CB3A18912F2B63271F1F30254C298"
      unitRef="day">19</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e539-wk-Fact-BE69E1EEFA5EEA8678AFF1F30272DAF1"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e543-wk-Fact-6F651CDA976CE77A4E8BF1F30260FABA"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentCumulativeSinkingFundPayments
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e547-wk-Fact-ACBAAC5F79CB34D42E4FF1F3025AE53E"
      unitRef="usd">0</us-gaap:DebtInstrumentCumulativeSinkingFundPayments>
    <ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e554-wk-Fact-26B5A22DC18B934BFABBF1F30299E181"
      unitRef="number">1</ptct:ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault>
    <ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e561-wk-Fact-2671A8D37CB99E0F7F94F1F3029634CC"
      unitRef="number">0.25</ptct:MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e565-wk-Fact-1C03816B19929BD3E461F1F3027D1E8E"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_DebtInstrumentRedemptionPeriodAxis_ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e569-wk-Fact-1C03816B19929BD3E461F1F3027D1E8E"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d41046530e580-wk-Fact-1B8CFC653E566EC7573FF1F3026A24DF"
      unitRef="usd">57500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments
      contextRef="I2015Q3Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="d41046530e591-wk-Fact-E59C4AE167646188831FF1F3026BA71F"
      unitRef="usd">22300000</ptct:NetDeferredTaxLiabilitiesConvertibleDebtInstruments>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-35CC4DAE940965DECA23F1F302C379F2-0-wk-Fact-73247683427E4C3C769BF1F302A393AA">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes consist of the following:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Liability&#160;component&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: Debt discount, net(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(30,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(35,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net carrying amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;117,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;113,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the Convertible Notes using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e684-wk-Fact-8363C7A7E31D2D913852F1F3025D7236"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      id="d41046530e703-wk-Fact-C355729C41B48FB1A7F9F1F30274C970"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e723-wk-Fact-C335721B93ADFD0648E9F1F3026A3860"
      unitRef="usd">1544000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e743-wk-Fact-D77E3F9942D6150148E4F1F302591FCB"
      unitRef="usd">1746000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e769-wk-Fact-EFE07A57E4E9F098B044F1F3027463DD"
      unitRef="usd">30999000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e789-wk-Fact-D3CCE67420F073871852F1F30271F31D"
      unitRef="usd">35054000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e820-wk-Fact-A25994A587E575E1F5FCF1F30260FCE1"
      unitRef="usd">117457000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e839-wk-Fact-A04793096E3D117E73CAF1F3025CCF0A"
      unitRef="usd">113200000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      id="d41046530e875-wk-Fact-D748F214996095FD6699F1F3029E9CD2">P3Y1M6D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-905615E676B6C0025346F1F302C356F5-0-wk-Fact-58FAC39D3E9112D47C70F1F3029763A1">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth total interest expense recognized related to the Convertible Notes:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,074&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,067&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective interest rate of the liability component&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1103-wk-Fact-5F0B231EDA660D8AC687F1F302960998"
      unitRef="usd">1131000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1122-wk-Fact-04248ED55D03F2E4A05FF1F302972DE9"
      unitRef="usd">1131000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1142-wk-Fact-17E01F6225C3B73D37A6F1F302979153"
      unitRef="usd">2241000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1161-wk-Fact-7E870CE7F9E51D23D06DF1F3028FCDCD"
      unitRef="usd">2241000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1181-wk-Fact-BE6BF72969CFAA440C84F1F30296A9BD"
      unitRef="usd">103000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1200-wk-Fact-5A7C47B87D16E3C18EE4F1F30288F9F4"
      unitRef="usd">93000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1219-wk-Fact-A0069D950F0CC7DC2343F1F3028D9CF4"
      unitRef="usd">202000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1239-wk-Fact-43E888E7ABA1E4FA2A66F1F302AB340C"
      unitRef="usd">182000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1264-wk-Fact-B7922CA296632AC424F3F1F3028D8A98"
      unitRef="usd">2074000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1283-wk-Fact-68E7DD095275C0761E75F1F30295CA30"
      unitRef="usd">1863000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1302-wk-Fact-1F7A40AC889CB77EB0E1F1F30285F6A6"
      unitRef="usd">4055000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1322-wk-Fact-3CBF5548F1BF2F3DE1D5F1F30271226E"
      unitRef="usd">3644000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1352-wk-Fact-C0918BFD1F671436F41BF1F30296CE89"
      unitRef="usd">3308000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2018Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1371-wk-Fact-2916279B00BE5DFF2BF7F1F30295544C"
      unitRef="usd">3087000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2019Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1391-wk-Fact-C942C58363440820EFE2F1F302920BB4"
      unitRef="usd">6498000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2018Q2YTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="-3"
      id="d41046530e1410-wk-Fact-E348A69F4187E718FF36F1F302AD0670"
      unitRef="usd">6067000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e1430-wk-Fact-8067E274E0C7082064FEF1F3028A1C05"
      unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2018Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e1450-wk-Fact-3D228D9A4DCBB30B5056F1F3028CB2E5"
      unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e1470-wk-Fact-8067E274E0C7082064FEF1F3028A1C05"
      unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"
      decimals="2"
      id="d41046530e1491-wk-Fact-8400E5C0710CB060B868F1F302A661CF"
      unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FE55791C4872D1C1DB94F1F302C3A965-0-wk-Fact-C18D2EF16D6DEB8AD9B2F1F3025D9699">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;and contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company's oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program.  Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company&#x2019;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company&#x2019;s first such milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; payable to Wellcome Trust occurred in the second quarter of 2016.  Additional milestone payments of up to an aggregate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$22.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; may become payable by the Company to Wellcome Trust under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from its licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#x2019;s obligation to make such payments would end upon the Company's payment to the SMA Foundation of a specified amount.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Merger Agreement with Agilis, Agilis equityholders may become entitled to receive contingent consideration payments from the Company based on (i)&#160;the achievement of certain development milestones up to an aggregate maximum amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, (ii)&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$535.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, (iii)&#160;the achievement of certain net sales milestones up to an aggregate maximum amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and (iv)&#160;a percentage of annual net sales for&#160;Friedreich Ataxia and Angelman Syndrome during specified terms, ranging from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company is required to pay &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$40.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company also has a Collaboration and License Agreement with Akcea Therapeutics, Inc. ("Akcea") for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean (the "Akcea Collaboration and License Agreement").  Pursuant to the agreement, the Company paid Akcea an upfront licensing fee, which included an initial payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. An additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was paid to Akcea in the three month period ended June 30, 2019 upon regulatory approval of Waylivra from the EMA. In addition, Akcea is eligible to receive milestone payments, on a Product-by-Product basis, of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon receipt of regulatory approval for a product from ANVISA, subject to a maximum aggregate amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for all such products. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement. The Company filed a request for marketing authorizations for Tegsedi with ANVISA. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna and Emflaza product net sales, payable quarterly or annually in accordance with the terms of the related agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in the Company's clinical trials or otherwise gain access to its product candidates. The Company is not currently aware of any material legal proceedings against it.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="FI2016Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d41047457e372-wk-Fact-A8AD0EAF1A667269BA27F1F3029DC110"
      unitRef="usd">800000</ptct:DevelopmentMilestonePaymentObligations>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_RangeAxis_srt_MaximumMember"
      decimals="-5"
      id="d41047457e376-wk-Fact-9C1E25C6F3769A608565F1F3026336B5"
      unitRef="usd">22400000</ptct:DevelopmentMilestonePaymentObligations>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41047457e386-wk-Fact-E4352FF052F170C6ED82F1F30299E272"
      unitRef="usd">60000000.0</ptct:DevelopmentMilestonePaymentObligations>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
      contextRef="FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41047457e390-wk-Fact-ECD1AF8A8D555426A41DF1F3024EF182"
      unitRef="usd">535000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="-5"
      id="d41047457e394-wk-Fact-8607AC3A8D258E7A38B4F1F3029A2C54"
      unitRef="usd">150000000.0</ptct:ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="FI2019Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="2"
      id="d41047457e398-wk-Fact-78682E0B45B76933DD4BF1F3025DE7B1"
      unitRef="number">0.02</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
      contextRef="FI2019Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember"
      decimals="2"
      id="d41047457e402-wk-Fact-7C7A49C16B45D88375A2F1F30262CA18"
      unitRef="number">0.06</ptct:ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage>
    <ptct:DevelopmentMilestonePaymentObligations
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="-5"
      id="d41047457e407-wk-Fact-9EFF4764375FB458FD8FF1F302AFC239"
      unitRef="usd">40000000.0</ptct:DevelopmentMilestonePaymentObligations>
    <ptct:UpfrontLicensingFee
      contextRef="FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember"
      decimals="-5"
      id="d41047457e414-wk-Fact-EF3A00E4AE8943DD6374F1F3026B7149"
      unitRef="usd">12000000.0</ptct:UpfrontLicensingFee>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="-5"
      id="d41047457e418-wk-Fact-FD8341D271A3D00AB5FCF1F30264A297"
      unitRef="usd">6000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember"
      decimals="-5"
      id="d41047457e422-wk-Fact-7F06E055EDF0F850595CF1F3025CCBC7"
      unitRef="usd">4000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_srt_RangeAxis_srt_MaximumMember"
      decimals="-5"
      id="d41047457e426-wk-Fact-7086229CAB0BE4D78BCAF1F3025942F0"
      unitRef="usd">8000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-EE71FA280AD76CF140DBF1F302C40070-0-wk-Fact-AC08DABB5723D94A3A9CF1F302A132DB">&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue recognition&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; operating segment. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net product sales in the United States were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively, consisting solely of Emflaza, and net product sales not in the United States were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$57.8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$47.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, consisting of Translarna and Tegsedi.  During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, net product sales in the United States were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$39.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; respectively, consisting solely of Emflaza, and net product sales not in the United States were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$93.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$84.6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million, respectively, consisting of Translarna and Tegsedi.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;December&#160;31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;June&#160;30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company did not have any contract assets for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue in the period from:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts included in contract liabilities at the beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Performance obligations satisfied in previous period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Performance obligations satisfied in current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;138,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124,151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total product revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;138,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124,151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Remaining performance obligations&#160;represent the transaction price for goods the Company has yet to provide. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the aggregate amount of transaction price allocated to&#160;remaining performance obligations&#160;relating to Translarna net product revenue was&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company expects to recognize revenue over the next &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers&#x2019; needs and schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has ongoing collaborations with the Spinal Muscular Atrophy Foundation ("SMA Foundation") and F. Hoffman-La Roche&#160;Ltd and Hoffman- La Roche&#160;Inc. (collectively, "Roche") and early stage discovery arrangements with other institutions. The following are the key terms to the Company&#x2019;s (i)&#160;ongoing collaborations and (ii)&#160;early stage discovery and development arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Roche and SMA Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2011, the Company and the SMA Foundation entered into a licensing and collaboration agreement with Roche for a spinal muscular atrophy program. Under the terms of the agreement, Roche acquired an exclusive worldwide license to the Company&#x2019;s spinal muscular atrophy program, which includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; compounds currently in preclinical development, as well as potential back-up compounds. The Company received a nonrefundable upfront cash payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the research term, which was terminated effective December&#160;31, 2014, after which Roche provided the Company with funding, based on an agreed- upon full-time equivalent rate, for an agreed-upon number of full-time equivalent employees that the Company contributed to the research program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company identified &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; material promises in the collaboration agreement, the license and the research activities. The Company evaluated whether these material promises are distinct and determined that the license does not have standalone functionality and there is a significant integration of the license and research activities. As such, both promises were bundled into one distinct performance obligation. As a result, the Company deferred the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment which was recognized over the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;estimated performance period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years, which was the contracted research period. As of adoption of ASC Topic 606 on January 1, 2018, all performance obligations had been satisfied and the balance of the remaining deferred upfront payment was fully recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$135.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in research and development event milestones, up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$325.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2013, a lead development compound, RG7800, was selected to move into IND-enabling studies, which triggered a milestone payment to the Company from Roche of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2013.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2014, the Company announced the initiation of a Phase&#160;1 clinical program in its spinal muscular atrophy collaboration with Roche and the SMA Foundation which triggered a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payment from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2014.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2014, the Company announced the initiation of a Phase&#160;2 study in adult and pediatric patients in its spinal muscular atrophy collaboration with Roche and the SMA Foundation which triggered a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; payment from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2014.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2017, the Company announced that the Sunfish, a two-part clinical trial in pediatric and adult type 2 and type 3 spinal muscular atrophy initiated in the fourth quarter of 2016 with Roche and SMA Foundation, had transitioned into the pivotal second part of its study. The achievement of this milestone triggered a&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;payment to the Company from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The remaining potential research and development event milestones that can be received as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$87.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The remaining potential sales milestones as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$325.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon achievement of certain sales events. In addition, the Company is eligible to receive up to double digit royalties on worldwide annual net sales of a commercial product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue related to the licensing and collaboration agreement with Roche of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue related to the licensing and collaboration agreement with Roche of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Early stage collaboration and discovery agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company has arrangements with several organizations pursuant to which the Company uses its discovery technologies to help identify potential drug candidates. The Company does not take ownership of the potential compounds, but rather provides research services to the collaborator using its specialized technology platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Generally, these arrangements are structured such that the collaborator and the Company work together to jointly select targets from which to apply its discovery technologies. The research period for the Company to apply its technology is generally &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years. The Company will typically receive a nonrefundable, upfront cash payment and the collaborator agrees to provide funding for research activities performed on its behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Generally, the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; material promises in these arrangements are the license and the research activities. The Company evaluated whether these material promises are distinct and determined that the license does not have standalone functionality and there is a significant integration of the license and research activities. As such, both promises are bundled into one distinct performance obligation. As of adoption of ASC Topic 606 on January 1, 2018, all deferred revenue related to these arrangements had been recognized. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;not&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; recognize any revenue related to discovery agreements. &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is eligible to receive additional payments from its early stage discovery research arrangements if the discovery compounds are ultimately developed and commercialized. The aggregate potential payments the Company is eligible for if all products are developed is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$143.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$252.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in sales milestones upon achievement of specified sales events and up to double digit royalties on worldwide annual net sales of the licensed product.  The Company will recognize revenue when it is probable the milestones will be achieved (see Note 2).  For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;not&lt;/span&gt; recognize any revenue related to early stage collaborations.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d41055937e369-wk-Fact-F37D3921A64F1450D66AF1F302A23204"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <ptct:NetProductSales
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d41055937e381-wk-Fact-F45A6BE0409031CA7044F1F302B3D48B"
      unitRef="usd">27600000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d41055937e385-wk-Fact-A18B1885EBA08BBD4586F1F3029FECB5"
      unitRef="usd">20300000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d41055937e390-wk-Fact-627A11DAFD39DA071FA9F1F302A167CB"
      unitRef="usd">57800000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2018Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d41055937e394-wk-Fact-0A6EFF80B46CA3073F0EF1F302A4A3AC"
      unitRef="usd">47800000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d41055937e406-wk-Fact-5B38A2F0C9B7F241E4D7415B9FD20D52"
      unitRef="usd">45400000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d41055937e411-wk-Fact-CAD236100DC7338EBA2B415BBBB6F75B"
      unitRef="usd">39500000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d41055937e415-wk-Fact-86DDBA47F855E8F7B6EE415C0C68ACB0"
      unitRef="usd">93000000.0</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2018Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d41055937e419-wk-Fact-06C09B99EF3754F8D510415C2ABF2F84"
      unitRef="usd">84600000</ptct:NetProductSales>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d41055937e601-wk-Fact-896D56AF2A39EC4539FCF1F302A0A2F6"
      unitRef="usd">12938000</us-gaap:ContractWithCustomerLiability>
    <ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41055937e620-wk-Fact-7F7B2A4E8C1C279CCF81F1F302A0A6C9"
      unitRef="usd">2864000</ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41055937e640-wk-Fact-EC02470105D9DE34E9C1F1F3029E201C"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41055937e659-wk-Fact-DF6CB9299E34F453677FF1F3029F8118"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41055937e678-wk-Fact-0777C08B9E325C5B472048BA3F88695B"
      unitRef="usd">15802000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2017Q4"
      decimals="-3"
      id="d41055937e841-wk-Fact-E858A5059B9BADFCCC95F1F3027C9FBE"
      unitRef="usd">11891000</us-gaap:ContractWithCustomerLiability>
    <ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41055937e860-wk-Fact-29E0A4A4E06A05FE4590F1F3027DF0C4"
      unitRef="usd">2586000</ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41055937e880-wk-Fact-E3706527A9E02EBFBDD9F1F3027D836B"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41055937e899-wk-Fact-23C0F9529FAE9EBB3BD6F1F3027C53C9"
      unitRef="usd">-3937000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q2"
      decimals="-3"
      id="d41055937e919-wk-Fact-754A4B5738D0E79C29E8F1F3027DC3B3"
      unitRef="usd">10540000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-A5BEA6C76CF81F9D9021F1F302C30C57-0-wk-Fact-000536BE7A1BC89EF927F1F302A0D53C">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue in the period from:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Six Months Ended June 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts included in contract liabilities at the beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Performance obligations satisfied in previous period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Performance obligations satisfied in current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;138,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124,151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total product revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;85,476&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;138,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;124,151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;December&#160;31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 606 Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Balance as of&lt;br/&gt;June&#160;30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,891&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41055937e1087-wk-Fact-5D05FBD3C1DE3D1625C7F1F3024E8263"
      unitRef="usd">0</ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod>
    <ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41055937e1106-wk-Fact-151261F48096A73F0B75F1F302515DB4"
      unitRef="usd">0</ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod>
    <ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41055937e1126-wk-Fact-F60135EBDC7EC3E5E3DAF1F30277F1A0"
      unitRef="usd">0</ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod>
    <ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41055937e1140-wk-Fact-B1FC2FA2F1FD7C7CAA711B6B0F151079"
      unitRef="usd">0</ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41055937e1160-wk-Fact-5F3122A9DB39C36298B6F1F3024E50A2"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41055937e1179-wk-Fact-AC5514D9E4B96551DB14F1F3024F5108"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41055937e1198-wk-Fact-521B1D6FA0819C172D9DF1F30279685B"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41055937e1213-wk-Fact-D7FC2371AEB5B05705111B6B100961CC"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41055937e1238-wk-Fact-B5D87C0E294BB46D4147F1F30278A5C1"
      unitRef="usd">85476000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41055937e1257-wk-Fact-40816A1D82A5B03175A6F1F302509192"
      unitRef="usd">68170000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41055937e1276-wk-Fact-4533BDB7A731C0C6EFEAF1F302784AA8"
      unitRef="usd">138530000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41055937e1291-wk-Fact-CAFD1880A4D9D8FD097148BA331B18B4"
      unitRef="usd">124151000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <ptct:NetProductSales
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d41055937e1321-wk-Fact-E9E34DA2CDA93D48CA40F1F302540F43"
      unitRef="usd">85476000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d41055937e1340-wk-Fact-F52D63DDF7FC1641C550F1F3024FDB8D"
      unitRef="usd">68170000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d41055937e1360-wk-Fact-92CB2F7965BB8E00AFCA48BA3301CBF1"
      unitRef="usd">138530000</ptct:NetProductSales>
    <ptct:NetProductSales
      contextRef="FD2018Q2YTD"
      decimals="-3"
      id="d41055937e1374-wk-Fact-C15A169D03222844F94A1B6B11FFCA18"
      unitRef="usd">124151000</ptct:NetProductSales>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2"
      decimals="-5"
      id="d41055937e1418-wk-Fact-DC5B0EF70E92BCF54974F1F302A15579"
      unitRef="usd">15800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q2"
      decimals="-5"
      id="d41055937e1422-wk-Fact-E0DB240141D4557587CA48BA35DA3FEA"
      unitRef="usd">10500000</us-gaap:ContractWithCustomerLiability>
    <ptct:CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment
      contextRef="D2011Q4Nov1-Nov30_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d41055937e1452-wk-Fact-A3F73705C6C007F816FDF1F302A6D67B"
      unitRef="compound">3</ptct:CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment>
    <ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts
      contextRef="D2011Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1456-wk-Fact-7303DBDAD072CC7A9E52F1F302B0EC76"
      unitRef="usd">30000000.0</ptct:ContractWithCustomerLiabilityIncreaseFromCashReceipts>
    <ptct:CollaborativeArrangementsNumberOfSignificantDeliverables
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_ptct_RocheAndSmaFoundationMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      id="d41055937e1463-wk-Fact-2BD5C9EF7CD37BC10CCFF1F302A23F7A"
      unitRef="deliverable">2</ptct:CollaborativeArrangementsNumberOfSignificantDeliverables>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="I2011Q4Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01"
      decimals="-5"
      id="d41055937e1467-wk-Fact-DF45766329A4D5CC79A9F1F302A3CDAD"
      unitRef="usd">30000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1481-wk-Fact-A827833681607E806697F1F302A0C334"
      unitRef="usd">135000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="D2011Q4Nov1-Nov30_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1485-wk-Fact-A833023FE51E2FA4F552F1F302A14BE0"
      unitRef="usd">325000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="D2013Q3Aug_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1492-wk-Fact-2AA439FAD912F7965D87F1F3024BC355"
      unitRef="usd">10000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="D2014Q1Jan1-Jan31_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1499-wk-Fact-3974780EB1182484CD50F1F302A1F01C"
      unitRef="usd">7500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="D2014Q4Nov1-Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-6"
      id="d41055937e1507-wk-Fact-C4561AAC0C145E7F20D7F1F302A6A9E4"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="D2017Q4Oct_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1514-wk-Fact-0BEC7561A6B07E941464F1F302B27D99"
      unitRef="usd">20000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1525-wk-Fact-7006AF0C7B164F013FE0F1F302A2DAAD"
      unitRef="usd">87500000</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1533-wk-Fact-079DE53E9589569B490BF1F302A83888"
      unitRef="usd">325000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1548-wk-Fact-131B8D30514C9DE1AD85F1F302A72DBA"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2QTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1552-wk-Fact-DF8EAD55F85EE0EB9E2148AD72CB28F0"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1569-wk-Fact-0D2C9799991712E92A2B4A11399C1FE5"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q2YTD_srt_MajorCustomersAxis_ptct_RocheMember_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember"
      decimals="-5"
      id="d41055937e1573-wk-Fact-0EDE2D6CE255B3BC665E4A1167E50F1B"
      unitRef="usd">100000</us-gaap:Revenues>
    <ptct:CollaborativeArrangementsNumberOfSignificantDeliverables
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_ptct_CollaborationAndDiscoveryAgreementsMember"
      decimals="INF"
      id="d41055937e1597-wk-Fact-10005E59551DEF55FCFAF1F3029FB78B"
      unitRef="deliverable">2</ptct:CollaborativeArrangementsNumberOfSignificantDeliverables>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember"
      decimals="-5"
      id="d41055937e1620-wk-Fact-155C73D4D67E1668E5A8F1F302987CDA"
      unitRef="usd">143000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <ptct:RevenueRecognitionMilestonePotentialAchievements
      contextRef="FD2019Q2YTD_ptct_MilestoneAxis_ptct_SalesMilestonesMember_srt_ProductOrServiceAxis_ptct_EarlyStageCollaborationsMember"
      decimals="-5"
      id="d41055937e1624-wk-Fact-8DD84FCF3A930C552CAFF1F302997E0D"
      unitRef="usd">252000000.0</ptct:RevenueRecognitionMilestonePotentialAchievements>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-F4D81D79033A62BE86D1F1F302C42CAD-0-wk-Fact-7C0A933EA2D2F0DF19B7F1F30276341D">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intangible assets and goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Definite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 20, 2017, the Company completed its previously announced acquisition of all rights to Emflaza pursuant to the Asset Purchase Agreement, dated March 15, 2017, and amended on April 20, 2017, by and between the Company and Marathon. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. In accordance with ASU No. 2017-01, the Company determined that substantially all of the fair value is concentrated in the Emflaza rights intangible asset and as such accounted for the transaction as an asset acquisition under ASC 805-50 and recorded an intangible asset of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$148.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Emflaza rights intangible asset is being amortized to cost of product sales over its expected useful life of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;seven&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company will record the milestone payment when it becomes payable to Marathon and increase the cost basis for the Emflaza rights intangible asset. For the three month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, milestone payments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were recorded, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Akcea Collaboration and License Agreement, in May 2019 the Company made a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payment to Akcea upon regulatory approval of Waylivra from the EMA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately ten years on a straight line basis. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement related to sales of Waylivra. In accordance with the guidance for an asset acquisition, the Company will record royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the three month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized amortization expense of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the Emflaza rights and Waylivra intangible assets. For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized amortization expense of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the Emflaza rights and Waylivra intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated future amortization of the Emflaza rights and Waylivra intangible asset is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;126,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In connection with the acquisition of Agilis, the Company acquired rights to PTC-AADC, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The Agilis platform also includes a gene therapy asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. An investigational new drug ("IND") submission with the FDA for this program is expected in late 2019. Additionally, the Agilis platform includes two other gene therapy programs targeting CNS disorders, including Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition.  The Company classified the fair value of the acquired IPR&amp;amp;D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts.&#160;The value allocated to the indefinite lived intangible assets was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$576.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result of the Merger on August 23, 2018, the Company recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$82.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of goodwill. There were no changes to the recorded value of goodwill for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; month periods ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2017Q2Apr-20_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember"
      decimals="-5"
      id="d41049013e368-wk-Fact-20C98DC26C1ACC727F69F1F302714175"
      unitRef="usd">148400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="FI2019Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember"
      decimals="-5"
      id="d41049013e390-wk-Fact-579B5043BED29B25D7761B76D93E1EA5"
      unitRef="usd">8300000</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="FI2018Q2_us-gaap_BusinessAcquisitionAxis_ptct_EmflazaassetacquisitionMember"
      decimals="-5"
      id="d41049013e394-wk-Fact-267D2AF2A31DE80E88241B772FB86C6F"
      unitRef="usd">3900000</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <ptct:MilestonePotentialAchievementsRegulatoryApproval
      contextRef="FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember"
      decimals="-5"
      id="d41049013e405-wk-Fact-FD8341D271A3D00AB5FCF1F30264A297"
      unitRef="usd">6000000.0</ptct:MilestonePotentialAchievementsRegulatoryApproval>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d41049013e420-wk-Fact-7232569FDF3B3D252437F1F302770C6C"
      unitRef="usd">6600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2QTD"
      decimals="-5"
      id="d41049013e424-wk-Fact-BA2068543A375AA18018F1F30255188F"
      unitRef="usd">5600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d41049013e441-wk-Fact-6814295B802475874516415D51ED620E"
      unitRef="usd">12700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q2YTD"
      decimals="-5"
      id="d41049013e445-wk-Fact-1CC91D1B6BAC2F187075415D7942A4B5"
      unitRef="usd">11000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-6B4B9C3AE12C44FFF745F1F302C4BD2A-0-wk-Fact-AB5E9CF463B446D8A475F1F3027256DA">&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated future amortization of the Emflaza rights and Waylivra intangible asset is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;126,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41049013e510-wk-Fact-FCFDF5C2C44B763604331B7335CEC1FC"
      unitRef="usd">13273000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41049013e530-wk-Fact-60FBBDE505E65DCE2D321B7343677E44"
      unitRef="usd">26566000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41049013e555-wk-Fact-C27AB59F31807FB725C31B735108D5F6"
      unitRef="usd">26566000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41049013e580-wk-Fact-DBE754D963C6D80ACA381B735D9DCC46"
      unitRef="usd">26566000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ptct:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41049013e605-wk-Fact-6FC1D4058DF54396572D1B736B2AFA90"
      unitRef="usd">33258000</ptct:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d41049013e635-wk-Fact-44AD0A35AB7AF9AF58A21B7376F2EE67"
      unitRef="usd">126229000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d41049013e655-wk-Fact-DF8B758291E61905CF81F1F30254BC1B"
      unitRef="usd">576500000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-5"
      id="d41049013e666-wk-Fact-CBB81CB885D77F156E2A49F757E9F36A"
      unitRef="usd">82300000</us-gaap:Goodwill>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1948262E7F892FE91559F1F302C45528-0-wk-Fact-6FAAFC5DDD2DD6189BC6F1F302774EA5">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent events&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On August 4, 2019, the Company and Bristol-Myers Squibb Company, (the &#x201c;Landlord&#x201d;) entered into a Lease Agreement&#160;(the &#x201c;Lease&#x201d;), relating to the lease&#160;of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;185,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of office, production and laboratory space at a facility located in Hopewell Township, New Jersey (the &#x201c;Campus&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The rental term of the Lease is currently estimated to commence on July 1, 2020 (the &#x201c;Commencement Date&#x201d;). Upon the Commencement Date, the Lease has an initial term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;fifteen years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (the &#x201c;Initial Term&#x201d;), with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;10&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year renewal periods at the Company&#x2019;s option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The aggregate rent for the Initial Term will be approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$88.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The rental rate for the renewal periods will be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the Prevailing Market Rate (as defined in the Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Subject to the terms of the Lease, the Company has a right of first refusal to rent certain other space of the Campus, which would be triggered upon the Landlord&#x2019;s issuance of a second round proposal or letter of intent to another tenant for such space. The Company also may seek to build a new separate building on the Campus, which may not contain less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet (the &#x201c;New Building&#x201d;). Upon receipt of notice of the Company&#x2019;s intention to build the New Building, the Landlord may, in its sole discretion, construct and lease the New Building to the Company or enter into a ground lease with the Company permitting the Company to construct the New Building. The term for the New Building will be &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;fifteen years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive five-year renewal rights. Rent terms for the New Building will be determined based on the land value, construction and project costs subject to whether the Landlord or Company constructs the New Building.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is also obligated to provide the Landlord with either an unconditional, irrevocable and transferable letter of credit (the &#x201c;Letter of Credit&#x201d;) in the amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, for a term of not less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as a security deposit, or the same amount as a cash security deposit within thirty days upon entering into the Lease. The Letter of Credit shall remain in effect continuously and shall either expire (i) sixty days after the Expiration Date (as defined in the Lease) or (ii) be automatically self-renewing until the Expiration Date. If the Lease is extended, the Company must continue to provide and maintain the Letter of Credit until sixty days after the extended Expiration Date. If after the fifth anniversary of the Commencement Date, the Company has not received notice of being in default of the Lease, then the Letter of Credit shall be reduced to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Lease contains customary events of default, representations, warranties and covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The foregoing summary of the Lease and Letter of Credit are not complete and are qualified in their entirety by reference to the Lease and Letter of Credit, which will be filed as exhibits to the Company&#x2019;s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ptct:Feet
      contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="0"
      id="d41056046e368-wk-Fact-889C5CEBE638BEEA7EA5630DCF3B0927"
      unitRef="Feet">185000</ptct:Feet>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d41056046e375-wk-Fact-03F7CD2D99605747FB22596F5934F927">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ptct:Numberofterms
      contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d41056046e379-wk-Fact-958BCC56444A041FB17F630B9DBC968B"
      unitRef="Term">2</ptct:Numberofterms>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d41056046e390-wk-Fact-450EF874FEBE8344B4095972DC02B510"
      unitRef="usd">88000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <ptct:PercentOfMarketRate
      contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d41056046e394-wk-Fact-064F91DD6B891B3F729C6315B4DC083A"
      unitRef="number">0.95</ptct:PercentOfMarketRate>
    <ptct:Feet
      contextRef="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="0"
      id="d41056046e401-wk-Fact-24BDD99087C66685D8A4630F44E65E4B"
      unitRef="Feet">75000</ptct:Feet>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d41056046e405-wk-Fact-89A3F4549E71471F5A436311EC1FA113">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ptct:Numberofterms
      contextRef="I2019Q3Aug4_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ptct_NewBuildingMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d41056046e409-wk-Fact-A4CAD95F40E65C622A9163128EF00D7E"
      unitRef="Term">2</ptct:Numberofterms>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d41056046e416-wk-Fact-B4A1385DF86BDAAEC2695973FF4D0662"
      unitRef="usd">7500000</us-gaap:LettersOfCreditOutstandingAmount>
    <ptct:Termforletterofcredit
      contextRef="D2019Q3Aug4-Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d41056046e420-wk-Fact-AE02DA7E8CCEF683970F63ABCA2F2E2A">P5Y</ptct:Termforletterofcredit>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="I2019Q3Aug4_us-gaap_DebtInstrumentAxis_ptct_FifthAnniversaryMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="d41056046e424-wk-Fact-39E589A8E59E1A8DA87F62DAB416FE21"
      unitRef="usd">3800000</us-gaap:LettersOfCreditOutstandingAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6826666832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Aug. 05, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CoverpageAbstract', window );"><strong>cover page [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,949,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CoverpageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>cover page [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CoverpageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6826696128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover DEI<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CoverpageAbstract', window );"><strong>cover page [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CoverpageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>cover page [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CoverpageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6826555104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 136,094<span></span>
</td>
<td class="nump">$ 169,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">227,447<span></span>
</td>
<td class="nump">58,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">77,104<span></span>
</td>
<td class="nump">67,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">16,897<span></span>
</td>
<td class="nump">16,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,424<span></span>
</td>
<td class="nump">9,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">474,966<span></span>
</td>
<td class="nump">320,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">15,391<span></span>
</td>
<td class="nump">12,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">702,729<span></span>
</td>
<td class="nump">701,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">82,341<span></span>
</td>
<td class="nump">82,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">16,145<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,291,572<span></span>
</td>
<td class="nump">1,119,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">122,375<span></span>
</td>
<td class="nump">128,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">11,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">8,005<span></span>
</td>
<td class="nump">3,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">4,179<span></span>
</td>
<td class="nump">3,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent', window );">Deferred consideration payable</a></td>
<td class="nump">19,400<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">173,959<span></span>
</td>
<td class="nump">166,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">7,797<span></span>
</td>
<td class="nump">9,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">135,683<span></span>
</td>
<td class="nump">141,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">336,200<span></span>
</td>
<td class="nump">310,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">18,800<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">122,032<span></span>
</td>
<td class="nump">122,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">8,416<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">802,887<span></span>
</td>
<td class="nump">768,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding 58,707,185 shares at June 30, 2019. Authorized 125,000,000 shares; issued and outstanding 50,606,147 shares at December 31, 2018.</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,539,530<span></span>
</td>
<td class="nump">1,288,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,052,825)<span></span>
</td>
<td class="num">(938,923)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">488,685<span></span>
</td>
<td class="nump">350,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,291,572<span></span>
</td>
<td class="nump">$ 1,119,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6819794144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">58,707,185<span></span>
</td>
<td class="nump">50,606,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="nump">57,707,185<span></span>
</td>
<td class="nump">50,606,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6823003344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Performance obligations satisfied in current period</a></td>
<td class="nump">$ 85,476<span></span>
</td>
<td class="nump">$ 68,170<span></span>
</td>
<td class="nump">$ 138,530<span></span>
</td>
<td class="nump">$ 124,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">85,522<span></span>
</td>
<td class="nump">68,743<span></span>
</td>
<td class="nump">139,105<span></span>
</td>
<td class="nump">124,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">5,587<span></span>
</td>
<td class="nump">5,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">6,575<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
<td class="nump">12,652<span></span>
</td>
<td class="nump">11,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59,979<span></span>
</td>
<td class="nump">32,607<span></span>
</td>
<td class="nump">112,544<span></span>
</td>
<td class="nump">63,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">49,215<span></span>
</td>
<td class="nump">33,545<span></span>
</td>
<td class="nump">89,760<span></span>
</td>
<td class="nump">66,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Change in the fair value of deferred and contingent consideration</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">124,280<span></span>
</td>
<td class="nump">74,317<span></span>
</td>
<td class="nump">247,003<span></span>
</td>
<td class="nump">147,122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(38,758)<span></span>
</td>
<td class="num">(5,574)<span></span>
</td>
<td class="num">(107,898)<span></span>
</td>
<td class="num">(22,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(2,074)<span></span>
</td>
<td class="num">(2,884)<span></span>
</td>
<td class="num">(4,362)<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(673)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(41,015)<span></span>
</td>
<td class="num">(9,131)<span></span>
</td>
<td class="num">(112,552)<span></span>
</td>
<td class="num">(28,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(774)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="num">(1,350)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (41,789)<span></span>
</td>
<td class="num">$ (9,520)<span></span>
</td>
<td class="num">$ (113,902)<span></span>
</td>
<td class="num">$ (28,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">55,912,748<span></span>
</td>
<td class="nump">46,137,833<span></span>
</td>
<td class="nump">57,113,141<span></span>
</td>
<td class="nump">46,257,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share-basic and diluted (in dollars per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share&#8212;basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,170<span></span>
</td>
<td class="nump">$ 138,530<span></span>
</td>
<td class="nump">$ 124,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_GrantAndCollaborationMember', window );">Collaboration and grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_GrantAndCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_GrantAndCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6819755472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (41,789)<span></span>
</td>
<td class="num">$ (9,520)<span></span>
</td>
<td class="num">$ (113,902)<span></span>
</td>
<td class="num">$ (28,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation gain (loss)</a></td>
<td class="nump">278<span></span>
</td>
<td class="num">(3,138)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="num">(2,031)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (40,672)<span></span>
</td>
<td class="num">$ (12,618)<span></span>
</td>
<td class="num">$ (113,442)<span></span>
</td>
<td class="num">$ (30,896)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6831080720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>AOCI Attributable to Parent</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,612,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2017</a></td>
<td class="nump">$ 156,437,000<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 966,534,000<span></span>
</td>
<td class="nump">$ 3,969,000<span></span>
</td>
<td class="num">$ (814,108,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">117,874,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">117,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">3,592,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock vesting and issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">1,299,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">15,831,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,831,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,782,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,782,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="num">(2,114,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,114,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,680,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2018</a></td>
<td class="nump">267,402,000<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="nump">1,105,124,000<span></span>
</td>
<td class="nump">1,855,000<span></span>
</td>
<td class="num">(839,624,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,809,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Mar. 31, 2018</a></td>
<td class="nump">150,309,000<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">975,418,000<span></span>
</td>
<td class="nump">4,953,000<span></span>
</td>
<td class="num">(830,104,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">117,874,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">117,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">2,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">1,298,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">8,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,520,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,520,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="num">(3,098,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,098,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,680,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2018</a></td>
<td class="nump">267,402,000<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="nump">1,105,124,000<span></span>
</td>
<td class="nump">1,855,000<span></span>
</td>
<td class="num">(839,624,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adjustment to accumulated deficit</a></td>
<td class="nump">3,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,266,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,606,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2018</a></td>
<td class="nump">350,727,000<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="nump">1,288,137,000<span></span>
</td>
<td class="nump">1,462,000<span></span>
</td>
<td class="num">(938,923,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,563,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">224,545,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">224,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">4,129,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">1,564,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">20,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor', window );">Adjustments to Additional Paid In Capital, Receivable from Investor</a></td>
<td class="nump">978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(113,902,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,902,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,707,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2019</a></td>
<td class="nump">488,685,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">1,539,530,000<span></span>
</td>
<td class="nump">1,922,000<span></span>
</td>
<td class="num">(1,052,825,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,418,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Mar. 31, 2019</a></td>
<td class="nump">512,942,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">1,523,115,000<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="num">(1,011,036,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to equity offering</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">2,847,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting and issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with an employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with an employee stock purchase plan</a></td>
<td class="nump">1,564,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">10,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor', window );">Adjustments to Additional Paid In Capital, Receivable from Investor</a></td>
<td class="nump">978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,789,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive income</a></td>
<td class="nump">1,117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,707,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2019</a></td>
<td class="nump">$ 488,685,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 1,539,530,000<span></span>
</td>
<td class="nump">$ 1,922,000<span></span>
</td>
<td class="num">$ (1,052,825,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6819897568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (113,902)<span></span>
</td>
<td class="num">$ (28,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">14,760<span></span>
</td>
<td class="nump">12,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in valuation of deferred and contingent consideration</a></td>
<td class="nump">26,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on MRI investment</a></td>
<td class="num">(129)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">3,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of asset</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discounts on investments, net</a></td>
<td class="num">(907)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">20,184<span></span>
</td>
<td class="nump">15,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency transaction gains, net</a></td>
<td class="nump">62<span></span>
</td>
<td class="num">(764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(852)<span></span>
</td>
<td class="num">(3,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(7,250)<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Trade receivables, net</a></td>
<td class="num">(9,702)<span></span>
</td>
<td class="num">(20,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits and other assets</a></td>
<td class="num">(9,656)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(7,546)<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">8,651<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">3,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(72,931)<span></span>
</td>
<td class="num">(15,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(4,851)<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of equity investment in MRI</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(226,261)<span></span>
</td>
<td class="num">(28,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">58,424<span></span>
</td>
<td class="nump">35,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisition of product rights and licenses</a></td>
<td class="nump">11,981<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in (provided by) investing activities</a></td>
<td class="num">(188,669)<span></span>
</td>
<td class="nump">6,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offerings</a></td>
<td class="nump">224,545<span></span>
</td>
<td class="nump">117,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from shares issued under employee stock purchase plan</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">228,571<span></span>
</td>
<td class="nump">122,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(33,404)<span></span>
</td>
<td class="nump">111,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">169,498<span></span>
</td>
<td class="nump">111,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">136,094<span></span>
</td>
<td class="nump">223,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,111<span></span>
</td>
<td class="nump">3,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">898<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">11,643<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</a></td>
<td class="nump">$ 8,269<span></span>
</td>
<td class="nump">$ 3,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6612500352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221; or &#8220;PTC&#8221;) is a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company&#8217;s ability to globally commercialize products is the foundation that drives its continued investment in a robust pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> products, Translarna</span><span style="font-family:inherit;font-size:8pt;">&#8482; </span><span style="font-family:inherit;font-size:10pt;">(ataluren) and Emflaza&#8482; (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna received marketing authorization from the European Commission in August 2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged five years and older in the </span><span style="font-family:inherit;font-size:10pt;"><span>31</span></span><span style="font-family:inherit;font-size:10pt;"> member states of the European Economic Area, or EEA. In July 2018, the European Commission approved a label-extension request to the marketing authorization for Translarna in the EEA to include patients from two to up to five years of age. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a pipeline of gene therapy product candidates, including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, or AADC deficiency.  The Company is preparing a biologics license application, or BLA, for PTC-AADC for the treatment of AADC deficiency in the United States, which it anticipates submitting to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2019, with anticipated commercial launch in the United States in 2020, subject to approval. The Company is also preparing a marketing authorization application, or MAA, for PTC-AADC for the treatment of AADC deficiency in the European Union, or EU, for submission to the European Medicines Agency, or EMA, which will follow its BLA submission to the FDA. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company holds the rights for the commercialization of Tegsedi&#8482; (inotersen) and Waylivra&#8482; (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean. Tegsedi has received marketing authorization in the U.S., EU and Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis. The Company filed for marketing authorization with ANVISA, the Brazilian health regulatory authority, which granted priority review. It expects approval in Brazil by the end of 2019. Waylivra has received conditional marketing authorization in the EU for the treatment of familial chylomicronemia syndrome, or FCS. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has a spinal muscular atrophy ("SMA") collaboration with F. Hoffman-La Roche&#160;Ltd and Hoffman-La Roche&#160;Inc., referred to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation. Currently, its collaboration has two pivotal clinical trials ongoing to evaluate the safety and effectiveness of risdiplam (RG7916, RO7034067), the lead compound in the SMA program. Roche is preparing an NDA and a MAA for risdiplam for the treatment of SMA in the United States and the EU, respectively, which Roche anticipates submitting to the FDA in the second half of 2019 and the EMA in the first half of 2020. In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The marketing authorization in the EEA was last renewed in July 2019 and is effective, unless extended, through August 5, 2020. The renewal was based on the Company&#8217;s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2014, the Company initiated reimbursed early access programs, or EAP programs, for Translarna for nmDMD patients in selected territories in the EEA and recorded its first sales of Translarna in the third quarter of 2014 pursuant to an EAP program. In December 2014, the Company recorded its first commercial sales in Germany. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, Translarna was available in over </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> countries on a commercial basis or pursuant to an EAP program. The Company expects to expand its commercial </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">activities across the EEA pursuant to the marketing authorization granted by the EMA throughout 2019 and future years, subject to continued renewal of its marketing authorization following annual EMA reassessments and successful completion of pricing and reimbursement negotiations. Concurrently, the Company plans to continue to pursue EAP programs in select countries where those mechanisms exist, both within the EEA and in other countries that will reference the marketing authorization in the EEA.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied PTC&#8217;s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients&#8217; muscles. The Company intends to follow the FDA&#8217;s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. The Company expects that a potential re-submission of an NDA could occur in 2020. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emflaza was initially approved in the United States for the treatment of DMD in patients five years and older. In June 2019, the FDA approved the Company's label expansion request for Emflaza for patients two to five years of age. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 20, 2017, the Company completed its acquisition of all rights to Emflaza, or the Transaction.  Emflaza is approved in the United States for the treatment of DMD in patients two years and older. The Transaction was completed pursuant to an asset purchase agreement, dated March 15, 2017, as amended on April 20, 2017, (the "Asset Purchase Agreement"), by and between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon. The Transaction was accounted for as an asset acquisition. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. The Company assumed certain liabilities and obligations in the Transaction arising out of, or relating to, the assets acquired in the Transaction. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the closing of the Transaction, the Company paid to Marathon total upfront consideration comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, funded through cash on hand, and </span><span style="font-family:inherit;font-size:10pt;"><span>6,683,598</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. The number of shares of common stock issued at closing was determined by dividing </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> by the volume-weighted average price per share of the Company&#8217;s common stock on the Nasdaq Stock Market for the </span><span style="font-family:inherit;font-size:10pt;"><span>15</span></span><span style="font-family:inherit;font-size:10pt;"> trading-day period ending on the third trading day immediately preceding the closing. Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza, up to a specified aggregate maximum amount over the expected commercial life of the asset, and a single </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> sales-based milestone, in each case subject to the terms and conditions of the Asset Purchase Agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the &#8220;Merger Agreement&#8221;), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC (the "Merger"). </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$49.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and </span><span style="font-family:inherit;font-size:10pt;"><span>3,500,907</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock (the &#8220;Closing Stock Consideration&#8221;). The Closing Stock Consideration was determined by dividing </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> by the volume-weighted average price per share of the Company&#8217;s common stock on the Nasdaq Global Select Market for the </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders may become entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products. Under the Merger Agreement, the Company is required to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,052.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has financed its operations to date primarily through the private offering in August&#160;2015 of </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2022 (see Note 10), public offerings of common stock in February 2014, October 2014, April 2018 and January 2019, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company&#8217;s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Company&#160;expects&#160;that&#160;cash&#160;flows&#160;from&#160;the&#160;sales&#160;of&#160;its&#160;products,&#160;together&#160;with&#160;the&#160;Company&#8217;s&#160;cash, cash equivalents and marketable securities,&#160;will&#160;be&#160;sufficient&#160;to&#160;fund&#160;its&#160;operations&#160;for&#160;at&#160;least&#160;the&#160;next&#160;twelve&#160;months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816025840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of significant accounting policies</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company&#8217;s audited financial statements as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> included in the Company&#8217;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (the "SEC") on March 1, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> (the "</span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Form&#160;10-K"). Additional significant accounting policies adopted during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are discussed in further detail below.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of presentation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying financial information as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and notes thereto included in the </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Form&#160;10-K.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the unaudited financial information as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or for any other interim period or for any other future year.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#8217;s research and development expenses, stock-based compensation, valuation procedures for the convertible notes, allowance for doubtful accounts, inventory, acquired intangible assets, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory and cost of product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Translarna and Emflaza product which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,362</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value.  No write downs were recorded for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.  Additionally, though the Company&#8217;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, these amounts were immaterial.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, including personnel costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-9, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;.  ASU No. 2014-9 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-15, Revenue Recognition-Products (Topic 605) and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net product revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#8217;s performance obligations are to provide Translarna or Emflaza based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#8217;s customer obtains control of either Translarna or Emflaza, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to either product sales of Translarna or Emflaza.  In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. Historically, returns of Translarna and Emflaza are immaterial to the financial statements, except as related to labeling changes and changes in specialty pharmacies. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of ASC Topic 606 on January 1, 2018, the Company elected the following practical expedients:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying ASC Topic 606 to each individual contract.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant Financing Component - the Company expects the period between when it transfers a promised good to a customer and when the customer pays for the good or service to be one year or less. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immaterial Performance Obligations - the Company disregards promises deemed to be immaterial in the context of the contract. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and Handling Activities - the Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#8220;Collaborative Arrangements&#8221; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Allowance for doubtful accounts</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#8217;s financial condition and current economic trends. The allowance for doubtful accounts was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Bad debt expense was immaterial for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets consist of in-process research and development ("IPR&amp;D"). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D acquired in a business combination. The Company utilizes the "income method&#8221;, and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&amp;D intangible assets that are determined to have had a drop in their fair value are adjusted downward and an impairment is recognized in the statement of operations. These assets are tested at least annually or sooner when a triggering event occurs that could indicate a potential impairment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded a deferred tax liability in conjunction with the Merger of $</span><span style="font-family:inherit;font-size:10pt;"><span>122.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the tax basis difference in the IPR&amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-2, &#8220;Leases (Topic 842)&#8221; along with other amendments issued in 2017 and 2018. Topic 842 supersedes the lease accounting requirements in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Standards Codification Topic 840, Leases</span><span style="font-family:inherit;font-size:10pt;">&#160;(Topic 840). Topic 842 requires organizations to recognize leased assets and liabilities on the balance sheet. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the standard, operating leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease payments associated with the Company&#8217;s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company&#8217;s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term.  The Company applies this policy to all underlying asset categories.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Topic 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The lease term for all of the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See the "Impact of recently adopted accounting pronouncements" section within this Note below and Note 3 Leases for additional information.  The information presented for periods prior to January 1, 2019 has not been adjusted and is reported under Topic 840. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently issued accounting standards</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#8220;Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This standard requires financial assets measured at amortized cost basis to be presented at the </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. The Company expects to adopt this guidance when effective and is assessing what effect the adoption of ASU 2016-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;. ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No. 2018-18 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of recently adopted accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-2, &#8220;Leases (Topic 842)&#8221;. This standard requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018, with early adoption permitted.  Additionally, in March 2019, the FASB issued ASU 2019-01,"Leases (Topic 842): Codification Improvements&#8221;.  ASU 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. The Company adopted the new guidance on January 1, 2019 using the modified retrospective method. Prior period results were not adjusted and continue to be presented under Topic 840 based on the accounting standards originally in effect for such periods. As part of the adoption, the Company has elected to utilize practical expedients including the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to: 1) carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements, 2) not separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component (the Company elected to apply this practical expedient to all underlying asset classes), 3) not apply the recognition requirements in ASC 842 to short-term leases, and 4) not record a right of use asset or right of use liability for leases with an asset or liability balance that would be considered immaterial. Upon adoption, the Company recorded an operating lease liability with a corresponding operating lease ROU asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The adoption did not have a material impact on the consolidated results of operations, stockholder's equity, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. As the Company is not a lessor, the aspects of the new guidance pertaining to lessors was not applicable for the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, "Income Statement &#8212; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income". This standard permits the reclassification of tax effects stranded in other comprehensive income as a result of tax reform to retained earnings related to the change in federal </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">tax rate in addition to other stranded effects that relate to the 2017 Tax Act but do not directly relate to the change in the federal rate. ASU 2018-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance. The Company adopted this guidance on January 1, 2019 and elected not to reclassify the tax effects in other comprehensive income related to the 2017 Tax Act, as these amounts were immaterial. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "Compensation &#8212; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting". This standard expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in the entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The ASU retains the existing cost attribution guidance, which requires entities to recognize compensation cost for nonemployee awards in the same period and in the same manner they would if they paid cash for the goods or services, but it moves the guidance to ASC 718. ASU 2018-07 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance.  The Company adopted this guidance on January 1, 2019. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;.  ASU No. 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-15, Revenue Recognition-Products and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  On January 1, 2018, the Company adopted ASC Topic 606 using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The Company calculated a one-time transition adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded on January 1, 2018 to deferred revenue and accumulated deficit, related to the product sales of Emflaza. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January&#160;2016, the FASB issued ASU No.&#160;2016-01, &#8220;Financial Instruments &#8212; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&#8221;. This standard enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The new guidance affects all reporting organizations (whether public or private) that hold financial assets or owe financial liabilities. The Company adopted the guidance on January&#160;1, 2018.  In March 2018, the FASB issued ASU 2018-04, "Investments - Debt Securities (Topic 320) and Regulated Operations (Topic 980): Amendments to SEC Paragraphs Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 117 and SEC Release No. 33-9273 (SEC Update)". This standard supersedes SEC paragraphs in ASC 320, Investments- Debt Securities, as a result of the issuance of SAB 117 and also updates the Codification for a 2011 SEC release and is effective when a registrant adopts ASU 2016-01, which in the case of the Company was on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221;. This standard clarifies the presentation of certain specific cash flow issues in the Statement of Cash Flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-16, &#8220;Intra-Entity Transfers of Assets Other Than Inventory&#8221;.  ASU 2016-16 requires companies to account for the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) when the transfer occurs. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows (Topic 230): Restricted Cash&#8221;. This standard requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows and no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In May 2017, the FASB issued ASU No. 2017-09, "Stock Compensation (Topic 718): Scope of Modification Accounting". This standard clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as a modification, with entities applying the modification accounting guidance if the value, vesting conditions or classification of the award changes. In addition to all disclosures about modifications that are required under the current guidance, entities will be also required to disclose that compensation expense has not changed if applicable.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Company adopted the guidance on January&#160;1, 2018.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6643951648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases office space in South Plainfield, New Jersey for its principal office under </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> noncancelable operating leases through May 2022 and August 2024, in addition to office space in various countries for international employees primarily through workspace providers. The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company&#8217;s operating leases have remaining lease terms ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span><span style="font-family:inherit;font-size:10pt;"> years to </span><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span><span style="font-family:inherit;font-size:10pt;"> years and certain of the leases include renewal options to extend the lease for up to </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease expense were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Lease Cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost is a component of operating expenses on the consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities- current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities- noncurrent</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,416</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset is a component of deposits and other assets on the consolidated balance sheet. The current portion of operating lease liability is a component of other current liabilities on the consolidated balance sheet. The long term portion of operating lease liabilities is a component of other long term liabilities on the consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental lease term and discount rate information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:74%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease terms - operating leases (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable leases as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (Excludes the six months ended June 30, 2019)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,371</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had no operating leases that had not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816755008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value of financial instruments and marketable securities</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of financial instruments and marketable securities</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company follows the fair value measurement rules, which provide&#160;&#160;&#160;&#160;guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules&#160;establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,&#160;etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#183;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3&#8212;Inputs are unobservable and reflect the Company&#8217;s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents and investments are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2019, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of shares of MRI Interventions, Inc.'s ("MRI") common stock, at a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.10</span></span><span style="font-family:inherit;font-size:10pt;"> per share, in connection with a securities purchase agreement that the Company entered into with MRI, a publicly traded medical device company. The Company determined that the equity investment represents a financial instrument and therefore, recorded it at fair value, which is readily determinable. The equity investment is a component of deposits and other assets on the consolidated balance sheet. During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded an unrealized gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is a component of other (expense) income, net within the consolidated statement of operations. The fair value of the equity investment was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company classifies its equity investment in MRI as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of certain marketable securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining investments, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews its investments on a periodic basis for other-than-temporary impairments. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may have a significant adverse effect on the fair value of the investment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents the fair value using the hierarchy described above for the Company&#8217;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity investment in MRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock appreciation rights liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- net sales milestones and royalties </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">markets&#160;for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">identical&#160;assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock appreciation rights liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- net sales milestones and royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;"> transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of marketable securities accounted for as available-for-sale securities at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,706</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>656</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company held securities with an unrealized loss position that were not considered to be other-than-temporarily impaired as the Company has the ability to hold such investments until recovery of their fair value. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders&#8217; equity. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company did </span><span style="font-family:inherit;font-size:10pt;">not</span><span style="font-family:inherit;font-size:10pt;"> have any realized gains/losses from the sale of marketable securities.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position greater than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position greater than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities on the balance sheet at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> mature as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,639</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company classifies all of its securities as current as they are all available for sale and are available for current operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible 3.0% senior notes</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2015, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due August&#160;15, 2022 (the &#8220;Convertible Notes&#8221;). Interest is payable semi-annually on February&#160;15 and August&#160;15 of each year, beginning on February&#160;15, 2016. The Company separately accounted for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and equity component, as further discussed in Note&#160;10. The fair value of the Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading which are Level&#160;2 inputs. The estimated fair value of the Convertible Notes at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$166.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$146.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and borrowings under the credit and security agreement with MidCap Financial Trust and other financial institutions (as further discussed in Note 10) approximate fair value because of the immediate or short-term maturity of these financial instruments. The carrying amounts for the credit and security agreement approximate fair value based on market activity for other debt instruments with similar characteristics and comparable risk.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred consideration payable</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Merger Agreement, Agilis equityholders may become entitled to receive contingent consideration payments from the Company based on&#160;the achievement of certain development milestones up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$535.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is required to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved.  The fair value of the deferred consideration payable at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was estimated to be </span><span style="font-family:inherit;font-size:10pt;"><span>$38.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> by applying a discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#8217;s estimated development timelines for the acquired product candidates. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$19.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the deferred consideration payable was classified as current on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3 valuation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The stock appreciation rights ("SARs") liability is classified in other liabilities on the Company&#8217;s consolidated balance sheets. The SARs liability is marked-to-market each reporting period with the change in fair value recorded as compensation expense on the Company&#8217;s consolidated statements of operations until the SARs vest. The fair value of the SARs liability is determined at each reporting period by utilizing the Black-Scholes option pricing model.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss in the consolidated statements of operations. The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company&#8217;s estimated development timelines for the acquired product candidate. The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The changes in the fair value of the Company's Level 3 valuations for the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> were immaterial.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3 liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">SARs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent consideration payable- development and regulatory milestones</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent consideration payable- net sales milestones and royalties</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the SARs liability, and the contingent consideration payable for the periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:19%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:2%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value </span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SARs</span></div></td><td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$1,960</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.70%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.09%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Strike price</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6.76 - $30.86</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$45.00</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.52 years</span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$277,400</span></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability-adjusted discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $555 million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 94%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.8% - 5.7%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2026</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent considerable payable- net sales milestones and royalties</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$58,800</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model with Monte Carlo simulation</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential net sales milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $150 million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 89%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential percentage of net sales for royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2% - 6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2038</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:19%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:2%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value </span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SARs</span></div></td><td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$3,814</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46.53% - 59.59%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.44% - 2.63%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Strike price</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6.76 - $30.86</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$34.32</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.01 - 1.01 years</span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$257,040</span></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability-adjusted discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $555 million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 94%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.8% - 8.0%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2026</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent considerable payable- net sales milestones and royalties</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$53,200</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model with Monte Carlo simulation</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential net sales milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $150 million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 89%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential percentage of net sales for royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2% - 6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.0%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2038</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The contingent consideration is classified as&#160;&#160;&#160;&#160;a Level 3 liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, including but not limited to, assumptions involving probability adjusted sales estimates for the Agilis platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6643951648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other comprehensive income (loss) and accumulated other comprehensive items</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other comprehensive income (loss) and accumulated other comprehensive items</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as unrealized gains and losses on marketable securities.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">On</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities,&#160;net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at March&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from other comprehensive items</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>839</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">On</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities,&#160;net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from other comprehensive items</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816665648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts payable and accrued expenses</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounts payable and accrued expenses</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> consist of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee compensation, benefits, and related accruals</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and contracted research</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,373</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,574</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales allowance and other costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,794</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales rebates and royalties</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6648320032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Capitalization</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2019, the Company closed an underwritten public offering of its common stock pursuant to a registration statement on Form S-3. The Company issued and sold an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>7,563,725</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under the registration statement at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.20</span></span><span style="font-family:inherit;font-size:10pt;"> per share, including </span><span style="font-family:inherit;font-size:10pt;"><span>843,725</span></span><span style="font-family:inherit;font-size:10pt;"> shares issued upon exercise by the underwriter of its option to purchase additional shares in February 2019. The Company received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$224.5</span></span><span style="font-family:inherit;font-size:10pt;"> million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s outstanding warrants were classified as liabilities as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> because they contained non-standard antidilution provisions. The fair value of the warrants as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was immaterial.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s outstanding warrants as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,520.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6647575072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares plus the effect of any dilutive potential common shares outstanding during the period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables set forth the computation of basic and diluted net loss per share:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41,789</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,520</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(113,902</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,782</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator for basic and diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,912,748</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,137,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,113,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,257,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.99</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.62</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*In the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company experienced a net loss and therefore did not report any dilutive share impact.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,853,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,166,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>665,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>584,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,518,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,750,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816025840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock award plan</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock award plan</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March&#160;5, 2013, the Company&#8217;s Board of Directors approved the 2013 Stock Incentive Plan, which provides for the granting of stock option awards, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards in the aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>739,937</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. On March&#160;5, 2013, the Board approved a grant of </span><span style="font-family:inherit;font-size:10pt;"><span>735,324</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted stock and </span><span style="font-family:inherit;font-size:10pt;"><span>4,613</span></span><span style="font-family:inherit;font-size:10pt;"> stock options. There are </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> additional shares available for issuance under this plan.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2009, the Company&#8217;s shareholders approved the 2009 Equity and Long-Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards, subject to certain adjustments and annual increases. In May&#160;2013, the Company&#8217;s Board of Directors and stockholders increased by </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> the number of shares authorized under the 2009 Equity and Long Term Incentive Plan, which provides for the granting of stock option awards, restricted stock awards, and other stock-based and cash-based awards. There are </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> additional shares available for issuance under this plan.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May&#160;2013, the Company&#8217;s Board of Directors and stockholders approved the 2013 Long Term Incentive Plan, which became effective upon the closing of the Company&#8217;s initial public offering.&#160; The 2013 Long Term Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards. The number of shares of common stock reserved for issuance under the 2013 Long Term Incentive Plan is the sum of (1)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>122,296</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock available for issuance under the Company&#8217;s 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan, (2) the number of shares (up to </span><span style="font-family:inherit;font-size:10pt;"><span>3,040,444</span></span><span style="font-family:inherit;font-size:10pt;"> shares) equal to the sum of the number of shares of common stock subject to outstanding awards under the Company&#8217;s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan and 2013 Stock Incentive Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right plus (3)&#160;an annual increase, to be added on the first day of each fiscal year until the expiration of the 2013 Long Term Incentive Plan, equal to the lowest of </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of the number of shares of common stock outstanding on the first day of the fiscal year and an amount determined by the Company&#8217;s Board of Directors. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, awards for </span><span style="font-family:inherit;font-size:10pt;"><span>302,538</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock are available for issuance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From January&#160;1, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company issued a total of </span><span style="font-family:inherit;font-size:10pt;"><span>2,845,620</span></span><span style="font-family:inherit;font-size:10pt;"> stock options to various employees.&#160; Of those, </span><span style="font-family:inherit;font-size:10pt;"><span>579,700</span></span><span style="font-family:inherit;font-size:10pt;"> were inducement grants for non-statutory stock options. The inducement grant awards were made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company's new hires&#8217; employment compensation and not under the 2013 Long Term Incentive Plan.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of stock option activity is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of<br/>options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-<br/>average<br/>exercise<br/>price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>intrinsic<br/>value                 (in<br/>thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,534,358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,845,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(311,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/Cancelled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,853,301</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.59 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested or Expected to vest at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,334,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.01 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,446</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,138,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.98 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of grants made in the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was contemporaneously estimated on the date of grant using the following assumptions:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:65%;"/><td style="width:2%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.98 - 2.63%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61.90 - 63.09%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.11 years</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assumed </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> expected dividends for all grants. The weighted average grant date fair value of options granted during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$20.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the &#8220;simplified method&#8221; to determine the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term. The expected volatility of share options was estimated based on a historical volatility analysis of peers that were similar to the Company with respect to industry, stage of life cycle, size, and financial leverage. The risk-free rate of the option is based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Awards</span><span style="font-family:inherit;font-size:10pt;">&#8212;Restricted stock awards are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards, which has been determined based upon the market value of the Company&#8217;s shares on the grant date, is expensed over the vesting period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</span><span style="font-family:inherit;font-size:10pt;">&#8212;Restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock units, which has been determined based upon the market value of the Company&#8217;s shares on the grant date, is expensed over the vesting period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes information on the Company&#8217;s restricted stock awards and units:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted&#160;Stock&#160;Awards&#160;and&#160;Units</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of<br/>Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(179,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(31,449</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>665,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights</span><span style="font-family:inherit;font-size:10pt;">&#8212;SARs entitle the holder to receive, upon exercise, an amount of the Company's common stock or cash (or a combination thereof) determined by reference to appreciation, from and after the date of grant, in the fair market value of a share of the Company's common stock over the measurement price based on the exercise date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May&#160;2016, a total of </span><span style="font-family:inherit;font-size:10pt;"><span>897,290</span></span><span style="font-family:inherit;font-size:10pt;"> SARs were granted to non-executive employees (the "2016 SARs"). The 2016 SARs will vest annually in equal installments over </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;"> years and will be settled in cash on each vest date, requiring the Company to remeasure the SARs at each reporting period until vesting occurs. For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a total of </span><span style="font-family:inherit;font-size:10pt;"><span>157,930</span></span><span style="font-family:inherit;font-size:10pt;"> SARs vested. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in compensation expense related to the 2016 SARs.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</span><span style="font-family:inherit;font-size:10pt;">&#8212;In June 2016, the Company established an Employee Stock Purchase Plan (&#8220;ESPP&#8221; or the "Plan&#8221;) for certain eligible employees. The Plan is administered by the Company&#8217;s Board of Directors or a committee appointed by the Company's Board of Directors. The total number of shares available for purchase under the Plan is </span><span style="font-family:inherit;font-size:10pt;"><span>one million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. Employees may participate over a </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month period through payroll withholdings and may purchase, at the end of the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;">-month period, the Company&#8217;s common stock at a purchase price of at least </span><span style="font-family:inherit;font-size:10pt;"><span>85%</span></span><span style="font-family:inherit;font-size:10pt;"> of the closing price of a share of the Company&#8217;s common stock on the first business day of the offering period or the closing price of a share of the Company&#8217;s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company&#8217;s common stock under the Plan if such participant would own more than </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in compensation expense related to the ESPP.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,932</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$105.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2009 Equity and Long Term Incentive Plan, the 2013 Long Term Incentive Plan and equity awards made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception for new hires. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3.10</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646851248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Credit Facility</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the Company entered into a credit and security agreement (the "Credit Facility") with MidCap Financial Trust, a Delaware statutory trust (&#8220;MidCap&#8221;), as administrative agent and MidCap and certain other financial institutions as lenders thereunder (the &#8220;Credit Agreement&#8221;) that provides for a senior secured term loan facility of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was drawn by the Company on May 5, 2017. The Company's ability to draw on the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> under the senior secured term loan facility expired on December 31, 2018. The Company capitalized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of debt issuance costs, which were netted against the carrying value of the Credit Facility and will be amortized over the term of the Credit Facility.  As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had made loan repayments of $</span><span style="font-family:inherit;font-size:10pt;"><span>1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the Credit Facility.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowings under the Credit Agreement bear interest at a rate per annum equal to LIBOR (with a LIBOR floor rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.00%</span></span><span style="font-family:inherit;font-size:10pt;">) plus </span><span style="font-family:inherit;font-size:10pt;"><span>6.15%</span></span><span style="font-family:inherit;font-size:10pt;">. The Company was obligated to make interest only payments (payable monthly in arrears) through April 30, 2019. Commencing on May 1, 2019 and continuing for the remaining </span><span style="font-family:inherit;font-size:10pt;">twenty-four</span><span style="font-family:inherit;font-size:10pt;"> months of the facility, the Company is required to make monthly interest payments and monthly principal payments. The principal payments are to be made based on straight-line amortization of the principal over the </span><span style="font-family:inherit;font-size:10pt;">twenty-four</span><span style="font-family:inherit;font-size:10pt;"> month period. The maturity date of the Credit Agreement is May 1, 2021, unless terminated earlier.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Facility is subject to certain financial covenants. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company was in compliance with all required covenants.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Notes</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In&#160;August&#160;2015, the Company issued, at par value,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;aggregate principal amount of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;convertible senior notes due 2022 (the "Convertible Notes"). The Convertible Notes bear cash interest at a rate of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per year, payable semi-annually on&#160;February&#160;15&#160;and&#160;August&#160;15&#160;of each year, beginning on&#160;February&#160;15, 2016. The Convertible Notes will mature on&#160;August&#160;15, 2022, unless earlier repurchased or converted. The net proceeds to the Company from the offering were&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$145.4 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;after deducting the initial purchasers&#8217; discounts and commissions and the offering expenses payable by the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes are governed by an indenture (the "Convertible Notes Indenture") with U.S Bank National Association as trustee (the "Convertible Notes Trustee").</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding&#160;February&#160;15, 2022&#160;only under the following circumstances:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> during any calendar quarter commencing on or after&#160;September&#160;30, 2015&#160;(and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least&#160;</span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;">&#160;trading days (whether or not consecutive) during a period of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;">&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the conversion price on each applicable trading day;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> during the&#160;</span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">&#160;business day period after any&#160;</span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">&#160;consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the Convertible Notes Indenture) per </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of Convertible Notes for each trading day of the measurement period was less than&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#183;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> upon the occurrence of specified corporate events.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or after February&#160;15, 2022, until the close of business on the business day immediately preceding the maturity date, holders may convert their Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Convertible Notes to be converted and deliver shares of its common stock in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of Convertible Notes being converted.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion rate for the Convertible Notes was initially, and remains, </span><span style="font-family:inherit;font-size:10pt;"><span>17.7487</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock per </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$56.34</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share of the Company&#8217;s common stock.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was not permitted to redeem the Convertible Notes prior to August&#160;20, 2018. As of August 20, 2018, the Company may redeem for cash all or any portion of the Convertible Notes, at its option, if the last reported sale price of its common stock has been at least </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price then in effect on the last trading day of, and for at least </span><span style="font-family:inherit;font-size:10pt;"><span>19</span></span><span style="font-family:inherit;font-size:10pt;"> other trading days </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(whether or not consecutive) during, any </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> sinking fund is provided for the Convertible Notes, which means that the Company is not required to redeem or retire the Convertible Notes periodically. There have been no redemptions to date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the Indenture governing the Convertible Notes Indenture), subject to certain conditions, holders of the Convertible Notes may require the Company to repurchase for cash all or part of their Convertible Notes at a repurchase price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes Indenture contains customary events of default with respect to the Convertible Notes, including that upon certain events of default (including the Company&#8217;s failure to make any payment of principal or interest on the Convertible Notes when due and payable) occurring and continuing, the Convertible Notes Trustee by notice to the Company, or the holders of at least </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> in principal amount of the outstanding Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the Convertible Notes Trustee at the request of such holders (subject to the provisions of the Convertible Notes Indenture) shall, declare </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal of and accrued and unpaid interest, if any, on all the Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal of and accrued and unpaid interest on the Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the Convertible Notes as a liability and equity component where the carrying value of the liability component will be valued based on a similar instrument. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Convertible Notes as a whole. The excess of the principal amount of the liability component over its carrying amount, referred to as the debt discount, is amortized to interest expense over the </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;">-year term of the Convertible Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The equity component recorded at issuance related to the Convertible Notes is&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$57.5 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and was recorded in additional paid-in capital.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accounting for the transaction costs related to the issuance of the Convertible Notes, the Company allocated the total costs incurred to the liability and equity components of the Convertible Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;">-year term of the Convertible Notes, and transaction costs attributable to the equity component are netted with the equity components in stockholders&#8217; equity. Additionally, the Company initially recorded a net deferred tax liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the Notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes consist of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability&#160;component</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,544</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,746</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Debt discount, net(1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the Convertible Notes using the effective interest rate method.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the remaining contractual life of the Convertible Notes is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth total interest expense recognized related to the Convertible Notes:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816639952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>- (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">and contingencies</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company's oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program.  Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company&#8217;s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company&#8217;s first such milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> payable to Wellcome Trust occurred in the second quarter of 2016.  Additional milestone payments of up to an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> may become payable by the Company to Wellcome Trust under this agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has also entered into a collaboration agreement with the SMA Foundation. The Company may become obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, if the Company outlicenses rights to a collaboration product, a specified percentage of certain payments the Company receives from its licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company&#8217;s obligation to make such payments would end upon the Company's payment to the SMA Foundation of a specified amount.&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Merger Agreement with Agilis, Agilis equityholders may become entitled to receive contingent consideration payments from the Company based on (i)&#160;the achievement of certain development milestones up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, (ii)&#160;the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$535.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, (iii)&#160;the achievement of certain net sales milestones up to an aggregate maximum amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and (iv)&#160;a percentage of annual net sales for&#160;Friedreich Ataxia and Angelman Syndrome during specified terms, ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;">-</span><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is required to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has a Collaboration and License Agreement with Akcea Therapeutics, Inc. ("Akcea") for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean (the "Akcea Collaboration and License Agreement").  Pursuant to the agreement, the Company paid Akcea an upfront licensing fee, which included an initial payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. An additional </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid to Akcea in the three month period ended June 30, 2019 upon regulatory approval of Waylivra from the EMA. In addition, Akcea is eligible to receive milestone payments, on a Product-by-Product basis, of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon receipt of regulatory approval for a product from ANVISA, subject to a maximum aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for all such products. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement. The Company filed a request for marketing authorizations for Tegsedi with ANVISA. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna and Emflaza product net sales, payable quarterly or annually in accordance with the terms of the related agreements. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in the Company's clinical trials or otherwise gain access to its product candidates. The Company is not currently aware of any material legal proceedings against it.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6612527664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company views its operations and manages its business in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> operating segment. During the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, net product sales in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$27.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$20.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, consisting solely of Emflaza, and net product sales not in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$57.8</span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$47.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, consisting of Translarna and Tegsedi.  During the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, net product sales in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$45.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$39.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> respectively, consisting solely of Emflaza, and net product sales not in the United States were </span><span style="font-family:inherit;font-size:10pt;"><span>$93.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$84.6</span></span><span style="font-family:inherit;font-size:10pt;"> million, respectively, consisting of Translarna and Tegsedi.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the Company&#8217;s contract liabilities from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606 Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>June&#160;30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,864</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>December&#160;31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606 Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>June&#160;30, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,937</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company did not have any contract assets for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue in the period from:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied in previous period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied in current period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remaining performance obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining performance obligations&#160;represent the transaction price for goods the Company has yet to provide. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the aggregate amount of transaction price allocated to&#160;remaining performance obligations&#160;relating to Translarna net product revenue was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$15.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company expects to recognize revenue over the next </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers&#8217; needs and schedules.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has ongoing collaborations with the Spinal Muscular Atrophy Foundation ("SMA Foundation") and F. Hoffman-La Roche&#160;Ltd and Hoffman- La Roche&#160;Inc. (collectively, "Roche") and early stage discovery arrangements with other institutions. The following are the key terms to the Company&#8217;s (i)&#160;ongoing collaborations and (ii)&#160;early stage discovery and development arrangements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Roche and SMA Foundation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2011, the Company and the SMA Foundation entered into a licensing and collaboration agreement with Roche for a spinal muscular atrophy program. Under the terms of the agreement, Roche acquired an exclusive worldwide license to the Company&#8217;s spinal muscular atrophy program, which includes </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> compounds currently in preclinical development, as well as potential back-up compounds. The Company received a nonrefundable upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the research term, which was terminated effective December&#160;31, 2014, after which Roche provided the Company with funding, based on an agreed- upon full-time equivalent rate, for an agreed-upon number of full-time equivalent employees that the Company contributed to the research program.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company identified </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> material promises in the collaboration agreement, the license and the research activities. The Company evaluated whether these material promises are distinct and determined that the license does not have standalone functionality and there is a significant integration of the license and research activities. As such, both promises were bundled into one distinct performance obligation. As a result, the Company deferred the </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment which was recognized over the </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">estimated performance period of </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> years, which was the contracted research period. As of adoption of ASC Topic 606 on January 1, 2018, all performance obligations had been satisfied and the balance of the remaining deferred upfront payment was fully recognized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to </span><span style="font-family:inherit;font-size:10pt;"><span>$135.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development event milestones, up to </span><span style="font-family:inherit;font-size:10pt;"><span>$325.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2013, a lead development compound, RG7800, was selected to move into IND-enabling studies, which triggered a milestone payment to the Company from Roche of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2013.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2014, the Company announced the initiation of a Phase&#160;1 clinical program in its spinal muscular atrophy collaboration with Roche and the SMA Foundation which triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2014.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2014, the Company announced the initiation of a Phase&#160;2 study in adult and pediatric patients in its spinal muscular atrophy collaboration with Roche and the SMA Foundation which triggered a </span><span style="font-family:inherit;font-size:10pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:10pt;"> payment from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2014.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, the Company announced that the Sunfish, a two-part clinical trial in pediatric and adult type 2 and type 3 spinal muscular atrophy initiated in the fourth quarter of 2016 with Roche and SMA Foundation, had transitioned into the pivotal second part of its study. The achievement of this milestone triggered a&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;payment to the Company from Roche. Under ASC Topic 605, the Company considered this milestone event substantive because the applicable criteria of its revenue recognition policy would be satisfied and recorded it as collaboration revenue for the year ended December&#160;31, 2017.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The remaining potential research and development event milestones that can be received as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$87.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The remaining potential sales milestones as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$325.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon achievement of certain sales events. In addition, the Company is eligible to receive up to double digit royalties on worldwide annual net sales of a commercial product.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue related to the licensing and collaboration agreement with Roche of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1</span></span><span style="font-family:inherit;font-size:10pt;"> million and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue related to the licensing and collaboration agreement with Roche of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.   </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Early stage collaboration and discovery agreements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company has arrangements with several organizations pursuant to which the Company uses its discovery technologies to help identify potential drug candidates. The Company does not take ownership of the potential compounds, but rather provides research services to the collaborator using its specialized technology platform.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, these arrangements are structured such that the collaborator and the Company work together to jointly select targets from which to apply its discovery technologies. The research period for the Company to apply its technology is generally </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;"> years. The Company will typically receive a nonrefundable, upfront cash payment and the collaborator agrees to provide funding for research activities performed on its behalf.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, the </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> material promises in these arrangements are the license and the research activities. The Company evaluated whether these material promises are distinct and determined that the license does not have standalone functionality and there is a significant integration of the license and research activities. As such, both promises are bundled into one distinct performance obligation. As of adoption of ASC Topic 606 on January 1, 2018, all deferred revenue related to these arrangements had been recognized. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company did </span><span style="font-family:inherit;font-size:10pt;">not</span><span style="font-family:inherit;font-size:10pt;"> recognize any revenue related to discovery agreements. </span></div><span style="font-family:inherit;font-size:10pt;">The Company is eligible to receive additional payments from its early stage discovery research arrangements if the discovery compounds are ultimately developed and commercialized. The aggregate potential payments the Company is eligible for if all products are developed is </span><span style="font-family:inherit;font-size:10pt;"><span>$143.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$252.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in sales milestones upon achievement of specified sales events and up to double digit royalties on worldwide annual net sales of the licensed product.  The Company will recognize revenue when it is probable the milestones will be achieved (see Note 2).  For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company did </span><span style="font-family:inherit;font-size:10pt;">not</span> recognize any revenue related to early stage collaborations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816665648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible assets and goodwill</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Definite-lived intangibles</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 20, 2017, the Company completed its previously announced acquisition of all rights to Emflaza pursuant to the Asset Purchase Agreement, dated March 15, 2017, and amended on April 20, 2017, by and between the Company and Marathon. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. In accordance with ASU No. 2017-01, the Company determined that substantially all of the fair value is concentrated in the Emflaza rights intangible asset and as such accounted for the transaction as an asset acquisition under ASC 805-50 and recorded an intangible asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$148.4 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Emflaza rights intangible asset is being amortized to cost of product sales over its expected useful life of approximately </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> years on a straight line basis.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company will record the milestone payment when it becomes payable to Marathon and increase the cost basis for the Emflaza rights intangible asset. For the three month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> were recorded, respectively. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Akcea Collaboration and License Agreement, in May 2019 the Company made a </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment to Akcea upon regulatory approval of Waylivra from the EMA. The payment was recorded as an intangible asset and is being amortized to cost of product sales over its expected useful life of approximately ten years on a straight line basis. Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Akcea Collaboration and License Agreement related to sales of Waylivra. In accordance with the guidance for an asset acquisition, the Company will record royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra intangible asset. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized amortization expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the Emflaza rights and Waylivra intangible assets. For the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized amortization expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$12.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the Emflaza rights and Waylivra intangible assets. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated future amortization of the Emflaza rights and Waylivra intangible asset is expected to be as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,566</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,566</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,566</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Indefinite-lived intangibles</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Agilis, the Company acquired rights to PTC-AADC, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The Agilis platform also includes a gene therapy asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. An investigational new drug ("IND") submission with the FDA for this program is expected in late 2019. Additionally, the Agilis platform includes two other gene therapy programs targeting CNS disorders, including Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition.  The Company classified the fair value of the acquired IPR&amp;D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts.&#160;The value allocated to the indefinite lived intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$576.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the Merger on August 23, 2018, the Company recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$82.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill. There were no changes to the recorded value of goodwill for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6651365504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent events</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 4, 2019, the Company and Bristol-Myers Squibb Company, (the &#8220;Landlord&#8221;) entered into a Lease Agreement&#160;(the &#8220;Lease&#8221;), relating to the lease&#160;of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>185,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of office, production and laboratory space at a facility located in Hopewell Township, New Jersey (the &#8220;Campus&#8221;).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The rental term of the Lease is currently estimated to commence on July 1, 2020 (the &#8220;Commencement Date&#8221;). Upon the Commencement Date, the Lease has an initial term of </span><span style="font-family:inherit;font-size:10pt;"><span>fifteen years</span></span><span style="font-family:inherit;font-size:10pt;"> (the &#8220;Initial Term&#8221;), with </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;">-year renewal periods at the Company&#8217;s option.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate rent for the Initial Term will be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$88.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The rental rate for the renewal periods will be </span><span style="font-family:inherit;font-size:10pt;"><span>95%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Prevailing Market Rate (as defined in the Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject to the terms of the Lease, the Company has a right of first refusal to rent certain other space of the Campus, which would be triggered upon the Landlord&#8217;s issuance of a second round proposal or letter of intent to another tenant for such space. The Company also may seek to build a new separate building on the Campus, which may not contain less than </span><span style="font-family:inherit;font-size:10pt;"><span>75,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet (the &#8220;New Building&#8221;). Upon receipt of notice of the Company&#8217;s intention to build the New Building, the Landlord may, in its sole discretion, construct and lease the New Building to the Company or enter into a ground lease with the Company permitting the Company to construct the New Building. The term for the New Building will be </span><span style="font-family:inherit;font-size:10pt;"><span>fifteen years</span></span><span style="font-family:inherit;font-size:10pt;"> with </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive five-year renewal rights. Rent terms for the New Building will be determined based on the land value, construction and project costs subject to whether the Landlord or Company constructs the New Building.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also obligated to provide the Landlord with either an unconditional, irrevocable and transferable letter of credit (the &#8220;Letter of Credit&#8221;) in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, for a term of not less than </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, as a security deposit, or the same amount as a cash security deposit within thirty days upon entering into the Lease. The Letter of Credit shall remain in effect continuously and shall either expire (i) sixty days after the Expiration Date (as defined in the Lease) or (ii) be automatically self-renewing until the Expiration Date. If the Lease is extended, the Company must continue to provide and maintain the Letter of Credit until sixty days after the extended Expiration Date. If after the fifth anniversary of the Commencement Date, the Company has not received notice of being in default of the Lease, then the Letter of Credit shall be reduced to </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Lease contains customary events of default, representations, warranties and covenants.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The foregoing summary of the Lease and Letter of Credit are not complete and are qualified in their entirety by reference to the Lease and Letter of Credit, which will be filed as exhibits to the Company&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6676208928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of presentation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying financial information as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> has been prepared by the Company, without audit, pursuant to the rules&#160;and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules&#160;and regulations. These interim financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and notes thereto included in the </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> Form&#160;10-K.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the unaudited financial information as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or for any other interim period or for any other future year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company&#8217;s research and development expenses, stock-based compensation, valuation procedures for the convertible notes, allowance for doubtful accounts, inventory, acquired intangible assets, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock', window );">Inventory and cost of product sales</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory and cost of product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Translarna and Emflaza product which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,362</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value.  No write downs were recorded for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.  Additionally, though the Company&#8217;s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, these amounts were immaterial.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of product sales</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, including personnel costs, storage costs, amortization of the acquired intangible asset and royalty payments associated with net product sales.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-9, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;.  ASU No. 2014-9 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-15, Revenue Recognition-Products (Topic 605) and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net product revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD.  The Company recognizes revenue when its performance obligations with its customers have been satisfied.  The Company&#8217;s performance obligations are to provide Translarna or Emflaza based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies.  The performance obligations are satisfied at a point in time when the Company&#8217;s customer obtains control of either Translarna or Emflaza, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date.  The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to either product sales of Translarna or Emflaza.  In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. Historically, returns of Translarna and Emflaza are immaterial to the financial statements, except as related to labeling changes and changes in specialty pharmacies. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract.  These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of ASC Topic 606 on January 1, 2018, the Company elected the following practical expedients:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying ASC Topic 606 to each individual contract.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant Financing Component - the Company expects the period between when it transfers a promised good to a customer and when the customer pays for the good or service to be one year or less. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immaterial Performance Obligations - the Company disregards promises deemed to be immaterial in the context of the contract. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and Handling Activities - the Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration revenue</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in ASC Topic 808 &#8220;Collaborative Arrangements&#8221; to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer.  If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement.  If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license.  If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation.  The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time.  If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved.  If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved.  Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company's control.  If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method.  The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for doubtful accounts</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Allowance for doubtful accounts</span></div>The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer&#8217;s financial condition and current economic trends.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-lived intangible assets</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets consist of in-process research and development ("IPR&amp;D"). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D acquired in a business combination. The Company utilizes the "income method&#8221;, and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&amp;D intangible assets that are determined to have had a drop in their fair value are adjusted downward and an impairment is recognized in the statement of operations. These assets are tested at least annually or sooner when a triggering event occurs that could indicate a potential impairment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. government enacted the 2017 Tax Cuts and Jobs Act ("the 2017 Tax Act"), which significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. The Company </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded a deferred tax liability in conjunction with the Merger of $</span><span style="font-family:inherit;font-size:10pt;"><span>122.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the tax basis difference in the IPR&amp;D indefinite-lived intangibles acquired. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently issued accounting standards</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &#8220;Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This standard requires financial assets measured at amortized cost basis to be presented at the </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">net amount expected to be collected. This standard is effective for public companies who are SEC filers for fiscal years beginning after December&#160;15, 2019, including interim periods within those years. The Company expects to adopt this guidance when effective and is assessing what effect the adoption of ASU 2016-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement". This standard eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. Entities can elect to early adopt in interim periods, including periods for which they have not yet issued financial statements or made their financial statements available for issuance. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15,"Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract". ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities.  The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No.&#160;2018-13 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18,"Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;. ASU 2018-18 provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. For public business entities, the guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. For all other entities, it is effective for annual periods beginning after December 15, 2020 and interim periods in annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period for all entities. The Company expects to adopt this guidance when effective and is currently assessing what effect the adoption of ASU No. 2018-18 will have on its consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of recently adopted accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-2, &#8220;Leases (Topic 842)&#8221;. This standard requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations created by those leases on their balance sheets. The ASU also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018, with early adoption permitted.  Additionally, in March 2019, the FASB issued ASU 2019-01,"Leases (Topic 842): Codification Improvements&#8221;.  ASU 2019-01 clarifies the transition guidance related to interim disclosures provided in the year of adoption. The Company adopted the new guidance on January 1, 2019 using the modified retrospective method. Prior period results were not adjusted and continue to be presented under Topic 840 based on the accounting standards originally in effect for such periods. As part of the adoption, the Company has elected to utilize practical expedients including the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to: 1) carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements, 2) not separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component (the Company elected to apply this practical expedient to all underlying asset classes), 3) not apply the recognition requirements in ASC 842 to short-term leases, and 4) not record a right of use asset or right of use liability for leases with an asset or liability balance that would be considered immaterial. Upon adoption, the Company recorded an operating lease liability with a corresponding operating lease ROU asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The adoption did not have a material impact on the consolidated results of operations, stockholder's equity, and cash flows for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. As the Company is not a lessor, the aspects of the new guidance pertaining to lessors was not applicable for the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, "Income Statement &#8212; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income". This standard permits the reclassification of tax effects stranded in other comprehensive income as a result of tax reform to retained earnings related to the change in federal </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">tax rate in addition to other stranded effects that relate to the 2017 Tax Act but do not directly relate to the change in the federal rate. ASU 2018-02 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance. The Company adopted this guidance on January 1, 2019 and elected not to reclassify the tax effects in other comprehensive income related to the 2017 Tax Act, as these amounts were immaterial. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "Compensation &#8212; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting". This standard expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in the entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The ASU retains the existing cost attribution guidance, which requires entities to recognize compensation cost for nonemployee awards in the same period and in the same manner they would if they paid cash for the goods or services, but it moves the guidance to ASC 718. ASU 2018-07 is effective for fiscal years beginning after December&#160;15, 2018, including interim periods within those fiscal years with early adoption permitted for periods for which financial statements have not yet been issued or made available for issuance.  The Company adopted this guidance on January 1, 2019. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;.  ASU No. 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under FASB Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-15, Revenue Recognition-Products and replaced it with a principle-based approach for determining revenue recognition.  ASC Topic 606 requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  On January 1, 2018, the Company adopted ASC Topic 606 using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The Company calculated a one-time transition adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was recorded on January 1, 2018 to deferred revenue and accumulated deficit, related to the product sales of Emflaza. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January&#160;2016, the FASB issued ASU No.&#160;2016-01, &#8220;Financial Instruments &#8212; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&#8221;. This standard enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The new guidance affects all reporting organizations (whether public or private) that hold financial assets or owe financial liabilities. The Company adopted the guidance on January&#160;1, 2018.  In March 2018, the FASB issued ASU 2018-04, "Investments - Debt Securities (Topic 320) and Regulated Operations (Topic 980): Amendments to SEC Paragraphs Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 117 and SEC Release No. 33-9273 (SEC Update)". This standard supersedes SEC paragraphs in ASC 320, Investments- Debt Securities, as a result of the issuance of SAB 117 and also updates the Codification for a 2011 SEC release and is effective when a registrant adopts ASU 2016-01, which in the case of the Company was on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&#8221;. This standard clarifies the presentation of certain specific cash flow issues in the Statement of Cash Flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-16, &#8220;Intra-Entity Transfers of Assets Other Than Inventory&#8221;.  ASU 2016-16 requires companies to account for the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) when the transfer occurs. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows (Topic 230): Restricted Cash&#8221;. This standard requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows and no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company adopted the guidance on January&#160;1, 2018. The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In May 2017, the FASB issued ASU No. 2017-09, "Stock Compensation (Topic 718): Scope of Modification Accounting". This standard clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as a modification, with entities applying the modification accounting guidance if the value, vesting conditions or classification of the award changes. In addition to all disclosures about modifications that are required under the current guidance, entities will be also required to disclose that compensation expense has not changed if applicable.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Company adopted the guidance on January&#160;1, 2018.  The adoption of the guidance did not have a material impact on the consolidated financial statements and accompanying notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_InventoriesAndCostOfProductSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inventories and cost of revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_InventoriesAndCostOfProductSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6644100080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the components of the Company&#8217;s inventory for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,362</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6651324016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease costs</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease expense were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:79.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Lease Cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease cost is a component of operating expenses on the consolidated statements of operations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental balance sheet information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities- current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities- noncurrent</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,416</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease liability</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental lease term and discount rate information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:74%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease terms - operating leases (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average discount rate - operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases was as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lease payments</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable leases as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (Excludes the six months ended June 30, 2019)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,371</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816630400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents the fair value using the hierarchy described above for the Company&#8217;s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices<br/>in&#160;active<br/>markets&#160;for<br/>identical&#160;assets<br/>(level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>other<br/>observable<br/>inputs<br/>(level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>unobservable<br/>inputs<br/>(level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity investment in MRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock appreciation rights liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- net sales milestones and royalties </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">markets&#160;for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">identical&#160;assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(level&#160;3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock appreciation rights liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred consideration payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,700</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,040</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- net sales milestones and royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of marketable securities accounted for as available-for-sale securities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of marketable securities accounted for as available-for-sale securities at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,706</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>656</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,657</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of unrealized losses and fair values of available-for-sale securities in a continuous unrealized loss position</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;</span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position greater than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position less than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities in an unrealized loss position greater than 12 months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable securities on the balance sheet</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities on the balance sheet at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> mature as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,639</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;Than</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12&#160;Months</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Marketable securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability and SARs liability</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the SARs liability, and the contingent consideration payable for the periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:19%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:2%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value </span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SARs</span></div></td><td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$1,960</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.70%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.09%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Strike price</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6.76 - $30.86</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$45.00</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.52 years</span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$277,400</span></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability-adjusted discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $555 million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 94%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.8% - 5.7%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2026</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent considerable payable- net sales milestones and royalties</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$58,800</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model with Monte Carlo simulation</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential net sales milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $150 million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 89%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential percentage of net sales for royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2% - 6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2038</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:19%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:2%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value </span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td rowspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SARs</span></div></td><td rowspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$3,814</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46.53% - 59.59%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.44% - 2.63%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Strike price</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$6.76 - $30.86</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$34.32</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.01 - 1.01 years</span></div></td></tr><tr><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payable- development and regulatory milestones</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$257,040</span></span></div></td><td rowspan="4" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability-adjusted discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential development and regulatory milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $555 million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 94%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.8% - 8.0%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2026</span></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent considerable payable- net sales milestones and royalties</span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$53,200</span></span></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option-pricing model with Monte Carlo simulation</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential net sales milestones</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$0 - $150 million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probabilities of success</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25% - 89%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential percentage of net sales for royalties </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2% - 6%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.0%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected years of payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021 - 2038</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss in the consolidated statements of operations. The fair value of the development and r<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuations for the SARs liability, and the contingent consideration payable for the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The changes in the fair value of the Company's Level 3 valuations for the period ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> were immaterial.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3 liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">SARs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent consideration payable- development and regulatory milestones</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent consideration payable- net sales milestones and royalties</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257,040</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance as of June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6644925408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize other comprehensive income (loss) and the changes in accumulated other comprehensive items for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">On</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities,&#160;net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at March&#160;31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from other comprehensive items</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>839</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">On</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities,&#160;net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Items</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from other comprehensive items</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>460</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>993</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6622742112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued expenses - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of components of accounts payable and accrued expenses</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> consist of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee compensation, benefits, and related accruals</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and contracted research</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,373</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,574</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales allowance and other costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,794</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales rebates and royalties</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6644925408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the Company's outstanding warrants</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s outstanding warrants as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,520.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6648484432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss available to common stockholders</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables set forth the computation of basic and diluted net loss per share:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41,789</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,520</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(113,902</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,782</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator for basic and diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,912,748</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,137,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,113,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,257,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.99</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.62</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*In the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company experienced a net loss and therefore did not report any dilutive share impact.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of historical dilutive common share equivalents outstanding</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,853,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,166,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>665,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>584,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,518,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,750,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816647632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of stock option activity is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of<br/>options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-<br/>average<br/>exercise<br/>price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate<br/>intrinsic<br/>value                 (in<br/>thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,534,358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,845,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(311,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/Cancelled</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,853,301</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.59 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested or Expected to vest at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,334,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.01 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,446</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,138,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.98 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate fair values of grants made on the date of grant</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of grants made in the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was contemporaneously estimated on the date of grant using the following assumptions:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:65%;"/><td style="width:2%;"/><td style="width:33%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.98 - 2.63%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61.90 - 63.09%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.11 years</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of information on the Company's restricted stock</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes information on the Company&#8217;s restricted stock awards and units:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted&#160;Stock&#160;Awards&#160;and&#160;Units</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of<br/>Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(179,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(31,449</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested at June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>665,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense recorded in the statement of operations</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,516</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,932</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,203</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6645389952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of convertible notes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes consist of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability&#160;component</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Principal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,544</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,746</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Debt discount, net(1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net carrying amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:19.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1)&#160;Included in the consolidated balance sheets within convertible senior notes (due 2022) and amortized to interest expense over the remaining life of the Convertible Notes using the effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock', window );">Summary of interest expense recognized related to the Convertible Notes</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth total interest expense recognized related to the Convertible Notes:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,074</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective interest rate of the liability component</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense recognized related to convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6643794544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract liabilities, rollforward and revenue recognition</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue in the period from:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied in previous period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance obligations satisfied in current period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total product revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124,151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the Company&#8217;s contract liabilities from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606 Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>June&#160;30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,864</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>December&#160;31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606 Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of<br/>June&#160;30, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,937</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646138528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Future amortization expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated future amortization of the Emflaza rights and Waylivra intangible asset is expected to be as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,566</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,566</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,566</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830591456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 23, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>member_state</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>product </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NumberOfProducts', window );">Number of products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NumberOfStatesInEuropeanEconomicArea', window );">Number of member states of the European Economic Area | member_state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,052,825)<span></span>
</td>
<td class="num">$ (938,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity Interest Issued, number of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,683,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity', window );">Numerator for calculation of number of shares of equity interests issued to acquire entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod', window );">Trading day period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_TranslarnaMember', window );">Translarna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NumberOfCountries', window );">Number of countries ( over ) | country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">$ 49,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity Interest Issued, number of shares (in shares) | shares</a></td>
<td class="nump">3,500,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity', window );">Numerator for calculation of number of shares of equity interests issued to acquire entity</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod', window );">Trading day period</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Non-collaborative Arrangement Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NumberOfCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NumberOfCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NumberOfStatesInEuropeanEconomicArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of states in European economic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NumberOfStatesInEuropeanEconomicArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_TranslarnaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_TranslarnaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6625867344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,089<span></span>
</td>
<td class="nump">$ 1,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">8,341<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">6,467<span></span>
</td>
<td class="nump">5,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 16,897<span></span>
</td>
<td class="nump">$ 16,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6748855456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">$ 10,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">122,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="num">(1,052,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (938,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">ASC 606 Adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6643843712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>operating_lease</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NumberOfOperatingLeases', window );">Number Of Operating Leases</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal Term ( in years )</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract ( in years )</a></td>
<td class="text">4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract ( in years )</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6755431808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Assets and Liabilities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">10,387<span></span>
</td>
<td class="nump">10,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities- current</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities- noncurrent</a></td>
<td class="nump">8,416<span></span>
</td>
<td class="nump">8,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 10,559<span></span>
</td>
<td class="nump">$ 10,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms - operating leases (years)</a></td>
<td class="text">4 years 6 months 3 days<span></span>
</td>
<td class="text">4 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases ( as a percent)</a></td>
<td class="nump">7.18%<span></span>
</td>
<td class="nump">7.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,643<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6657793584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (Excludes the six months ended June 30, 2019)</a></td>
<td class="nump">$ 1,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">3,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter', window );">2023 and thereafter</a></td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">11,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest</a></td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 10,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6645537408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,200<span></span>
</td>
<td class="nump">$ 310,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Estimated fair value of deferred consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,800<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">$ 49,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity Interest Issued, number of shares (in shares)</a></td>
<td class="nump">3,500,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity', window );">Numerator for calculation of number of shares of equity interests issued to acquire entity</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod', window );">Trading day period</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Milestone, potential achievements, priority review voucher amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Milestone, potential achievements, net sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Milestone, potential achievements, product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Milestone, potential achievements, product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646214592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Consideration Transfered (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 23, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Estimated fair value of deferred consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,800<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,200<span></span>
</td>
<td class="nump">$ 310,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">$ 49,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6647045984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 82,341<span></span>
</td>
<td class="nump">$ 82,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6830840976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 23, 2018</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Estimated fair value of deferred consideration payable</a></td>
<td class="nump">$ 18,800,000<span></span>
</td>
<td class="nump">18,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent', window );">Deferred consideration payable</a></td>
<td class="nump">19,400,000<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_InvestmentInMRI', window );">Investment In MRI</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member', window );">3.00% Convertible senior notes due 2022 | Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible notes</a></td>
<td class="nump">$ 166,200,000<span></span>
</td>
<td class="nump">$ 166,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Milestone, potential achievements, product sales</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Milestone, potential achievements, product sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Milestone, potential achievements, priority review voucher amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Milestone, potential achievements, net sales amount</a></td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Estimated fair value of deferred consideration payable</a></td>
<td class="nump">38,200,000<span></span>
</td>
<td class="nump">38,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Investment Owned, Balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable- Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_InvestmentInMRI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment In MRI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_InvestmentInMRI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For investments which are quantified by principal amount, the principle balance held at close of period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6832745248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 227,447<span></span>
</td>
<td class="nump">$ 58,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">18,800<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">336,200<span></span>
</td>
<td class="nump">310,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">227,447<span></span>
</td>
<td class="nump">58,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">3,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">38,200<span></span>
</td>
<td class="nump">37,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">277,400<span></span>
</td>
<td class="nump">257,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">58,800<span></span>
</td>
<td class="nump">53,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted prices in active markets for identical assets (level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI</a></td>
<td class="nump">4,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant other observable inputs (level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">227,447<span></span>
</td>
<td class="nump">58,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">38,200<span></span>
</td>
<td class="nump">37,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant unobservable inputs (level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_StockAppreciationRightsLiabilityOutstanding', window );">Stock appreciation rights liability</a></td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">3,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable', window );">Deferred consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">277,400<span></span>
</td>
<td class="nump">257,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Significant unobservable inputs (level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">$ 58,800<span></span>
</td>
<td class="nump">$ 53,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration, Liability, Deferred Consideration Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_StockAppreciationRightsLiabilityOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of outstanding stock appreciation rights liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_StockAppreciationRightsLiabilityOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6644960368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Available for sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 226,801<span></span>
</td>
<td class="nump">$ 58,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized, Gain</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized, Loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">227,447<span></span>
</td>
<td class="nump">58,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">70,185<span></span>
</td>
<td class="nump">31,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized, Gain</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized, Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">70,301<span></span>
</td>
<td class="nump">31,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">129,252<span></span>
</td>
<td class="nump">26,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized, Gain</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized, Loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">129,706<span></span>
</td>
<td class="nump">$ 26,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">27,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized, Gain</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized, Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 27,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816816000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">$ 3,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(3,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember', window );">Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">277,400<span></span>
</td>
<td class="nump">257,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">20,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Significant unobservable inputs (level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">58,800<span></span>
</td>
<td class="nump">53,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Milestones and Royalties | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">58,800<span></span>
</td>
<td class="nump">53,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Milestones and Royalties | Agilis | Significant unobservable inputs (level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration payable- net sales milestones and royalties</a></td>
<td class="nump">58,800<span></span>
</td>
<td class="nump">$ 53,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6809023360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">17,684<span></span>
</td>
<td class="nump">16,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="nump">17,684<span></span>
</td>
<td class="nump">26,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">17,684<span></span>
</td>
<td class="nump">14,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="nump">17,684<span></span>
</td>
<td class="nump">$ 24,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Securities in an unrealized loss position less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Securities in an unrealized loss position greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6756585040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Marketable securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">$ 161,132<span></span>
</td>
<td class="nump">$ 58,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">66,315<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">70,301<span></span>
</td>
<td class="nump">31,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">70,192<span></span>
</td>
<td class="nump">26,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">59,514<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Marketable securities on the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Total Marketable securities, Less Than 12 Months</a></td>
<td class="nump">20,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue', window );">Total Marketable securities, More Than 12 Months</a></td>
<td class="nump">$ 6,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6833338784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments and marketable securities - Warrants and SARs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2018</a></td>
<td class="nump">3,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(3,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">June 30, 2019</a></td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">$ 3,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember', window );">Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2018</a></td>
<td class="nump">257,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">20,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">June 30, 2019</a></td>
<td class="nump">277,400<span></span>
</td>
<td class="nump">257,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2018</a></td>
<td class="nump">3,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">June 30, 2019</a></td>
<td class="nump">$ 1,960<span></span>
</td>
<td class="nump">$ 3,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.4970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.0209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="nump">128.00<span></span>
</td>
<td class="nump">128.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="nump">6.76<span></span>
</td>
<td class="nump">6.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Option Volatility | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.4759<span></span>
</td>
<td class="nump">0.5939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Option Volatility | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Risk Free Interest Rate | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Expected Term | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Expected Term | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="nump">2,520.00<span></span>
</td>
<td class="nump">2,520.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="nump">30.86<span></span>
</td>
<td class="nump">30.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Option Volatility | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.4841<span></span>
</td>
<td class="nump">0.6048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Option Volatility | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Risk Free Interest Rate | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Expected Term | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Expected Term | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Measurement Input, Share Price | SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input | $ / shares</a></td>
<td class="nump">45.00<span></span>
</td>
<td class="nump">34.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Milestones and Royalties | Minimum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember', window );">Milestones and Royalties | Maximum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.89<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Minimum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember', window );">Development and Regulatory Milestone | Maximum | Probability of Success [Member] | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.94<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Milestones and Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2018</a></td>
<td class="nump">$ 53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">June 30, 2019</a></td>
<td class="nump">$ 58,800<span></span>
</td>
<td class="nump">$ 53,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Milestones and Royalties | Measurement Input, Discount Rate | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.145<span></span>
</td>
<td class="nump">0.140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Milestones and Royalties | Minimum | Sales Milestones | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Milestones and Royalties | Minimum | Percentage of Sales for Royalties | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Milestones and Royalties | Maximum | Sales Milestones | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Milestones and Royalties | Maximum | Percentage of Sales for Royalties | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2018</a></td>
<td class="nump">$ 257,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">June 30, 2019</a></td>
<td class="nump">277,400<span></span>
</td>
<td class="nump">$ 257,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Minimum | Development and Regulatory Milestone | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Minimum | Measurement Input, Discount Rate | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.038<span></span>
</td>
<td class="nump">0.058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Maximum | Development and Regulatory Milestone | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AlternativeInvestmentMilestone', window );">Alternative Investment, Milestone</a></td>
<td class="nump">$ 555,000<span></span>
</td>
<td class="nump">$ 555,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Development and Regulatory Milestone | Maximum | Measurement Input, Discount Rate | Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair value of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0.057<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (level 3) | Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2018</a></td>
<td class="nump">$ 53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">June 30, 2019</a></td>
<td class="nump">58,800<span></span>
</td>
<td class="nump">$ 53,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs (level 3) | Agilis | Milestones and Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in the fair value of warrant liability and SARs liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2018</a></td>
<td class="nump">53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">June 30, 2019</a></td>
<td class="nump">$ 58,800<span></span>
</td>
<td class="nump">$ 53,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AlternativeInvestmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AlternativeInvestmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityNetSalesMilestonesandRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_ProbabilityofSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_PercentageofSalesforRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_PercentageofSalesforRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ptct_DevelopmentandRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ptct_DevelopmentandRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6816983952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 512,942<span></span>
</td>
<td class="nump">$ 350,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from other comprehensive items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="nump">488,685<span></span>
</td>
<td class="nump">488,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains/(Losses) On Marketable Securities, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from other comprehensive items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">278<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from other comprehensive items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">278<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Other comprehensive income (loss) and accumulated other comprehensive items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period</a></td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="nump">$ 1,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6645480944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable and accrued expenses - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation, benefits, and related accruals</a></td>
<td class="nump">$ 19,039<span></span>
</td>
<td class="nump">$ 27,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_AccruedConsultingAndContractedResearchCurrent', window );">Consulting and contracted research</a></td>
<td class="nump">12,373<span></span>
</td>
<td class="nump">11,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">4,116<span></span>
</td>
<td class="nump">5,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SalesAllowanceAndOtherRelatedCosts', window );">Sales allowance and other costs</a></td>
<td class="nump">36,794<span></span>
</td>
<td class="nump">29,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_SalesRebatesAndRoyaltiesCurrent', window );">Sales rebates and royalties</a></td>
<td class="nump">29,449<span></span>
</td>
<td class="nump">31,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,219<span></span>
</td>
<td class="nump">6,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">10,385<span></span>
</td>
<td class="nump">16,437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 122,375<span></span>
</td>
<td class="nump">$ 128,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_AccruedConsultingAndContractedResearchCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_AccruedConsultingAndContractedResearchCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SalesAllowanceAndOtherRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Allowance And Other Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SalesAllowanceAndOtherRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_SalesRebatesAndRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Rebates And Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_SalesRebatesAndRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6625981888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">7,563,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 30.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offerings</a></td>
<td class="nump">$ 224,500<span></span>
</td>
<td class="nump">$ 224,545<span></span>
</td>
<td class="nump">$ 117,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">843,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6654613088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capitalization - Warrants (Details) - Common stock - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant shares (in shares)</a></td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 128.00<span></span>
</td>
<td class="nump">$ 128.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Period Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant shares (in shares)</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 2,520.00<span></span>
</td>
<td class="nump">$ 2,520.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6826653616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Numerator and Denominator (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (41,789)<span></span>
</td>
<td class="num">$ (9,520)<span></span>
</td>
<td class="num">$ (113,902)<span></span>
</td>
<td class="num">$ (28,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator for basic and diluted net loss per share (in shares)</a></td>
<td class="nump">55,912,748<span></span>
</td>
<td class="nump">46,137,833<span></span>
</td>
<td class="nump">57,113,141<span></span>
</td>
<td class="nump">46,257,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6808927728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Antidilutive (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation (in shares)</a></td>
<td class="nump">11,518,303<span></span>
</td>
<td class="nump">8,750,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation (in shares)</a></td>
<td class="nump">10,853,301<span></span>
</td>
<td class="nump">8,166,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember', window );">Unvested restricted stock awards and units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation (in shares)</a></td>
<td class="nump">665,002<span></span>
</td>
<td class="nump">584,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ptct_RestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6832892832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2013</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>May 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,920<span></span>
</td>
<td class="nump">$ 8,084<span></span>
</td>
<td class="nump">$ 20,184<span></span>
</td>
<td class="nump">$ 15,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining service period for recognition of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,845,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions', window );">Inducement grants for non-statutory stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">739,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="nump">735,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member', window );">2013 Stock Incentive Plan | Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member', window );">2009 Equity and Long Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member', window );">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member', window );">2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan | 1998 Employee, Director and Consultant Stock Option Plan | Common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards', window );">Number of shares subject to outstanding awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,040,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member', window );">2013 Long Term Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber', window );">Annual increase in the number of shares (in shares) on the first day of the fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding', window );">Annual increase in the number of shares outstanding on the first day of the fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent', window );">Employee stock purchase plan, voting percentage limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Voting Percentage Limit, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares subject to outstanding awards used to calculate authorized shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the inducement grants for non-statutory stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_EquityAndLongTermIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptct_EmployeeDirectorAndConsultantStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptct_EmployeeDirectorAndConsultantStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptct_LongTermIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6873107120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Share Base Compensation (Details) - Stock option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">8,534,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,845,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(311,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="num">(215,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">10,853,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested or Expected to vest at the end of the period (in shares)</a></td>
<td class="nump">5,334,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">5,138,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 28.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">33.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">16.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in dollars per share)</a></td>
<td class="nump">36.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">30.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested or Expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">29.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 30.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average remaining contractual term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested or Expected to vest at the end of the period</a></td>
<td class="text">9 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period (in dollars)</a></td>
<td class="nump">$ 178,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested or Expected to vest at the end of the period (in dollars)</a></td>
<td class="nump">84,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period (in dollars)</a></td>
<td class="nump">$ 88,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">61.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">2.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">63.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6748689216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Restricted Stock (Details) - Unvested restricted stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the beginning of the period (in shares) | shares</a></td>
<td class="nump">571,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">304,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(179,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(31,449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at the end of the period (in shares) | shares</a></td>
<td class="nump">665,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">32.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">17.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">21.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749024224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock award plan - Share-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 10,920<span></span>
</td>
<td class="nump">$ 8,084<span></span>
</td>
<td class="nump">$ 20,184<span></span>
</td>
<td class="nump">$ 15,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5,516<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">10,203<span></span>
</td>
<td class="nump">7,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock option plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 5,404<span></span>
</td>
<td class="nump">$ 4,152<span></span>
</td>
<td class="nump">$ 9,981<span></span>
</td>
<td class="nump">$ 8,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6832741888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 05, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,667,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate ( as a percent )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days, number | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days, period | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentConvertibleThresholdBusinessDays', window );">Business days, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod', window );">Consecutive trading-day period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock', window );">Common stock per principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum', window );">Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.7487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault', window );">Convertible instruments principal and unpaid interest payable upon events of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders', window );">Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Adjustments to additional paid in capital, equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments', window );">Net deferred tax liability in connection with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining contractual life of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022 | Redemption on or after August 20, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days, number | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days, period | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCumulativeSinkingFundPayments', window );">Sinking fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ptct_MidCapFinancialTrustMember', window );">MidCap Financial Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_LineOfCreditFacilityAdditionalCapacityAvailable', window );">Line of credit facility, additional capacity available, net product revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentFloorInterestRate', window );">Debt instrument, floor interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DebtInstrumentInterestPaymentPeriod', window );">Debt instrument, interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the debt instrument principal and unpaid interest payable upon events of default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentConvertibleThresholdBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentConvertibleThresholdBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Floor Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the denomination of the principal amount of debt that is used in conversion calculations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_LineOfCreditFacilityAdditionalCapacityAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Capacity Available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_LineOfCreditFacilityAdditionalCapacityAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum percentage of debt principal amount by instrument holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net deferred tax liability attributable to taxable temporary differences from issuance of convertible debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCumulativeSinkingFundPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount paid into a fund, which is used to retire the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCumulativeSinkingFundPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ptct_MidCapFinancialTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ptct_MidCapFinancialTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6814468784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Convertible Notes (Details) - 3.00% Convertible senior notes due 2022 - Convertible debt - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: Debt issuance costs</a></td>
<td class="num">(1,544,000)<span></span>
</td>
<td class="num">(1,746,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount, net</a></td>
<td class="num">(30,999,000)<span></span>
</td>
<td class="num">(35,054,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 117,457,000<span></span>
</td>
<td class="nump">$ 113,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6676721696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 3.00% Convertible senior notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">3,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 3,308<span></span>
</td>
<td class="nump">$ 3,087<span></span>
</td>
<td class="nump">$ 6,498<span></span>
</td>
<td class="nump">$ 6,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_ConvertibleSeniorNotes3.0PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6808956672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Aug. 23, 2018</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_AkceaMember', window );">Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_UpfrontLicensingFee', window );">Upfront licensing fee</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone, Potential Achievements, Regulatory Approval</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_AkceaMember', window );">Akcea | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone, Potential Achievements, Regulatory Approval</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone, Potential Achievements, Regulatory Approval</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount', window );">Milestone, potential achievements, priority review voucher amount</a></td>
<td class="nump">535.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone', window );">Milestone, potential achievements, net sales amount</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage', window );">Milestone, potential achievements, product sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember', window );">Agilis | Non-collaborative Arrangement Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Wellcome trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Wellcome trust | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Other Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_DevelopmentMilestonePaymentObligations', window );">Development milestone payments which the entity is obligated to pay</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_DevelopmentMilestonePaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_DevelopmentMilestonePaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestonePotentialAchievementsRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment which the entity is obliged to receive upon regulatory approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestonePotentialAchievementsRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_UpfrontLicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Licensing Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_UpfrontLicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_AkceaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_AkceaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6832049104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2011 </div>
<div>USD ($) </div>
<div>compound</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>segment </div>
<div>deliverable</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>deliverable</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,802,000<span></span>
</td>
<td class="nump">$ 10,540,000<span></span>
</td>
<td class="nump">$ 15,802,000<span></span>
</td>
<td class="nump">$ 10,540,000<span></span>
</td>
<td class="nump">$ 11,891,000<span></span>
</td>
<td class="nump">$ 12,938,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetProductSales', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,476,000<span></span>
</td>
<td class="nump">68,170,000<span></span>
</td>
<td class="nump">$ 138,530,000<span></span>
</td>
<td class="nump">124,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864,000<span></span>
</td>
<td class="nump">2,586,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,522,000<span></span>
</td>
<td class="nump">68,743,000<span></span>
</td>
<td class="nump">139,105,000<span></span>
</td>
<td class="nump">124,805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Performance obligations satisfied in current period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,476,000<span></span>
</td>
<td class="nump">68,170,000<span></span>
</td>
<td class="nump">138,530,000<span></span>
</td>
<td class="nump">124,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember', window );">Licensing And Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Performance obligations satisfied in current period</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember', window );">Licensing And Collaboration Agreement | Research And Development Event Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RevenueRecognitionMilestonePotentialAchievements', window );">Revenue recognition, milestone, potential achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember', window );">Licensing And Collaboration Agreement | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RevenueRecognitionMilestonePotentialAchievements', window );">Revenue recognition, milestone, potential achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_DiscoveryAgreementsMember', window );">Discovery Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_EarlyStageCollaborationsMember', window );">Early Stage Collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_EarlyStageCollaborationsMember', window );">Early Stage Collaborations | Research And Development Event Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RevenueRecognitionMilestonePotentialAchievements', window );">Revenue recognition, milestone, potential achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptct_EarlyStageCollaborationsMember', window );">Early Stage Collaborations | Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_RevenueRecognitionMilestonePotentialAchievements', window );">Revenue recognition, milestone, potential achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetProductSales', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,600,000<span></span>
</td>
<td class="nump">20,300,000<span></span>
</td>
<td class="nump">45,400,000<span></span>
</td>
<td class="nump">39,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetProductSales', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,800,000<span></span>
</td>
<td class="nump">47,800,000<span></span>
</td>
<td class="nump">$ 93,000,000.0<span></span>
</td>
<td class="nump">84,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Roche And Sma Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment', window );">Number of compounds in preclinical development | compound</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables', window );">Number of significant deliverables | deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptct_CollaborationAndDiscoveryAgreementsMember', window );">Collaboration And Discovery Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables', window );">Number of significant deliverables | deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Collaboration And Discovery Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology', window );">Collaborative arrangements research period for applying discovery technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Collaboration And Discovery Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology', window );">Collaborative arrangements research period for applying discovery technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ptct_RocheMember', window );">Roche | Licensing And Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of compounds included in preclinical development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CollaborativeArrangementsNumberOfSignificantDeliverables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of significant deliverables under a contractual agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CollaborativeArrangementsNumberOfSignificantDeliverables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the research period for applying discovery technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Increase from Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of revenue earned from product sales during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_RevenueRecognitionMilestonePotentialAchievements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone, Potential Achievements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_RevenueRecognitionMilestonePotentialAchievements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestoneAxis=ptct_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestoneAxis=ptct_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_DiscoveryAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_DiscoveryAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_EarlyStageCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_EarlyStageCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_RocheAndSmaFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_RocheAndSmaFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptct_CollaborationAndDiscoveryAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptct_CollaborationAndDiscoveryAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ptct_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ptct_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6653731616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Contract Liabilities, Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 12,938<span></span>
</td>
<td class="nump">$ 11,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts', window );">Additions</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">ASC 606 Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 15,802<span></span>
</td>
<td class="nump">$ 10,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Increase from Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6814234016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Recognized revenue in the period (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod', window );">Amounts included in contract liabilities at the beginning of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Performance obligations satisfied in current period</a></td>
<td class="nump">85,476<span></span>
</td>
<td class="nump">68,170<span></span>
</td>
<td class="nump">138,530<span></span>
</td>
<td class="nump">124,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_NetProductSales', window );">Total product revenue</a></td>
<td class="nump">$ 85,476<span></span>
</td>
<td class="nump">$ 68,170<span></span>
</td>
<td class="nump">$ 138,530<span></span>
</td>
<td class="nump">$ 124,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Amounts Recognized Beginning Of Measurement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_NetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of revenue earned from product sales during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_NetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6675856912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Performance Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="nump">$ 15,802<span></span>
</td>
<td class="nump">$ 12,938<span></span>
</td>
<td class="nump">$ 10,540<span></span>
</td>
<td class="nump">$ 11,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2018-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-10-01 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, performance obligation, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2018-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-10-01 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, performance obligation, period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2018-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-10-01 | Licensing And Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, performance obligation, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2018-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2018-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6809277888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 20, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 6,575<span></span>
</td>
<td class="nump">$ 5,593<span></span>
</td>
<td class="nump">$ 12,652<span></span>
</td>
<td class="nump">$ 11,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Total allocation of IPR&amp;D assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">82,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59,979<span></span>
</td>
<td class="nump">32,607<span></span>
</td>
<td class="nump">112,544<span></span>
</td>
<td class="nump">63,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptct_AkceaMember', window );">Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone, Potential Achievements, Regulatory Approval</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_UpfrontLicensingFee', window );">Upfront licensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Non-collaborative Arrangement Transactions | Akcea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone, Potential Achievements, Regulatory Approval</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ptct_EmflazaassetacquisitionMember', window );">Emflaza asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_MilestonePotentialAchievementsRegulatoryApproval', window );">Milestone, Potential Achievements, Regulatory Approval</a></td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_MilestonePotentialAchievementsRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment which the entity is obliged to receive upon regulatory approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_MilestonePotentialAchievementsRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_UpfrontLicensingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Licensing Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_UpfrontLicensingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptct_AkceaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptct_AkceaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ptct_EmflazaassetacquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ptct_EmflazaassetacquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6651931680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets and goodwill - Future Amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2019</a></td>
<td class="nump">$ 13,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2020</a></td>
<td class="nump">26,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2021</a></td>
<td class="nump">26,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2022</a></td>
<td class="nump">26,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter', window );">2023 and thereafter</a></td>
<td class="nump">33,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 126,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6645872736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 04, 2019 </div>
<div>USD ($) </div>
<div>Feet </div>
<div>Term</div>
</th>
<th class="th"><div>Aug. 02, 2019</div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Aggregate rent, Initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Feet', window );">Square feet of office | Feet</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract ( in years )</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Numberofterms', window );">Number of terms | Term</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Aggregate rent, Initial term</a></td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_PercentOfMarketRate', window );">Percent Of Market Rate</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Renewal Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Termforletterofcredit', window );">Term for letter of credit (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptct_FifthAnniversaryMember', window );">Fifth Anniversary [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_NewBuildingMember', window );">New Building | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Feet', window );">Square feet of office | Feet</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract ( in years )</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_Numberofterms', window );">Number of terms | Term</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Renewal Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_Feet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_Feet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_Numberofterms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_Numberofterms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_PercentOfMarketRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent Of Market Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_PercentOfMarketRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_Termforletterofcredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term for letter of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_Termforletterofcredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptct_FifthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptct_FifthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_NewBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ptct_NewBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MG\)<%^%*QC Q%3S[%.:Z"%<RAHFM,3S[%.:Z"%<RAHG\QRB>?0IS703_L>V
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MT3RE%-M,3,0BI8C8:+$\EBEF57X6,"Z4489#?0:T)<$^2WK2.9.<-( I9;3
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M1?IN34^3;8']IL ^"NS_6^(&)OV[2+;JJ0;3Q&FRI,2ABY.\\BX#>\?CFWS
MIVE_$*:1G25G=/YE8_]K1 <^E>3*CU#K/]AB**A=.-[XLYG&;#(<]O,/8LLW
M+OX 4$L#!!0    ( ".*!D]\_!\TM0$  - #   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;'U3VV[<(!#]%<0'A#7>-*N5;2F;JFJE5EJE:O/,VF,;
M!3PNX'7Z]P7L.%;C]@68X9PS%X9L1/-L6P!'7K3J;$Y;Y_HC8[9L00M[@SUT
M_J9&HX7SIFF8[0V(*I*T8GRW^\"TD!TMLN@[FR+#P2G9P=D0.V@MS.\3*!QS
MFM!7QZ-L6A<<K,AZT<!W<#_ZL_$66U0JJ:&S$CMBH,[I?7(\[0,^ GY*&.WJ
M3$(E%\3G8'RI<KH+"8&"T@4%X;<K/(!20<BG\6O6I$O(0%R?7]4_Q=I]+1=A
MX0'5DZQ<F],#)1748E#N$<?/,-=S2\E<_%>X@O+PD(F/4:*R<27E8!WJ6<6G
MHL7+M,LN[N-TDQYFVC:!SP2^$ XQ#IL"Q<P_"B>*S.!(S-3[7H0G3H[<]Z8,
MSMB*>.>3M]Y[+>[2C%V#S@PY31"^@B0+@GGQ)0+?BG#B[^A\FYYN)IA&>KJF
M)_\0V&\*[*/ _G\5OH?P)/TK!EMU5(-IXBQ94N+0Q3E>>9=QO>?Q1=[@TZQ_
M$Z:1G247=/Y=8_=K1 <^E=V-'Z#6?Z_%4%"[<+SS9S,-V60X[.?_PY9/7/P!
M4$L#!!0    ( ".*!D\G]151M0$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;'U3VV[<(!#]%<0'A#7K7+2R+6535:W42*M$;9]9>WQ1@'$!
MKY._#V#'=5NK+\ ,<\Z<&89L1/-B6P!'7I74-J>M<_V!,5NVH(2]PAZTOZG1
M*.&\:1IF>P.BBB E&=_M;I@2G:9%%GTG4V0X.-EI.!EB!Z6$>3N"Q#&G"?UP
M/'5-ZX*#%5DO&G@&][T_&6^QA:7J%&C;H28&ZIS>)X=C&N)CP(\.1KLZDU#)
M&?$E&%^KG.Z"()!0NL @_':!!Y R$'D9OV9.NJ0,P/7Y@_USK-W7<A86'E#^
M["K7YO2.D@IJ,4CWA.,7F.NYIF0N_AM<0/KPH,3G*%':N))RL [5S.*E*/$Z
M[9V.^SC=[&]GV#: SP"^ .YB'C8EBLH_"2>*S.!(S-3[7H0G3@[<]Z8,SMB*
M>.?%6^^]%#Q),W8)1'/,<8KAJYADB6">?4G!MU(<^3]PO@W?;RK<1_C^#X77
MVP3I)D$:"=+_EK@5<_-7$K;JJ0+3Q&FRI,1!QTE>>9>!O>?Q37Z'3]/^*$S3
M:4O.Z/S+QO[7B Z\E-V5'Z'6?[#%D%"[<+SU9S.-V60X[.<?Q)9O7+P#4$L#
M!!0    ( ".*!D_G!_"KM $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;'U386_;(!#]*X@?4&*2K5ED6VHZ39VT25&GM9^)?;91P><"CKM_
M/\".ZVW6O@!WW'OW[CC2 <V+;0 <>=.JM1EMG.L.C-FB 2WL#7;0^IL*C1;.
MFZ9FMC,@R@C2BO'-YB/30K8T3Z/O9/(4>Z=D"R=#;*^U,+^.H'#(:$*OCD=9
M-RXX6)YVHH8?X'YV)^,M-K.44D-K);;$0)71N^1PW(7X&/ D8;"+,PF5G!%?
M@O&US.@F" (%A0L,PF\7N >E I&7\3IQTCEE "[/5_8OL79?RUE8N$?U+$O7
M9'1/20F5Z)5[Q.$!IGH^4#(5_PTNH'QX4.)S%*AL7$G16X=Z8O%2M'@;=]G&
M?1AOME?8.H!/ #X#]A' QD11^6?A1)X:'(@9>]^)\,3)@?O>%,$96Q'OO'CK
MO9><)[<INP2B*>8XQO!%3#)',,\^I^!K*8[\'SA?AV]7%6XC?/N'POTZP6Z5
M8!<)=O\M<2WFTU])V**G&DP=I\F2 OLV3O+".P_L'8]O\AX^3OMW86K96G)&
MYU\V]K]"=."E;&[\"#7^@\V&@LJ%XZT_FW',1L-A-_T@-G_C_#=02P,$%
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MGNSX$>9Z;BF9B_\,5U 8'I5@CLHJGU92#3Y8/;.@%"U>IUV:M(_3#;^;8=L
M/@/X KA/>=B4*"E_+X(H<V='XJ;>]R(^\?[(L3=5=*96I#L4[]%[+3D_Y.P:
MB>:8TQ3#5S'[)8(A^Y*";Z4X\7_@?!M^V%1X2/##'PJS;8)LDR!+!-E_2]R*
MN?TK"5OU5(-KTS1Y4MG!I$E>>9>!?>#I37Z'3]/^1;A6&D\N-N#+IOXWU@9
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MZKFE9"K^*UQ!A?"H).0H4;FTDK)W'O7$$J1H\3+NTJ1]&&]N^01;!_ )P&?
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MX@=;# 6U#\<;/-MIS";#FW[^06SYQL5O4$L#!!0    ( ".*!D_?\;--M0$
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MUF:!;:#I,&S !@0=MCTK-FT+U<63Y+C[^U&RZWFML1=)I'@.#RDJ&ZQ[\BU
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M(1[O\.S&,1N-8+OI!['Y&Q=_ %!+ P04    "  CB@9/K2/F."@"   #!P
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M-2YX;6QM5-MNW" 0_17$!P2;7:?;E6TIFZAJI59:I6K[S-KCBP+&!;Q._[Z
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M ;4+YL[;9ERST7&ZFUX0F9]Q\0E02P,$%     @ (XH&3SAVB7RV 0  T@,
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M4[*#LR%VT%J8/R=0..8TH6^.9]FT+CA8D?6B@>_@?O1GXRVVJ%120V<E=L1
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MG_S93&,V&0[[^0>QY1L7?P%02P,$%     @ (XH&3^H)OH#" 0  -P0  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL;53M;ML@%'T5Q .4F,1M%MF6
MFE;5)FU2U&G=;V)??ZA\>(#C[NT'V/&\C#^!>WW.N><"-]FH]+MI 2SZ$%R:
M'+?6]@="3-F"8.9.]2#=EUIIP:P+=4-,KX%5@20XH9O-/1&LD[C(0NZDBTP-
MEG<23AJ900BF?Q^!JS''";XF7KNFM3Y!BJQG#7P'^Z,_:1>11:7J!$C3*8DT
MU#E^3 ['U.,#X*V#T:SVR'=R5NK=!U^J'&^\(>!06J_ W'*!)^#<"SD;OV9-
MO)3TQ/7^JOX2>G>]G)F!)\5_=I5M<[S'J(*:#=R^JO$SS/VD&,W-?X4+< ?W
M3ER-4G$3?E$Y&*O$K.*L"/8QK9T,ZSCK7VEQ IT)](9 ID+!^3.SK,BT&I&>
MSKYG_HJ3 W5G4_ID.(KPS9DW+GLIZ#[-R,4+S9CCA*$K3+(@B%-?2M!8B2/]
MCT[C]&W4X3;0MVMZLH\+[*("NR"P^Z?%^YL68YB'>)$T6B2-".QOBL0PGVZ*
MD-7%"=!->+(&E6J085Q6V64J'FFX^+_P::2^,=UTTJ"SLN[YA$NNE;+@K&SN
MG)?63?$2<*BMWSZXO9[>\A18U<]C2I;_BN(/4$L#!!0    ( ".*!D\X+VTK
MVP$   $%   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;'54ZV[;(!1^
M%<0#%(=<W$6VI:95M4F;%'5:]YO8QQ<5C <X[MY^@!W/\^B?P#G^+N<0#LD@
MU9NN 0QZ%[S5*:Z-Z8Z$Z+P&P?2=[*"U7TJI!#,V5!71G0)6>)+@A$;1@0C6
MM#A+?.ZLLD3VAC<MG!72O1!,_3X!ET.*-_B6>&FJVK@$R9*.5? =S(_NK&Q$
M9I6B$=#J1K9(09GBA\WQ%#N\![PV,.C%'KE.+E*^N>!+D>+(%00<<N,4F%VN
M\ B<.R%;QJ])$\^6CKC<W]2??>^VEPO3\"CYSZ8P=8KO,2J@9#TW+W+X#%,_
M>XRFYK_"%;B%NTJL1RZY]K\H[[618E*QI0CV/JY-Z]=ATK_1P@0Z$>B*0$8C
M7_D3,RQ+E!R0&L^^8^XOWARI/9O<)?U1^&^V>&VSUXQ^BA)R=4(3YC1BZ *S
MF1'$JL\6-&1QHO_1:9B^#5:X]?3MDDX_\-\%!79>8/=/BYM5BR',!U7N@R;[
M@,!V91+"[,(FAZ#)(2"P7YF$,(>P21PTB0,"\<HDA+E?F9#%%12@*C]\&N6R
M;_W@+[+S?#]0?X7_PL?'X1M35=-J=)'&#H*_KJ64!FPIT9T]U=J^1W/ H31N
M&]N]&J=R#(SLI@>'S*]>]@=02P,$%     @ (XH&3R^1H3S& 0  -P0  !D
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MS;DW24$)GL-'<_A(CGC41JL)KG)\(*X/$8P6Y0$1QC2*@>(5!6A%P;0B</$
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M0<[V0IV&\KQN/SS:@>!5]U'E]%]VFW]02P,$%     @ (XH&3T.&>L[[ 0
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MM=UF9B^'H3$$6G3C/$334"[_ E!+ P04    "  CB@9/YYO.9;(!  #3 P
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MNPKK?FMJHFI&/Q8L#F;.1^M(8I8]A@XP<:1"5B:$7!!.0^#"@B(62VJ84RW
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MEV>9&GGEQ,RQ46E9?UJ;4ZE5UD8Q5K+XK?E.\OK[TL9_'X8'\'8 OPY@WN0
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MWO T)UH=V[=7SO45VO(_4$L#!!0    ( ".*!D\P.UJ1"P,  !0-   9
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MVY]'CYP+)E.&]Y+R67ZBC(N2'86ZS>1].YS3AX7@C?X&"<8/H>U?4$L#!!0
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M 3""PZGRPWI&D*"3B:,(EBH.YY<%PU+%:$99+.B]LD"PZ;)@6/@8$#Y))US
M0L4?.$$QK$(,J- MBZM"L"SN6?M666"Q8DB'X\W'@F9L/AB6*@:DZFP^%O0J
M[60R'5C0&#B^G;T'NT?SF"48W PK)@[F$BV]+3_5Y@8_F.TOZG?8W"Q?X-TM
M_P<5AZ*6WB-7^GYJ;I%[SA73D80W.MFC_K#H!R7;J_8UU>^BNUUW \4;^^40
M])\OJ_]02P,$%     @ (XH&3X+#^6YZ P  $A(  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&ULE9A1;YLP%(7_"N*]!5\#(542:<TT;=(F59NV/=/$
M25 !9T":[M_/$!HEW&/"7A(@Q]?G^MI?;&9'7;Y4.Z5JYRW/BFKN[NIZ_^!Y
MU6JG\J2ZUWM5F%\VNLR3VMR66Z_:ERI9MXWRS"/?C[P\20MW,6N?/96+F3[4
M65JHI]*I#GF>E'\?5::/<U>X[P^^I]M=W3SP%K-]LE4_5/US_U2:.^\<99WF
MJJA273BEVLS=#^)A*:.F0:OXE:IC=7'M-*D\:_W2W'Q9SUV_<:0RM:J;$(GY
M>E5+E65-)./C3Q?4/??9-+R\?H_^J4W>)/.<5&JIL]_INM[-W=AUUFJ3'++Z
MNSY^5EU"H>MTV7]5KRHS\L:)Z6.ELZK]=%:'JM9Y%\58R9.WTW=:M-_'+OY[
M,]R N@9T;B""P0:R:R![#;R3LS;5CTF=+&:E/CKEJ5K[I)D4XD&:P5PU#]NQ
M:W\SV5;FZ>LBD/',>VT"=9K'DX8N-'2M6')%.#U+/&/@[(*@"VK;RRL7E@ 2
M!I!M@. R0.#WTCAIHE93M)H[T=,L@2;&/@+H(P ^1,_'21->]-%WP15W$KL(
MH8N0N1"R/QHA[X.-!M((;"2"1B)>5PIQ@ D,,!E1UPES*291'/1R :J(R#*L
M,303CRAN?+.X7"%\/YY@(U-H9#JBOM-1H\)5%,F+>7!E1O@8(3X?%XHL(2P4
M$N,!(#!"!(V8*IUHJ#Q <F>9\P*S2" 8]>=))QIT,B2Y-H)A)#B-^#P1MW$$
M)-8AP4 2X7@0"(P2$8VI;W0[&2X1TZF% P)322 LL0ISXC O0Y)K(YA(@B,)
M5/@VDX!D8% PE 2G4D 6K!$F"?GC,4"8)"1&3)-.-/SGAT2V="R[&H2D_C2A
MVT@"$MM^@#"2B".)SQ/BO &C,BRZ-H.Q1,%X&!#F"?$=#J@RW[Z@OT D"TC:
M<L)T(D0G5NK;= *2@=T!83P1QQ.H]KAM4R>[W!%3((7-$,84@9T36?;5A.E"
MT_\X(F"Z2+!/X8<$?RR2)0:01 #JSP3)V6+K!:-%<K3P$LLAM%SW8CE5R?$K
M5>+%+M&)B!D=VH-<]X)Y(!$/V*#SA6[K!2]RR1<Y&/2(+9A^+][%X;QY6_(M
M*;=I43G/NC;G_/8TOM&Z5B:<?V_L[E2R/M]D:E,WEQ-S79[>4IQN:KWOWL!X
MY]= BW]02P,$%     @ (XH&3^*+R'UT @  [@@  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#DN>&ULE5;1CILP$/P5Q <<&(.!$T'JI:I:J96BJWI]=A(G
MH -,;2=<_[ZV(8A@$]&7@,WL>'8G:SOK*'OG!2'"^:BKAF_<0HCVV?/XH2 U
MYD^T)8W\<J*LQD(.V=GC+2/XJ(/JR@M\'WDU+ALWS_3<CN49O8BJ;,B..?Q2
MUYC]?2$5[38N<&\3K^6Y$&K"R[,6G\E/(GZU.R9'WLAR+&O2\)(V#B.GC?L)
M/&\!4@$:\5:2CD_>'97*GM)W-?AVW+B^4D0J<A"* LO'E6Q)52DFJ>//0.J.
M:ZK Z?N-_8M.7B:SQYQL:?6[/(IBXR:N<R0G?*G$*^V^DB&AR'6&[+^3*ZDD
M7"F1:QQHQ?6O<[AP0>N!14JI\4?_+!O][ ;^6Y@](!@"@C$ A \#X!  9P%>
MKTRG^AD+G&>,=@[KW6JQ^E. 9RB+>5"3NG;ZF\R6R]EK'H9!YET5T8!YZ3'!
M!#-#;$U$E(X03PH85016%8&.AW<JH)T 6@F@)@CO",)9&CT&:4RC,0 ! .>Y
MF+ H\9/$KB:TJ@DM:J*9FAX3399!"((9:FNB?+N0R"HD,H4$R$Z K 1HO3&Q
ME2!>84QL)!G[T >S4I@H"%"Z\#=+K&*2%;XD#RK>"WF$N!.16D6D%D]B.P'P
M[3WKKW<%++0]6.'+ +HW!J1&\YNP ,%DP1E@WP% L,*; 31=*4HC$,X%!48+
M+S@$[+L)L&PGP<(. .Q;  C_PR-[\P)+]YH>16;Q?027BF_O<H#6%!\9547)
MI$O[A;S)P:-N C\P.Y<-=_94R#-,GS0G2@61C/Z35%W(R\<XJ,A)J-=8OK/^
M!.X'@K;#[<(;KSCY/U!+ P04    "  CB@9//\G\.:H'  !E,P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,"YX;6R5FUMOXS80A?^*X??:O%\628"-BZ(%
M6F#1HNVS-E$28VTKM95D^^\KV;)KD>?8TCYL8N>0G*'X<7@9W7Q4VV^[E[*L
M)]_7J\WN=OI2UZ^?YO/=PTNY+G:SZK7<-']YJK;KHFX^;I_GN]=M63SN"ZU7
M<R6$FZ^+Y69Z=[/_[LOV[J9ZJU?+3?EE.]F]K=?%]M_[<E5]W$[E]/C%[\OG
ME[K]8GYW\UH\EW^4]9^O7[;-I_FIEL?ENMSLEM5FLBV?;J>?Y:>%U+8ML9?\
MM2P_=F>_3UI?OE;5M_;#+X^W4]&:5*[*A[JMHVA^O)>+<K5JJVH,^:>K=7IJ
MM"UX_ONQ]I_VWC?>?"UVY:):_;U\K%]NIV$Z>2R?BK=5_7OU\7/9>62GD\[]
M7\OW<M7(6TN:-AZJU6[__^3A;5=7ZZZ6QI1U\?WP<[G9__SHZC\6PP545T"=
M"FAYL8#N"NBDP/Q@V=[5'XNZN+O95A^3[>%QO1;MJ)"?=-.9#^V7^[[;_ZWQ
M=M=\^WYGC+N9O[<5=9K[@T:=:61?L<@5QOB39MY8<#)#(3/N%:@@)(T@3<2-
M:.BKWE>@SRNP E=@8 5F7X$YKT"+I+,.&K?7;/8:TH2%35C0A,05.%B!&^ZD
MAQ7XW *;/._[@\:>.:F#-+B5 %L)P$^5M!*R5F1TI#,B;"6"5G322LQ:^:%Q
MQN)FI, 4"=!IJ3N=*/%'I"B); #QOI4$:@G\9E5 (#]+-7P<28R;U -&4B<Z
M[Q1EO3"L*0RF'$)F)[+7T92838G@S)ZRS1T2VK&6,,32#1BX4,3&+69=(M@S
MCW+:E?=&9",7Z"X]2CPQ2#0S$.@EIE[&X6-78: 5 CH=NRH'FJ.J,*H*H)H]
M@4[D+L\<0'7!'(R]4L <3:K V"L49ID5&&<%<+8V[92#*)[C/#.1+3LPT@H@
M;1VI K.J4,1E_F(,%<(P\]<#?X429 FD,%X*X&59GV&\%,*+.*PQ7AKAE:SW
M[J&(+?@P71K0Q:9BC8G0*! R;\FZ$P1"ETXF.@^$4J5+X"NBOC&8+0W8<HI4
M@:'1=D278&@TB%UYEQQ$[8KHY*Z;>9=VRC59WR",H 8(.C+Q:8R6#B.Z!:.E
MP8(UFP@Z43+Q^3,TNGY!.ALU0<A@5 V@T!&O#*;0R.$=8S"%!L6EI&,6G2CI
M&,?BE\&T&D0K6589LD\T(QS&C!D4F#*'+0P)AC6%632(14*/P?08/\)A3(]!
M@2D=^IVHA[J8D=6AP8P9Q%@ZT2*1(V'28G L H?,U1:#8T> 8S$X%H&3>HM$
MCDP3%E-C 36>G7Q@:NP(:BPY/0'49&'%@AV:5>EJ^IJJ;PXFRP*R/!FM%I-E
M1Y!E,5D6D)5W"B!+BUE(@^UU7=\DS* %>'FR"'$8+R>&=XS#>#FT]TJGG$Z4
M!)5@TB-0J'/"$.(=QM4!$CV)7PZ3Z$;LOQPFT0W8?RT<VG_9R%;H#A/K +&>
M64M./$=LP!RFS W8@"T<WH"Q5:+#-#I HR?+"X?I<2,V8![3X]'>*AWZG2B)
MMHKXZS%D'D&6!B D8@MXC\GQB!P2L3TFQX\@QV-R/"(G\Q:(/)DG/,;&(VP(
M>1YCXT=@X\E5 =HT97<%^;&@2='J-/VH8F::A 2/T?( K<#N/C!:?@1: :,5
MAJ 5,%IIOUR5]0W"! 8 5R"KD(#A"B,.00*&*Z#;@*Q;-/(WI#O;J[*^01C5
M "@,9, %3&$8<1 2,(4!+!'S;@$G'&BT7)/U#<),!\!T(%-^('=[(PY" N8P
M##D(Z42)OU''WK^TD\85ZE\R8N(C(#X0?R-F-**='IFZ(F8THIU>.AEWHO,[
M JN58"UAE"-".;VSZ$2]ED+(+HV0[()!&.6(4";#/F*4XPB4(T8Y#D&Y$TG9
M/\'((B+3$8LPRQ&Q3)95$;,<1[ <R24\8#GXM%]B-@ZRH7))DMS2LVMZ1"I9
M>4E!+M?%B%,9*<CUNAAPH'E_5"63E4A86US7)4:1"WL!P&9150IR%2]&'.-(
M06[:!5C?9F/FJ.K=BUHA\IOIZ\+$+'(M+P#BD59"[MS%B",=*<@MN1AR7'I4
MI>,B/=2YKDN,(O?N I >V=T]2Z61Z&"']3%-@$&[SBSW1.8WYA<S%EBNC$0P
M9VD4G>IZ'H7,@_1ELPC.* $GLCF!9=;(,3BSQ!F4.9/C+'-*\[ZYI$F,(1"C
MO)E(5KB2)<[(,1"S5!>4ZY)#W*F2I8#0Z;$"$UH6X%CZC$08T_0Q@K$:<3XK
M27*,1-DQ^;@!B2_66A &K@L3LUAN'. ]LLPKDB8CQ^3)2)(H(P=ERAQ5V<#P
M60<9& ?8 "))-1)EU4063$A:C81Y-?1)$4QA9DT6!SK5P$V()*DU$N;69&%
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M$]7FXRTR=B3KIQL2S-=T\0]02P,$%     @ (XH&3P?XGV)  @  P08  !D
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ML^.B)D>AIK&<L[[9] M!NZ&/>F,S7_\!4$L#!!0    ( ".*!D_0- YE.@(
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MRBQ3O1;#H!PVBG?C)8"FFZCX"U!+ P04    "  CB@9/XB@PK(@$  #"&
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MZ^.B>ZO>G53YL?_%P#__;+'\#U!+ P04    "  CB@9/I?D7+)@#  #U#P
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M2=%ZLOOX#;/_&&VQ^3:9772?PNV9X)59?:0QPKO@885ZFV-G@T<V:+ (C/J
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M[! G00N8VDZR_?O:AK#$>-.\!'LXYWCF8,UD>F'\31PIE=Y[5=9BYA^E;"8
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MEWTY!H59:%VDU1B$8 !#R]@Q*HF3U%U5ZJPJ=?B:N 4RIT#VN*^JW3L;!'S
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M&]!J6E!RD_#4UPS8$(BK=LF=WAY!Z81+R)N)T.9,V!4(L 7NM#<"^2K"ED"
M)W"GO1'(TW84NP(%KB#L]@8@)E(/#[8%"A0O[/8VH&E[BT0LV"GU+!6 [(7=
MX@8T):.4+9%A@Z"N]GEL=<0CA2L+BMZ1",JE7!H8=A0*'$4P>V N2'"/)"@V
M% J\0OA28*^@\NH%#<4.0($#..]0 YJM5'PT6/X4K0ILHS&@:UZB%*N?HA6!
M[3(0Y'$9AM7/D/KM<A#(YV8,JY\A]=OU,%?]GEEC6/8,R=XW4,\F@5V_R\"J
M8TAU]N:,N>]QN;@.9EAZ#$G/VN7=&="4C"^389$R\$*7L5V9NQF@RV18SPSH
M61*;+/%4YJ'"FF:NIL'.$"SUDR4N+&P&-"NI718">19?' N; \U*JZ9["/+L
MR3D6-@?"EM+F02!;E]'D TG_U>W/K'[+JR9XU6VKR^&+R$'K5G4)XYNNO8XJ
MVU\N"G5H^].D.Z_'KUWC1:M/YDM>=/F<N/T/4$L#!!0    ( ".*!D]E='1R
M%0(  !<&   9    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;(U578_:,!#\
M*U'>>\Z';0X4(A50U4JMA*YJ^VQ@(=$Y<6H;<OWWM9V0!N*KR$/L=69F9]?8
M9*V0KZH T,%;Q6NU# NMFP5":E] Q=23:* V7XY"5DR;4)Z0:B2P@R-5'"51
M1%'%RCK,,[>VE7DFSIJ7-6QEH,Y5Q>2?%7#1+L,XO"Z\E*="VP649PT[P7?0
M/YJM-!$:5 YE!;4J11U(."[#C_%B0RW> 7Z6T*K1/+"5[(1XM<&7PS*,K"'@
ML-=6@9GA FO@W H9&[][S7!(:8GC^57]DZO=U+)C"M:"_RH/NEB&SV%P@",[
M<_TBVL_0UT/"H"_^*UR &[AU8G+L!5?N'>S/2HNJ5S%6*O;6C67MQK;7O]+\
MA*0G) ,AQO\EI#TA?92 >P+^1W#M1UTIKC<;IEF>2=$&LMO=AMD?4;S IOM[
MN^B:[;Z9]BBS>LDI?<[0Q0KUF%6'24:8Y!:QGB+(_!:RF4+2F X89$P.3A.O
MT\0)I".!V=S/3[W\U/'QB(\C<E=IAZ$.4SM,3*+NN:OX8>3F$>2-?>RUCR?V
M*;WK\:K#D%&J#S'!>.K>!YQA^JXEXK5$II9F=YE69)HIC>;S^=23#TDB@M\U
M1;VFJ,=4?&>*3K?$E$]F4U,^9)KX-@^-3IR],K\Q>2IK%>R$-H?7';&C$!J,
M:O1DJBS,+3T$'([:3F=F+KN[J@NT:/IK& W_!?E?4$L#!!0    ( ".*!D_<
M")"3Q (  &L*   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;(U6VV[C
M(!#]%<L?4(,OV(Z22,U-N]*N%'75W6>2D,2J;;Q DN[?+V#7=8$V?@DP/F=F
M#D-@IC?*7OB9$.&]5F7-9_Y9B&82!'Q_)A7F#[0AM?QRI*S"0B[9*> -(_B@
M2549A "@H,)%[<^GVK9E\RF]B+*HR99Y_%)5F/U;D)+>9C[TWPQ/Q>DLE"&8
M3QM\(K^(>&ZV3*Z"WLNAJ$C-"UI[C!QG_B.<;* F:,3O@MSX8.XI*3M*7]3B
M^V'F Y41*<E>*!=8#E>R)&6I/,D\_G9._3ZF(@[G;]XW6KP4L\.<+&GYISB(
M\\S/?.] COA2BB=Z^T8Z08GO=>I_D"LI)5QE(F/L:<GUK[>_<$&KSHM,I<*O
M[5C4>KRU7Y*\H[D)84<(>X*,_14AZ@C1.R'^DA!WA'ALA*0C)&,CH(Z #$+0
M;I;>_146>#YE].:Q]@ U6)U3.$&ROGMEU.74WV0!N+1>YR@-I\%5.>HPBQ83
M#C!Y]A&RLB&P1P0R@3Z+T)7%(K3H1@Y+&Y'G1@YWG:SO.]G8$)1&;BF1<T,C
M[2 :.$AS-S]V\F/-CX<[B<S=;C%(8^I6:08,K0Y,@MR)),Y$$BN1* 1N!\CI
M (W>B=3)3ZT$4!H;1S.U5$(80>/LC &M6E RW*\P-D#K.Z /HC*GJ.Q^>1>9
M%06"R-!D8W(#LK(A(3#_$8Y06>C6DSOUY(XB)8:>W)&(6<FE#8(9,B79H!@D
M1KBU#8I0'+M%0>"^%8%=I@B8UR*PSE44 :.82Q<*9*EY?]HH%)NW[-J% BC]
M1-HG%SYT5 R9TER@U%0V K0: UJ/ 6WN@%KMP>#=JP@[Z:Z%>WMZJ86ZBP;6
MOC-Z#-6[:=@7<+*$#OL*3M9MW_/NOFW#?F)V*FKN[:B0K[5^4X^4"B)S!P_R
M-)YEY]<O2G(4:IK*.6O;GW8A:-.U=D'?7\[_ U!+ P04    "  CB@9/N?"3
M,  #  #/#   &0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R55V%OFS 0
M_2N('Q#P&0BIDDA-HVF3-JG:M.TS39P$%3##3M+]^QGC4H+/'?T2L//NGM_A
M9X[EE3?/XL28]%[*HA(K_R1E?1<$8G=B929FO&:5^N? FS*3:M@< U$W+-OK
MH+((( R3H,SRRE\O]=QCLU[RLRSRBCTVGCB79=;\W;""7U<^\5\GON?'DVPG
M@O6RSH[L!Y,_Z\=&C8(^RSXO625R7GD-.ZS\>W*WI6$;H!&_<G85@WNOE?+$
M^7,[^+)?^6&[(E:PG6Q39.IR80^L*-I,:AU_3%*_YVP#A_>OV3]I\4K,4R;8
M R]^YWMY6OFI[^W9(3L7\CN_?F9&4.Q[1OU7=F&%@K<K41P[7@C]Z^W.0O+2
M9%%+*;.7[II7^GKM_IDG)@P/ !, ?8#B?B^ F@#Z%A"]&Q"9@&@4$'12=&VV
MF<S6RX9?O:9[O'76[B)R%ZGJ[]I)76S]GRJ/4+.7=3)/E\&E360PFPX# PSI
M$8'*WE, 1K$!*QQN"1YL!$WI+69K8V*:XLN@J%*J$T0W2A=X@@A-$.D$=)@@
M#?$$,9H@ME>0DE&M.TRB,557:\ Y$I0C03A&Y=YTF'C $>$4<Y1BCE!0/$&*
M)DBG%W*!)EA,$+FP1#IV"PEQ8X0(B:-.Q.$M,ETH0;US3V""5 ,::DT<++@U
MB.T-2AW;CN#F(!]P!\'M06Q_4%B,C@IB&R1RT> .(;9%HM"U-W 'D/D'Q.(>
M(.G_Q6X,Z.;!NFAPIQ#;*C2USG?;*S&-'4<\[A:PW4+3L1P#NCG<8H<>P"T%
MQ.99A&,>#.1Z9>&^ ]MWE#K<#[BI@$[?)(";"J()F\2 IC@"<.,!]F)R/7_<
M5)!\0"QN*K#?*Y;8K0$1&*@-9P[W FX]L*V7I(X#$W!;P6*Z7(H[AB*.L9ZM
M =W(!9B--V(PZ/9*UAQU)RV\'3]7NHT?S/;=^CWH;O$-WK7ZW[+FF%?">^)2
M]9RZ,SQP+IE:33A3^^2DOB[Z0<$.LKV=J_NF:[&[@>2U^7P(^F^8]3]02P,$
M%     @ (XH&3\:*"=4_!0  %1T  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C4N>&ULE5G;<J,X$/T5ES]@0#<0+L=5N4P2DFQ5:K9V]YG$2NP:,!X@\<S?
M+Q?% 76W R^Q44YWJULZIX6U/.3%SW)C3#7[G:6[\FR^J:K]PO/*YXW)DO);
MOC>[^C\O>9$E5?U8O'KEOC#)NC7*4H_[?N!ER78W7RW;L<=BM<S?JG2[,X_%
MK'S+LJ3X<V'2_' V9_./@1_;UTW5#'BKY3YY-7^;ZI_]8U$_>4<OZVUF=N4V
MW\T*\W(V/V>+!R4:@Q;Q[]8<RM[W69/*4Y[_;![B]=G<;V9D4O-<-2Z2^N/=
M7)HT;3S5\_AEG<Z/,1O#_O</[]=M\G4R3TEI+O/TO^VZVIS-]7RV-B_)6UK]
MR ^WQB:DYC.;_8-Y-VD-;V92QWC.T[+].WM^*ZL\LU[JJ63)[^YSNVL_#];_
MAQENP*T!/QIP=M) 6 ,QUD!: SG60%D#-=8@L ;!IT%TTB"T!N'8"-H:Z+$&
MD36(C@;B])28_[%R_M@8[+C8GZLM^&F3C^5F[GI[W<9J=^I54B6K99$?9D5'
MMGW2<)HM:JO:>3/:[OWVG_5N+>O1]U6@PZ7WWGBRF(L.PWL8Q8(AY@9B(CV$
MQ!#"AHA[B)#R<S)>G<DQ'8ZF<\&!AT [\[C$,-$0<X5@(G^(^8YAG(RN,0QW
M2@<Q(I1#S"WB1SBQ8BR6&&+N1OBYQ_PX\WE YLP4OE("WWBB]2#Z'J3 /4C<
M@VP]R,$\E5/;#A.TF%VWYY3VZR[E+.8M O25] $P'NOQ;JS'>P3(=,0 \ $!
M\DCH/G!0-X7732%U<^@<=QC5#X7'"/ 8 8C!N)/.30!B:"7# *X-! ::A<C:
M!+! 0BL!D7?0)>.2*4;6,L3S#)%:.O(9AR 6UX&$<T)P2@?DC#0^(PTK[[N*
MHY'**XZP @+K[B %K#P$,E%O806S1)!<ZB%RD&>$YQDA>;H[+!J[PR"0V&$0
M2.TP!'EZAS4'!K1#^\@>TX0/JLNS\6K+\-9ZSOC7>_W:@OH4;(M#9TVT!R:^
M7M\+"^I'XVZTKN<C2(8BKQ!DJ!#@]S$NAZD2?8QAC2PB?!":SM2$!28TFT'1
M#MVLKQFBG$)AE8P1J'9+.9P8(;(,JFSH$_V($;+(](0"$9+#H.8@!8H@ SA1
M(*@1$#H\]1(:P:%&A#W5'_H@-()/T A.: 2'&A'ZSADTMJ!^VJYXGH0,9T+H
M!X?Z$?J2\$$0D\L)%2&(R>%I"ZD(/&Z!BIR"#&="T)MC]";.[)Q@(@\G5(1@
M(H<G%,"BF"/'!"E.4H,@+<=(&^ ^!$$OX8]/6Q#T$FQ$VA8T/ /R4VD+@HD"
M8R+Q+BVH5[0)[VB"X)" S0V^"5C0(.WVF 8.:AC2%YBX(DC9O7ZYU$*0(CK5
MIP3!=8%QG3BI"8*E(IA0<X*E O9+I.;P=4.%&JTY1$H4&5MDO_=%+FEMS:%/
M+8-3-2?41&!J0AR>!"$1(IKP6P0A$1+IP,P]&UC08*<180@5D8B*,/<''(FH
M"!&&4 ^)J >C?!#J(:?\PD/]Q /5 Z0;2T03B# $<25"7$9-E2"NG$!<21!7
M(@==)MUT,1#1QR7!&HFPAA%-41*LD1-8HPC6*(PU;L((2"DB847P1F&\(=JA
M(DBA^(2$"5(H[%CJ' =O%/5FZ0CS2%P\$G?W-:[+T>O=+F2F>&WOT<K9<_ZV
MJYK<>J/'N[KS]D+#&;]@BVN&C-^PQ2TV'K/%77?+\1FVNS#\*RE>M[MR]I17
M59ZU%QHO>5Z9.BW_6\WNC4G6QX?4O%3-U[#^7G07==U#E>_M):1WO E=_0]0
M2P,$%     @ (XH&3UA/14\Z @  C 8  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C8N>&ULA55=CYLP$/PKB/<>8#X3 =*%JFJE5HJNNO;9(9N SF!J.^'Z
M[VL;PA'P75^PO<S,SBZPI#UE+[P"$-9K0UJ>V940W=9Q>%E!@_D#[:"5=TZ4
M-5C((SL[O&. CYK4$ >Y;N0TN&[M/-6Q/<M3>A&D;F'/+'YI&LS^[H#0/K,]
M^Q9XJL^54 $G3SM\AI\@GKL]DR=G4CG6#;2\IJW%X)39C]ZV2!1> W[5T//9
MWE*5'"A]48=OQ\QVE2$@4 JE@.5RA0((44+2QI]1TYY2*N)\?U/_HFN7M1PP
MAX*2W_515)F=V-813OA"Q!/MO\)83VA;8_'?X0I$PI43F:.DA.NK55ZXH,VH
M(JTT^'58ZU:O_:A_HYD):"2@B2!S?T3P1X+_1@AT\8,S7>IG+'">,MI;;'A8
M'5;OA+?U93-+%=2]T_=DM5Q&KWGL):ES54(C9C=@T SC30A'JD\ID"G%#JWH
MZ#Y!L49L-N8,OK$(7_/]NR+>$0B, H$6".8"R%UT8<!$&M,.74 ;?]&KPH#R
MDLT[_0J-9L*5F<!?FADPX2P-2J)@X<4 "I/(;"4R6HD,??$65J)5EH79XB/$
MG8G8:")>F?"#:&$B_J^)->*3O_%CLY'$:"0Q=&/Q*N^2]?,/$W?YPAM0;A@L
MN^+,/N(&V%G/.VZ5]-(*];G,HM-(?41J""SB.SEJA\GX)C/,Z1^8G>N66P<J
MY(C1@^!$J0!ITGV0S:KDKV$Z$#@)M8WEG@T#<C@(VHVSWYE^0/D_4$L#!!0
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MC6DT!H6).ZX:@/)2?^1X Z#<,'!'M0-0*$D1;"P C0438['_1" $!<+YI8U
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MA.<$(;*RX6(H&U')0"?,(<"(62NCPT0MIFPQ$>,6:.F"&$NH)=<%81(QNX
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M](-<;%7SRO5[U1WWNX&2!W.5"?K[U/P_4$L#!!0    ( ".*!D])U[QJ\@$
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MS%Z&AG,%VC)XT$6W^K5;%PP:9::IGHOYSL\+Q<?E.4/KFUK^!5!+ P04
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M,=RTAHGB_7B+C*:K[/(O4$L#!!0    ( ".*!D]FW"%&[;8  -/N @ 4
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M+JM6&:C9F^CLPX_SB^$LCC[\-!^,)X/9_)S1#50G]E'@.O4H<>& -(!=F[[
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MA&?QC[PJ-PG*O28?^1CTDE6Q)?;F'5=5]HEQRXA:\$3(+R4":;FO)(5.PV=
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MG\+I(Q@\H ;U-^K"H_@PN>XWEYKB0EQ!I;;0E@,[X7%]@VTUD?#WN-A^L)3
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M/YW]TS=KTXDQ5X 'D\"&!H= H5%6JS+%0PK2';6GAFT11=BR]D*!,+Q"]ZV
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MXJP,LR*I7DZ%3:A'5NFZ6[KN)W"CT'$CCP:#\2KJ=V$<8A@N;Y^;2=F$Q:U
M=RT*)X!GOQ'5+ZG83YVX2NM!VA@'P>RYR;)65V\'<;VF'57IU]@P 6<0<7^#
MY]!:L*;/LE/=5)<9]Q@7G;J5 #=MPF2M6^TVL)TA7"+RAR5A-06)VU)XJQD)
M;R +. AC?2^TD/DF(N@J_Z1=6SUY7.U=H*.)E\Z))[""KKV)A6-:D]Q%*#!L
M]T"["8C/)Z;D)W:>0W,8"1QO/[QFL00-YAPF_#I?]G\#./8,?GMV3M($O$7!
MP[%TB9*!I2\U.]U!\]]BQ"<.'4LETMS44:'T8\?-W1"^E%>#O*9T_U;,,F@(
M6%%,\TLU() SD"ANTI4D$DAVL\0%ASCFB\SK1!P";5#%5EQ/6B64L&1R[(,*
MLEV(+Z95>[T^%&/MQ]8%?&4U]<7>E?_^W(#N[M#W?>X*K=Z)W>CYH#]L!%UT
MJ9MG<@O.Q=,34^D5DW#2;NIH*=??T@6C"5)JW#(QZVM3+FHA)UK"D MJM1Q3
M3C>'S,3*BZ6HK-]&FZ2F(; J#1DRERC34MK*3=\YBLAR4P-?F\_4CT(!6\UZ
M[>)T%G3EL5-J9;0O$IGD)4'--79-6"5/KOT$X1N1+"?2*GX>:FWB%7Y#UAO5
MSU9UJ"=!%S]@J5SPRYUBLGK(*,F -VRXXA&!HEZ7F5L;AZ-+43S>,N9$4^VA
M6^7D/1RUYXML^VX'*GWSL*8I HDZV YDYWUMFR1/?/-*U_-30UJP6@GW0BA-
MX+PMK%AQS]NE+U5!Y-%6R\9"R^)/LIW0 'IHYS<UO7>M-]*#1.ZLZSY=ZV]A
M7O5!:%X' 95^668W2(-NBH=&&DA+]Z<.Z=3)::ZK%>M,MG"4W09'<R" <%%\
MCEW-GYJ=GNK6+-;[_RVX7+:+M/W\MO7J/H]&HWD\F<SAD\:$M7WWLHML/8\F
M\7!T8?[UPX21["BF4 4V,G)QBG%@=HTO9H/6]_4W5\"^WK.$A:/GT7@1CP;A
M&(VOKGSCP=9A>HT&>*:'H.E_!U": Y0&74O67X_/AQR+ _YLU\?<]BY^'DT7
M\:)S+OFQB3!M"'(B]3U;,R\Z#["(J5B3NLG3H_#I0#L(GQR?=V(D[&:P6-0W
M&'YU&DJ-X\5PT@$S_NTX2LWC>1VEZE]]192:SN/!I!.EY->OA5+CQFTQ$.<?
MWQ6M\3$:XB#RBK&M "JI::79/,@:U3PQ=@QCY27,8UWIVKK@A0R!BQ3M-QOD
MB%@4H17;FJYZU05[\$4/81@\OOLB.GWI2@?^6&*/CI^]U$MRUH^4G2+%"Z_0
MY%H2T]DFJ 8]C^:#>+@@3^-P%IP2_# >#.&5<DN:.Y<]-0L&DAR/IJ-H,IM$
M9Z!6G=,W\\&,XZUZ-\GR%Q2,_1M ^L?P\'SFIB%F,'!&YM%H!M1F")]F4UP-
M#^N91A,<?OOD1VV' 5M_CT$"QIQ-D3%-QC0US8Q?7EP<@ *L> P/Z(9XQ?CE
MXL)M"TD,[4=&YJ&%\%R>=NXU(SL5W_:KT*QBH_-0QQ;2R<CJ60ML=SG%+%.T
MR'JH"FIOJ:YFHL:B2-''9%FVLB7W>Y-&*RI?!TW2^O:T[J0[J&L#RN*/% ]-
M&HJ:C7MOR_4[PV%4?T/N9'*+*Y'$1&WJM[HV3CF+,):)!&V[G6]E*ZZ/*5W\
M+JK!I*9VC$)@:WT=#Y,3<;<\I)+$E!]$CWH[@S5W[$TX=OV.JK.(AN'KOK0*
MES7G5RTTPBAVAQ?D%^#G._WMC@7S??RY 5Q#)+[\QQ:*TL;\3OO436^$TL[C
MV6+B'@^IC_S8187K+QW[5ZF8$F,9OGT#M8?^T9"Y>=?K"-U\XK\84@MC!+7I
M8MR)!.:1 Z@\1V2=Q*/Q(#H;X^<!<,2Y\M!)/,:<;,6^!8\YBT<CXJ)C_IM?
M\5P562^\WZX J)4^;"=P&@/>L'&[F[BA$YVCR^%P)(;B+9;+JGW7+H2-2>PY
M?O]17KL81=.+>#KLON.C03P;7T0L33$(NU2BX6P8#\<CE+D0=-.6K?^*G8G\
M=,K.1&@*R<[)BER'753JX*/-R\K:KDZ<2#;<500?#M-[B1"19Z2L9_[J -;6
M>X7]>TIN*C[N#[Z!.?.,2]"G59B5,@V%" E-?CZ<#D(?" VS-.,&0Z(?1L:4
MVGPCKJ@C<?-V05@*7G-0L..UN@TS[P.JTDW6\^UC3;T2P L3T@I_89-!S*'$
MT"5;3"Q\B1!H%MHAM=#0^JFF(I$IUK=YP6(/;!H*XS,9;+5]H=D4"SLM.>9D
MQPF/RS1=A0T4_?AA@:/Z3&3!=.VYLVJYIQ8M6<X5]8>#+L-^8V5J!N=.=5X.
MA!?#YJY8XQ&9P.V:FD*R);CFVVTS))),*V9X\IN8OQ\*],PZ>&9U2[/Q<[>#
ME8TLO'.QOJ,WBZLJ4H4MN!BA/[[1E?HXC$ZEP>0C&<YF_9'WDN1X:R:S_LPX
M=GQ3R_53JT?4M"1H<^:$U0;YNG=E7,3>E>I]K'&[?]5U[JA,63/IJ$E'QR3J
MR;@;V:&8K:Z2K4F!_5CNJUUKO4+T 6:[O61.'D'B<^O@M0=UDRZ3O4_VRS;H
MNY3*X\;A2SPQVZEB5Z7MX5(=1Z!8=Q@ 72M4?Y1@I;9D\JX+Z=-R:ML5+K.W
M0=I$77"SZI?^,1M>/=]4&EA>ZN)C^ BW3UUSHGB2IP(@C#JI2Y?G[/X4M=;E
M 1O<QE=XL^RC5O;O/DL??":/EO<WAD)CNN. >!2.[V#9=PCF3?*)(B%]],#S
MF65+KNIE^T3& DF'!P=F)]P5=^SU$7>[^\FEO'A+&WO5**&2,V0TEDK=3@_%
M?LD]-$_9Q70\-=L(V1*YLKRC!=82/9_4F'$K"/VQ8.:6%]%)U\?>>NB-SC/T
M0B7.!H*5T-F;=VLP!RG775*NUM*7.>ASZ"N+&6!ZI4@.8]7%F%:'4;E!@9'6
M>B+.9J+GXX4AO3=//K\H<6'*J:G3YDHM\**"2&9IR>MFX.*17-1,1<0?(@E
M*K"$$%,;\J[2CC@U! 41[8/B3B*X#W6&Z>>TYXGE&M;4L-*%7&E+5RV=L 3$
M)PY1M5N+8N!$%_V)Q9@3((^ #IL1.M&RM3>HVL!]2.-'2M[K\EI@FON'ZMEY
M&.5O9G2%LEK"Z@^VEVLKRHMSA3,1@5[U=D5/2#7)C;[,@2CJKB6?*=[FD=@'
M=E1A=237<_#7M,-C,^5.EX_VRZYKU-R?D:B2KLW!5?'XC</\L :=K7>]!):
MP):"11*,1G4J-#7IL#\&%^ 7N?K5L$TD5J9DX\/!2)=&4D\7X3G%0955K;2
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MY])<,G%#WW/B8O&-EP2XQ&#Q%=#3A!?H03+7D7.DJW'@!*D%L#VO4.AUJ:"
MW;(D8.(I!["8$,).JE(M[X'"4XEE [1V+&;Q;YT^)-1DUTV#\@]9X67ISGLJ
M_<5R7AC:T#C\8^F*2E)?RXI2&1Q%:5"Q^)2-G$ >=W6A+8[N/X^$*\FN5R)F
MV@K?%0W:VH]^WI*!1\^_)I(AT\=JRB2></@O_GY84&J_.RSW.D% 3&EKK*UL
MO .-K&GVS&]]#I/(^"NLN)Q1YE_L7W1H+'H)!8SD9,SQL#B\^C8!C> 6BC#U
M*]-=AI_E6A)-UD^:XH]; -45%/+Y9#'_#/?(,<+3N@;3SM?GFDG1;96:FL2\
M;FIZ/IWUQQ.3"WB2-Z>N,2*GVZ)^L1.M$>]JNND GI,^G&2O!@16*&I?A^B+
M]T9&]VT ,!V;&0NY3KV*U0(UN%0^0_TDB:"!ORZ,PXD!!SGH[IY[)(4=;UOX
MN4106?D"-"KI)OR94D9,X.@6+XRWF(4,GMS%R,0!/SU,XE;"7SP?UM-RQK$V
M;B%MX0U=9WAYN60P,"SR\X@2XPBJAV3KT&H@'*&R3;*5U\RP/A;6S.+B1V[O
M-7Y#GB^@^+^0;6+/W3MD?ZMN4J'7%,2!7.+N:B8*3D7U9@K!;LHBV&5EVG6+
MI$,T4B!-4O+5Y_/"K)]@(F$6H:^+!/6[ GF-BEJXM02E%J0?5&9)O=XMXI03
MGD11\I$.W6)6:]*:C[GR+++SA)D&$,2"W1#PG->Q3A[0FRAC=G);^_Y714:G
M.7\Y/C8/QJ[6%Z8^ 'LM&8$E[8&441@["T1LB+U-]NM=(_:S Z]].!UA-<E@
M+OZA,>B9?;RE^W:2K?=L22,S'1$/2>W%J%5O*BNM-;*+/5/%ZCT[:D7I/Q?A
MT!;884MCW#&**-ZH^@OY"LT:L3KE#<)ZQ7#Z#5Z2+DRQR2RMS9-:9W3"?>=B
M8[P<\?'G-%P"KY$DZY!BH%LY,W=4-!2I(]*-ZT:3 EEBO8[A\)=K%"K:[PZ"
MRQ1J:KD*1AK,Z1H?NF2U\Z:0,@SPI*2<!E[>)/DOY7Z[6Y)_O2K6#U0-C*AN
M4=XEN1AK8U,N,7#!E+6^]CZ@(/[B_1[ :)3:DSW>V1W3?.U8T]@V2?]<IT\.
MP%F=86K0IDK9&(<X> 0]]2S4IU*;V0H(H8CH>B]U"]24V7.XV1C>:B'X[?Z?
MMEYBNE9IQV!"Y340W#<D(HR1M5H'A/--=0N5%C.TGUK7#21/ZI&^:JT=F@[N
M$[-1M"@_62O9_N!L,D&4LM^]'XN(^*I@64V;YV)&"-DJ28?V.[E-R6I\<)F-
M\W-9$KHHJ]NQH$4>SR":-30'-\L7M0'#F9N=6Z";:!'B/6+;#\V_L&IE%_EN
MFY6<.*0KA/"(.2)7I#LIX4%.3S5A4]RV]U!2D(T0A$98084D+.I1AF/@P:SO
M3+93/P0G</;$0,75J I*1(+E*U]DLKK!AIQR5!H3?\NF0QHV*%/8,:-O9V+<
MO+70I99;@C6.Y[;.5\X&-#<<E3IPV?A(JWH4B4M^YZZ[3!WNDZ4+@:GJ*_G,
MRRX]#N6R:QA:1;TTI-6]9L5^<2=%$S6=E;Q>5.:X26&?"U@&6TIJA6B[,):R
M4[\RVHGL<=*:&JB2>'>_:Y'3A-2QON$.*=9U?[!:; Q.DM_*=83""J$>4@45
MFS.1>JRHY"EOS"W1W+?F\777DWS3<B2A,[69 _K>$22,%./<:O\)&\-B2^1&
M0$5T-HRGDTETCA_FDQE\,,]Z.@3 P#(&9["""RK3=#:>QH,IOHB%G^J4'F8>
MSN/)E(H\#KDB.;[_NE;5Z% S1X1BE@?<)7#"GJD75JHAGX:O/FB TM0Z+Y=/
MR/05,L)$2\[Z.^3L]G/9E+[#\V;U"+YQ7Q(R._)SI.\E8AP1F<;639S:,>+Z
M-<,HK\R6&VO"*K!#J8#+_X[BT<3_>UF+BF@)!0)9>AQ=C!$#HN%BU/Z**SX^
MB@?S"4RVF(VC"2#N-!K',\![#;O$A&7N0L-=JF?QY&)!_PYF\^AE!PH<8/K#
M8?1-[3_UH+M>=$90/V\I++[)3*$>UQ=@B?F,)P7TU8=8VB$^ZV%)=-5R 2ZF
MKVKQ'MRDC=:,OEPLA=$T>S$Z%XVT#[C=-]LT+%V_:G/ XANK0I4"3;!!:"):
M1X@RN84S?<:7_I2NUZ0K<9O6-U(7_^Q9^,.S<Q-SU!$<C'KR!C71#4B,2PPX
M)5S8YZNJBSOXP+PB7Q;KXNY)2E/ C>2&IRB^E,5=F6PXJ*;N<2/T9JDL7 W[
MV3E@NF6T&.4Y;(()TAT\QX&M8H3T1^2K_9K0KD9'4P!Q#8RLDF+#2>?O1Q.:
M[[4*0)2"QBBJJ<U*B!)3,2]5G]*RPR^O[A$073B(7$.TY/-D0RU"Q.=SI_XT
MY+<F"L4^2WA'SI6Z]586736P-W4S$BE9 ZX0A80OMT"*GU@%A=7UX)M;."6L
MTTC]*-+U+=NX8+SU.KDI1'N7H#XT8N88G^HLSW8]9<K6/62#B*3$CPJR/#P6
MY7KU"&\T;]EYT\/2!<\F%GS>N7'B1'ZW3GNK[ [V[>D&&BVH"G7!I3_=%51
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M45O#L1B_GY1R=6TUJZS9D135Q!2PDR;L5JI>BLSH(H-RRDDG=)/D0ZHU8'5
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MULADZPH*5=_(NGKT[.S#ZV<O@/MS%2)'%F]?GP0P-!ZYFT[@/')YM#"OKKK
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M)7CICBU9HEV J0?VY$;)^3EN1?AHV"!!.PTX*D9DK:20@.%:I-XJYKA>%W
M""S9'B6-#=*VM##'=P>0&O&1I"#QV;O1[G?J+49-6>[2#0TE1(I\J"U*X2[9
M<,)V_1QD7=T\L%^%PX'\70:2VD.6>VC@<'Y:L 9WD<FOH.GQ15BXX #O\O-^
M )?>CN/_/,>Y:O3ADT74N<J$M]4A2WBA8%^I&A9-)-<>(NMS[*Q[AP[:EN[C
MK:"KR)JL""H#DT6*B/W*+IBZ;&VQ!M986NUN+H&I%9CX (40WX2YH;"#9X46
M#,2YVR)'N ^;?7F3S4OKG7)I)VKF=$9C54<??"CU#8"E84S;;$77T)^%TV"T
M=]X&^+IJNV=7(0 4[H4VOS@[/ 8:KVBET/ 06T$&(2N<8.WBK 'I" TCVWL7
MAVDNN<T*A_,^A #1RI=7W286M. ">EO,7@U+W0^19EW!2 S-+M8DC$O)-"S]
M*&*;P/=4GL.@;&2]5YJ2Q+Q'[036=*_9#=&9R:L:+B]!3>+#.O-+%$NLHPZ(
M5Z)&' $A6:(^0U$^[&K,2;%P;(2OR$NRF]Y30K 56_;Z"DABRF\NH22I19"I
ME:%(*B8'60U0JJO,9.6M(G.PCG$K&\FZE8',W3 Y&C5JD=D3<";#T49>#$+)
MRY\E#/<;ZD1S$3C0V>9TH-HN%+IBU0%[TAR:%@93U:)"<)3:X5\T04W(*^SB
MHHNU(^$WM1,^>F8SQ:&NMDH;%X?VTOQWP46 YIZ9FC/H0(>?NQ*HB\W-I90#
MA@@I&Y6UE N2$YW<M70%<.!9H: '-X4404R,'@+<AC*S2!,Q<L9O5"S)%H+A
MM-F&0WO\!'PW-=N_<MI'Q\^WB)N!42T9CY>X0NG%8@6G. 8&(*I;9*7SNG6L
M6(\AFU,"E)YQ7"*-AQ4"+MD!1R5 7P%[MXM)=C<+J ) 46+R_!\R5I'1TQI$
MH5W7)/(.L<'Q-W;9G/>(K9E21KK(5D8S LY*";:EF0Q8^+<<+[:E5F@2UD(.
M/A'13L7[#XY46UMJWTP9,G9MK>).JI4@<-J@'0-'>S*/-:47XD=3: X%NW3%
M8+CWD-*ENQ=>00@5Q2)VIB-^]+77MP.\LLAK#AW= [8J,&P*X*PV5U>4*^?F
MJ$]_.&1%*%H%P5,*F*[S9&D:<JE"BN(]NS=$; %S)EOK&FW;>4&"N*>YB#='
M1^2[B/G8%F0E!Z!"6NDVL76_04C<F-NW("UG+KG%:+Y!7'H4' 23'NV5$KR'
M$KE@JKJQ5F^'Y/O-ZB7F#O_',Z2FXBY[YL X[1\VGXNE:IONZ!O;33<2%0&L
M(,16Y-#N *4DA,&H.KXM?U$@(V4%:-')0_M 5Q0$!]<#=\3(H&PJ+D[M-6P6
M9TO/+? @Q?=NVNT3V7MXEU 5-4H=&I$]/OM5C8_Z!S8>WKW(13]#='?3,X#*
ML.&;_;X&.<4(CZ]P ND,9^NY-?=C#6330'*ZXQ2!WV\N2["IF@O8>\'\].R%
MN!R5U,LQF<#2L:.M>7<U_Y9<WF,\&JSDUH*LEY24@C'8LI,4@)(M\?:"0[5#
M\=Z%M1-4@MFE?N^'%)9J0WP0PN>6I N8,T1%ZEP9#OQRXPK9KE0!,\A&-#,
M6&1@15Q)2L*Z</<+$OU\= ,[HJ7%HB(6_]N5D8I7&M;VW>9;!][D/3IZ]MNS
M=Y_/GKU0ZR"$H)=80J8\,=(E1$EP ZZ97B%TA-IY 0AJOLPQ=9.GZ!]:E%Y
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MD4#9 F*)%+/MW1KIS!R!V/?RS.(_5.&![G%:SY/!-.UW_3:"GTYK*I]*,YT
MNU#!/RKH0K-*$[-*W;HAR]/]_4'V-7E0-&"G!SO]/!E-TVEM7_PP))@8@6"Q
M6PH:1I(@]S7!\BX<I1^M8!D@@E53$5F:-I?@:F/PC-N=>[OOO[U;U[XY>%%+
MD68V72/952;H_]2.I ;IM#>L63-ZMI^D)NFD2E+5GYZ0I$:3M#NL)2E^^E0D
M-0A.BUIQ?-B@_L6OB]"6(*$-'?-#!\:D7F]FZ92W^;0] C]^"*<]L6@*ORT
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MC@%C8IQ9$(9/$=*O?9$5(;G\]M/<;GN]*9"L'S(NTUUK&FQJI(GF^MWN3.H
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M%.>#(CW(YH.,'E3/!]7TH/OYH'MZT,-\T ,]R*^!C&M^$L*:K[4'7'N^UQZ
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M$B3'*4B./R Y^ (E"(JH'(54CF(J1T&5HZC*45CE**YR%%@YBJP"15:!(JM
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M<F]P<R]A<' N>&UL4$L! A0#%     @ (HH&3P<DD37P    *P(  !$
M         ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ (HH&
M3YE<G",0!@  G"<  !,              ( !N (  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  BB@9/\/<J6_0"   \#0  &
M@ 'Y"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ (HH&
M3]XC<*SL 0  604  !@              ( !(PP  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( "**!D]%,OQY3P0  * 4   8
M      "  44.  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  BB@9/R:KNE/D!  ")!0  &               @ '*$@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ (HH&3\ON4Q:I!   ^14  !@
M             ( !^10  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( "**!D]O^#4,B0(  %T(   8              "  =@9  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  BB@9/S%#5TBP'  !G
M*@  &               @ &7'   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ (XH&3XOA)W\Z!0  I!H  !@              ( !^2,
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ".*!D\11]\!
ML0$  -(#   8              "  6DI  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  CB@9/T[3*J+,!  #2 P  &0
M@ %0*P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ".*
M!D]5X=3&M $  -(#   9              "  3HM  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ (XH&3T"@BXZU 0  T@,  !D
M         ( !)2\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  CB@9/RRWDM;4!  #2 P  &0              @ $1,0  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ".*!D]\_!\TM0$  - #
M   9              "  ?TR  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ (XH&3R?U%5&U 0  T@,  !D              ( !Z30
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  CB@9/YP?P
MJ[0!  #2 P  &0              @ '5-@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( ".*!D^#S)*@LP$  -(#   9
M  "  < X  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M(XH&3[%*YMZU 0  T@,  !D              ( !JCH  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  CB@9/ SS\3+<!  #2 P  &0
M            @ &6/   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( ".*!D]ACMEKLP$  -(#   9              "  80^  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ (XH&3]_QLTVU 0
MT@,  !D              ( !;D   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  CB@9/RK#L!;8!  #2 P  &0              @ %:
M0@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ".*!D^M
M(^8X* (   ,'   9              "  4=$  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ (XH&3XLKDO>W 0  T@,  !D
M     ( !ID8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ".*!D]RH+6<MP$  -(#   9              "
M 910  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ (XH&
M3^H)OH#" 0  -P0  !D              ( !@E(  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  CB@9/."]M*]L!   !!0  &0
M        @ %[5   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( ".*!D\OD:$\Q@$  #<$   9              "  8U6  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ (XH&3RY\9=^W 0  T@,
M !D              ( !BE@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  CB@9/+8/!(;<!  #2 P  &0              @ %X6@
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ".*!D\0XQ5D
M&@,  .4-   9              "  69<  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ (XH&3T.&>L[[ 0  =04  !D
M ( !MU\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  C
MB@9/2YFT08X"  "$"   &0              @ 'I80  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ".*!D\GF#^;XP$  (\%   9
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M970T,BYX;6Q02P$"% ,4    "  CB@9/YYO.9;(!  #3 P  &0
M    @ %'<0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M ".*!D_*4X$A'00  /P4   9              "  3!S  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ (XH&3[CT\[>Z P  3A,  !D
M             ( !A'<  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    "  CB@9/,#M:D0L#   4#0  &0              @ %U>P  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ".*!D^+"C[N_@(
M ,H,   9              "  ;=^  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ (XH&3X+#^6YZ P  $A(  !D              ( !
M[($  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  CB@9/
MXHO(?70"  #N"   &0              @ &=A0  >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ".*!D\_R?PYJ@<  &4S   9
M      "  4B(  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ (XH&3T/4/E5H P  SP\  !D              ( !*9   'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  CB@9/7VG32%T"  "R!P
M&0              @ '(DP  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( ".*!D\'^)]B0 (  ,$&   9              "  5R6  !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ (XH&3X'6M?,%
M @  ,@8  !D              ( !TY@  'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    "  CB@9/M_1E&G\"  #8!P  &0
M@ $/FP  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ".*
M!D_0- YE.@(  )4&   9              "  <6=  !X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ (XH&3^(H,*R(!   PA@  !D
M         ( !-J   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    "  CB@9/I?D7+)@#  #U#P  &0              @ 'UI   >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ".*!D_M^!2O< (  ,\'
M   9              "  <2H  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ (XH&3V+@=XM_ @  20@  !D              ( !:ZL
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  CB@9/?<>Q
MPP$$  !:%   &0              @ $AK@  >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( ".*!D]E='1R%0(  !<&   9
M  "  5FR  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M(XH&3]P(D)/$ @  :PH  !D              ( !I;0  'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    "  CB@9/N?"3,  #  #/#   &0
M            @ &@MP  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( ".*!D_&B@G5/P4  !4=   9              "  =>Z  !X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ (XH&3UA/14\Z @
MC 8  !D              ( !3<   'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    "  CB@9/QY9(@U\"   #"   &0              @ &^
MP@  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ".*!D^S
M0P[940(  $0(   9              "  53%  !X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ (XH&3^^.N)\Y P  6PT  !D
M     ( !W,<  'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
M"  CB@9/2=>\:O(!  !?!0  &0              @ %,RP  >&PO=V]R:W-H
M965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ".*!D]W#*?LL (  -8*   9
M              "  77-  !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L!
M A0#%     @ (XH&3V;<(4;MM@  T^X" !0              ( !7-   'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ (XH&3YQFVAEE @  1 T
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;72YX;6Q02P4&     %  4 #B%0  :)0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>283</ContextCount>
  <ElementCount>430</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover DEI</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CoverDei</Role>
      <ShortName>Cover DEI</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Company</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair value of financial instruments and marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities</Role>
      <ShortName>Fair value of financial instruments and marketable securities</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Accounts payable and accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts payable and accrued expenses</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/NetLossPerShare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stock award plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockAwardPlan</Role>
      <ShortName>Stock award plan</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ptcbio.com/role/Notes</Role>
      <ShortName>- (Notes)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Intangible assets and goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible assets and goodwill</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of significant accounting policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies - (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of significant accounting policies - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Leases - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesTables</Role>
      <ShortName>Leases - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair value of financial instruments and marketable securities - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables</Role>
      <ShortName>Fair value of financial instruments and marketable securities - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Accounts payable and accrued expenses - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts payable and accrued expenses - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Capitalization - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CapitalizationTables</Role>
      <ShortName>Capitalization - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Net loss per share - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net loss per share - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stock award plan - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockAwardPlanTables</Role>
      <ShortName>Stock award plan - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Debt - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DebtTables</Role>
      <ShortName>Debt - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Revenue recognition - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue recognition - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Intangible assets and goodwill - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible assets and goodwill - (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - The Company - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CompanyNarrativeDetails</Role>
      <ShortName>The Company - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of significant accounting policies - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of significant accounting policies - Inventory (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of significant accounting policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of significant accounting policies - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Leases - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease costs (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Leases - Lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/LeasesLeasePaymentsDetails</Role>
      <ShortName>Leases - Lease payments (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Business Combination - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails</Role>
      <ShortName>Business Combination - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Business Combination - Consideration Transfered (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails</Role>
      <ShortName>Business Combination - Consideration Transfered (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Business Combination - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails</Role>
      <ShortName>Business Combination - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair value of financial instruments and marketable securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Hierarchy (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Fair value of financial instruments and marketable securities - Available for sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Available for sale (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2405406 - Disclosure - Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2405407 - Disclosure - Fair value of financial instruments and marketable securities - Marketable securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Marketable securities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2405408 - Disclosure - Fair value of financial instruments and marketable securities - Warrants and SARs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails</Role>
      <ShortName>Fair value of financial instruments and marketable securities - Warrants and SARs (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails</Role>
      <ShortName>Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Accounts payable and accrued expenses - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails</Role>
      <ShortName>Accounts payable and accrued expenses - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Capitalization - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CapitalizationNarrativeDetails</Role>
      <ShortName>Capitalization - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Capitalization - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CapitalizationWarrantsDetails</Role>
      <ShortName>Capitalization - Warrants (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Net loss per share - Numerator and Denominator (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails</Role>
      <ShortName>Net loss per share - Numerator and Denominator (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Net loss per share - Antidilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails</Role>
      <ShortName>Net loss per share - Antidilutive (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stock award plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails</Role>
      <ShortName>Stock award plan - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stock award plan - Share Base Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails</Role>
      <ShortName>Stock award plan - Share Base Compensation (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Stock award plan - Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails</Role>
      <ShortName>Stock award plan - Restricted Stock (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Stock award plan - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock award plan - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Debt - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ptcbio.com/role/DebtConvertibleNotesDetails</Role>
      <ShortName>Debt - Convertible Notes (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Commitments and contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Revenue recognition - Contract Liabilities, Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails</Role>
      <ShortName>Revenue recognition - Contract Liabilities, Rollforward (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Revenue recognition - Recognized revenue in the period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails</Role>
      <ShortName>Revenue recognition - Recognized revenue in the period (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2415405 - Disclosure - Revenue recognition - Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails</Role>
      <ShortName>Revenue recognition - Performance Obligations (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Intangible assets and goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails</Role>
      <ShortName>Intangible assets and goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails</Role>
      <ShortName>Intangible assets and goodwill - Future Amortization (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ptct0630201910-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2417401 - Disclosure - Subsequent events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent events - Narrative (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ptct0630201910-q.htm">ptct0630201910-q.htm</File>
    <File>ex101employmentagreeme.htm</File>
    <File>exhibit102utteremploym.htm</File>
    <File>ptct-20190630.xsd</File>
    <File>ptct-20190630_cal.xml</File>
    <File>ptct-20190630_def.xml</File>
    <File>ptct-20190630_lab.xml</File>
    <File>ptct-20190630_pre.xml</File>
    <File>ptct06302019ex-311.htm</File>
    <File>ptct06302019ex-312.htm</File>
    <File>ptct06302019ex-321.htm</File>
    <File>ptct06302019ex-322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ptct0630201910-q.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "contextCount": 283,
   "dts": {
    "calculationLink": {
     "local": [
      "ptct-20190630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptct-20190630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ptct0630201910-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20190630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20190630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20190630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 590,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 76,
    "http://www.ptcbio.com/20190630": 13,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 94
   },
   "keyCustom": 53,
   "keyStandard": 377,
   "memberCustom": 31,
   "memberStandard": 42,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20190630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover",
     "role": "http://www.ptcbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Leases",
     "role": "http://www.ptcbio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Fair value of financial instruments and marketable securities",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities",
     "shortName": "Fair value of financial instruments and marketable securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items",
     "role": "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems",
     "shortName": "Other comprehensive income (loss) and accumulated other comprehensive items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Accounts payable and accrued expenses",
     "role": "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "Accounts payable and accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Capitalization",
     "role": "http://www.ptcbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Net loss per share",
     "role": "http://www.ptcbio.com/role/NetLossPerShare",
     "shortName": "Net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Stock award plan",
     "role": "http://www.ptcbio.com/role/StockAwardPlan",
     "shortName": "Stock award plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Debt",
     "role": "http://www.ptcbio.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - - (Notes)",
     "role": "http://www.ptcbio.com/role/Notes",
     "shortName": "- (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": null,
     "groupType": "document",
     "isDefault": "false",
     "longName": "0001001 - Document - Cover DEI",
     "role": "http://www.ptcbio.com/role/CoverDei",
     "shortName": "Cover DEI",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - Revenue recognition",
     "role": "http://www.ptcbio.com/role/RevenueRecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Intangible assets and goodwill",
     "role": "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "Intangible assets and goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - Subsequent events",
     "role": "http://www.ptcbio.com/role/SubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of significant accounting policies - (Policies)",
     "role": "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of significant accounting policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of significant accounting policies - (Tables)",
     "role": "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of significant accounting policies - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Leases - (Tables)",
     "role": "http://www.ptcbio.com/role/LeasesTables",
     "shortName": "Leases - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair value of financial instruments and marketable securities - (Tables)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables",
     "shortName": "Fair value of financial instruments and marketable securities - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)",
     "role": "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables",
     "shortName": "Other comprehensive income (loss) and accumulated other comprehensive items - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Accounts payable and accrued expenses - (Tables)",
     "role": "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "Accounts payable and accrued expenses - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Capitalization - (Tables)",
     "role": "http://www.ptcbio.com/role/CapitalizationTables",
     "shortName": "Capitalization - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Balance Sheets (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Net loss per share - (Tables)",
     "role": "http://www.ptcbio.com/role/NetLossPerShareTables",
     "shortName": "Net loss per share - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Stock award plan - (Tables)",
     "role": "http://www.ptcbio.com/role/StockAwardPlanTables",
     "shortName": "Stock award plan - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Debt - (Tables)",
     "role": "http://www.ptcbio.com/role/DebtTables",
     "shortName": "Debt - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315301 - Disclosure - Revenue recognition - (Tables)",
     "role": "http://www.ptcbio.com/role/RevenueRecognitionTables",
     "shortName": "Revenue recognition - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316301 - Disclosure - Intangible assets and goodwill - (Tables)",
     "role": "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "Intangible assets and goodwill - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptct:NumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - The Company - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/CompanyNarrativeDetails",
     "shortName": "The Company - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptct:NumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of significant accounting policies - Inventory (Details)",
     "role": "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails",
     "shortName": "Summary of significant accounting policies - Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of significant accounting policies - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of significant accounting policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptct:NumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "operating_lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptct:NumberOfOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "operating_lease",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Leases - Lease costs (Details)",
     "role": "http://www.ptcbio.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Leases - Lease payments (Details)",
     "role": "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails",
     "shortName": "Leases - Lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Business Combination - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
     "shortName": "Business Combination - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptct:BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Business Combination - Consideration Transfered (Details)",
     "role": "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
     "shortName": "Business Combination - Consideration Transfered (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Business Combination - Assets and Liabilities (Details)",
     "role": "http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails",
     "shortName": "Business Combination - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "I2019Q1SD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Fair value of financial instruments and marketable securities - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "I2019Q2May_invest_InvestmentAxis_us-gaap_CommonStockMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Fair value of financial instruments and marketable securities - Hierarchy (Details)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Fair value of financial instruments and marketable securities - Available for sale (Details)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Available for sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405405 - Disclosure - Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405406 - Disclosure - Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Unrealized Loss Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405407 - Disclosure - Fair value of financial instruments and marketable securities - Marketable securities (Details)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Marketable securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Operations (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "Consolidated Statements of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405408 - Disclosure - Fair value of financial instruments and marketable securities - Warrants and SARs (Details)",
     "role": "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
     "shortName": "Fair value of financial instruments and marketable securities - Warrants and SARs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2_us-gaap_FairValueByLiabilityClassAxis_us-gaap_StockAppreciationRightsSARSMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails",
     "shortName": "Other comprehensive income (loss) and accumulated other comprehensive items - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Accounts payable and accrued expenses - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails",
     "shortName": "Accounts payable and accrued expenses - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "D2019Q1Jan",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Capitalization - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
     "shortName": "Capitalization - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "D2019Q1Jan",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Capitalization - Warrants (Details)",
     "role": "http://www.ptcbio.com/role/CapitalizationWarrantsDetails",
     "shortName": "Capitalization - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Net loss per share - Numerator and Denominator (Details)",
     "role": "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails",
     "shortName": "Net loss per share - Numerator and Denominator (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Net loss per share - Antidilutive (Details)",
     "role": "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails",
     "shortName": "Net loss per share - Antidilutive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Stock award plan - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
     "shortName": "Stock award plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Stock award plan - Share Base Compensation (Details)",
     "role": "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails",
     "shortName": "Stock award plan - Share Base Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Stock award plan - Restricted Stock (Details)",
     "role": "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails",
     "shortName": "Stock award plan - Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Stock award plan - Share-based compensation expense (Details)",
     "role": "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails",
     "shortName": "Stock award plan - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "D2015Q3Aug1-Aug31_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Debt - Convertible Notes (Details)",
     "role": "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
     "shortName": "Debt - Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD_srt_CounterpartyNameAxis_ptct_AkceaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ptct:UpfrontLicensingFee",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413401 - Disclosure - Commitments and contingencies - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2_srt_CounterpartyNameAxis_ptct_AkceaMember_srt_RangeAxis_srt_MaximumMember",
      "decimals": "-5",
      "lang": null,
      "name": "ptct:MilestonePotentialAchievementsRegulatoryApproval",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - Revenue recognition - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415403 - Disclosure - Revenue recognition - Contract Liabilities, Rollforward (Details)",
     "role": "http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails",
     "shortName": "Revenue recognition - Contract Liabilities, Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415404 - Disclosure - Revenue recognition - Recognized revenue in the period (Details)",
     "role": "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails",
     "shortName": "Revenue recognition - Recognized revenue in the period (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptct:ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415405 - Disclosure - Revenue recognition - Performance Obligations (Details)",
     "role": "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails",
     "shortName": "Revenue recognition - Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "I2011Q4Nov30_srt_ProductOrServiceAxis_ptct_LicensingAndCollaborationAgreementMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2018-10-01",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Intangible assets and goodwill - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails",
     "shortName": "Intangible assets and goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IndefinitelivedIntangibleAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416403 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)",
     "role": "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails",
     "shortName": "Intangible assets and goodwill - Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417401 - Disclosure - Subsequent events - Narrative (Details)",
     "role": "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails",
     "shortName": "Subsequent events - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "I2019Q3Aug4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": "0",
      "lang": null,
      "name": "ptct:Feet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Feet",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - The Company",
     "role": "http://www.ptcbio.com/role/Company",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ptct0630201910-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverDei"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverDei"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverDei"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverDei"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverDei"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "invest_InvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentAxis",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "invest_InvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentDomain",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_AccruedConsultingAndContractedResearchCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.",
        "label": "Accrued Consulting and Contracted Research Current",
        "terseLabel": "Consulting and contracted research"
       }
      }
     },
     "localname": "AccruedConsultingAndContractedResearchCurrent",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Adjustments to Additional Paid In Capital, Receivable from Investor",
        "terseLabel": "Adjustments to Additional Paid In Capital, Receivable from Investor"
       }
      }
     },
     "localname": "AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AgilisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agilis [Member]",
        "label": "Agilis [Member]",
        "terseLabel": "Agilis"
       }
      }
     },
     "localname": "AgilisMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails",
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_AkceaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Akcea [Member]",
        "label": "Akcea [Member]",
        "terseLabel": "Akcea"
       }
      }
     },
     "localname": "AkceaMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_AlternativeInvestmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alternative Investment, Milestone",
        "label": "Alternative Investment, Milestone",
        "terseLabel": "Alternative Investment, Milestone"
       }
      }
     },
     "localname": "AlternativeInvestmentMilestone",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.",
        "label": "Available For Sale Securities Debt Maturities Over One Year Fair Value",
        "terseLabel": "Total Marketable securities, More Than 12 Months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period",
        "label": "Business Acquisition, Equity Interest Issued Or Issuable, Trading Day Period",
        "terseLabel": "Trading day period"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableTradingDayPeriod",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity",
        "label": "Business Acquisition, Numerator For Calculation Of Number Of Shares Of Equity Interests Issued To Acquire Entity",
        "terseLabel": "Numerator for calculation of number of shares of equity interests issued to acquire entity"
       }
      }
     },
     "localname": "BusinessAcquisitionNumeratorForCalculationOfNumberOfSharesOfEquityInterestsIssuedToAcquireEntity",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration, Liability, Deferred Consideration Payable",
        "label": "Business Combination, Consideration, Liability, Deferred Consideration Payable",
        "terseLabel": "Estimated fair value of deferred consideration payable",
        "verboseLabel": "Deferred consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationLiabilityDeferredConsiderationPayable",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration, Liability, Deferred Consideration Payable- Current",
        "label": "Business Combination, Consideration, Liability, Deferred Consideration Payable- Current",
        "terseLabel": "Deferred consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_CollaborationAndDiscoveryAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to early stage collaboration and discovery agreements.",
        "label": "Collaboration And Discovery Agreements [Member]",
        "terseLabel": "Collaboration And Discovery Agreements"
       }
      }
     },
     "localname": "CollaborationAndDiscoveryAgreementsMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of compounds included in preclinical development.",
        "label": "Collaborative Arrangements Number of Compounds in Preclinical Development",
        "terseLabel": "Number of compounds in preclinical development"
       }
      }
     },
     "localname": "CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_CollaborativeArrangementsNumberOfSignificantDeliverables": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of significant deliverables under a contractual agreement.",
        "label": "Collaborative Arrangements Number of Significant Deliverables",
        "terseLabel": "Number of significant deliverables"
       }
      }
     },
     "localname": "CollaborativeArrangementsNumberOfSignificantDeliverables",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the research period for applying discovery technology.",
        "label": "Collaborative Arrangements Research Period for Applying Discovery Technology",
        "terseLabel": "Collaborative arrangements research period for applying discovery technology"
       }
      }
     },
     "localname": "CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone",
        "label": "Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone",
        "terseLabel": "Milestone, potential achievements, net sales amount"
       }
      }
     },
     "localname": "ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount",
        "label": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount",
        "terseLabel": "Milestone, potential achievements, priority review voucher amount"
       }
      }
     },
     "localname": "ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage",
        "label": "Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage",
        "terseLabel": "Milestone, potential achievements, product sales"
       }
      }
     },
     "localname": "ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails": {
       "order": 1.0,
       "parentTag": "ptct_NetProductSales",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Liability, Amounts Recognized Beginning Of Measurement Period",
        "label": "Contract With Customer, Liability, Amounts Recognized Beginning Of Measurement Period",
        "terseLabel": "Amounts included in contract liabilities at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Liability, Increase from Cash Receipts",
        "label": "Contract With Customer, Liability, Increase From Cash Receipts",
        "terseLabel": "Additions",
        "verboseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the debt instrument principal and unpaid interest payable upon events of default.",
        "label": "Convertible Instruments Principal And Unpaid Interest Payable Upon Events Of Default",
        "terseLabel": "Convertible instruments principal and unpaid interest payable upon events of default"
       }
      }
     },
     "localname": "ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_ConvertibleSeniorNotes3.0PercentDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to 3.00% convertible senior notes due 2022.",
        "label": "Convertible Senior Notes3.0 Percent Due2022 [Member]",
        "terseLabel": "3.00% Convertible senior notes due 2022"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes3.0PercentDue2022Member",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_CoverpageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "cover page [Abstract]",
        "label": "cover page [Abstract]"
       }
      }
     },
     "localname": "CoverpageAbstract",
     "nsuri": "http://www.ptcbio.com/20190630",
     "xbrltype": "stringItemType"
    },
    "ptct_DebtInstrumentConversionPeriodOnOrAfterAugust202018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the debt instrument redemption period on or after August 20, 2018.",
        "label": "Debt Instrument Conversion Period On Or After August202018 [Member]",
        "terseLabel": "Redemption on or after August 20, 2018"
       }
      }
     },
     "localname": "DebtInstrumentConversionPeriodOnOrAfterAugust202018Member",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_DebtInstrumentConvertibleThresholdBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.",
        "label": "Debt Instrument Convertible Threshold Business Days",
        "terseLabel": "Business days, period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdBusinessDays",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.",
        "label": "Debt Instrument Convertible Threshold Consecutive Trading Day Period",
        "terseLabel": "Consecutive trading-day period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.",
        "label": "Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum",
        "terseLabel": "Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_DebtInstrumentFloorInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Floor Interest Rate",
        "label": "Debt Instrument, Floor Interest Rate",
        "terseLabel": "Debt instrument, floor interest rate"
       }
      }
     },
     "localname": "DebtInstrumentFloorInterestRate",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_DebtInstrumentInterestPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Payment Period",
        "label": "Debt Instrument, Interest Payment Period",
        "terseLabel": "Debt instrument, interest payment period"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentPeriod",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the denomination of the principal amount of debt that is used in conversion calculations.",
        "label": "Debt Instrument Principal Amount Denomination For Conversion Into Common Stock",
        "terseLabel": "Common stock per principal amount"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits and Other Assets Noncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DevelopmentMilestonePaymentObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.",
        "label": "Development Milestone Payment Obligations",
        "terseLabel": "Development milestone payments which the entity is obligated to pay"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentObligations",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_DevelopmentandRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development and Regulatory Milestone [Member]",
        "label": "Development and Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentandRegulatoryMilestoneMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_DiscoveryAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discovery Agreements [Member]",
        "label": "Discovery Agreements [Member]",
        "terseLabel": "Discovery Agreements"
       }
      }
     },
     "localname": "DiscoveryAgreementsMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EarlyStageCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early Stage Collaborations [Member]",
        "label": "Early Stage Collaborations [Member]",
        "terseLabel": "Early Stage Collaborations"
       }
      }
     },
     "localname": "EarlyStageCollaborationsMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EmflazaassetacquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emflaza asset acquisition [Member]",
        "label": "Emflaza asset acquisition [Member]",
        "terseLabel": "Emflaza asset acquisition"
       }
      }
     },
     "localname": "EmflazaassetacquisitionMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EmployeeDirectorAndConsultantStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the 1998 Employee, Director and Consultant Stock Option Plan",
        "label": "Employee Director And Consultant Stock Option Plan [Member]",
        "terseLabel": "1998 Employee, Director and Consultant Stock Option Plan"
       }
      }
     },
     "localname": "EmployeeDirectorAndConsultantStockOptionPlanMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent",
        "label": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent",
        "terseLabel": "Employee stock purchase plan, voting percentage limit"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanVotingPercentageLimitPercent",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan.",
        "label": "Equity2009 And Long Term Incentive Plan And Stock Incentive Plan2013 [Member]",
        "terseLabel": "2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "Equity2009AndLongTermIncentivePlanAndStockIncentivePlan2013Member",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_EquityAndLongTermIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2009 Equity and Long-Term Incentive Plan.",
        "label": "Equity And Long Term Incentive Plan2009 [Member]",
        "terseLabel": "2009 Equity and Long Term Incentive Plan"
       }
      }
     },
     "localname": "EquityAndLongTermIncentivePlan2009Member",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_Feet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Feet",
        "label": "Feet",
        "terseLabel": "Square feet of office"
       }
      }
     },
     "localname": "Feet",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_FifthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fifth Anniversary [Member]",
        "label": "Fifth Anniversary [Member]",
        "terseLabel": "Fifth Anniversary [Member]"
       }
      }
     },
     "localname": "FifthAnniversaryMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter",
        "label": "Finite-Lived Intangible Assets, Amortization Expense Year Five And Thereafter",
        "terseLabel": "2023 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_GrantAndCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant And Collaboration [Member]",
        "label": "Grant And Collaboration [Member]",
        "terseLabel": "Collaboration and grant revenue"
       }
      }
     },
     "localname": "GrantAndCollaborationMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_InventoriesAndCostOfProductSalesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for inventories and cost of revenue.",
        "label": "Inventories And Cost Of Product Sales [Policy Text Block]",
        "terseLabel": "Inventory and cost of product sales"
       }
      }
     },
     "localname": "InventoriesAndCostOfProductSalesPolicyTextBlock",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptct_InvestmentInMRI": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment In MRI",
        "label": "Investment In MRI",
        "terseLabel": "Investment In MRI"
       }
      }
     },
     "localname": "InvestmentInMRI",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five and Thereafter",
        "terseLabel": "2023 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LiabilityDevelopmentandRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability, Development and Regulatory Milestone [Member]",
        "label": "Liability, Development and Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "LiabilityDevelopmentandRegulatoryMilestoneMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_LiabilityNetSalesMilestonesandRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability, Net Sales Milestones and Royalties [Member]",
        "label": "Liability, Net Sales Milestones and Royalties [Member]",
        "terseLabel": "Milestones and Royalties"
       }
      }
     },
     "localname": "LiabilityNetSalesMilestonesandRoyaltiesMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_LicensingAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing And Collaboration Agreement [Member]",
        "label": "Licensing And Collaboration Agreement [Member]",
        "terseLabel": "Licensing And Collaboration Agreement"
       }
      }
     },
     "localname": "LicensingAndCollaborationAgreementMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_LineOfCreditFacilityAdditionalCapacityAvailable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Additional Capacity Available",
        "label": "Line Of Credit Facility, Additional Capacity Available",
        "terseLabel": "Line of credit facility, additional capacity available, net product revenue threshold"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalCapacityAvailable",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_LongTermIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2013 Long Term Incentive Plan.",
        "label": "Long Term Incentive Plan2013 [Member]",
        "terseLabel": "2013 Long Term Incentive Plan"
       }
      }
     },
     "localname": "LongTermIncentivePlan2013Member",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MarathonPharmaceuticalsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marathon Pharmaceuticals, LLC [Member]",
        "label": "Marathon Pharmaceuticals, LLC [Member]",
        "terseLabel": "Marathon Pharmaceuticals, LLC"
       }
      }
     },
     "localname": "MarathonPharmaceuticalsLLCMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MidCapFinancialTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MidCap Financial Trust [Member]",
        "label": "MidCap Financial Trust [Member]",
        "terseLabel": "MidCap Financial Trust"
       }
      }
     },
     "localname": "MidCapFinancialTrustMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by categories of milestones achieved.",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptct_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different categories of milestones defined by agreements.",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_MilestonePotentialAchievementsRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payment which the entity is obliged to receive upon regulatory approval",
        "label": "Milestone, Potential Achievements, Regulatory Approval",
        "terseLabel": "Milestone, Potential Achievements, Regulatory Approval"
       }
      }
     },
     "localname": "MilestonePotentialAchievementsRegulatoryApproval",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the minimum percentage of debt principal amount by instrument holders.",
        "label": "Minimum Percentage Of Debt Principal Amount By Instrument Holders",
        "terseLabel": "Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default"
       }
      }
     },
     "localname": "MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_NetDeferredTaxLiabilitiesConvertibleDebtInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net deferred tax liability attributable to taxable temporary differences from issuance of convertible debt instruments.",
        "label": "Net Deferred Tax Liabilities Convertible Debt Instruments",
        "terseLabel": "Net deferred tax liability in connection with convertible notes"
       }
      }
     },
     "localname": "NetDeferredTaxLiabilitiesConvertibleDebtInstruments",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_NetProductSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of revenue earned from product sales during the reporting period.",
        "label": "Net Product Sales",
        "terseLabel": "Net product revenue",
        "totalLabel": "Total product revenue"
       }
      }
     },
     "localname": "NetProductSales",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_NewBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Building [Member]",
        "label": "New Building [Member]",
        "terseLabel": "New Building"
       }
      }
     },
     "localname": "NewBuildingMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_NumberOfCountries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents number of countries.",
        "label": "Number Of Countries",
        "terseLabel": "Number of countries ( over )"
       }
      }
     },
     "localname": "NumberOfCountries",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_NumberOfOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Operating Leases",
        "label": "Number Of Operating Leases",
        "terseLabel": "Number Of Operating Leases"
       }
      }
     },
     "localname": "NumberOfOperatingLeases",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_NumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Products",
        "label": "Number Of Products",
        "terseLabel": "Number of products"
       }
      }
     },
     "localname": "NumberOfProducts",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_NumberOfStatesInEuropeanEconomicArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of states in European economic area.",
        "label": "Number of States In European Economic Area",
        "terseLabel": "Number of member states of the European Economic Area"
       }
      }
     },
     "localname": "NumberOfStatesInEuropeanEconomicArea",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_Numberofterms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of terms",
        "label": "Number of terms",
        "terseLabel": "Number of terms"
       }
      }
     },
     "localname": "Numberofterms",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptct_PercentOfMarketRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent Of Market Rate",
        "label": "Percent Of Market Rate",
        "terseLabel": "Percent Of Market Rate"
       }
      }
     },
     "localname": "PercentOfMarketRate",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_PercentageofSalesforRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of Sales for Royalties [Member]",
        "label": "Percentage of Sales for Royalties [Member]",
        "terseLabel": "Percentage of Sales for Royalties"
       }
      }
     },
     "localname": "PercentageofSalesforRoyaltiesMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_ProbabilityofSuccessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probability of Success [Member]",
        "label": "Probability of Success [Member]",
        "terseLabel": "Probability of Success [Member]"
       }
      }
     },
     "localname": "ProbabilityofSuccessMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_ResearchAndDevelopmentEventMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved.",
        "label": "Research And Development Event Milestones [Member]",
        "terseLabel": "Research And Development Event Milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentEventMilestonesMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_RestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Restricted Stock and Restricted Stock Units (RSUs).",
        "label": "Restricted Stock And Restricted Stock Units [Member]",
        "terseLabel": "Unvested restricted stock awards and units"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_RevenueRecognitionMilestonePotentialAchievements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Milestone, Potential Achievements",
        "label": "Revenue Recognition, Milestone, Potential Achievements",
        "terseLabel": "Revenue recognition, milestone, potential achievements"
       }
      }
     },
     "localname": "RevenueRecognitionMilestonePotentialAchievements",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_RocheAndSmaFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Roche and SMA Foundation",
        "label": "Roche And Sma Foundation [Member]",
        "terseLabel": "Roche And Sma Foundation"
       }
      }
     },
     "localname": "RocheAndSmaFoundationMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_SalesAllowanceAndOtherRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Allowance And Other Related Costs",
        "label": "Sales Allowance And Other Related Costs",
        "terseLabel": "Sales allowance and other costs"
       }
      }
     },
     "localname": "SalesAllowanceAndOtherRelatedCosts",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain sales events on the basis of which certain milestones are achieved.",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_SalesRebatesAndRoyaltiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Rebates And Royalties, Current",
        "label": "Sales Rebates And Royalties, Current",
        "terseLabel": "Sales rebates and royalties"
       }
      }
     },
     "localname": "SalesRebatesAndRoyaltiesCurrent",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of interest expense recognized related to convertible debt.",
        "label": "Schedule Of Interest Expense Recognized Related To Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of interest expense recognized related to the Convertible Notes"
       }
      }
     },
     "localname": "ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of shares outstanding to be added annually on the first day of each fiscal year in the number of shares authorized.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase as Percentage of Stock Outstanding",
        "terseLabel": "Annual increase in the number of shares outstanding on the first day of the fiscal year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseAsPercentageOfStockOutstanding",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares to be added annually on the first day of each fiscal year in the number of shares authorized.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Annual Increase Number",
        "terseLabel": "Annual increase in the number of shares (in shares) on the first day of the fiscal year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualIncreaseNumber",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares subject to outstanding awards used to calculate authorized shares.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Number of Shares Authorized Shares Subject to Outstanding Awards",
        "terseLabel": "Number of shares subject to outstanding awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedSharesSubjectToOutstandingAwards",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the inducement grants for non-statutory stock options.",
        "label": "Inducement Grants For Non-Statutory Stock Options",
        "terseLabel": "Inducement grants for non-statutory stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Roll Forward]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptct_StockAppreciationRightsLiabilityOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of outstanding stock appreciation rights liability.",
        "label": "Stock Appreciation Rights Liability Outstanding",
        "terseLabel": "Stock appreciation rights liability"
       }
      }
     },
     "localname": "StockAppreciationRightsLiabilityOutstanding",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the 2013 Stock Incentive Plan.",
        "label": "Stock Incentive Plan2013 [Member]",
        "terseLabel": "2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_Termforletterofcredit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term for letter of credit",
        "label": "Term for letter of credit",
        "terseLabel": "Term for letter of credit (in years)"
       }
      }
     },
     "localname": "Termforletterofcredit",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptct_TranslarnaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Translarna [Member]",
        "label": "Translarna [Member]",
        "terseLabel": "Translarna"
       }
      }
     },
     "localname": "TranslarnaMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptct_UpfrontLicensingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront Licensing Fee",
        "label": "Upfront Licensing Fee",
        "terseLabel": "Upfront licensing fee"
       }
      }
     },
     "localname": "UpfrontLicensingFee",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptct_WellcomeTrustLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to The Wellcome Trust Limited.",
        "label": "Wellcome Trust Limited [Member]",
        "terseLabel": "Wellcome trust"
       }
      }
     },
     "localname": "WellcomeTrustLimitedMember",
     "nsuri": "http://www.ptcbio.com/20190630",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r50",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r128",
      "r213",
      "r218",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r126",
      "r213",
      "r216",
      "r362",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r127",
      "r213",
      "r217",
      "r364",
      "r380",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discounts on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r38"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r58",
      "r59"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains/(Losses) On Marketable Securities, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Other comprehensive income (loss) and accumulated other comprehensive items"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r51",
      "r58",
      "r59",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Adjustments to additional paid in capital, equity component of convertible debt"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r224",
      "r226",
      "r260",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r226",
      "r254",
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r129",
      "r150",
      "r152",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Alternative Investment, Measurement Input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r74",
      "r89",
      "r310"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r71",
      "r89",
      "r312"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r171",
      "r176"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total shares excluded from calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r142",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r124",
      "r340",
      "r354"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r49"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized, Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized, Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r134",
      "r158"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of unrealized losses and fair values of available-for-sale securities in a continuous unrealized loss position"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r138",
      "r140",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Total Marketable securities, Less Than 12 Months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r132",
      "r135",
      "r158"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r227",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails",
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails",
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails",
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity Interest Issued, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails",
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r88",
      "r284"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "negatedTerseLabel": "Change in the fair value of deferred and contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r88",
      "r284"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in valuation of deferred and contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r280",
      "r281"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r278",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r31",
      "r91"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r104",
      "r202",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrant shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r99",
      "r202",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r221",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsMember": {
     "auth_ref": [
      "r15",
      "r183",
      "r343",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements.",
        "label": "Commitments [Member]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding 58,707,185 shares at June 30, 2019. Authorized 125,000,000 shares; issued and outstanding 50,606,147 shares at December 31, 2018."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r65"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other comprehensive income (loss) and accumulated other comprehensive items"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Contract liabilities, rollforward and revenue recognition"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r204",
      "r205",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contract with Customer, Liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "terseLabel": "ASC 606 Adjustment"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails",
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r204",
      "r205",
      "r214"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r204",
      "r205",
      "r214"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails": {
       "order": 3.0,
       "parentTag": "ptct_NetProductSales",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Performance obligations satisfied in current period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails": {
       "order": 2.0,
       "parentTag": "ptct_NetProductSales",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligations satisfied in previous period"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionRecognizedRevenueInPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r221",
      "r223",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales, excluding amortization of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Adjustment to accumulated deficit"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r341",
      "r342",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r41",
      "r196",
      "r197",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining contractual life of the convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days, period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Trading days, number"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentCumulativeSinkingFundPayments": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative amount paid into a fund, which is used to retire the debt instrument.",
        "label": "Debt Instrument, Cumulative Sinking Fund Payments",
        "terseLabel": "Sinking fund"
       }
      }
     },
     "localname": "DebtInstrumentCumulativeSinkingFundPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r311",
      "r313"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal",
        "verboseLabel": "Debt principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r40",
      "r192",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate ( as a percent )"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Five [Member]",
        "terseLabel": "Period Five"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFiveMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r101",
      "r196",
      "r198",
      "r199",
      "r200",
      "r310",
      "r311",
      "r313",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of the convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r310",
      "r313"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: Debt discount, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r146",
      "r161"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "Securities in an unrealized loss position greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r146",
      "r161"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Securities in an unrealized loss position less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r144",
      "r159"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r268",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r89",
      "r180"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock award plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share-basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in dollars per share)",
        "verboseLabel": "Net loss per share\u2014basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation, benefits, and related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average remaining service period for recognition of unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity Securities, FV-NI"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r291",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r290",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r294",
      "r295",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value of financial instruments and marketable securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r291",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted prices in active markets for identical assets (level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r291",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant other observable inputs (level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r291",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant unobservable inputs (level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Changes in the fair value of warrant liability and SARs liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r296",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r296",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of changes in the fair value of the Company's Level 3 valuation for warrant liability and SARs liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "June 30, 2019",
        "periodStartLabel": "December 31, 2018",
        "terseLabel": "Contingent consideration payable- net sales milestones and royalties"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Measurements, Nonrecurring Value Measurement [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringValueMeasurementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r299",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r162",
      "r163",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r90",
      "r306",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign currency transaction gains, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Loss on disposal of asset"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r167",
      "r168"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails",
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r96",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "auth_ref": [
      "r96",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in unrealized loss position.",
        "label": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months.",
        "label": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value",
        "terseLabel": "Securities in an unrealized loss position less than 12 months"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer.",
        "label": "Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value",
        "terseLabel": "Securities in an unrealized loss position greater than 12 months"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r106",
      "r339",
      "r345",
      "r361"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r123",
      "r274"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r96",
      "r266",
      "r267",
      "r271",
      "r272",
      "r273",
      "r275",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.",
        "label": "Increase (Decrease) in Deposit Assets",
        "negatedLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Total allocation of IPR&amp;D assets"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible assets and goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r170",
      "r173"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r74",
      "r193"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r84",
      "r86",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r48",
      "r166"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investment Holdings [Line Items]",
        "terseLabel": "Marketable securities on the balance sheet"
       }
      }
     },
     "localname": "InvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentHoldingsTable": {
     "auth_ref": [
      "r370",
      "r373",
      "r376",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.",
        "label": "Investment Holdings [Table]",
        "terseLabel": "Investment Holdings [Table]"
       }
      }
     },
     "localname": "InvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentOwnedBalancePrincipalAmount": {
     "auth_ref": [
      "r367",
      "r371",
      "r374",
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For investments which are quantified by principal amount, the principle balance held at close of period.",
        "label": "Investment Owned, Balance, Principal Amount",
        "terseLabel": "Investment Owned, Balance, Shares"
       }
      }
     },
     "localname": "InvestmentOwnedBalancePrincipalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r369",
      "r372",
      "r375",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r369",
      "r372",
      "r375",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Aggregate rent, Initial term",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails",
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2019 (Excludes the six months ended June 30, 2019)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal Term ( in years )"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of Contract ( in years )"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesNarrativeDetails",
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Renewal Term",
        "terseLabel": "Renewal Term (in years)"
       }
      }
     },
     "localname": "LessorOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of Credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r344",
      "r357"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r189",
      "r342",
      "r355"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails",
      "http://www.ptcbio.com/role/DebtInterestExpenseDetails",
      "http://www.ptcbio.com/role/DebtNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r2",
      "r37"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of marketable securities on the balance sheet"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Measurement Input, Option Volatility"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Measurement Input, Share Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInDeferredRevenueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Deferred Revenue [Roll Forward]",
        "terseLabel": "Movement in Deferred Revenue [Roll Forward]"
       }
      }
     },
     "localname": "MovementInDeferredRevenueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionContractLiabilitiesRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r112",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Company"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in (provided by) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r60",
      "r63",
      "r70",
      "r90",
      "r110",
      "r346",
      "r360"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncollaborativeArrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangement Other than Collaborative [Member]",
        "terseLabel": "Non-collaborative Arrangement Transactions"
       }
      }
     },
     "localname": "NoncollaborativeArrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of information on the Company's restricted stock"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r320",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liability",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails",
      "http://www.ptcbio.com/role/LeasesLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities- current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities- noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r317",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease ROU asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails",
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r326",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - operating leases ( as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r325",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms - operating leases (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r38"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Commitments [Abstract]",
        "terseLabel": "Other Commitments [Abstract]"
       }
      }
     },
     "localname": "OtherCommitmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r286",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r286",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r58",
      "r67"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other comprehensive income before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r61",
      "r64",
      "r67",
      "r195"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r61",
      "r64",
      "r286",
      "r287",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r38"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r79",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchases of equity investment in MRI"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Acquisition of product rights and licenses"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r227",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesHierarchyDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from public offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r82",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r81",
      "r257"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from shares issued under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue",
        "verboseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r181",
      "r359"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r19",
      "r25",
      "r358",
      "r368"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r25",
      "r96",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r58",
      "r67"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTerseLabel": "Amounts reclassified from other comprehensive items"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of Debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.ptcbio.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r265",
      "r384"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r201",
      "r356"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Deferred consideration payable"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, performance obligation, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r68",
      "r121",
      "r122",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r324",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of other comprehensive income (loss) and the changes in accumulated other comprehensive items"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of historical dilutive common share equivalents outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of marketable securities accounted for as available-for-sale securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r139",
      "r141",
      "r145",
      "r146",
      "r147",
      "r149",
      "r347",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/BusinessCombinationAssetsAndLiabilitiesDetails",
      "http://www.ptcbio.com/role/BusinessCombinationConsiderationTransferedDetails",
      "http://www.ptcbio.com/role/BusinessCombinationNarrativeDetails",
      "http://www.ptcbio.com/role/BusinessCombinationProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of basic and diluted net loss available to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r226",
      "r253",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense recorded in the statement of operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r172",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r227",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r232",
      "r242",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate fair values of grants made on the date of grant"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r99",
      "r202",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of the Company's outstanding warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Future amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73",
      "r165"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants in period (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock option plan",
        "verboseLabel": "Restricted Stock Awards and Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end of the period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r234",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested or Expected to vest at the end of the period (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested or Expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested or Expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r225",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanRestrictedStockDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)",
        "verboseLabel": "Fair value of shares (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r248",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at the end of the period (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested or Expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r321",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "SARs"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails",
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r195",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock in connection with an employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r195",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock related to equity offering (in shares)",
        "verboseLabel": "Stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r195",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r17",
      "r18",
      "r195",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock vesting and issuance (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r195",
      "r201",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r195",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock in connection with an employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r195",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock related to equity offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r17",
      "r18",
      "r195",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock vesting and issuance"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r195",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock vesting and issuance"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r195",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/StockAwardPlanNarrativeDetails",
      "http://www.ptcbio.com/role/StockAwardPlanShareBaseCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r131"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.ptcbio.com/role/OtherComprehensiveIncomeLossAndAccumulatedOtherComprehensiveItemsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activity"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesAvailableForSaleDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesUnrealizedLossPositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://www.ptcbio.com/role/CompanyNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/IntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.ptcbio.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Less: Debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DebtConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized gain on MRI investment",
        "terseLabel": "Unrealized Gain (Loss) on Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r322",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CapitalizationWarrantsDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.ptcbio.com/role/FairValueOfFinancialInstrumentsAndMarketableSecuritiesWarrantsAndSarsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Denominator for basic and diluted net loss per share (in shares)",
        "verboseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:",
        "verboseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.ptcbio.com/role/NetLossPerShareNumeratorAndDenominatorDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5144-111524"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=77929361&loc=d3e25218-109307"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28)",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r387": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r388": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r389": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001070081-19-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-19-000050-xbrl.zip
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M 3+!>^5V,8 ^"#JL=:@AE(':3I-^F58&]Z"2"UU6&&=2W(?N8XU/Q$.!,&#
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M8G5IB4[=P[UM^+F,ID6I^9>VNW?;<S>98XJCA3"R+>_$%NMM%) BK#]=EC"
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MHQ/)<*\P)ZBQGGUHYJ*.VTZW"95,,+M])Z?0D05#?3$+A,$^7E*K<>@&D*F
M4Q#]1&;P>=PE_8P?W&^QPG@@^EB9-1&^GQ_ )%!N#!E^A&[\3I<F*G%90&6K
M1L^Q3/0'Q[7J@9BI$).9T-"_I3 !A"O"SXJJ(A>F4,:Y=V^"6+H_V-"66+IY
M" EW<R=,I'KY[Y9%F_I(:G'+!<L=+^E91"$:=>4G5?98M,I2"TO"AE'Z)=IZ
M:@-%+A[2 R5=Y"X-MH$[CL-PD&A]Y *964'0T\HP/ C3\2G("NQX+_HFEK\A
MXHD\X:I:UH."CO)\!T2/,)YQ,"JBD!,*&L&RD AS*B4(,P<BE]3X$;(2I],J
M;J4@2("!R+-57;/+'E<8.I<PRW>2#M(Z.@[&[8R?VAJNH*2WRBI.ADP3MJH]
M@GV*/YHU1XF5*4?0,-4PK9EYPU8";_%)=CRB1H9*3Z1M3%1G^MZ1T];>QH=/
MH>.8T"IE,J1"7UH-LZ+2;:[U-HF[H?<G5T!R8;P&;EKE[+'MRA,1_8;^G3J1
M4=4Y\L".2M4DE'TXU"ICU]FP1*HM174Z&9]$_Y7BY+2'AG"<!GW]+U]JR!Q!
MKSAOSZ8,=-9T>RD?M5R.E7S/YZ5AN[!7@V3=4(ZK^W0B7*&(M@3_\4J"__55
M<A]#49R'.U3DXJ9T9V+],*2P[0#Z(A'OA0*[P:];)B,9:@&D(PCE][?-L$+I
MI?,A;ND0,@_G%H(;GQK"IS"0W\VX:>MR>*K>AP7A@2[6L@X6SJ/1E^N"(E"^
MUARFTRW,4E@\Y-?0%5B;(>@G]C]V2<6F4CU-..-S1$'NQJN,X&=S1ILL<'&Q
MT"9PR]L=]0;),V&,+6T.9\D\W=OL_ NL-[#BG#QXO]?C_7[VO7B_OT<"WJZ3
MVA1R(H\)"Z4@ZR]QT)*)SG=TCJ>=3APRR5HN M=GP( 4=;:Q9 [S=]^HYBU7
M"L$)2SU-$0;DGZ1^H;H^W\S"P]X[;^495Q^E0;Y#J%;86L6< E$8)E!*4B <
MGD3S7O4(^0Z5C[6)_?''*ZV>'7 N3;@V'0^D/<D7V8RVUG, (Z/4"*Q+Y)"&
M!@+@&ZR(,!,STB40"ORD%#/!$FJ$%-_$?$$V/^9L?*FU'& .="IK@'MN&[2E
M=\>[<73RX?79\780>WC+ 0[),=],N^$>"8*K6"^RU"F]/MW);>)CG\($(J\4
M5,>2!-N0ABMN^5-ZR5IZPV5&"1PCR0PBF&F'^/*CNUO$:>'Y2ICDGVGO#47+
M5DC!W_(_;9LJ90P_9@6Z6YKU&L$$N].,$E0V6'] T)L@F>:]O-)M SYTG]F!
M] ./CA^,C:O^G-^^X=[,4L#[]V8[@B%?,\\#BDIS7G#!(F>2KCB-;MZ6[HRH
M!J6SYD6L7+*;; )YLN-\#XE+?9F 7$MB_?FV7>X'M?PD=SHMJ88-'JTV!P8W
M2H)56'GYPHD%O9Q;GRH%P?JVOV3,&%H*/&SJT$,WP\U6UQPX\@^5H!<;N80/
M[M,2'L4](;2;BEGVF[CU%/O.5*:TM:1:KFRQ0<=:8=U/J.5/_#:Y)/(;[S:[
MGZ8J":HI\W6L)+I3PIQU=D-NYL([_%X7WEH7W5<]-_>/COZ"J:>G-]RV2=.O
MRD3,*+7 ^;MX7[-A%G-0"^]&0S<LHLDE><FE326?M#!=]:]'42%CZS'T5E4U
M@7=R^A<=F6@9B6WE%WOG_@7K;M'QW_/ &W,1[J/Z?K1M63(EIT>.9CJ-!1'0
M;2"["8+#OE_:=HAIKB]Y7^%EF[D#[U4Z["UV8,_>,Z=[4"FW8QG" 83!"X(7
MB4/&%."+D36)G\8!20E$]N^D]$N0!;K4V7RS R1TC5 #7(8:G5:VU%'ZQ2:W
M(K0SQ]_G8C[2IE@D*[:*DJPWK<"*1TK:GN)9L-TGV\+J:E7J(.)EL>\/GO2U
M>-*??Y>>]'7IF*U0+UB$:HYV&Y'$P>'<3!OVB7KAQLYVQGU$6RX, OJ^H"MV
MWS*!L&@[FH"=YSCU-YISM'!G; -OH'&XJH1K= &:0_7&9T)\%ZV:%)=XI-RB
M4=8-/T/(%D&)>BK2FWKOGN!F/YOP=K3.NJO..9KK9($VY IF^D^ELGVF2J8[
M- CBX"\Z0KAF2LK/VL)V)HS T7RKT)';W4LZ&%B LIS8$N<P+L,^5<]7\5[P
M41QM^5F2K=:1VY6XY"^*#(X]XKOMWS7;PDO8/9(0FY&.' R 73Y,L8ICLJI.
M:AIL2A'3L(9X 'Q\IN!G*G3?9T6"-E'@=*HO%!#J(00,?@KX )>K^IOI"3BZ
M1ZHH(==TR[D.AA8Y)RE1!8VNU>5X1Y5#D(4%2H>>'SI@N.:C(>@G-#L(<LYH
MM6G^(H!,(;'01HE76\T3PE]S/FW;.;LHEF(+0M@0I*L#80'F6>:J(> 9=#EI
M#0%#RR7(AZ!-M"'A\,S'L.1->+!MV>UC,V@4\,^AK1-S4B1Z,Y?]DWNT[(^S
M+,RAX!,HS7<^IS<(#+ CLPQ RWVJB2AHXI*W#JZ*#?G0(>_.N59#B:VJU<ZE
M]19\N@+.?O=0T)UFT7NW)/<DS#-)@R24RJ67B#[9%1.8'4]0/DS8D:O$=\(E
MFKQJT9'S#W8<#R8?)@0^V(8$P?JPS?:E(4T+)NN1FL)("1[WJY\FE!*%(/>\
M)\9>EDO9SNG& B7FH2:%Q]"Q&"<X16A&3$0>GJAUAV0F/#V[IZ9Y1^K-$2?B
M7&R'T:3.!..@!)#DFOASB.D 5HFK=&?KP9G4+1X469*;*:*>WB,1U:[& D-,
MG P&T&(JP\!]98>,/&3(SE+E>"&<;Y[3O#H5TZ10[Q61TDFWX(N+Q9(*KK_
MV29P7L+0,$BB[F(DZ&Y:>(6YR[]A$Y*>[@\']-TF/04U] +"R 4)4'B38)[Y
MBK138VR!YPVO?^/1Y]3&_1]DPUPC?ZJ+Y#,;I(4INT:JJ7<:^(:B$] =T)WC
MJ_2U!:=\JNT'=KFU.4!^-=Q!9GP/GN_]%)TT]4 -/Z\Q.?S!VWL3;^^+[]+;
M>Y=Y5HNV5H\R80Y]X\WKJZ[L9%40%'3"*D%+>;N/JM47U+0CQ^AK<S46;56W
M#WZAS)."2KQ97( 7FF6P8)^:(W&B,)/=X(+]HZ&3 &[M>X36CK'M/GE$]%%4
MH,7-:1VO8NH[DML.\1(S?X667JZQWCE1%Q9H)PA"V6L@SD-%]0[5<(+%369+
M6N9-$$H[]&;L!^Z#;3J4;:,75=F6A_ "PJDV8[]\L$B),YWP7#XE.55Y'%05
M>3FOI^[J]H@;X+@:CQ$+4%OKS\>4]AC;RSU"."P[^W'T_ST^WCG<,^5M7=UY
MNR>\8;O#3A]3EW9;U=(W2_* 5K>J[&E!F7V<#\F3;>(P#2M]X1Q?/0>A=W%$
M-4_Q;9VQ1KK$Z8PRQ4Q>'D-->&=Z$8UMDH$ZJ:@ *1[?UO5OER1Z)K%5S'QZ
M\Y7)P]5:GONT!^C/@R4KM;)+-:38,(0!EMC(1?UQI'R>-@^T-6H/FQUCOW=7
M#AT5AJ60 =&M,@V<SY[IN)>$C@D;A*PDW%;Q_/:T(S91#12R<'&43F>44>YC
M5%^\>.&+/9O=V 9_"P7U2OL\906^6D K(YN;RB+R1*PHH0]#"1W;@*BAP:*=
M@Z-B. $P Z3$(\[DXEQOLX"XKQJTQLVT=<0];>I%DDPYHH>^VSY(XXQ0"XX8
M>\+@>38NU6QBPKMV&2 E1<W,E=YZL,NVKT1NBU*BNVCBUO9@RXP>[-5 $;$
MZV@*YFDZR^9&9H4)5]WG&\O7Q"OA60.:;M,I FJU>L55,:TER)QA&YKEGR[6
M/Y<I&"3V:>0\MR9'[D,(O)?0X5+'!&A7;6I"Q:(1NY:>S .%0X&.;GL+#EI0
MA]YE\9E:RJTREJY<AG>?26B3W']?B:9]48%QT"F(N?P4;(N_@[] ?.O@RKE<
M+I/[)M.5VR8_E+AAM\TD@?QI2MV!*1A\C@E+T7\=L?56;S#+./?0;MEF F1I
M=Y)6C"?@T$PBU=%7.=F&+</#X@[32A(::3BNP'^[5;)UC IB^$R$2T3+]TF;
M!GHSY>O%P@5VW"K+'H1B_*(K2=,RB9U,O7(,:=Z&= 1[3+\#*DZ/3![0[']I
M Z=N%S.5D2??[Y6ZB4^(]+% &QG%SH/3;2U.M_V][]?KMH:VMSP4VZ$/BB1M
MB%7V_/RV&E6_NGV!JOWO+ D/]YA=A9',E&G%:3HFS.MMX;0D<!:JE%6ONVG+
M 'I,R5N,I( HV*9:0$LW8\#G3QKS<BG1YY^STL P="$RS0NPM+F]X7HXJL2L
M--HWF%0"/R DO ]9PO('^R:-V,D+*TXHMSZMT6]VE>B)R<SO]QE0 /U09+ 9
MT9KH$Y:90)0"90$7BV;8S]ZD89;"3KZPCCO9H7(71]-F6">]3:GFBU)W]YE<
M[19QS9,L6:F8*,#XD\?DZ0 =H5K,YQ3BQT+#T@>.6I2H,"2Y-V"5#.\E- #!
M4V.';T"^H!M&;NCC)4N1 =C4AC+GQH$@;/R]:0NM".>GW_JR9$M4$XM)"P[O
M%4YGV"+S!5N$O19;_]J.;K$]ED2OD>0PHQ+A=N%[V$2[JKMH&@N,1QD:]R[B
M-$]IB,+%;!T#(Z0(;+&%L3%?&66\IR%VA=^717*MK=PGR[%(#GW=LZ@"Q=)J
M]%@JSQ9U:#&&6:G7DEK&Q](=T2T)21G044\SA!!8("6B\89GLY<?Q"MBR499
MD*OL3F+XACGA\42]^1)I"\'5IB>/33UZBZ5[NK=PF!>.JW^TF)A+./%8+-$C
M&M4CE#(5:QE5@94&>3C3"AUH/ S^-P9;)E?;E#*ZYNG>#F+=3%G!X#Y7"U37
MI-C "LA@/5U(81Q5#M):H,AH?A8--.]CIM(<[%7,;7NO+Z._@Z*BYPN35)D@
M1$;G> K-&()D.?:>?%Q1*0$QKW7N6):@JW]ODC$I2Z90.2K*#KEL6EB4K@8Z
M52 5-"'85&6-;BZ<JS^;,JV2="CLA!W,2GQ'.RN6K1U":=!;V[,K%$V\7?ZE
MS*Z=LX&N+W4+K8/+RCW:*7?>43'WSB7:;^W=3@OC'F[Y<U)0,[^NS94/7FD:
M^?""'>-H9<-=MHF>##K"MA9[,\Y7"<3P!'LIV7W1*H\K>H%# C^:'\V K^:N
MB\[PXQ)H@"UN?M6#1.#F',$QK5@E% 6"C/P\XS2GUGL'Q_)7V@LGL$"PN.E*
MG16DP)4MLT^OU/3JMM"C1>A?=:T7CH*ATJT4$:GV:5VF9KNLUF!#F"N"F%.<
MS*/8DN?D0_-N,KSO<$SL24RWM#JWVH!5W1$C=ZFMB,!F]98IJ\",\/_29;'M
M"D'89;G2JE(1/$)?.2)V1>%N)QJ%FVR[(/ Q(CYA60MY,]5TYG)"$TKME $8
M'*9_\":NQYNX_^!-O$7;PS12='Y=M?S)7C#IF#6H;*B*,BT8>:DZB.U>$K(7
M+UYLJ2".$EMI V=]02=IS]Z!#=8XWF@^@\7+V,:0Y!9B<>U.BDRUY3;%>AI*
MR0',IN%BHEQ<U 24/&7 BRV)/+@BN#'00ZH';X\157OY-.84\&)J_M<75$T!
M'1F6FTUHN_VQ7*",$+""W&*BJH.!A2&[$JLMVF+*Y!*18N:U3(6\"P>.55I7
M *'7RIF"HETD15:,&9;?UGOLR[QN>,3</@)T%7P=8I8.*(L1_7W#[;7CVK]2
MW.UB,:SAO -EZP(;VIDQ06(\H7PXBZ'+TQ>4(EY.)VF081SX4_[7E.W>"L[S
M(]J!!-G(5[L -S-^>K$$G]+&*+K$3(8D[N JH$R98A1[ 1ZL8R+!:MJZ%(JA
MT<7:)376R6H&(/4PATZ7<B6R*Z-OD>LH!S/3AZ1.ZU[1P6E7'D# +1T/8\>K
MS-O/**ND'84D4]N L1$PZ)R@*L%A5FLL&6,]":]QVZS:ZD 5:RE]0^RNHS1+
MF4F$AI3P!D5IZ0I,/WR,76P]!>T(@\<J'<+7>W9$3/LA=FS-\%M9XM%@+(:B
M[/C?KMT;'TL1&Z]0%;+Y7A.\*"U G(<J62B$=W*Z+O1N:+=^#TX4G_F//,65
M\(E=D_@8*OU!)J@E_94B0:TIZ/<+>K$[SR\([QPV5&L;ZY9K!#'"3%P44H\:
M1$HU$H7=\%]YUX&8A#93G24O.3F@N*)#:!>/H-T^</=_@O;PZGCGV0:4V'RR
M$24VW4EQ4H!X@AUXB^JO&Y#B=G_J:RXG'\]':2*^QG<Y%:W'B]93/QQT@F*<
MPZ^<!ZR&G_/B,M/)6+-!0+BS.K6! RP]6::ZYKJ:J/Y;O[KU<;:// L*NS(O
MU&6MQBNWT817)E3FTU3?;155,/4_L7EU$4N]2ZDJTWL'@><O.)0A9W8"AW96
MS.0@B:-%,]/G+&P!U*+HN(JH4JAAR73>D=YG]H('$TM24I=X8%=Z"(=6%4=V
M@+R"R$/_R:G7VO9TM=5&'"<UY  KI6YPT3=._"8R%#P.T76.EBO_1KXKUPK"
MQ;@WXH'I*G&Z9_.9:TIG34SE92GH5EI#ANH_B&.5P22K+4)KZJ(1A:VS6?:F
MZ!]K<QZEABU(BMYGSCU[&:%IG>M+W P(R:]B\Q<&1E!;T2:OGH<>%A*..^AB
M%,U#EC:^!]<C\J"RY89_H%,2)LC[4W#F2NX7/AUT%):6HP?S)?1PDE/%"FD+
M837P%0D<TH;^Q,X!#$BFL' A8M9-]>PA*"*5V>9R8QQ515,.)7R&+R$#DP?4
M^ZEJR.Z!OTHI" +K/ZVP)J+ME#<D9NA>16A 8O0]ITK>O,')U<&N6#1S\:HA
M8Q)X!==S5VY*8QL1 @1213&57.Y*1S)]PA#L<[RJ 9U\JHE"U@9DO$T-PUGG
M]#,L B38H.YCQU+Z%G97DN*CG$J-MZ3:,@,9AT)0B->]"DZT?"S)+0[;R^H8
M6]GDMW @&2$>BD/[S]]+'?R6X2H*2P+[J??4".\E#Z[2];A*#[X75^D:6BJK
ME#- T8TBF3DPO\6HOD2G2E-UHWD^!Y,A2#&;NNL$(6)I%ND@FJR[93/=&_>G
M5,ZC']%["Y(M*] !485T\"*5I49?3>XO]+A6;#[+B=Y&.L(1&T<)J '#.I,T
M%?.)RT,V>+BA$]14EZ7J&.E%DXVU\;8)P0VZENF0(+&)!FR0#^TJ3<'Y;ST1
M'<>$]\ MCQ7%6V%2C&>1RN:GU[N"&UQGTV;&"6,*:8F@%?Z#S//52^'PP5![
M9X-Q;K=L_$ 7\K! #$CR$'>PO::S.NL 2W"2%O?4R_GL*DSNX!4N<SY0X8H*
MC^M1FHG6(:<].<FZO<:JZ;"AA9Z*79S=JR3Q*3!R1DWIO$2^S4!:/S:6L#'$
M!@;:I$'MS%)6;3Q<C:ON98V&"@.H)D6X-6C--:=S0R73?1)-'0BU$1?I%$NZ
M@0CI6=OPO\""<OK=0AN/3!(*BU&DA93(=HQ,-B9MR844>D%=*\_J EF)7C]8
M\.-<#%^[6?G;=C=ZG@WM+H4-#K1.3!P00P !;)7PW24F27I19ZE4&0*PZ+4>
M4$/,S]BFBM.F]\"E]&9J<C&@G353M3@O87_-F:9NQA5QS4VE9J0?WA^Z,LFJ
M@!V(?2<3H80=&HR:&R)#$**("=+Z+[$+7'Z"R#CX2W\0Z58TK*R_HZ*:LWZY
M65H  C_&K\>8JTWC@A8,V))#H2!=VEF;[0]C!K98\/!."ON2<V:IJ"M,S5P:
MB*08-LXX==-9F55 <I#RY16R?@?,)1=TE/AIH\+2#%LJTQPX1O>0+L$\DXE/
M\Y857@6#C8X .:08*5)ICZNK5=*MD^/B/.[LEX\N.3+<MR^5N6,\Q@!)C]M#
MR'#]=[C;9?>6% TM(UCKK&]>%N5GBBA,X!#SF&RG::7;"NFF"O?[+-U]_1)4
M#Y#9EA 4%SA7&0S/WU9@%62L),6$Q(G^TIB"Y"+IE>;6C1;4;R7MU<A QE69
M^"!Z)G3>U<&(,4\41(-_P%7%&#!=TO86O&D/@5Y#7H=1V-*(U7*_H%NFQ[PM
MR?6Y%99?]='\5*]=5#])X6KABFFWA\^3]O=)J\#=Z 0D^<)@ _(.WP[5^;%P
M)]'16UTE]()$DL $(8$"%]G &58NP UM;9.N64D76I>2! J5YUAJG[;$+MO
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MITJP"BFO>-F,WN(^YA*R^R\.#XD@&#3,/''E:KTK;7/<+4?N%IULV]J95[^
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MW6U''TE)"_ I!1L0D82$8E>UV2%O:.L*.-\RR&$T7!GZJ78*CJ--3)E(F(Q
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M)HF?^;;[UIU(*1/<H2P'J7?$SG2XH!U :L7\8M-&&T(CPA()H05.9<,QNW^
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M?7RF)RSU@PV[_^+984]7GCTLJ-5&UF5G?2A1B]C?/SAZVO?U_M&^V=N@')^
M)9#6,"=$T0AKCC;V_I/V\?OT^<,\K#0/)CQMH5FPGU/FP$4@$D:X/\&4E)@F
MYY;^D=W:IV?O/ATOV=O[>P\[8L69H(H=IJS7JR6:/LZ71T[]B[H$!8HMC5")
MBJ/WNW_?);+JW>@XSW<=0-[&-O=>/MFYQ]+7ZZ<<[MZ!WNJ=67.'1R_W]U]O
M2*^P8-@P)<KIIG+;\&-9U(*"6]C5<":QUR_N:Z>-F+ER/=+<[3QYNGLO.\(!
M#&_V]#_13X,Q[4Q=;B_8Q,5T"M.(I0=D/U]E8@OY!9A B88FR5XF#FEVMU%&
MMV-)U]-"OD_0]Z0K]%VE5;NHY:A431)'EV61CT=-YKQSPMUB:>Z,+\;'I)G\
M<FJH/+!'1%E_0A^PD<>#BK*P%TSP&)<3:':F!QGQ1,D3)=8_55_2:3-=PI[L
M&B$$17F1[UQ0:>6HN$1/WB2=<7U-I&%.\]#?83K;,&6T]=._LM@:>CJQ%I&_
MJ2V.;^AI"3Q0\HX1.7%JA8Y1N&=;7"S4"+>*X"%%.9<D?C.(L8PK?)L5:/C@
MQX:_*!"@0'&+-H&5D,XFG*/]RB(>/!@2N;CR5I&93L"=P1W(53[#F$7.7C'J
M\XA9\94X&FE\<-B9@\VL+<MUG6)]IUI>)G38EFB? 8NTOFCG>:OL@Y?0#T,L
M7D(:)1F:$6J0WD3-<-JQQ#8Y=8<P(U+ZQGKU_'"._=*4F"HU\653&]'92002
M%NF1=B'AEI"-)MLX7L-: MM2BWH;"S>6J CC*WTJN<HV@@FT":F"<>YISO4%
M6F 553D<BXQH%ZG8YO:FEY8= %4;$7;"10V&$I1&A9&]U3+R@_D.+-@V9\Y#
M\/::!P]]# /RA]\?ON(]B'74;[," RDQ.M-V* Y;IS:Q#+_[5,#1F-Z*\;MG
MP&]7CL5#<P1"A8%,& LKIWR0N/ %;KK/6L^H@%&*XYQ*3 BE3\(CH2/&G>8[
MLP;NQ!*0SMT(-PZU0;R'&QQ%U#!+N3J*$W=":.C!K!V[9N\Y%QRE(&I(TB9,
M#\>L+R$-[N)\COB^S!5'\QE22'(<^Q$93LU$P#@=^-U=1N6_,]*0PTV)S#^<
M9-<>V:/O[^"21 60?48"?Y2:6&N#"/(944Z=+"?ED#&RKGBR/0% H'TF5 (H
MYYJ#\E0C98NCWG[Q*K!JD>=V1M)ZZPK3%2$$34VA\#*Y5'A,5\6HOJ2,)()A
MD!V&U3=3!(Q4%5R9)U32)M'(O(50 -@_G&@P ;4:(053L O,!]ISQ!I:#W>A
M<1;T2">DB3_$UGIC!+9<M8,&86)KDJ%TIV-M5E25M@8#F80%G[4TCKB,T(($
M>X'&CE#M8$;#>6M>;W'9OM'<':*(*Q@YQ!CT6F?0&D(.P#C,^#+YVIS$K;-7
M@.R&]JQ_\H=H\66(,B.OA  P7!J)F"JQE!V*6Y;Q?U5$YK"\.S&6$T6/_!#F
M&R<'1H8FRA@W\GTXI<8ZMFL@4;5R+>0U* O)?/L "5V_+'[R_<GBUZ:^]*D!
M N%J>TL953ZH<WV2N=>'0!N4. E+G4X'J&+W9ID0$[)ILL4NP8YLRI+M>=C[
M7&/!3SP'X496@%##MS5W]L:26\>6?9!6<-5C%-?%)4LBN+DE;A;W2+"LB07.
M>MHS^_ZX B.FS>"D+.A"N[WAP/@2R<^-P^=?,AYL4.2-F5M)@HM[4^3BGK$8
M^JEZ:>4/A*V-[/E4\)1,V[2&#^)I#>+IZ?<GGL3'00E3MV.?#>30>9 WU_:A
M,_3<L;,ZNE<IC%-1@18!^])>,_M.ML52?+SL$$?Q$/-V-3G;</.(')U:E54K
MAY3275@/;:793C$5G<2DRA!UG,BH22TTZ$LQ1A#N/')%X$V H%VYW)<HY,W%
MC%9T[X.B&8<9?HY8HC35@-"5XH&)'<*X@QIFC&: &Z;G##"2T.=?M:)?C=!Y
M;;##Z,M'7Y"=D]WH+<OFFPUM'.4Z)=D7B-D\[*.VV S312H$P!AI<]'K L:*
ML_=X3#(:*@0URR><.'+V<[%*]E]/5:)C-YUNSA#/BX>&=2F#;9*3?N]/.!T8
M,+(->_T>A/'ZA?&S[T\8GQ2<:9Y$QV :<D63V\GC'=8(/=%*?!5]V?*.:T0T
M#=)O2JU <O'J-0$T]A0O4)!ZX\O4F[9 JT%R5RSA:3O]60S ^A3D?.\=')_6
MAOW"8-W)M(-&5X;''*]%U/38;F*ON)K[@74Q45W-?5+[5U6?*SR';/^Y^@X'
M>4/U\&'S?X7PT_/O41K8_79?(A774>]$Z!16;ICX3#N,8]Q M+4K$YZN),'&
MA*(%<5&4%JW"+BV580V N6?@#HA[!,NU8<4@M%MS5 -F+#=($^!;I=B07&^:
M,6HHT<:(%]0 L+8RZ($CFW#"#5_?K-PT%"7S>3G1POI : 4#/\"*60)XH6J'
MK.]T?ALCJ(#KO#$L@2O^LE):$YH#AG*0<HX9F^8E6]G^D="#/W#8@V#B3)UA
MJ@+GW+HP%?ZA,2"NJZ 6Y%1KB0*BBZ[25'-^1E4JM008S;MD,:&'T%V"JBK5
M<K %[2C'BK1./Y..BUBJ4E1[,Q0&W2%C84+ J.,/Q6B!QI'Z?#DA3TO_@1&I
MVC]7:Y+H8*R Y%$]QTO4/L/M0<T$4\&C,7UM5F=V4S$TQ@5<D7T+M%N="$($
M4R%GA<X5*\V+[H'CD'T25C= 6$Z92!4W>M:"0#!UV**=9D4M<66;_$>J.:&1
MS)X+>_\0];RCJ.?10]3S^U&@7GQ_"M0Q@F*M_YE+T-X[36H)N!%U$Z'ZLR1^
MID8.]LC@ M&=422,Q1/ '2SL')TSXC[&PJ:Y5X[09R9B^*WH22B+,3D>3R[X
M1"X;X33$2HL-YKHU]:0HH2M)U[4T"MHXH3H^ILACIY-I%7:/TNQ%-:!49U8R
M)6K8?K@ O,/L>Y,KC^;C&-.Q\0*;KLVI]S:1G[V.0?X\UV3EZL&H^!A,9^O\
M7E!&V"_+NF!*%Y0!IK/6.+\X/H(/1$HO>Q675L5'C5,DD&JUJ>")IVJ9PZ&B
M9KL2V9;.I\B-;J!J6A#D/75#+^N)JEH2E1^U=*!**5$;EBZ6RK>Y7Z957OY@
M%=\!Q]7>]R?$?X.V).FZD"N?F(E/-&4N +J0/9A+PH)J6C)8@CXR#Q;+0X;)
M2QUYBN*1/>Q7D3=PZ2RCZC^D9%]@ES@OYT)Z9TLD$PB0 XU4J98)Z]@D-O5*
M@YVJ:&L3YR93^=!>5FG2\TYZ*#\S>&2G JZ0K.+CZ9Z%0_2PR^]@EW^'5'8G
M'N)X;9O]O@4A.P24-<?H%NPME\067JJC7(_!\F?*&4M[U#!)#:I#36;2618\
MV.YWE#:U(GF&=35]W#>,DJ&3%DYL;;!2;;VOHSX8K'AB%-"01]76L1_8;")2
M/,DSA0E'S,3J&,P45\N"IWB*ZX,7_LXET?4I_#9>$JVO(.^=V8Q_+)5;_:I,
MBM*LLI*J35P+BQFWKE?,7CRBE=&0#+$5&4:4T4G\6)%GE[;<XRNX[A[VY/7W
MY'>8B'5L\7^$JEGS?C3;ZL;[<@70)9OL\#6RL-4+:UD83M#E"H$*/.2V\ 9Q
M5B\IOF%PF<5ESL44R,PHTZ(T!146LN)+#,(3.D%RJC!>]TN>-CXHH+^NO (:
MBRMW=(II^,40C)*TP.,B&HGG 4$0%B57D?!I0-O)HK[Z&&G5HNIF.DJZ0%B[
MKQ#%T&QRE;,R1CH0RN&PU@"&5TSQ<9]T3W)O"YN?3J--#A=:5\;9M"J9F6,)
M,)K3!^2?%):E*GIM$HG;3!#!=(>HVY##=J#GA5V@A9=R< FJ,*5I(^5$-K=L
MM \ZVQV<#]]AOM-O10;;&+/ACZMJ;1A6$NLCE^=B\=J&(I3,%$L=:GRBQ-CI
M)#\"#8WO5*#FQG741H7"CE%U51"S)PIR@BN*5%]6UBC8H(RQ""0UF'E:V:)4
MS.JQV*,C)2LL9X8U]EI" +E'X7@I/!8$:">_7NQ14U<IU9>>\;O0W=8^L5I9
M %<W:0BRE!N F)!%P]4:&VM<L\&.K"5:"Z??A2PLXOBK*K']/5K5WGH2 A\F
MJQBGC4Y=3&T*CF!\#0;&KQ2"#_'M&\:WGSS$M_^ZQ]QWF$IV/)MEZ9#6RB_J
M<DT^TN7Q9TJ>!6%;2ZUZ%Q<4'1+95JPCM!9:%L=7%5L:)TYJ$ .%N*3(JX"W
MN]"&2'R)9/@$\%4SF*8L?2G%JLUH,2S ?/D7,_4$\1=I&X5IEK>4*[&I&>;J
MEBE7*@L!=$1T5'.4?<%CHBU6>_E]G!TQ:\I94>FEGEXA&:+PK&MK?TP)^<$-
M#Q!2HAL"+\LFY3,8A=Q1<OH)V*M;0K9O,11L9< ,_(D5T::*?N=#[D&#OP/1
M]AVFH9WF2 )Z:Y?K2L(-%3YB6K$"C3R>%3L!N"%.1S1J<S^%50AUX5TD>!3+
MB;^H!K'HGQ6T+].FZHMAM^LB(;FYE&)?F8)V9%##!A6:'O2)@+0(XD-^=0.3
MZ Z2E#^',H BR-B%F_(5+O:PW<;M_;Y%!6>+NWF<<7Q@$0H*&?9HE!C+A$86
MR/ VU]'BZK8/^;5W)]F^PYRN<_4E<O[K-0JW!27@)4;MI)OSS]D,<HE?AV1[
MO7J)+W]XC^&+L'*-Z%VBE)$M##T5<& M="Z1FC+#AHWX"K^DTV0I$F\8 *W>
MB3(4VVYJ:RHISB@WP:MTU9&VE&ZPI/]][S;H^C[W/2IES+N8S0,0)GK<A[J=
M7.N433-B[0::4:HQ&<U(?$EX78(D""352J7J5_$I+-Q!7[>L,]>M@3&@7 E&
M--CT9-8U*RK;4QJ]NW>ASKAX^9". 8V1EO77(OQ(5#+OJ<CHS6L2KKV,:BB;
MGS\W1\OMIN<WS(P!4R\C&$A9Q3=RI=QA U_/7WJDU.&___?*_UM3;PX/[8S(
MH7*TEN[UK<+W:NI*85Y[Z1P>]"P=O^'<E3MI.55LNGG3[TP"&4>#355<Z-)U
M(IAXBV$/OUMW=)=>*4\=(F<784<9N2ZQ53E^")5/E=.I'>30MW'A?L<ZG:I4
M7$%9T'W7HIEJ:Y58J/L(WA 6-I[.6W7IPXCN[NKSW)U#[^I@G^VU=AE^]A^7
M8^999A<.:(ZH-Y-R=RT]?9E.WE+)60,GC_N@P-HA.U@B3\TJ_=+\T5<&4?1R
MN 1>G__MT<&CQ5H[O^()O.%11U?N_K:2VM\2QE[Y1APS_[-L/O\K"DG3-_U3
MU;%N;K<_5Q+@-XUE>)[Y]6D(MII"CZR^IJVSIJFYRVE8N-'O:#WX-:X7*;:M
M*,NJ1\SS\(197P3HO&!SQM%B3F]*Z;'(NW)C311.OC5N 2$=)2H18Z/JW?%N
M'!WL\Q%(Y/RFGCAA2&;M./0MU.H;JQ=W-O?=Z-^];=5?(,"L*,3^MT?5V[=/
M#@Y.WCY__N;)Z9/CI\]>'SU]]O39FX/73YX>O#XX>8KGI5JILW=2='SEJ/"W
M7RS7<G0=_WKZ_@W\[SPZ_Q"=_OKQEP]_T*?CG\Y.3_&OM>G_6 XP'<WOP.P"
M>8VRR"4.;WF%CNVWML(Q7$KP'LFZ,FKT*96-^AF5;ENUS%"9V7OQAH_G)]$Y
M-$3--/PXK&(L:+$;O-0C:*/;6G68Y2J\H55^^>;R\&L.]^\_GYZ='G_RZ_#!
MH J/'069<8Q\1Z7*>SU>;O#M@\P()Q2R?0/G#3INHOU].)'V]I\%P]SW2#.2
M7)=G?4Z;KS*>8"K^7>4-8N*XOR_ZUW)T:H&Q>'*[PGH]X>%@$1-=("+A"J;2
M"HS&RL\21RL6Y1%Y[V@"E7T[?.X^M7=^X<I2CS+RI**53D6@07GXI'-$,/^&
M#MF/I:XH?RDV+#&YH?8:3E0^UK;(4^\K.NY:?$?L94WX1*V&[SM'8A.B?XUJ
M)*"N7VW$0GG_X?<X.L?5\O;#V2GC%,9%P6[]"Y4U0OGF^<]C@0$@%V-*Y8M@
M^!GM@!/N/.B)^%5BP1NVW/#BMYXVQ EC*[+3Q72@U.HSC(KO=#'0/$_.A2DO
MVN.:K+3P#"UQD#.IC<"A.9(AA424H:TD^C=YQ*+M\G)=ZMW=376/JFY""/M;
M"C;ZNDR I>F="ETM]?SE[4-?_F$J\2(B- I#Y=4BN? S D.I<A06;(,+SJB$
M/2=.FAJOL/<_U4WT46?UOSB*C&7J&(3*CW74I*KJ"9*A"('IW(VB=ENYA-;$
MBW!)??=8N ]9K$@8C:NP@<AIB#7"!?D*(4Y<+  7=Q2=AIC<)8FMO2)X5J93
M/#L,'V.[&T*:&(Z,,&V/BH#65;)I2Y$F56U%+2&53$]N-&6J,B1N'D\CDW_P
MP>/:S=7PTBG[>?&_@F!#;^A%FJ LHJ0%N*RB^<'54!GT$]/,0BO>&.+==K#/
M/U[I:JNS\2-"IA*F^]*Z(GH4374JL Y=QA@S&I%:I.O2P;?#;F.G?;R^IDP:
M\9HE_P2]@.-JEAW/(-O@I6#CP?WF^A-FCOLU39),5_I+9 GM3^A4CZ-/!:S6
MZ"-R>8U2G25Q]/[O4;3W;._Y7FQ18W1\NZ[!&C=2Z&!KN(UE_(PCP 4Q90#7
M)6,[$8\[%[#8M:\C8-_H49I;D2"K\"<\S\]H8[2&\O9=C!&IA/D)6#IP/6+]
M&,.]FNCY5'*!L!W1VGKH=[H2RS+'6M%9E!TA>S,ITX[J,\!3$>%_C^@T$JW#
M<TF,&A2$@2>:ON+>P]T4-)4Y"6U/0(+V==F^*9TR02&F+82<VZ&Z K+F;1\>
M-;EB]<2R?")E?EPP4^8ZUPCEBQ*>39>7)Q20%/Y/,'FM,<EKMN_V6.R;328Q
M M%79)2Q4==E.FAJ0Q=)N%]^9UAIQHZ@J]:*J.8A97XC':5-B'84!/*@[BRL
MUE13Z1/[)A-WH86F:]M[31]D9!%)^^8+R,.MP5<2D*_10KNEG&II3:06(.CD
MD\I 5PI-8%1+L$JS[XX(K<507X!OG&NH:O$,604D-DL=EA%7 :B&I:8&;:6U
M4*8*=A6W+VV0[I)E0S5LCE4?X(ZCO?] 01!T#K>%Z%H3&'+&D'/]9.&<0\Y_
ML]&L L2RV39S6]2=UN]ZR#Q$2/!150U&J5^S2>VK<*8\+]7LI>).]$I/L<X+
M2?0UH7(U@ '#^+DW4B+.6:.#%XQ+Q2AW83WBSZ8%&-]VA'A4UP!IV: =_+ND
M-_>V:8!PO#2Q7$M)6RDE:9 U4Y _S11;GRFF9X?%\JLJX9C9?U)/; Z#RL ,
M-:\(!7WX&^9'TRG%'<5V7L*J@I]@12T4&VL* CR[KI1XMM0K?I\SS XV)<-L
MPSP31U_G4.C'6ZY322;1P7V"HVX]>O*[#DMS5\)[M:S0=\;(5]"4:BGZ (((
M;:Z!?T"Q)//4/EL9O*5_FY2N$U2!^S#">/ %<HY\:%P6*_K@,/BA)V+E)SF'
MK"U^[ER%A(MB'\2ESN".K?V#;2R77D_\@C0]AZ)7#P,$KC>"_DGMELQ'HH"P
MX18^U[RH-G6BVU*_-#HIWV;->QQ\2%6/+R; <<_D?C'<^%R;.?>(*?#%$26N
MX.E6(>^YF-P!SFP,S<&L$2R'J+C:,F>>\)*%^VNV30PI/OH;0+]6PXFX=]&3
MC^;/!'3<.CH.!NF,G]H:&[=\$,R=51X@#MY"SN>10O5W"W4-L\CP#H-8<ZDK
MVX9<75 %_@)IT:,8(T-Z(FV#4?+Z[FYOE\3#AQL4,GOU$+0C*>Y,<=8J=1KL
M*8^N#,_ZY,)4R'-S*(>[;9>4VT[SBR*SI"#"Y4A6QJA431(SQ;K*&/XLW!]8
M=;,V7/L5YOSA^/*F&1:SL*__584%/G&.$J3"11M*6M:S@-OK]H@L,.?FL?(N
M33VOCKT:Q.#:H!IW&2!!\?ANM%RTM@3J\4H"]?55\A39A;DXUA 7A!1UP&?9
MVCU"T0(O92FT2'2ZMN#C GV>G [D*V^G:##Q)^5Y8)7<_HP-X^1MRT.C+SL)
M H]5&5,-9YE-.\,JJV5"-[;]),Z_H>9E08ENF-\Z9/<-C@ZK^!V/;BS><@1U
M1H=[ CH*U&1' V1P2.1$]60_GDGW8=JE#N]:9GOA;,7&3"AJE!VT$GS;94X3
M'EHIWAB'!DN5?JGGT=;3O>WVR%_CL(7A1YU *W*QX;C8A!YNE[Q>"R$OV5?.
MN#+"WTC3":P8@F@+CCJQ59J]!=WA=:+;B Z* X(BHI_NP4)%(J@5>[8A<@X$
MW0=B!=_\99_V^C9B1\+*<'7G?++U",T.Z9K/B_7"8CALJ++X/=M#\=?8$"0W
M48ANRBJ'97[>63^8"XX5]_S2-B&":,)';KZC<SR,D-(66DN)B591EU3$<5DT
M,PRP992JAT';D%P_>)N:>QF2MKH!9E3" @D..C_MH^?$6GP6>\M,GG'U^1>$
M[,)3WR:'>#Q.V@]JSHH,H2'5JYX%V'&]6S/0'WN\TFJ:Q,R$18)J6_58!M+*
MH44F$L59L-]VLD940 $':.QSYV'@9(B"PK//QJ6:BB'E/'^"22M%44:=;$P$
MJ OJ)E#N#B7F"-67T!_*&C!EDJ1!6XR4/OGP^NQX.^!'?BL$))2K*A;5>CW^
MZX"=&17.0^%8SX>("^<(.=I&R5L+,CZG?$H+PQG!W["$DPY:@&/UF&;A64VY
MONP^FHZT5L:67;OFA5+ZA#==:LJ>.".%'J*JGJ_3]1DP=Q1Q>;2VU);EI:.C
M#W1P<URONBEKA'BW3FVE<SAH4(Y0T3XC1V@2EP' $,]%^=JFJ+H _E K,>BM
MY?"_@%RU[XHNAZ:/%8ZE>$/EUZ 7\<]BM[ML_@*P^V_@=3_\ZWO=[R[5X"^>
MC_GB:/<H^+^'[,R[7D9W$0BBI)$WT?%[^-_)R>G'\],W=_?^;]"__LR/S>WB
MW3\?Z1YNDO1K27\6:#&/J\<8:O\<G>Y&K[$X%&RE6R@R_GEZ[=N79]5NP"1A
MVO/=3-/:INB*U.6['N0[2HTFAHV[&?F37SZ0#GOZV\=;#OJ=CSRE9$37S5:_
M&WUP4[/][\-1OSBM9A,[Z-)!-[=;FWV^=V?@-A)LLX_H:\C(^\^N\9?G,CA\
M<_ST]?'1Z=LG+PZ?/'_R[-G>TR?,9?#LQ>'SO:,;<QG0";*.WE[/P["L!5_'
MQ_&]M.#:#JD>;T@Z'4=5.?S;(Q=;M#"R2?I_TRFLXOW=/V?C1Y'*ZE4NDY?+
M>Y\AD2R[2@X/GPF5[;4;^BTG<%T-^%7-HT-)U/^F#?GF([&"MO0UFK%_\"3Z
M*=/Y)>$9"I5<@__A#IISEB9CC6VAY,J]9T=/]K[O9?(&<1JT5FY!3/I7&(B3
M(A^#VMO89$6I-V2I.3#F=3))]2AZF^8J'V+6W@?D<,!8]A]X:=4,AX0&K(DO
MQ4)$TBF2&U<&"7&IHZPH/F-8ZU)29^A-!M7 )8T->I1B;? X&Y*7MTC\O M$
M:+4ZK2)?*#)4G")N&/,MBXQ+8Q&8V,=5<-XV=?KT@TOCOQ;K[E]QG7QHZHSS
MR0@@C['21-<JS:KNX+^\=X.UMJ#1BL3ZSPZ^!;'^#?GHN3+PP=.VS7&E"^J*
MIM[!S)*\P0UL\'F(2:L8I I;^W\=[3^)]_;VY&=DN/+02(E.&D&4$.2)2.!1
M,G'$WS#3$W>,J@(4#3.]KY$5O2]>VYW+A[WPL!>6[P6?.:I[F UT=+2WN\?I
MN"2C9=_0EDD1C*C*G!8\ :$7 .LM7L]CM(9/_NDLSTUS=,[@L>QS746S3.6[
MM]H^#WOE8:_<;J_P[I#2PY$"15?O4/:'TQDEDWL4/=FC4Z2JB^'GJ)A9?736
ME,,)'3D34(!,B;4I9M_QI;0IA#WNX EM.W,[TH)0.A9EX2"Y.V+%;?WI/'JZ
MBW>8RX1C)YLS.(WN(MTWK3HM#A.H1H2=X4)T%\J6&@U*@IQ0)ERM=9C-[O,3
MK;,&R)6G'94$^NIJ\FIX\G4HSUC<>J*RD5TA&8AKI,O'.ETH5HT-QE9)QPB#
MF?^]:SZ).?,%&Z-G*+W9H(*U28OE(V/V1UIG7"Z6BPC4:D@O3Q=64*'<0#H8
MVNVX9WK]5V[ )SS?L)Q/O*ARR*;\>TP5&$BYO08)X1T,J>!G0.9%9_I+6:CD
M/@S/*O_V1P:_SXT1SN"WW:._?8RCGQM0NJ Y%4@O3/S\OF?G9/ART2*V#J[-
M"8/^CQ\>#XID_N.__?!X4D^S'_]_4$L#!!0    ( ".*!D^R0;FVG70  %/.
M @ :    97AH:6)I=#$P,G5T=&5R96UP;&]Y;2YH=&WMO6MSVU:6+OQYYE?@
M>&9ZI"I(UMVW=.K(LIRX)[']2DIR4EU=4R"P22(& 38NDMF__EVW?0- 2J(H
M6XQUZDS:(D%@8U_6]5G/^N[_O/EP<O'[Q]-@7$^RX.,OKW]Z=Q(\V7KZ]+?]
MDZ=/WUR\"7Z\^/FGX&![9S>X**.\2NNTR*/LZ=/3]T^")^.ZGKY\^O3JZFK[
M:G^[*$=/+\Z>XJT.GF9%4:GMI$Z>?/_OW^%'W__[OWTW5E$"__MOW_V?K:W@
M31$W$Y7705RJJ%9)T%1I/@I^2U3U*=@-MK;,E2?%=%:FHW$=[.WLO@A^*\I/
MZ66DKZC3.E/?GWX>IX.T_NXI_PD/>RI/^VY0)+.@JF>9^NN389'76\-HDF:S
MEQ?I1%7!>W45G!63*']%WU7IO]3+W9UI_0H'GJ27WW\7!7DT@=]6!\=O]M\^
M/WQS^/9@_WCW^.3USM'^\9O3W9/]-_O'QP<OGGS_W=,(_H]^I?^CGYREN=H:
M*WR-E[M[.__UJE:?ZZTH2T?Y2WHY]_E[]/SO\).^D:?Y6)5IYQ?TYQ4_8E!D
M"=Q"IB78W=E^]MU3O$"/SQGEH'3^G#O>:90DL$!;@Z*NB\G+W:/I9_-974SY
M ^>E8EA;5;IC/+CU6QW,>:N?/_[TX?>?3]]?!,<_G)V>XK_\M[OMBSCCSM2P
MYK_3/(%W>'GP'"ZX\^(\^?YBG%9!W]"#C7JL@K_\Q_.]O9U7QZ-2*3P7]/?N
MJ\T ?C6)$A5$55 ,@^-FU%2PH$<AGH8#[[>GPZ&*Z_12!6_@1.D;A,%@%D1Y
M$@Q4?:54'GR\. DN8)#15#5U&E=A\"Z/M\,@"MZH++J*2A7$13DMR@A/N_>$
MDV(RC?*9&1O>]F1<IE4-LQS\4L.*!QMZ-)]5W.!H]-7; 3P(;@UB)%%R<W@C
MO/VDJ9LH@^\N51[E=857U1'<,PG2'*Z .3 3$](O9"0T O.D(,*+<*:&1985
M5]7+VV\+7/^7.\[FOM4^:6V,F]SC!IM'WX8$A7[0[K9^N5MN11I HF)9X)<-
MC+_$^<"C-9EFQ0RG><F;/_D>EOG"72!<DBJH"UK3-&\4_EO1<]R5ZZYCYT<#
M);^#;0%[VMT&14Y_POZ;5'0O^%U"VJH**E7#?BCK<7<O;=^?V'AQM!JQL1%M
M+K$4K,'^\A^[1SNONO^]AXUS$DVC.*UG=]DV=OVK<91EL' E_-L[[57P:QJK
MX&.I4(B@,'B;@L2 CTH%$JM&$P)VRODX GGT/\5EA.+MY.V',"C*H&KB<5#
M_>"?*D_A$V5W7.4]2 8P57$ZG/4,;1S)R& @4Y1H@S2#[:;@:4F#_TN;,&KJ
M<0%O.X/M.(']5C4P<RJX2F$OXH^G!5M4* ;GO!<+3=Q[="&\FR=7=Y^]JH)I
MF4ZB<B9/#CN#G:H2]O_$?__R$AZ(@K+T7KP>1W7 *@#>JJK10J/QPKEYBK\T
M8UZP%A&JK!F>5[#M*K 8!QFN704'!8ZN^P[!L"PF00VF&'Y,_RLG&XY1>IDF
MJ!;@FZLQ7(8#D'6N AGWZR(J$YR_-VD)RJ\H*ZU3]!NY^HNN-MJ+;Y&6M(BB
M.<'\Q%&J2L08S&T>IU,815;$K+-@@J[&*4SEPGDV,\S?#;R-;)9.*UH5H+GZ
MSR8J083!QTU9PHS"K-%38=(B-.)VX/?Z^I.B*6'*?TZ3)%.5^AR\1@-:555P
M0I97&)P7L/V"CQGHT6&JLB0,WO\M"':>[3S?"6&,@S_@E7%N2V5?#3;M.<X$
M_'MO(][<2#=Y.M=-: [60FB^49>%/O]OZ/"^"L[4%+8C3 9=7MU%GKYI2I*'
ML.\N0#$&&W N$S4DLVH BWY%B]N5)\H8 594R<;M"I<$WT$9\3!08)VJX9#.
M*&ZG88.[7^]-.N'XL<I5.4I9Q^/]S14D-X?#*.V<Y)"^XZ<JF,7H$@]P88X=
M7NH(7W, T83 5Z)S!&-4M 3ZP49"P0O!E%?#*'8MTVOE$#[*"**>2;_[#.<%
MG'.\#,XSJXT2==<5+#N(YR":3DM0=%E'[J'9[[T+#1'\ 7K_.OJ$*S$3A>",
MB$0R?@,36^&OX5LPPD"+%:7H9-A(49"(Q,7;VQO%_/A7 8X*] *(G7%QI2Y1
M(I%R09GBCO,JI?6L<4A@H)7JGPWLH8HT<N'J+&>(\%#]]&J<3BNT[$9% ;LM
MPNG$-=E(X3EV*NDI:$""X$EQL7'C@+1-4;C7J&[XE8LLC6<H$B-M2\"LHWZC
MN;PD'<_O 2(1IAXNC^1V^%)MNZ*CC6A[TXI9(Y9U6#1$[XDV,>N#4A5#V%!!
M\/!]V[UE?)$O+F[->5R!D[,&.O#A. X8B%H@ JU,9H%G?#[QZORXAFN-W^1N
M W8+P32E*.-4;CH$!4/F3Q&#M:6/*<<-8+F6C1S0B5IJR;]@Z !$\-(K^0X<
MF22%N03CE":SNQB@FNOQJ]6>D.XDW\N929>:F2\NR5Y[T8^EUW*)37[C-7IQ
M=%]K=/Q@EH@60MMA8*:A.^QYM\I(+J/70="03<.7AU;BT"5OTBJB4,+,,QQ!
MYHD':R\0-S:8J"@7D\0^&(TL,%":7!LG*A]%(V/F@/=7U1%(63 ;1^@?-IFV
M;V9HE;!1K T[// QB-(9G&P1I7C7Z7A6X>=HC:'DA7^EL!_3DNU:<I'C*">K
MZS/ZU^S[@W?39#6.A.0$_KKGJBRJ*&H'=J:H@Z*IT")-"W+W8?J"C#R*,?RX
MLX];68T;IV*Z68N=6V]3_L7NS<[6CO]\*];I7L]N^W#Y ;V\^WC^[[BTVF6D
MM@:PS)^VR.Y\&657T:QZ<M?96O90;P5[P=;-I=&]C&'>K-TQ27:]E%S!V'?W
M@@E\-JXHT$F^3UJ%]WV4;W=(G3&"ZZ9 V(#02W-P&,F;SJ*8PDOPD%P-T[J2
M.\^[73W&7 _?D5U:>$.08C$%(\G1&JLH PD#M\XIMT2>N:00.JX9R-AS%,PP
M(HEE6P-23Q;[;)',5XJW'1?@\[73$?AP)_1I @M%.?,5Q :\8M> RM0(5J!T
M(D&7:I.M+?4Y(E,6W7IQE;O9D V*5/@A2C2+!VXZ!G3 )*TWMX/W18W1!50(
MB=9#,/5J5,!?(6LK1R]-,/]HA;A]P@!LE0G>P%55F=+Q5@IAI&Q\H\["*V$%
M=+CQ8.?%,;@L&WN;&R>;>FG>X=G.82[.U*5"C^"D2$B%[KYX?A12&&*"H:"D
ME:5,E)>BQ.]&39I0<#JMJD;19^(GP,)OO&MGAH(KW)1#CA.Y8[2[)N%(%D[X
M_)OC&&58[EUL3G0M3;#7:V."A3>SP<K@)&HJU1,B?84R<2T7Z60M%PGD@@(I
ML_%B9Q,6:U:UXV+^VG&DU^8RS!F3^)D-G-+ZXF*NJ5^Z-HZI6=5'M_2K';?C
MFM22SJ=VCYZ7<+"'#],VLZTA628'AS<Y@$L.D?[T45W+O^U?_F-_[]6]'NQO
M6).Z=B7JR1\PS7+&3D576[J;20*MM&D829$RGLO9/BN.HZ]@12X$1G1MXJYE
M<TM2T3<BX0\R(DOVEU GI;G&FHA9B%F);;$'UR"KL"Z9==B5!ENC_0(T 5HS
M?>L) &_A+1R#:5-.P?.KNO"(L.]Q[$J&^+.JB?*Z)_OLY"^-;TXO0![G)/J#
MD41N+C?84)_CK"&OS>S53=Q?B:"K^<#AJ29?#GQ;N%R]7)W4)MF[]&3J7#!F
M9RD&R<@]RO[09&1-21K,>IGLN>KH938SZ?_N89V Y"DQQ"FH@*+LP+7ZC^T&
M)YPIS$#"*C)CH<RW>+^$.M)^,3@*%'8A]U_2[N5#F6?PRZM*]I*=RC2_+#**
MPNCYA\L0.-G$E&(?E455!;D:@4A1Z-T25J%4(]QZ;2."XPUC1@:HNDPECL3Z
M0"N#$XT.((NV9\W@\9>I02W O(-:(1LEI25)"4"<BY5O@72\!\@%[Y7;Q0#>
M@1$U;:6&4 H:.RWZ55IIW$647*JRPCQ7Q._0O:V.B3@H% 8L.(\K=")2;T>\
M8?O6/@3&( TP4C9M& H4DH0@' /<,IU@.-^/8"V[/^[A6%_RN38G$$/-."^T
MI"ELL%0 B[/6<I"[O3'GY][NU:B3H6!BBLNTX@GO2F2-11%X(_S,#FCQ9I$M
M3_A Q\&L@D,<Z%'?PQQW%$<6H]@PPPLD I:#\D*T2(T'*W0CC7"71*L0/0':
M/B PJ!Z-O#E&QFJTPZJX3 <L\.,,=4]%:2 "P\"$1H,"/>TNRG6$LVGG54P_
MG1 7N0=_>H>LE!D,717&D!WT.L* XKGT</A%SD>7IB,M036A_(YQ?U,$+=C?
MV0)7(RBFB*EJ<CE2.'/MM:/C==V@V.ZRR%-8%YT'BT6(^Q%=JU%AE!AZK@JX
M/ %I6"I<[JZ9>N,$T^($S]+I)=]R6I<DS_ZWDN2Y%],[7E_3V_$:OX !'LU_
MK-;%*LI=]6&R\(B.I!R3-DT'495R*HI$C^O^I@34!@DBF8W(E84V;451F U'
MX(@DS*BF40; <@F!@=,2T34&%TN/US$7Y^DAV N4@,D+5@%>:BPM,8:ZO[,)
M7Y?!I"@5?]..KFXZT1VM%3@Y!S/;"@9LL)E$^1^"]M-E">-%7:0E348GCBLO
M2GL#[<+/5%U@-8VIV$&%A$9IB::8AH Z;[ZIZS)TLFK!$NEDJ),'B\C(K-@Y
MTCK:/)N4S%719(EC#\+;1LY3G ?<9ZCR'J/)#T:0//G^.(AA8S(TI;YQP848
M!95%>;>L>O@SLG>P!V"8#G%7'L*NA'%A 0SN7MHW?4_.DZ<,,G=N!@/%JN'?
MB_)3<(*FRH8X)["1)55.;^3;6KCO')O$$0>1.1L.\#>438A;M4[KIE84!!![
MV)^RD2I&932%1]]ISC9[;:W(K0\Q@'3'5#402G:E/?L.Q@!OTV-B=_QPS&6G
M)=813*B. #/8.,%HKMNW<OQR/K:]U3.,&Y@KBU_=9SKOFX FXJDU>U%\6;TG
M6V'1M!<@*H5JMCZN+S2SH,"L!:K7 !7R>7KJXW3)6KO6@HM*"8 "=W3\<U*E
MWH!HB':\M 47/"EU4+(^PJ\#9NXU9I)KC*A0FS-1VU5LK8>^S@XB<HO(>,WL
ML98 (9E&20KRJ=$BS[Q[N"B<IBLCT']"SZNNP2=M:K=$PI==[8*XX@I\1:SI
M@.U8-G%-\3\P=)("[HXCM%I9;M03E;G14#%VJJ9D0D6R<)=*G-5-YS'M"$#?
MJ'7H9L7IC&\PN>R)%K"MFUAOP.XZ@T6FJ-Y(Y95P%?#^Q6W^&K\\C[*HG&T&
M>JF'@43=S7VKOI!B!"H5=H$W L&?64L"%I%_ZSP?[?3K*H#DUIG4VI+NK*2F
M2[:7S:'IC"O^L'ULUQ1A?_DP]YH-"+:2 2V%9N/<; :!?^0Y@:[OY:3/VXE5
MMO*\B.;:@E,>THJ^E= @6J4#*BC$Q8NJJIE,641P'3HN;4]M,W.E($ ^!O.U
MLD=2@T37($.;/*#EH#S"79()MT_RMJ3D%\SW]C^Y'7%R'21*SI) :5?%IBQ?
MJ*:T 7>-(B)2ABM%'!-5CK"J%EW$(DL344&E>$D@7\I1E*?_$M5(X1&\$[Y$
M3H0,H.@PEYHFE(U! W<X!//(Z!Q3]VO=+C"52G69%DV5H2P$JW*VA39;XMW)
MTW@Z,^IE'E26@0.0@3'+YAEH:)HT^L,!*2O,FM-E[E5!Q%DP/Q-,'PXI?@^'
M7-5T!UN9W"EGWO#>ZS8O(WG>]AUU@IW-;-D6H[)HIL9<;Y6C@[C1D,7=?3BY
M&_L&^PR?-R6;JJ?ZM8\Y[;/[8O_ R?V'PN(!>T:VJ1]ZP!F%_SDW[Q3JCS06
M7F/N&2K?,ECF_[SO#<V.EB5ZS)RL)'-R\*UD3E8PTKE28:(F PP08?[<_BG^
MA!5^%1'@6.*'RISPE$):!7V/N $,;O'1B=&&9.>U=7ZL:]O4IL8"= *XE+[5
MKR/CTV:0I3'<94@%*R&Z+02QF'/?JB[B3YMA$,440J/18E&?ZTQCD1U,4UED
MCH]DP=$9N/I".!*"+WR%;P&C0F8/DD?6ZSD$KT?&T?,^<T:(+"=X$0XTV$"W
M30JQY0MZ(B/M"3K0 MD4O;@/KCGB^A>5*>.E&6*(4$-#*DKDP[+1>B7SB((&
M"JM>..II;B@5Z:2 F([,#<?V8;(6<!&!+7%-L4UT,V." B$4=&U-593/VT;S
MU@:9J? ]<6U8L+?NV&]GA&W[@D,L$K,A!<A^#^D""9!O[&[>:MIDRV:.[2.T
M5)7D_F^XM-XY6_)]<'/NN9DDQ!U41"*BK27SU23*08.00U&K:,*>OCMT7T21
ME1=-5$":E*25(WQ\:KRTTI@'+I]#&PY.;Q;!>(M,\9DV']F()9>D>1%-U_[1
MUM>- G<]03J0/W29R3MP?B_QI_Z:.;[^? S%\IA&!,(E66?J!1UN'\UBUE<:
MLO/B6-M'K3@HI3:](RZGT;ZZEJ*4<EU<V7:!&8@&+,@S-6HR?F-C[&WC,+;V
MP>S?.$2:K>UUH'G97PN:EQ,G(O=(\/+5E\,)Q*Z$'-+">T'339H)AX$K>D"0
MM-BW#*XN8E^Z%-_V/^%4ASL[.RA+@YD"2>G1!-HA.^2USJ?VOB"(2$9268,K
MT]4_D3(,K+ :_F19E5)Y<E%RJ6@[&6632-$,E1Y(3@2"QIP)@]\*DK;#F!AR
MNHJ QY.BP2=)-C41UE1\U%AEB2Z3MK15670E1(?NVVFR+$=Z1LD?(!PM/YA'
MV2BRKP6:\_3[*S^W[#NHEO>7\T>U8^90!)YK-]TA4KF)74;-!NE< 7_GSK2Y
M&;F63M(A?@?Y8_6M8$4L&9FYWI;:_WER"O>JAKZQ&I371=[<B;^Q1?S:VN#^
M$4*^51 <'J,R_/\<A=  !]+B085/;(G\7#ALJ.U!@<4ZAWLCQ>P'"EMZ9_ ?
M"H&-="5U'8'%7?O#<27S/CN5WLMATE=(9,>PY1!>4P89.HHZ_DEB6T2/(79E
M?($9YJ:6;O[W*F8P-LPJ5>S#Z:0I\<D9-"<@T00V:$[3(QT&8,3>>?4-T0 F
M#$W'.6(0'S J(Z8PI "O_EN/0!0)4CO I_A I*(]AG'P]T**T3LFTD=I@O>V
MTK;]1D'63,!P!\69(X-'K3V GZ,2I-ONX=([]KNJF>H?7"H<7Y2)**B+Z:N.
M^+ W>#ZMGWQ?C[]["G?X_FZY!NTY1IG*$ST[/@+#_\[$*WF-<(JOX$# 5W 8
MUL$*7 ]4\"D8)/4L6(UMCM8@)?1QH3ZC,9,B5[(E>B?K(.S#G>&"=:LZ%(_.
M@0]PK*J@G&&U:<\7T<@PAO?CQ8FM"^4;H).=%;C/T/B$NV'4 J%W691O5)O"
M2PN'EVIBG4<$,1Z881I3^%&G0-ALQ!-/N6D2%"O7T-\<YG31-CV.8Y5A<PI8
MXE\5MK48K="%?$Q]+)/Z./Q64A_?(%'%6W'<HLM"&)0P@E\T@SK4IAT7-\RQ
M+'MY7\$!<QA?V_@=EP^&PH<S/Z;K%UF C=3DEY)E$"%_!89<Q=)8)::"N.O(
MMY3"UAREX%LG#@;<:AW7$:?Z8BNE+EE*:8@;@LD-=-$8@</"6,J.\T\O8C6-
MY%ETB'*?^?\W7F^R.GVDJEH!"_*"-9JS/@_B'+@1;@=,3PQ\"%D0%CX3<-A
M[XU )ND0"\B+.I5Z6I=9G>YF'9E..-Z-95#&-:<L@([EZ3@&E=/:HE7+G, =
M/JY4AG0VNWMFF)R9ZL%!NP]L1Q(WN/(TA=^J?(ON)%/!CKAXUA_+HF9^Q(_T
MI>W"5>1PKF%AT'J$'\9$-(":GC*LDJ7N*49VLJQ?6Q+AT]U VJI%PI\<#K?(
M\/PUBE?@%#E)0M/H@+!!*94X#%':P&Z9T+;*W&+$]H[![HC!!_C%1^J(T-,"
M"910B1SME[+G?+<:IBD ^<*I6 I*7,H;8DN#4R=3.M-W:J8H%/9VG!\ZO_F
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ME.KR71CMBQ<O7-UK:D3;^'0A\K[1.4_9QZCFD//(X:;^AKP0-S03]GTS(33
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MMU17$;4OP#F!DY).*DZ\E78#R\FP^W -HC3/UB)*\X99.1!3 Y/^ELLX3C4
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MB.A"X37!C\/7XU(V?(-8B$6)A8>IQ80HJ6I2F@DIMDW4H*;%G-!5X$TJ:NQ
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M9O'V])NY4_1XRN_AE'^#5'HG#N)X98?]H24A.P28->?HYIPM6\3F7ZJ"7(W
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M8?MJL'FU.-G;B#>Q"9YVGVWZ3R9P5<*RDRNX=TF)K_9E).4;-4QS<]9E%_Z
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M?TD6<C6E%+;*A HS\N;>^K8'QH6<2-7Z'[%3N) B<VU+] 6A3O^!G3+J/*B
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MO5LOV(K#5^RZ<&&JWL#7*>;8R2-26N+G81.>Z2G4M,1#O_WR_U!+ P04
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M%.NUL<@YQQ!UWB1G;#!)',\6\4.PI7<(QR+)BM#'V/R[,Q;)*J65-\@RYE'
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M84<"PM$"'@FTNS?44=)A\6+:];#!R=4?J)-1:UOHB$-XM2U_D:0/C#N)$F6
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MP+(4%A2\H5A["KU\^G=,^F7M:<(^8IR,]4+(!LM?8/"F<O^FS;T<!3306Y/
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M^:Z"05S9A)( M&0.@A]CX)WB3XZSS7E:Q#L2UM.EWHMJV=\,?%U@H8A,B0M
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M+.7(>,L1PYA9XWCX#CT5=A8/7N?%!O)NI8WGFB]7L^SB:H< "_W]T5]K*AY
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M.\$"&6OI!E& '.QS>=*MVZJR1O/F,-6T(*JK=N_Z\UF)Q#LGB8(" X>P)1X
M;,M^:^K@.!U--;%_KKE&&)R/#D?E .I7=?VI[/?TV_1V=7M0:4_*)%@XC[PT
MEGDM)5;6\:WLE-'ZAG3K"_[:J.?MR-ZIW@)^1_7VN$SB%0BS@Y*4!-DQ!\3P
M4GH(I2'C67:WHK<&L@_I7Z^W2:>LM,@0(K6%DEOJ7+D:]-! T*=+95S63KO
MO8Z-%^!D$%%HPR&W@$IHZ59FB*T:I^W4FB9/WH&IA]>/P951V6CCI<A0FW1,
MA2YA(B%SRC$>-Z9(V:\PD-+QV&H=8+UWD^XT5%[#)EU8IC#--*;1-2P"J6RY
M/>V10K1/)UD;SN^Z[K*6<1IPB+^_M:.\'F'Q9K%899<71?P9[:1WJXCNQ=4Z
M]<;FV]/F@1H/2*"$,0[6>"Z@H @+8DNU( Y)?98-L[%7EV6#H-EXP_A1;[<)
M&'U>F'0VB>G8PL<75T_[>7&U4ZSMR^7FRT<WR^S;2^[JN0F%7',9I@=OJ>!
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M7,<-X>A+Q3;[O'PS7P1C(U+\0W:9W:X]6_>NBR.S_/'*B;9(&Q53J"&EF'#
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MH%ARJE79?R_HB/*@=:27O#NT^K(PW^;SZP#!;9PIHP5^Q-NQJW@B(#2 ,,Y
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M)Y>^M:?#EH'I,=A[G17Y7]/EC5DMEOEM5FPS87_(OF3S5?8AF^37\^E_#NY
MGM90@@!6@"GNL&,Z#'L$$UVB(14?8:Q1BR9[IUCUYW==][/*U4?/BR9 \V#/
MAH&(:,^Y=<2Z\EV@84*L?VU.9Q%)+6J_(1H]Z]<'*';Q]<U\,EO%'2$5@R_"
MPO%3^NTX!4YI+7'6(B218HP)+(P4B(H2%V_@""_&JJ_:W1SI$*Z^:+3QE\VO
MW;>[8#%7&B_VUDG":.<4DQY[BIB$QE"UE=%QWF?:K/X'CK9@Z<^V6"POKOZ>
MYY>/[:N/^>RP';&O4B)D3,5BJ&7!, ;.6+BUH"CW=$2W0;>HL1>F0TOP]$4"
M=9L7R^E_-L$J;^;+='X=X^7CR+4S-KU:Q40PKJ%F84FDB"&2@C#&;:1EQN'Z
M!F1W-[.U3H96(>K/KEADX5DW@;Z/X@XVF!RT( [42XQ!1'H>AM+P&P9&H*W#
ME"FAZ[L.NKMIK74ZM(E07VSXF,U"F]=_S^8!C5GHN;J\#4J(2,3\6<=I4:V!
MQ <X$0QR6P!P&!T1H:B4/N9OJ<V/[BY.:YT?G4#5=PBUR6\_3^?K(>_A[JZX
M63N]W&S,/L[U9F[BKV_F]U<(QHWDW57B@ D/L*R'IR>*A'E:"JZ! "[8\,&8
MQUO<":]_B+J[J]A:I^CX<!YLG73*^BC12F)$I4.44"LP9[0,UV%,4E/_9$AW
MU[.USIVFJ/2NZ;"*#XOYMX</!>THG0BB (,2*@>!T,Q2O+E;+LBEC:N?6Z.S
MR:R+57!M0/I2]#:4>MW1#2O?Y?.\E.!==L@+4J5ZXFB\B\8$\0VQV$K"K-](
MSCUT];=$.YLT6J1"!PCU-@C$VRD?=_6)#(?&@X,5$Q_> N]<&.FL$I &^$"Y
M:<C#$-AG)I8!AH8VL>EOE"B'L=+;.YVO0M\? @UU=I47V7VY3^FW;.&^A9DR
MZ"582,7W-63KO,/S9<!]MA;[_KTX.+AT]M0$ F(]5U(RB:T!@E((2YRE)/6=
MM)T=K6EU3!H+L/T2.$BR><]T6%]>'3QUL:=&(JR%PAN)B*;0*R0=+RUS'CZO
MORW8V3&<UHG3%)2^E!YFUDKFZY-RB?&>6VZ0<%(3@+W@3FQ'8 CK>_ [.TO3
MHH*;0-&76O^53:]OEMFE^A)&J^MG9YLO5LO%,IVO]QV/;^*=VE2BG6?0(V:"
M_-YK'JSXTEW-F2!C/#W3(CLZAFL,!'HDA4X7TTGT4T]GJ^7!N*)Z#28"&L !
M\ ;&BSLY0;H\7,0$X T<(IWM%79'@!.8UAJB??&M/)/X/BO6 E08F/952;1!
MRA(D-5740FE\&*-+"1F!#5*6GD-06DNP#*7XZB/*D9H)HQX(*3D@5$&G*49E
MVB\FXNU"XQLZFJON"!>:0=3CT<W')_4^+O/)GS?Y+&"_N,]M\+1;9W10CV+J
M'=/(2 T4QYKRL/#CQAD@K3>B4NZOCB4[\:">59)CI+@P5@"LJ O$V4BDN;3U
MEWK=']2KK(S#!_5.0Z#/@WKU27#_FL73NOE\?=76X4S2!^LE&%D"$ GK)"H,
M0%@SAS8 &0M!GZ=!FASEJZSG?71I 9S>)N6G73V:2WAG^81!;:CV1@H $ T"
M$@9*V;A6>)SG^UK6V_,9N46D7A<;AF'!D;328R+!4,&_M[?Y?&V#5;A!XEG9
MQ+M@3$K"I=8Z6J^ <K)%R) 1G01L23<OPGR;(=);=._EY1KA=/8^G5Z^F9OT
M;KI,9\<OK#U4+XEH&:Z H4);Y7&0UY06EL2D_D*\L]C>=K7?)CJ],>$A*=1Z
M&_9)RI9[O_=Q5E1M(S$,$8>!L%8SB3V%E-@2 XY!?89T%N[;,D,Z0JJ_(/"G
M*<6.4F-WA<1#P;0EG$,05F14*:>W:S%L9/UT'YU%0K7+@U9@Z7&CN,C216:S
M^Y]OYB]=-!_RV<SGQ=>T..3".[&E!&FE-68*"V>M""860B6\#BK69U:8^H[=
MNGZ';L'J[:! M4383[,P2^49$D@Q$N_35$KQ<J9T854^PCO(.M/5<^="?9AZ
M4_A>]^U.3]+SP@DSRG*G- A3'N0<0<K15BH!ZT=&=F9$]J;\IF#UMH:\MW'B
MV92KJVRRO+AZEWT-ID^,\@^SW?MB.I],[V8!J/N<Q!=7ZC*_6S[RSNU:;-9N
M-"%AW8ZX@PXI*" !T#Z\*)+K^L&5G5F=?5&J-U!['7WNQT>[*J((ZW[?CYM!
MMO57AWW;51I(O.%<,$DH#ZMX0"G#9".] M"(^MZMS@S87D>IM@$<F#[_3&>K
MK %[GM9/D/4V+!:\#+:@5<(XS5PINS --M$Z"_X?F#R-\!O%T+/^\F(]<B[<
MMZR83!>'[>&3&TL@81+'^VD9\I!9 @#E)2K>V/J7P'1VA& 40U(;8(YA>&J)
M8?O;2H!EFF'-%<0 $&,@!1M7MH*T29Q59^<#QC!LM8'E*(:P#]EB64PGZVB=
M4$Q%Q(Y=C5:OP00P(Z"-(4J",Q/^1Q0MT1%(Z]I,Z^Q P2B&LK8 '<-PUB+;
M#K<77D7-M/,<0TV<"LIPI0]704MU_?CUS@XWC&%8:PO/T0YM[[*P&@X(7F73
MY:JHOV:LTG;B,282.^H=-)PX+"SQ)6;8VC&>H1CMB-<0W+$.?LWY6+GIQ%',
M)%=R?5   ^@M*1=8D+,F"9W/WP/?+[:C&![=[=TL_Y[=F[+O5\7D)@#\?I;N
MO+^M88L)Y]I;9:,G&RO*%;:8/)@JOOY]R?!U; !T#ND8!L"]PM0<]?:VEQ#J
M$$3.>@QQ3%V#@XF\P099V,!K L]^<Z /0/L+>/N_J\6RO(-Z=YS6^CWZ'.2X
MC&$>V7RQ/O?_(;N_:3/;).V\!V&3YCL66.-Q,&:NVT<G6F"$-62&<DVT9501
M52)N%&XP8I[]9L3(L#_.]CV7/3R28[E/CM"W;/HEGEV(>+^9?XD7@NZ]"Z)^
MBPD B& BI.4DO.!$2VW*Z80C1AKD\SW;_8M^(1UWL@CD.100<D^E=S*LL !#
MI2P0X08SZMEO1#0!JB^E[XM+C5U>+V8^I=_>Q_S%03?+L-SYO%JN[YG.[V^[
M/$"3ABTG 'G/$*).(FLUX%+*\B414KL&N0'.?@.B7V@[/QC\Y0'3#BX(#:W;
M;-K9 ^)5NITV;O(P;01=!@6^RY?9PL9@XMEBSS/[OJ[Y;86CTOMN+[:02$8]
M]SHL5S&QV*#[1%D&28>J'1_J0\9CAZ9WE$ZD4>&_ A!KM"02AA6YW\C&/6%]
M7H)W\.1T8]T<O%FZ#A:C/D/]5+PC!Z=?%DZLC'([AI340C#G'+$E%):0/A/>
MG'1:NI%:#U*D!BQ]V49/._HNO<V.'H[=5R7QBD6[SVFJ$05>4K:Y8L@@$=XT
M/>[3TDU4=E#[C1%ZC5P8A@-'SDJ/@0(MN5<>650?L_DT+]9V%?X5O \#8CSM
MM<I0,,4/WZYY4B,)$]QH@8TUGAF$E'6JG$Y%O'"L3Y576\LT5U+>$UI]#0%O
M\_GU,BMN(S*?PI./S/Z[BB?2QR!H;!2)EY9BAP%UI618H/JO_NF[78/-_RT
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MX3[J[543GAV$NP^O64R#]M<CG/Y>7KAZT-]VI&Y"#/ 6:*X5U4!AA8'S6Z"
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MM?OU2[E8SB>Q=\VF<=CL^L5/_@@H[Z]@</(W"H>PAG$U84F*6L>Y-O6Z7-#
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M^3;Z2WU?'(K83C%<X6-M1^\U1UQ3BY@6G-7(&F/;6\[I[I.&XL,,\!Z*DYN
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MO=L;V?.28+"B/=,UL;>^UU=P1\ULMFA20X[[0*%<,&%XM.&U\0 9S&VMS?E
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MCI##5C/A-"3,:5#7W":< 7Y4H?M$R%U4[Q_.B>6&0*-T-,>-1ZCN<<V(=VQ
M13AU[Y^C6299[Y_3P![EW/OGPRSL:N7795 YXI@?(V-$+)H[ 36\52#-) 46
M6<8L56&7EE37X'A"AC3)SE21_FCVJ%*A.I0ZN&?&!WNF-+Y78 BH8M@"+(%
M6'CA8;U6937,L[9]KU0\CC,ZX?6^>>0\O'&@04Y^K'$>EOA2+LHPUETP/VSY
MHYQ6#W'J6XWY8"><(]XNH&9$" "!,TA@#ZF#=8=3CCEMGWV=S"_8$QVKU%@-
MYFDHI^&;M[^5LW(^FH;YJ^O[0(YHH2XG/\KM$A:'^R:=\IT" N$=M09#&A!
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MII+'*QZS\28J)@S8!1B@@5Y>&#K0P)M=8,YQ=59PE)"\%@%28\PS05+($:]
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M>(V0 @H5,*S@LBG!T;#=P!52LAD\(+ POJ0GY);"<59M]T5?"B4Y7@1^W_J
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MDX=FO9,!.Z++=Q_I"S9:B' =;!'#(M +(H\*F$4L/&1$EB54+6(1@#.JD]1
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M&=/O5]@Q1P[V-)\:6P0:D\!OS"C06+74L%B%1WB&P+-Z?AVQ82';3PUM%_
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M3,>1W0PZN5W-BCU<LBZ>8&MA67@I?%:")VGQ6(I'2CQXX&S>K)_YB<7T9O*
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MY$ - FEC4;MYI+%)8%%M3N=R+*FNU*]BDCYVZ<B*\:8NZM+6D$=E,AN7,EM
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M"XG.B[2<D9MI-*Y#:";:4*A\L<3$Y6W.+I<OR@?:TL8A@6,3A'R3"ID=^U:
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M;$MS_Z:(0[<1!9+8QG'D6MBS \>R+!+ KBUD(K'JA'(M:(X(O^9?*2PJ .6
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MV?H1\!:O4Q\!7QW/+UTY#P/HX123:ED/\Z&0&!=GC8+:>#@$X,MI 'X[!N"
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M/&IIE#J%YH3I#"D7)6DLD4L1H]%^O)(A,\S("Q#<;&KQ!EKWGX]%F7LKXH$
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MV@SPHG9KI\;9+K^MZJ<5QCS"21*2E((D2<3EY'2PXL=0^L:PSK>G$9D6DS.
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M%B*Q#'6UX=C9>Y^&N9/:&*+W-]OLO[),6,G6_]X732'4_+>\?=L9HLB+2!B
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M/$EO5VC2NPP-,^/*Q:V*4?SH:95H6*1HV@HLG^O\OMC?KUP<>$%"89RR ,:
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MZFN/P_6_]T6=<YC<]N[I,^];.UAN*/_3!_$C*]]+_"@-_03A.$$^(A@>QBN
MO5#M+(%!P_9/G/(_O\O$4=/JQKDI_A85=#5.%)CD6D[3IR99LWC:T^%-AQZF
M,^"\<EJD5^T6V0'LU)759$F\(+P6(K$,<;7AV*L*;9:XTQ9)87#W]%N^NZLV
MI_4]HB!U 0,H15'JAKY/8( '\Q1!IG'!R)AM#974N&OT3"KS%NI)K2.Q./';
MEP\C95.;?4W1M,JX,<GL4#H=S/G*%\FRIZ*58P.P4*4<[=9[.FF&-VV5_"VK
M_\QWXE3"UWR]K[M5#Q= %,5^$L, ( B#2)0>Z6TCA,'(+%++YK0)Y/T!HM,<
M,(Z41#VJ-?70'L?&Q/ (T?GZ/L?3".%;M*FHX"C:%RJ!XWQZ3_\,,"8M?G6U
MSO--P[C/7[/V'-9OV4[8?+J^>1,'='T,0HA#'P8D2EA(HGC $> D5JH?;MRZ
MY<54 ;*=T]7Y)K]_&$IDFI!&\X&0E,E98Z HF3W6;B7[$(P!KPC%$A14E=%+
M:FHM.@M15GO^O519RTR.6;G<[,5::M[?1Z )2E.?,1>G ( H8#CMCR,$7LS_
M4NV%AK'6K)_VY[".];\?.GA.7=S>'>HAK36._!N@67^MTA[#1I8H>WBS7(!Z
MER[%Q4@]JA<B?N;\D5AZ',.4^5W\E0^CQ =1E(8N23"._-!+!P!<;6,#9YYT
MS$Y]YNFGA^.N[\^3;LZ_'P'3&_!&R;>^R;[4+70CV^32H5B&4MIP3'N[6Y&[
MD=K)BC(KU_+[[3%F+$B]E,0DI!QIR'QW (<0<@V<@#(-:>(34#<#?-,B:SQ4
MHP1XSB@9%>>#(S_>"2C%&*A+NZT@+UKVK3DM-R38Y5QKY797K?^\;I<C&_IW
M7J\+#G3EN0%Q4Q>'#"'@(BJ&K,$NC:G:2X^CK5D6^>=+@WD/2RPI5!W2$<NQ
M>NQJ++]:)W;4<JM Y_3PG .^&==6WZ)+=BUU%-7+4$>#_EQ:*S7 E(ZF?6B:
M/9?97#Q=?7]?E2V.E4]I1!* HL@'7#TQ<"-ZL$OT-4W/FF5-$WG1P[,^^+#_
MOBUXT[JYR6L^V(P0-4UZU47-/K-C1&U )P:*#E^G<_.IVIM\2:K:.*Z7IVHC
M_;F@:B:8TL[4Q/G/9D7=%-$H98''&, $H0B%O3&>)"H^Q*UG8M*<K!&O.C5.
MP9GG$[M]R=N1D]\_;*NG/'>:-KEXZ,\;.0_\.R,3-DF2-;,T\_R.3\U:3#.G
M8RT&E1Q,C<CE292.$^]E6SJ<F%]E7 &*,0U9%%&781A0Z ^5B@,?$8(,[-#H
MF)UJA^9D8V;2)</W>3>]+&B4<NM+?TM=V#.R>"<=BF4HH0W'M!?A%+F354S*
M)UOKW?4-_7O=OMSU)=OEUZ7 !,N-^(\XKOZ8;=LCZI[O0@H ];"'@]2- ?/1
M  %C'ZHD=48-6T[U.JSMY9D>K5-SN,ZZ?^R,SZN$J*IIIEGFY51S-M+5=//(
M]P#4$4@%SZV<BH-3[2].X$XKG"I$7I!.*_%8AGC:<:V:H#VK">C;QC[G=2&N
M]SPOU;1*"<"I#Q#U(8P\#[MA.AQS]X$7*R6=1@U/D';^M#DI<M87/BLZX6P[
M=/N+7*)#3Q &.36=+0)J:GI6,J^<#JOS1B&Z:>54A<D+<FHE(,N04SNN51,T
M:!-R"GF67-=//"'^9[;=YZL( 8_ Q(UC_M^4T9C&<+!-41BN'EK,7W=9O1NC
MIJIV53KQ2XCJ_?FE8EXYW_/;HBS%C%*<-F\-+*$COZ!1N0?KAF')75?;)ZD^
M.XXQLYW5 R0$),(0IX0PEP8>&$Z(!*D7>'UGI:7D]6(S5M6[Z@#01$?-Q2LX
M_YV[J"S]/U(7E?9)JXNJ,2;;1;_N'QZVN;@ND6T% +:M_OI0WE3U?7N.Z_CR
MLXN!1V,W!3%("/3YV#ZL+@4)_Z7*THXIFY97=4YA.INB66^K9E^WF^5MARV.
MD-7F(L8XEYN&S$&WV@SD&=.M*@J,S@G(V8ZV2I)W00]-T[\,133N566WT:J^
M <#U(F]VG[-B\RG?K5S7#2$%)'9CF!(6$!(<M#>,D9+ZJ7[;LLJUW:U]_9>3
MRS6M Z=:R5^1+CGALLF4FD -2!P!Y4JL.F_W&S&-PME#P5MH\5^Y6"7I?NAJ
M 26E7U!W09YT25Z&#&FC?U4T?PP+"D^+5/?YM^SOO!D,!8F+XI2X@+B!"P !
M.!IN4P4P#I6VS#0^/[&X"'S.3@!4?BI$F3A9C;'*F:K,M 2U:'JI^73A\69;
MSWF\(.2B>&BSMQ3]T'?@];L;X[@8,V6CW1\<K]V0&($T33PW]E(7!5'@'VIJ
M!CYUE2Y"&C$XWV2MK,I?^@G;X7YYN7E]JNG\NSD6PZ _A;,: 2/SMP'AHB9O
M+VE3G+EIL[X,O3/KDL2<;21?T@<[N?O<XG7].:MW_6].BNOP](ZWUT(\M=D6
M .GK@FR\58I0X 8,XHB&C(8(A738] ^1&Q"E"^.V0%C6SAXJ;WV.0.X,OS_!
M?N4<T?>5<X::.N>7IR>.E)R4+B)(:O)J*SYVCHQJ\GOI *GMD"U#F^V[^?)P
MZ32\:M>&0_NF*'-NN_FUKIIF!5G"I]Y\S/!]0H ;!R0 ?-2("68^]",ZJC2<
MJK$I9LZ\X33%IK]2/[("G#*9<G(Z*8]JLOE6_;<CNBNGQ3=S_;<7;%T006-$
M+T/LS+GS7O&W<3S)BM=@Y40_NT+NP\IB\Z&]^G==MY<ON:A^VM]_S^OKFZ_M
MS<#N;U=>ZOFNGV"6  ]$?@!" @=PB1<J2=Q$D"P+8?]"PF$%OD-UY90M5C&_
M[Z]6_E24_2_/'TZ<-71R@KK J*G)[N# \_3T[3"*E'9PX\KY= AIY\JTVFR&
M^ L*/G%DEZ'S4SM=S=J;Y,:,A]UZ]Q8R;EKD>E7-JAIGV_5^VR9^US?/,5W?
MO.G"\0&1<B?>=8Z\!"5IZA%&(I"X@/AI.&!F@2NULK$,I+:7/P9GVDVJ]=&=
M=O'XY3!S^D)2[]5PJY_GF5F?9^:M9W+CT#)(?F=X6@;(J4>M8]/@[CDG_CG7
M-\-P=3T,5^)7+X:Y9ACGOIT\^?3C-8U-M=ZWR[K"R'^C)O+,KQ^OJ;Q(@P3_
M;7+#YS1NF]I,$I$W,IYEM81Y$Z&%<5$ML:^.2YN>0WF9SWVK,W%2BV1/W3VE
M59Q2/PI@XL$4)@&-8>H=YO\4@&!,7F08BN7$I\?C;+*G]VX:S!((O8QDQAA8
MG"A?GTZ4A\!Q+_HKFLL*W+A\8<8 FDP(# =2>[!7HU-A-+<4IV4.U[:<?6<\
MMLJQ_(&S[PV?\_)^01_Y__LF3*^BT'=AC) ?80HC_C\<1W$"$+<3N= #:@?,
M- Q8/U V8'):4,X?+:SS)Y@,4B=[*,PR:ZJ'P!0)LW3DZS4I%X]XC>!P&2NL
MXUQX=81K-!_OJ4I3[U9?\FQ+&S[,BH?HX)H/NF*BD6](_E#GZZ(=?DG>K.OB
MH9M^#(_'P[^+9D5B;C^%;H0BAN($8L15KL,3(S^6NHUC'X7M5<OLOCW=.F!R
M_A"H).5I@AA<UK!ET:]X'$N1>1F=XWR<:!S_W4M]&TW8&R(X71#F5<H)_:RF
M;MYF-5<T[2,04MUG1;F*F"@*@;TX@M -"491F Q00LBDKA)8!3"YTG:X#&NM
M'O=F9-8Z[6,5]CW&)]78M]@:(:^CR/\QE'6<BXJB:H!/J:7H3_E?:%]LQ0S\
MMURLCJ\0"2+$_#A)0N+%@$_&O7 P0E-?*C'5_+1M#<S_<@9$"FN-&A1)+/K:
M94=1JDZ(<?[HX$@.#+H,*:RNVF5*;[54C3&Y9<]7?IY;QM0G9 '+DB/ 5T8:
MA8(XLN)F=P?+LGCD8I/53[TE/X4PB!GP*<4I TF$*.XM)1YR4VF%U/R^99EL
M43DGL'0D09<Z">6<@#4U^9R5, 4AG8 X/375(%!.4M_V^)RNCN1G >(ZUH/*
M7&L9MSO#_W&[@N"1-"*1[U/L)RC $ 4)&ZPE/I,ZYS#6QM1[- *8TD+H:!+U
MMFIL\#=RMT:&NDEV;'IN%#9M5-E<YKZ-LA?O;-WHL3)"=?J9=@I\/TJ]*'!]
M,;4.00##@\JY4"K%&V]E'N516A@T0*6V^EA@T8C^F%CG,Z% 9Q?US'&Z6!52
M]>-]'=)B1E.)^EPK1!Z-20I(Q"*("(K\8%CO SZ.V @5DK0PL0*-TAQ9TK3T
MQ@)?([5&=8ID16;.3JC,T+A(>5'UX;*T:#&B*2L?BS+_L,OOFU5"8A(EF'J0
MTC#FO^;_[V N2J(1RB)O9/+#;P*:TV(;E]TH\*@E-G8H'*LW,NQ-H3D'=N1E
M1YW012J/AAN7Q4>7%[G5\SS?K?S 0PR$(4O< !,O#+UX. ("1/(DOU8N\S7;
MBO+O?5;GS@V'(G;VJYN;8IVKK/%*,2*S!&Z:#,4%[_Q"05==MU46LDV[K[EL
M?8D&R07J_,W2M.I>+F'Q60EOI1M/E<,-[7V_ZH9W=2YQD>?2)"3<1I"D7L(2
M;J,WD (OD)I-:7S6]J&&P]W^%H[*KKT:.Q*R9(\8-7V:C!.54PS6N-$\P2#)
MD>39A5/OSIY;T*)@ <JF";P:'7ZUV=Y'42 L/[S;\%&\8/BQR+X7VV+W-)04
M(_M\%0?83WWHA@PE21"&XKU8;I[XV/=#YB4JLS]C1BWK)+R]K?-;\<!RS1&)
M4J/%KLBV;>N?=CHCR]B%Z8UQTI<QW3'O5F6YL2HD(Y]SWC#+W?7-;UG]9[X3
MKSBO/!KY%"* ,?(Q26$00'_0 3<.0^F41.?CECM<#TE4">E M<^;*XS%6H1)
M9"FVN5++5>:A22%QL4V77OJB2)M<%O.&J^=RF3&L+""C&06_,M0ZU+.;JGZN
MW5_R,O\KVW[C8_@*Q@'Q H^G4SRH' '7:V^PBE*HG-2,L6596GLHCL#2E@Q]
MRK-:M6+H:#[EEK:GI%)->3MDIP^=M>"NG%-ZIT\-+Y#U3D9H@N;E)()&O'DC
M_S/'DKQR[40GO[[!=;XI=M?[7;/+2G%T'=Y7^W*W8B2,0IA@-Q1+7PD$(#D(
M)D6^TCM'HXU9UJX>GUAXZ!"JJM98+F5E:T(:577K!8/.";HKI\,WM6Y=9NNB
M<!DB>BG*9<J=5])EE">I*:O0Q)NJWK:FJYMU:WF5,!0D?DH8PC%!!,:>>Q#)
MT&?RUU_T/F]9G]J<2M30[6"U#V5WO4PUT1I#H<0TUCY[:K)TECC[;"G,9NVS
MIC>?56=/;DK[IK_G)K7CR%G M':D Y6QAJ*6(+*LJ/^9;?>'M<@B;W[CN>F>
M&[TNO^3K?5USH4=94S2_E]7W)J\?15&C#^7#?L?_FC/#_U7;X+IB1T'@$00@
M%>]V$C[E]D(_Z$JH(3_%OM)<>')PE@5>^..T#ETY)RXY@T].53H'KYS6K2OG
MU#&G]<QY[II>9;7I R^7_2XZYFK#TDSAMI)FFP[+A;1\MA:PC#1^/O>KA?1$
MA6G"80>-Y(_YMGIHLY]R\R6_%75-JOKIMV*;-[NJS/O#SA@'2> G+N3M7+R>
M&A,X8(A2SY4_%&C<LN6QYP1F^WSS$:AS0*J0+ILG7F+>,2OGBBLE ]0K1X9Y
MG6O[YD.@,)F9-11Z\QSC(9&;!JDR=6Z&9(WQ!4R>[/E63=%F%6_&B/);PC;>
M9DUS??-U5ZW_;*\:H]2GGA\ G'@$IEX, A -]OPP5+OZJVW%\D#4XFD?J1.(
M]*H-Z#,H-PF9ACRU$46--SNW8<[1<B&;'T_E,M)R WZ\O!!CB!E9W3DUT]\H
MYM]CU <4(Y=!C!+@160P%)!8J0B]QN<G5AJMZ@(ZK,F)C&7"QJG++(4$7C-R
M05A&T+<,11GC0&6L*:EI2#__%ZK53O.OV]K+_ZS$,U<BL^H3IP@0KEQ>0F@*
M0C<)<0R3WG@2,E=I$=B02<M:<X*R6[43AWO:Y;HC4C7A,46UG!C-P+*:0,D0
M/%-A CGN+DB98?*7(6^FG:JL-MAQ,MB^ZO>Y+M;#S-%U$4IP 'T(4PA E$ 4
M]V8!99%28C7:V/32UT)T6HSC1$^=6#VYL\KI:*$[H7,A$O>2+P5QTZ9ZF;*F
M[\X[@C:2)[F+077UO5\3JVZ^[M?KO&EZ:X3XL1_C.$A@0! 739"@P5I,787[
M0?HV+ O7";)VYM-ATUF*'\.CQ+['1!2JZ=0RV%.Y330-BYJ7BC39E+Q==-;U
M<[L-!LA:P+Z""2\JLTU(_=IF=IMS8]DV;VZJ^DOUE&V[G?AN4" >8P'E^L]2
M+X@AB5,XF TQ4[[&.<J8;;T^0&R[B #9GEL\P%2_NCB.6QGIGIA610U_CU$M
M.3=!K?HMT<DH'G5K= S52C=)+]%Q5O0-,KD$]3?ISALW3PWR)#4>R&Y;IS3%
M<>)Y'$$8A#$-@@0/IAF?/DB/":8,_EA'FXS1+#$\S,&PVA!AZ_22,9851HHY
MV-8;+:8\H#3R7))I4A<P<!AWJ;+8",>M7).B68L[?*)Z0F^8NB[U,4ZBP',1
M%F.7[_:&4T "J2F%07/3KUX/(!7*H9BD5V\%VS*SH]>PGY&ZD%7LUYPIK&./
M('R9*]EC''IG+7LT5S-<9_MX*% <, IC *,DBF+J>G% R7"4 C),E&HDS +0
MLH2V]YP>A5-B:OM75M<9[^?;X;3M;/?2%"(HI[F+#YZ:2MNZG_9QKFKM-N)S
M8428M3DL8PR9EP)[%]9TXR$[3L$MU]F2FWKDUA]YWB^&RI>CY@K2B(^,A"8^
MA9Y+@<L1]+91PBA6&7C,6+0\DIR =(XHKYQ7^:3:F&*(;;E!8GJBU51_/,=6
MM%N*M@MB;);V9:BK89\JFPU5\0Z4.-SR/6OR#:[N'_*R:547BLSQMC6.GHX_
MTE?'A3RSW!PT'C;-_KX]\]?0OQ_R]2[?B+H9W@H@#] T]5,4!7Y"_,A-AF,R
M* ">VKNM\\&TK+0#F+8(M78AQSG#**?&/T@$U22\1?Q+"]DY=<LY\<OY_N2<
M_ESOF],Z=^4<<W_GQ,$KY] NIJ] :2]4%X:-!;2/98PU2R#BY06Y!4"2WYU]
M>S@=%O57;LP03C&,J.=3'R$<@W"PF.(426_*CK0S5P:OL1$[EE&)_=<)R324
MI<_ H\(.ZX1\ZFVLZO,JMYEZF8!S>ZB&:%O UJDI3RKSC6JVG02<;==BDY?_
M\DNUW;*J%H/4RO4QH#X$@"20D( %?"P:<(=Q1&;:5M!$:WE<P7=BT&\</E'9
MW>7.S>4MA_;,Q%?XI5G +H1N]"??DI@@\$O8G[AR3AQU_A"N.KVO/^YVQ=NQ
MFV;O8F2[6<;T9T%\V-O5,!(IY0'T9$GQ7\7N[A7&YCG(YKE+AZ)-[;=6D>]A
MSV7=8:C4IXE/O $KCJ-D]9#71;7YNLOJG>+0.2E.%=5\Z9+"*<)U>]C"";PK
MAXL0F$G?3#(KHVFS1')A.C8/!^>T:\:(S*M7!!(., [Y%,4+0P:@&PQ8<> 1
MW.L5+3=SJM5[*-75:G!(6JO^[WV9.X';ZE3Z_^N4O1C^=]8I:0XFT2FUB,CJ
MU(=R7=WGA^)Q'T4@Q;*X*!SGHSB-7.*3."813%/^N_X2:ABS,/14EA3&V+&\
M&-!!<P[8G &<5C7)483*S=*GXE)M?JU-HQ45OL#1!2TUP>PR%-&()Y7Y=F=$
MG?JB=('G1N*A.S=(7> '@ 'F#38A02;T2=+2? JE585R)*VC5,H"H\9T:I8R
ME1=Y4M<J17X7K5:JOLCIE19#LHKU)6]R_K-WL-R<7,T3QP7*9KBLXJ$X!,#U
M7(I]$# OHEY_""Y,@B12NA)GPIYE]1H@MMLHFR-(-<TR0JR<<DW-J9I^/:/S
M]&9O#W"FVW 2I%T0,Y.4+T/2C'I4V6N@BB=M\RW_V]M?\S*OLRVW#S?W15DT
MN[K=4.\A#%4K/!<P&A$^/8VX93_U_! .&.(T4;IQ8-:R9<GKP5XYMQW<MJ]F
MSP K'HTUR[N<#LY'N9HB'MC^]83MYU@'<52OBV/H-*H*E9<.F%H)R3(4TY)O
M+X^!6F10Z;X">O\H*GIY%/7CX2)9FO@^#0B* 45>&%/D8GP YB:1\KT$NW!L
MZVW[S$#55?!^X'\UPUGS402^=Z9\FN@L1 <F=/BM,^)3<BU_P[.-2KYY&V&O
M6JN8Q,"EC(9QPBTGQ&<>&XPGBL56#)FTW?-/+J6L3R^OY!T^U:N=9FB6RZ]F
M8%@QL7KKQL^Q,UP-6=74=SME:+N@J(9Y7X9JFG;JU?5."YR]IWZ;O%C1<E?L
MGC!O;CQ=^U!N\K__=_ZTPC@$C+C$!RS$*4A#[':'S B(,(-22__Z7[>L:1TH
MIT?EM+ <CDM.RT:0=EFVIN%+3:&4J7I#D9I!DII\_8_;ZO$_N*.=&O%?O!2A
MLR2\H3?C"9M76@S@KTPU'7G!@'QHVHCAB6VSVU6(XS3PPY2P( [=P$N"  W?
M]V.YHA?J7[4L$ <PCD C+PN*U+PO!_9849,!24),=/YG+I_I]'JTS-_9-7%7
M8QN$?.?&^[H67R^:=;;]/WE6TW)#>%JR<G'LX20.( O]D(1>'(;T8 K+O3TY
MRH#E+M_C<CI@CD#F4+$!)%U4<AQ][VO!),RIR8(6:29$XAP79_1B-'7S2\=X
M%RJ#34E>4$A_[_=HB_$_:58I\7$40H 8#4""6 "(WUN*4X:DZKZ,^;YE.1E@
M/>L:+3)Y,=&F[GTMF8(U-2G1(,R$D)PAXHR.C*5M?AD9[4%EKA'IBLCG]LI"
M9PLQ''B!GP*:,.JG,.#&!EN1QZ2*O8ZS,+&0=-#&28D2@:IB8HN[<7(B19MY
M03DA0TI2=,A;FJAH^7!65O09D=WZP=7]?=$6J6A@N<%5N2O*V[Q<%WDC"F%O
M*W'%!'X7&]CKW2HF@<]B'( X\;#K^<0#:;< ZR$O364?<#9KU&*&?\39GOIX
MAM0Y0G7^&,!._0B]"I$7]BSL!&096Q>6?'OYJKU%!HWVY6_YWSO$^?ESA=,H
M"-+(=WWF4I>C83 <0* P5GKXWK!IV\L=+_KU^A2OVIZN:<X-"J@=NFTIJ$#K
MM'"7J*$'+L>*J'I0?B 5U7!.1T9U.90JC?A;5F>[NZK\?)?5]]DZW^\*GH@U
M'S_B_M!>Q*#KQRB&R(O=*$B3"'6']H@/&8B8=''$T98LJ^2 SWD!\,KA$!5*
M^HUG]+(H3D^FF@9>Y%'G.;KQA"I429R46+TZB2,)EBN6^!X/;PP,9OE;0,%$
M<[Y4-EJ8@LI_VHLO7]]\KJO-?KUK5A#%KI>$ ?]/$J $(+=_P8[X&,5 :BE-
M[\N65;S#(RH//O2(%)1&G28)J;;*D)HT]^1<WSB?IR!'07:MDJ0GLPIDR4GJ
M2Q_/2:@V%PN03'WLE8G6H"&)[8WFYD-)]W7UD&<EY6Y6]\4:UGFV"JD;DB0,
MHX@A#%P2QB0<[%*/21T!-V=M,NF\[TK3-2U8\0>BKNL V1DP.P*TAH",8UQ!
M<2<C6TN%Q5/S'<$?RJ60JZ'8DY&LI^)?\@?^M^V"C&C$Y8'[OG$7)]SG _<9
MQ_X/0VI_B9_W1@ CW"YH5##CSULCA4&FE$8/+)Y.K8N\605NBF-*H1\$* QC
M$'I!OQ'N$T!2J4/TFI^>;%Q8#Y"<GYSJD?^9Y)M$NI0I:+T=MG33ZP,:N_QH
MR+4=GD9K<_FZC9D2X(/'[ZFM.C4+DE8-\&_IJ"X'\A5]'O-RGW_)1=6@HKS]
MG-<W57V?<4>OOV^+V\/]I_8]H.*>_P@7=_ZGS4VV%G_W3=1[7($HI!C2$ 8>
M"CTW):G;G85&."8T5-K+FPB299'NO;AR#GXX)XXX1T].WQ%KG6D3T1-WG#]:
MAQ2KH$T56+D-PP7&5&THF3"<E@H8F0C A=W'B2.\C%W)J9U^52EI!LXG&UG:
M(O[B8'Q;@C/P8D:9N#1'8A<A&F,:#2 !D%L@GPG:#S/27#FM8^T-$JWRP%/'
M?*+!QUZXYQJ$5"*]S/'H64QLCDMZP?]O,CYI.F]ZG!H3@\G&JX^'*CF>#V'(
M7((BQKR4!=0-AP$5!/QO)AVKY&'],..4\X=PRFF]FGJ$4HCR1*.3G0#/-SV2
MB>TRQZ2/$@7/9@CW?Y.Q2,-QT^.0+O=&QZ"53X(8>C0.(S=*F><CXH:][33U
M(_-3H7<M6AXY2'Z3UW5; ZUL"MY.NR)H#]F3F+]:& #>I]B@MAMEUYILPWNQ
M$KU 01ZKM=+T_T R*N^3CD(J,C99 M[=5O16S*.!CR#R:0#]&&.7,#; "P&5
MJFXP.:BIDN^'D_Y=G?3O[BFZB9-IZ8A-E$K;"-9\2SR?+X=TF3ET'P*;&;1J
ME'\@X3?JMNGL68]WZ;+CPTLXXO!1M?[SKMKRB#3TW_MB]W2X^>KYV$4A!H3X
M49KB%":>'R>88C=-J1?+%K<U8\R>C!S??VI/-1X1_@^GPSC;E7$IYB[T?K/,
M+Z-K&_;I9=EO"XPI=\INIY' - E\F !,@!O B,: ]D90DA*ES$SQTY;SJV.'
MTSJMH<J3HDJ9ITA7CF8Y_/"<!QEQ42-L82JB"/Z<7.AP(%WQ?[,I1$J0;3]G
MQ>9#B;.'8I=M^PMW*7!=G$ 71P 1R((41;BW2=(@C)4*_8^R9%DUCN"<!X[N
MEZ)TUAT^Q<K^X^B44Y/IF%03EQ,2/_<D]M!F>@[I(E$7U,<,P<L0(T.^O*S3
M;Y A^66I'9_OY!N:U6+6,[R=Q#P0(Q(FB>?&R(\@I,@;C 4X53SQJF7"MCBM
MU_O[_58\B^!L\IMB72@_:JG'G.QBCW725)=N.D#.@&BVMRK?(N;B@LHH)I<A
M.&.=>+7888 3Y5G2<7\Q"B)&N0F<(A<F 8H2[V"(8:#T^K?&YZ>;+7W4/<FA
M0YKBM,D.7]I3)QFJ[,Z?/LJ\Z*;/WC*49(P#Y^92NES(*LB'<EWG69.3O/OO
MA_+U4L^7:KME52T>=%N)Y5<4Q#  E!! /-?WW1X%]:!:[3W3MBUKSP#7^6D
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M'%^\O:5\O^O\PABO_+DM*R,NZ\8XL$'UK:QR@W%":+3I!WIHDC[N^.EZ65V
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MK$KOLF&QZ*K*UQG=8GO;;['U3!N&(2EO[<0*7!0%%DP&0[#M*E4O"? ER]L
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M:-IYSG*M^J-D$^+ZA,0D8X&.^S%RCR4<)S@E62SVJC*5*99$")&LRPMPC&R
M_,"+T; -,(Y"F__0D&;X-5C_5IML2.D$:K**I>.OZP+X1\D0]$H%9/:VCZ'Y
M4CTD6-SE1_,]%7]LULWL98[/!&)>U/GZMW2[:R_.Q/W%F1"'5N)#Q\1)"%P8
M668"QY0#Q$P+ PM#E*S%\.ZN:E_\-/(!HO%$,;()\-+Q.ZVQ9Q2Z"3)J1&PR
MVG_NA8P.*FJ,UAFM><;OU$"CM_#X0KA6G6!3KG?TZ]H6/T)G>&$0:Z=X1;.O
MDAEJ?9NBF+YCM@F*7'^\D8-H$H!ETPQ=G%!J-2@6.W'\$OHJQE'DP"!$<1 D
MP$U\VQ^G**"+T8)GC#F1:GBJ>+F+J'FCK&:KG9K@:K(?X%6><5X[[(Y&2LU!
M\HF]0Z-Z>ED_R#LL/BLR^AP/'XO 5_8DMAMX($:F%\&([IJ']BC?CFLK/=LE
MSPK]5MH75$V)G46-JNK13\YA47T_]7/6XCPYX(N>^I[;"3^&N"OPD_*SWF(B
MN\#R]TN\U@J@&$!DNQ% $"#322Q[>"X26;YE+[3*S0M3@\7LN7J^4'R5+V#+
M#*TFZ]3+2ZV44*E9<I[:/S02RX4=(6\!>5YLI-?".,VK%AFLZ]U#?SRNV/R:
M-?<E8>;R[GD\%^>'D16Z'G*0#6'BAAX>S\4AZ ?\I\D6QBN[OB4H.VY,]U 5
M%:TBHRJY/%THH,IEC]K9KR4?6-K6HP>VGM]A:_;XR:@K)?0>C411%X^(JA6E
M16L1F?R6UW_@*J,*GQ'N:+Z1VG856Q@DP 5^@%R +9MN_AIP)Z&IYM)086@E
M2R3%].F6@**;K%I41D7GW7Y)"3'2&G%-+%(UT2LNQ LHIO3H:J*7%P:UU*"F
M&H.M!C7VC-7RK=BITLI9_>8#*N4\?\C420&16D0EA_G@W\HM^9IMWCRWR",7
M1R&&$%A^#!,0N-%XUQAR?1PLII,3\4J?3>V7K)Y&6/JHY-00+Z"3"J*KC5*.
M?69O[+E+Y=OA4R66,SO/!Y3+N1Z1*9A"HL4JF;^63RW SP7*;K.JRC;?LJ>L
M>+GK%R1)[#EV&*/$=A([1G9LMDU'R/(!YMHV)*1!R:(U8*2/EPTHC1[FI ,5
M8KW-)C_*'<VG'R)\+(7W6?QV@KB%NET/YA5K4BFQF_)QWW 4\A]Y<Q_OZJ9\
MR*HO>7K3<NXJA(F50-]R,";$ZR1N9"=#FY:)_/[HP/<FK1HVZIO7'O\!@#TT
MYE$997=YT1ZRODFW] U0M6/OI(=.##HQGM5CM FRI931]SC. )]L\'.QKC*2
M"V%B?9S6]]^R=98_-O4JPB&.0\ORG0";2>0GH0\'(,#V(N;SO7*:EWUVM[_>
M]?AJ*]LAP$G&'SO@)]>3&AS>DVQ@J:Q7"E2_^)Y6+I^+Z_PANZW2A^PJJV[+
MZH%*PN7--K]K"YSOY+_U;;Z7[&Q=WA7Y?V:;E14! .TH@I;K13:R7<L)>\PV
M\KQD5;1;*C?7[)7#LH"9AC[HAOY/MC$S ,HVN_6$#1<+!Y.M(CF# $XJ90:[
MC#^)8<9@V84QVG9A=-;16F>T[\(XL-#8FVB,-EZ,]=#>3(WRL;D1FYK/*>LI
M9Y /JO,%3SZI.$)BZKT(P1CY$-H QB&.L G1V":(_(CWJ/B\UOBK/>[CWDEW
MTOL#%7JL3CV#@<UN"U>AQ^<AYG77]3W)6[;9Y2U<K\M=T=17Z7-[=*;8D)]4
MNVPS0,BS^IK^YCK[T43$&W^L8OHV!?!C""V$XC#R@\#KYK5!0B"%7 NJ,H%(
M+OX&[/2DR;I\>"R+C."G?TM[6XS'SIAV[V7:F6-D/^AZ0\:[05=JQ!C71W4)
M%N?"YT&<!N#&U4%D>NS& 7CC]Q:^0?$;K0&J=\G.\/6I54H5(=2#K=68^GI=
M49U_^;D^IN??;LJ*I'%/V<%:)]T9^Y4X]<BOK\F?ZK0K<EO$J]A/"# ((\OQ
M/,=S72MV.Z"6;;G!1 50!D^R+KRPX\7NBI9L#OY^V=QGE=&0Y-MX^8\Z]N%<
MJUPBT+S"H66,>2</I(=7LJ*("@*3SBB/N&[JH]X!1S5IH5BP*M555=+)U%^S
MAYNL6L6!C>+(BQR D1N (,#])'IL.;YM>ZNGK+HI666&[[MYV.,0!C.)]'#X
M")[3/VS<+,\Q?+3:XS!^[Y H)L<77CC!:].\I0<E3<1>BN@O'.O0_\BV6U).
M9]?5KFZ^Y ]YDVWZUB(S3FSD0^PZ,?9,:#JDJ:XU+[1"IKQS;AN2D\<!F=%0
M:!RW_\YQVVFF4.DQ/LX8G=6B,GI8[U.(6.]Q7'ZLR(N3;B_^Z[?LD?RVG</*
MBW;VOUW=>LRJIG_'H2F-Z_O,>-OM_S9S#\1QWQS;Z"# FQKL9A!A12FVCW%.
M,)!^UN:)7_(B^TS^6*_,)(Q,%X$81S &F/P/MOJ&_ @X@"]WF]" ] 1NQ&3\
M3E$9+2S5%=U/?CE5D4UWHA[IRQP#7E=$<WW!.C3:&8"X?""#L*NSAD/GMN>;
M(,!.$(1N&$2>C8=KN:W ILD[QPS:Y$8DIS+=],<!,)8K)P2[D:T&4N)!OM1F
MDO.DL,PQYYS@FMG^U(-QYIM1"NYG4V?^/Q=/I+VR>HYW545G=%XN/%BQ#V)@
MFR!Q4( 1W;^!VN:1!3'YP;3Y_)F-*ER]'9%.G7"?ZU_>:72%KIV^UCJ"O#!Z
MF!JMJI[V(-/,MJ @Z,%UXLTZ.@LMU&^L7#B>V_Q</.Z:^DOVE&VMOBSR7#L,
M8H^41  ZV'-<Q^HORD,1?2Z5A_[FM".9\?[7KJ2S(X]5OLYHB6_0*?VGS'A(
MJS\RDF"0DI^XC00D7Z=;>I4<_>$O6VJ!87&>^I_E;C8V5.5I/@+<'Y&G-XU2
M8!?&E\Z%"TUMG_#3"9H3X5T]F$V():7XOC>?O^R^19([.AX&@!XN@7YB0I3$
M?8MQ:-I<UT3/:4=VQI;?%?DM(2>22)1M>53>U%GUU*84>0MWH"M; %TQ>W<Z
M7<EPK"BZLC6B*WL27?%Z5U^ZXK:$@:ZF>8>5KN!3FF_IP,1E]3W=9M^S]:YJ
M][RA[*;9_VUE)\A/X@"$I%WRG\0%?K_GC>1[7L3%7<(:E4QDO[8)5TM;]0A*
M[2AC==6)(2?<VWJ,/_%FE9)[*=_(3/ZYRYOG?3/XZ6N^<NS AB:P0\NQ/"<&
M)@JLH2G@V%QWB4YJ0/*(ZS 9>U 7!O[MT]?/?%G"-->QI0?2O<:7%W [3 I+
MO>64$XPTRX=ZL,\\$TJ!?8KG]?BF7/\!'Q^K;)VW>P:^T9?LZ_$0T\%S?2L[
MAA%A,ROQS=@-$?8Q')M'T(?L[\$+;%1VX4*A&ND!5J-JP1K; 2W/,]\BO7V:
MG!9U-.?$<^OC0YA&AW-_J/OP.=2E_,WS4/I"?I^]>8B^NI0^T,,O=!6@/'BC
MN'Y_(,S=1<3AM6/;BF0X7H-]1E+,*B5W6+[<MC^7WM['\L:IVOT:@V.:,4H2
M&/D>##QL1J0([D[5)L 'F"O?%=:H9!4:KJ:HNE/[-$!\Z:\X[[*EQ(LXED]U
M!I_2H6:\?:N(\?MBJYVL#CR14@N/@1YIMGBS2LE]5]3T&T63%[MR5_^]J+)T
M2V_O^%+6]559MY0 UT3]=UMZ&Q+]\;A#)?"L 'FVC2TG@2& (#"#CK!C@&W+
M%S-/)PN=9&K=@S6V!!;OV?X%HL7&P'H'BH^JZ>3:B_F,T;A/MV7UJ4[IVY '
M@:2PC<&<"^/ H.Y72VW'$QZ325.\LN.OATPL:#_SI+&:2+ *S\LI[->HW\/Z
M):OKZ_NTL.Q?R2?OZU?85PX"H8U"+PGCQ,,X@3&T!\QV ,()=Q0N"YB)[F;?
M4;BWK]WU4QB[EWIE//;F&%MB3W=@W;*-A]8D/BE;./YLLG8&,9<G<7OS3JC=
ME\-^T)GYLP2JU3VI03NA@7IT%CWT4!-?E#H.9Y4Z.6"]K+Z4Q5U6O<8,DLA'
MP,2.[YN1@Z#GP/YZAABZK@.4Z^1<P+KIY!WY>3/<[;*(5,[N BJD4DG8%Y;*
M42 )_1J=F><ME>\$39I4BNHL'T$JA?E"J%2*C9 8J60J>E=18#FAZ6 702+B
M5I1X*!Z086C#41#+)MV*$$0QL*;(WF@!,Q>V_T2D=@F*B0B%4A@''68E==(9
M)M=/5A.Q@3T'S1!L,9<RR/ V]\F77[.TWE7=A75?2X*(H*WRXN[U+\<ISCA,
MDA@X5NQXD14 W\+FB,<*33#I7(QP%)+7IO8G/"8>B1'O=C9BU\/C?'1^\$#N
M(>H+XQ#WSQ]8;#%ILH]9CN)(BYL>;*W SF/'>"1[EI69_R/;DGSSU[2AJO',
MOB0U3+E=_YEMG[*NIAAM(U6$ SS+!R%VK(#4$2Z.K!&K%20\K+T,0MG;B=4M
MYRP483:!T#^X,VL!:N"GIOSTT)LX9_&&(0V0HC!2@G1"?9;M%'HHT\(^*'4:
MIFH4[1#C,#NVQQIX -B>B1U,\/D)")$YS(M%P(=,9UZ61:B-HHE8>%DHR')%
M35U\EQ&U-Y=9SDW43@9)@JB)Z13G+6J"?"!(U$1&1+:H[7%!Z$//LD,$S2@(
M$C=TAEO>XPAA>FB3?=U$/AHNL5*R7*(@ G+518[SA2O)<?DX-Z60J0K\P3QO
M!9A@KR"VG^IIYO=QMVE=7][^(Z5O]32757O@LGNAA^B(;P-@N5:";1C;?A#U
M,WXAL".;ZT[#&<U(+AQ:9/24<8^-)H<MNFDOJ,WQ)QL!*W(E'[-.]Z*<IX:/
M^N@$&0IPK!XL)\*0UR\,B_(-SY:=ST7=5.U% M^R3?;P2/GPJGWW^K+(^KO'
M3 M&<1 E001-Y.,HA#[N6X](XUPD):I-R8S5P3$('OX=-T)<RKZK1K4W)Z2#
M>X@7QA[DA;'W\D*W&#+Z[YWM+R(CH >[";?JC6TLXKTFAO=P_C0TCV(7F(X'
M,*GXH>6$+K""H7DGAEQKG,(:5<-\%)!(ZN/QJ@CND^10\>2'VY=F-62_O0<G
MT]^$()P#_TTQBXL )_MM5D4*?^3U*O#="+F>Z8# "BP$+!R:0WLD^71F%Z1,
MK2Q7CU)X(LI1-F?.J$:%^U%8,7K:A>IJ48J#MQ3E\JH>7"7 #I9"=()G9K$1
M*A_2O%CYR$DBS[?L./+M((P2TXV&%HFW\&P^8FQG.4;J (K@)%:7SF E"=X4
MQDOO.5(=,W5(>+F)T[<:LQ.O)2S\-,D[LQCJR_@J)?+BT'6]!"21ZX1QX 5.
MOR <QE'@S9_%9V]*,D_UL#BW\LQUWPQ"DN,Y89ST9:E':4\[BY>:^+VL,3M-
M,(:%H*;Z:!9''5[F&GH!"@D]NB%T'#,,O&AX\2B,0Y*_S68IGL;4\)11WZ?D
M4\8O>='_D?/%H?E.G<%=LOPIB+TNF&[J5L=>I^^,%NYIC1ELDCDL'#;=3[-8
M+/F15>N\SJ[HFXCC+^O^M[6U"B(WCA#$,486"A/7-..142V";C:US48@F>\&
M?-VSD2W?;<KM-JUJXS&K.NX307WS(S&##Y4&01A)CJ%I81]\IAX_I/A"@$G.
MY:548<'2F&?%V<A"OH(]ROP2U</CMGS.LO;=@,L_"T).]_GC%>G^R??+*Y37
MZVU)3[+6T3/]83M/:$/?!5;H$4?[B>>Z(/#Z_2I^Z!.47 ]526A?-AOWD(WN
MN9,1M$$!&K]0W'\QOJ8/V:3U!BD!8:/EI6/!1\K"PB#GU2Q^7Y[@8)F1T8.!
MI5KX^DDNZ=X4P[[T?_N)3RM)0@OZL9D$KN^%"6%\:V@^\8- '.5R-*H!SUYT
M?YFVC"+.^R+X59+CQ9,JJ\\7X-6]#R>3Z80PG .#3C&+BS8G^VT25_;[9^B]
M*6'HD[[B8<=, (I .+*RQ;>%;\KWJV7 *_*Q^Y36FN13,ZB.U7D36$V"WV81
MV#);[]YP"2L?<3I00^KAM> 4RTSR!BNAT%%$ZX,VOX,1='W+)=\+Z546"0P\
MIV^"GL%P>9B$ZXME;_BE4CVY&.5S$1M?2/,.'U$P.T8*0QPZX00U3/*5'IPP
M#7HIH*],8X$^=T$.PJ3"0[9KQMAQ3-<S\= (X1VN'6F<7ZV."2952[R.XF,#
M"3Z:S >+%#8O'<' "9P>TXL5>,$?X85)/F!_3OTSL:EH\J>,MD?BYO3YB&5'
M20( 3!(8QJ:+8L))0WL6Q$P[PN:W(IDO*)(^BQX1<E0> KQXFD'4.I"/3-YR
M6^O/=^L1T3[D?>M<A2]G/VZ>%[=E]="]7?Z850WA 'JE;U.VSYX?[;A"GC4_
MXJ W"%N<4W5YN'RV'3^]5"[&,TR,GOQSES?/L-C0"Y^NL^KA5=LFZ-O&<8 =
M8,8! *%IQHX;PV!LVX[8V5U8B]*9W@1&!]9(BTU[LYM!\4XG?G'.9A"!1?S,
M.2W5>1>>\&X;A0GZ(,[5'%JQB,NEZ\;/P^#3&X&:*R.LOCLF*<)]KX&\B+>I
ME-E;N66'MG&L??+SDUIH1E$(+<N!#O"09X>VXXV@D.<P34DH@J*)4+6_%%&_
M* @>L[[I$K<IPM<&[I3XM;\4634IB!RW7.H2P05TE'^4BE'9&2X_+;\J8JF-
M+BLQ]F?!5N=C)B4_DCR,3;;[P2P< F1Y8>0FMC,<G_=!%'HVLT[/;4C%Q*"
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M3942)^=%6CU_;K*'FH"F4__$A]L6=L?"*\MT$0X@ #YP4&R&GF<-1Z8" %S
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M$=\AZ)F-,5'5G+/07[*Z_G>#0C/R'INQ+FO>EV[F^I1-/E0X<Q+O'P#K?#E
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M\MPP"$TSLNP$ ]>U/91T)Y9B8#I6S+7T-KT5V>MG:;?KH 5D_$XA'9_X$>U
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MS8OI=7&]/ 5;OWM2CK8)N13P)I]]64JYF/U\F^</OT3S_DLQF<_JGRP-_L\
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M\Y%P;T'WHXBXMZ?,>P.Q\0A(BSE2AE).'S]*F&(<!U@>\RQD;%,!/9ZU:!C
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MFB*V/9I1$\8K@7!"(L A\TP_FC;I4@ZD)X4U!TZ#)!0[I4(,2%7!/"VUL3R
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MDNADC/MBT1_3_#Z>S/MW<;T<^6RVR*>CPGV+MX3L"P'N;YAY[DA 3U,B)9+
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M(AA0ZZ+<]68U-R+IDG%^N>3J&.:6+%!-]0\K:[B*=S6S0EN;9I1',*BC5A#
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MWI<;D4ZBY^4 UM9IA06$R.]C>5)*9LZ6.&2KK7-<U:-WO\=O&R.UUM';_LV
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MXA4_MQ%:GY:+Z_NK=3(]5T=WT2:'#S(:LQ @JJTDQC#K#"YO<YT$66%-(\T
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M,LWXT^1'D9J.O)M?S>ZCX?.OZ?K63%:W<>WI7^[?]].?4?:K5EJI-VB0D55
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M<S,XP+N:X2(MES/=98FDD/,?D;%76SI\GM[<KE=?U.<O)]%W\MT H83"$$$
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ME%<A+D=FBV=BXGDZ>JNT[@I[<=I7BUF$TF+KG:N:R#MKG*!3GRS#J9?,>B"
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M0'=D@&"$HE& 853_AG,KJ:>R7#TPU=H-7-!9<%M0:X[$/0#LD+EP#L:.CQ&
M=T)*(@"*A ;0*4IL20.++,J V1!#.-J"6:-4'A#2DCI^7R4_\<RA@HJTI4Q
MXZV$DCL/H[HO9<_BD>4A=N("M,R#[ES.ARCFK;P>]3.?/QR@]T);CK1-Y4B=
MP@+XW:J<DJ+3\* ?Q7*ZN(XV^W(]!'S58/T+-S.3WEVAZ'-Q-9NL5M/OTZL-
M%].=;P4JF?MEHO>G#=_..&9LXW/!$VB,]YHCKJE%3 O.2LH:8W..22Y71^9C
M> "\ZDH*CA%2%]\7R^(Y,5;ERHZ /6/4@#GEVC/@M-'(4HD!@GMM046GR4)/
M\R\>TH586Q#O%WG/^P=VQL5>=?[B:OHZ_=;KY?3;_7J;0/5IP[]S%?PY8P>
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M,>+W,B'LB+:8/):^Q$8V,6L[O+NR]\OYY+B7^_RY0#4%J8L(%09)+C76H%2
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M)C),GN2YK$JMN6G*?#^_7KV;?UH65W'$36C'@PM\&)2Y(P>BC+<*(!T=+&<
M( CN91'CK-2F,85E9N.S8T:U!]8OTYOYIA_8?&V+67QH^:2WT-D0/3!>8) H
MSHCP5!IHHD4*%"S7*PD$&< <4Q!/V\!LACT9)[;/JR3N3X8^+=9QHHE:D;;%
MMK#D01B>.TZ@R2$27@*C$:#".E<>73E(-<\YNQW3[4XF_%IF2\?'@(?*%$8#
M9'9_G:(@5JLB_N_Z>%/*&J.%Z%A%8QI:Q'&40R^@L*4WCSR2.==/8SKHR_=T
MVV?.($[W&JMF_[+<.8L+EX R0P"CA &)!2JI :7+\;GE&U2[XDO'JK7"/4FT
M20!ST.-TL$GB7F 4=@\K@"0K-Q&\02N?Y,U[)>65\7;)?K%,9/@5]>\^RNQK
M<74[7\P6-Z_=6#0W>& ".>I2YT8+@)6&255:)D@ZGP6^MWN-7IGU -L.J\&_
MVD5D]?<I#2^M0<:D-":O&$ $&K$[G#/,.U?I8*I5&GPN4HQ#!-BKG')__8BP
MC_;?]"X^$OWH2>K_LJUX4K%$?.8'@J#$&>6(PE!'CUS&W5V7%+2.Y$0H#U<A
M-8>KU[>\;IG2L955?W&;)GEVLCX4/]O.AP*.[I3SQD?GB@$=-Q+C:$E-(43.
M(>%P(=X9!)N6@!S>#3G?E#BJ:?3D,53"$,*DD+)<B7$F)\IJN&$&7:.P(>I?
M1MZIHP9@XXF@&F*G8%S?+O'2\!3R.@Z]EL_22GFGYQ&S^[Q3@HGU5(+4N<9)
MS)@L6U,9#@$;R2;6$(^.YIV>1\GAYYTZR5/12RZA4-H3&CUD6*['N*SZ:P/:
M6%I 1DL4;G/SJ-Z-0T*/F1/:0*<\]@X+QLHY:R6[Z>_Z=S WZI*\=9A4[LI!
M//(06: =M=(K+&%9N]X(0F2.93JPK:4&KPYTY3B/9FWR^ORN'-9;18S5A&KM
M.?7,\A+E@CDTDA+HM3EVL"O'>71KE>=G=^6(>Y?$AG+H$"<1X);3$N]" CZ2
M(/=&>)Y!MXLYB7M?/;.L@8\$B)0B'EA-O8?28P?(7G)P_$V7$<ZC-49ZY]L@
M8E+JAJ $:414%$!BI EW@*82\+NU2@'P2!SL/D%R5N;9>>P8E.+-U:D!6<P4
M=(Q00&7<P+0%I%R[1#0'B@/:K <$Q3;8,BA('B/?-A8"MFD)[#X1/'11GI5&
M#BO$C '6[X6:"(??#B7Z ';SG.LE%N8A2G$?=K2=_=\G'(9)H:#%&'$$I.-8
M:E_"Q&);+;RLB;Q)=9<J2*\>.**+F^E\OD'7;\5D=;_<'*]NV7,XXJZI+P1&
MN&7>&AO=]"@NE CD2KH 8D=R4]8:6BHG4;;)E3Z]BU?5YE9-3HOK33;>S^GB
M?G40T,T-'A QJ0*)H80:9+G#I$SQ,XX9.++^8&UAN3>&#,));C%QP\MH'V"O
M$$6$Q/]9M;=4'-(TYW!YN"9>I_!LC/B=U]&PP$.(HF?O,7 &0T5+_\EIFI5%
M?OXIX&(]F5TD-!H@;2_F^=<G&> C-L)QM&-4U/P4.8@HIDKH,MN%&^DJ%?GM
M;D](*8AK-;_>:Y4-G[Y&SN@XB3_.W!A.C!:<IY@C80B QG-B,81EH1].*1S)
MU6-KB*FP.S3+@0XTQ9=UG);Z<[*\_C2;S'O3#RD!:+9('LJVSD8Q7TVVIPJS
MR;JX-HO5>O7E-K+]VV157'^:_-JVK#VM-O(&#E2HZ!591#P$R"LG]0X;A@L%
M>*6N CU33#]>6!7-DCER  1#3C@P%F&NA;20F9)F5-N<,NL#U#)= 6S1)Y,Z
M5T0?4A_JE#[8]^GA4!63)L!%!X-ZCXP2U$A/MVZO8=Q;5RFBI!V*?;FZ+:[O
M9W%9#_A[O,#'":'ZUPN,;B!P*ONNL6\$ZR"F''FN(M&PC]@WI*2C0"3'*QJ?
MLJH,NL4PV-75:8^[^S%;_"J*C0[[^.<\\O%V^B/I,??EXZ<'HL?%I1^>R+^K
M,5I BA$)!8V08(X2(CG=J7,FF"8C:8+6(YX67?-H&-A-_SZ8'W7N$ $Z)Z!B
M!CA.&!7.0 Q+"CC&1Y;MW"I&SL)C;1;T L*3G65?>3HH*( 0+(Y/TQF<M%J*
M/>&@&MD=8_/L/H:G6B3N"CI;;^'N5%+[X\="ZE;%((G35Y #[12G>+<2B716
M"/X +_'ZWRTSB-\UC$YN=D\?#.F2(*KJZ, #XS$&A )?KB9*R$BR=_(8>0 -
MM2A8^]9LH\G>S:]2P<J?19I#? :?:!9TY)T D79.2N6<$@80:R(ARGE#Y7-R
M.@;,^7.9MFB'G+5AX/Y]GR)EYM?O%_.;K\7R[ME\@#S18K+B^\$;[K$$ADLI
M #"8&,7WZT%Z)"D_3<*C)=)F0B5]]]"<4B9T#;62/7  6@L%(5984DN10'%;
M+BE@*<[9=088YM$<N+JC>?W"!:^#_Q2F3KP6-EXD].F@GPI-',("E+/7@N;$
MK0TP!ZP)Q#1+T:[LV*VU'C]YPA]Z\EQ0Q&/..5 *2:)L5*)*[M:BG 8YQX<#
MU"?].T0YU.\*2?5I\["Z^75EOZJ-SP5EN((:*2:$]8XK#D4I^)'861V_!VBC
MUT35\\N:_AG17?+6:KV<IN2;:@>/KSX?#8-T@0XHI9'B0%#"C"[7)A@>V]U+
MK_!XD6"5SY#.].GFK/;'IH'&*:"]>#8(0)2@GEK!#/**""E*ZU-)I',TV0#=
MR4&!+)<9]1W0W2&\G2Z+J\C.3:&L^>I^MI[,UX]FE=9YPN,\>Z2@)531XY$$
MNF@O\\VYS&Z-6D37>V0FX1  UPVK.M5WZD?D]-5T&V0RO;E=K[ZHSU^JZ;]C
M[T;:4NJ(=MA!S8UEVI%2QVMB9$[OIP'ZLX. 9UO,Z0Z0D_6&6&8V6:VB\[=9
MQW$W^> [@7#/$%7($>202IW5]C?U6C)?*3+X@@#8N\O<%"<ZRP!\-,V3SN_+
MAP.@SB&CI<0"0F"@AKJDD]9,C2Q7HP'N/L_.R"5I=ZFB=W>I[GH5!_3%LX%
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MN<X#/F!MD?%_)T$>N/0& .,>@02"F"E%/*6.EIN$(]!UVF1Q1.>V[4C/ +7
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ML 58 H&P\,+#>JS*Z@OC72=2;\:DH_#MBTNW46#QNQZB26NSE^RQ?$ZOOK+
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M6;1>U/-S?/.%=%<W\I<7+%(.RLDD&\^^5:-BNB@.ON]:9[N. XRF$A=60RZ
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M#Y6/O_C;N.4;TV%K0=9.D6XPZU=_2!^IQNP___$_4$L#!!0    ( ".*!D_
M/IB"^UL" $19'0 4    <'1C=# V,S R,#$Y,3 M<2YH=&WLO6EWVTB6(/JY
M^U?@J6?F99XCV=@79Z;G8*U6M2W9DK*SZWW) X%!$6408 *@)-:O?S<"*TF
MB\0%(*-FVFDS D#$W;>X\>O_?1T'S#.*$S\*?[O@/K 7# J]:."'3[]=_/[@
M7*D7__?SO__Z_UQ=_8]Q]X6Q(F\Z1F'*F#%R4S1@7OQTQ/PQ0,D/9AA'8^:/
M*/[A/[M75]E#DT^:91@BQRJ.*$B2R,F&RIH<IQFR;HJBH+&7KY\\EA<1/Y0T
M27!%P>5455*0*_'*4'*1]#@H7E9]W<N_/DU@G?GGF7*:&4UFL?\T2AF>Y;1B
M2=GX*(7]PI[#Y+>+49I./GW\^/+R\N%%^!#%3Q\Y3=,^ON(Y%]FD3XDW0H/(
MOQJB01BEJ'QHZ":/Y)&!GWQ<F/01?_:*Y:X$KGC-,+GRPQ3%*$F;7U&;T/!X
M,IQ<^8_1\J-).OZ8#[8\EJQZ+&E^S/>NDG10/O;Z& <?$N1]>(J>/^:#^#%N
MX;%T$J]X+A\M_@^_0)U_@3>-8R"^V16@N/U%B[,:-A @MQG*,- PW4L?@^;Y
M>*3A@:>I&S<_@$<:'HBGS=/C:1/X,:3<(%@!1Q@M_J\!CK#+I'7_20N=>$&,
M5E *&6YXU'<CO_E;>*3I6\ G?MBP/O*E;+ )1]$T3.-UI#$_";]&:7S-RL<;
M'B/<F;0053[8L.C0];VD^5MDJ&F!7HN,@8$F\(?/+= /G]L6M!J&<U,:%IC$
M\P]7^(O;V)&0+'[C:J+.9ZP@['+::BF3SU@A:0J![?MN"U+K,QJV-$VNW-B+
MHP U4')ML.'1@>=-HI:O9F,M7),\-G!:P34PV+S,)]>=S &^OLQBL.F+WO J
M:4(S_B 9:^)2Y 6>&WA"FSPMQQL>?DVJ_=5T,L^RW,?_^?KE'C R=C&KI6[H
MH1*<R%]-6[4)30R41"+/*7,?)H_GGQ8^YC.J[TUBY&'KH_49[6.._H_5Y'D.
M;%UL.=S >7&+9(B;! /FQG0V:2+/<JA)42&8T?:9;'L-(LAK4!RY$/*:E,:<
M"F^%Q>*L52]:;RTTBZ:Y;P"V-E@)S&IXD1NWP  &&J:C5V_4_"T\TO! Y$V&
M+4J=#*W8V^H]M6J)-1JB73LT"IM\H%&S#_RA#TP"'LC5Q(T;#.2E*<T$W_C5
M)@E<<B6W@H=;&!B@<-7&B=E8J]'3M,#2Z&E:*!K_LT6]XY&F[\ "DNEDXK6O
MCPPW?>NOJ9_.6KY&QIIX_[4-@!P(SC#P0X3=QFIY;>MJH@N0H8\M:@0/->UA
MT":)\$C# VT.7:,/AQ7)2BW33-]@'CXVZ-'<<GQLDDH@-\$/;/]8-4X@/?_P
MJ T&HT80X#6T^Z2/360)AD.[Y=-J]K1X3(,F?PFU25/4*$WK=G^[.IF?U"2\
M<ILOBKR7U58AGM%B_K0;/DWJ=M)"&3#0:)-EGT^FXU$4M#RZ,&F%E<:O-M+X
M)C64C@+?;6'+?+!%_J&G<;O\@\%5^QU%<;K!CHMIS2MH_7H3M?JC-A,=1AJ%
M0QL7X9$5>UN_K98=A=-QL_ =I/%';-]]A!DH]KT%J=*JUZOQ!JGR"K+\1WO(
M#(\N.AV+CMJ2X]$>P'EL46"/39H+1Z16>Y?5A(:P%3:X5CN5]1GMTGKE$N;G
M-, W]EJV# --@J--;C32_G!R-?56AG?(<),@GK9$=V"@646VJL<FHWG2_'*W
MR<+&8B)&_@HC"H\V:[AQU&0=YCH.#[;84O#&IE!59>LU!ZN6>&7>H\3#CVZ"
MZE_RPL'0;U&1U7BCW=OR4-/DTI%9[W2U1P4&K1'E;+ 9!<-1T*(V\L%F$W#2
M;@).FAXIO/U69JY-:#9M6KSF8J0%*(V!N (HS<&X;&3@QPV:IGH2CS=)R"0:
M#EN$)!YJ\3E72ZGZC";EWR(+5L1Y5^RN'&\*!<&J_!4<M!@$*NVR-!FUL$-M
M1HN(;*?K;+")0%N$=J/,#J-P YT-'NZ"W@923QY;)&4VUFC )-&D171E8XW1
MGR'"W(]:09^[Q>7$<HVMKGNKPYY; :WF04M0J\7S*(=6N =K\P;-,8T0I>O@
M 5.6N'H-4S>!/PC;_!XRU.3 MJ X;8)#87>M-,J:Y6*5%5@3NFSWKH!F6L$H
M8XJ:TS&KX-<,/2S85TK]EIVU"+6P4:B!)FZW)8K1)@7H#Y_;@@!XJ-G5 AY[
M;6'\8K1%KS1%J KP-4>H8.W/?[7OZ_FOUG!3@UM7!9N:W#JB9E9;V\VXFJ3>
M/"O"#X]^],&+LL^PLL#.6^6KK/$&*[S- FNVO$;(:W,J\5 3&41>FQT*(XU:
MM$'#9.JST17"B9E5YEESPM\/O=1];=DZ&6M"QJ0E> 8#*X3PVOA,L_3P7\%D
M0]X<]BMT%H'&CVGLALDPBL<D5HS?(UVQZMPRPA9-FDUO\2U7ED/4S$EN:=7-
M,F_=DODK7F[P+]?Y[K65+%!VEJ1N-<";_1C49D&@1O,!)U];H 0C'Y?3L+[[
MU)8Y@I$FFG-;(M0PT(R]5JPU8"OUVZR88J3)A_50BQ&(1U9H882I_5ODART9
MD^9Y+<;R8,'O+O5J-E@JNQ;ITYA]2)K2"$20-"<0L-Q>[5JTI& '308=H8)!
ML[^5I3%6NN;9> M'KXP4-4>)7H-F1B;NR/]\J86_8O04M2AM,M3B?7A!6TU,
M-M@H4ELBJH4^; J@K J?-+O@3ZA-9)*Q59YF:T:U/J/)*$-/:S+LN=G]5$_-
MH;9859,J)HR1-G*-E'%->O'YW__MUQ%R!_#??_MUC%*7P;.O<#H,O'TS"E.\
MA0?PVRX8+_O7;Q<I>DT_9B6$'\F#J9\&Z'-1N_CKQ^S?\.J/^;M_?8P&,R9)
M9P%@9PCON1JZ8S^8?7KPQRAA;M +<Q>-W? 7,I;X_T*?.':2_@+K^W7@/Q=/
MPE8G@3O#?B:Z^/RK__H)OQ_%V5_]P0"%Y*\P?I-YF-FB7],[;)H[%@;2=_X?
M#]8%$[IC_$;D?])AT0.\<"=PGRX8'Y#BN%YZ)?".8@N*9"FJ)DBJI3CP/\X1
M6%Y59(6SKUY^7&TT\8+)E-]O%Z M/SU&@%@W'+I! IL@__GUX]RBW[ 'DP2U
M4L=//#?X!W)C.QQ80#FU[3BJ8BNV+G&2PHNB:&F*K.6K5#51E,KMK)MX\?GJ
MBN.!T-Z_[()DLG5_@\>B@0._);5UJ[HDZCK+6:J@ZQ*K2;(IY<O15-W4RW6O
MFWCQ^3N_ZR5C4"\N6!=9C54E1[ TU=%YCK,EI5B'PAEJN>!U$R\^XQ6\?\EV
M" PY,[&:=8/K<(!>_PO-:@OF#5&1!)EW!%E4-)8W5+98ARQ9NE8N>-W$B\\L
MRW*LPK)J&W$X,;P(K$!F /[#V,4JX0KLP&GH9UN8)H.+^3U=8ZOJN_AG$J=_
MWKGA$])?_83\ZZO[ZH^GXZ]H_(CB/W-KXD\#ETRC)-$]$&*)CS]&GL"NU9_Z
MDQ_XR<(36,SY\.(PA;\EH))C8J@:,RSWJF>_^.XC/)W.+/2,@FB"J< -!W?H
M:1JX:13/OOH!F*@@FQ;>[[A^_-]N,$7&K'R'&;BP1/SN:A7CL9_BERZN[RMR
MDVF,\-!U.)FF\\O:<#4%0>!G/NE!BN(0=OF,KHE=C9\N'ZC3LL/:)L=KCJZ:
MLJ/;O,$5HDW21-.L:'G-Q(O/DB2QY'\%912D<$JD<8/2>Q? 6,(RP3B)9FZ0
M^FCQY?NEBX5UO(<*+,.6+5VU=5VP15:03=LJD0M#E41;-_'B,Y<3P6&HP ^I
M@-BO@) 4R91Y0],EBW-DVU0=K<"X*:ML956LFPBZ8QN2D'I&$J<I&$1.!EO1
MT00-^%KF+8LWS!RIHF/SE6!8-W%+[*\7"& %=4@MG)% 4 5;4311$@51EB5>
MDGDYYW/1LD +5.;ZFHE[LQBZ11JG*1@$@Q55U>8LD==YT39Y1\OY71-X<!TJ
MWWG-Q+U9#"U40"V&?0L(FU<<PW8,A34%59-54Y>Y N.V8L@E::R;N'.+H5LD
M<9J"050=@]-T45<U7G<,TS(T-D,J>(V*5 75UDU<@?TUH9&-A3\&PNU0CV,\
M%V^H@H@9!8'[&&4HU,.!Y2=>](SBF?X4(U2#\!R4:D\]H]I[DSN4(#?V1D4$
M+-8GDV &U%*^]P%YHS *HJ=ZX,8067"W-)'5+,<2.(<5#3Z#D2ZHK":4P%PW
M\>+S-_$?;PLT;<PQG8<FYZBFI:FF:G&::AL6!XYL+F\TG5>K,-BZB0!-81MH
M8F!*WP5]^L1=P1\"5\+,0H_ CTD:3Q<!!DP6I_YC@.Y1Z$?Q392B1/C PI8]
MF&E-$<_R_ (&OD3A$[#I&+^U9/":>"I>B<<;X#V_F-K\AU&,$ES#70A%RYW5
M Z(\IPH.C@(9@LU*K,7J3D%]ABT*E3&P;B( 5K+.$;!88R!OB@G](79QZPH
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M]<%UZ>A0'Z?#U-LITXKZ..^,52RX+'LXET-=EA[R5:?(M6,5E"JE;TK?)UJ
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M"P]B\PF3,_!"4.AD&,)Z#ZM[8KAE=_1D/<?*XS+WZ70P8UB1*]Y4,N97'!'
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MK3[[FF "\)/10@^+&$C^*4_Q%H9$G3V:C:D-'%NL07!DLL8=A;.[<#9VGJ'
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MYW%[HYC<,O] SJVY X2/@.#N9/COI#=T?MH#Q<_X1A<RG-TH0,IZM[@C&L<
M\JN1LD!F5LOFQX6Y3KI4O(3 _93HR1,Z&"DO"-"4DJYJ<79;Y1/ *=P6\$.B
M=4NY!+-RN8L'L3BL7\?^B*4?N2SV&?>^#7\0UB'EW5$\B>)"/!9KJ[^87,%+
M5E:HH:,C,T^C+"RB2]DPX?W9,)?Q![]=)(JE"R!!'(VU+4EF65T4#%F5),61
M-,%A]8MZIND,TV@;4E^.^7>CEOSS)?O&8Q0,X!7?]+N'7$23^UKX7YSK&_W&
MO-:_,-<WSNW=5_WA^O9F<Z;9G[@KJ4H%TE$XPW%809,D4=,-7=0 A8ZCVX*F
MFXM4M;^U-@ T<]<^U J4[RMG^:!@;!,T!11MPW9DW; $7I!,5=$L!3B5UT7.
M,D48.RH45Y@1!X1AP\* PY,H(-&X 6/D-Y#>CQ"NY_EI&KK3 3Y5__-Q%TG,
MTVB:N+C?Z4^Y73_!!7XCK&!A\6ZYPKT;(\L;K,V>"Q'CN#21>GZ(^QR3?]=?
M%V*U'ORR%">_V#+0OBJ&OK#:+&+.L;"/1W(>]XI$4B<)^E3\I2ZH\39J87>8
M@J'TVX56A-L;HNS9)Q3X0A63GQ_CWC;$[_R-[_[8^B1#ENN83QWPM5P(1CJ_
MG!NI_T0JZ,@O%VVF%,%3#=5;,UXSWS6QQNI,Q1ZWBQ/NPR!Z^33R!\!.^U+,
MQ?Y*6A<N5N\UYZ,BJ35Y98A 9?Z#)?_;-^J7;"EU6V"HS<C_^S1$>5")O62(
M\N593J/4<);4L!QF+"A";4L^K4N^_O+H>C^>8IPAPUHHBC_]A^<A-!SN!4C[
ML$MT4O?\!HXXZ,Z/Q2K\.E;9)1!:.8) Y;VZ\1VJL'67&ROS'?I+E#@WEN.'
M!,(A!'@K5#:3U0<V8-^*>S-O!IF=2/ETYL;*.@E\4H*VL_+TE"AJG=@\4^FX
MF;;@.BPWW;QEEH?_@A.VSVXP%_FG]L->&/UXYN'_V@=J=Z(XWBR@L_WXKY_"
M*'1BG&'%*=/!;Q<#D6-YCI44) GBU<N/*UQV=F5PHL7;G,W:!BLKFN0HG.AP
MCL#RLF)S%G=!,O2_74R3JR?7G7S"3**' _P?N^(0/37=.)[!;O_;#:;HHJB
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M<V>>IR0\XUX :+H%FH?$Y#*R0-X6GXKQHIA!W\'3ZD^QBP$-?0<!G !. ">
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M9<ED$YG&F/?#N%\.H U)#$$<0!Q '+X5!UFWE4%66T:0LEQXCJB7TJS'DM%
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M;I)"K?RPMA@75\.7^RB^UQ@,"I2!;J=,-U[3C7HB98Q$2,\M8H9)O9X.QIW
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M!1HJM#$O@&C'?2@'!AB,%>,"KR8",5>VD3@J#?<>)$)M>@R D\#)!SEY)_\
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M9932,4QH6=6#F""12K1O:PDLG O+:_F]F/=&D]DN'<J[2#CP^9^TN .D %(
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MZ>F2E8@Z7J>D*2<&QJAE"#8&JJIT'^^UMI+SYRR;7>%J)]R)0%&@*&1I *0
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M0**>+U$:U940WA-$= P$1<P9==88LY0H1KC3C7F+;4M42^JRAW*'CJG+A51
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M(R>&(EK91R9:@<3#PRIWMH_:LFEDJT6PG>/E>>6_AB_%M#^<57['I;_Z4#T
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MV^P0VME%^)+6VM-EJ*A+H!%V.+$2!R,)=\I0)47)4(F""PCYYRRICQ(4,J6
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M'#^XG_\5ME^P_8(-/2#JQ!#5YH8>=U?H?7&;Q'U83=GMY>-!+[\IFW?^4?T
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M8RA+>QW''%,R>D105';E?4 2TX;W83DWXO\;CM._2[CLTQ!@&6JUA?Q%^0F
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M#$2V%6TFZS@O-P?S>+-_VWG)4H3U3=#0!+9>M+T2: ?:^&EIX\>RAQF^1-V
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MWSC1-L/HJG$%EW7"$WFI+&()>FHG&!AUM<>9Y$MX405K!M(5%QDX0;R\0#X
MU.!NGC0<:(^!!)CT@@VY;1G-C!:";&9V!M\OVNY&<0"PE+&( UC 355VC+F
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MW_PM^D)&<$#G5=?! 0%'PK'1]W-5@7(%LZ&'1_(.?6%3>R^F%O.I%=(90 <
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ME'D-L71N6K&KU!GE&2RM;40"@'Y1R+/+Z\/1)T]&C'HWQPJ1OG/R?:#IANL
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M]*?LG+V_.6FZP!3E;^?GB+B W(02.;Z JG%I?)J6=7..(. C8@__C=Y&5EV
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M(=RZ;<^^X#\_8H5;#_F.E=ZZ(#KDG>""WL.)ZYFV-#%S*_'3/ _!@L^C-,K
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MAALGD).I+0Y#!KY5=FR*:[+&KWP03>>[[_L1BIU@Z.XS QSWMCFH@1XVBS5
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MQ3V?);X'OH.KC1;-K&S*"Z[(MD;% G,5AB>9R@;$<$6"I#,X4">JR'4W7LZ
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M+R!+[,CR>CSSM:Y>DW19/;0HH+5&Z-V,DWON,K0^ZP/C.EN0!AEDABNG1!J
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MN 5P"^ 6P.VEECO1) 8!R76LM4V02:R(8PPXK=V[TN@7YMV_PKT;['/!/A?
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M9CV$6@W&V9EVNAFM$S T8&C T%V$5X9$ Z(<4HP2PZU@+#&:$UW'"[B_C.R
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MI+6^40[J&5'OIM")Z+LCKN@73QZ122?#<90/[KP@OR;2OJ'-XZ1M<XU*M0F
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M[^\GX[1_VW-7](<SOQ_1E]FT&,IPX)#0/6LZ[BV]93#Z-AY^\U?>-P[ :.X
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MN:\VX[9\.AGT_9]Y(;*DW]/)=6F3]*2QD^QRLFFX$.&FF@700ED*26Q! @S
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M)/ZU*SB_K!I)R<#E;, (?4'QZ?A,9SU8O* J>6).S'WA\OC1T6QZ[UG"L5E
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M,@.:O+@JTN2/"UG ^*=D<I?<E_"JO]T4>C:)))XR\&WLF<4\W_&X[0A/6&;
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MF =:IM6.>XMK>*CZ&W:>KV):N4A'LJ7X#"0[J6P-]J2VG;1NRVS\\#2BC-/
M-)EE$\),RXQTVH#/A.VMJ1HK$EHR3+W;?+':Z1=%,_X;@_FW)+/EGS8'?&N/
MOTF;AMQH=DET$^%P@;E:ICKSZZ>AZVQ>N<[N9^E2QFSKD7B].RLMY8>T[JC-
M3ZX!CJ^E9%\?*XE<Y/W1:"=ID+4TT8"8PB>VL"P[Y!:322;*@A=QWUXK<[*\
MQVW97:8XCYHVT:=%,'O)EVP#R>PM7BI"&+;P41L$I[@8QFB!D4ZF6?FW5G'T
MW8=*/EVYH-3,85+>;-(U7X@ [9X 3X0 T?B 04H#H])9RO0VNT![!$@BZ*M0
M]\7I5;%(BGOUB7(-==/1^DE97009-4V&-_KQ5^EU-ITJ[6;S(Z5T93]$UM)4
M*87@M'["\ENES&O6,J\6=-$(J%NKC[ AN^:X5(O5TU2Z4Z7CJ@H.K [X<9'?
MRB_R\1C6$(:.%M<7.>&M)A[$@=,]));PG-",G,@QJ26J9N.<N6M1Z6TW')+B
MIW3^>;QD:%]7Y17GT(NC99]GFRPM?D#[O&8"C(&#P8T60QE,BA2382 BZJ::
M](H2/?C4^=D89>4098%2J_6WMR!'JJ@ W76XIC8=&%K6K+GL1SP%G:!J"+W*
MS:BJ7Z.N/06NO$)GA*'Z&"-[/W#D&1^K.ZKPCM\OOQE^,OW#^)0H+R-H?&4.
M6J"*.BY52$?Z\!._J^MPF)[$6O[??"*#1FY!Q=<XA@21%9M6N+JDNF!+&0 P
M;9[=2KD4;4@*[;"[O#0H7"U*]-J7E2F^_CR"UV6WMZ"&*Y_BK$B'*<[W81PW
M37T&H%VLL8FK1MI(V\.L&"YNRSF"TDLTUEX*-90!CNWFV1>FU45XED0$ESWC
M<& M/#GTO\^W2HT6$I>4QQDCF$#2_#=L/>+?<,E\B7%)"(OJC=_2V5PB^I(A
M18L)[Q'W))WHQY<+$!I6G_]A8&3*YC5)9/K!+"]DS@'<A_0\;&QB"ATUWI9R
M8-((B/W=9<#4W)BD224W/'LUL'C'7N?&O$B0))&]2N/]W4TJ0\:4!H#LC9$!
M&&CVH5[W)NS_):1XNQ72946.Y;LAXYYKA1YW+9=;'B$DBD(1\+7J6LN20PN<
ML%UR>0,P%C3S^Z[6(81EV.!E> G19/EI7]-1>BM!4^46-$_?-*VRON_S]'/A
M(=$KL13>0ZC;I1 $A-(6@D@M Y''M8>M56:>K[Q6>V@L$3-PKL:!FF%;URM&
MW7BDK -+ABE#:3*71T@BH:7RD[X(%S0!<1Z/PMBF,?<L:H:.YPNGJC$7<T'6
MHL.W<T&CS7X>?T. ^H)(]KW(KJ]QYT].3%_7<LV=O:\;R+0C'5?3V[#FU^K
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M4=Z %#' C9B@J_7 K-$DRM& ,)?:/A7"%'[((LO6'@LGI)&[12OJ[0%OU1Z
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M3V'$?6GP^/&YQZ(>BS9CD=M@$18]BVS',DE,'.8ZM#;/._ O[02+WIC$Q_B
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M<%/(0!T9B[*O#DC=:*EF)X,$E<2MS.O+'M4I0,!06XPR7,3:L)487VZ24D<
M4*/V&FEC-L(S[L)#_LKEQ6VY6Q_PXJZ#R<'1H2D7S(1C 09&/J6N:;E6$%;I
MB1Z-"=VI@.13T,'ZC<*FT OXA]'C 0GG@,%B&\Z&YC X2P"Q3@9 VC$9ST40
M4\H-T@>=C!839:F?I2.XO8#]GL&O4M7,]+1AA9/&+AY8W*:>%Y" 6CQR8I.$
ME7)J>R+JM(*.@I47]3_;.\L>AT.5'DM.#$L^#^>YAA+G82C17KMOB^DX*V]0
M?YG?Y1?HCVT$D;ET V),2XTBN*X*7>;WL]0P%2K@G^Q!1-&8I>KTSF4\V*(
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MRU)Y@.L$T;SX ];O6F>/Y<:_\DRF0:L8-]BK J[I@&A-*[FJE_<(C53&KZ7
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M_^WU=;<VN.YVL5S)J-9JW]3[S=ZHT^K<]$:-]D9W6'U''ZWC/KB82/TIJXG
M>>B*D"1J@W1%Q2F"$*4OD-Q,ORYS%H9QZQ>-6'(69://,%NP6#1U.P%7=7V'
MU6ZC,^BTV]TJL.YF[[IU/:S56L/&=;7:OJGV<G5]RR*W3U#DMOG#BMQ^2<>Q
M_'>J>RS$>_.]:KUFM]ZNWW1&W5Y]=-.KM5H]S0):K7K7RO=JC_K]T: U' [K
MPV&[UNU=#]HZ^[Q)E9?V%&*]=Y[G+VV;P4T5WC]]-=L'0.%L&>Y'PU:;3+D*
M2B;0V>O(BY/0O_JP!FW=^0(2_GBL'W"=M_CX?_RE6Z]7W_T*C_M ^>EC[=W/
M#HF1NMV4<'Z5N5*M3#)S ^ #^FV5EXFZJFY+S#_C6Z<K6[C?WMUJ5YOM7"G/
M;K<W: UN0/9K@ !XT^_ )6DWJL/!",ANKYXO!32219,V<_L& +UI*O,4[C:6
M\<E5[BG\OE&AAV?)!(;JCF9M&S;Q;LNM5C?S;(\6%>)_IV@TFTFNLQK.9MY$
MNK9=B^P#NFGAVD$6)-%(($#CGWC4%4WKSE[@_#-<R3O@5,[7\"[ WJ(NL9K_
M H24ZQP*#L1RE<8:A2Y!F^-4U8@-5%B/1PN^?%NPHFX:X<^ Y)GMA4H-+>$6
M8;NVP/FOU%?]U^K5/#S40V2G&,*K!C3.[]JBL_&,:\V_T"60/&J;I!=XFNNF
M>6#AMG4R T6U,>H,@#7U>NUJJ]/LC*[K]5:O/6KU&LV1==LTF_Q5QK&4'U=D
MD0WFM(>OL.:/,U2T$,&?[#H6NR).T\AT19QYH+WJJDZ;3.?(ZV8?^'MU4+CI
MC)*2C?%I260GZ\_>:W6O!X-6N]EL]JO-VNBZUAD!B;SN#:\'O7:A-R:WP QG
M5(KJZ6DEPN6<6EO"?F&>E-P'!X]2JQ[\ZA6B))(?>8<ER95"I,RUBLLC'M4Z
M[V*'FT!>#E7-:N(B 37*IWU'LD9'IQ0G=K?RXLMBE3YMMJHWHVZG.0*1HMMH
M-J^;U5ZKUZD/!]7Z=:M6?0B%TT6_UY]46;1A*I_^*AULIN@^86T/W:&:V"D6
MH3>G7L1Q??!/2Q:M JG5-K"L&FA9U]U>[1H86[TW:#=JK>LFG'6WD>_@]TE&
M:(7]./L@HF\R^0P[>?H3#5+^8CMYO*KO/=;>IE7^KZ<P.N'9?8KDK0 ,!UV
MX>$@0)RW()R00R)K-4#WX>=B9UY%ST!Z,GXD^1U+8,?FLT*/?%]@75\1Z\4
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MD1=_XW5AWW;RRN!**TXA:G^)LMP,F'F(V7W<U#M6:)1K-?8),(1A\?Z]J_Y
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MK%Y%6+V(* W&4U,_GM@!3*%8*U'0E:Y_5;K2/3 J-I/:<L\M82L+L]<>+ZO
M#&D[>V2PGBJ*B088*UQ_TQ:VE=@8^4O'F:,-QX;)+M-$$3(?^L= QGA5?@_T
M@#>_NZHDU=B*SE8F_5S:FQ*QD;K!^6QY 96J@XE5NT"KVC^05/6_3:2@'!"X
MM5@N^.QWP90LU&X?COS1F+ UU^"KG(-BZ)DH3@_3HJ)8!WG^(=:^=QME49Z@
M#PK0Y4)^9"N2Z>!W)H1%:^NO: IP^E020)C4K0$@_'@,*&BR^0&1L; FF92
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MK#4^JG4%+K6+3..G>C8@RSBL@MZW0JZ^2Q1%5UUS=,$U3@-<BD35"K:R C9
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MQ$:RMD&;[B27VVLA(<8$]PS0Y)U4*BB%XL5RZ5VI!'HN>HC.1!"+1&3"\!7
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M.]I])7M0YDU.*]/Z()^K$I.6-IID8$M LYS3C8,CKE4K&73UX;(@0M$T*A?
M2AI ,8I[+>9OIRE>M=%P;3L.-LZ\W$>GC+)Y$5$V6:" '3J9J_4CG$_DXJYE
M,7NF\C]C?N[.="S->(,:;5R>I[@[S8NA:QL\O[E!V93_Z5^A5[ U:<X(1!]Y
MXOTL&3VS5$[8.M.Z2E$TR;-D?9!3.'GL!:_3_)Z&<#[WV3_9L>8+V&T>*&[D
ML0>ZY3#)!DB"MI8/24I026,J^0G3 G3<"I^U2ADS[D(LB84QLZR34 89/,])
M8I1 :M"!O7N()MA!VZG_K<$RVJ%84C\UEB!LO2719VL9ET .MND?_QE9%IZC
M58P1]35"Z""B>$NI.P11R32*S#;&'(+^+2C"6!,F']F-4=QV>/8XG%(]6CQZ
M'=Z-%M/U2MGQ\>9RAE:6QJ4%7!453H8MWU>F;5Z*,9I0J7F[*5-6=.@R#W:+
M!>7S/3[4"]CG_9N(M9W%5(??;BO.F=)03:..P:[M7]__-A5'S9!-&==<W?*#
M@P2E$6:T\WLS*R%V"^$-N5TIYQ\11;-,-DVSO=#R'\\\+!MHLK(>#JA?GO[H
MZ2LO0 W\EWKS%!UVB>9T&ZI!W^:_Z >-N+7)?9 P/@@V"QA-W%0'SU+?J#4+
M>EW-J)N)(E8M76K_K()MLD'RY[TY )X,,$"D<^]>Y-'H2!V-QYF#5!7$5!U2
M8H$]*]2UT9U^;2\JA<&J@!^TR\ H*AU>RW(K&<7H,O!U05?35[QP@XO8D5VW
M=_C;2SP'E1Y A&^*;4<F7E93B!U>P#'#R=XSFGJ15"V.-A]6-F.5X44IIS+0
MS:.LZ55UA*^NLZ#F-5C#.(TFTO:]F>PMU9"EN&@8T4>G--6 \I945<.R)/\[
M]59LH:2*22S7A>K@LQG\BZGA_8>D"I@46Z0NE"(_N4@\"Y23"*-E35ZY(6$
M*BSNLA$CQ3=DBY.)PI.0#G[+3MKB2>1_*JCQBK*I1#Z;-6:>*S17KCAZB[H
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M3P%_+-UE!CPUF+O(GF(Y21/Z,)4S&4PU6Y4!,#1BLBN!,BGH.L);VBH.\$]
M%SE)4J!;,-(*]@K,$;<25^[#OS,U8_2=R4($<\/;PS0!Z8A@IJ0>^!9@>"N
M6L-&8C8Q -5> 2"TB6*?]6.[H#0)4Q]D$@G+%4X,F_)F@#8(]=QR)F&<Y$A
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M%BO2/"R!I2::55'E!II"1@";D*X\B!ZQ!TBT8]J=D_TAUKYW&W']AZ]R#A3
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MJX6 N8F$D#:9",^WOH0UDF"V9XUF/RCS"*!('AN"R3Q+("+B9=9'T09DVDM
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M8ZU\JHV\SOG85<VD2<@Q*..USEGCDD#Z -&(""3I+?G9N/2ATA7DSS9YL4I
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M^YX8@]9-1BX,M_ %Z.,H1LD5KAYN<[H*^7I/T3KOC5.M3J] PZ8%B A#+"A
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M:_<I"-"1/79B7=6<\@1YK^]5OQN !P!+5R6".4V..A:P8N,/@(C2_P$=L18
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M2*I(M4R#@:KS#5Z=H0<S)<@L5=#C$%RNZT0_R)JB]<O:4=)3+?0I8JX33;X
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M8.MN(85Z7SVN^X"S&Z9U<'6R7K?::GCU9Y;)>@^7R=9J!U+P6BSDD1UJS5\
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M&C<0_IS\"I5,._8,K\9V8B">P9A,/9,FKD,GTWX3=WN<QKK35=*!Z:_OKNZ
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M]\8KOO,"NG-Q_(27]F\#=>E!X*<<I%F+I%O"HEKO>_ENG]5B'_!,_])R>Z&
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M?M8ET%K;T!=?G?5V>B/7^1=02P$"% ,4    "  CB@9/7ZN=UDQR  #0KP(
M&@              @ $     97@Q,#%E;7!L;WEM96YT86=R965M92YH=&U0
M2P$"% ,4    "  CB@9/LD&YMIUT  !3S@( &@              @ &$<@
M97AH:6)I=#$P,G5T=&5R96UP;&]Y;2YH=&U02P$"% ,4    "  CB@9/<96C
MC:\4  # YP  $0              @ %9YP  <'1C="TR,#$Y,#8S,"YX<V10
M2P$"% ,4    "  CB@9/F_P62Z0B  #[= $ %0              @ $W_
M<'1C="TR,#$Y,#8S,%]C86PN>&UL4$L! A0#%     @ (XH&3\;WS9J!@@
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M8W0P-C,P,C Q.3$P+7$N:'1M4$L! A0#%     @ (XH&3V[-<'X-"   HS<
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J8W0P-C,P,C Q.65X+3,R,BYH=&U02P4&      P #  M P  LL(%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
